2021”N

  • ’˜‘
    1. ‘«—§—YˆêDƒNƒŠƒjƒJƒ‹ƒKƒCƒh ¬Ž™‰ÈFê–åˆã‚Ìf’fEŽ¡—ÃD…Œû ‰ëAŽRŒ`âM—Ï•Ò. “Œ‹ž: “ìŽR“°: 2021. ‹CŠÇŽxšb‘§Dp476-84D
    2. ŽíŽsq’ˆ. ¬Ž™”Å‘ŸŠí’ñ‹Ÿƒnƒ“ƒhƒuƒbƒN.@ŠÄC—ߘaŒ³”N“xŒú¶˜J“­‰ÈŠwŒ¤‹†”ï•â•‹àˆÚAˆã—Êî”Õ®”õŒ¤‹†Ž–‹Æu¬Ž™‚©‚ç‚Ì‘ŸŠí’ñ‹Ÿ‚É•K—v‚ŗ̏®”õ‚ÉŽ‘‚·‚鋳ˆçƒvƒƒOƒ‰ƒ€‚ÌŠJ”­vŒ¤‹†”Ç.@“Œ‹žF‚Ö‚é‚·o”ÅF2021D”í‹s‘ÒŽ™‚ÌœŠO. p33-35.
    3. ŽíŽsq’ˆ. JPLSƒKƒCƒhƒuƒbƒN.@ŠÄC@“ú–{¬Ž™‰ÈŠw‰ïi•ÒW@JPLSˆÏˆõ‰ïj“Œ‹žF‚Ö‚é‚·o”ÅF2021DŒÄ‹záŠQ‚ɑ΂·‚鉊ú‘Ήž. p36-39.
    4. ŽíŽsq’ˆ. JPLSƒKƒCƒhƒuƒbƒN.@ŠÄC@“ú–{¬Ž™‰ÈŠw‰ïi•ÒW@JPLSˆÏˆõ‰ïj“Œ‹žF‚Ö‚é‚·o”ÅF2021DˆÀ’艻‚Æ”À‘—. P48-53.
    5. ŽíŽsq’ˆ. JPLSƒKƒCƒhƒuƒbƒN.@ŠÄC@“ú–{¬Ž™‰ÈŠw‰ïi•ÒW@JPLSˆÏˆõ‰ïj“Œ‹žF‚Ö‚é‚·o”ÅF2021Dd“ĬŽ™‚̈À’艻‚ÆŽ{ÝŠÔ”À‘—. P137-144.
    6. ŽíŽsq’ˆ. JRC‘h¶ƒKƒCƒhƒ‰ƒCƒ“2020DŠÄC@“ú–{‘h¶‹¦‹c‰ï@“Œ‹žFˆãŠw‘‰@F2021DJPLSì‹Æ•”‰ïƒƒ“ƒo[.
    7. ˆî‘º@¸A–x•ÄmŽuA‘ë•·òGAa’J˜a•FA—^“cmŽuA‰Í’×R‹IŽqAœA–ìŒbˆê•Ò. ‘ÙŽ™SƒGƒR[ŒŸ¸ƒKƒCƒhƒ‰ƒCƒ“i‘æ2”Åj“ú–{‘ÙŽ™S‘Ÿ•aŠw‰ïE“ú–{¬Ž™zŠÂŠíŠw‰ï: 2021.
    8. œA–ìŒbˆê. zŠÂŠíf—ÃRƒ“ƒvƒŠ[ƒg@S‹ØÇ. –k‰ª—TÍ•Ò. “Œ‹ž: ŠwŒ¤ƒƒfƒBƒJƒ‹GŽÐ: 2021 Mar. d—v‚È“ñŽŸ«S‹ØLJD¶Žºãk–§‰»áŠQ. p161-175.
    9. œA–ìŒbˆê. ìè•aŠw‰ü’ù‘æ‚Q”Å “ú–{ìè•aŠw‰ï•Ò. “Œ‹ž: f’f‚ÆŽ¡—ÃŽÐ: 2021 Dec. ŠwZ‚Å‚ÌŠÇ—. p215-9.
  • Œ´’˜
    1. Taguchi M, Kawasaki Y, Katsuma A, Mito A, Tamura K, Makimoto M, Yoshida T. Pharmacokinetic Variability of Caffeine in Routinely Treated Preterm Infants: Preliminary Considerations on Developmental Changes of Systemic Clearance. Biol Pharm Bull. 2021 Jan 1; 44(1):69-74.
    2. Nakashima Y, Sakai Y, Mizuno Y, Furuno K, Hirono K, Takatsuki S, Suzuki H, Onouchi Y, Kobayashi T, Tanabe K, Hamase K, Miyamoto T, Aoyagi R, Arita M, Yamamura K, Tanaka T, Nishio H, Takada H, Ohga S, Hara T. Lipidomics links oxidized phosphatidylcholines and coronary arteritis in Kawasaki disease. Cardiovasc Res. 2021 Jan 1;117(1):96-108.
    3. Hirono K, Hata Y, Ozawa SW, Toda T, Momoi N, Fukuda Y, Inuzuka R, Nagamine H, Sakaguchi H, Kurosaki K, Okabe M, Takarada S, Miyao N, Nakaoka H, Ibuki K, Origasa H, Bowles NE, Nishida N, Ichida F; for LVNC study collaborators. A burden of sarcomere gene variants in fetal-onset patients with left ventricular noncompaction. Int J Cardiol. 2021 Apr 1; 328:122-129.
    4. Kawasaki Y, Oishi K, Hernandez A, Ernst T, Wu D, Otsuka Y, Ceritoglu C, Chang L. Brain-derived neurotrophic factor Val66Met variant on brain volumes in infants. Brain Struct Funct. 2021 Apr; 226(3):919-925.
    5. Yoneda N, Yoneda S, Tsuda S, Ito M, Shiozaki A, Niimi H, Yoshida T, Nakashima A, Saito S. Pre-eclampsia Complicated With Maternal Renal Dysfunction Is Associated With Poor Neurological Development at 3 Years Old in Children Born Before 34 Weeks of Gestation. Front Pediatr. 2021 Apr 29; 9:624323.
    6. Ichimata S, Hata Y, Hirono K, Yamaguchi Y, Nishida N. Clinicopathological features of clinically undiagnosed sporadic transthyretin cardiac amyloidosis: a forensic autopsy-based series. Amyloid. 2021 Jun;28(2):125-133.
    7. Sone N, Konishi S, Igura K, Tamai K, Ikeo S, Korogi Y, Kanagaki S, Namba T, Yamamoto Y, Xu Y, Takeuchi K, Adachi Y, Chen-Yoshikawa TF, Date H, Hagiwara M, Tsukita S, Hirai T, Torisawa YS, Gotoh S. Multicellular modeling of ciliopathy by combining iPS cells and microfluidic airway-on-a-chip technology. Sci Transl Med. 2021 Jul 7;13(601):eabb1298.
    8. Nishijima T, Kawasaki Y, Ueno K, Inomata S, Yoshida T. Renal impairment following perinatal asphyxia. Pediatr Neonatol. 2021 Jul;62(4):451-452.
    9. Nakamura M, Matsumura K, Ohnuma Y, Yoshida T, Tsuchida A, Hamazaki K, Inadera H; Japan Environment and Childrenfs Study Group. Association of cesarean birth with prevalence of functional constipation in toddlers at 3 years of age: results from the Japan Environment and Children's Study (JECS). BMC Pediatr. 2021 Sep 23;21(1):419-428.
    10. Wada T, Adachi Y, Murakami S, Ito Y, Itazawa T, Tsuchida A, Matsumura K, Hamazaki K, Inadera H; Japan Environment and Children's Study (JECS) Group. Maternal exposure to smoking and infant's wheeze and asthma: Japan Environment and Children's Study. Allergol Int. 2021 Oct;70(4):445-451.
    11. Nagaoka M, Akaishi M, Iida K, Yoshida T. Diazoxide toxicity with hypoglycemia in infants with trisomy 13. Pediatr Neonatol. 2021 Nov;62(6):679-680.
    12. Yoshida S, Tanaka S, Adachi Y, Yoshisue H, Kozawa M, Kawakami K. Assessment of asthma severity according to treatment steps in Japanese pediatric patients: a descriptive cross-sectional study using an administrative claims database. J Asthma. 2021 Dec;58(12):1574-1580.
    13. Nii M, Inuzuka R, Inai K, Shimada E, Shinohara T, Kogiso T, Ono H, Ootsuki S, Kurita Y, Takeda A, Hirono K, Takei K, Yasukochi S, Yoshikawa T, Furutani Y, Shinozaki T, Matsuyama Y, Senzaki H, Tokushige K, Nakanishi T. Incidence and Expected Probability of Liver Cirrhosis and Hepatocellular Carcinoma After Fontan Operation. Circulation. 2021 Dec 21;144(25):2043-2045.
    14. Ozawa SW, Takarada S, Okabe M, Miyao N, Nakaoka H, Ibuki K, Ichida F, Hirono K; Fetal CM Study Collaborators. Clinical Characteristics and Prognosis of Fetal Left Ventricular Noncompaction in Japan. Circ J. 2021 Dec 24;86(1):98-105.
    15. Yoshinaga M, Horigome H, Ayusawa M, Yasuda K, Kogaki S, Doi S, Tateno S, Ohta K, Hokosaki T, Nishihara E, Iwamoto M, Sumitomo N, Ushinohama H, Izumida N, Tauchi N, Kato Y, Kato T, Chisaka T, Higaki T, Yoneyama T, Abe K, Nozaki Y, Komori A, Kawai S, Ninomiya Y, Tanaka Y, Nuruki N, Sonoda M, Ueno K, Hazeki D, Nomura Y, Sato S, Hirono K, Hosokawa S, Takechi F, Ishikawa Y, Hata T, Ichida F, Ohno S, Makita N, Horie M, Matsushima S, Tsutsui H, Ogata H, Takahashi H, Nagashima M. Electrocardiographic Diagnosis of Hypertrophic Cardiomyopathy in the Pre- and Post-Diagnostic Phases in Children and Adolescents. Circ J. 2021 Dec 24;86(1):118-127.
    16. ¼“‡‹IA‹g“cärA¼‘ºŒ’‘¾A’––”’qŽÀA’·‰ªvGA“c‘ºŒ«‘¾˜YAìè—TŽqA–q–{—D”üD‹É’áo¶‘ÌdŽ™‚É‚¨‚¯‚é3ÎŽžBayleyŒŸ¸‚Æ6ÎŽžWISCŒŸ¸‚Æ‚Ì‘ŠŠÖD“úV¶Ž™¬ˆçˆã‰ïŽ 2021 Feb 33(1): 68-73.
    17. ’†—¢Œ\‹MA’––”’qŽÀAìè—TŽqA’·‰ªvGA“c‘ºŒ«‘¾˜YA–q–{—D”üA¡‘º”Ž–¾A‹g“cärDNICU“à‚ŖʉïŽÒ‚©‚犴õ‚µ‚½ƒqƒgƒpƒŒƒRƒEƒCƒ‹ƒX3Œ^Š´õÇ‚Ì‘o‘ÙD“úŽüŽYŠú¥V¶Ž™‰ïŽ 2021 Feb 33(1): 111-7.
    18. ‰Á“¡‘וãAˆÉ“¡–õ“TA´…@”VA”ÂàVŽõŽqA‘«—§—zŽqA‘«—§—YˆêD‚킪‘‚É‚¨‚¯‚鬎™ƒAƒŒƒ‹ƒM[Ž¾Š³‚ɑ΂·‚é•ÛŒ’Žw“±‚ÌŒ»ó‚ÉŠÖ‚·‚錟“¢D“ú¬Ž™ƒAƒŒƒ‹ƒM[‰ïŽ 2021 Mar ;35(1): 94-100.
    19. ŽOŒ´@OAœAìTˆê˜YAˆÉˆä‚Ý‚¸•äAŽá™‰ë_A‘Ñ“cF”VAΖØ@ŠwAŠÝ@_KA–kŒ[ˆê˜YAŠÖª“¹˜aA‘«—§—YˆêDƒrƒfƒIŠwCEƒrƒfƒI•]‰¿‚É‚æ‚éˆãsˆ×ŒP—û‚Ì‹³ˆçŽÀ‘H -ƒRƒƒi‰Ð‚Å‚ÌV“ü¶‘h¶uK‰ï‚ÆŠî–{“If—ËZ”\ŽÀK-DˆãŠw‹³ˆç2021 Jun; 52(3):1-6.
    20. ŽR“c¯—˜“ÞA“c‘ºŒ«‘¾˜YA’·‰ªvGA’––”’qŽÀAìè—TŽqA–q–{—D”üA‹g“cärD–³Ž¡—ÂÌæ“V«”畆ƒJƒ“ƒWƒ_Ç‚É”x‰Š‚ð‡•¹‚µ‚½late pretermŽ™D“úŽüŽYŠú¥V¶Ž™‰ïŽ 2021 Sep 57(2): 343-7.
    21. ûüú±–ƒ”üAŽíŽsq’ˆA‚ˆä“Þ”üA‘å‹´–¢—ˆA”ª–ØMˆêDƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ2019—¬s‰º‚É‚¨‚¯‚é—cŽ™‚̃}ƒXƒN’…—p󋵂ƕیìŽÒ‚Ì”FŽ¯D“úŽ™Ž 2021 Nov 125(11):1581-84.
    22. Ž›‰ºV‘¾˜YAŽíŽsq’ˆAûüú±–ƒ”üA‰Á“¡‘וãAˆÉ“¡’å‘¥A–ìŒû@‹žA‘«—§—YˆêDMRIŒŸ¸Žž‚Ì’ÁÂɊւ·‚鋤“¯’ñŒ¾‚ðŠˆ—p‚µ‚½ˆã—ÈÀ‘S„i‚Ì‚½‚ß‚ÌŽæ‚è‘g‚ÝD“úŽ™Ž 2021 Nov 125(11):1591-7.
    23. ‰Á“¡‘וãA‰ªú±ŽjŽqA•½ŒûáŽqA“ñ‘º¹Ž÷AˆÀ•y‘fŽqA–{‘º’m‰ØŽqA‘ê‘ò‘ôŒÈA‰ºð’¼Ž÷AXì‚Ý‚«. ƒLƒƒƒŠƒAŽx‰‡ƒ[ƒLƒ“ƒOƒOƒ‹[ƒvƒAƒ“ƒP[ƒg’²¸Œ‹‰Ê. «•ÊE”N—îE“­‚«•û‚ð–â‚í‚È‚¢ƒLƒƒƒŠƒAŽx‰‡‚ð–ÚŽw‚µ‚Ä. “ú¬Ž™ƒAƒŒƒ‹ƒM[‰ïŽ 2021 Dec ;35(5): 442-50.
  • Ç—á•ñ
    1. Hiraiwa A, Matsui K, Nakayama Y, Komatsubara T, Magara S, Kobayashi Y, Hojo M, Yamamoto T, Tohyama J. Polymicrogyria with calcification in Pallister-Killian syndrome detected by microarray analysis. Brain Dev. 2021 Mar; 43 (3): 448-453.
    2. Kato R, Taneichi H, Takarada S, Okabe M, Miyao N, Nakaoka H, Ibuki K, Ozawa S, Adachi Y, Yoshimura N, Saito K, Ichida F, Hirono K. Reversible left ventricular noncompaction caused by hypertensive hydrocephalus: a pediatric case report. BMC Pediatrics 2021 Apr 28;21(1):205.
    3. Tamamitsu AM, Nakagama Y, Domoto Y, Yoshida K, Ogawa S, Hirono K, Shindo T, Ogawa Y, Nakano K, Asakai H, Hirata Y, Matsui H, Inuzuka R. Poor Myocardial Compaction in a Patient with Recessive MYL2 Myopathy. Int Heart J. 2021 Mar 30; 62(2):445-447.
    4. Oka H, Nakau K, Imanishi R, Furukawa T, Tanabe Y, Hirono K, Hata Y, Nishida N, Azuma H. A Case Report of a Rare Heterozygous Variant in the Desmin Gene Associated With Hypertrophic Cardiomyopathy and Complete Atrioventricular Block. CJC Open. 2021 May 12; 3(9):1195-1198.
    5. Ando T, Nakajima T, Fukuda R, Nomura K, Niida Y, Sakumura M, Motoo I, Mihara H, Nanjo S, Kajiura S, Fujinami H, Hojo S, Fujii T, Yasuda I. Intensive surveillance endoscopy for multiple gastrointestinal tumors in a patient with constitutional mismatch repair deficiency: case report. BMC Gastroenterol. 2021 Aug 23;21(1):326.
    6. •½ˆäGŽqA’‡‰ª‰pKAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀA–{ŠÔ’_A‹´–{ˆè•vA‰ª•”@ŒhAŽs“c•™ŽqA—v@‹§AœA–ìŒbˆê. RASA1ˆâ“`Žq‚ÌV‹K•ÏˆÙ‚ªŒ©‚¢‚¾‚³‚ꂽˆâ“`«oŒŒ«–Ñ׌ŒŠÇŠg’£Ç. “úŽ™Ž 2021 Jan 125(1): 37-41.
    7. ŒÜ\—’“oA‚ŒK–ƒˆßŽqA–쑺ŒbŽqA¼“c’¼“¿AmˆäŒ©‰pŽ÷. Melting Temperature mapping–@‚É‚Ä‹H—L‚È‹N‰Š‹Û‚𓯒肵“¾‚½ƒŠƒ“ƒp߉Š‚Ì2Ç—á. ¬Ž™‰È 2021 Jan 62(1): 93-8.
    8. “c”öŽ¶AœA–ìŒbˆêA”¨—R‹IŽqA¼“c®Ž÷AVˆä“c—v. ˆÙ‚È‚é”­ÇŒ`‘Ô‚ð’悵‚½NoonanÇŒóŒQ‚ɇ•¹‚µ‚½”ì‘åŒ^S‹Øǂ̬Ž™2—á. S‘Ÿ 2021 Mar 53(3): 275-9.
    9. –x]’åŽuAŽíŽsq’ˆAâV“¡@—IA˜a“c‘ñ–çA‘q–{@’A“c’†•ü”üA‘«—§—Yˆê. ’˜–¾‚È”]•‚Žî‚ÆoŒŒ«”][ǂ𶂶‚½“œ”A•a«ƒPƒgƒAƒVƒh[ƒVƒX‚Ì‚P¬Ž™—á.@¬Ž™“à‰È 2021 Apr; 53(4): 694-699.
    10. –x]’åŽuA´…@”VA’Ô¦áÁˆê. Ž©‘R‘Þk‚µ‚½ä`‘Ñ֬ᎂÌ1—á-‘ÙŽ™Šú‚©‚ço¶Œã‚ÌŒo‰ß. ŽüŽYŠúˆã 2021 Oct 51(10): 1562-5.
    11. ²“¡@Œ[A“¡“cC•½A‰P“c˜a¶AœA–ìŒbˆêA”¨èŠì–F. ‘½Œ¹«S–[•p”‚É‚æ‚èSŒ´«ƒVƒ‡ƒbƒN‚ɊׂÁ‚½•s®–¬—U”­«S‹ØÇ‚Ì4ƒ•ŒŽ“ûŽ™—á. “ú¬zŽ 2020 Dec; 36(4): 321-7.
  • ‘à
    1. œA–ìŒbˆê. y¬Ž™ˆâ“`ŽqŽ¾Š³Ž«“TzACTC1iŠÖ˜AŽ¾Š³FS‹ØŽ¾Š³AŠg’£Œ^S‹ØÇ‚È‚Ç@ŠÖ˜Aˆâ“`ŽqFLMNAAPRKAG2AGLAj. ¬Ž™f—à 2021 Jan; 84(11): 1581-4.
    2. ‹g“cärDyV‹»EÄ‹»Š´õÇA—A“üŠ´õÇ‚ÆŽüŽYŠúˆãŠwzƒgƒLƒ\ƒvƒ‰ƒYƒ}DŽüŽYŠúˆã 2021 Mar 51(3): 383-5.
    3. ‘åŽR¸ˆêAÔ—ä—zŽqA•ŸŒ´—¢ŒbAr–xm”üAΖÑ@’AÎè—DŽqAˆÉ“¡—F–íA]Œ´@˜NA“ú‰º@—²AŽíŽsq’ˆAà_“c—m’ÊA•½–{—´ŒáA˜Ô“cŒõ˜aA“¹’[L–¾Aâ“Œ—R‹IA‹àé‹IŽqA¼Œ´’m‘ãA•½ŽR‰ë_, “ú–{¬Ž™‰ÈŠw‰ï“­‚«•û‰üŠvŒŸ“¢ƒ[ƒLƒ“ƒOƒOƒ‹[ƒv.@‚±‚ê‚©‚ç‚̬Ž™‰Èˆã‚ª‚ß‚´‚·¬Ž™•ÛŒ’Eˆã—Â̕ûŒü«. “úŽ™Ž 2021 MarG125(3): 540-4.
    4. œA–ìŒbˆê. y“ñŽŸ«S‹ØÇ-Present and Futurez‚»‚Ì‘¼‚ÌS‹ØÇ@¶Žºãk–§‰»áŠQ. ˆãŠw‚Ì‚ ‚ä‚Ý 2021 May; 277(5): 436-41.
    5. ‘«—§—YˆêDŠP‚Ì‚ ‚ꂱ‚ê`‘½Šp“I‚É‚Ý‚éF“Ë‘R‚ÌŠP@‹C“¹ˆÙ•¨Dƒ`ƒƒƒCƒ‹ƒhƒwƒ‹ƒX2021 Jul 24(7):507-10.
    6. ‹g“cärDyÝ‘Ù22`23T‚Ì’´‘ŽY‚ð‚ß‚®‚é‰Û‘è‚Æ“W–]z’·Šú—\Œã@“à‰ÈŽ¾Š³‚̃ŠƒXƒNDŽüŽYŠúˆã 2021 Aug 51(8): 1207-10.
    7. ŽíŽsq’ˆ. yƒRƒƒi‰Ð‚ÆŽq‚Ç‚à‚ÌŒ’N-“úí‚ðŽæ‚è–ß‚·‚½‚ß‚ÉzŠwZsŽ–‚𕜊ˆ‚³‚¹‚銴õ‘Îô‚ƈã—Ãê–åE‚Ì–ðŠ„. •Û’c˜A 2021 Sep ; 1353: 16-21.
    8. ŽíŽsq’ˆ. •xŽRŽs—§ŠwZVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ‘ÎôŒŸ“¢‰ï‹c‚ÌŠT—v. ‚Æ‚â‚ܬŽ™•ÛŒ’2021 Nov 19: 20-1.
    9. ûüú±–ƒ”üDŽq‚Ç‚à‚ÌVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ`ÅV‚Ì’mŒ©‚©‚ç`D‚Æ‚â‚ܬŽ™•ÛŒ’2021 Nov 19: 22-3.
    10. œA–ìŒbˆê. yŽ„‚̈•û2021zS‹Ø‰ŠES–Œ‰Š. ¬Ž™—Õ°2021 Dec 74(‘): 1723-30.
    11. ŽíŽsq’ˆ. Žq‚Ç‚à‚½‚¿‚ÌŽ‹“_‚Ål‚¦‚éVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ`Žq‚Ç‚à‚½‚¿‚Ì“úí‚ðŽæ‚è–ß‚µ‚½‚¢`.@Žq‚Ç‚à‚Ì‚©‚炾‚ÆS@”’‘2021; 17-19.
    12. ŽíŽsq’ˆ. Žq‚Ç‚à‚½‚¿‚É‚Æ‚Á‚Ä‚ÌVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ. ƒNƒŒƒXƒR 2021; 246:12-17.
    13. ŽíŽsq’ˆ. ¬Ž™‚É‚¨‚¯‚éVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ‚Ì“Á’¥‚Æ‘Îô.@é‹ÊŒ§ˆãŽt‰ïŠwZˆã‰ïƒjƒ…[ƒX 2021; 19: 20-3.
    14. ŽíŽsq’ˆ. VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ‚©‚çŽq‚Ç‚à‚½‚¿‚ðŽç‚邽‚ß‚É@`–{“–‚Ì“G‚Í‚Ç‚±‚É‚¢‚é‚Ì‚©`@•xŽRŒ§¬Ž™‰Èˆã‰ï‰ï•ñ@2021; 68:5-6.
  • 2021”NŠw‰ï•ñ
    1. Hirono K. Genetics in Pediatric Cardiomyopathy. The 16th Japan-China-Korea Pediatric Heart Forum; 2021 Jul 9-11; WEBŠJÃ.
    2. Hirono K. Genetics in Pediatric Cardiomyopathy. The 8th Congress of the Asia-Pacific Pediatric Cardiology Society; 2021 Jul 15-18; WebŠJÃ.
    3. Nakaoka H, Saito K, Takarada S, Okabe M, Miyao N, Ibuki K, Ozawa S, Hirono K, Ichida F. MicroRNA-93 encapsulated in peripheral blood mononuclear cells contributes to the progression of vasculitis in acute Kawasaki Disease. The 13th International Kawasaki Disease Symposium; 2021 Oct 29-31; WebŠJÃ.
    4. Kato T, Kobayashi T, Ayusawa M, Fukazawa R, Fuse S, Hirono K, Mitani Y, Suda K, Maeda J, Miura M. Analysis of the Long-term Clinical Course and the Factors Associated with Coronary Arterial Aneurysm Regression in Kawasaki Disease Patients. The 13th International Kawasaki Disease Symposium; 2021 Oct 29-31; WebŠJÃ.
    5. Yoshikane Y, Fukazawa R, Takatsuki S, Hirono K, Kobayashi N, Imanaka-Yoshida K, Katsube Y. Biomarkers of Tenascin C and Pentraxin 3 Predict the Treatment-Resistant Kawasaki Disease. The 13th International Kawasaki Disease Symposium; 2021 Oct 29-31; WebŠJÃ.
    6. ˆî“c—S“ÞA¼ˆäŽOŽ}A‹g“cärAìè—TŽq. ’áo¶‘ÌdŽ™‚ÌBayley-III‚É‚æ‚é”­’B“Á’¥‚Ìc’f“IŒŸ“¢D‘æ25‰ñ”F’m_Œo‰ÈŠw‰ï; ”F’m_Œo‰ÈŠw22(2):109 2021 Jan: Ž†ãŠJÃ.
    7. ’؈䗢A‘ŠJË•½A‘OâO‹PA´…@”VA‰Á“¡‘וãAûüú±–ƒ”üAŽíŽsq’ˆA‘«—§—YˆêD‘½Ê‚ÈtŠO‡•¹Ç‚ð’悵‚½Žu‰ê“Å‘fŽY¶«‘å’°‹Û‚É‚æ‚é—nŒŒ«”A“ÅÇÇŒóŒQD‘æ55‰ñ¬Ž™t‘Ÿ•aŠw‰ï; 2021 Jan 9-10; WebŠJÃ.
    8. “c’†•ü”üA•½ˆäGŽqA‘ŠJË•½A“¡–Ø–õŽqA“c’‡çHA‹{@ˆêŽuA‘«—§—Yˆê. ‘å”]”’Ž¿‚ÉL”Í‚ÈMRIM†ˆÙí‚ð”F‚ß‚½ˆê’jŽ™—á`‘±•ñ`. ‘æ78‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï; 2021 Feb 7; WEBŠJÃ.
    9. –q–{—D”üA‹g“cärA“ñ’J@•A¡‘º”Ž–¾. •xŽRŒ§‚É‚¨‚¯‚éNICU‘Þ‰@Œã‚ÌÝ‘îˆã—ÓIƒPƒAŽ™‚ÌŽÀ‘Ô’²¸. ‘æ331‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2021 Mar 14; WEBŠJÃ.
    10. ’†—¢Œ\‹MA’––”’qŽÀAìè—TŽqA’·‰ªvGA“c‘ºŒ«‘¾˜YA–q–{—D”üA‹g“cärDNICU“à‚Å”­Ç‚µ‚½HPeV3Š´õÇ‚Ì‘o‘ÙŽ™D‘æ331‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2021 Mar 14; WEBŠJÃ.
    11. ‹àŽqC–çAŒÜ\—’“oA…•yTˆê˜YAã–ì˜a”VA“¡“cC•½A”¨èŠì–FAŽíŽsq’ˆA”óŒû@Žû. —ÇD‚È“]‹A‚ð’H‚Á‚½’x”­Œ^NP«GBSŠ´õÇŽ™. ‘æ331‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ïG2021 Mar 14; WEBŠJÃ.
    12. Hirono K, Hata Y, Miyao N, Okabe M, Takarada S, Nakaoka H, Ibuki K, Ozawa S, Yoshimura N, Nishida N, Ichida F, and LVNC study collaborators. Genotype-Phenotype correlation for children with left ventricular noncompaction and congenital heart disease. ‘æ85‰ñ“ú–{zŠÂŠíŠw‰ï; 2021 Mar 26-28; WebŠJÃ.
    13. ‹g“cärA’––”’qŽÀA’·‰ªvGA“c‘ºŒ«‘¾˜YAìè—TŽqA–q–{—D”üD6΂ɂ¨‚¯‚é’m“I”­’B‚Æ3ÎBayleyŒŸ¸‚Æ‚Ì‘ŠŠÖ@‹É’áo¶‘ÌdŽ™‚É‚¨‚¯‚錟“¢D‘æ124‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï; 2021 Apr 16-18; WEBŠJÃ.
    14. –q–{—D”üA’·‰ªvGA’––”’qŽÀAìè—TŽqA“c‘ºŒ«‘¾˜YA‹g“cärD“–‰@‚É‚¨‚¯‚éÝ‘îˆÚs‚µ‚½ˆã—ÓIƒPƒAŽ™‚ÉŠÖ‚·‚錻ó‚ƉۑèD‘æ124‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï; 2021 Apr 16-18; WEBŠJÃ.
    15. ŽíŽsq’ˆAûüè–ƒ”üA”ª–ØMˆêA‹{ŒûŽŽuA‚ˆä“Þ”ü.@“Á•ÊŠé‰æ@ˆã—ÂƋ³ˆç‚̘AŒg@ŠwZ‹³ˆç@uƒRƒƒi‰Ð‚É‚¨‚¯‚鬎™‰Èˆã‚Æ‹³ˆçˆÏˆõ‰ï‚̘AŒgvD‘æ124‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï; 2021 Apr 16-18; WEBŠJÃ.
    16. œA–ìŒbˆê. •½¬30”N“x¬Ž™ˆãŠwŒ¤‹†U‹»à’cŒ¤‹†•¬‹àŽóÜŽÒƒZƒbƒVƒ‡ƒ“.S‹Øãk–§‰»áŠQ‚Ì•a‘ԉ𖾠- “]ŽÊˆöŽqTBX5 ‰º—¬Œo˜H‚Ìd—v«‚É’…–Ú‚µ‚Ä. ‘æ124‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï; 2021 Apr 16-18; WEBŠJÃ.
    17. œA–ìŒbˆêA›“c^–çA‰ª•”^ŽqA‹{”ö¬–¾A’‡‰ª‰pKAˆÉŒ\“ñ˜YA¬àVˆ»‰À. æ“V«SŽ¾Š³‚𔺂¤S‹Øãk–§‰»áŠQ‚Ì—Õ°‘œ. ‘æ124‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï; 2021 Apr 16-18; WEBŠJÃ.
    18. “c‘ºŒ«‘¾˜YA’·‰ªvGA’––”’qŽÀAìè—TŽqA–q–{—D”üA‹g“cärD’´‘ŽYŽ™‚É‚¨‚¯‚錌´ƒTƒCƒgƒJƒCƒ“‚Ì„ˆÚ‚ƃXƒeƒƒCƒh‘Sg“Š—^Œã‚̕ω»D‘æ124‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï; 2021 Apr 16-18; WEBŠJÃ.
    19. ’·‰ªvGA“c‘ºŒ«‘¾˜YA’––”’q”üAìè—TŽqA–q–{—D”üA‹g“cärDƒWƒAƒ]ƒLƒTƒCƒh‚É‚æ‚è’˜‚µ‚¢’áƒiƒgƒŠƒEƒ€ŒŒÇ‚𗈂µ‚½ƒgƒŠƒ\ƒ~[13‚̈ê—áD‘æ124‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï; 2021 Apr 16-18; WEBŠJÃ.
    20. ‰Á“¡—ŽqA¬ŒI^lA’Ô¦áÁˆêA‘«—§—YˆêD•Ö’†ƒoƒCƒIƒ}[ƒJ[‚ð—p‚¢‚Ä’°ŠÇ‰ŠÇ‚ð•]‰¿‚µ‚½IgAŒŒŠÇ‰ŠD‘æ124‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï; 2021 Apr 16-18; WEBŠJÃ.
    21. …–ì«Ž¡A•½ˆäGŽqAŽ›‰ºV‘¾˜YA‰Á“¡‘וãAûüú±–ƒ”üA“c’†•ü”üA‘«—§—Yˆê. COVID-19—¬sŠú‚Ì‹xZ‚ðŒ_‹@‚É‹­”—“I‚ȉߊˆ“®‚ð‚«‚½‚µ‚½_Œo«‚₹ǂ̗Ž™—á. ‘æ124‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï; 2021 Apr 16-18; WEBŠJÃ.
    22. “yˆä¯ŽO˜YA‚‹´@Œ’A“à“cŒhŽqA¼ˆä•F˜YAŒ¢’Ë@—ºAˆ¼‘ò@‰qAŽíŽsq’ˆ. “Á•ÊŠé‰æ@ˆã—ÂƋ³ˆç‚̘AŒg@ŠwZ‹³ˆç@ŠwZ‹³—@‚Æ‚Æ‚à‚Éì‚éu‚¢‚Ì‚¿‚ÌŽö‹ÆvVŠwKŽw“±—v—Ì“±“ü‚ɇ‚킹‚ÄD‘æ124‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï; 2021 Apr 16-18; WEBŠJÃ.
    23. Ž›‰ºV‘¾˜YA…–ì«Ž¡A•½ˆäGŽqA‰Á“¡‘וãAûüú±–ƒ”üA’·X–œ—¢Žq. ‰º‚‘ÌŽî‘å‚ð”F‚ß‚½ƒAƒ“ƒhƒƒQƒ“ŽY¶•›tŽîᇂ̗Ž™. ‘æ94‰ñ“ú–{“à•ª”åŠw‰ïŠwp‘‰ï; 2021 Apr 22-24; WEBŠJÃ.
    24. ‘«—§—YˆêD‹¤“¯Šé‰æi“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïj¶ŠU‚ð’Ê‚¶‚½—ÇD‚Èšb‘§ƒRƒ“ƒgƒ[ƒ‹‚ð–ÚŽw‚µ‚ÄF¬Ž™Šú”­Çšb‘§‚Ì—\ŒãD‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ï; 2021 Apr 23-25; WEBŠJÃ.
    25. “c‘ºŒ«‘¾˜YAÄ“¡@—IA’·‰ªvGA’––”’qŽÀAìè—TŽqA–q–{—D”üA‹g“cärD¬‹…«’áF‘f«•nŒŒ‚ðŒ_‹@‚Éf’f‚µ‚½16”ÔõF‘ÌŠÖ˜Aƒ¿ƒTƒ‰ƒZƒ~ƒA/¸_’x‘ØÇŒóŒQ(ATR-16)D‘æ65‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2021 May 7?9; WEBŠJÃ.
    26. ’––”’qŽÀA’·‰ªvGAìè—TŽqA“c‘ºŒ«‘¾˜YA–q–{—D”üA‹g“cärDŒo’°‰h—{Šm—§Œã‚É‚ƒgƒŠƒOƒŠƒZƒ‰ƒCƒhŒŒÇ‚ð’悵‚½‘ŽYŽ™‚Ì“Á’¥D‘æ65‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2021 May 7?9; WEBŠJÃ.
    27. ¼“‡FŽ¡Aìè—TŽqA“c‘ºŒ«‘¾˜YA’––”’qŽÀA–q–{—D”üA‹g“cärDt‘ŸMRI‚ªf’f‚É—LŒø‚Å‚ ‚Á‚½dÇV¶Ž™‰¼Ž€‚ɇ•¹‚µ‚½—¼‘¤t“û“ª‰óŽ€‚Ì1—áD‘æ65‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2021 May 7?9; WEBŠJÃ.
    28. ’†—¢Œ\‹MA’––”’qŽÀAìè—TŽqA“c‘ºŒ«‘¾˜YA–q–{—D”üA‹g“cär. NICU“à‚Å”­Ç‚µ‚½ƒpƒŒƒRƒEƒCƒ‹ƒX3Œ^”]‰Š‚Ì‘o‘ÙŽ™D‘æ65‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2021 May 7?9; WEBŠJÃ.
    29. •½ˆäGŽqA“c’†•ü”üAŽ›‰ºV‘¾˜YA‰Á“¡‘וãAûüú±–ƒ”üA“¡–Ø–õŽqA“c’‡çHA‹{@ˆêŽuA‘«—§—Yˆê. V¶Ž™Šú‘Šú‚É”­Ç‚µ‚½—V‘–«Å“_”­ì‚𔺂¤“ûŽ™‚Ä‚ñ‚©‚ñ‚Ì—Ž™—á. ‘æ63‰ñ“ú–{¬Ž™_ŒoŠw‰ïŠwpW‰ï; 2021 May 27-29GWEBŠJÃ.
    30. ¼–{”üŽqA‰±–{çŽjA’·’Jì‚Æ‚à‚ÝA‚–؉€ŽqAŽRŒû’mŽ}Aó–ì‚Ý‚Ç‚èA‘«—§—YˆêD¬Ž™ƒAƒŒƒ‹ƒM[ƒGƒfƒBƒP[ƒ^[iPAEj‚É‚æ‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ƉƑ°‚Ö‚ÌŠ³ŽÒ‹³ˆç‚ÌŽÀ‘Ô’²¸-Š³ŽÒ‹³ˆç€–Ú‚ÌŽÀŽ{—¦‚Æ‹³ˆçŠJŽn”N—î-D‘æ37‰ñ“ú–{¬Ž™—Õ°ƒAƒŒƒ‹ƒM[Šw‰ï; 2021 May 31-Jun 23; WEBŠJÃ.
    31. ¼–{”üŽqA‰±–{çŽjA’·’Jì‚Æ‚à‚ÝA‚–؉€ŽqAŽRŒû’mŽ}Aó–ì‚Ý‚Ç‚èA‘«—§—YˆêD¬Ž™ƒAƒŒƒ‹ƒM[ƒGƒfƒBƒP[ƒ^[iPAEj‚É‚æ‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ƉƑ°‚Ö‚ÌŠ³ŽÒ‹³ˆç‚ÌŽÀ‘Ô’²¸-PAE‘®«‚Æ‹³ˆç€–ÚŽÀŽ{‘½”ŒQ‚ÌŠÖ˜A-D‘æ37‰ñ“ú–{¬Ž™—Õ°ƒAƒŒƒ‹ƒM[Šw‰ï; 2021 May 31-Jun 23; WEBŠJÃ.
    32. –––Ø‚ß‚®‚ÝAŽR–ìD]A¬“c‰ë”üA‹g“cKˆêA•B“c“ߒÊóA—é–Øç’ßAŽO‰YŽŽuAˆÉ“¡_–¾A‘«—§—YˆêA‘«—§—zŽqA•½£rŽuAŒiŽR‰ÀŽqA•½’JŠG—¢A‹àŽqŒb”üA’r“c“Þ‰›DH•¨ƒAƒŒƒ‹ƒM[‚ÌŽ™‚ð‚à‚‰Ƒ°‚ÌЊQŽž‚Ì”õ‚¦‚ÉŠÖ‚·‚éŽÀ‘ÔD‘æ37‰ñ“ú–{¬Ž™—Õ°ƒAƒŒƒ‹ƒM[Šw‰ï; 2021 May 31-Jun 23; WEBŠJÃ.
    33. ŽíŽsq’ˆ. ¬Ž™‹~‹}‚É‚¨‚¯‚é”]‘h¶‚ÆŽ¡—Â̌ÀŠE‚ɂ‚¢‚Äl‚¦‚é-”]Ž€‚Ƃ͉½‚©@‚±‚Ç‚à‚Ì”]Ž€‰º‘ŸŠí’ñ‹Ÿ‚Æ”í‹s‘ÒŽ™œŠO‚ÉŠÖ‚·‚錟“¢. ‘æ34‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ïŠwpW‰ï; 2021 Jun 18-20; “Þ—ÇiWEBŠJÃjD
    34. –x]’åŽuAˆÀì‹v”üA²–쌫‘¾˜YAˆ¢•”ŸGA¼ˆä‘ñ–çA•½ˆä@ŠóA‘O“c‘×GA–{“c—²•¶Aà_“c—m’ÊAûü—œˆêA‘ºŽRŒ\. ‹}«‘ˆ«‚ð”F‚ß‚½ƒ~ƒgƒRƒ“ƒhƒŠƒA•a‚Ì1—á. ‘æ34‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ïŠwpW‰ï; 2021 Jun 18-20; “Þ—ÇiWEBŠJÃjD
    35. ”ª–ØMˆêA¼‘òƒŽqAŒÜ\—’“oA‘ºã”ü–çŽqA“ˆ”ö@’qAŽíŽsq’ˆA“‡“c‰Á“ÞŽqA‰±–{çŽj. •xŽRˆã—ÃŒ—‚É‚¨‚¯‚鬎™ˆã—ÓIƒPƒAŽÀKŒ¤C‰ï‚Æ•xŽRŒ§ˆã—ÓIƒPƒAŽ™‚ÌЊQŽž‘Ήžƒ}ƒjƒ…ƒAƒ‹‚Ìì¬. ‘æ34‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ïŠwpW‰ï; 2021 Jun 18-20; “Þ—ÇiWEBŠJÃjD
    36. ”ª–ØMˆêA“ˆ”ö@’qAŽíŽsq’ˆ. •xŽRŽs‚É‚¨‚¯‚鎞ŠÔŠO¬Ž™‰Šú‹~‹}‘̧‚ÆVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õǂ̉e‹¿‚ɂ‚¢‚Ä. ‘æ34‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ïŠwpW‰ï; 2021 Jun 18-20; “Þ—ÇiWEBŠJÃjD
    37. –쑺@—A’rŽR—R‹IAˆäãM–¾AA¼ŒåŽqA‘å–ì’¼Š²A‰Á“¡—²GA–Ø‘º@ãÄA™’†Œ©˜aA’|ˆäŠ°˜aAŽíŽsq’ˆA“SŒ´Œ’ˆêA¼ŽR˜aFA”‹Œ´—C—ºA¬Ž™‹~‹}ˆã—Â̋³ˆçEŒ¤C–Ú•W‰ü’èƒ[ƒLƒ“ƒOƒOƒ‹[ƒv. u¬Ž™‹~‹}ˆã—Â̋³ˆçEŒ¤C–Ú•Wv‰ü’è•ñ-V‚µ‚¢‹³ˆç–Ú•W‚ÌŒø‰Ê“I‚ÈŠˆ—p•û–@@ƒRƒ“ƒsƒeƒ“ƒV[Šî”ÕŒ^ˆãŠw‹³ˆç‚̘g‘g‚Ý‚ð—p‚¢‚½¬Ž™‹~‹}ˆã—Â̋³ˆçEŒ¤C–Ú•W‚̉ü’è. ‘æ34‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ïŠwpW‰ï; 2021 Jun 18-20; “Þ—ÇiWEBŠJÃjD
    38. ’rŽR—R‹IAˆäãM–¾AA¼ŒåŽqA‘å–ì’¼Š²A‰Á“¡—²GA–Ø‘º@ãÄA™’†Œ©˜aA’|ˆäŠ°˜aAŽíŽsq’ˆA“SŒ´Œ’ˆêA¼ŽR˜aFA–쑺@—A”‹Œ´—C—ºA¬Ž™‹~‹}ˆã—Â̋³ˆçEŒ¤C–Ú•W‰ü’èƒ[ƒLƒ“ƒOƒOƒ‹[ƒv. u¬Ž™‹~‹}ˆã—Â̋³ˆçEŒ¤C–Ú•Wv‰ü’è•ñ-V‚µ‚¢‹³ˆç–Ú•W‚ÌŒø‰Ê“I‚ÈŠˆ—p•û–@@ŠwK•û—ª‚Æ•]‰¿@Œ»ê‚Å‚ÌŠˆ—p•û–@. ‘æ34‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ïŠwpW‰ï; 2021 Jun 18-20; “Þ—ÇiWEBŠJÃjD
    39. ‘å–ì’¼Š²A’rŽR—R‹IAˆäãM–¾AA¼ŒåŽqA‰Á“¡—²GA–Ø‘º@ãÄA™’†Œ©˜aA’|ˆäŠ°˜aAŽíŽsq’ˆA“SŒ´Œ’ˆêA¼ŽR˜aFA–쑺@—A”‹Œ´—C—º, ¬Ž™‹~‹}ˆã—Â̋³ˆçEŒ¤C–Ú•W‰ü’èƒ[ƒLƒ“ƒOƒOƒ‹[ƒv. u¬Ž™‹~‹}ˆã—Â̋³ˆçEŒ¤C–Ú•Wv‰ü’è•ñ-V‚µ‚¢‹³ˆç–Ú•W‚ÌŒø‰Ê“I‚ÈŠˆ—p•û–@@ƒRƒAƒRƒ“ƒsƒeƒ“ƒV[‚ƃTƒuƒRƒ“ƒsƒeƒ“ƒV[. ‘æ34‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ïŠwpW‰ï; 2021 Jun 18-20; “Þ—ÇiWEBŠJÃjD
    40. ŽíŽsq’ˆA”ª–ØMˆêA‚è–ƒ”üA–x]’åŽuA‚ˆä“Þ”üA’Ò@Œ³”ü. ƒRƒƒi‰Ð‚É‚¨‚¯‚éŠwZ¶Šˆ‚ÍŠ´õƒŠƒXƒNˆöŽq‚Å‚Í‚È‚¢. ‘æ46‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2021 Jul 4; •xŽR.
    41. ’Ò@t]AŒÜ\—’“oAŽíŽsq’ˆA˜a“c‘ñ–çA¬¼“¹—YA“n•Óˆê—m. •xŽRŒ§‚É‚¨‚¯‚éVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õ¬Ž™‚Ì—Õ°ÇóA“Á‚ÉškŠo–¡ŠoˆÙí‚ɂ‚¢‚Ä. ‘æ46‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2021 Jul 4; ‚‰ª.
    42. ’|“à–œ•FA‘«—§—YˆêDP1H1D3‚̃Rƒs[”‘½Œ^‚É‚æ‚錴”­«ü–щ^“®•s‘SÇ—áD‘æ16‰ñ“ú–{¬Ž™Ž¨•@ˆôA‰ÈŠw‰ï; 2021 Jul 8-9; ‘åã.
    43. Hirono K, Tsuboi K, Takarada S, Oguri M, Okabe M, Miyao N, Nakaoka H, Ibuki K, Ozawa S. ƒVƒ“ƒzKƒVJƒEƒ€FS‹ØÇ‚ÌŠî‘b‚Æ—Õ°‚̉˂¯‹´‚ð’T‚é. The elucidation of thromboembolic events and its risk factor in the patients with left ventricular noncompaction. ‘æ57‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïG2021 Jul 9-11; WebŠJÃ.
    44. Hirono K, Tsuboi K, Takarada S, Oguri M, Okabe M, Miyao N, Nakaoka H, Ibuki K, Ozawa S. ‰ï’·ÜŒó•âu‰‰ The elucidation of thromboembolic events and its risk factor in the patients with left ventricular noncompaction. ‘æ57‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïG2021 Jul 9-11; WebŠJÃ.
    45. ¬àVˆ»‰ÀA›“c^–çA‰ª•”^ŽqA‹{”ö¬–¾AˆÉŒ\“ñ˜YAœA–ìŒbˆêAŽs“c•™Žq. ¶ŽºS‹Øãk–§‰»áŠQ‚É‚¨‚¯‚é”ñãk–§‰»‘w/ãk–§‰»‘w”ä(N/C”ä)‚Ì‘ÙŽ™Šú‚©‚ço¶Œã‚É‘‘å‚·‚é. ‘æ57‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïG2021 Jul 9-11; WebŠJÃ.
    46. ˆÉŒ\“ñ˜YA‹{”ö¬–¾A’‡‰ª‰pKA¬àVˆ»‰ÀAœA–ìŒbˆêA“Œ“c–¾•FA–سÆA–F‘º’¼Ž÷. ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“ PAVSD BT shuntpŒã‚ÉSpO2’ቺ “®–¬ŠÇ‚ªŠJ‚¢‚Ä‚¢‚é‚̂ŃXƒeƒ“ƒg“ü‚ê‚Ä‚à—Ç‚¢‚Å‚·‚©? ‘æ57‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïG2021 Jul 9-11; WebŠJÃ.
    47. ˆÉŒ\“ñ˜YA›“c^–çA’‡‰ª‰pKA¬àVˆ»‰ÀAœA–ìŒbˆêA–سÆA’¹’Ë‘å•ãA“Œ“cº•FA–F‘º’¼Ž÷. ’PSŽºzŠÂSŽ¾Š³Ž™‚ւ̉ߓx‚ȉ¡Šu–Œ–Dk‚Íd“Ä‚È‘Ì”x“®–¬‘¤•›ŒŒŠÇ‘¶‚ÌŒ´ˆö‚ƂȂ肤‚é. ‘æ57‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïG2021 Jul 9-11; WebŠJÃ.
    48. ’‡‰ª‰pKA›“c^–çAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêA“cŒû‰ë“oA’¹’Ë‘å‰îA“Œ“cº•FA–F‘º’¼Ž÷. •ÂÇ«”ì‘åŒ^S‹ØÇpŒã‚Ì㎺«•p”‚É‚—p—ʃÀŽÕ’f–ò‚ª—LŒø‚Å‚ ‚Á‚½NoonanÇŒóŒQ‚̈ê—á. ‘æ57‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïG2021 Jul 9-11; WebŠJÃ.
    49. Ž›¼•ä”gA•Ä“c“¿ŽqAV‹ŠG—¢A“c’†’qŽqA–ؗ•ŽqA’†“‡²rA•Ä“c@“NAìè—TŽqA“c‘ºŒ«‘¾˜YA‹g“cärD‘½EŽí‚̉î“ü‚É‚æ‚莙‚Ì—ÇD‚Ȏ󂯗e‚ꂪ“¾‚ç‚ꂽ”DP21T‘OŠú”j…‚̈ê—áD‘æ57‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2021 July 11?13; ‹{èDiƒnƒCƒuƒŠƒbƒhj
    50. ŽR“c´‹MA“c‘ºŒ«‘¾˜YA’·‰ªvGA’––”’qŽÀAìè—TŽqA–q–{—D”üA‹g“cärDHaemophilus parainfluenzae‚ÌãO–Ñ–Œ—r–Œ‰Š‚Æ‘ÙŽ™‰ŠÇ‚É‚æ‚趉ºŽˆ“®–¬ŒŒð‚ð”­Ç‚µ‚½‘ŽYŽ™D‘æ57‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2021 July 11?13; ‹{èDiƒnƒCƒuƒŠƒbƒhj
    51. Ž›‰ºV‘¾˜YA“c’†•ü”üA’·X–œ—¢ŽqA‘«—§—YˆêDŽvtŠú‘”­Ç‚ðŒ_‹@‚ÉTempleÇŒóŒQ‚Æf’f‚µ‚½1—áD‘æ322‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ïG2021 Jun 13G•Ÿˆä.
    52. ¼ŽR^–¢AŽ›‰ºV‘¾˜YA‚ú±–ƒ”üA’·X–œ—¢ŽqA‘«—§—YˆêA’––”’qŽÀAìè—TŽqD«‘B‚Ì“¯’肪¢“ï‚Å‚ ‚Á‚½æ“V«ƒŠƒ|ƒCƒh‰ßŒ`¬Ç‚Ì1—áD‘æ322‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ïG2021 Jun 13G•Ÿˆä.
    53. ‘«—§—YˆêD“Á•Êu‰‰u¬Ž™‹C“¹ˆÙ•¨‚Ìf’f‚Æ—\–hvD‘æ68‰ñ“ú–{Ž¨•@ˆôA‰ÈŠw‰ï’†•”’n•û•”‰ï˜A‡‰ï; 2021 Jul 17; WEBŠJÃ.
    54. ‘«—§—YˆêDƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u¬Ž™šb‘§Ž¡—Âɂ¨‚¯‚é‹z“ü—Ö@‚ÌV‚½‚Ȉʒu‚¯`¢ŠE‚̃KƒCƒhƒ‰ƒCƒ“‚©‚ç`vD“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï‘æ7‰ñ—Õ°Œ¤‹†Žx‰‡ƒZƒ~ƒi[; 2021 Aug 29; WEBŠJÃ.
    55. ¼‹´—SŽ÷A¼ŽR^–¢A’؈䗢A‹{”ö¬–¾A’‡‰ª‰pKAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêA‘«—§—Yˆê. “–‰@‚É‚¨‚¯‚éìè•a‹}«Šú 3rd lineƒCƒ“ƒtƒŠƒLƒVƒ}ƒuŽ¡—ÂɊւ·‚é—LŒø«‚ÌŒŸ“¢D‘æ56‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ïG2021 Aug 29GWEBŠJÃ.
    56. ŽíŽsq’ˆ. •xŽRŽs—§ŠwZVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ‘ÎôŒŸ“¢‰ï‹c‚ÌŠT—v. ‘æ60‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï; 2021 Oct 3; WEBŠJÃ.
    57. ûüú±–ƒ”üDŽq‚Ç‚à‚ÌVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ@`ÅV‚Ì’mŒ©`DiƒVƒ“ƒ|ƒWƒEƒ€uVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ‚ÆŽq‚Ç‚à‚½‚¿‚̶Šˆ`•xŽRƒXƒ^ƒCƒ‹‚ð‹‚ß‚Ä`vj. ‘æ60‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï; 2021 Oct 3; WEBŠJÃ.
    58. “y“c‹ÅŽqAˆäã^—ŽqA–k£»ŽqA’Ò¬–é‰ÂAŽRè‹P”üA“c’†•ü”üA¼‘ºŒ’‘¾A•lè@ŒiA‘«—§—YˆêAˆîŽ›G–MDƒGƒRƒ`ƒ‹’²¸•xŽRƒ†ƒjƒbƒgƒZƒ“ƒ^[ 10”N‚Ì‚ ‚ä‚݇@D‘æ60‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï; 2021 Oct 3; WEBŠJÃ.
    59. ¼‘ºŒ’‘¾Aˆäã^—ŽqA–k£»ŽqA’Ò¬–é‰ÂAŽRè‹P”üA“y“c‹ÅŽqA˜a“c‘ñ–çA“c’†•ü”üAŽOàV@ŒbA•lè@ŒiA´…’‰“¹A‘«—§—YˆêAˆîŽ›G–MDƒGƒRƒ`ƒ‹’²¸•xŽRƒ†ƒjƒbƒgƒZƒ“ƒ^[ 10”N‚Ì‚ ‚ä‚݇AD‘æ60‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï; 2021 Oct 3; WEBŠJÃ.
    60. ‘«—§—YˆêDƒVƒ“ƒ|ƒWƒEƒ€u‹C“¹ƒAƒŒƒ‹ƒM[‚Ì•¹‘¶Ç‚ª—^‚¦‚éƒCƒ“ƒpƒNƒgF”ì–žvD ‘æ70‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï; 2021 Oct 8-10; ‰¡•l.
    61. ”ÂàVŽõŽqA‹à’J‹v”üŽqA‘«—§—YˆêDƒVƒ“ƒ|ƒWƒEƒ€u¶ŠˆŠÂ‹«‰˜õ‚ƃAƒŒƒ‹ƒM[F‰©»‚ƃAƒŒƒ‹ƒM[v. ‘æ70‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï; 2021 Oct 8-10; ‰¡•l.
    62. ˜a“c‘ñ–çA‘«—§—YˆêA‘ºã«Œ[AˆÉ“¡–õ“TA”ÂàVŽõŽqA“y“c‹ÅŽqA¼‘ºŒ’‘¾A•lè@ŒiAˆîŽ›G–M. •ê‘Ì‹i‰Œ‚Æ“ûŽ™‚Ìšb–‚¨‚æ‚Ñšb‘§”­Ç‚Æ‚ÌŠÖ˜Aˆê‚±‚Ç‚à‚ÌŒ’N‚Ɗ‹«‚ÉŠÖ‚·‚é‘S‘’²¸iƒGƒRƒ`ƒ‹’²¸j. ‘æ70‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï; 2021 Oct 8-10; ‰¡•l.
    63. ‰Á“¡‘וãAˆÉ“¡–õ“TA‹g“cKˆêA•Ÿ‰Æ’CŽ÷A•Ÿ•y—F”nA‚‹´‹•½A¡–ì@“NAŒã“¡@÷A“c’†‹Å¶AŽè’˃ˆê˜YA¼èŠ°ŽiA’·”ö‚݂ÂÙA’†‘ºDˆêA‘«—§—YˆêDƒAƒŒƒ‹ƒM[Ž¾Š³‚Ì‘½—l«A¶ŠˆŽÀ‘Ô‚ð”cˆ¬‚·‚邽‚߂̉uŠwŒ¤‹†ƒpƒCƒƒbƒgƒXƒ^ƒfƒB‚̉ۑè. ‘æ70‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï; 2021 Oct 8-10; ‰¡•l.
    64. ŽíŽsq’ˆA‚è–ƒ”üA”ª–ØMˆêA’Ò@t]AŒÜ\—’“oA‚ˆä“Þ”ü. •xŽRŒ§‚É‚¨‚¯‚éVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õ¬Ž™‚ð„‚é•ïŠ‡“I‘Ήž@‘æ3•ñ@‹³ˆç‚ƈã—Â̘AŒg@Žq‚Ç‚à‚½‚¿‚ÌŒ’N”íŠQ’²¸. ‘æ53‰ñ“ú–{¬Ž™Š´õÇŠw‰ï‘‰ïEŠwpW‰ï; 2021 Oct 9-10; WEBŠJÃ.
    65. ŒÜ\—’“oAŽíŽsq’ˆA’Ò@t]A˜a“c‘ñ–çA¬¼“¹—YA“n•Óˆê—m. •xŽRŒ§‚É‚¨‚¯‚éVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õ¬Ž™‚ð„‚é•ïŠ‡“I‘Ήž(‘æ1•ñ)@î•ñE‰Û‘苤—L‚ð„‚éƒVƒXƒeƒ€ì‚è‚ÆŽ–Œã‘Ήž. ‘æ53‰ñ“ú–{¬Ž™Š´õÇŠw‰ï‘‰ïEŠwpW‰ï; 2021 Oct 9-10; WEBŠJÃ.
    66. ’Ò@t]AŒÜ\—’“oAŽíŽsq’ˆA˜a“c‘ñ–çA¬¼“¹—YA“n•Óˆê—m. •xŽRŒ§‚É‚¨‚¯‚éVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õ¬Ž™‚ð„‚é•ïŠ‡“I‘Ήž(‘æ2•ñ)@—Õ°ÇóA“Á‚ÉškŠo–¡ŠoˆÙí‚ɂ‚¢‚Ä. ‘æ53‰ñ“ú–{¬Ž™Š´õÇŠw‰ï‘‰ïEŠwpW‰ï; 2021 Oct 9-10; WEBŠJÃ.
    67. ’‡‰ª‰pKA›“c^–çA¼ŽR^–¢A’؈䗢A‰ª•”^ŽqA‹{”ö¬–¾AˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêAŽs“c•™Žq. S‘©Œ^S‹ØÇ‚É—ÞŽ—‚µ‚½ŒŒs“®‘Ô‚ð’æ‚·‚鶎ºS‹Øãk–§‰»áŠQ‚Ì—\Œã’²¸. ‘æ30‰ñ¬Ž™S‹ØŽ¾Š³Šw‰ï; 2021 Oct 16; WebŠJÃ.
    68. ‘“c‘×”VA‰¬–ì‰À‘ãAX‰º@ŠxA¼”öŽü˜NA“yˆä—IŽiAã“c˜a—˜A—Ñ@’mGA˜e@Œ¤Ž©AVŠ_‹`•vA›“c^–çA’‡‰ª‰pKAœA–ìŒbˆê. MYBPC3ˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚½¶ŽºS‹Øãk–§‰»áŠQ‚ÌEbstein•a‡•¹—á. ‘æ30‰ñ¬Ž™S‹ØŽ¾Š³Šw‰ï; 2021 Oct 16; WebŠJÃ.
    69. ‰Á“¡‘וãAŽ›‰ºV‘¾˜YA‚è–ƒ”üA‘«—§—Yˆê. 1Δ­Ç‚ÅŽvtŠú‚É‚È‚Á‚ÄŽ¡—Ã’ïR«‚Æ‚È‚Á‚½“Á”­«”xƒwƒ‚ƒWƒfƒ[ƒVƒX‚̈ê—á. ‘æ35‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2021 Oct 22-23; WEBŠJÃ.
    70. ‰Á“¡‘וãA‘«—§—YˆêA“ñ‘º¹Ž÷A‘ê‘ò‘ôŒÈA“¡àV—²•v. ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“‚Ì‚³‚ç‚È‚é•‹y‚ÉŒü‚¯‚½‰Û‘è. ‘æ58‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2021 Nov 13-14; ‰¡•l.
    71. ‚£‹M•¶AŠLÀŒ\ŒáA’·”ö‚݂ÂÙA“ñ‘º¹Ž÷A‘ê‘ò‘ôŒÈA‹T“c@½A‘«—§—YˆêA“¡àV—²•vD¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“iJPGLj‚ÉŠî‚¢‚½¬Ž™šb‘§ƒRƒ“ƒgƒ[ƒ‹ƒeƒXƒgiC-ACTj‚Ì•]‰¿D‘æ58‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2021 Nov 13-14; ‰¡•l.
    72. ŽíŽsq’ˆ. ƒVƒ“ƒ|ƒWƒEƒ€. ЊQŽž‚É‹N‚±‚邱‚Æ‚Æ‚»‚̑Ήž`DMAT‚ÌŽÀÛ`. ‘æ79‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ïG2021 Nov 14; ‹à‘òiWEBŠJÃj
    73. ‘«—§—YˆêD‹³ˆçu‰‰u¬Ž™‚Ì‹CŠÇŽxšb‘§FÅV‚̘b‘è`¢ŠE‚̃KƒCƒhƒ‰ƒCƒ“‚Æ”äŠr‚µ‚Ä`D‘æ3‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï–k—¤’n•û‰ï; 2021 Nov 28; WEBŠJÃ.
    74. ‰Á“¡‘וãA˜a“c‘ñ–çA‘«—§—zŽqA‘«—§—Yˆê. “–‰@‚É‚¨‚¯‚é—‘‰©‚É‚æ‚éÁ‰»ŠÇƒAƒŒƒ‹ƒM[Ç—á‚Ì‚Ü‚Æ‚ß. ‘æ3‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï–k—¤’n•û‰ï; 2021 Nov 28; WEBŠJÃ.
    75. ‘«—§—YˆêD‹³ˆçu‰‰u¬Ž™‚ÌdÇšb‘§v. ‘æ30‰ñ‘Ûšb‘§Šw‰ï “ú–{E–kƒAƒWƒA•”‰ï; 2021 Dec 3-4; ‚’m.
    76. âˆä’m‰pA‹{”ö¬–¾A’‡‰ª‰pKAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêAŽR“cŒbŽqA‘«—§—Yˆê. S–[‘e“®‚É‚æ‚é•p–¬—U”­«S‹Øǂɑ΂µ‚ÄW’†Ž¡—ÊǗ‚ð—v‚µ‚½“ûŽ™—á. ‘æ333‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2021 Dec 5; WEBŠJÃ.
    77. “n•Óˆê—mAŽíŽsq’ˆAŒÜ\—’“oA˜a“c‘ñ–çA’Ò@t]A¬¼“¹—Y. •xŽRŒ§‚É‚¨‚¯‚éVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õ¬Ž™‚̕“I‘Ήž. ‘æ333‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2021 Dec 5; WEBŠJÃ.
    78. “Œ“cº•FAŒ³–ì@‘sA–سÆA–F‘º’¼Ž÷A‹{”ö¬–¾A’‡‰ª‰pKAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêAŠâú±G‹IA’†‘º‘¾’n. ‚“x‘“®–¬Š²•Ù‹t—¬‚𔺂Á‚½‘“®–¬Š²Ç‚Ì1—á. ‘æ333‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2021 Dec 5; WEBŠJÃ.
    79. ŽíŽsq’ˆ. Vaccine Hesitancy‚Ìl‚¦•û‚ƑΉž@`ƒƒNƒ`ƒ“ÚŽí‚ðçSçO‚·‚élX`. ‘æ80‰ñ“ú–{ŒöO‰q¶Šw‰ï‘‰ï; 2021 Dec 21-23; “Œ‹ž.
    80. –k£»ŽqA”©ŽRŠx‘åAˆäã^—ŽqAŽRèi’·ˆäj‹P”üA“c’†•ü”üA“y“c‹ÅŽqA¼‘ºŒ’‘¾A•lè@ŒiA‘«—§—YˆêAˆîŽ›G–MDƒGƒRƒ`ƒ‹’²¸•xŽRƒ†ƒjƒbƒgƒZƒ“ƒ^[ 10”N‚Ìi’»D‘æ80‰ñ“ú–{ŒöO‰q¶Šw‰ï‘‰ï; 2021 Dec 21-23; “Œ‹ž.

    2020”N

  • ’˜‘
    1. ‘«—§—YˆêD¡“ú‚ÌŽ¡—ÃŽwj2020”N“x”Å\Ž„‚Í‚±‚¤Ž¡—µ‚Ä‚¢‚éD•ŸˆäŽŸ–îA‚–Ø@½A¬Žºˆê¬•ÒD“Œ‹žFˆãŠw‘‰@F2020. ƒNƒ‹[ƒvÇŒóŒQDp1447-8.
    2. ‘«—§—YˆêD“úíf—Âɶ‚©‚·f—ÃKƒCƒhƒ‰ƒCƒ“UP-TO-DATE 2020?2021”N”ÅD–å˜e@FA¬Žºˆê¬A‹{’n—ÇŽ÷•ÒD‘åãFƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐF2020D¬Ž™šb‘§Dp957-62.
    3. ŽíŽsq’ˆD¡“ú‚̬Ž™Ž¡—ÃŽwj@‘æ17”ÅD…Œû@‰ëAŽs‹´@ŒõAèŽR@OAˆÉ“¡Gˆê•Ò. “Œ‹žFˆãŠw‘‰@G2020D‚P‹~‹}ˆã—Ã@”M’†ÇGp 18-9.
  • Œ´’˜
    1. Kigawa M, Tsuchida A, Tanaka T, Hamazaki K, Adachi Y, Saito S, Inadera H, and The Japan Environment and Childrenfs Study Group. Characteristics of postpartum Japanese mothers who were non-respondents to the Japan Environment and Childrenfs Study. J Pediatr Congenit Dis 2020 Jan; 6(1): 1-8.
    2. Morikawa E, Sasaki M, Yoshida K, Adachi Y, Odajima H, Akasawa A. Nationwide survey of the prevalence of wheeze, rhino-conjunctivitis, and eczema among Japanese children in 2015. Allergol Int. 2020 Jan; 69(1): 98-103.
    3. Itazawa T, Adachi Y, Takahashi Y, Miura K, Uehara Y, Kameda M, Kitamura T, Kuzume K, Tezuka J, Ito K, Ebisawa M. The severity of reaction after food challenges depends on the indication: A prospective multicenter study. Pediatr Allergy Immunol. 2020 Feb; 31(2): 167-74.
    4. Yoshida T, Matsumura K, Tsuchida A, Hamazaki K, Inadera H and Japan Environment and Childrenfs Study Group. Influence of parity and mode of delivery on mother?infant bonding: The Japan Environment and Childrenfs Study. J Affect Disord. 2020 Feb 15; 263: 516-20.
    5. Hirono K, Hata Y, Miyao N, Okabe M, Takarada S, Nakaoka H, Ibuki K, Ozawa S, Yoshimura N, Nishida N, Ichida F, Lvnc Study Collaborators. Left ventricular noncompaction and congenital heart disease increases the risk of congestive heart failure. J Clin Med. 2020 Mar 13; 9(3): 785.
    6. Miyao N, Hata Y, Izumi H, Nagaoka R, Oku Y, Takasaki I, Ishikawa T, Takarada S, Okabe M, Nakaoka H, Ibuki K, Ozawa S, Yoshida T, Hasegawa H, Makita N, Nishida N, Mori H, Ichida F, Hirono K. TBX5 R264K acts as a modifier to develop dilated cardiomyopathy in mice independently of T-box pathway. PLoS One. 2020 Apr 1; 15(4): e0227393.
    7. Tamura K, Williams EE, Dassios T, Pahuja A, Hunt KA, Murthy V, Bhat P, Bhat R, Milner A, Greenough A. End-tidal carbon dioxide levels during resuscitation and carbon dioxide levels in the immediate neonatal period and intraventricular haemorrhage. Eur J Pediatr. 2020 Apr; 179(4): 555-9.
    8. Nakaoka H, Tsuda E, Morita Y, Kurosaki K. Cardiac Function by Magnetic Resonance Imaging in Coronary Artery Occlusions After Kawasaki Disease. Circ J. 2020 Apr 24;84(5):792-8.
    9. Yuzawa K, Terui K, Toki T, Kanezaki R, Kobayashi A, Sato T, Kamio T, Kudo K, Sasaki S, Endo M, Ozono S, Nomura K, Ito E. Clinical, cytogenetic, and molecular analyses of 17 neonates with transient abnormal myelopoiesis and nonconstitutional trisomy 21. Pediatr Blood Cancer. 2020 Apr; 67(4): e28188.
    10. Takeuchi M, Kobayashi T, Biss T, Kamali F, Vear SI, Ho RH, Bajolle F, Loriot MA, Shaw K, Carleton BC, Hamberg AK, Wadelius M, Hirono K, Taguchi M, Wakamiya T, Yanagimachi M, Hirai K, Itoh K, Brandao LR, Ito S. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis. Pharmacogenomics J. 2020 Apr; 20(2): 306-319.
    11. Itazawa T, Kanatani KT, Hamazaki K, Inadera H, Tsuchida A, Tanaka T, Nakayama T, Tohshin G, Onishi K, Kurozawa Y, Adachi Y; Japan Environment, Childrenfs Study Group. The impact of exposure to desert dust on infants' symptoms and countermeasures to reduce the effects. Allergy. 2020 Jun; 75(6): 1435-45.
    12. Hirono K, Miyao N, Yoshinaga M, Nishihara E, Yasuda K, Tateno S, Ayusawa M, Sumitomo N, Horigome H, Iwamoto M, Takahashi H, Sato S, Kogaki S, Ohno S, Hata T, Hazeki D, Izumida N, Nagashima M, Ohta K, Tauchi N, Ushinohama H, Doi S, Ichida F; Study group on childhood cardiomyopathy in Japan. A significance of school screening electrocardiogram in the patients with ventricular noncompaction. Heart Vessels. 2020 Jul; 35(7): 985-95.
    13. Yoshida T, Hiraiwa A, Ibuki K, Makimoto M, Inomata S, Tamura K, Kawasaki Y, Ozawa S, Hirono K, Ichida F. Neurodevelopmental outcomes at three years for infants with CHD and VLBW. Pediatr Int. 2020 Jul; 62(7): 797-803.
    14. Saito Y, Matsumura K, Kageyama M, Kato Y, Ohta E, Sumi K, Futatani T, Yoshida T. Impact of prematurity and the CTG repeat length on outcomes in congenital myotonic dystrophy. BMC Res Notes. 2020 Jul 23; 13(1): 350.
    15. Hirono K, Hata Y, Miyao N, Okabe M, Takarada S, Nakaoka H, Ibuki K, Ozawa S, Origasa H, Nishida N, Ichida F; LVNC study collaborates. Increased burden of ion channel gene variants is related to distinct phenotypes in pediatric patients with left ventricular noncompaction. Circ Genom Precis Med. 2020 Aug; 13(4): e002940.
    16. Hiraiwa A, Ibuki K, Tanaka T, Hirono K, Miya K, Yoshimura N, Ichida F. Toddler neurodevelopmental outcomes are associated with School-Age IQ in children with single ventricle physiology. Semin Thorac Cardiovasc Surg. 2020 Summer; 32(2): 302-10.
    17. Sasaki M, Morikawa E, Yoshida K, Fukutomi Y, Adachi Y, Odajima H, Akasawa A. The prevalence of oral symptoms caused by rosaceae fruits and soybean consumption in children; A Japanese population-based survey. Allergol Int. 2020 Oct; 69(4): 610-5.
    18. Kanai T, Takeshita S, Kawamura Y, Kinoshita K, Nakatani K, Iwashima S, Takizawa Y, Hirono K, Mori K, Yoshida Y, Nonoyama S. The Combination of the Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as a Novel Predictor of Intravenous Immunoglobulin Resistance in Patients With Kawasaki Disease: A Multicenter Study. Heart Vessels. Oct; 35(10): 1463-72.
    19. Ishikawa T, Mishima H, Barc J, Takahashi MP, Hirono K, Terada S, Kowase S, Sato T, Mukai Y, Yui Y, Ohkubo K, Kimoto H, Watanabe H, Hata Y, Aiba T, Ohno S, Chishaki A, Shimizu W, Horie M, Ichida F, Nogami A, Yoshiura KI, Schott JJ, Makita N. Cardiac Emerinopathy: A non-syndromic nuclear envelopathy with increased risk of thromboembolic stroke due to progressive atrial standstill and left ventricular non-compaction. Circ Arrhythm Electrophysiol. 2020 Oct; 13(10): e008712.
    20. Miyazaki M, Tanaka T, Adachi Y, Miya K. Learning difficulties in Japanese schoolchildren with focal epilepsy. Brain Dev. 2020 Oct; 42(9): 655-62.
    21. Hiraiwa A, Kawasaki Y, Ibuki K, Hirono K, Matsui M, Yoshimura N, Origasa H, Oishi K, Ichida F. Brain development of children with single ventricle physiology or transposition of the great arteries: A longitudinal observation study. Semin Thorac Cardiovasc Surg. 2020 Winter; 32(4):936-44.
    22. Noguchi-Shinohara M, Domoto C, Yoshida T, Niwa K, Yuki-Nozaki S, Samuraki-Yokohama M, Sakai K, Hamaguchi T, Ono K, Iwasa K, Matsunari I, Komai K, Nakamura H, Yamada M. A new computerized assessment battery for cognition (C-ABC) to detect mild cognitive impairment and dementia around 5 min. PLoS One. 2020 Dec 11;15(12):e0243469.
    23. Oya Y, Watahiki D, Matsunaga M, Hirono K, Ichida F, Aoki M, Yoshimura N, Taguchi M. The pharmacokinetics of sildenafil may be affected by intestinal absorption rate in children admitted to the intensive care unit. Biol Pharm Bull. 2020 Dec 1; 43(12):1917-23.
    24. ˆî“c—S“ÞA¼ˆäŽOŽ}Aìè—TŽqA‹g“cär. Bayley”­’BŒŸ¸‚Ìc’f”äŠr‚É‚æ‚é‹É’áo¶‘ÌdŽ™‚Ì”­’B“Á’¥. ”]‚Æ”­’B 2020 Jan; 52(1): 6-21.
    25. H“cç—¢A‘å’ËŠxlAŽ™‹Ê—SˆêAŽÅ“c–¾˜aA’Þ@_”VAŒÃŽs@O. RƒCƒ“ƒtƒ‹ƒGƒ“ƒU–ò‚ðŠî‘bŽ¾Š³‚Ì‚È‚¢“ûŽ™‚̃Cƒ“ƒtƒ‹ƒGƒ“ƒUŠ³ŽÒ‚³‚ñ‚É“Š—^‚·‚é‚©”Û‚©. ¬Ž™‰È—Õ°2020 Mar; 73(3): 364-7.
    26. ’Þ@_”VA‰Íç³TŽiA“c‘º‰pˆê˜YAät‰zN’qAŒÃŽs”ü•äŽq. 6‚©ŒŽ`6Ζ¢–ž‚̬Ž™‚ւ̃Cƒ“ƒtƒ‹ƒGƒ“ƒUƒƒNƒ`ƒ“‚ÌÚŽí‚Í1‰ñ‚Å‚æ‚¢. ¬Ž™‰È—Õ°2020 Aug; 73(8): 1219-22.
    27. ŒÜ\—’“oA‘ºã”ü–çŽqA‹{è‚ ‚ä‚ÝA”ª–ØMˆêA“ˆ”ö@’qAŽíŽsq’ˆDHPVƒƒNƒ`ƒ“uÏ‹É“IŠ©§‚̈ꎞ’†Ž~v‚̎󂯎~‚ß•û‚ÆÚŽí‚ÉŠÖ‚·‚éEŽí•ÊˆÓŽ¯’²¸D¬Ž™‰È 2020 Sep 61(9): 1341-6.
  • Ç—á•ñ
    1. Hata Y, Oku Y, Taneichi H, Tanaka T, Igarashi N, Niida Y, Nishida N. Two autopsy cases of sudden unexpected death from Dravet syndrome with novel de novo SCN1A variants. Brain Dev. 2020 Feb; 42(2): 171-8.
    2. ’·‰ªvGA–q–{—D”üA’––”’qŽÀAꎓ¡@—IA“c‘ºŒ«‘¾˜YAìú±—TŽqA‹g“cärD”ñNP“IˆêŽ_‰»’‚‘f‹z“ü—Ö@‚ðŽ{s‚µ‚½dÇV¶Ž™–«”xŽ¾Š³‚̈ê—áD“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŽGŽD2020 Jan 56(1): 182-7.
    3. ‘¾“cˆÀFA’†’Ø‹v”TA“n•Óˆê—mAŽÂ茒‘¾˜Y. ƒRƒ‹ƒqƒ`ƒ“‚Æ’á—e—ʃsƒ‹‚ʼnü‘P‚µ‚½”ñ“TŒ^“I‰Æ‘°«’n’†ŠC”M‚Ì14ΗŽq—á. ¬Ž™Š´õ–Ɖu 2020 Aug; 32(3): 202-7.
    4. •½ˆäGŽqAŽíŽsq’ˆA˜a“c‘ñ–çA“c’†•ü”üA‘«—§—YˆêDf’f‚ɃKƒŠƒEƒ€ƒVƒ“ƒ`‚ª—LŒø‚Å‚ ‚Á‚½”]Žº• oƒVƒƒƒ“ƒg‚ÉŠÖ˜A‚µ‚½• o“àŠ´õ‚Ì1—áD¬Ž™‰È—Õ°2020 Nov; 73(11)F1525-30.
  • ‘à
    1. Szefler SJ, Fitzgerald DA, Adachi Y, Doull IJ, Fischer GB, Fletcher M, Hong J, Garcia-Marcos L, Pedersen S, Ostrem A, Sly PD, Williams S, Winders T, Zar HJ, Bush A, Lenney W. A worldwide charter for all children with asthma. Pediatr Pulmonol. 2020 May; 55(5): 1282-92.
    2. Arakawa H, Adachi Y, Ebisawa M, Fujisawa T; Committee for Japanese Pediatric Guideline for Childhood Asthma; Japanese Society of Pediatric Allergy and Clinical Immunology; Japanese Society of Allergology. Japanese guidelines for childhood asthma 2020. Allergol Int. 2020 Jul;69(3):314-30.
    3. ‘«—§—YˆêD¬Ž™Ž¾Š³f—Â̂½‚ß‚Ì•a‘Ô¶—1FƒNƒ‹[ƒvÇŒóŒQD¬Ž™“à‰È 2020; 52: s55-9 .
    4. ŽíŽsq’ˆDVaccine Hesitancy‚ÆVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ(COVID-19)D•ÊûBio Clinica: –«‰ŠÇ‚ÆŽ¾Š³ 2020 Jan; 9(1): 128-31.
    5. ŽíŽsq’ˆD¢ŠE‚Ƃ킪‘‚É‚¨‚¯‚éVaccine Hesitancy‚Æ‚»‚Ì‹ºˆÐDBIO Clinica 2020 Feb; 35(2): 136-9.
    6. Ž­“‡”ü—F‹IA“c‘º@ˆ¤A‹g“cärDyNIICU‚ÅŠÅŒìŽt‚ðˆç‚Ä‚éz’´’áo¶‘ÌdŽ™‚ÌŠÇ—‚ÅŠw‚Ԃׂ«’mŽ¯‚ð®—‚µ‚½ƒc[ƒ‹‚Ì쬂Ɗˆ—p‚ÌŽÀÛ@ŒoŒ±”N”2”NˆÈ‰º‚ªŽå—Í‚ÌŠÅŒìƒ`[ƒ€‚É‚¨‚¢‚ÄA•sˆÀŒyŒ¸‚ÆŠÅŒì‚Ì•W€‰»A‚³‚ç‚Ȃ鎿Œüã‚ð–ÚŽw‚µ‚½Œ»ê–Úü‚Ì‹³ˆçƒVƒXƒeƒ€D‚±‚Ç‚à‚ƉƑ°‚̃PƒA 2020 Feb: 14(6): 29-47.
    7. ‹g“cärD y[[•KŒg]]êUˆã‚ÆŽw“±ˆã‚Ì‚½‚ß‚ÌV¶Ž™f—Óž’B–Ú•WzŒŸ¸@ƒ‚ƒjƒ^[@ƒxƒbƒhƒTƒCƒhƒ‚ƒjƒ^[@SpO2DŽüŽYŠúˆãŠw 2020 Apr; 50(4): 496-8.
    8. œA–ìŒbˆê. S‹Ø‰Š‚ª‹^‚í‚ê‚é‚Æ‚«. ¬Ž™‰Èf—à 2020 Apr; 83(‘): 282-6.
    9. œA–ìŒbˆê. æ“V«SŽ¾Š³A”x‚ŒŒˆ³AS‹ØÇ@S‹ØÇ. ¬Ž™‰Èf—à 2020 May; 83(5): 647-52.
    10. ŽíŽsq’ˆDŽq‚Ç‚à‚Ì”­’B‚ÆŽ–ŒÌ—\–hD‘–¯¶Šˆ 2020 Jun; 94(6): 1-3.
    11. ‹g“cärDŽüŽYŠú‚ÌÅVî•ñ@C--A--T--C--H THE NOW@’鉤؊J•ª•Ø‚ƕꎙŠÖŒWV’mŒ©@ƒGƒRƒ`ƒ‹’²¸AŽYŒã1”NŽž“_‚ł̃{ƒ“ƒfƒBƒ“ƒO‚ð•]‰¿DƒyƒŠƒlƒCƒ^ƒ‹ƒPƒA 2020 Oct; 39(10): 1082-6.
    12. âV“¡@Ž AŒKŠÔ’¼ŽuA‹g“cärDyHTLV--1•êŽqŠ´õ‚ð‚à‚Á‚Æ’m‚낤zŠe’nˆæ‚Ì•êŽqŠ´õ—\–h‘Îô‚ÌŽÀÛ@•xŽRŒ§ŽüŽYŠúˆãŠw 2020 Oct; 50(10): 1751-4.
    13. ŽíŽsq’ˆDyŽ™“¶‹s‘Ò‚ðŠw‚Ôz‘ŸŠí’ñ‹Ÿ‚ÆŽ™“¶‹s‘ÒD‹~‹}ˆãŠw2020 Nov; 44(11): 1470-5.

  • 2020”NŠw‰ï•ñ
    1. Honjo S, Murakami Y, Odajima H, Adachi Y, Yoshida K, Ohya Y, Iino A. Sex difference, severity of asthma and exercise-induced wheezing among children. Japanese Allergology Society/World Allergy Organization Joint Congress, 2020 Sep 17-20; Kyoto(online).
    2. œA–ìŒbˆêAˆÉŒ\“ñû¶A¬àVˆ»‰ÀA–F‘º’¼Ž÷AŽs“c•™ŽqA•½ˆä’‰˜a. ŒÇ—§«‰EŽº’áŒ`¬‚ɂĉES•s‘S‚ð’悵‚½1—á. ‘æ22‰ñ¬læ“V«SŽ¾Š³Šw‰ï‘‰ïEŠwpW‰ï; 2020 Jan 17-19; “Œ‹ž.
    3. ˆÉŒ\“ñ˜YA‹{”ö¬–¾A’‡‰ª‰pKA¬àVˆ»‰ÀAœA–ìŒbˆêA’¹’Ë‘å‰îA“Œ“cº•FA–F‘º’¼Ž÷.@”NŠú‚©‚ç¬lŠú‚É‘å“®–¬‹·ó•a•Ï‚ɑ΂µ‚ÄlHŒŒŠÇ’uŠ·p‚ðs‚Á‚½5Ç—á‚ÌŒŸ“¢. ‘æ22‰ñ¬læ“V«SŽ¾Š³Šw‰ï‘‰ïEŠwpW‰ï; 2020 Jan 17-19; “Œ‹ž.
    4. ˆÉŒ\“ñ˜YA‰ª•”^ŽqA‹{”ö¬–¾A’‡‰ª‰pKA¬àVˆ»‰ÀAœA–ìŒbˆê. “®–¬ŠÇƒXƒeƒ“ƒg—¯’up‚ðŽŽ‚Ý‚½“®–¬ŠÇˆË‘¶«”xŒŒ—¬«SŽ¾Š³‚Ì3Ç—á. ‘æ31‰ñ“ú–{Pediatric Interventional CardiologyŠw‰ïŠwpW‰ï; 2020 Jan 23-25; “ß”e.
    5. ’‡‰ª‰pKA›“c^–çA‰ª•”^ŽqA‹{”ö¬–¾AˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆê.@ ŒŒð«•ÂÇŒŒŠÇ‚ɑ΂·‚éƒJƒe[ƒeƒ‹Ž¡—Âɂæ‚éÄŠJ’Ê‚Ì“–‰@‚Å‚ÌŽæ‚è‘g‚Ý.@ ‘æ31‰ñ“ú–{Pediatric Interventional CardiologyŠw‰ïŠwpW‰ï; 2020 Jan 23-25; “ß”e.
    6. ‘ŠJË•½A’؈䗢A´…@”VA‰Á“¡‘וãAûüú±–ƒ”üA“c’†•ü”üA‹{@ˆêŽuA‘«—§—YˆêD“–‰È‚ŃGƒxƒƒŠƒ€ƒX‚𓱓ü‚µ‚½Œ‹ß«d‰»Ç‚̬Ž™‚Q—á‚É‚¨‚¯‚éf—ØAŒgD‘æ77‰ñ¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ïG2020 Feb 2G‹à‘ò.
    7. ‘å–î—RŠó”TA¼‰iŒõŠóAœA–ìŒbˆêAŽs“c•™ŽqA–سÆA–F‘º’¼Ž÷A“cŒû‰ë“o. ¬Ž™ICUŠ³ŽÒ‚É‚¨‚¯‚éƒVƒ‹ƒfƒiƒtƒBƒ‹‚Ì‘Ì“à“®‘Ô•Ï“®‹@\. “ú–{–òŠw‰ï‘æ140”N‰ï; 2020 Mar 25-28; ‹ž“s(ƒIƒ“ƒ‰ƒCƒ“).
    8. Ž›‰ºV‘¾˜YA㌴ŠG—A‰i“c’m—TA¼–{^–¾A‘¾“c’mŽqAŽRŒû•üŒbA‹gˆäŒ[‰îA“à–ØN”ŽA–xì—æŽq. ƒIƒNƒgƒŒƒIƒ`ƒhLARŽ¡—ÂðŒp‘±‚µ‚Ä‚¢‚éKCNJ11ˆâ“`Žq•ƒ—R—ˆ•ÐƒAƒŠƒ‹•ÏˆÙ‚ð—L‚·‚éˆê—á. ‘æ93‰ñ“ú–{“à•ª”åŠw‰ïŠwp‘‰ï 2020 Jul 20-Aug 31; •l¼(ƒIƒ“ƒ‰ƒCƒ“).
    9. Ž›‰ºV‘¾˜YA‹gˆäŒ[‰îA“à–ØN”ŽA–xì—æŽq. Mesalazine•s‘Ï«’×ᇫ‘å’°‰Š‚𔺂Á‚½Basedow•a—Ž™‚ÌŽ¡—ÃŒo‰ßD‘æ93‰ñ“ú–{“à•ª”åŠw‰ïŠwp‘‰ï 2020 Jul 20-Aug 31; •l¼(ƒIƒ“ƒ‰ƒCƒ“).
    10. ¬ŒI^lAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêAŽíŽsq’ˆA‘«—§—Yˆê. SŒ´«ƒVƒ‡ƒbƒN‚ð’悵‚½“ú—î14‚ÌV¶Ž™—áBŠî‘bŽ¾Š³‚Íc ‘æ33‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï; 2020 Jun 21-22; WEBŠJÃ.
    11. œA–ìŒbˆê. ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“@ŠwZS‘ŸŒŸf‚ðŠˆ‚©‚·: ¬Ž™“Ë‘RŽ€—\–h‚ɉʂ½‚·–ðŠ„@uS‹ØÇv. ‘æ84‰ñ“ú–{zŠÂŠíŠw‰ï; 2020 Jul 27- Aug 2; ‹ž“s(ƒIƒ“ƒ‰ƒCƒ“).
    12. ‘«—§—YˆêDƒ[ƒNƒVƒ‡ƒbƒvu¬Ž™šb‘§FŽ¡—ÂÌÅ‘Oüv.@‘æ1‰ñ“ú–{šb‘§Šw‰ï‘‰ïŠwp‘å‰ïA2020 Aug 8-9; ‘åã(ƒIƒ“ƒ‰ƒCƒ“).
    13. ‘«—§—YˆêDƒXƒ|ƒ“ƒT[ƒhƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹CŠÇŽxšb‘§‚Ì’·ŠúŠÇ—‚É‚¨‚¯‚é‹z“ü—Ö@v. ‘æ1‰ñ“ú–{šb‘§Šw‰ï‘‰ïŠwp‘å‰ïA2020 Aug 8-9; ‘åã(ƒIƒ“ƒ‰ƒCƒ“).
    14. ‘ŠJË•½A“c’†•ü”üA“c’‡çHA‹{@ˆêŽuA‘«—§—YˆêAŽOŒ´@OD•Ö’†ƒJƒ‹ƒvƒƒeƒNƒ`ƒ“‚ª•a¨‚Ì”cˆ¬‚É—L—p‚Å‚ ‚Á‚½Ž©•ÂƒXƒyƒNƒgƒ‰ƒ€Ç‚Ì‚ ‚éƒNƒ[ƒ“•a‚Ì—Ž™—áD‘æ62‰ñ“ú–{¬Ž™_ŒoŠw‰ïŠwpW‰ïG2020 Aug 18-20CWEBŠJÃ.
    15. ŽíŽsq’ˆD‘‡ƒVƒ“ƒ|ƒWƒEƒ€@“­‚«•û‰üŠv‚Æ«—ˆ‚̬Ž™ˆã—Ã’ñ‹Ÿ‘̧‚ÌŽpD‘æ123‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ïG2020 Aug 21-23G_ŒË(ƒIƒ“ƒ‰ƒCƒ“).
    16. ûüè–ƒ”üA•Ÿ“‡@—DA‰Á“¡‘וãA‘ŠJË•½A’‡‰ª²’qŽqA“c’†•ü”üAŽíŽsq’ˆA‘¾“cˆÀFA’†’Ø‹v”TA‘«—§—YˆêD‘‰t‚©‚烀ƒ“ƒvƒXƒEƒCƒ‹ƒXƒƒNƒ`ƒ“Š”‚ªŒŸo‚³‚ꂽ‹}«”]‰Š‚̈ê—áD‘æ123‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ïG2020 Aug 21-23G_ŒË(ƒIƒ“ƒ‰ƒCƒ“).
    17. ‰Á“¡‘וã, ’†‘ºŒ’‘¾˜Y, •Ÿ“‡@—D, •½ˆäGŽq, ‘ŠJË•½, ’‡‰ª²’qŽq, ‚è–ƒ”ü, ŽíŽsq’ˆ, ‘«—§—Yˆê. ”]Žº• oƒVƒƒƒ“ƒg‚É‚æ‚é• –Œ‰Š‚Ìf’f‚ɃKƒŠƒEƒ€ƒVƒ“ƒ`ƒOƒ‰ƒtƒB‚ª—L—p‚Å‚ ‚Á‚½2—á. ‘æ123‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ïG2020 Aug 21-23G_ŒË(ƒIƒ“ƒ‰ƒCƒ“).
    18. ‰Á“¡‘וãAˆÉ“¡–õ“TA’·”ö‚݂ÂÙA‘ºˆäG¶A•Ÿ‰Æ’CŽ÷AŽè’˃ˆê˜YA²“¡‚³‚­‚çA“¡àV—²•vA‘«—§—YˆêD¬Ž™ƒAƒŒƒ‹ƒM[‹³ˆçƒZƒ~ƒi[‚ÌŠT—v‚Æ‚»‚ÌŠwKŒø‰Ê‚ɂ‚¢‚ÄD‘æ123‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ïG2020 Aug 21-23G_ŒË(ƒIƒ“ƒ‰ƒCƒ“).
    19. •Ÿ“‡@—DA’†‘ºŒ’‘¾˜YA‘ŠJË•½A‰Á“¡‘וãA’‡‰ª²’qŽqA‚è–ƒ”üA’†’Ø‹v”TAŽíŽsq’ˆA‘«—§—Yˆê. ƒuƒhƒE‹…‹Û«”M—l”畆njóŒQ‚Æ‚ÌŠÓ•Ê‚É‹ê—¶‚µ‚½ƒqƒgƒpƒŒƒRƒEƒCƒ‹ƒXŠ´õÇ‚ÌV¶Ž™—á. ‘æ123‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï@2020 Aug21-23G_ŒË(ƒIƒ“ƒ‰ƒCƒ“).
    20. ’؈䗢A´…@”VA‹{”ö¬–¾A’‡‰ª‰pKAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêA’¹’Ë‘å‰îA“Œ“cº•FA–F‘º’¼Ž÷AŽR–{^—RA–k–ì—T”VA’†ì@—º. V¶Ž™‚̓«“û‚Ñ‹¹‚ɑ΂µ‚ăŠƒsƒIƒh[ƒ‹ƒŠƒ“ƒpŠÇ‘¢‰e‚ðŽ{s‚µAŠO‰È“I‰î“ü‚ð‰ñ”ð‚µ“¾‚½ˆê—á. ‘æ123‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï 2020 Aug21-23G_ŒË(ƒIƒ“ƒ‰ƒCƒ“).
    21. V“c‰ë•FA‰ê—ˆ“T”VA¼ŽR˜aFA–â“cç»AŽç’J rA´…’¼Ž÷AŽíŽsq’ˆAˆÉ“¡‰p‰îA’†—Ñ—m‰îA‘¾“c–M—Y.Žq‚Ç‚à‚Ì‹~‹}ˆã—Âð‚É‚È‚¤ŽŸ¢‘ã‚ðˆç¬‚·‚é`¬Ž™‹~‹}ˆã—˳ˆç‚Ì‚±‚ê‚©‚ç`@ƒvƒŒƒzƒXƒsƒ^ƒ‹‚̬Ž™‹~‹}‹³ˆç@“àˆö«‚ð’†S‚É.‘æ23‰ñ“ú–{—Õ°‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ïG2020 Aug 27-28; “Œ‹ž(ƒIƒ“ƒ‰ƒCƒ“).
    22. ‘«—§—YˆêD‹³ˆçu‰‰u¬Ž™‹CŠÇŽxšb‘§f—Âɂ¨‚¯‚é‰Û‘èFƒKƒCƒhƒ‰ƒCƒ“‰ü’ù‚̃|ƒCƒ“ƒgvA‘æ69‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ïE¢ŠEƒAƒŒƒ‹ƒM[‹@\‡“¯‰ï‹c 2020 Sep 17- Oct 20; (webŠJÃ).
    23. Kato T, Ito Y, Yamamoto T, Shimizu M, Adachi Y, Kadowaki M, Adachi Y. An evaluation of the effects of Kakkonto in combination with dietary advice in children with food allergies through a non-randomized controlled trial . ‘æ69‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ïE¢ŠEƒAƒŒƒ‹ƒM[‹@\‡“¯‰ï‹c2020 Sep 17- Oct 20; (webŠJÃ).
    24. œA–ìŒbˆêA@“à~A›“c^–çA’‡‰ª‰pKAˆÉŒ\“ñ˜YA¬àVˆ»‰À. ŒÇ—§«‰EŽº’áŒ`¬‚Ì—Õ°‘œ. ‘æ29‰ñ“ú–{¬Ž™S‹ØŽ¾Š³Šw‰ï; 2020 Oct 10; “Œ‹žiƒIƒ“ƒ‰ƒCƒ“jDiŠw‰ïÅ—DG‰‰‘èÜŽóÜj
    25. –{ŠÔ—F‰ÀŽqAœA–ìŒbˆêA‘ŸºNM. RYR2ˆâ“`Žq‚̃~ƒXƒZƒ“ƒX•ÏˆÙ‚ð”F‚ß‚½¶Žºãk–§‰»áŠQ‚Ì‚P—á. ‘æ29‰ñ“ú–{¬Ž™S‹ØŽ¾Š³Šw‰ï; 2020 Oct 10; “Œ‹ž(ƒIƒ“ƒ‰ƒCƒ“).
    26. ’‡‰ª‰pKA›“c^–çA‰ª•”^ŽqAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêAŽs“c•™Žq. ƒVƒ“ƒ|ƒWƒEƒ€ Functional analysis of the specific microRNA encapsulated in endothelial microparticles contribute to the progression of vasculitis in acute Kawasaki Disease using in silico. ‘æ40‰ñ“ú–{ìè•aŠw‰ïŠwpW‰ï; 2020 Oct 30-31; ’Ã(ƒIƒ“ƒ‰ƒCƒ“).
    27. ‘«—§—YˆêD‹³ˆçƒZƒ~ƒi[uV‚½‚ȬŽ™‹CŠÇŽxšb‘§‚ÌŽ¡—ÃEŠÇ—‚ɂ‚¢‚Ä`JPGL2020‚ʼn½‚ª•Ï‚í‚Á‚½‚©`v. ‘æ57‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï 2020 Oct 31-Nov 30; (WEBŠJÃ).
    28. ‰Á“¡‘וãA‰ªèŽjŽqA•½ŠâáŽqA“ñ‘º¹Ž÷AˆÀ•y‘fŽqA–{‘º’m‰ØŽqA‘ê‘ò‘ôŒÈA‰ºð’¼Ž÷AXì‚Ý‚«. “ú–{ƒAƒŒƒ‹ƒM[Šw‰ïuƒLƒƒƒŠƒAŽx‰‡ƒAƒ“ƒP[ƒgv?WŒvŒ‹‰Ê‚©‚猩‚¦‚½Œ»ó‚Æ“W–]?. ‘æ57‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï 2020 Oct 31-Nov 30; (WEBŠJÃ).
    29. ŽíŽsq’ˆDŠw‰ïˆÏˆõ‰ïŠé‰æ@10”NŒãA‚±‚̃Vƒ“ƒ|‚ªuƒŒƒKƒV[v‚ɂȂ邽‚ß‚ÉDu‚±‚Ç‚à‚Ì”]Ž€‰º‘ŸŠí’ñ‹Ÿ‚É‚¨‚¯‚é”í‹s‘ÒŽ™œŠO‚ðÄl‚·‚évD‘æ56‰ñ“ú–{ˆÚAŠw‰ï‘‰ïG2020 Nov1-23; H“ciƒIƒ“ƒ‰ƒCƒ“jD
    30. ‰Z¶Œ´—tŽqAr–Ø@®A‘½“c—…—³•½A¼ŽR˜aFAŽíŽsq’ˆA“úÀçqA•ÊŠ»Žq. ’†Šw‹³—@‚Ìs“®•Ï—e‚ðŽx‰‡‚·‚éƒc[ƒ‹ŠJ”­. ‘æ56‰ñ“ú–{ˆÚAŠw‰ï‘‰ïG2020 Nov1-23; H“ciƒIƒ“ƒ‰ƒCƒ“jD
    31. ´àV‘׌ßA¬—ÑŽDAŠ|‰ºK‘¾A—LàV@—IA‘ºˆä¹–ëA´…‰pŽqA“¡‰ª—ElAŽRèGŒ›A¬’r@‹ÎA–쑺ŒbŽqA¼“c’¼“¿A’Þ@_”VA’؈䗢AŒ¦ìOˆê˜Y. ‹}«’P‹…”’ŒŒ•a‚ɑ΂·‚鉻Šw—Ö@’¼Œã‚ɶ‚¶‚½Žîᇕö‰óÇŒóŒQ‚ɑ΂µ‚Ä‹}«ŒŒ‰tò‰»—Ö@‚ðŽ{s‚µ‚½ˆê—cŽ™—á. ‘æ65‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ï‘‰ï 2020 Nov 2-24; (WEBŠJÃ).
    32. ‘«—§—YˆêD‰ï’·Šé‰æƒVƒ“ƒ|ƒWƒEƒ€uЊQŽž‚̃AƒŒƒ‹ƒM[Ž¾Š³Š³ŽÒ‚ւ̉e‹¿‚ƑΉž‚ɂ‚¢‚ÄF¬Ž™šb‘§v. ‘æ51‰ñ“ú–{E‹ÆEŠÂ‹«ƒAƒŒƒ‹ƒM[Šw‰ï; 2020 Nov 5-6; ‰ªŽR(ƒIƒ“ƒ‰ƒCƒ“).
    33. ŽíŽsq’ˆD¬Ž™‰Èˆã‚É‚æ‚éVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ‚Ì•ÎŒ©E·•Ê‘ÎôD‘æ52‰ñ“ú–{¬Ž™Š´õÇŠw‰ïŠwpW‰ï 2020 Nov7-8; (WEBŠJÃ).
    34. “c‘ºŒ«‘¾˜YAŒÃ“c@“ÕA’؈䗢AV‹ŠG—Aꎓ¡—IA’·‰ªvGA’––”’qŽÀAìú±—TŽqA–q–{—D”üA‹g“cär. “–‰@NICU/GCU‚É‚¨‚¯‚é‰ß‹Ž10”NŠÔ‚ÌESBLŽY¶‘å’°‹Û‚ÌŒŸoó‹µD‘æ52‰ñ“ú–{¬Ž™Š´õÇŠw‰ïŠwpW‰ï 2020 Nov7-8; (ƒIƒ“ƒ‰ƒCƒ“).
    35. •Ÿ“‡@—DA’†‘ºŒ’‘¾˜YA‘ŠJË•½A‰Á“¡‘וãA’‡‰ª²’qŽqA‚è–ƒ”üAŽíŽsq’ˆA‘«—§—YˆêA¬Ÿº³ŽŸ. ƒqƒgƒ{ƒJƒEƒCƒ‹ƒXŠ´õ‚É‚æ‚èŒÄ‹z•s‘S‚ð’悵‚½–«”xŽ¾Š³‚Ì2Î’jŽ™. ‘æ52‰ñ“ú–{¬Ž™Š´õÇŠw‰ïŠwpW‰ï 2020 Nov7-8; (WEBŠJÃ).
    36. ŽR“c¯—˜“ÞA“c‘ºŒ«‘¾˜YA’·‰ªvGA’––”’qŽÀAìú±—TŽqA–q–{—D”üA‹g“cärDæ“V«”畆ƒJƒ“ƒWƒ_Ç‚É”x‰Š‚ð‡•¹‚µ‚½late pretermŽ™D‘æ52‰ñ“ú–{¬Ž™Š´õÇŠw‰ïŠwpW‰ï 2020 Nov7-8; (ƒIƒ“ƒ‰ƒCƒ“).
    37. ‘«—§—YˆêDŠî’²u‰‰uŠwZ‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[‚Ìŋ߂̘b‘èv. ‘æ51‰ñ‘S‘ŠwZ•ÛŒ’EŠwZˆã‘å‰ï 2020 Nov 14; •xŽR(ƒIƒ“ƒ‰ƒCƒ“).
    38. ŽíŽsq’ˆD‹Ù‹}ƒƒbƒZ[ƒW@VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ‚©‚çŽq‚Ç‚à‚½‚¿‚ðŽç‚邽‚ß‚É`–{“–‚Ì“G‚Í‚Ç‚±‚É‚¢‚é‚Ì‚©`D‘æ51‰ñ‘S‘ŠwZ•ÛŒ’EŠwZˆã‘å‰ï 2020 Nov 14; •xŽR(ƒIƒ“ƒ‰ƒCƒ“).
    39. ‰Á“¡‘וãA‘«—§—Yˆê. ˆã–ò•i“Y‰Á“û“œ‚É‚æ‚éƒAƒiƒtƒBƒ‰ƒLƒV[‚̈ê—á. ‘æ2‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï–k—¤’n•û‰ï 2020 Nov 15; (ƒIƒ“ƒ‰ƒCƒ“).
    40. ŽíŽsq’ˆDƒVƒ“ƒ|ƒWƒEƒ€@–@‰ü³‚©‚ç10”N‚ðŒ}‚¦‚½‚킪‘‚̬Ž™‚Ì”]Ž€‰º‘ŸŠí’ñ‹Ÿ`ŽŸ‚Ì10”N‚ÉŒü‚¯‚ĎЉ–ÚŽw‚·‚ׂ«•ûŒü‚Æ‚Í`@”]Ž€‰º‘ŸŠí’ñ‹Ÿ‚É‚¨‚¯‚é”í‹s‘ÒŽ™œŠO‚̉ۑè‰ðŒˆ‚ÉŒü‚¯‚ÄD‘æ48‰ñ“ú–{‹~‹}ˆãŠw‰ïŠwpW‰ïG2020 Nov 18-20; Šò•ŒiƒIƒ“ƒ‰ƒCƒ“jD
    41. …–ì«Ž¡A‘¾“cˆÀFAŽ›‰ºV‘¾˜YA’Þ@_”VA–쑺ŒbŽq. W’†ŠÇ—‚ð—v‚µ‚½“ûŽ™ŠÌŒŒŠÇ“à”çŽî‚̈ê—á. ‘æ62‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ïŠwpW‰ï; 2020 Nov 20-22; (WEBŠJÃ).
    42. œA–ìŒbˆê. ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“@–«S‹Ø‰Š‚ðl‚¦’¼‚·@u¬Ž™zŠÂŠí—̈æ‚É‚¨‚¯‚é–«S‹Ø‰Šv. ‘æ56‰ñ“ú–{¬Ž™zŠÂŠúŠw‰ï‘‰ïEŠwpW‰ï; 2020 Nov 22-24; ‹ž“s(ƒIƒ“ƒ‰ƒCƒ“).
    43. œA–ìŒbˆêA@“à@~A›“c^–çA‰ª•”^ŽqA‹{”ö¬–¾A¬ŒI^lA’‡‰ª‰pKAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀA–F‘º’¼Ž÷AŽs“c•™Žq. ŒÇ—§«‰EŽº’áŒ`¬‚Ì—Õ°‘œ‚ɂ‚¢‚ÄF2Ç—á‚Æ•¶Œ£“IƒŒƒrƒ…[‚©‚ç‚ÌlŽ@. ‘æ56‰ñ“ú–{¬Ž™zŠÂŠúŠw‰ï‘‰ïEŠwpW‰ï; 2020 Nov 22-24; ‹ž“s(ƒIƒ“ƒ‰ƒCƒ“).
    44. ’‡‰ª‰pK. microRNA‚É’…–Ú‚µ‚½ìè•aŠ¥“®–¬áŽ‚É‚¨‚¯‚錌ŠÇ”÷¬—±Žq‚Ì–ðŠ„‰ð–¾‚ÆV–òŠJ”­. (Miyata Foundation Award “ú–{¬Ž™zŠÂŠíŠw‰ïŒ¤‹†§—ãÜ‹L”Ou‰‰). ‘æ56‰ñ“ú–{¬Ž™zŠÂŠúŠw‰ï‘‰ïEŠwpW‰ï; 2020 Nov 22-24; ‹ž“s(ƒIƒ“ƒ‰ƒCƒ“).
    45. ’‡‰ª‰pKA›“c^–çA‰ª•”^ŽqA‹{”ö¬–¾AˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêAŽs“c•™Žq. S‘ŸMRI‚ð—p‚¢‚½¶ŽºS‹Øãk–§‰»áŠQ(LVNC)‚̶SŽº‹@”\‰ðÍ. ‘æ56‰ñ“ú–{¬Ž™zŠÂŠúŠw‰ï‘‰ïEŠwpW‰ï; 2020 Nov 22-24; ‹ž“s(ƒIƒ“ƒ‰ƒCƒ“).
    46. ˆÉŒ\“ñ˜YA›“c^–çA‰ª•”^ŽqA‹{”ö¬–¾A’‡‰ª‰pKA¬àVˆ»‰ÀAœA–ìŒbˆêA’¹’Ë‘å‰îA“Œ“cº•FA–F‘º’¼Ž÷. æ“V«SŽ¾Š³V¶Ž™‚É‚¨‚¯‚élHS”x‰ºŽèpŒã‚Ì“ªŠW“àoŒŒ«•a•Ï‚ÌŒŸ“¢. ‘æ56‰ñ“ú–{¬Ž™zŠÂŠúŠw‰ï‘‰ïEŠwpW‰ï; 2020 Nov 22-24; ‹ž“s(ƒIƒ“ƒ‰ƒCƒ“).
    47. ‹{”ö¬–¾A›“c^–çA‰ª•”^ŽqA’‡‰ª‰pKA¬ŒI^lAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆê. TBX5 R264K‚ÍŠg’£Œ^S‹Øǂ̈êˆö‚Æ‚È‚èS‹Ø“à‚ÌACTA1‚ð‘ãž«‚É‘‰Á‚³‚¹‚é. ‘æ56‰ñ“ú–{¬Ž™zŠÂŠúŠw‰ï‘‰ïEŠwpW‰ï; 2020 Nov 22-24; ‹ž“s(ƒIƒ“ƒ‰ƒCƒ“).
    48. ›“c^–çA‰ª•”^ŽqA‹{”ö¬–¾A’‡‰ª‰pKA¬ŒI^lAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêAŽs“c•™ŽqA–F‘º’¼Ž÷. MYH7ˆâ“`Žq•ÏˆÙ‚̬Ž™S‹ØÇ‚É‚¨‚¯‚鑽—l«‚ɂ‚¢‚Ä. ‘æ56‰ñ“ú–{¬Ž™zŠÂŠúŠw‰ï‘‰ïEŠwpW‰ï; 2020 Nov 22-24; ‹ž“s(ƒIƒ“ƒ‰ƒCƒ“).
    49. ’؈䗢A›“c^–çA‹{”ö¬–¾A’‡‰ª‰pKAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêA’¹’Ë‘å‰îA“Œ“cº•FA–سÆA–F‘º’¼Ž÷. V‹K‚ÌZEB2ˆâ“`Žqƒiƒ“ƒZƒ“ƒX•ÏˆÙ‚𔺂¤Mowat-Wilson syndromeCƒŒ^”x“®–¬•Â½Ç‚Ì3ΗŽ™—á. ‘æ56‰ñ“ú–{¬Ž™zŠÂŠúŠw‰ï‘‰ïEŠwpW‰ï; 2020 Nov 22-24; ‹ž“s(ƒIƒ“ƒ‰ƒCƒ“).
    50. “c”öŽ¶AÎŒ´–õ‹IAœA–ìŒbˆêA”¨—R‹IŽqA¼“c®Ž÷CVˆä“c—v. SOS1ˆâ“`ŽqˆÙí‚ðŽ¦‚µ‚½NoonanÇŒóŒQ‚ÉMYH7•ÏˆÙ‚Ì“ñd•ÏˆÙ‚𶂶‚½”ì‘åŒ^S‹Øǂ̈ê—á. ‘æ56‰ñ“ú–{¬Ž™zŠÂŠúŠw‰ï‘‰ïEŠwpW‰ï; 2020 Nov 22-24; ‹ž“s(ƒIƒ“ƒ‰ƒCƒ“).
    51. Ž›‰ºV‘¾˜YA…–ì«Ž¡A‘¾“cˆÀFA’Þ@_”VA–쑺ŒbŽq. Liothyronine‚ª‘¬‚â‚©‚Ébó‘B‹@”\‚ð‰ü‘P‚µ‚½“ûŽ™‘½”­«ŠÌŒŒŠÇŽî. ‘æ30‰ñ—Õ°“à•ª”å‘ãŽÓUpdate“ú–{¬Ž™“à•ª”åŠw‰ïŠwpW‰ï 2020 Nov 13-14; “Œ‹ž(ƒIƒ“ƒ‰ƒCƒ“).
    52. ‘«—§—YˆêDƒCƒuƒjƒ“ƒOƒZƒ~ƒi[uƒKƒCƒhƒ‰ƒCƒ“‚𓥂܂¦‚½šb‘§Ž¡—Ãí—ª`¬Ž™‚©‚ç¬l‚Ü‚Å`F¬Ž™šb‘§v. ‘æ29‰ñ‘Ûšb‘§Šw‰ï“ú–{E–kƒAƒWƒA•”‰ï 2020 Dec 11-12; ‰F“s‹{(ƒIƒ“ƒ‰ƒCƒ“).

    2019”N

  • ’˜‘
    1. ‘«—§—YˆêD 60Ž¾Š³ ŽÀ‘H“IƒKƒCƒhƒ‰ƒCƒ“Šˆ—ppDˆÉ“¡Gˆê•Ò. “Œ‹žF’†ŽR‘“XF2019D‹CŠÇŽxšb‘§Gp19-24.
    2. ‘«—§—YˆêD¡“ú‚̈•ûD‰Y•”»•vA“‡“c˜aKA‰Í‡áÁˆê•Ò. “Œ‹žF“ì]“°F2019. ¬Ž™Ž¾Š³F‹CŠÇŽxšb‘§Dp743-6.
    3. ‘«—§—YˆêD¡“ú‚ÌŽ¡—ÃŽwj2019”N“x”Å\Ž„‚Í‚±‚¤Ž¡—µ‚Ä‚¢‚éD•ŸˆäŽŸ–îA‚–Ø@½A¬Žºˆê¬•Ò. “Œ‹žFˆãŠw‘‰@F2019. ŠwZ‚É‚¨‚¯‚銴õÇ‚Ì—¬s‚Æ‘ÎôiŠwZ•ÛŒ’ˆÀ‘S–@jDp1418-20.
  • Œ´’˜
    1. Hirono K, Saito K, Munkhsaikhan U, Xu F, Wang C, Lu L, Ichida F, Towbin JA, Purevjav E. Familial Left Ventricular Non-Compaction Is Associated With a Rare p.V407I Variant in Bone Morphogenetic Protein 10. Circ J. 2019 Jul 25; 83(8): 1737-46.
    2. Kawasaki Y, Yoshida T, Matsui M, Hiraiwa A, Inomata S, Tamura K, Makimoto M, Oishi K. Clinical Factors That Affect the Relationship between Head Circumference and Brain Volume in Very-Low-Birth-Weight Infants. J Neuroimaging. 2019 Jan; 29(1): 104-10.
    3. Tamura K, Kawasuji H, Tachi S, Kawasaki Y, Nagaoka M, Makimoto M, Sakamaki I, Yamamoto Y, Kanatani J, Isobe J, Mitarai S, Yoneda N, Yoneda S, Saito S, Yoshida T. Congenital tuberculosis in an extremely preterm infant and prevention of nosocomial infection. J Infect Chemother. 2019 Sep;25(9):727-30.
    4. Miyao N, Hirono K, Hata Y, Yoshimura N, Ichida F. Novel compound heterozygous TBX5 variants may induce hypoplastic left heart syndrome. Pediatr Int. 2019 Jun; 61(6):607-9.
    5. Hoshino A, Yang X, Tanita K, Yoshida K, Ono T, Nishida N, Okuno Y, Kanzaki T, Goi K, Fujino H, Ohshima K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Kojima S, Morio T, Kanegane H. Modification of cellular and humoral immunity by somatically reverted T cells in X-linked lymphoproliferative syndrome type 1. J Allergy Clin Immunol. 2019 Jan; 143(1): 421-4.e11.
    6. Shigetomi N, Kamiya K, Takamori T, Yoshimura N, Ozawa S, Hirono K, Ichida F, Taguchi M. Determination of the serum unbound fraction of Tadalafil in children with protein-losing enteropathy and its specific binding to human serum proteins in Vitro. Biol Pharm Bull. 2019; 42(1): 110-5.
    7. Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A; KAICA trial Investigators. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet. 2019 Mar 16; 393(10176): 1128-37.
    8. Hata Y, Ichimata S, Yamaguchi Y, Hirono K, Oku Y, Ichida F, Nishida N. Clinicopathological and Genetic Profiles of Cases with Myocytes Disarray-Investigation for Establishing the Autopsy Diagnostic Criteria for Hypertrophic Cardiomyopathy. J Clin Med. 2019 Apr 5;8(4). pii: E463.
    9. Hata Y, Hirono K, Yamaguchi Y, Ichida F, Oku Y, Nishida N. Minimal inflammatory foci of unknown etiology may be a tentative sign of early stage inherited cardiomyopathy. Mod Pathol. 2019 Sep;32(9):1281-90.
    10. Armaroli G, Verweyen E, Pretzer C, Kessel K, Hirono K, Ichida F, Okabe M, Cabral DA, Foell D, Brown KL, Kessel C. Monocyte-Derived Interleukin-1ƒÀ As the Driver of S100A12-Induced Sterile Inflammatory Activation of Human Coronary Artery Endothelial Cells: Implications for the Pathogenesis of Kawasaki Disease. Arthritis Rheumatol. 2019 May; 71(5): 792-804.
    11. Ono Y, Tamura K, Inomata S, Futatani T, Saito S, Yoshida T. Effect of postnatal hydrocortisone on 18-month neurodevelopmental outcomes in very-low-birth-weight infants. Pediatr Neonatol. 2019 Jun; 60(3):339-41.
    12. Ali K, Dassios T, Khaliq SA, Williams EE, Tamura K, Davenport M, Greenough A. Outcomes of infants with congenital diaphragmatic hernia by side of defect in the FETO era. Pediatr Surg Int. 2019 Jul; 35(7):743-7.
    13. Ali K, Kagalwalla S, Cockar I, Williams EE, Tamura K, Dassios T, Greenough A. Prediction of prolonged ventilator dependence in preterm infants. Eur J Pediatr. 2019 Jul; 178(7):1063-8.
    14. Tamura R, Watanabe N, Nakamura S, Yoshimura N, Ozawa S, Hirono K, Ichida F, Taguchi M. Evaluation of the effects of ontogenetic or maturation functions and chronic heart failure on the model analysis for the dose-response relationship of warfarin in Japanese children. Eur J Clin Pharmacol. 2019 Jul; 75(7):913-20.
    15. Otsuka Y, Chang L, Kawasaki Y, Wu D, Ceritoglu C, Oishi K, Ernst T, Miller M, Mori S, Oishi K. A Multi-Atlas Label Fusion Tool for Neonatal Brain MRI Parcellation and Quantification. J Neuroimaging. 2019 Jul;29(4):431-9.
    16. Kimura M, Ito Y, Shimomura M, Yoneda K, Naito C, Adachi Y, Meguro T. Neutrophilia and hyperamylasemia in patients with immediate food allergy. Pediatr Int. 2019 Jan; 61(1): 23-30.
    17. Okuda M, Nomura K, Kato M, Lin Y, Mabe K, Miyamoto R, Okumura A, Kikuchi S. Gastric cancer in children and adolescents in Japan. Pediatr Int. 2019 Jan; 61(1): 80-6.
    18. Honjo S, Murakami Y, Odajima H, Adachi Y, Yoshida K, Oya Y, Akasawa A. An independent relation of atopic dermatitis to exercise-induced wheezing in asthmatic children. Allergol Int. 2019 Jan; 68(1): 26-32.
    19. Kanatani KT, Nakayama T, Adachi Y, Hamazaki K, Onishi K, Konishi Y, Kawanishi Y, Go T, Sato K, Kurozawa Y, Inadera H, Konishi I, Sasaki S, Oyama H; Japan Environment and Children's Study. High frequency of vitamin D deficiency in current pregnant Japanese women associated with UV avoidance and hypo-vitamin D diet. PLOS ONE. 2019 Mar 4; 14(3): e0213264.
    20. Kanatani KT, Adachi Y, Hamazaki K, Onishi K, Go T, Hirabayashi K, Watanabe M, Sato K, Kurozawa Y, Inadera H, Oyama H, Nakayama T; Japan Environment and Childrenfs Study Group. Association between vitamin D deficiency and allergic symptom in pregnant women. PLOS ONE. 2019 Apr 10; 14(4):e0214797.
    21. Yanagaisawa R, Matsuda K, Oga S, Kanegane H, Morimoto A, Okamoto Y, Ohara A, Fukushima K, Sotomatsu M, Nomura K, Saito AM, Horibe K, Ishii E, Nakazawa Y. Factors predicting the recurrence of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol. Int J Hematol. 2019 May; 109(5): 612-7.
    22. Kigawa M, Tsuchida A, Miura K, Ito M, Tanaka T, Hamazaki K, Adachi Y, Saito S, Origasa H, Inadera H; Japan Environment and Childrenfs Study (JECS). Analysis of non-respondent pregnant women who were registered in the Japan Environment and Children's Study: a longitudinal cohort study. BMJ Open. 2019 Jun 27; 9(6): e025562.
    23. Katsunuma T, Fujisawa T, Maekawa T, Akashi K, Oya Y, Adachi Y, Hashimoto K, Mizuno M, Imai T, Oba MS, Sako M, Ohashi Y, Nakamura H. Low-dose l-isoproterenol versus salbutamol in hospitalized pediatric patients with severe acute exacerbation of asthma: A double-blind, randomized controlled trial. Allergol Int. 2019 Jul; 68(3):335-41.
    24. Lenney W, Adachi Y, Bush A, Fischer GB, Hong J, Ostrem A, Pedersen S, Sly PD, Szefler SJ, Tilak R, Zar HJ. Asthma: moving toward a global children's charter. Lancet Respir Med Apr 2019; 7(4): 299-300.
    25. Sasaki M, Morikawa E, Yoshida K, Adachi Y, Odajima H, Akasawa A. The change in the prevalence of wheeze, eczema and rhino-conjunctivitis among Japanese children: Findings from 3 nationwide cross-sectional surveys between 2005 and 2015. Allergy. 2019 Aug;74(8):1572-5.
    26. Ugai S, Iwaya A, Taneichi H, Hirokawa C, Aizawa Y, Hatakeyama S, Saitoh A. Clinical Characteristics of Saffold Virus Infection in Children. Pediatr Infect Dis J. 2019 Aug; 38(8):781-5.
    27. Kigawa M, Tsuchida A, Matsumura K, Takamori A, Ito M, Tanaka T, Hamazaki K, Adachi Y, Saito S, Origasa H, Inadera H; Japan Environment and Childrenfs Study (JECS) Group. Factors of non-responsive or lost-to-follow-up Japanese mothers during the first year post partum following the Japan Environment and Children's Study: a longitudinal cohort study. BMJ Open. 2019 Nov 12; 9(11): e031222.
    28. ŽíŽsq’ˆA”‘òŽõŽqA–x]’åŽuA–쑺ŒbŽqA‘«—§—YˆêA≺—TŽqD‹}«‚ÌŒo‰ß‚Å‚±‚Ç‚à‚ð‘rŽ¸‚µ‚½‰Æ‘°‚Ö“n‚·ƒOƒŠ[ƒtƒJ[ƒh‚̈Ӌ`D“ú¬Ž™‹~‹}ˆã‰ïŽ 2019; 18(1): 6-11.
    29. œA–ìŒbˆêA‹{”ö¬–¾A¬—Ñ@“OA·ˆê‹úºA›“c^–çA‰ª•”^ŽqA’‡‰ª‰pKA¬ŒI^lAˆÉŒ\“ñû¶A¬àVˆ»‰ÀAŽs“c•™Žq. ¬Ž™–«“Á’莾•aƒŒƒ|ƒWƒgƒŠ[‚ÉŠî‚­ƒAƒ“ƒP[ƒgŒ‹‰Ê‚©‚ç‚Ý‚½S‹Øãk–§‰»áŠQ‚Ì—Õ°‘œ. ¬Ž™zŠÂŠíŠw‰ïŽGŽ 2019; 35(3): 172-8.
    30. ˆÉ“¡–õ“TA’·”ö‚Ý‚¸‚ÙA‘ºˆäG¶A•Ÿ‰Æ’CŽ÷AŽè’˃ˆê˜YA²“¡‚³‚­‚çA“¡àV—²•vA‘«—§—YˆêDƒAƒNƒeƒBƒuƒ‰[ƒjƒ“ƒO‚𓱓ü‚µ‚½¬Ž™ƒAƒŒƒ‹ƒM[ƒXƒLƒ‹ƒAƒbƒvƒR[ƒX‚ÌŠwKŒø‰ÊD“ú¬ƒAƒŒƒ‹ƒM[‰ïŽ 2019; 33(2): 180-8.
    31. –F‘º’¼Ž÷A–سÆA“Œ“cº•FA’¹’Ë‘å‰îA—•Œ´—²[A[Œ´ˆêWAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêAŽs“c•™Žq. y¬læ“V«SŽ¾Š³‚ÌŠO‰ÈŽ¡—Ãz‰EŽº—¬o˜HÄŒšpŒã‚̬lŠúÄŽèp@“K‰ž‚ÆŒÀŠE. ‹¹•”ŠO‰È. 2019 Apr;72(4):251-5.
  • Ç—á•ñ
    1. Hirono K, Ichida F, Nishio N, Ogawa-Tominaga M, Fushimi T, Feichtinger RG, Mayr JA, Kohda M, Kishita Y, Okazaki Y, Ohtake A, Murayama K. Mitochondrial complex deficiency by novel compound heterozygous TMEM70 variants and correlation with developmental delay, undescended testicle, and left ventricular noncompaction in a Japanese patient: A case report. Clin Case Rep. 2019 Feb 7; 7(3): 553-7.
    2. Terashita S, Tanaka T, Taneichi H, Adachi Y, Mori M. Mycophenolate mofetil and prednisolone for cerebral sinus venous thrombosis with Behcet's disease. Pediatr Int. 2019 Sep;61(9):920-2.
    3. Terashita S, Nakaoka HCIbuki KCOzawa SCHirono KCAdachi YCFujita SCNakanishi TCIchida F. Only characteristics vascular lesions of Williams-Beuren syndrome in a girl with a novel nonsense ELN mutation. J Pediatr Cardio Cardiac Surg. 2019;3(1): 56-60.
    4. Matsukura H, Inomata S, Tanaka T. Unintentional drowning associated with multiple cerebral cavernous malformations. Am J Case Rep. 2019 Jul; 7(9): 217-8.
    5. ˆÉŒ\“ñ˜YA’·‰ªF‘¾AŽRŒû‰p‹MA´…@•A‘åŽRL—YA“¡ˆä—²¬A•x“c@‰p. ’áo¶‘ÌdŽ™‚ɇ•¹‚µ‚½¶”x“®–¬‹ßˆÊ•”Œ‡‘¹‚ɑ΂µ‚Ä“®–¬ŠÇƒXƒeƒ“ƒg—¯’up‚ðŽ{s‚µ‚½ˆê—á. J JPIC 2018; 3(2): 56-60.
    6. –x]’åŽuA“c’†•ü”üA˜a“c‘ñ–çAŽíŽsq’ˆA‘«—§—Yˆê. Mycoplasma pneumoniae‚É‚æ‚é‹}«¬”]Ž¸’²Ç‚Ì1—á. ¬Ž™“à‰È2019; 51(9): 1342-5.
    7. ‘ºã«Œ[AŽíŽsq’ˆA“c’†•ü”üA‘ŠJË•½AŽu“c@”EAŽRèGŒ›A¬’r@‹ÎA“¡“c—FŽkA‘«—§—YˆêDƒGƒ`ƒŒƒ“ƒOƒŠƒR[ƒ‹’†“łɑ΂µŒŒ‰t“§Í‚ƃzƒƒsƒ][ƒ‹‚𕹗p‚µ‚½‹~–½‚µ‚½¬Ž™D“ú¬Ž™‰ïŽ 2019; 123(6): 1032-7.
    8. ŽOàV@ŒbA–q–ì‹P•FA‰º‘º@—TA‘«—§—YˆêA´…’‰“¹DyV¶Ž™E“ûŽ™‚̔畆•az—Õ°—á@EDAˆâ“`Žq‚ÉV‹K•ÏˆÙ‚𓯒肵‚½X˜A½«’ኾ«ŠO”x—tŒ`¬•s‘SÇ‚Ì1‰ÆŒnD”畆f—à 2019; 41(5): 465-8.
  • ‘à
    1. ‘«—§—YˆêD¬Ž™‹CŠÇŽxšb‘§‚ÌŽ¡—à -ƒKƒCƒhƒ‰ƒCƒ“‚ð‚Ó‚Ü‚¦‚Ä-: Š³ŽÒ‚Ö‚ÌŽw“±Eà–¾.¬Ž™—Õ2019 FebG 72(2)F131-6.
    2. ‘«—§—YˆêD¬Ž™ŒÄ‹zŠíŽ¾Š³‚̃tƒ@[ƒXƒgƒ^ƒbƒ`‚©‚çê–åf—ÂÖF‹C“¹ˆÙ•¨A¬Ž™f—à 2019; 82:39-42.
    3. ‘«—§—YˆêDy¬Ž™ ˆêŽŸ‹~‹}ƒ}ƒjƒ…ƒAƒ‹-‹A‘î‰Â”\‚©? “ñŽŸ‹~‹}‚©? ”»’f‚Ì‚½‚ß‚ÌŽèˆø‚«-zÇó•ÊƒAƒvƒ[ƒ`@šb–ÂD¬Ž™‰È 2019 Apr; 60(5): 540-6.
    4. ‘«—§—YˆêDy¬Ž™ ˆêŽŸ‹~‹}ƒ}ƒjƒ…ƒAƒ‹-‹A‘î‰Â”\‚©?“ñ ŽŸ‹~‹}‚©? ”»’f‚Ì‚½‚ß‚ÌŽèˆø‚«-zˆêŽŸ‹~‹}‚É•K—v‚Ȉ’u@‹C“¹ˆÙ•¨œ‹ŽD¬Ž™‰È 2019 Apr; 60(5): 864-7.
    5. ”ÂàVŽõŽqA×–Ø‹»ˆŸD’m‚Á‚Ä‚¨‚«‚½‚¢ÅV‚̃AƒŒƒ‹ƒM[E–ƉuŠw—pŒê@BAFFD“ú¬Ž™ƒAƒŒƒ‹ƒM[‰ïŽ 2019 Jun; 33(2): 244-5.
    6. ”ÂàVŽõŽqA×–Ø‹»ˆŸD’m‚Á‚Ä‚¨‚«‚½‚¢ÅV‚̃AƒŒƒ‹ƒM[E–ƉuŠw—pŒê@epsilon germline transcripts (ƒÃGLT) D“ú¬Ž™ƒAƒŒƒ‹ƒM[‰ïŽ 2019 Jun; 33(2): 246-7.
    7. ‹g“cärDyV¶Ž™‚ÌŠÏŽ@‚ÆŒ©‚«‚í‚ßE‰î“üƒ|ƒCƒ“ƒg FGRClate pretermC‹zˆøEççŽq•ª•ØC’ጌ“œCŒÄ‹záŠQetcDo¶‘OEŒã‚̃ŠƒXƒN‚ðŒ©‚Ì‚ª‚³‚È‚¢!zŒy“xFGRŽ™DƒyƒŠƒlƒCƒ^ƒ‹ƒPƒA 2019 MayG38(5)F428-32D
    8. ŽíŽsq’ˆDy¬Ž™ ˆêŽŸ‹~‹}ƒ}ƒjƒ…ƒAƒ‹-‹A‘î‰Â”\‚©? “ñŽŸ‹~‹}‚©? ”»’f‚Ì‚½‚ß‚ÌŽèˆø‚«-zŽ–ŒÌEŠOˆö«Œ´ˆö•ÊƒAƒvƒ[ƒ`@“M…D¬Ž™‰È 2019 Apr; 60(5): 795-801.
    9. ŽíŽsq’ˆD‚킪‘‚É‚¨‚¯‚鬎™‘ŸŠí’ñ‹Ÿ‚̉ۑè‚Æ‚»‚̉ðŒˆ. “ú—ÕtˆÚA‰ïŽ2019 Jan; 7(1): 44-50.
    10. ŽíŽsq’ˆD¬Ž™‚Ì‹~‹}E”À‘—ˆã—Ã@‹}«táŠQi‹}«t•s‘Sj. ¬Ž™“à‰È@2019G51(‘)F648-51.
    11. ŽíŽsq’ˆ. Ž™“¶‚Ì‘ŸŠí’ñ‹ŸE‘ŸŠíˆÚA‚ðl‚¦‚é. Organ Biol. 2019; 26(2): 23-9.
    12. œA–ìŒbˆêDyˆâ“`«SŒŒŠÇŽ¾Š³‚Ì‚·‚ׂÄzS‹ØŽ¾Š³ ¶ŽºS‹Øãk–§‰»áŠQD2019 MarGˆãŠw‚Ì‚ ‚ä‚ÝD268(9)F723-9D
    13. œA–ìŒbˆêDy¬Ž™zŠÂŠí—̈æ‚̶ŠU•ïŠ‡ˆâ“`ˆã—ÃzŽ¾Š³Še˜_ S‹Øǂ̈â“`ŠwD¬Ž™f—ÃD2019 JulG82(7)F931-7D
    14. ¼“c’¼“¿AŽs“c•™ŽqDyDownÇ‚ðŒ©‚Â‚ß‚éz–ƉuˆÙí‚ÆŠ´õÇD¬Ž™‰È 2019 Jan ; 60 (1) : 25-32.
    15. “c‘ºŒ«‘¾˜YC‹g“cär. Q145“ª‚ð‰Ÿ‚·‚Æ‚Ô‚æ‚Ԃ悵‚Ä‚¢‚Ü‚µ‚½D‚»‚Ì‚¤‚¿–Ú‚ÌŽü‚肪•‚­‚È‚è‚Ü‚µ‚½‚©HŽüŽYŠúˆãD2019 DecG49(‘)F339-41.
    16. ìè—TŽqC‹g“cärDQ142“ª‚Ì‘O‚ªƒyƒRƒyƒR‚µ‚Ä‚¢‚Ü‚·‚ª‘åä•v‚Å‚·‚©H ŽüŽYŠúˆãD2019 DecG49(‘)F332-3D
    17. ’––”’qŽÀC‹g“cärDyŽüŽYŠú‘Š’k310 ‚¨•ê‚³‚ñ‚ւ̉ñ“šƒ}ƒjƒ…ƒAƒ‹z“ª‚ª•ÏŒ`‚µ‚Ä‚¢‚Ü‚·‚ª’¼‚è‚Ü‚·‚©HDŽüŽYŠúˆãD2019G49(‘)F334-6D
    18. ¬‰Y@ŽAŽíŽsq’ˆAŒÜ\—’“oD¬Ž™‰È—Õ°‹³ˆç‚ÌŽÀÛ(‘æ7‰ñ)@¬Ž™‰È‰Šú—Õ°Œ¤C‚É‚¨‚¯‚éŽw“±ˆã‚Ì–ðŠ„‚ÆŽÀÛD¬Ž™‰È 2019Jul; 60(8): 1207-12.
    19. ˆÉ“¡—z—¢A’·‘º•q¶AŽsìŒõ‘¾˜YA“c‘º‘ì–çA‘º“c—S“ñAŒE“c@–žA•½–{—´ŒáA¬ŽR“T‹vA–Øè‘P˜YAŽR–{‰pˆêA_‰€~ŽiAˆäãM–¾A•‚ŽR‰zŽjA²“¡Œú•vAŽíŽsq’ˆA‰ª“c@LA´àVLKA“ú–{¬Ž™‹~‹}ˆãŠw‰ïE’²¸Œ¤‹†ˆÏˆõ‰ïD¬Ž™‹~‹}d“ÄŽ¾Š³“o˜^’²¸‚ð’Ê‚¶‚Ä‘S‘‹K–͂̃f[ƒ^ƒx[ƒX‚ð\’z‚·‚鎎‚ÝD¬Ž™‰È 2019G60i4jF411-6.
    20. –F‘º’¼Ž÷A–سÆA“Œ“cº•FA’¹’Ë‘å‰îA—•Œ´—²[A[Œ´ˆêWAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêAŽs“c•™Žq. y¬læ“V«SŽ¾Š³‚ÌŠO‰ÈŽ¡—Ãz‰EŽº—¬o˜HÄŒšpŒã‚̬lŠúÄŽèp@“K‰ž‚ÆŒÀŠE. ‹¹•”ŠO‰È. 2019 Apr;72(4):251-5.

  • 2019”NŠw‰ï•ñ
    1. Itazawa T, Okabe Y, Wada T, Murakami S, Ito Y, Adachi Y, Adachi Y. Comparison of bronchodilator response in asthmatic children using spirometry and oscillometry. 2019 American Academy of Allergy Asthma & Immunology Annual Meeting, 2019 Feb 22-25; San Francisco, USA.
    2. Kawasaki Y, Oishi K, Hernandez A, Wu D, Otsuka Y, Ceritoglu C, Ernst T, Chang L. The brain-derived neurotrophic factor Val66Met variant is associated with hippocampal volumes in newborn infants. ISMRM 27th Annual Meeting & Exhibition in Montreal; 2019 May 11-16; Montreal.
    3. Kusabiraki S, Tanaka T, Tamura K, Yoshida T, Adachi Y, Kato M, Miyamoto S, Nakashima M, Saitsu H. Effectiveness of ACTH therapy for infantile spasms with a novel TUBB2A mutation; a case report. The 20th Annual Meeting of Infantile Seizure Society; 2019 May31- Jun 1; Nagoya.
    4. Hirono K, Hata Y, Takarada S, Okabe M, Miyao N, Nakaoka H, Ibuki K, Ozawa S, Nishida N, Ichida F. A distinct phenotype of fetal patients with left ventricular noncompaction in a large cohort in Japan. ESC congress 2019; 2019 Aug 31- Sep 4; Paris.
    5. Yoshida T, Matsumura K, Tsuchida A, Hamazaki K, Inadera H and Japan Environment and Children's Study Group. Association Between Cesarean Section And Constipation In Infants: The Japan Environment And Childrenfs Study (JECS). The 11th DOHaD World Congress; Oct 20-23; Melbourne, Australia.
    6. Nakaoka H, Hirono K, Yamamoto S, Takasaki I, Takahashi K, Okabe M, Miyao N, Ibuki K, Ozawa S, Ichida F. MicroRNA-145-5p and microRNA-320a encapsulated in endothelial microparticles contribute to the progression of vasculitis in acute Kawasaki Disease. AHA Scientific Sessions 2019; 2019 Nov 16-18; Philadelphia, U.S.A.
    7. ˆÉŒ\“ñ˜YA’·‰ªF‘¾AŽRŒû‰p‹MA´…@•A’Mˆä@rAŠ`–{‹vŽqAŠø@‹`mA“¡ˆä—²¬A‹{Œ´‹`“TAΖìKŽOA•x“c@‰pA‘]‰ä‹±Ži. ‰‰ñ—¯’u7mmˆÈã‚Í”xÖ¬ƒXƒeƒ“ƒg‚Ì—\Œã‚ð‰ü‘P‚·‚é‰Â”\«‚ª‚ ‚é. ‘æ30‰ñ“ú–{Pediatric Interventional CardiologyŠw‰ïŠwpW‰ï; 2019 Jan 24; ‚³‚¢‚½‚Ü.
    8. ˆÉŒ\“ñ˜Y. ¬Ž™‰È—̈æ‚É‚¨‚¯‚éRubyTM coil‚ÌBig advantages. ‘æ30‰ñ“ú–{Pediatric Interventional CardiologyŠw‰ïŠwpW‰ï; 2019 Jan 24; ‚³‚¢‚½‚Ü.
    9. ŽíŽsq’ˆDtˆÚA‚É‚¨‚¯‚é‘ŸŠí’ñ‹Ÿ‚ðl‚¦‚é`”]Ž€ES‘ŸŽ€‚É‚¨‚¯‚é‘ŸŠí’ñ‹Ÿ`@¬Ž™‰Èˆã‚Ì—§ê‚©‚çl‚¦‚鬎™‘ŸŠí’ñ‹Ÿ‚̉ۑèD‘æ52‰ñ“ú–{—Õ°tˆÚAŠw‰ï; 2019 Feb 13-15; ‘åã.
    10. ¬àVˆ»‰ÀA›“c^–çA‰ª•”^ŽqA¬ŒI^lAˆÉŒ\“ñ˜YAœA–ìŒbˆêAŽs“c•™Žq. ‘ÙŽ™Šú”­ÇS‹ØÇ‚Ì‘S‘‰uŠw’²¸@\Œ‹‰Ê•ñ|i2010|2016j. ‘æ25‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŠw‰ïŠwpW‰ï; 2019 Feb 16; ‘åã.
    11. –x]’åŽuAŽíŽsq’ˆAꎓ¡@—IA˜a“c‘ñ–çA“c’†•ü”üAa’JLŽqA‘«—§—YˆêD’˜–¾‚È”]•‚Žî‚ÆoŒŒ«”][ǂ𶂶‚½“œ”A•a«ƒPƒgƒAƒVƒh[ƒVƒX‚Ì1¬Ž™—áD‘æ46‰ñ“ú–{W’†Ž¡—ÈãŠw‰ï; 2019 Mar 1-3; ‹ž“s.
    12. ‰Á“¡‘וãAŽÄ“c@KA‹´–{ˆè•vA”‹–ì–Α¾A²X–ØÈŽO. —‘‰©ŒŒŠÇˆâŽciMesodiverticular vascular bandj‚𔺂¤ƒƒbƒPƒ‹ŒeŽº‚É‚æ‚鬒°iN«ƒCƒŒƒEƒX‚Ì’jŽ™—á. ‘æ55‰ñ“ú–{• •”‹~‹}ˆãŠw‰ï‘‰ï; 2019 Mar 7-8; å‘ä.
    13. –x]’åŽu, ´…@”V, ’Ô¦áÁˆêDä`‘Ñ֬ᎂÌ1—á. `‘ÙŽ™Šú‚©‚ço¶Œã‚ÌŒo‰ß`. ‘æ325‰ñ¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ïE‘æ41‰ñ¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2019 Mar 10; •xŽRD
    14. ŽíŽsq’ˆAŽá™‰ë_A‰œŽ›@ŒhDW’cŠ´õŽž‚É‚¨‚¯‚é‹Ù‹}ˆã—Ãî•ñŠÇ—ƒVƒXƒeƒ€‚¨‚æ‚ÑŽ–Œã‰ð̓VƒXƒeƒ€‚ÌlŽ@D‘æ24‰ñ“ú–{ЊQˆãŠw‰ï‘‰ïEŠwpW‰ïG2019 Mar 18-20; •ÄŽq.
    15. ‘«—§—YˆêD“Á•Êu‰‰u“û—cŽ™‚É‚¨‚¯‚éšb–‚Ìf’f‚ÆŽ¡—Ãv ‘æ146‰ñ“ú–{¬Ž™‰ÈŠw‰ï“È–ØŒ§’n•û‰ï; 2019 Mar.24; ‰F“s‹{D
    16. Hirono K, Hata Y, Nakazawa M, Momoi N, Tsuji T, Matsuoka T, Ayusawa M, Abe Y, Hayashi T, Tsujii N, Abe T, Sakaguchi H, Wang C, Takasaki A, Takarada S, Okabe M, Miyao N, Nakaoka H, Ibuki K, Saito K, Ozawa S, Nishida N, Bowles NE, Ichida F. Clinical and echocardiographic impact of TAZ gene variants on the DCM phenotype of LVNC patients during early infancy. ‘æ83‰ñ“ú–{zŠÂŠíŠw‰ï; 2019 Mar 29-31; ‰¡•l.
    17. ŽíŽsq’ˆA´…’¼Ž÷DgPros & Consh? Breaking the Stereotype ?@Round 3. ”]‹@”\’âŽ~‚Æf’f‚³‚êA‘ŸŠí’ñ‹Ÿ‚ð–]‚Ü‚È‚¢ê‡‚Å‚àAˆê’è‚ÌW’†Ž¡—Â͒ñ‹Ÿ‚µ‚¤‚é?ˆÙ‚Ȃ鉿’lŠÏ‚ðŽó—e‚·‚é?D‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2019 Apr 19-21; ‹à‘ò.
    18. œA–ìŒbˆêC‹g‰i³•vCˆÀ“c˜aŽuC¼Œ´‰h‹NCˆ¼‘ò ‰qC–x•ÄmŽuC¬Š_Ž –LC—§–ì Ž CŠâ–{áÁ—C“yˆä¯ŽO˜YCò“c’¼ŒÈCZ—F’¼•ûC”¥–Ø‘å—SC‘¾“c–M—YC”¨ ’‰‘PC‹ƒmà_‘å–çC“c“àé¶C’·“ˆ³›‰C²“¡½ˆêDŠwZS‘ŸŒŸf‚©‚猩‚½S‹Øãk–§‰»áŠQ‚Ì—Õ°‘œD‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïG2019 Apr 19-21G‹à‘òD
    19. ˜a“c‘ñ–çAˆÉ“¡–õ“TA–x]’åŽuA“c’†•ü”üA‘«—§—YˆêD’á’`”’ŒŒÇA•‚ŽîA‘Ìd‘‰Á•s—Ç‚ð’悵‚½•ê“û‚É‚æ‚é food protein induced enteropathy ‚ª‹^‚í‚ꂽ“ûŽ™—áD‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2019 Apr 19-21; ‹à‘ò.
    20. ”ª–ØMˆêA“ˆ”ö@’qAŽíŽsq’ˆA‘«—§—YˆêD•xŽRŽsEˆãŽt‰ï‹}Š³ƒZƒ“ƒ^[¬Ž™‰Èf—Ņ̃‚ɂ‚¢‚ÄD‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2019 Apr 19-21; ‹à‘ò.
    21. ”ª–ØMˆêA¼‘òƒŽqA“ˆ”ö@’qAŽíŽsq’ˆD•xŽRˆã—ÃŒ—‚É‚¨‚¯‚édÇSgáŠQŽ™EŽÒ‚̈ã—Ņ̃‚ɂ‚¢‚Ä‚Ì’nˆæˆã—ØAŒg‘̧‚ɂ‚¢‚ÄD‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2019 Apr 19-21; ‹à‘ò.
    22. ‰Á“¡—ŽqA‘ŠJË•½AˆÉ“¡–õ“TA“c’†•ü”üAŽíŽsq’ˆA›“c^–çA‰ª•”^ŽqAÖ“¡˜a—RA¬àVˆ»‰ÀAœA–ìŒbˆêA‘«—§—YˆêAÔˆä‘ì–çDƒVƒƒƒ“ƒg‹@”\•s‘S‚É‚æ‚é…“ªÇ‘ˆ«‚©‚ç_ŒoŒ´«”x…Žî‚Æ‚½‚±‚‚ÚS‹ØÇ‚ð’悵‚½ˆê—áD‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2019 Apr 19-21; ‹à‘ò.
    23. X‚±‚¸‚¦AŒÜ\—’“oA‚”ö@Š²A‘«—§—YˆêDˆŸ‰”Œ‡–RÇ‚ð‡•¹‚µ‚½dǃAƒgƒs[«”畆‰Š‚Ì“ûŽ™—áD‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2019 Apr 19-21; ‹à‘ò.
    24. ‘ºã«Œ[A”ÂàVŽõŽqA¬àVˆ»‰ÀAˆÉ“¡–õ“TAœA–ìŒbˆêA‘«—§—YˆêDŽ_‘f•¹—p‰º”rá‚•â•‘•’u“±“ü‚ª—LŒø‚Å‚ ‚Á‚½–³‹C”x‚ðŒJ‚è•Ô‚·ƒ`ƒAƒm[ƒ[«SŽ¾Š³Ž™—áD‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2019 Apr 19-21; ‹à‘ò.
    25. •½Šâ–¾ŽqAìè—TŽqA‘ŠJË•½A“c’†•ü”üAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêA‹{@ˆêŽuA¼ˆäŽOŽ}A–F‘º’¼Ž÷A‘åÎŒ’ˆêAŽs“c•™ŽqA‘«—§—YˆêDdÇæ“V«SŽ¾Š³Ž™‚ÌŠw“¶Šú‚Ü‚Å‚Ì”­’B—\Œã@’PSŽº‚ÆŠ®‘S‘匌ŠÇ“]ˆÊ‚É‚¨‚¯‚é”­’BŒŸ¸‚ÆMRI‚ð—p‚¢‚½”]‘ÌÏ‚Ì”äŠrŒŸ“¢D‘æ61‰ñ“ú–{¬Ž™_ŒoŠw‰ï; 2019 May31-Jun 2; –¼ŒÃ‰®. i—DGŒû‰‰Üj
    26. ’†‘ºŒ’‘¾˜YA•Ÿ“‡@—DA‰Á“¡‘וãA‘ŠJË•½A’‡‰ª²’qŽqA“c’†•ü”üAŽíŽsq’ˆA‘«—§—YˆêA”öèO“TDRmyelin oligodendrocyte glycoprotein(MOG)R‘Ì—z«Ž‹_Œo‰Š‚Ì‚P—áD‘æ326‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2019. Jun 9; •Ÿˆä.
    27. Adachi Y. JSA-APAAACI symposium: gZeroh asthma mortality among Japanese children. ‘æ68‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïG2019 Jun 14-16; “Œ‹ž.
    28. Itazawa T, Kanatani K, Adachi Y, Nakayama T, Kurozawa Y, Hamazaki K, Tsuchida A, Inadera H. The impact of exposure to desert dust in infantsf symptoms and the countermeasure to reduce the effects. ‘æ68‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïG2019 Jun 14-16; “Œ‹ž.
    29. ˆÉ“¡–õ“TDƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™“šb‘§‚ƃtƒFƒmƒ^ƒCƒvvD‘æ68‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïG2019 Jun 14-16; “Œ‹ž.
    30. ˜a“c‘ñ–çA‘ºã«Œ[AˆÉ“¡–õ“TA”ÂàVŽõŽqA‘«—§—zŽqA‘«—§—YˆêDH•¨ƒAƒŒƒ‹ƒM[Ž™‚̶ŠˆŠÇ—Žw“±•\‚É‚¨‚¯‚霋Žª‹’‚ÌŒoŽž“I•Ï‰»D‘æ68‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïG2019 Jun 14-16; “Œ‹ž.
    31. ‰Á“¡‘וãAŽÄ“cKA‹´–{ˆè•vA–쑺‰ÀO. R¶Ü‚É‚æ‚è‹}«”Ä”­«”­]«”^ávÇiAGEPj‚ð”­Ç‚µ‚½’jŽ™—á. ‘æ68‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïG 2019 Jun. 14-16; “Œ‹ž.
    32. –x]’åŽuAŽíŽsq’ˆAꎓ¡@—IA‘«—§—YˆêD•xŽRŒ§“à‚É‚¨‚¯‚鬎™Ž€–SÇ—á‚Ì‚Ü‚Æ‚ß@Œ»ó‚ƉۑèA‚»‚µ‚ÄCDRŽÀŒ»‚ÉŒü‚¯‚ÄD‘æ33‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï; 2019 Jun 21-22; ‚³‚¢‚½‚ÜD
    33. œA–ìŒbˆêDƒVƒ“ƒ|ƒWƒEƒ€FS‹ØÇÇ—á‚©‚ç‚Ý‚½ŠwZS‘ŸŒŸf‚ÆS‘Ÿ“Ë‘RŽ€D‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïG2019 Jun 27-29GŽD–yD
    34. œA–ìŒbˆêA›“c^–çA‰ª•”^ŽqA’‡‰ª‰pKA¬ŒI^lAˆÉŒ\“ñû¶A¬àVˆ»‰ÀAŽs“c•™ŽqA”¨—R‹IŽqA¼“c®Ž÷. ƒVƒ“ƒ|ƒWƒEƒ€Fˆâ“`ŽqŒŸ¸‚ÄJS‹ØÇ‚ª‚ÆJ‚±‚Ü‚ÄJ‚í‚©‚é‚©? —L—p«‚Ɖۑè‚ɂ‚¢‚Ä. ‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2019 Jun 27-29; ŽD–yD
    35. œA–ìŒbˆêC‹{”ö¬–¾C‹g‰i³•vCˆÀ“c˜aŽuC¼Œ´‰h‹NCˆ¼‘ò ‰qC–x•ÄmŽuC¬Š_Ž –LC—§–ì Ž CŠâ–{áÁ—C“yˆä¯ŽOû¶Cò“c’¼ŒÈCZ—F’¼•ûC”¥–Ø‘å—SC‘¾“c–M—YC”¨ ’‰‘PC‹ƒmà_‘å–çC“c“à‹X¶C’·“ˆ³›‰C²“¡½ˆêCŽs“c•™ŽqDŠwZS‘ŸŒŸf‚©‚猩‚½S‹Øãk–§‰»áŠQ‚Ì—Õ°‘œD‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïG2019 Jun 27-29GŽD–yD
    36. ¬àVˆ»‰ÀA›“c^–çA‰ª•”^ŽqA¬ŒI^lAˆÉŒ\“ñ˜YAœA–ìŒbˆêAŽs“c•™Žq. –{–M‚É‚¨‚¯‚é‘ÙŽ™Šú”­ÇS‹ØÇ‚Ì•aŒ^•Êf’f‚Æ—\Œã. ‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2019 Jun 27-29; ŽD–yD
    37. ˆÉŒ\“ñ˜YA›“c^–çA‰ª•”^ŽqA¬ŒI^lA‹{”ö¬–¾A¬àVˆ»‰ÀAœA–ìŒbˆêAŽs“c•™ŽqA–F‘º’¼Ž÷D‘½E«‹Ø«•”SŽº’†ŠuŒ‡‘¹‚ÌÚׂÈ\‘¢•]‰¿‚É‚¨‚¢‚ÄMDCT 3DÄ\¬‰æ‘œ‚ª—LŒø‚Å‚ ‚éD‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2019 Jun 27-29; ŽD–yD
    38. ¬ŒI^lA›“c^–çA‰ª•”^ŽqA‹{”ö¬–¾AˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêAŽs“c•™ŽqA’¹’Ë‘å‰îA“Œ“cº•FA –F‘º’¼Ž÷D¶”x“®–¬Œ‡‘¹A”x“®–¬•ÙŒ‡‘¹‚ð‡•¹‚µ‚½ƒtƒ@ƒ[Žl’¥Ç‚ÌŠ·‹CŒŒ—¬•s‹Ït‚ɃXƒeƒ“ƒg—¯’u‚©J’˜Œø‚µ‚½22q11.2 Œ‡Ž¸ÇŒóŒQ‚̈ê—áD‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2019 Jun 27-29; ŽD–yD
    39. ‹{”ö¬–¾A›“c^–çA‰ª•”^ŽqA’‡‰ª‰pKAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêAŽs“c•™ŽqDS‹ØÇŠ³ŽÒ‚ÉŒ©o‚³‚ꂽTBX5 ƒ~ƒXƒZƒ“ƒX•ÏˆÙ‚Ì•a“IˆÓ‹`‚ÌŒŸ“¢D‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2019 Jun 27-29; ŽD–yD
    40. ‰ª•”^ŽqA›“c^–çA¬ŒI^lAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêAŽs“c•™ŽqA“cŒû‰ë“oA“Œ“cº•F. ƒ^ƒ_ƒ‰ƒtƒBƒ‹’†Ž~Œã‚Ƀ^ƒ“ƒpƒN˜Ro«ˆÝ’°Ç‚ÌŒy‰õ‚ð”F‚ß‚½’PSŽº‚ÌFontan/GlennpŒã‚Ì3—á. ‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2019 Jun 27-29; ŽD–yD
    41. ›“c^–çA‰ª•”^ŽqA‹{”ö¬–¾A¬ŒI^lA¬àVˆ»‰ÀAˆÉŒ\“ñ˜YAœA–ìŒbˆêAŽs“c•™ŽqA’¹’Ë‘å‰îA“Œ“cº•FA–F‘º’¼Ž÷DõF‘̃}ƒCƒNƒƒAƒŒƒC‰ðÍ‚É‚æ‚Á‚Äf’f‚µ‚½‘å“®–¬“ñë•ÙA‘å“®–¬kóÇASŽº’†ŠuŒ‡‘¹‚𔺂¤1q31.1-q32.1Œ‡Ž¸‚̈ê—áD‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2019 Jun 27-29; ŽD–yD
    42. ‰Á“¡—ŽqA›“c^–çA¬ŒI^lA‰ª•”^ŽqAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêA–F‘º’¼Ž÷A“Œ“cº•FAˆÀ“¡F«Aì•”GlDƒtƒ@ƒ[Žl’¥ÇpŒã‚ÌÁ‰»ŠÇoŒŒ‚ðŒ_‹@‚ÉŠÌŠO–å–¬•ÂÇÇ‚Æf’f‚³‚ꂽˆê—áD‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2019 Jun 27-29; ŽD–yD
    43. ’‡‰ª‰pKDŠCŠO—¯Šw•ñ‰ï -AHA’ZŠú—¯Šw(Boston Childrenfs Hospital)D‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïG2019 Jun 27-29GŽD–yD
    44. œA–ìŒbˆêD‹{“cÜŽóÜŽÒ•ñƒZƒbƒVƒ‡ƒ“DŽŸ¢‘ãƒV[ƒPƒ“ƒT[‚ð—p‚¢‚½–Ô—…“Iˆâ“`Žq‰ðÍ‚É‚æ‚éS‹Øãk–§‰»áŠQ‚̈â“`Žqf’f‚Æf—Â̋’“_Œ`¬D‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïG2019 Jun 27-29GŽD–yD
    45. ‘q–{@’A¼àVƒŽqA–{‹½˜a‹vA‘ŠJË•½A’‡‰ª²’qŽqA•½Šâ–¾ŽqA“c’†•ü”üA‹{@ˆêŽuAX‚±‚¸‚¦A‘êàV@¸D•xŽRŒ§‰º‚Ì‘‡•a‰@E¬Ž™‰È‚ðŽóf‚µ‚½_Œo«‚₹ǔ­ÇŽÒ‚ɂ‚¢‚ẴAƒ“ƒP[ƒg’²¸•ñi‘æˆê•ñjD‘æ42‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2019 Jul 7; •xŽR.
    46. ‹{”ö¬–¾A’‡‰ª‰pKAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆêA–q–{—D”üA‹g“cärD•xŽR‘åŠwNICU‚É‚¨‚¯‚éæ“V«SŽ¾Š³‚Ìf’fAŽ¡—ÂƂ»‚Ì—\ŒãD‘æ42‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2019 Jul 7; •xŽR.
    47. ¼“‡FŽ¡Arˆä”ü•äA’Þ@_”VA¼“c’¼“¿A–쑺ŒbŽqA‘«—§—YˆêA’†’Ø‹v”TD¶Œã1‚©ŒŽ‚É“_óoŒŒ‚Å”­Ç‚µ‚½V¶Ž™“¯Ží–Ɖu«ŒŒ¬”ÂŒ¸­ÇiNAITj‚Ì‘o‘Ù—áD‘æ42‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2019 Jul 7; •xŽR.
    48. ‹g“cärDŽüŽYŠúˆã—Âɂ¨‚¯‚é—Õ°—Ï— ‰ïê‚Ì200l‚É•·‚«‚Ü‚µ‚½ ‚ ‚È‚½‚Í‚Ç‚¤‚·‚éH—\Œã•s—Ç‚ÆŽv‚í‚ê‚éV¶Ž™‚ɑ΂·‚鎡—Õûj‚ɂ‚¢‚Ä ŠeŽ{Ý‚ÌŠî–{•ûj‚ð”äŠrŒŸ“¢‚·‚éD‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïG2019 Jul 13-15G¼–{D
    49. ’––”’qŽÀC’·‰ªvGCˆÀ“cˆê•½C–ؗ•ŽqCìè—TŽqC“c‘ºŒ«‘¾˜YC–q–{—D”üC‹g“cärD•ê‘Ì‚Ö‚Ì—°Ž_ƒ}ƒOƒlƒVƒEƒ€“Š—^‚ªŽ™‚Ìœ‘ãŽÓ‚É—^‚¦‚é‰e‹¿D‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïG2019 Jul 13-15G¼–{D
    50. ¼“‡FŽ¡C‘ºã«Œ[C‘ŠJË•½CˆÉ“¡–õ“TC“c’†•ü”üC‘«—§—YˆêC“c‘ºŒ«‘¾˜YC‹g“cärDTUBB2A•ÏˆÙ‚ð—L‚·‚éInfantile spasms‚ɑ΂µACTH—Ö@‚ª‘tŒ÷‚µ‚½’jŽ™—áD‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïG2019 Jul 13-15G¼–{D
    51. ˆÉ“¡–õ“TA´…@”VA‰Á“¡‘וãA”ÂàVŽõŽqA‘«—§—zŽqA‘«—§—YˆêD•êŽq•ÛŒ’Ž–‹Æ‚ł̬Ž™ƒAƒŒƒ‹ƒM[Ž¾Š³‚ɑ΂·‚é•ÛŒ’Žw“±‚ÌŽÀ‘Ô‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²¸D‘æ36‰ñ“ú–{¬Ž™—Õ°ƒAƒŒƒ‹ƒM[Šw‰ï; 2019 Jul 27-28; ˜a‰ÌŽR.
    52. ‘ŠJË•½DŠááÙ‰º‚‚ð’æ‚·‚邪Ž©ŒÈR‘̉A«‚Ì 12 Î’jŽ™—áD‘æ9‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï‰Ä‹GƒZƒ~ƒi[; 2019 Aug3-4G•xŽR.
    53. ’†—ÑŒºˆêA’|“à–œ•FA’·”ö‚݂ÂÙA‘«—§—YˆêD“ûŽ™Šú‚æ‚è•p‰ñ”­”M‚ª13”NŠÔŽ‘±‚µA“dŒ°ŠŒ©‚ª³í‚Å‚àŒ´”­«‘@–щ^“®•s‘SÇiPCDj‚Ìf’f‚ÉŽŠ‚Á‚½1—áD‘æ55‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï; 2019 Aug 25; •xŽRD
    54. ´…@”VA¬àVˆ»‰ÀA’؈äD—¢A‹{”ö¬–¾A’‡‰ª‰pKAˆÉŒ\“ñ˜YAœA–ìŒbˆêA–쑺ŒbŽqA‘«—§—YˆêDŠÔŽ¿«”x‰Š‚ð‡•¹‚µ‚½‰Ì•‘ŠêÇŒóŒQ‚̈ê—áD‘æ55‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï; 2019 Aug 25; •xŽRD
    55. ”ª–ØMˆêA“ˆ”ö@’qA–x]’åŽuAŽíŽsq’ˆA‘«—§—YˆêD•xŽRŽs‚É‚¨‚¯‚鎞ŠÔŠO¬Ž™‰Šú‹~‹}‘̧ˆÛŽ‚ɂ‚¢‚Ä‚Ì•af˜AŒg‚Ì–â‘è‚ƉۑèE[–é‘Ñ‚ÌŽóf‚ÌŽ¾•a•ª—ނɂ‚¢‚ÄD‘æ29‰ñ“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ï; 2019 Aug 31- Sep 1; •Ÿ‰ªD
    56. ˆÉ“¡–õ“TDŒú¶˜J“­È‚̃AƒŒƒ‹ƒM[Ž¾Š³‚ɑ΂·‚錻݂̎æ‚è‘g‚ÝD‘æ2‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠÖ“Œ’n•û‰ï; 2019 Sep 14; “Œ‹ž.
    57. rˆä”ü•äAŠì´‰èAÝ“cK‘¾˜YA˜a“c‹Å–@A‘ºã@ƒA²“¡@•×. DPP8 is a novel therapeutic target for multiple myelomaiDPP8‚Í‘½”­«œ‘Žî‚ÌV‚½‚ÈŽ¡—ÕW“I‚Å‚ ‚éj. ‘æ81‰ñ“ú–{ŒŒ‰tŠw‰ï; 2019 Oct 11-13; “Œ‹ž.
    58. œA–ìŒbˆêA›“c^–çA‰ª•”^ŽqA‹{”ö¬–¾A’‡‰ª‰pKAˆÉŒ\“ñ˜YA¬àVˆ»‰À. æ“V«SŽ¾Š³‚𔺂¤S‹Øãk–§‰»áŠQ‚Ì—Õ°‘œ. ‘æ28‰ñ“ú–{¬Ž™S‹ØŽ¾Š³Šw‰ï; 2019 Oct 19; ‘åã.
    59. ‹{”ö¬–¾A›“c^–çA‰ª•”^ŽqA’‡‰ª‰pKAˆÉŒ\“ñ˜YA¬àVˆ»‰ÀAœA–ìŒbˆê. S‹ØÇŠ³ŽÒ‚ÉŒ©o‚³‚ꂽTBX5 ƒ~ƒXƒZƒ“ƒX•ÏˆÙ‚Ì•a“IˆÓ‹`‚ÌŒŸ“¢. ‘æ28‰ñ“ú–{¬Ž™S‹ØŽ¾Š³Šw‰ï; 2019 Oct 19; ‘åã.
    60. ’‡‰ª‰pKC›“c^–çC‰ª•”^ŽqC‹{”ö¬–¾CˆÉŒ\“ñ˜YC¬àVˆ»‰ÀCœA–ìŒbˆêDStevens-JohnsonÇŒóŒQ‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚½IVIG•s‰ž‚ÌŠ¥“®–¬•a•Ï‚ð—L‚·‚éìè•a‚̈ê—áD‘æ39‰ñ“ú–{ìè•aŠw‰ïEŠwpW‰ïG2019 Oct 25-26G“Œ‹žD
    61. ŽíŽsq’ˆA”ª–ØMˆêD4‚©ŒŽŒ’f‚ð—˜—p‚µ‚½ƒƒNƒ`ƒ“çSçO‚ւ̃Aƒvƒ[ƒ`D‘æ51‰ñ“ú–{¬Ž™Š´õÇŠw‰ï, 2019 Oct 26-27; ˆ®ìD
    62. ‘«—§—zŽqA‘«—§—YˆêDƒCƒuƒjƒ“ƒOƒVƒ“ƒ|ƒWƒEƒ€uƒAƒŒƒ‹ƒQƒ“ƒRƒ“ƒ|[ƒlƒ“ƒgAra h 2 ‚ð—p‚¢‚½ƒs[ƒiƒbƒcƒAƒŒƒ‹ƒM[‚Ìf’f\œ‹Ž‰ðœ‚ð–ÚŽw‚µ‚Ä‚æ‚èˆÀ‘S‚È•‰‰×ŽŽŒ±‚ðŽÀŽ{‚·‚邽‚ß‚É\ vD‘æ56‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2019 Nov 2-3; ç—t.
    63. ˜a“c‘ñ–çA‘ºã«Œ[A´…@”VA‰Á“¡‘וãAˆÉ“¡–õ“TA”ÂàVŽõŽqA‘«—§—zŽqA‘«—§—YˆêDH•¨ƒAƒŒƒ‹ƒM[Ž¾Š³¶ŠˆŠÇ—Žw“±•\‚ð—p‚¢‚½”ñƒAƒŒƒ‹ƒM[ê–åˆã‚Ìf—ÃŽÀ‘ÔD‘æ56‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2019 Nov 2-3; ç—t.
    64. ‰Á“¡‘וãAˆÉ“¡–õ“TA’·”ö‚݂ÂÙA‘ºˆäG¶A•Ÿ‰Æ’CŽ÷AŽè’˃ˆê˜YA²“¡‚³‚­‚çA“¡àV—²•vA‘«—§—YˆêD‘æ‚Q‰ñ¬Ž™ƒAƒŒƒ‹ƒM[‹³ˆçƒZƒ~ƒi[iPediatric Allergy Skill Up Course: PASCOj‚É‚æ‚éŠwK•]‰¿‚ÌŒŸ“¢D‘æ56‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2019 Nov 2-3; ç—t.
    65. ¬ŒI–G‰ÔA”ÂàVŽõŽqA‰Á“¡‘וãA´…@”VA’†—ÑŒºˆêA˜a“c‘ñ–çAˆÉ“¡–õ“TA”óŒû@ŽûAŽRŒ³ƒŽqAìK”ü˜aA”öã—mˆêA‚”ö@Š²A‘ºãIŒ[A‘«—§—zŽqA‘«—§—YˆêDH•¨ƒAƒŒƒ‹ƒM[Ž™‚É‚¨‚¯‚éŒëHEŒëÚG‚É‚æ‚èƒAƒŒƒ‹ƒM[Çó‚ð—U”­‚µ‚½Ž–—á‚Ì”wŒi‚ÉŠÖ‚·‚é’²¸D‘æ56‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2019 Nov 2-3; ç—t.
    66. œA–ìŒbˆêD¬Ž™S‹ØÇ‚É‚¨‚¯‚鎟¢‘ãƒV[ƒPƒ“ƒT[‚É‚æ‚é–Ô—…“I‰ð̬͂‰ÊD“ú–{l—Þˆâ“`Šw‰ï‘æ64‰ñ‘å‰ïG2019 Nov 6-9G’·èD
    67. ŽíŽsq’ˆDŽq‚Ç‚à‚Ì‘ŸŠí’ñ‹Ÿ‚ÆI––Šú‚É‚¨‚¯‚é‰Æ‘°Žx‰‡D‘æ15‰ñ“ú–{ˆÚAEĶˆã—ÊŌìŠw‰ï ŠwpW‰ïG2019 Nov 9; ‰º–ìD
    68. rˆä”ü•äA’Þ_”VA¼“c’¼“¿A’|‘º‹žŽqA’†“‡²rA–쑺ŒbŽq. SwyerÇŒóŒQ‚É”­Ç‚µ‚½–¢•ª‰»ãó×–EŽî‚̈ê—á. ‘æ61‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ï; 2019 Nov 14-16; L“‡.
    69. ¼–ì³’mAŒÜ\—’—²•vA‘«—§—YˆêDŽ¡—ÃI—¹Œã‚ÉÇó‚ªÄ”R‚µ‚½šb‘§Ç—á‚ÌŒŸ“¢. ‘æ52‰ñ¬Ž™ŒÄ‹zŠíŠw‰ï; 2019 Nov 15-16; Ž­Ž™“‡.
    70. ’†—ÑŒºˆêA’|“à–œ•FA‘ƒ”V“à‘å•ãA“´Œû‘ñ–çA’·”ö‚Ý‚ÂJ‚ÙA‘«—§—Yˆê. “ûŽ™Šú‚©‚玑±‚·‚é•p‰ñ”­”M‚ɑ΂µ‚ÄAŒÄ‹z—Šw—Ö@‚Æ‹z“ü—Ö@‚É‚æ‚é”rá‚‚ª‘tŒ÷‚µ‚½“dŒ°ŠŒ©³í‚ÈŒ´”­«‘@–щ^“®•s‘SÇ‚Ì13ΗŽq—á. ‘æ52‰ñ¬Ž™ŒÄ‹zŠíŠw‰ï; 2019 Nov 15-16; Ž­Ž™“‡.
    71. ”óŒû@ŽûA‹”ö@—IA²‹vŠÔ—FŽqA¬ìŽŸ˜YA¡‘º”Ž–¾AŒE“c”Ž“¹A‘«—§—YˆêDƒ‰ƒCƒmƒEƒCƒ‹ƒXŠ´õ‚É‚æ‚èŠw“¶Šú‚ÉdÇ”x‰Š‚𗈂µ‚½2Ç—áD‘æ52‰ñ¬Ž™ŒÄ‹zŠíŠw‰ï; 2019 Nov 15-16; Ž­Ž™“‡.
    72. ‰Á“¡‘וãAˆÉ“¡–õ“TA’·”ö‚݂ÂÙA‘ºˆäG¶A•Ÿ‰Æ’CŽ÷AŽè’˃ˆê˜YA²“¡‚³‚­‚çA“¡àV—²•vA‘«—§—YˆêD¬Ž™ƒAƒŒƒ‹ƒM[‹³ˆçƒZƒ~ƒi[iPediagtric Allergy Skill Up Course: PASCOj‚ÌŽæ‚è‘g‚݂Ƭ‰ÊD‘æ1‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï–k—¤’n•û‰ï; 2019 Nov 24; ‹à‘òD
    73. “c‘ºŒ«‘¾˜YD²‘½ƒtƒFƒ[ƒVƒbƒvƒLƒ“ƒOƒXƒJƒŒƒbƒWƒvƒƒOƒ‰ƒ€—¯Šw•ñD‘æ64‰ñ“ú–{V¶Ž™¶ˆçˆãŠw‰ïG2019 Nov 27-29GŽ­Ž™“‡D
    74. –q–{—D”üC’·‰ªvGC“c‘ºŒ«‘¾˜YC’––”’qŽÀCìú±—TŽqC‹g“cärD“–‰@‚ÅŒoŒ±‚µ‚½CPTiƒJƒ‹ƒjƒ`ƒ“ ƒpƒ‹ƒ~ƒgƒCƒ‹ ƒgƒ‰ƒ“ƒXƒtƒFƒ‰[ƒ[j‡UŒ‡‘¹Ç‹U—z«Ç—á‚ÌŒŸ“¢D‘æ64‰ñ“ú–{V¶Ž™¶ˆçˆãŠw‰ïG2019 Nov 27-29GŽ­Ž™“‡D
    75. “c‘ºŒ«‘¾˜YC’·‰ªvGC’––”’qŽÀCìú±—TŽqC–q–{—D”üC‹g“cärDMelting Temperature (Tm) mapping–@‚É‚æ‚é‘Šú‚Ì”sŒŒÇ‹N‰Š‹Û“¯’è‚̉”\«D`‘”­Œ^‘å’°‹Û”sŒŒÇ‚ÅŽ€–S‚µ‚½‘ŽYŽ™‚ÌŒoŒ±‚©‚ç`D‘æ64‰ñ“ú–{V¶Ž™¶ˆçˆãŠw‰ïG2019 Nov 27-29GŽ­Ž™“‡D
    76. ìè—TŽqC’·‰ªvGC’––”’qŽÀC“c‘ºŒ«‘¾˜YC–q–{—D”üC‹g“cärD”]ŽºEƒNƒ‚–Œ‰ºo‚ÌŠg‘å‚Í—\Œã•s—LjöŽq‚©\–žŠú‘Š“–‚Ì“ª•”MRI‰æ‘œ‚ÆC³18‚©ŒŽŽž—\Œã‚ÌŒŸ“¢|D‘æ64‰ñ“ú–{V¶Ž™¶ˆçˆãŠw‰ïG2019 Nov 27-29GŽ­Ž™“‡D
    77. ‘«—§—YˆêD‹³ˆçu‰‰u¬Ž™‚Ì‹C“¹ˆÙ•¨Ž–ŒÌ‚ÌŒ»ó‚Æ—\–hv. ‘æ53‰ñ“ú–{¬Ž™ŠO‰ÈŠw‰ï“ŒŠC–k—¤’n•û‰ï; 2019 Dec 1G•xŽR.
    78. ûüú±–ƒ”üAŽíŽsq’ˆA‰Á“¡‘וãAœA–ìŒbˆêA‘«—§—Yˆê. •xŽRŒ§‚É‚¨‚¯‚éCDR (child death review) ŽÀŒ»‚Ö‚ÌŽæ‚è‘g‚Ý. \u–h‚°‚éŽq‚Ç‚à‚ÌŽ€v‚ðŒ¸‚ç‚¹\. ‘æ327‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2019 Dec 8G‹à‘ò.

    2018”N

  • ’˜‘
    1. ‘«—§—Yˆê.Ç—á‚ð’Ê‚µ‚ÄŠw‚Ô ”N‘ã•ÊH•¨ƒAƒŒƒ‹ƒM[‚Ì‚·‚×‚Ä ‰ü’ù2”ÅDŠC˜VàVŒ³G•Ò. “Œ‹ž: “ìŽR“°; 2018. H•¨ƒAƒŒƒ‹ƒM[ ЊQŽž‚̑Ήž. p110-3.
    2. ‘«—§—Yˆê. ¡“ú‚ÌŽ¡—ÃŽwj 2018”N“x”ÅDŽRŒû@“O, –kŒ´Œõ•v•Ò. “Œ‹ž: ˆãŠw‘‰@: 2018: ¬Ž™‚Ì”­]«Ž¾Š³Dp1402-4.
    3. –q–{—D”ü. ¡“ú‚ÌŽ¡—ÃŽwj@Ž„‚Í‚±‚¤Ž¡—µ‚Ä‚¢‚é@2018”N”ÅD•ŸˆäŽŸ–•ÒD“Œ‹ž; ˆãŠw‘‰@; 2018. V¶Ž™‚Ì”sŒŒÇC‘–Œ‰ŠDP1373-4
    4. œA–ìŒbˆê, Žs“c•™Žq. ¬Ž™‰Èf—Ãi81‘ju“ÁWF¬Ž™‚ÌŽ¡—ÃŽwjv. “Œ‹ž; f’f‚ÆŽ¡—ÃŽÐ; 2018 Apr. ”ì‘åŒ^S‹ØÇ; p371-3.
    5. œA–ìŒbˆê, Žs“c•™Žq. ¬Ž™‰Èf—Ãi81‘ju“ÁWF¬Ž™‚ÌŽ¡—ÃŽwjv. “Œ‹ž; f’f‚ÆŽ¡—ÃŽÐ; 2018 Apr. Šg’£Œ^S‹ØÇ; p374-6.
    6. œA–ìŒbˆê, Žs“c•™Žq. ¬Ž™zŠÂŠíŠw. “Œ‹ž; f’f‚ÆŽ¡—ÃŽÐ; 2018. ”ì‘åŒ^S‹ØÇ; p601-4.
    7. œA–ìŒbˆê, Žs“c•™Žq. ¬Ž™zŠÂŠíŠw. “Œ‹ž; f’f‚ÆŽ¡—ÃŽÐ; 2018. S‹Øãk–§‰»áŠQ; p618-22.
    8. ˆÉ“¡–õ“T. H•¨ƒAƒŒƒ‹ƒM[‚Ì’mŽ¯FŠÇ—@Çó‚ƑΉž.@V”ÅH•¨ƒAƒŒƒ‹ƒM[‚̉h—{Žw“±. ŠC˜VàVŒ³GŠÄC. “Œ‹ž: ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ; 2018 p40-3.
  • Œ´’˜
    1. Yoshida T, Matsumura K, Tsuchida A, Hamazaki K, Inadera H; Japan Environment and Childrenfs Study Group. Association between cesarean section and constipation in infants: the Japan Environment and Children's Study (JECS). BMC Res Notes. 2018 Dec 12; 11(1): 882.
    2. Hirono K, Hata Y, Nakazawa M, Momoi N, Tsuji T, Matsuoka T, Ayusawa M, Abe Y, Hayashi T, Tsujii N, Abe T, Sakaguchi H, Wang C, Takasaki A, Takarada S, Okabe M, Miyao N, Nakaoka H, Ibuki K, Saito K, Ozawa S, Nishida N, Bowles NE, Ichida F. Clinical and Echocardiographic Impact of Tafazzin Variants on Dilated Cardiomyopathy Phenotype in Left Ventricular Non-Compaction Patients in Early Infancy. Circ J. 2018 Sep 25; 82(10): 2609-18.
    3. Hirono K, Sakai T, Hata Y, Nishida N. The presence of multiple variants affects the clinical phenotype and prognosis in left ventricular noncompaction after surgery. J Thorac Cardiovasc Surg. 2018 Mar; 155(3): e101-9.
    4. Kawasaki Y, Makimoto M, Samejima A, Yoneda N, Higashimoto K, Soejima H, Yoshida T. Hepatoblastoma in an extremely low birth-weight infant with Beckwith-Wiedemann syndrome. Pediatr Neonatol. 2018 Oct; 59(5): 523-4.
    5. Nakaoka H, Hirono K, Yamamoto S, Takasaki I, Takahashi K, Kinoshita K, Takasaki A, Nishida N, Okabe M, Ce W, Miyao N, Saito K, Ibuki K, Ozawa S, Adachi Y, Ichida F. MicroRNA-145-5p and microRNA-320a encapsulated in endothelial microparticles contribute to the progression of vasculitis in acute Kawasaki Disease.Sci Rep. 2018 Jan 17; 8(1): 1016.
    6. Takasaki A, Hirono K, Hata Y, Wang C, Takeda M, Yamashita JK, Chang B, Nakaoka H, Okabe M, Miyao N, Saito K, Ibuki K, Ozawa S, Sekine M, Yoshimura N, Nishida N, Bowles NE, Ichida F. Sarcomere gene variants act as a genetic trigger underlying the development of left ventricular noncompaction. Pediatr Res. 2018 Nov; 84(5): 733-42.
    7. Okabe M, Hirono K, Tamura K, Ichida F, Kanegane H. Reactive peripheral blood plasmacytosis in Kawasaki disease. Pediatr Int. 2018 Sep; 60(9): 884-5.
    8. Shimomura M, Ito Y, Tanaka H, Meguro T, Kimura M. Increased serum cortisol levels on oral food challenge in infants with protein-induced enterocolitis syndrome. Pediatr Int. 2018 Jan; 60(1): 13-8.
    9. Hamazaki K, Takamori A, Tsuchida A, Kigawa M, Tanaka T, Ito M, Adachi Y, Saito S, Origasa H, Inadera H; Japan Environment and Children's Study (JECS) Group. Dietary intake of fish and n-3 polyunsaturated fatty acids and risks of perinatal depression: The Japan Environment and Children's Study (JECS). J Psychiatr Res. 2018 Nov 28; 98:9-16.
    10. Yoshida K, Sasaki M, Adachi Y, Itazawa T, Odajima H, Saito H, Akasawa A. Childhood asthma control in Japan: A nationwide, cross-sectional, web-based survey. Asian Pac J Allergy Immunol. 2018 Mar; 36(1): 16-21.
    11. Takase N, Igarashi N, Taneichi H, Yasukawa K, Honda T, Hamada H, Takanashi JI. Infantile traumatic brain injury with a biphasic clinical course and late reduced diffusion. J Neurol Sci. 2018 Jul; 390:63-6.
    12. Hosoki K, Jaruga P, Itazawa T, Aguilera-Aguirre L, Coskun E, Hazra TK, Boldogh I, Dizdaroglu M, Sur S. Excision-release of oxidatively-induced DNA base lesions from the lung genome by cat dander extract challenge stimulates allergic airway inflammation. Clin Exp Allergy. 2018 Dec; 48(12): 1676-87.
    13. Yoneda S, Yoneda N, Shiozaki A, Yoshino O, Ueno T, Niimi H, Kitajima I, Tamura K, Kawasaki Y, Makimoto M, Yoshida T, Saito S. 17OHP-C in patients with spontaneous preterm labor and intact membranes: is there an effect according to the presence of intra-amniotic inflammation? Am J Reprod Immunol. 2018 Sep; 80(3): e12867.
    14. Imai-Okazaki A, Kishita Y, Kohda M, Yatsuka Y, Hirata T, Mizuno Y, Harashima H, Hirono K, Ichida F, Noguchi A, Yoshida M, Tokorodani C, Nishiuchi R, Takeda A, Nakaya A, Sakata Y, Murayama K, Ohtake A, Okazaki Y. Barth Syndrome: Different Approaches to Diagnosis. J Pediatr. 2018 Feb; 193:256-260.
    15. Aoki M, Hirono K, Higuma T, Suzuki Y, Nakayama K, Ichida F, Origasa H, Nishida N, Imura J, Emoto N, Yoshimura N. Endothelin-1 may play an important role in the Fontan circulation. Interact Cardiovasc Thorac Surg. 2018 Mar 1; 26(3): 480-6.
    16. Aoki M, Hirono K, Higuma T, Suzuki Y, Nakayama K, Yamashita A, Fukahara K, Ichida F, Emoto N, Yoshimura N. Pulmonary vascular disease in a failed Fontan patient with Down's syndrome. Gen Thorac Cardiovasc Surg. 2018 May; 66(5): 299-302.
    17. Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T, Ogihara Y, Ito S, Takatsuki S, Katsumata N, Suzuki Y, Takenaka S, Hirono K, Kobayashi T, Suzuki H, Suganuma E, Takahashi K, Saji T; Committee of Survey on Infliximab use for Kawasaki disease. Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan. J Pediatr. 2018 Apr; 195:115-120.e3.
    18. Miura M, Kobayashi T, Kaneko T, Ayusawa M, Fukazawa R, Fukushima N, Fuse S, Hamaoka K, Hirono K, Kato T, Mitani Y, Sato S, Shimoyama S, Shiono J, Suda K, Suzuki H, Maeda J, Waki K; and The Z-score Project 2nd Stage Study Group, Kato H, Saji T, Yamagishi H, Ozeki A, Tomotsune M, Yoshida M, Akazawa Y, Aso K, Doi S, Fukasawa Y, Furuno K, Hayabuchi Y, Hayashi M, Honda T, Horita N, Ikeda K, Ishii M, Iwashima S, Kamada M, Kaneko M, Katyama H, Kawamura Y, Kitagawa A, Komori A, Kuraishi K, Masuda H, Matsuda S, Matsuzaki S, Mii S, Miyamoto T, Moritou Y, Motoki N, Nagumo K, Nakamura T, Nishihara E, Nomura Y, Ogata S, Ohashi H, Okumura K, Omori D, Sano T, Suganuma E, Takahashi T, Takatsuki S, Takeda A, Terai M, Toyono M, Watanabe K, Watanabe M, Yamamoto M, Yamamura K. Association of Severity of Coronary Artery Aneurysms in Patients With Kawasaki Disease and Risk of Later Coronary Events. JAMA Pediatr. 2018 172(5): e180030.
    19. Yokoyama R, Kinoshita K, Hata Y, Abe M, Matsuoka K, Hirono K, Kano M, Nakazawa M, Ichida F, Nishida N, Tabata T. A mutant HCN4 channel in a family with bradycardia, left bundle branch block, and left ventricular noncompaction. Heart Vessels. 2018 Jul; 33(7): 802-819.
    20. Fujino M, Tsuda E, Hirono K, Nakata M, Ichida F, Hata Y, Nishida N, Kurosaki K. The TNNI3 Arg192His mutation in a 13-year-old girl with left ventricular noncompaction. J Cardiol Cases. 2018 Jul 1; 18(1): 33-36.
    21. ‹g“cär, •½Šâ–¾Žq, ˆÉŒ\“ñ˜Y, –q–{—D”ü, ’––”’qŽÀ, “c‘ºŒ«‘¾˜Y, ìú±—TŽq, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. 3ÎŽ™Bayley”­’BŒŸ¸‚É‚æ‚éæ“V«SŽ¾Š³Ž™‚Æ‹É’áo¶‘ÌdŽ™‚Ì”­’B—\Œã. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ 2018 122(6): 1010-7.
    22. “c‘ºŒ«‘¾˜Y, ’©“c—T‹M, ›@ÊŽq, ŠâŒ©—TŽq, Œ´“c–¾‰À, ‘å¼@‘, “c’†—TŽq, ŽsꔎK. –{–M‚É‚¨‚¯‚é‘ŽYŽ™‚ÌÇŒó«Œã“V«ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠ´õÇ‚Ì”­Ç—lŽ®‚ÉŠÖ‚·‚镶Œ£“IlŽ@. “ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŽGŽ 2018 May; 54(1): 39-45.
    23. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—zŽq, ”óŒû@Žû, •£àV—³–ç, ŽRŒ³ƒŽq, ‚”ö@Š², ‘ºãIŒ[, ‘«—§—Yˆê. H•¨ƒAƒŒƒ‹ƒM[Ž™‚¨‚æ‚Ñ‚»‚Ì•ÛŒìŽÒ‚ɑ΂·‚éƒAƒhƒŒƒiƒŠƒ“Ž©ŒÈ’ŽËŠíiƒGƒsƒyƒ“Rj‚ðŽg—p‚·‚é“K؂ȃ^ƒCƒ~ƒ“ƒO‚Ì—‰ð“xD“ú–{¬Ž™—Õ°ƒAƒŒƒ‹ƒM[Šw‰ïŽGŽ 2018;16:347-53.
    24. ¡ˆää‰p, ‘«—§—Yˆê, ŽsŠÛ’q_, ã“cN‹v, ”óŒû¹F. ‘æ2‰ñ¬Ž™‹CŠÇE‹CŠÇŽxˆÙ•¨‚ÉŠÖ‚·‚é‘S‘’²¸Œ‹‰Ê. “ú–{¬Ž™ŒÄ‹zŠíŠw‰ïŽGŽ2018 Jun; 29(1): 114-21.
    25. Šâ“c‚Ý‚Ç‚è, ‹g“c—TŽq, •ŠÝ’t“Þ, ’†ŽR”üç, ì㮎q, ’†ŽR”üŽ÷, “‡“c‰pŽi, Œ@@D, ¬ŒI^l, ’†‘ºí”V. ŠwZS‘ŸŒŸf‚ÉS‘Ÿ’´‰¹”gŒŸ¸‚𓱓ü‚µ‚½¬‰Ê. —\–hˆãŠwƒWƒƒ[ƒiƒ‹ 2018 Jul; 501:18-23.
    26. ŽsìŒõ‘¾˜Y, r–Ø@®, ÎŒ´—BŽj, ”~Œ´@ŽÀ, ’·‘º•q¶, –Ø‘º@ãÄ, ŽíŽsq’ˆ, ûñ@’mŒõ, V’ÃŒ’—T, ¼ŽR˜aF, ŽR–{„Žm, “ú–{¬Ž™‹~‹}ˆãŠw‰ï”]Ž€–â‘茟“¢ˆÏˆõ‰ïDˆê”ÊŽÐ’c–@l“ú–{¬Ž™‹~‹}ˆãŠw‰ï‰ïˆõ‚Ì”]Ž€E”]Ž€‰º‘ŸŠí’ñ‹Ÿ‚É‚¨‚¯‚é‹s‘ÒŽ™‚Ì”–â‘è‚ÉŠÖ‚·‚éˆÓŽ¯’²¸D“ú–{¬Ž™‹~‹}ˆãŠw‰ïŽGŽ 2018; 17(3): 548-64.
    27. ˆÉ“¡—z—¢, ’·‘º•q¶, ŽsìŒõ‘¾˜Y, “c‘º‘ì–ç, ‘º“c—S“ñ, ŒE“c@–ž, •½–{—´Œá, ¬ŽR“T‹v, –Øè‘P˜Y, ŽR–{‰pˆê, _‰€~Ži, ˆäãM–¾, •‚ŽR‰zŽj, ²“¡Œú•v, ŽíŽsq’ˆ, ‰ª“c@L, ´àVLK, “ú–{¬Ž™‹~‹}ˆãŠw‰ï’²¸Œ¤‹†ˆÏˆõ‰ïD¬Ž™‹~‹}d“ÄŽ¾Š³“o˜^’²¸‚Ì“à—e‚Æ‘S‘ÌWŒvŒ‹‰Ê@‘S‘‹K–͂̃f[ƒ^ƒx[ƒX\’z‚ÌŽŽ‚ÝD“ú–{¬Ž™‹~‹}ˆãŠw‰ïŽGŽ 2018; 17(3): 565-7.
    28. •½–{—´Œá, ’·‘º•q¶, ˆÉ“¡—z—¢, ŽsìŒõ‘¾˜Y, “c‘º‘ì–ç, ‘º“c—S“ñ, ŒE“c@–ž, ¬ŽR“T‹v, –Øè‘P˜Y, ŽR–{‰pˆê, _‰€~Ži, ˆäãM–¾, •‚ŽR‰zŽj, ²“¡Œú•v, ŽíŽsq’ˆ, ‰ª“c@L, ´àVLK, “ú–{¬Ž™‹~‹}ˆãŠw‰ï’²¸Œ¤‹†ˆÏˆõ‰ïDV‚½‚ÉlHŠ·‹C—Ö@‚ðŽÀŽ{‚µ‚½Ç—á‚Ì‚Ü‚Æ‚ß@¬Ž™‹~‹}d“ÄŽ¾Š³“o˜^’²¸(Japan Registry System for Children with critical disease;JRSC)‚ÌWŒvŒ‹‰Ê‚æ‚èD“ú–{¬Ž™‹~‹}ˆãŠw‰ïŽGŽ 2018; 17(3): 568-9.
    29. ŽR–{‰pˆê, ’·‘º•q¶, ˆÉ“¡—z—¢, ŽsìŒõ‘¾˜Y, “c‘º‘ì–ç, ‘º“c—S“ñ, ŒE“c@–ž, •½–{—´Œá, ¬ŽR“T‹v, –Øè‘P˜Y, _‰€~Ži, ˆäãM–¾, •‚ŽR‰zŽj, ²“¡Œú•v, ŽíŽsq’ˆ, ‰ª“c@L, ´àVLK, “ú–{¬Ž™‹~‹}ˆãŠw‰ï’²¸Œ¤‹†ˆÏˆõ‰ïD‰»”^«‘–Œ‰ŠÇ—á‚Ì‚Ü‚Æ‚ß@¬Ž™‹~‹}d“ÄŽ¾Š³“o˜^’²¸(Japan Registry System for Children with critical disease;JRSC)‚ÌWŒvŒ‹‰Ê‚æ‚èD“ú–{¬Ž™‹~‹}ˆãŠw‰ïŽGŽ 2018; 17(3): 570-1.
    30. ¬ŽR“T‹v, ’·‘º•q¶, ˆÉ“¡—z—¢, ŽsìŒõ‘¾˜Y, “c‘º‘ì–ç, ‘º“c—S“ñ, ŒE“c@–ž, •½–{—´Œá, –Øè‘P˜Y, ŽR–{‰pˆê, _‰€~Ži, ˆäãM–¾, •‚ŽR‰zŽj, ²“¡Œú•v, ŽíŽsq’ˆ, ‰ª“c@L, ´àVLK, “ú–{¬Ž™‹~‹}ˆãŠw‰ï’²¸Œ¤‹†ˆÏˆõ‰ïDV‚½‚É‹s‘Ò‚ª‹^‚í‚ꂽ“ü‰@Ç—á‚Ì‚Ü‚Æ‚ß@¬Ž™‹~‹}d“ÄŽ¾Š³“o˜^’²¸(Japan Registry System for Children with critical disease;JRSC)‚ÌWŒvŒ‹‰Ê‚æ‚èD“ú–{¬Ž™‹~‹}ˆãŠw‰ïŽGŽ 2018; 17(3): 572-3.
    31. –Øè‘P˜Y(“ú–{¬Ž™‹~‹}ˆãŠw‰ï), ’·‘º•q¶, ˆÉ“¡—z—¢, ŽsìŒõ‘¾˜Y, “c‘º‘ì–ç, ‘º“c—S“ñ, ŒE“c@–ž, •½–{—´Œá, ¬ŽR“T‹v, ŽR–{‰pˆê, _‰€~Ži, ˆäãM–¾, •‚ŽR‰zŽj, ²“¡Œú•v, ŽíŽsq’ˆ, ‰ª“c@L, ´àVLK, “ú–{¬Ž™‹~‹}ˆãŠw‰ï’²¸Œ¤‹†ˆÏˆõ‰ïDŽ€–SÇ—á‚Ì‚Ü‚Æ‚ß@¬Ž™‹~‹}d“ÄŽ¾Š³“o˜^’²¸(Japan Registry System for Chidren with critical disease;JRSC)‚ÌWŒvŒ‹‰Ê‚æ‚èD“ú–{¬Ž™‹~‹}ˆãŠw‰ïŽGŽ 2018; 17(3): 574-5.
    32. “¡“cC•½, ’†ì@—º, ¼“cŒ\Œá, ²“¡@Œ[, ‰P“c˜a¶, œA–ìŒbˆê, Žs“c•™Žq, “ñ’J@•, ŒÜ\—’“o, ”¨èŠì–F. Wolff- Parkinson-WhiteÇŒóŒQ‚É‚¨‚¯‚éSŽº‘Šú‹»•±‚ªS‹@”\‚É‹y‚Ú‚·‰e‹¿. “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 2018 Apr; 34(2): 63-71.
  • Ç—á•ñ
    1. Kohashi K, Ishiyama A, Yuasa S, Tanaka T, Miya K, Adachi Y, Sato N, Saitsu H, Ohba C, Matsumoto N, Murakami Y, Kinoshita T, Sugai K, Sasaki M. Epileptic apnea in a patient with inherited glycosylphosphatidylinositol anchor deficiency and PIGT mutations. Brain Dev. 2018 Jan; 40(1): 53-57.
    2. Watanabe N, Higashi H, Nakamura S, Nomura K, Adachi Y, Taguchi M. The possible clinical impact of risperidone on P-glycoprotein-mediated transport of tacrolimus: A case report and in vitro study. Biopharm Drug Dispos. 2018 Jan; 39(1): 30-37.
    3. rˆä”ü•ä, ŽíŽsq’ˆ, ˜a“c‘ñ–ç, ›“c^–ç, ’†—ÑŒºˆê, ‘«—§—Yˆê, ’ß“cŽu, ’·’Jì‹v–í. dÇA“ª“î‰»Ç‚ð‡•¹‚µ‚½‘æ4”ÔõF‘Ì’·˜r’†ŠÔ•”Œ‡Ž¸‚Ì’jŽ™—á. ¬Ž™‰È—Õ° 2018 Jan; 71(1): 7-14.
    4. ˜a“c‘ñ–ç, ’‡‰ª²’qŽq, “c’†•ü”ü, ’†—ÑŒºˆê, ŽíŽsq’ˆD’†•«ŽO‘Š«”A•öÇ‚ð‡•¹‚µ‚½BŒQ˜A½‹…‹Û‘–Œ‰Š‚̈ê—áD“ú–{¬Ž™‹~‹}ˆãŠw‰ïŽGŽ 2018; 17(3): 468-72.
    5. –x]’åŽu, ŽíŽsq’ˆ, “c’†•ü”ü, ‹{@ˆêŽu, –{‹½˜a‹v, ‘«—§—Yˆê, ¼–ìˆêŽO. ’ág’·‚Å,ŒJ‚è•Ô‚·‚¯‚¢‚ê‚ñ”­ì‚ðŒ_‹@‚Éf’f‚³‚ꂽMELAS‚Ì1—á. ¬Ž™‰È 2018 AprG59(4)F353-4.
    6. –x]’åŽu, ‘ŠJË•½, ’†’Ø‹v”T, ŽÂ茒‘¾˜Y, ŽíŽsq’ˆ, ‘«—§—Yˆê, ‚—œˆê. •a‰Šú‚ɉ‹t«”]—À–c‘å•”•a•Ï‚ð—L‚·‚éŒyÇ”]‰ŠE”]Ç‚Æf’fŒãA“ÁˆÙ‚ȉ摜•Ï‰»‚𗈂µ‚½12Î’jŽ™—á. ¬Ž™‰È—Õ° 2018 Jun; 71(6): 1057-63.
    7. ‹”ö@—I, ”óŒû@Žû, ²‹vŠÔ—FŽq, 㨌hˆê˜Y, ¬ìŽŸ˜Y, ¡‘º”Ž–¾, ŒE“c”Ž“¹, ‘«—§—Yˆê. •S“úŠP‚ÌázŠP‚É‚æ‚éƒ`ƒAƒm[ƒ[‚ɑ΂µNasal high-flow therapy‚ª‘tŒø‚µ‚½4ƒ•ŒŽ—Ž™—á. ¬Ž™‰È—Õ° 2018 Jun; 71(6): 1077-81.
    8. •½ŠC—Ç”ü, ²“¡—L”ü, ‹Tˆä’¼Æ, éŒË²’mŽq, œA–ìŒbˆê, Žs“c•™Žq, ”¨—R‹IŽq,¼“c®Ž÷, “c’†•qŽ. ‘ÙŽ™Šú‚æ‚èŠg’£Œ^S‹ØÇ‚Æf’f‚³‚êŽüŽYŠúŽ€–S‚µ‚½ŒZ’í—á. “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 2018 Jan; 34(1): 39-45.
    9. ‰i”öG”V, ¼ˆä@‰s, ¬ì’õŽ¡, X’å’¼Æ, Š¢–칑å, ŠŒ´L‰î, œA–ìŒbˆê, Žs“c•™Žq, •àVŠ°Žj. ”­”M‚𔺂¤‚¯‚¢‚ê‚ñdÏó‘Ô‚Å”­Ç‚µ‚½SCN5A•ÏˆÙ‚É‚æ‚éSŽº•p”‚Ì’jŽ™—á. “ú–{¬Ž™‹~‹}ˆãŠw‰ïŽGŽ 2018 17(3): 512-6.
  • ‘à
    1. ‘«—§—Yˆê. y¬Ž™Ž¾Š³:f’f‚ÌŠî‘b‚ƃ|ƒCƒ“ƒgzŒÄ‹zŠíŽ¾Š³. ŒŽŠÔƒŒƒWƒfƒ“ƒg. 2018 Jun; 11(6): 30-6.
    2. ‘«—§—zŽq, ‘«—§—Yˆê. y¬Ž™‚ÌŽ¡—ÃŽwjz ŒÄ‹zŠí@‹C“¹ˆÙ•¨. ¬Ž™‰Èf—à 2018 Apr; 81(‘): 432-4.
    3. ‹g“cär. y¬Ž™‚ÌŽ¡—ÃŽwjz V¶Ž™@V¶Ž™ˆê‰ß«‘½ŒÄ‹z. ¬Ž™‰Èf—à 2018 Apr; 81(‘): 939-40.
    4. ‹g“cär. yV¶Ž™‚ÌŒŸ¸’lƒAƒZƒXƒƒ“ƒg@‹êŽè‚ÈŒŒƒKƒX‚à‚µ‚Á‚©‚èƒ}ƒXƒ^[!z ŒŒ‰tƒKƒX•ªÍ@ŒŒ‰tƒKƒX•ªÍ‚Æ‚Í?@pHAPaCO2APaO2AHCO3-ABE‚ÌŠî–{. ƒyƒŠƒlƒCƒ^ƒ‹ƒPƒA 2018May; 37(5): 447-52.
    5. ‹g“cär. yŽY‰È‚Å‚ÌV¶Ž™ˆã—Ë@ŠíƒKƒCƒhz ŒŸ¸‹@Ší@ŒŒ‰tƒKƒX•ªÍ‘•’u. ŽüŽYŠúˆãŠw 2018 Jun; 48(6): 693-6.
    6. ”ÂàVŽõŽq. y¬Ž™‚ÌŽ¡—ÃŽwjz ‚æ‚­‚Ý‚ç‚ê‚éÇóEÇŒó‚Ö‚Ì‘ÎǗÖ@@ŠPšuEšb–Â. ¬Ž™‰Èf—à 2018 Apr; 81(‘): 9-12.
    7. œA–ìŒbˆê, Žs“c•™Žq. “KØ‚ÈŠwZS‘ŸŒŸf-Œ©“¦‚µ‚Ä‚Í‚¢‚¯‚È‚¢ƒ|ƒCƒ“ƒg‚ÆŠÇ—z S‹ØÇ. “ú–{ˆãŽ–V•ñ 2018 Mar; 4898: 32-9.
    8. œA–ìŒbˆê, Žs“c•™Žq. y¬Ž™‚ÌŽ¡—ÃŽwjz zŠÂŠí@”ì‘åŒ^S‹ØÇ. ¬Ž™‰Èf—à 2018 Apr; 81(‘): 371-3.
    9. œA–ìŒbˆê, Žs“c•™Žq. y¬Ž™‚ÌŽ¡—ÃŽwjz zŠÂŠí@Šg’£Œ^S‹ØÇ. ¬Ž™‰Èf—à 2018 Apr; 81(‘): 374-6.
    10. œA–ìŒbˆê. ‚±‚±‚Ü‚Å’m‚Á‚Ä‚¨‚«‚½‚¢S‹ØÇ@‰ð–U‚©‚番ŽqˆãŠw‚Ü‚Å.@¬Ž™zŠÂŠíŠw‰ïŽGŽ@2018 34(3): 111-20.
    11. ŽíŽsq’ˆ, ‘¾“c–M—Y. y¬Ž™‚ÌŽ¡—ÃŽwjz ‹~‹}ê–Ê‚É‚¨‚¯‚鉊ú‘Ήž@“M…. ¬Ž™‰Èf—à 2018 Apr; 81(‘): 86-8.
    12. ˆÉ“¡–õ“T. yƒAƒŒƒ‹ƒM[Ž¾Š³‚É‚¨‚¯‚éÅV‚ÌŽ¡—Ãz H•¨ƒAƒŒƒ‹ƒM[‚̖Ɖu—Ö@‚ÌŒ»ó. ƒAƒŒƒ‹ƒM[‚Ì—Õ° 2018 Sep; 38(9): 859-62.
    13. ˆÉ“¡–õ“T, ‘ê‘ò‘ôŒÈ, ‘«—§—Yˆê. ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÊǗƒKƒCƒhƒ‰ƒCƒ“2017. ’·ŠúŠÇ—‚̉ü’ù‚̃|ƒCƒ“ƒg. ƒAƒŒƒ‹ƒM[ 2018 67(9):1258-62.
    14. ˆÉ“¡–õ“T, ‘ê‘ò‘ôŒÈ, ‘«—§—Yˆê. ƒKƒCƒhƒ‰ƒCƒ“‰ðà.@¬Ž™‹CŠÇŽxšb‘§Ž¡—ÊǗƒKƒCƒhƒ‰ƒCƒ“2017.@‘æ7Í ’·ŠúŠÇ—‚ÉŠÖ‚·‚é–ò•¨—Ö@.@“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ2018;32(5): 824-31.
    15. ¼“c’¼“¿. yƒEƒCƒ‹ƒXŠ´õÇ-Å‹ß‚Ì“®ŒüEƒgƒsƒbƒNƒXz ‘“à‚Řb‘è‚ÌŠ´õÇ@f’f‚ÆŽ¡—Ã@ƒqƒgƒRƒƒiƒEƒCƒ‹ƒX. ¬Ž™“à‰È 2018; 49(11): 1659-63.
    16. ìú±—TŽq. yˆê”Ô‚»‚΂ÅAƒi[ƒX‚ªŽç‚é@ŒÄ‹zŠÇ—’†‚ÌÔ‚¿‚á‚ñ@ŠÏŽ@EŠÅŒì‹ZpƒPƒAƒ|ƒCƒ“ƒgz V¶Ž™–³ŒÄ‹z”­ì. Neonatal care 2018 Sep; 31(9): 832-8.
    17. ¡ˆää‰p, ‘«—§—Yˆê, ŽsŠÛ’q_, ã“cN‹v, ”óŒû¹F. h‘è•ñu‘æ2‰ñ¬Ž™‹CŠÇE‹CŠÇŽxˆÙ•¨‚ÉŠÖ‚·‚é‘S‘’²¸Œ‹‰Êv. “ú–{¬Ž™ŒÄ‹zŠíŠw‰ïŽGŽ 2018; 29: 114-21.
    18. •Ä“c@—§, ’Þ@_”V, ’†‘º°“Þ, ‹g“cØ•äŽq, “c‘º‰pˆê˜Y, ˆÉì‘×L, ‹v•Û“c^’Ê׋ۊ´õǂƉ@“àŠ´õÇ‘Îô-Pros and Cons- p‘O‚ÉMRSA‚Ìœ‹Û‚ðs‚¤‚±‚Æ‚Ì¥”ñ(Pros). ¬Ž™‰È—Õ° 2018 Mar; 71(3): 388-91.

  • 2018”NŠw‰ï•ñ
    1. Itazawa T, Hosoki K, Sur S. Cat dander extract directly stimulates BAFF-dependent class switch recombination to IgE in B cells without T-cell help. Annual Meeting of American Academy of Allergy, Asthma and Clinical Immunology; 2018 Mar 1-5; Orlando, Florida, USA.
    2. Yoshida T. The effect of prematurity on caffeine metabolism in preterm infant . 22rd Edition of International Conference on Neonatology and Perinatology, 2018 May 7-8; Frankfurt, Germany. (invited speaker)
    3. Hirono K, Hata Y, Takarada S, Miyao N, Okabe M, Saito K, Ozawa SW, Nishida N, Ichida F. Cardiomyopathy phenotypes and genotypes for children with left ventricular noncompaction. ESC Congress 2018; 2018 Aug 25-29; Munich, Germany.
    4. Ibuki K. Neurodevelopmental issues and brain volume growth in Fontan patients. The 21st UPDATE SYMPOSIUM Korea ; 2018 Aug ; Korea.
    5. Hirono K, Murayama K, Okazaki Y, Ohtake A, Ichida F. Novel compound heterozygous TMEM70 variants impaired the activity of ATP synthase of complex V. The 2nd JCS Council Forum on Basic CardioVascular Research; 2018 Sep 22-23; Nara, Japan.
    6. Adachi Y. Management of exacerbation in childhood asthma. XXIV World Congress of Asthma; 2018 Oct 3-6; TokyoD(Invited speaker)
    7. Hirono K, Hata Y, Takarada S, Okabe M, Miyao N, Ibuki K, Ozawa S, Nishida N, Ichida F, and for LVNC study collaborators. A TPM1 gene variant acts as a genetic trigger underlying the development of left ventricular noncompaction. 15th Annual Conference of the ESC Working Group on Myocardial & Pericardial Diseases; 2018 Oct 5-7; Belgrade, Serbia.
    8. Hirono K, Hata Y, Takarada S, Okabe M, Miyao N, Ibuki K, Ozawa S, Nishida N, Ichida F, and for LVNC study collaborators. Genotype-Phenotype correlation for children with left ventricular noncompaction and congenital heart disease. 15th Annual Conference of the ESC Working Group on Myocardial & Pericardial Diseases; 2018 Oct 5-7; Belgrade, Serbia.
    9. Kawasaki Y, Yoshida T, Matsui M, Hiraiwa A, Inomata S, Tamura K, Makimoto M, Oishi K. Head circumference and brain volume. 143rd Annual Meeting of the American Neurological Association, 2018 Oct 21-23; Atlanta, GA, USA.
    10. Kawasaki Y, Oishi K. Quantifying genetic effects in early brain development using Multi-atlas labeling. 21st Annual Division of MR Research, 2018 Oct 18-19; Cambridge, MD, USA, 2018. (Travel Award for the 143rd Annual Meeting of the American Neurological Association)
    11. Hirono K. Kawasaki disease: vasculitis and endothelial microparticles. The 9th Asian Congress of Pediatric Infectious Diseases (ACPID); 2018 Nov 10-12; Fukuoka.
    12. âV“¡˜a—R, ‹{”ö¬–¾, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, ’¹’Ë‘å‰î, –سÆ, –F‘º’¼Ž÷. pŒã––½«”x“®–¬‹·ó‚ɑ΂µ‚ĒጌŠÇƒoƒ‹[ƒ“ƒTƒCƒY”ä—¦‚Ìnoncompliant balloon‚ð—p‚¢‚½ƒoƒ‹[ƒ“Šg’£p‚̉“ŠuŠú¬Ñ. ‘æ29‰ñ“ú–{Pediatric Interventional CardiologyŠw‰ï; 2018 Jan 18-20; •Ÿ‰ª.
    13. Ibuki K, Mood MBC, Alwi MB, Samion HB. A case of Bail out for recurrent desaturation immediate after ductal stenting. ‘æ29‰ñ“ú–{Pediatric Interventional CardiologyŠw‰ï; 2018 Jan 18-20; •Ÿ‰ª.
    14. œA–ìŒbˆê. ‹³ˆçƒZƒ~ƒi[2@ˆâ“`Žqf’fuS‹Øǂƈâ“`Žqf’fv. ‘æ20‰ñ“ú–{¬læ“V«SŽ¾Š³Šw‰ï; 2018 Jan 27; “Œ‹ž.
    15. –x]’åŽu, “c’†•ü”ü, Ž›‰ºV‘¾˜Y, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ŽíŽsq’ˆ, ‘«—§—Yˆê. ‹}«’oŠÉ«Ò‘‰Š‚Ì10Î’jŽ™—á. ‘æ73‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï; 2018 Feb 4; ‹à‘ò.
    16. ŽíŽsq’ˆ, “c’†•ü”ü, ‘«—§—Yˆê. “Ë‘RŽ€‚ÌŒ´ˆö‚Æ‚µ‚ÄŒ©“¦‚µ‚Ä‚Í‚¢‚¯‚È‚¢¬Ž™ƒRƒfƒCƒ“’†“Å. ‘æ24‰ñ“ú–{SIDSE“û—cŽ™“Ë‘RŽ€—\–hŠw‰ï; 2018 Feb 23-24; ‹ž“s.
    17. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uÅV‚̬Ž™ƒAƒŒƒ‹ƒM[f—Ã`ƒKƒCƒhƒ‰ƒCƒ“‚̉ü’ù‚ð‚Ó‚Ü‚¦‚Ä`F¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2017vA‘æ322‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2018 Mar 11; •xŽR.
    18. ˆÉ“¡–õ“T. ƒVƒ“ƒ|ƒWƒEƒ€uÅV‚̬Ž™ƒAƒŒƒ‹ƒM[f—Ã`ƒKƒCƒhƒ‰ƒCƒ“‚̉ü’ù‚ð‚Ó‚Ü‚¦‚Ä`FH•¨ƒAƒŒƒ‹ƒM[ƒKƒCƒhƒ‰ƒCƒ“2016v. ‘æ322‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2018 Mar 11; •xŽR.
    19. ˜a“c—DŽq, ¬àVˆ»‰À, ‹{”ö¬–¾, ꎓ¡˜a—R, œA–ìŒbˆê. ”]”^ᇂ̊ù‰‚ª‚ ‚Á‚½”x“®Ã–¬á‘‚̈ê—á. ‘æ322‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2018 Mar 11; •xŽR.
    20. œA–ìŒbˆê. ‰ï’·“Á•ÊŠé‰æuLifelong Cardiology in the Young ‚Ì Futurability:”­¶A”­’B‚©‚猩‚½S‹ØŽ¾Š³‚̶ŠUzŠÂŠíŠwvwS‹Øãk–§‰»áŠQx‘æ82‰ñ“ú–{zŠÂŠíŠw‰ï; 2018 Mar 23-25; ‘åã.
    21. Hirono K, Hata Y, Ozawa S, Okabe M, Miyao N, Saito K, Nishida N, Ichida F. Genotype-Phenotype correlations in the fetal patients with left ventricular noncompaction. ‘æ82‰ñ“ú–{zŠÂŠíŠw‰ï; 2018 Mar 23-25; ‘åã.
    22. ‹g“cär. •ª–ì•ÊƒVƒ“ƒ|ƒWƒEƒ€‚h: ‹É’áo¶‘ÌdŽ™‚ÌŽvtŠúˆÈŒã‚Ì—\Œã. ƒCƒ“ƒXƒŠƒ“’ïR«‚̃ŠƒXƒN. ‘æ121‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2018 Apr 20-22; •Ÿ‰ª.
    23. ŽíŽsq’ˆ, Ô—ä—zŽq, ˆäŽèŒ’‘¾˜Y, ˆÉ“¡‰p‰î, ”~Œ´@ŽÀ, ‘¾“c–M—Y, ‰ê—ˆ“T”V, ´…’¼Ž÷, ’†—Ñ—m‰î, ¼ŽR˜aF, V“c‰ë•F, ¼— —Ts, ”ª–ØMˆê, “ˆ”ö@’q. “ú–{¬Ž™‰ÈŠw‰ï”ŬŽ™f—ÉŠú‘ΉžƒR[ƒXJPLS‚ª–ÚŽw‚·‚à‚Ì. ‘æ121‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2018 Apr 20-22; •Ÿ‰ª.
    24. ˆÉ“¡–õ“T, ˜a“c‘ñ–ç, ”ÂàVŽõŽq, ‘«—§—zŽq, ‚”ö@Š², ‘«—§—Yˆê. H•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éŒoŒû–Ɖu—Ö@“±“ü‚É‚æ‚Á‚Ä”­Ç‚µ‚½DŽ_‹…«ˆÝ’°‰Š‚̈ê—á. ‘æ121‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2018 Apr 20-22; •Ÿ‰ª.
    25. Ž›‰ºV‘¾˜Y, ’·X–œ—¢Žq, ŒÜ\—’“o, ‰ª•”@Œh, ŽÂ茒‘¾˜Y, ‘«—§—Yˆê. FreeStyleƒŠƒuƒŒ‚Ì“±“ü‚Å“œ”A•aƒTƒ}[ƒLƒƒƒ“ƒv’†‚Ì–éŠÔ’ጌ“œ‚Í–h‚°‚é‚©H ‘æ121‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2018 Apr 20-22; •Ÿ‰ª.
    26. ’†—¢Œ\‹M, Ž›‰ºV‘¾˜Y, –x]’åŽu, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, –쑺ŒbŽq, ‘«—§—Yˆê. _Œo‰èŽî‚ɑ΂·‚霑ˆÚAŒã‚É‘Ï“œ”\ˆÙí‚𗈂µ‚½2—á. ‘æ121‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2018 Apr 20-22; •Ÿ‰ª.
    27. ˆÉ“¡‰p‰î, Ô—ä—zŽq, ˆäŽèŒ’‘¾˜Y, ”~Œ´ ŽÀ, ‘¾“c–M—Y, ‰ê—ˆ“T”V, ´…’¼Ž÷, ŽíŽsq’ˆ, ’†—Ñ—m‰î, ¼ŽR˜aF, V“c‰ë•F, ’·‘º•q¶, ¼— —Ts, [”ö•qK. “ú–{¬Ž™‰ÈŠw‰ï¬Ž™f—ÉŠú‘ΉžƒR[ƒX(JPLS)ƒAƒ“ƒP[ƒgŒ‹‰ÊD ‘æ121‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2018 Apr 20-22; •Ÿ‰ª.
    28. Kusabiraki T, Yoneda N, Yoneda S, Kobayashi M, Fukuta K, Shiozaki A and Saito S. Correlation between intracranial imaging by MRI and development at age of 3 in the children born from mothers with hypertensive disorders of pregnancy or spontaneous preterm birth. 70th Annual Congress of the Japan Society of Obstetrics and Gynecology; 2018 May 11-13; Sendai.
    29. ‘ŠJË•½, ˆä㓹—Y, ÎŽRº•F, ‘å–î@”J, ‹{Œ´O–¾, ’|‰ºŠG—¢, –{‹´—TŽq, âV“¡‹MŽu, ¬–qG•¶, ’†ì‰h“ñ, {ŠLŒ¤Ži, ²X–تs, ¼–ìˆêŽO. ‹Ø—͒ቺ‚ð’悵‹Ø•a—ŠŒ©‚ÅŠÒŒ³¬‘Ì‚ð”F‚ßAFHL1ˆâ“`Žq•ÏˆÙ‚𓯒肵‚½¬Ž™Šú”­Ç‚Ì4—á‚É‚¨‚¯‚é—Õ°“I“Á’¥. ‘æ60‰ñ“ú–{¬Ž™_ŒoŠw‰ïŠwpW‰ï; 2018 May 31-Jun 2; ç—t.
    30. –x]’åŽu, ˜a“c‘ñ–ç, ŽíŽsq’ˆ, ꎓ¡@—I, “c’†•ü”ü, ‘«—§—Yˆê. “œ”A•aƒPƒgƒAƒVƒh[ƒVƒX‚Å”­Ç‚µA’˜–¾‚È”]•‚Žî‚É”][ǂ𕹔­‚µ‚½1Œ^“œ”A•a‚Ì—Ž™—á. ‘æ32‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï ŠwpW‰ï; 2018 Jun 2-3; ‚‚­‚Î.
    31. ‰Á“¡—Žq, ’Þ@_”V, ¼“c’¼“¿, –쑺ŒbŽq, ‘«—§—Yˆê, ´…@”V, –x]’åŽu, ’Ô¦áÁˆê. èò•”ƒŠƒ“ƒpߎ‚É‚æ‚è”­Œ©‚³‚ꂽãˆô“ªŠà‚̈ê—á. ‘æ323‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2018 Jun 10; •Ÿˆä.
    32. X‚±‚¸‚¦, ŒÜ\—’—², ”ª“c®l, ’r“c’q”V, ‚”ö@Š², ‘«—§—Yˆê. ˆŸ‰”Œ‡–RÇ‚ð‡•¹‚µ‚½dǃAƒgƒs[«”畆‰Š‚Ì“ûŽ™—á. ‘æ323‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2018 Jun 10; •Ÿˆä.
    33. Okabe M, Hirono K, Tamura K, Taneichi H, Ichida F, Kanegane H. Reactive peripheral blood plasmacytosis in Kawasaki disease. The 12th International Kawasaki disease symposium; 2018 Jun 12-15; Yokohama.
    34. Hirono K, Hata Y, Takarada S, Okabe M, Miyao N, Saito K, Ozawa S, Nishida N, Ichida F. Cardiomyopathy phenotypes and genotypes for children with left ventricular noncompaction. ‘æ54‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2018 Jul 5-7; ‰¡•l.
    35. ‘«—§—Yˆê. ƒCƒuƒjƒ“ƒOƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™dÇšb‘§‚Ì•a‘Ô‚ÆŽ¡—à up-to-dateF¬Ž™‚ÌdÇšb‘§‚Æ‚Í`v. ‘æ67‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2018 Jun 22-24; ç—t.
    36. Adachi Y. APAAACI symposium gEnvironmental factors and allergic diseases in children. ‘æ67‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2018 Jun 22-24; ç—t.
    37. ”ÂàVŽõŽq, ×–Ø‹»ˆŸ, Sanjiv Sur, ‘«—§—Yˆê. ƒlƒR”ç‹ûRŒ´‚ÌB×–E‚Ö‚Ì’¼ÚŽhŒƒ‚ÍIgE‚̃Nƒ‰ƒXƒXƒCƒbƒ`‘gŠ·‚¦‚ð—U“±‚·‚é. ‘æ67‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2018 Jun 22-24; ç—t.
    38. ˆÉ“¡–õ“T, ‘ºã«Œ[, ˜a“c‘ñ–ç, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê. H•¨ƒAƒŒƒ‹ƒM[‚̃nƒCƒŠƒXƒNŽ™‚ɑ΂·‚éH•¨•‰‰×ŽŽŒ±Œã‚ÌHŽ–Žw“±. ‘æ67‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2018 Jun 22-24; ç—t.
    39. ‘«—§—zŽqA˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ”ÂàVŽõŽq, ‘«—§—Yˆê. •xŽRŒ§“à‚Ì•ÛˆçŽ{Ý‚É‚¨‚¯‚éu•ÛˆçŠ‚É‚¨‚¯‚éƒAƒŒƒ‹ƒM[‘ΉžƒKƒCƒhƒ‰ƒCƒ“v‚Ì—‰ð“x‚ÆŽÀۂ̑Ήžó‹µ. ‘æ67‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2018 Jun 22-24; ç—t.
    40. ¼–ì³’m, ŒÜ\—’—²•v, ‘«—§—Yˆê. ¬Ž™Šú”­Çšb‘§‚̈ÚsŠú‚©‚ç”NŠú‚É‚©‚¯‚Ä‚Ì—Õ°Œo‰ß‚Æ‹C“¹‰ß•q«‚Ì„ˆÚ‚ɂ‚¢‚ÄD‘æ67‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2018 Jun 22-24; ç—t.
    41. ”ª–ØMˆê, ‘ºã”ü–çŽq, ŒÜ\—’“o, “ˆ”ö@’q, ŽíŽsq’ˆ, ¼‘òƒŽq, —щÀ“ÞŽq, ‚–؉€”ü, ‰±–{çŽj. •xŽRˆã—ÃŒ—‚É‚¨‚¯‚鬎™ˆã—ÓIƒPƒAŽÀKŒ¤C‰ï‚Ì[ŽÀ‚É‚Þ‚¯‚Ä‚Ì‘½EŽí˜AŒg‚ÌŽæ‚è‘g‚Ý. “ú–{¬Ž™‰Èˆã‰ï‘‰ïƒtƒH[ƒ‰ƒ€; 2018 Jun 23-24; ‰¡•l.
    42. ”ª–ØMˆê, ”öã—mˆê, ‘ºãIŒ[, ”¨èŠì–F, Ë“ckŠî, “ˆ”ö@’q, ŽíŽsq’ˆ, —Ñ@‰À“ÞŽq, ‚–؉€”ü, ‰±–{çŽj. •xŽRˆã—ÃŒ—‚É‚¨‚¯‚鬎™ˆêŽŸ‹~‹}‘̧‚ÌŒ»ó‚Æ‘½EŽí˜AŒg‚É‚æ‚鬎™‰Šú•]‰¿Œ¤C‰ï‚ɂ‚¢‚Ä. “ú–{¬Ž™‰Èˆã‰ï‘‰ïƒtƒH[ƒ‰ƒ€; 2018 Jun 23-24; ‰¡•l.
    43. ¬àVˆ»‰À, •½ˆäGŽq, âV“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq, –{ŠÔ’_, –F‘º’¼Ž÷, ‹´–{ˆè•v. RASA1ˆâ“`Žq‚ÌV‹Kˆâ“`Žq•ÏˆÙ‚ªŒ©‚¢‚¾‚³‚ꂽ”x“®Ã–¬á‘‚𔺂¤ˆâ“`«–Ñ׌ŒŠÇŠg’£Ç‚̈ê—á. ‘æ54‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2018 Jul 5-7; ‰¡•l.
    44. ˆÉŒ\“ñ˜Y, ’·‰ªF‘¾, ŽRŒû‰p‹M, ´…@•, “¡ˆä—²¬, •x“c@‰p. ƒXƒeƒ“ƒg—¯’u‚ðs‚Á‚½ˆÙŒ^‘å“®–¬kó‚Ì‚R‚©ŒŽ’jŽ™—á. ‘æ54‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2018 Jul 5-7; ‰¡•l.
    45. ˆÉŒ\“ñ˜Y, ’·‰ªF‘¾, ŽRŒû‰p‹M, ´…@•, ‚ˆä@r, â×@‹`m, “¡ˆä—²¬, ‹{Œ´‹`“T, ΖìKŽO, •x“c@‰p. MDCT 3D‰æ‘œÄ\¬‚ÌV‚½‚ȉ”\« ?S“à\‘¢‚ðŠÏ‚é-.‘æ54‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2018 Jul 5-7; ‰¡•l.
    46. âV“¡˜a—R, ›“c^–ç, ‰ª•”^Žq, ‹{”ö¬–¾, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, ‘ŠŒ´—²[, ’¹’Ë‘å‰î, “Œ“cº•F, –سÆ, –F‘º’¼Ž÷. Carotid-Subclavian Index„3/2‚¨‚æ‚ÑIsthmus/Descending Ratioƒ2/3‚ð–ž‚½‚·mild coarctationÇ—á‚Å‚ÍPGE1»Ü‚ª‘QŒ¸’†Ž~‰Â”\‚Å‚ ‚Á‚½. ‘æ54‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2018 Jul 5-7; ‰¡•l.
    47. ‹{”ö¬–¾, ›“c^–ç, ‰ª•”^Žq, âV“¡˜a—R, ¬àVˆ»‰À, œA–ìŒbˆê, ’¹’Ë‘å‰î, –سÆ, –F‘º’¼Ž÷, Žs“c•™Žq. “ûŽ™Šú‚æ‚èDDDƒy[ƒXƒ[ƒJ[‚ð‘I‘ð‚µ‚½¶S’áŒ`¬ÇŒóŒQAŠ®‘S–[ŽºƒuƒƒbƒN‚Ì2—á. ‘æ54‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2018 Jul 5-7; ‰¡•l.
    48. ‰ª•”^Žq, ‹{”ö¬–¾, âV“¡˜a—R, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. SCN5A‚ÌV‹Kˆâ“`Žq•ÏˆÙ‚ªŒ©‚¢‚¾‚³‚ꂽS‹Øãk–§‰»áŠQ‚Ì1—á. ‘æ54‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2018 Jul 5-7; ‰¡•l.
    49. ‹g“cär. ƒVƒ“ƒ|ƒWƒEƒ€ ‘ŽY3 Biological Network. ‘ŽY‚ÆãO–Ñ–Œ—r–Œ‰Š Žq‹{“àŠ´õEŽq‹{“à‰ŠÇ‚É‰ž‚¶‚½Ø”—‘ŽYŠÇ—‚ðŽó‚¯‚½Ž™‚Ì—\Œã.‘æ54‰ñ“ú–{ŽüŽYŠúV¶Ž™ˆãŠw‰ï; 2018 Jul 8-10; “Œ‹ž.
    50. ’·‰ªvG, ꎓ¡@—I, ’––”’qŽÀ, ìè—TŽq, “c‘ºŒ«‘¾˜Y, –q–{—D”ü, ‹g“cär. V¶Ž™–«”xŽ¾Š³‚É”º‚¤”x‚ŒŒˆ³Ç‚ɑ΂µ‚ÄNasal CPAP‰º‚É‚æ‚éNO‹z“ü—Ö@‚ª—LŒø‚Å‚ ‚Á‚½ˆê—á. ‘æ54‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2018 Jul 8-10; “Œ‹ž.
    51. –x]’åŽu, ŽíŽsq’ˆ, ꎓ¡@—I, ‘«—§—Yˆê. •xŽRŒ§“à‚É‚¨‚¯‚鬎™Ž€–SÇ—á‚Ì‚Ü‚Æ‚ß`Œ»ó‚ƉۑèA‚»‚µ‚ÄCDRŽÀŒ»‚ÉŒü‚¯‚Ä`. ‘æ40‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2018 Jul 8; ‚‰ª.
    52. ‘«—§—Yˆê. ‹³ˆçƒZƒ~ƒi[u¬Ž™‚Ì‹C“¹ˆÙ•¨‚ÌŒ»ó‚Æ—\–hv. ‘æ13‰ñ“ú–{¬Ž™Ž¨•@ˆôA‰ÈŠw‰ï; 2018 Jul 12-13; ‰¡•l.
    53. ˆÉ“¡–õ“T, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê. ‹CŠÇŽxšb‘§Ž™‚É‚¨‚¯‚éƒXƒM‰Ô•²Ç‚ªŒÄ‹CˆêŽ_‰»’‚‘f‚É—^‚¦‚é‰e‹¿. ‘æ13‰ñ“ú–{¬Ž™Ž¨•@ˆôA‰ÈŠw‰ï; 2018 Jul 12-13; ‰¡•l. (‰ï’·„‘E‰‰‘è)
    54. –x]’åŽu, ˜a“c‘ñ–ç, “c’†•ü”ü, ŽíŽsq’ˆ, ’·X–œ—¢Žq, ‘«—§—Yˆê. “œ”A•aƒPƒgƒAƒVƒh[ƒVƒX‚Å”­Ç‚µA’˜–¾‚È”]•‚Žî‚ÆoŒŒ«”][Ç‚ð‡•¹‚µ‚½1Œ^“œ”A•a‚Ì—Ž™—á. ‘æ24‰ñ“ú–{¬Ž™EŽvtŠú“œ”A•aŠw‰ï”NŽŸŠwpW‰ï; 2018 Jul 15; ‘åã.
    55. ”ÂàVŽõŽq, ‹à’J‹v”üŽq, •lè@Œi, ˆîŽ›G–M, ‘弈ê¬, •‘ò—mˆê, ’†ŽRŒ’•v, ‘«—§—Yˆê. ‰©»‚Ì“û—cŽ™‚ÌÇó‚ւ̉e‹¿. ƒGƒRƒ`ƒ‹’²¸’ljÁ’²¸ w‰©»‚ÆŽq‚Ç‚à‚ÌŒ’N’²¸iƒp[ƒg‚Qjx ‚æ‚è. ‘æ49‰ñ“ú–{E‹ÆEŠÂ‹«ƒAƒŒƒ‹ƒM[Šw‰ï; 2018 Jul 20-21; ‰¡•l.
    56. ˆÉ“¡–õ“T, ˜a“c‘ñ–ç, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê. RASTƒXƒRƒA5ˆÈã‚ÌH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚銮‘Sœ‹Ž‚ð‰ðœ‚·‚邽‚ß‚ÌH•¨•‰‰×ŽŽŒ±‚ÌŒŸ“¢. ‘æ35‰ñ“ú–{¬Ž™—Õ°ƒAƒŒƒ‹ƒM[Šw‰ï; 2018 Jul 28-29; •Ÿ‰ª.
    57. ‘«—§—zŽq, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê. Šî‘bŽ¾Š³‚ð—L‚·‚é‹CŠÇŽxšb‘§‡•¹Ç—á‚É‚¨‚¯‚éƒ_ƒj㉺–Ɖu—Ö@‚ÌŽ¡—ÃŒoŒ±D-‹CŠÇŽxšb‘§‚ւ̉e‹¿‚ɂ‚¢‚Ä-D‘æ35‰ñ“ú–{¬Ž™—Õ°ƒAƒŒƒ‹ƒM[Šw‰ï; 2018 Jul 28-29; •Ÿ‰ª.
    58. ”ª–ØMˆê, ”öã—mˆê, ‘ºãIŒ[, Ë“ckŠî, ”¨èŠì–F, “ˆ”ö@’q, ŽíŽsq’ˆ, ‘«—§—Yˆê. •xŽRˆã—ÃŒ—‚É‚¨‚¯‚鬎™ˆêŽŸ‹~‹}‘̧‚ÌŒ»ó‚ɂ‚¢‚Ä. ‘æ28‰ñ“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ï; 2018 Aug 24-26; “Œ‹ž.
    59. ‘ºã«Œ[, ”ÂàVŽõŽq, ‰ª•”^Žq, Ö“¡˜a—R, ¬àVˆ»‰À, ˆÉ“¡–õ“T, œA–ìŒbˆê, ‘«—§—Yˆê. Ž_‘f‚𕹗p‚µ‚½ƒRƒ“ƒtƒH[ƒgƒJƒtƒvƒ‰ƒX‚̃pƒbƒJ[ƒT[ƒ‚[ƒh‚É‚æ‚é”rá‚•â•‚ª—L—p‚Å‚ ‚Á‚½–³‹C”x‡•¹ƒ`ƒAƒm[ƒ[«SŽ¾Š³‚̈ê—á. ‘æ51‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2018 Sep 28-29; ŽD–y.
    60. ‹{”ö¬–¾, ›“c^–ç, ‰ª•”^Žq, âV“¡˜a—R, ¬àVˆ»‰À, œA–ìŒbˆê, ”¨—R‹IŽq, ¼“c®Ž÷, –F‘º’¼Ž÷, Žs“c•™Žq. ¶S’áŒ`¬ÇŒóŒQ‚𔺂Á‚½Holt-OramÇŒóŒQ‚ÉŒ©‚¢o‚³‚ꂽTBX5‚Ì•¡‡ƒwƒeƒÚ‡‘Ì‚ÌŠÖ—^. “ú–{l—Þˆâ“`Šw‰ï‘æ63‰ñ‘å‰ï; 2018 Oct 10-13; ‰¡•l.
    61. ‘ŠJË•½, “c’†•ü”ü, ’‡‰ª²’qŽq, ‹{@ˆêŽu, ‘«—§—Yˆê, •“àrŽ÷, ㌴•üŽq, —é–ØŽõl, ¬èŒ’ŽŸ˜Y. æ“V«”’“àáA—¼‘¤‘O“ª•”‘½¬”]‰ñAWestÇŒóŒQ‚ð”F‚ßDYNC1H1•ÏˆÙ‚𓯒肵‚½—Ž™—á. “ú–{l—Þˆâ“`Šw‰ï‘æ63‰ñ‘å‰ï; 2018 Oct 10-13; ‰¡•l.
    62. ‘«—§—Yˆê. ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[u¬Ž™‹CŠÇŽxšb‘§‚ÌŽ¡—Ãí—ªv. ‘æ55‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2018 Oct 20-21; ‰ªŽR.
    63. ˆÉ“¡–õ“T, ²“¡‚³‚­‚ç, Žè’˃ˆê˜Y, ’·”ö‚݂ÂÙ, ‘ºˆäG¶, •Ÿ‰Æ’CŽ÷, “¡àV—²•v, ‘«—§—Yˆê. ¬Ž™ƒAƒŒƒ‹ƒM[ƒXƒLƒ‹ƒAƒbƒvƒZƒ~ƒi[iPediatric Skill up Course: PASCOj‚É‚æ‚éŽQ‰ÁŽÒ‚ÌŠwKŒø‰Ê‚ÌŒŸ“¢. ‘æ55‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2018 Oct 20-21; ‰ªŽR.
    64. ˆÉ“¡–õ“T, ‹T“c@½, ’r“c­Œ›, “¡àV—²•v, ˆäãšæ–Î, “¿ŽRŒ¤ˆê, •½ˆäN‘¾, ¼Œ´’m‘ã, ‹g“c”V”Í, ‘«—§—Yˆê. ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“‚Ì•‹yE“à—e‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²¸. ‘æ55‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2018 Oct 20-21; ‰ªŽR.
    65. ”nꌒ‘¾˜Y, ˆÉ“¡–õ“T, ׈ä‹fˆ¤, —Rˆä¹˜a, —Ñ@ŽD, “ì•ÛGŽÀ, ‘ºã«Œ[, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê. ƒ\ƒo‚Ƃ̌𷔽‰ž«‚ª”F‚ß‚ç‚ꂽƒ}ƒJƒfƒ~ƒAƒiƒbƒcƒAƒŒƒ‹ƒM[‚Ì1—á. ‘æ55‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2018 Oct 20-21; ‰ªŽR.
    66. ŽíŽsq’ˆC”ª–ØMˆêC‰ª“cr‘¥. ‚킪‘‚É‚¨‚¯‚éVaccine HesitancyD‘æ50‰ñ“ú–{¬Ž™Š´õÇŠw‰ï; 2018 Nov 10-11; •Ÿ‰ª.
    67. –x]’åŽu, ŽíŽsq’ˆ, ´…@”V, ꎓ¡@—I, ˜a“c‘ñ–ç, ’Ô¦áÁˆê, ‘«—§—Yˆê, mˆäŒ©‰pŽ÷. Tm mapping–@‚ª—L—p‚Å‚ ‚Á‚½Œz•””^ᇂÌ2—á. ‘æ50‰ñ“ú–{¬Ž™Š´õÇŠw‰ï; 2018 Nov 10-11; •Ÿ‰ª.
    68. ”ª–ØMˆê, •½ˆäGŽq, ŽíŽsq’ˆ, ‘«—§—Yˆê, •Ä“c“N–ç, ¬Ÿº³ŽŸ. •xŽRŽs‚Ì’nˆæƒNƒŠƒjƒbƒN‚É‚¨‚¯‚é•Ûˆç‰€‚Å‚Ì“û—cŽ™‰º‹C“¹Š´õ‚É‚¨‚¯‚éŒÄ‹zŠíƒEƒCƒ‹ƒXŠw“IlŽ@‚ɂ‚¢‚Ä4”NŠÔ‚̂܂Ƃ߂ɂ‚¢‚Ä. ‘æ50‰ñ“ú–{¬Ž™Š´õÇŠw‰ï; 2018 Nov 10-11; •Ÿ‰ª.
    69. ¼“c’¼“¿, –쑺ŒbŽq, ’†’Ø‹v”T. ‹}«ƒŠƒ“ƒp«”’ŒŒ•aÄ”­‚ÌŽ¡—Ã’†‚ɃAƒVƒNƒƒrƒ‹‘Ï«‚Ì”dŽí«‘Ñóáv]‚Æ…“—”x‰Š‚ð‡•¹‚µ‚½ˆê—á. ‘æ60‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ï; 2018 Nov 16-19; ‹ž“s.
    70. –q–{—D”ü, ꎓ¡@—I, ’·‰ªvG, ’––”’qŽÀ, ìú±—TŽq, “c‘ºŒ«‘¾˜Y, ‹g“cär. NO‹z“ü—Ö@‚ðŽó‚¯‚½‹É’áo¶‘ÌdŽ™‚ÌŽüŽYŠú‚Ì“Á’¥‚Æ’ZŠú—\Œã. ‘æ63‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2018 Nov 22-24; “Œ‹ž.
    71. “c‘ºŒ«‘¾˜Y, ìú±—TŽq, ’·‰ªvG, ’––”’qŽÀ, –q–{—D”ü, ‹g“cär. NICU‚Å”­Ç‚µ‚½æ“V«Œ‹Šj_-‰@“àŠ´õ‘Îô‚ɂ‚¢‚Ä-. ‘æ63‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2018 Nov 22-24; “Œ‹ž.
    72. ꎓ¡@—I, “c‘ºŒ«‘¾˜Y, ’·‰ªvG, ’––”’qŽÀ, –q–{—D”ü, ‹g“cär. •a—‰ð–U‚Åf’f‚µ‚½æ“V«—¼‘¤”x–³Œ`¬. ‘æ63‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2018 Nov 22-24; “Œ‹ž.
    73. ¼“‡FŽ¡, ‘ºã«Œ[, ‘ŠJË•½, ˆÉ“¡–õ“T, “c’†•ü”ü, “c‘ºŒ«‘¾˜Y, ‹g“cär, ‘«—§—Yˆê. TUBB2A•ÏˆÙ‚ð—L‚·‚éinfantile spasms‚ɑ΂µACTH—Ö@‚ª‘tŒ÷‚µ‚½’jŽ™—á. ‘æ324‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2018 Dec 9; Îì.

    2017”N

  • ’˜‘
    1. ‘«—§—YˆêDÅVƒKƒCƒhƒ‰ƒCƒ“€‹’ ¬Ž™‰È f’fEŽ¡—ÃŽwj ‰ü’ù‘æ2”ÅD‰““¡•¶•v•Ò. “Œ‹ž: ’†ŽR‘“X; 2017. ‹}«×‹CŠÇŽx‰ŠDp516-9.
    2. ‘«—§—YˆêD¡“ú‚ÌŽ¡—ÃŽwj 2017”N“x”ÅDŽRŒû“O, –kŒ´Œõ’j•Ò. “Œ‹ž: ˆãŠw‘‰@; 2017. ¬Ž™‚Ì‹CŠÇŽxšb‘§D p1386-8.
    3. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj-2017”N”Å. ŽRŒû“O, –kŒ´Œõ’j•Ò. “Œ‹ž: ˆãŠw‘‰@; 2017. SŽ¾Š³‚ð‚à‚“û—cŽ™‚Ì“úí¶Šˆ‚ÌŠÇ—‚ÆŽw“±. p1360-1.
    4. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj-2017”N”Å. ŽRŒû“O, –kŒ´Œõ’j•Ò. “Œ‹ž: ˆãŠw‘‰@; 2017. SŽ¾Š³Š³ŽÒ‚Ì”DPEoŽY‚Ì“K‰žEŠÇ—. p429.
    5. ŽíŽsq’ˆ. _Œo“à‰È Clinical Question & Pearls _ŒoŠ´õÇ. “Œ‹ž: ’†ŠOˆãŠwŽÐ; 2017. ’°ŠÇoŒŒ«‘å’°‹ÛŠ´õÇ‚É‚æ‚é”]ǂ͂ǂ̂悤‚Éf’f‚µ‚ÄŽ¡—µ‚½‚ç‚æ‚¢‚Å‚µ‚傤‚©H p116-20.
    6. œA–ìŒbˆê, Žs“c•™Žq. f’fƒ‚ƒ_ƒŠƒeƒB‚Æ‚µ‚Ä‚ÌS‹Ø•a—. ˜aò“OEœA]“¹º•Ò. “Œ‹ž: “ì]“°; 2017. 3ÍuS”ì‘å‚ðŽå•a‘Ô‚Æ‚·‚鎾Š³v-2uƒŠƒ\ƒ\[ƒ€iƒ‰ƒCƒ\ƒ][ƒ€j•av-d)uS‹Øãk–§‰»áŠQv. p136-8.
    7. œA–ìŒbˆê, Žs“c•™Žq. ƒKƒCƒhƒ‰ƒCƒ“‚ÆÅV•¶Œ£‚ÅŠw‚Ô¬Ž™‰ÈŠwƒŒƒrƒ…[2016-17. “Œ‹ž: ‘‡ˆãŠwŽÐ; 2017. S‹ØŽ¾Š³. P313-25.
    8. œA–ìŒbˆê, Žs“c•™Žq. ÅVƒKƒCƒhƒ‰ƒCƒ“€‹’@¬Ž™‰Èf’fEŽ¡—ÃŽwj. “Œ‹ž: ’†ŽR‘“X; 2017. ŒÇ—§«¶Žºãk–§‰»áŠQ. P673?5.
    9. œA–ìŒbˆê, Žs“c•™Žq.¬Ž™—Õ°ŒŸ¸‚̃z?ƒCƒ“ƒg2017.¬Ž™“à‰È49i‘j. “Œ‹ž: “Œ‹žˆãŠwŽÐ; 2017. zŠÂŠíŽ¾Š³. p713- 732.
    10. œA–ìŒbˆê, Žs“c•™Žq. ìè•a‚Ì•aˆöŒ¤‹†ŠT˜_@ŠCŠO‚ÌŒ¤‹†‚©‚ç@“ú–{ìè•aŠw‰ï•aˆöŒŸ“¢¬ˆÏˆõ‰ï•Ò “ú–{ìè•aŠw‰ïŽ––±‹Ç 2017; p44-9.
    11. ¼“c’¼Ž÷, Žs“c•™Žq. f’fƒ‚ƒ_ƒŠƒeƒB‚Æ‚µ‚Ä‚ÌS‹Ø•a—. ˜aò“OEœA]“¹º•Ò. “Œ‹ž: “ì]“°; 2017. 2ÍuSŠg‘å‚ðŽå•a‘Ô‚Æ‚·‚鎾Š³v-7uDanon•av. p168-71.
    12. ¼“c’¼“¿. “ú–{¬Ž™Š´õÇŠw‰ïi•Òj“úíf—Âɖ𗧂¬Ž™Š´õǃ}ƒjƒ…ƒAƒ‹2017. “Œ‹ž: “Œ‹žˆãŠwŽÐ; 2017. ƒRƒƒiƒEƒCƒ‹ƒX, ƒuƒjƒ„ƒEƒCƒ‹ƒX, JCƒEƒCƒ‹ƒX, ƒvƒŠƒIƒ“. p426-33.
    13. ˆÉ“¡–õ“TD‚±‚±‚ª‚·‚²‚¢I•xŽR‘åŠw•‘®•a‰@‚ÌÅVŽ¡—ÃD•xŽR‘åŠw•‘®•a‰@•Ò’˜D“Œ‹ž: ƒoƒŠƒ…[ƒƒfƒBƒJƒ‹; 2017.uŒoŒû–Ɖu—Ö@v‚É‚æ‚éH•¨ƒAƒŒƒ‹ƒM[‚ÌŽ¡—ÃDp70-1.
    14. ’‡‰ª‰pK, Žs“c•™Žq. zŠÂŠíŽ¾Š³ ÅV‚ÌŽ¡—à 2018-2019. “Œ‹ž: “ì]“°; FontanŽèpŒã‚̉“ŠuŠúŠÇ—. p225-8.
  • Œ´’˜
    1. Makimoto M, Kawasaki Y, Inomata S, Tamura K, Yoshida T. Early upper lip pressure ulcer in a preterm neonate. Pediatr Int. 2017 May; 59(5): 633-4.
    2. Nakaoka S, Kawasaki Y, Inomata S, Makimoto M, Yoshida T. Caffeine toxicity in a preterm neonate. Pediatr Neonatol. 2017 Aug; 58(4): 380-1.
    3. Hoshino A, Okada S, Yoshida K, Nishida N, Okuno Y, Ueno H, Yamashita M, Okano T, Tsumura M, Nishimura S, Sakata S, Kobayashi M, Nakamura H, Kamizono J, Mitsui-Sekinaka K, Ichimura T, Ohga S, Nakazawa Y, Takagi M, Imai K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Kojima S, Nonoyama S, Morio T, Kanegane H. Abnormal hematopoiesis and autoimmunity in human subjects with germline IKZF1 mutations. J Allergy Clin Immunol. 2017 Jul; 140(1): 223-31.
    4. Wang C, Takasaki A, Watanabe Ozawa S, Nakaoka H, Okabe M, Miyao N, Saito K, Ibuki K, Hirono K, Yoshimura N, Yu X, Ichida F. Long-Term Prognosis of Patients With Left Ventricular Noncompaction@- Comparison Between Infantile and Juvenile Types. Circ J. 2017 Apr 25; 81(5): 694-700.
    5. Wang C, Yu X, Ichida F. Survival in Young Patients With Noncompaction May Not Only Depend on Cardiac But Also on Neuromuscular Comorbidity - Reply. Circ J. 2017 Jul 25; 81(8): 1239.
    6. Wang C, Hata Y, Hirono K, Takasaki A, Ozawa SW, Nakaoka H, Saito K, Miyao N, Okabe M, Ibuki K, Nishida N, Origasa H, Yu X, Bowles NE, Ichida F; for LVNC Study Collaborators. A Wide and Specific Spectrum of Genetic Variants and Genotype-Phenotype Correlations Revealed by Next-Generation Sequencing in Patients with Left Ventricular Noncompaction.J Am Heart Assoc. 2017 Aug 30; 6(9).
    7. Ikawa Y, Nishimura R, Araki R, Noguchi K, Muraoka M, Fukuda M, Fujiki T, Kuroda R, Mase S, Maeba H, Nomura K, Yachie A. Pathognomonic serum cytokine profiles identify life-threatening langerhans cell histiocytosis. Br J Haematol. 2017 Feb; 176(3): 495-497.
    8. Yamaguchi Y, Mizumaki K, Hata Y, Sakamoto T, Nakatani Y, Kataoka N, Ichida F, Inoue H, Nishida N. Latent pathogenicity of the G38S polymorphism of KCNE1 K+ channel modulator. Heart Vessels. 2017 Feb; 32(2): 186-192.
    9. Straus R, Rose T, Flint SM, Klotsche J, Haupl T, Peck-Radosavljevic M, Yoshida T, Kyogoku C, Flechsig A, Becker AM, Dao KH, Radbruch A, Burmester GR, Lyons PA, Davis LS, Hiepe F, Grutzkau A, Biesen R. Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options. J Mol Med (Berl). 2017 Jul;95(7):753-765.
    10. Aonuma K, Shiga T, Atarashi H, Doki K, Echizen H, Hagiwara N, Hasegawa J, Hayashi H, Hirao K, Ichida F, Ikeda T, Maeda Y, Matsumoto N, Sakaeda T, Shimizu W, Sugawara M, Totsuka K, Tsuchishita Y, Ueno K, Watanabe E, Hashiguchi M, Hirata S, Kasai H, Matsumoto Y, Nogami A, Sekiguchi Y, Shinohara T, Sugiyama A, Sumitomo N, Suzuki A, Takahashi N, Yukawa E, Homma M, Horie M, Inoue H, Ito H, Miura T, Ohe T, Shinozaki K, Tanaka K; Japanese Circulation Society and the Japanese Society of Therapeutic Drug Monitoring Joint Working Group. Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015)@- Digest Version. Circ J. 2017 Mar 24; 81(4): 581-612.
    11. Yoshida K, Adachi Y, Sasaki M, Akashi M, Itazawa T, Ohya Y, Odajima H, Akasawa A. Ultraviolet index is associated with childhood eczema prevalence: Sex and age differences. Pediatr Allergy Immunol. 2017 Jun; 28(4): 391-3.
    12. Chida A, Inai K, Sato H, Shimada E, Nishizawa T, Shimada M, Furutani M, Furutani Y, Kawamura Y, Sugimoto M, Ishihara J, Fujiwara M, Soga T, Kawana M, Fuji S, Tateno S, Kuraishi K, Kogaki S, Nishimura M, Ayusawa M, Ichida F, Yamazawa H, Matsuoka R, Nonoyama S, Nakanishi T. Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy. Heart Vessels. 2017 Jun; 32(6): 700-7.
    13. Kimura M, Ito Y, Shimomura M, Morishita H, Meguro T, Adachi Y, Seto S. Cytokine profile after oral food challenge in infants with food protein-induced enterocolitis syndrome. Allergol Int. 2017 Jul; 66(3): 452-7.
    14. Fujino N, Yoshimuta T, Ichida F, Kinugawa K, Usuda K, Kitayama M, Ino H, Kawashiri MA, Tada H, Mizuno S, Hayashi K, Takemura H, Yamagishi M; all the members of the Japanese Circulation Society in Hokuriku District. Overview of the 81st Annual Scientific Meeting of the Japanese Circulation Society@- Cardiovascular Medicine for the Next Generation. Circ J. 2017 Aug 25; 81(9): 1261-7.
    15. Hosoki K, Redding D, Itazawa T, Chakraborty A, Tapryal N, Qian S, Qi H, Aguilera-Aguirre L, Brasier AR, Phani VS, Hazra TK, Boldogh I, Sur S. Innate mechanism of pollen- and cat dander-induced oxidative stress and DNA damage in the airways. J Allergy Clin Immunol. 2017 Nov; 140(5): 1436-9.e5.
    16. Takatsuki S, Ogata S, Ishii M, Yokozawa M, Ono M, Fujiwara M, Ida H, Motomura H, Moriuchi H, Taketazu M, Kawamura Y, Kawano T, Izumi T, Shiono J, Tsuchiya S, Tsuchiya K, Goushi T, Ichida F, Saji T. Low risk of treatment resistance in Down syndrome with Kawasaki disease. Pediatr Int. 2017 Dec; 59(12): 1236-9.
    17. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—zŽq, ”óŒû@Žû, •£àV—³–ç, ŽRŒ³ƒŽq, ‚”ö@Š², ‘ºãIŒ[, ‘«—§—Yˆê. H•¨ƒAƒŒƒ‹ƒM[Ž™‚¨‚æ‚Ñ‚»‚Ì•ÛŒìŽÒ‚ɑ΂·‚éƒAƒhƒŒƒiƒŠƒ“Ž©ŒÈ’ŽËŠíiƒGƒsƒyƒ“Rj‚ðŽg—p‚·‚é“K؂ȃ^ƒCƒ~ƒ“ƒO‚Ì—‰ð“xD“ú–{¬Ž™—Õ°ƒAƒŒƒ‹ƒM[Šw‰ïŽGŽ@(in press)r–Ø@®, ŽsìŒõ‘¾˜Y, ¼ŽR˜aF, V’ÃŒ’—T, ŽR–{„Žm, ŽíŽsq’ˆ, ’·‘º•q¶, ’ß@’qŒõ, ”~Œ´@ŽÀ, —¢Œ©@º. ¬Ž™ˆã—Ã]Ž–ŽÒ‚Ì”]Ž€‚¨‚æ‚Ñ‘ŸŠíˆÚA‚ÉŠÖ‚·‚éˆÓŽ¯’²¸(‘æ“ñ‰ñ). “ú–{¬Ž™‹~‹}ˆãŠw‰ïŽGŽ 2017 16(1): 111-5.
    18. Ž›‰ºV‘¾˜Y, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, ‘«—§—Yˆê, “¡“cC•½, ’†¼•q—Y, Žs“c•™Žq. WilliamsÇŒóŒQ‚É“Á’¥“I‚ÈSŒŒŠÇ•a•Ï‚Ì‚Ý‚ð—L‚µ‚½ELNˆâ“`ŽqˆÙíÇ. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ 2017 July 121(7): 1179-83.
    19. ˆ¢•”@~, ¼“c’¼“¿, X–ìŽÑˆßŽq. ‰º—ŸÇŠ³Ž™‚ɃEƒCƒ‹ƒXRŒ´ŒŸ¸iƒƒ^ƒEƒCƒ‹ƒXAƒmƒƒEƒCƒ‹ƒXAƒAƒfƒmƒEƒCƒ‹ƒXj‚ðŽÀŽ{‚·‚邱‚Æ‚Ì¥”ñ. ¬Ž™‰È—Õ°@2017 Mar 70(3): 402-5.
  • Ç—á•ñ
    1. ˜a“c‘ñ–ç, ŽíŽsq’ˆ, rˆä”ü•ä, ’†—ÑŒºˆê, ‘«—§—Yˆê. high-flow nasal cannula —Ö@‰º‚Éq‹ó”À‘—‚ðs‚Á‚½dLjô“ª“ǂ̓ûŽ™—á. ‹~‹}ˆãŠw@2017 Mar 41(3): 364-8.
    2. Ž›‰ºV‘¾˜Y, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, ‘«—§—Yˆê, “¡“cC•½, ’†¼•q—Y, Žs“c•™Žq. WilliamsÇŒóŒQ‚É“Á’¥“I‚ÈSŒŒŠÇ•a•Ï‚Ì‚Ý‚ð—L‚µ‚½ELNˆâ“`ŽqˆÙíÇ. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ 2017 July 121(7): 1179-83.
    3. ›“c^–ç, •½Šâ–¾Žq, “c’†•ü”ü, ”ÂàVŽõŽq, ‘«—§—Yˆê. •ÂÇ«‡–°Žž–³ŒÄ‹z‚ª‹^‚í‚ꂽ‡–°Žž—VsÇ‚ÌDownÇŒóŒQ‚Ì1—á. “ú–{¬Ž™ŒÄ‹zŠíŠw‰ïŽGŽ 2017 June 28(1): 3-8.
    4. â“c“ÞûŽ, ‹´–{ˆè•v, ŽÄ“c@K, ‹à“c@®, “c’†•ü”ü, ‘«—§—Yˆê. V¶Ž™Šú‚æ‚è“TŒ^“I‚È—Õ°Çó‚ð’悵‘Šúf’f‚ª‰Â”\‚Å‚ ‚Á‚½”玿Œ`¬ˆÙí‚𔺂Á‚½’†ŠuŽ‹_ŒoˆÙŒ`¬Ç‚Ì‚P—á. ¬Ž™‰È—Õ° 2017 May 70(5): 679-84.
  • ‘à
    1. ‘«—§—YˆêD¬Ž™ƒAƒŒƒ‹ƒM[‚̃gƒsƒbƒNƒX@ŠÂ‹«‚ƬŽ™‚̃AƒŒƒ‹ƒM[D“ú–{¬Ž™‰Èˆã‰ï‰ï•ñ 2017 54:32-4.
    2. ‘«—§—YˆêD¬Ž™‹CŠÇŽxšb‘§‚̃tƒFƒmƒ^ƒCƒvD¬Ž™‰È—Õ° 2017; 70:2041-5.
    3. ‘«—§—Yˆê. •ÛˆçŒ»ê‚Å‚ÌH•¨ƒAƒŒƒ‹ƒM[Ž™‚ւ̑Ήž. •Ûˆç‚Æ•ÛŒ’. 2017 Jan ; 23(1): 26-8.
    4. ‘«—§—Yˆê. Žq‚Ç‚à‚Æ‘å‹C ŠÂ‹«‚ÆŽq‚Ç‚à‚̃AƒŒƒ‹ƒM[. Žq‚Ç‚à‚ÌŒ’N‰ÈŠw 2017 Jan 16(1): 7-11.
    5. ‘«—§—Yˆê. ¬Ž™šb‘§‚̃tƒFƒmƒ^ƒCƒv. ƒAƒŒƒ‹ƒM[@2017 Jan 66(1): 1-8.
    6. ‘«—§—Yˆê. ”ì–ž‚ƬŽ™šb‘§. ƒAƒŒƒ‹ƒM[@2017 Aug 66(8): 977-983.
    7. ‘«—§—Yˆê. “û—cŽ™šb–‚̃tƒFƒmƒ^ƒCƒv•ª—Þ. ¬Ž™“à‰È@2017 Jan 49(1): 43-46.
    8. ‘«—§—Yˆê. ƒAƒŒƒ‹ƒM[‚©‚ç‚Ý‚½ŒÄ‹zŠíŽ¾Š³. “ú–{¬Ž™ŒÄ‹zŠíŠw‰ïŽGŽ@2017 June 28(1): 28-32.
    9. ‘«—§—Yˆê. ƒAƒJƒfƒ~ƒbƒNƒXƒLƒ‹‚ð–‚­. ¸“ǂ̃|ƒCƒ“ƒgD“ú–{¬Ž™—Õ°ƒAƒŒƒ‹ƒM[Šw‰ïŽ 2017 15: 408-11.
    10. ‘«—§—YˆêD“û—cŽ™‚Ìšb–‚̊ӕʂƎ¡—ÃD“ú–{¬Ž™Ž¨•@ˆôA‰È 2017 38:326-9.
    11. –q–{—D”ü. NICU“ü‰@Ž™‚ւ̃Jƒ“ƒKƒ‹[ƒPƒA.ŽüŽYŠú‚É‚¨‚¯‚éƒtƒ@ƒ~ƒŠ[ƒZƒ“ƒ^[ƒhƒPƒA. ŽüŽYŠúˆãŠw; 2017 Jan; 47(1): 90-2.
    12. ŽíŽsq’ˆ. ¬Ž™‹~‹}‚©‚猩‚½•ÛˆçŽ{Ý‚ÌŠë‹@ŠÇ—. •Ûˆç‚Æ•ÛŒ’. 2017 Jan ; 23(1): 29-31.
    13. ŽíŽsq’ˆ. ¬Ž™‹~‹}‚©‚猩‚½•ÛˆçŽ{Ý‚ÌŠë‹@ŠÇ—. •Ûˆç‚Æ•ÛŒ’. 2017 Jan ; 23(1): 29-31.ŽíŽsq’ˆ. y’¥Œó‚©‚猩”²‚¯!¬Ž™‹~‹}Ž¾Š³@‰Ÿ‚³‚¦‚Ä‚¨‚«‚½‚¢Še’¥Œó‚Ì•a‘ԂƑΉžƒXƒLƒ‹z šq“f. Jmed mook 2017 52: 101-9.
    14. ŽíŽsq’ˆ. ¬Ž™dÇS•s‘SŽ¡—Â̌»ó‚Æ«—ˆ@‚±‚Ç‚à‚Ì”]Ž€‰º‘ŸŠí’ñ‹Ÿ‚ÌŒ»ó‚ƬŽ™‰Èˆã‚Ì–ðŠ„. “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 2017 33(2): 91-9.
    15. ŽíŽsq’ˆ. ”]Ž€‚Æ‚±‚Ç‚à‚Ì–½‚ƬŽ™‰Èˆã. “ú–{¬Ž™‰Èˆã‰ï‰ï•ñ 2017 54: 44-7.
    16. œA–ìŒbˆê, Žs“c•™Žq. u“KØ‚ÈŠwZS‘ŸŒŸf|Œ©“¦‚µ‚Ä‚Í‚¢‚¯‚È‚¢ƒ|ƒCƒ“ƒg‚ÆŠÇ—v. TŠ§“ú–{ˆãŽ–V•ñ . p - .
    17. ˆÉ“¡–õ“TDÁ‰»ŠÇƒAƒŒƒ‹ƒM[‚̃tƒFƒmƒ^ƒCƒvE—Õ°‘œD“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 2017 31:1-6.
    18. ˆÉ“¡–õ“TDH•¨ƒAƒŒƒ‹ƒM[‚Ì—U”­Çó?dÇ“x”»’è‚ƑΉž?@H•¨ƒAƒŒƒ‹ƒM[Œ¤‹†‰ïŽ2017 17(2):102-9.
    19. ˆÉ“¡–õ“TDH•¨ƒAƒŒƒ‹ƒM[‚Ì—U”­Çó‚ÌdÇ“x•]‰¿‚ƃAƒiƒtƒBƒ‰ƒLƒV[‚ւ̑ΉžD“ú–{¬Ž™“šb‘§ƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ïŽ 2017 15:1-7.
    20. ˆÉ“¡–õ“T, ŠC˜VàVŒ³GDH•¨ƒAƒŒƒ‹ƒM[ƒKƒCƒhƒ‰ƒCƒ“2016 Çó‚ÌdÇ“x”»’è‚Æ‘ÎǗÖ@D“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 2017 31:740-6.
    21. ¼“c’¼“¿. ƒEƒCƒ‹ƒXŠ´õÇ\Å‹ß‚Ì“®ŒüEƒgƒsƒbƒNƒX. ‘“à‚Řb‘è‚ÌŠ´õÇ\f’f‚ÆŽ¡—Ã@ƒqƒgƒRƒƒiƒEƒCƒ‹ƒX. ¬Ž™“à‰È; 2017 49(11): 1659-63.
    22. ¬àVˆ»‰À, Žs“c•™Žq. ”DPE•ª•ØŽž‚ÌŒŒs“®‘Ô‚ðŠÜ‚Þ•ê‘̂̕ω»@Heart View 2017 21: 26-30.
    23. “c‘ºŒ«‘¾˜Y, ‹g“cär. ‚¿‚å‚Á‚Æ‹C‚É‚È‚éV¶Ž™-”À‘—‚·‚ׂ«”»’f‚Í?@–³ŒÄ‹z”­ì. ŽüŽYŠúˆãŠw; 2017 Oct; 47(10): 1275-8.

  • 2017”NŠw‰ï•ñ
    1. Itazawa T, Hosoki K, Sur S. Cat Dander Extract Directly Stimulates B Cell to Induce Class Switch. 73th Annual Meeting of American Academy of Allergy, Asthma and Clinical Immunology; 2017 Mar 3-6; Atlanta(USA).
    2. Itazawa T, Hosoki K, Boldogh I, Sur S. Cat Dander Extract Requires Myd88 to Induce Innate Neutrophil Recruitment, and Allergic Sensitization and Allergic Airway Inflammation. 72th Annual Meeting of American Academy of Allergy, Asthma and Clinical Immunology; 2017 Mar 3-6; Atlanta(USA).
    3. Ichida F. The Zebras in Pediatric Cardiology. A National Registry of Rare Cardiac Disease in Children. The 51th Annual Meeting of AEPC; 2017 Mar 30; Lyon(France). (Invited Lecture)
    4. Hirono K, Hata Y, Ozawa S, Wang C, Toda T, Momoi N, Inuzuka R, Hiroki N, Sakaguchi H, Kurosaki K, Okabe M, Miyao N, Nakaoka H, Ibuki K, Saito K, Nishida N, Ichida F. Phenotype-Genotype correlations in the fetal patients with left ventricular noncompaction. The 13th Japan-China-Korea Pediatric Heart Forum with Asian Pacific Symposium; 2017 July 9; Hamamatsu.
    5. Ichida F. Clinical and molecular mechanism of left ventricular noncompaction. Scientific sessions of AHA; 2017 Nov. 14; Anaheim(U.S.A) (Invited Lecture)
    6. ’‡‰ª²’qŽqC‹v•ÛŸ”VC˜a“c‘ñ–çC“c’†•ü”üCŽíŽsq’ˆC‘«—§—Yˆê.@ƒ}ƒCƒRƒvƒ‰ƒYƒ}Š´õŒã‚É‹}«¬”]Ž¸’²Ç‚𗈂½‚µ‚½‚P—áD‘æ71‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï; 2017 Feb 5; ‹à‘ò.
    7. ¬àVˆ»‰À, ’‡‰ª‰pK, âV“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq, ’––”’qŽÀ, •Ä“c@“N, –F‘º’¼Ž÷. ‘ÙŽ™Šú‚Éf’f‚µŽèp‰î“ü‚ð‘I‘ð‚µ‚½‚ªAŒ‹‰Ê‹~–½‚Å‚«‚È‚©‚Á‚½ŽOë•Ù•Â½A”x“®–¬•Â½ASŽº’†ŠuŒ‡‘¹AŽå—v‘Ì”x‘¤•›“®–¬iMAPCAj‚É—¼”x‚Ìæ“V«”x‹C“¹ŠïŒ`iCPAMj‚ª‡•¹‚µ‚½ˆê—á. ‘æ23‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŠw‰ï; 2017 Mar 3-4; “Œ‹ž.
    8. ŽíŽsq’ˆ. ƒ[ƒŠƒ“ƒOƒŠƒXƒg‚ð—˜—p‚µ‚½W’cЊQŽž‚É‚¨‚¯‚é‹Ù‹}ˆã—Ãî•ñŠÇ—ƒVƒXƒeƒ€‚ÌlŽ@. ‘æ44‰ñ“ú–{W’†Ž¡—ÈãŠw‰ï; 2017 Mar 9-11; ŽD–y.
    9. Žs“c•™Žq. “Á•Êu‰‰@S‹Øãk–§‰»áŠQ‚Ì—Õ°``Ç—á•ñ‚©‚çˆâ“`Žq‰ðÍ‚Ü‚Å20”NŠÔ‚ÌŒ¤‹†‚©‚猩‚¦‚½‚à‚Ì`. ‘æ316‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2017 Mar 12; •xŽR.
    10. ”ª–ØGŽq, ¬àVˆ»‰À, ’‡‰ª‰pK, âV“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq. ‚΂¿Žw‚ðŒ_‹@‚É”­Œ©‚³‚ꂽ”x“®Ã–¬á‘‚Ì1—á. ‘æ316‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2017 Mar 12; •xŽR.
    11. ’·‰ªvG, ¼“cŒ\Œá, ˆÉ—Ç•”m, ’JŒûçq, ×–ì—RŽ—Žq, ã–ì˜a”V, “ˆ”öˆ»Žq, “ŒŽROK, “¡“cC•½, “ñ’J@•, ŒÜ\—’“o, ”¨èŠì–F, ’Þ@_”V, ¼“c’¼“¿, ’†’Ø‹v”T, –쑺ŒbŽq. ”jÓÔŒŒ‹…E•nŒŒ‚ð”F‚ßAVitB12‹zŽûáŠQ‚É‚æ‚é‹Ô‰è‹…«•nŒŒ‚Æf’f‚µ‚½’Z’°ÇŒóŒQ‚̈ê—á. ‘æ316‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2017 Mar 12; •xŽR.
    12. ‘¾“cˆÀF, ¼“c’¼“¿, ’†’Ø‹v”T, –쑺ŒbŽq, ‘«—§—Yˆê, à_“‡@ä, ùŒ´³´. “÷‰èŽî—l•a•Ï‚𔺂¢AŽ©‘R‘Þk‚ÆÄ‘‘å‚ð”F‚ß‚½cŠuƒZƒ~ƒm[ƒ}‚̈ê—á. ‘æ316‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2017 Mar 12; •xŽR.
    13. œA–ìŒbˆê. ‰ï’·“Á•ÊŠé‰æuzŠÂŠí—̈æ“«‹H­Ž¾Š³‚ÌŽ•ž‚É‚Þ‚¯‚Äv Left Ventricular Non-compaction. ‘æ81‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï; 2017 Mar 17-19; ‹à‘ò.
    14. œA–ìŒbˆê, Žs“c•™Žq. uƒJ?ƒCƒg?ƒ‰ƒCƒ“‰ðà3v2014-2015”N“xŠˆ“® ŠwZS‘ŸŒŸf‚̃J?ƒCƒg?ƒ‰ƒCƒ“ 4. S‹ØÇES‹Ø‰Š‚ÌŠÇ—. ‘æ81‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï; 2017 Mar 17-19; ‹à‘ò.
    15. ŽíŽsq’ˆ. ƒVƒ“ƒ|ƒWƒEƒ€@‚±‚Ç‚à‚Ì–ò@“K³Žg—pAˆÀ‘S«‚Æ“Y•t•¶‘‚Ì‚Í‚´ŠÔ‚Å ‚±‚Ç‚à‚ɑ΂·‚éOTCˆã–ò•i“K³Žg—p‰º‚É‚Ä”­Ç‚µ‚½ƒIƒsƒIƒCƒh’†“Å. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    16. ŽíŽsq’ˆ. ƒVƒ“ƒ|ƒWƒEƒ€@¬Ž™S‘ŸˆÚA‚Ì‘ÛƒVƒ“ƒ|ƒWƒEƒ€ “ú–{‚É‚¨‚¯‚éŽq‚Ç‚à‚Ì”]Ž€‚ÆS‘ŸˆÚA. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    17. ŽíŽsq’ˆ, ”ª–ØMˆê, ‰ª“cr‘¥. ƒƒNƒ`ƒ“ÚŽí‚ðs‚í‚È‚¢‰Æ‘°‚½‚¿‚ւ̃Aƒvƒ[ƒ``u‰‰‰ïŠJÂƃAƒ“ƒP[ƒgŒ‹‰Ê‚̉ðÍ‚ð’Ê‚µ‚Ä`. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    18. Žs“c•™Žq. “Á•ÊŠé‰æuæ”y‚ÉŠw‚ÔƒLƒƒƒŠƒA‚ÌÏ‚Ý•ûEŠˆ‚©‚µ•ûv’nˆæˆã—ÂðŽx‚¦‚é—«ˆãŽt‚ÌŠˆ–ô‚ðŽx‰‡‚·‚é•xŽR‘åŠw‚ÌŽŽ‚Ý. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    19. Žs“c•™Žq. •ª–ì•ÊƒVƒ“ƒ|ƒWƒEƒ€@‘Û“I‚ȬŽ™zŠÂŠíŒ¤‹†‚ðŠw‚ԌߌãuS‹Øãk–§‰»áŠQ‚Ì•ªŽqˆâ“`ˆãŠwv. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    20. ˆÉ“¡–õ“TDƒVƒ“ƒ|ƒWƒEƒ€uH•¨ƒAƒŒƒ‹ƒM[ƒKƒCƒhƒ‰ƒCƒ“2016FÇó‚ÌdÇ“x”»’è‚ƑΈ—Ö@ ?ƒAƒhƒŒƒiƒŠƒ“‚Æ•¹—p‹ÖŠõ–ò‚ɂ‚¢‚Ä-v. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    21. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. H•¨ƒAƒŒƒ‹ƒM[‚ɑ΂·‚éƒGƒsƒyƒ“‚Ì“K³Žg—p‚Ì•]‰¿. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    22. ”ª–ØGŽq, ŽíŽsq’ˆ, ˜a“c‘ñ–ç, ’‡‰ª²’qŽq, “c’†•ü”ü, ‘«—§—Yˆê. ”]Žº• oƒVƒƒƒ“ƒg‚©‚ç‚Ì‘‰tÌŽæ‚É‚æ‚é‚Æ l‚¦‚ç‚ê‚é• o“àŠ´õ‚Ì‚P—á. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    23. ‘«—§—Yˆê. ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u“û—cŽ™‚Ìšb–‚̊ӕʂƎ¡—Ãv. ‘æ12‰ñ“ú–{¬Ž™Ž¨•@ˆôA‰ÈŠw‰ï; 2017 June 2-3; ‰F“s‹{.
    24. ˆÉ“¡–õ“T, ‰ª•””üŒb, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. ƒAƒŒƒ‹ƒM[«•@‰Š‚ªŒÄ‹CˆêŽ_‰»’‚‘f‘ª’è‚É—^‚¦‚éƒCƒ“ƒpƒNƒg. ‘æ12‰ñ“ú–{¬Ž™Ž¨•@ˆôA‰ÈŠw‰ï; 2017 June 2-3; ‰F“s‹{.
    25. ‘«—§—YˆêD“Á•ÊŠé‰æ1u–k—¤‚©‚ç‚Ì”­M@¬Ž™ƒAƒŒƒ‹ƒM[‚̃gƒsƒbƒNƒXFŠÂ‹«‚ƬŽ™‚̃AƒŒƒ‹ƒM[v. ‘æ28‰ñ“ú–{¬Ž™‰Èˆã‰ï‘‰ïƒtƒH[ƒ‰ƒ€; 2017 June 10-11; •xŽR.
    26. ”ª–ØMˆê, ŒÜ\—’“o, ‘ºãIŒ[, Ë“ckŠî, ¬ŒIˆºŽq, “ˆ”ö@’q, ŽíŽsq’ˆ. •xŽRŒ§‚É‚¨‚¯‚é‚“x‚̈ã—ÓIƒj[ƒY‚Ì‚‚¢áŠQŽ™ŽÒ‚Ö‚ÌŽx‰‡‘̧‚Ö‚Þ‚¯‚Ä|ˆã—Ãî•ñƒlƒbƒgƒ[ƒN\’z‚É‚Þ‚¯‚Ä|. ‘æ28‰ñ“ú–{¬Ž™‰Èˆã‰ï‘‰ïƒtƒH[ƒ‰ƒ€; 2017 June 10-11; •xŽR.
    27. ”ª–ØMˆê, ŒÜ\—’“o, ‘ºã”ü–çŽq, ‘ºãIŒ[, ”öã—mˆê, ‰ª•”@Œh, Ë“ckŠî, “ˆ”ö@’q, ŽíŽsq’ˆ. •xŽRŽs‚É‚¨‚¯‚é’nˆæ¬Ž™‰Èˆã‚ƉŠú‹~‹}f—Ņ̃‚ɂ‚¢‚Ä. ‘æ28‰ñ“ú–{¬Ž™‰Èˆã‰ï‘‰ïƒtƒH[ƒ‰ƒ€; 2017 June 10-11; •xŽR.
    28. ŽíŽsq’ˆ. ‹³ˆçƒZƒ~ƒi[uƒƒNƒ`ƒ“ÚŽí‚ðçSçO‚·‚é‰Æ‘°‚½‚¿v. ‘æ28‰ñ“ú–{¬Ž™‰Èˆã‰ï‘‰ïƒtƒH[ƒ‰ƒ€; 2017 June 10-11; •xŽR.
    29. ìú±—TŽq, ¬–ì—m•ã, “c‘ºŒ«‘¾˜Y, ¼ˆäŽOŽ}, ‹g“cär. o¶Œã‚̃XƒeƒƒCƒh“Š—^‚ªC³18ƒ•ŒŽŽž‚Ì_ŒoŠw“I—\Œã‚É—^‚¦‚é‰e‹¿. ‘æ59‰ñ“ú–{¬Ž™_ŒoŠw‰ïŠwpW‰ï; 2017 June 15-17; ‘åã.
    30. •½Šâ–¾ŽqC“c’†•ü”ü, ‹{@ˆêŽu, ¼ˆäŽOŽ}, Žs“c•™Žq, ‘«—§—Yˆê. æ“V«SŽ¾Š³Ž™‚Ì“û—cŽ™‚Ì”­’BŽw”‚ÆŠw“¶Šú‚Ì’m”\Žw”EŠwKŽx‰‡‚Ì—L–³‚Í‘ŠŠÖ‚·‚éD‘æ59‰ñ“ú–{¬Ž™_ŒoŠw‰ïŠwpW‰ï; 2017 June 15-17; ‘åã.
    31. ˆÉ“¡–õ“T, ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uV¶Ž™E“ûŽ™Á‰»ŠÇƒAƒŒƒ‹ƒM[FV¶Ž™“ûŽ™Á‰»ŠÇƒAƒŒƒ‹ƒM[‚Ì•‰‰×ŽŽŒ±Ž{sŽž‚ÌŒoŽž“IƒTƒCƒgƒJƒCƒ“ƒvƒƒtƒ@ƒCƒ‹v. ‘æ66‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï; 2017 June 16-18; “Œ‹ž.
    32. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. ƒAƒhƒŒƒiƒŠƒ“Ž©ŒÈ’ŽËiƒGƒsƒyƒ“Rj‚ðŽg—p‚·‚é“K؂ȃ^ƒCƒ~ƒ“ƒO‚Ì—‰ð“x‚¨‚æ‚ÑŽè‹Z”\—Í‚Ì’²¸. ‘æ66‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï; 2017 June 16-18; “Œ‹ž.
    33. ŽRŒ³ƒŽq, “n•Ó—S‹I, •£àV—³–ç, ˆÉ“¡–õ“T, ‘«—§—Yˆê. ƒVƒCƒ^ƒP‚ƃzƒEƒŒƒ“ƒ\ƒE‚É‚æ‚éH•¨ˆË‘¶«‰^“®—U”­ƒAƒiƒtƒBƒ‰ƒLƒV[iFDEIAj‚̈ê—á. ‘æ66‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï; 2017 June 16-18; “Œ‹ž.
    34. ŽíŽsq’ˆ. ’n•û‘åŠw‚É‚¨‚¯‚鬎™‹~‹}. ‘æ31‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï; 2017 June 23-25; “Œ‹ž.
    35. ˜a“c—DŽq, –x]’åŽu, ˜a“c‘ñ–ç, “c’†•ü”ü, ˆÉ“¡–õ“T, ŽíŽsq’ˆ, ‘«—§—Yˆê. Ý‘î—×{’†‚ɉ¡–ä‹Ø—Z‰ðÇE‹}«t•s‘S‚ð”­Ç‚µ‚½dÇSgáŠQŽ™(ŽÒ)‚Ì1—á. ‘æ38‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2017 July 2; •xŽR.
    36. Žs“c•™Žq. ‚”öÜŽóÜ‹L”Ou‰‰uS‹Øãk–§‰»áŠQ@Ç—á•ñ‚©‚çˆâ“`Žq‰ðÍ‚Ü‚Å20”NŠÔ‚ÌŒ¤‹†‚©‚猩‚¦‚½‚à‚Ìv. ‘æ53‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2017 July 7-9; •l¼.
    37. œA–ìŒbˆê. ‹³ˆçƒZƒ~ƒi[ ‚±‚±‚Ü‚Ä?’m‚Á‚Ä‚¨‚«‚½‚¢S‹ØÇ:?u1.‰ð–U‚©‚番ŽqˆãŠw‚Ü‚Ä??v. ‘æ53‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2017 July 7-9; •l¼.
    38. âV“¡˜a—R, œA–ìŒbˆê, ‰ª•”^Žq, ‹{”ö¬–¾, ¬àVˆ»‰À, Žs“c•™Žq. V407I-BMP10•ÏˆÙ‚ÍS‹Ø‚Ì•ª‰»‚¨‚æ‚Ñ‘B‚ðáŠQ‚µA¶ŽºS‹Øãk–§‰»áŠQ‚ÌŒ´ˆö‚Æ‚È‚é‚©‚à‚µ‚ê‚È‚¢. ‘æ53‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2017 July 7-9; •l¼.(“ú–{¬Ž™zŠÂŠíŠw‰ï‰ï’·Ü)
    39. ’‡‰ª‰pK, ‰ª•”^Žq, ‹{”ö¬–¾, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, ‘q‹´£“ß, ŽR–{@Œ’, rˆäˆêˆ®, Ò“¡—F”ü, àF’J®Šó, ’·à_q‰i, ˆÉ“¡’å‘¥, X@Œõˆê. S‘ŸMRI‚ð—p‚¢‚½¶ŽºS‹Øãk–§‰»áŠQ(LVNC)‚ÌSŽº‹@”\‰ðÍ. ‘æ53‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2017 July 7-9; •l¼.
    40. ‰ª•”^Žq, ‹{”ö¬–¾, âV“¡˜a—R, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, ’¹’Ë‘å‰î, –سÆ, –F‘º’¼Ž÷. ìè•aœëŠ³Œã‚Ƀy[ƒXƒ[ƒJ[SŽºè‡’l‚Ì㸂ð”F‚ß‚½ŽOë•Ù•Â½EFontanpŒã‚Ì“´•s‘SÇŒóŒQ‚Ì1—á. ‘æ53‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2017 July 7-9; •l¼.
    41. ‹{”ö¬–¾, ‰ª•”^Žq, ’‡‰ª‰pK, Ö“¡˜a—R, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. ¬Ž™–«“Á’莾•aƒŒƒ|ƒWƒgƒŠ[‚ÉŠî‚­ƒAƒ“ƒP[ƒgŒ‹‰Ê‚©‚ç‚Ý‚½¶ŽºS‹Øãk–§‰»áŠQ‚Ì—Õ°‘œ. ‘æ53‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2017 July 7-9; •l¼.
    42. ‘«—§—zŽq, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ”ÂàVŽõŽq, ‘«—§—Yˆê. ¬Ž™‚É‚¨‚¯‚éƒOƒ‹ƒp[ƒ‹19S‚É‚æ‚鬔žƒAƒŒƒ‹ƒM[‚ÌŒo‰ßF¬l—á‚Æ”äŠr‚µ‚Ä. ‘æ41‰ñ“ú–{¬Ž™”畆‰ÈŠw‰ï; 2017 July 8-9; •Ÿˆä.
    43. ‹g“cär, ’––”’qŽÀ, ìú±—TŽq, “c‘ºŒ«‘¾˜Y, –q–{—D”ü. V¶Ž™Šú‚ÉŽèp‚ð—v‚µ‚½æ“V«SŽ¾Š³Ž™‚Ì—\Œã Žèp‚ðs‚Á‚½æ“V«SŽ¾Š³Ž™‚É‚¨‚¯‚é3΂Ì_Œo”­’B—\Œã. ‘æ53‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2017 July 16-18; ‰¡•l.
    44. “c‘ºŒ«‘¾˜Y, ’––”’qŽÀ, ìú±—TŽq, –q–{—D”ü, •Ä“c“¿Žq, •Ä“c@“N, ‹g“cär. •aŒ´”÷¶•¨‚É‚æ‚éŽq‹{“à‰ŠÇ‚Æ–«”xŽ¾Š³”­Ç‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ53‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2017 July 16-18; ‰¡•l.
    45. ‘¾“cˆÀF, ìú±—TŽq, ’––”’qŽÀ, “c‘ºŒ«‘¾˜Y, –q–{—D”ü, ‹g“cär. “–‰@‚ŃxƒoƒVƒYƒ}ƒuÉŽq‘Ì’ŽË“±“üŒã‚ÌROPŽ¡—ÂɊւ·‚錟“¢. ‘æ53‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2017 July 16-18; ‰¡•l.
    46. ˆÀ“cˆê•½, “c‘ºŒ«‘¾˜Y, ’––”’q”ü, ìú±—TŽq, –q–{—D”ü, ‹g“cär. ŒoŽž“I‚È“ª•”’´‰¹”g‚É‚æ‚èf’f‚ÉŽŠ‚Á‚½V¶Ž™”][Ç‚Ì1—á. ‘æ53‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2017 July 16-18; ‰¡•l
    47. ˆÉ“¡–õ“T, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê. ÅdǬ”žƒAƒŒƒ‹ƒM[Š³ŽÒ‚ɑ΂·‚é’ZŠú“ü‰@ŒoŒû–Ɖu—Ö@“±“ü‚ÌŽŽ‚Ý. ‘æ34‰ñ“ú–{¬Ž™“šb‘§ƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï; 2017 July 22-23; ‘å’Ã.
    48. ‘«—§—zŽq, ˆÉ“¡–õ“T, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, ”ÂàVŽõŽq, ‘«—§—YˆêDƒvƒŠƒbƒNƒeƒXƒg‚ÅŒ´ˆö‚ðŠm’è‚Å‚«‚½ƒiƒbƒcƒAƒiƒtƒBƒ‰ƒLƒV[‚Ì2Ç—á. ‘æ34‰ñ“ú–{¬Ž™“šb‘§ƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï; 2017 July 22-23; ‘å’Ã.
    49. ’·‰ªvG, ‹{”ö¬–¾, âV“¡˜a—R, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, ‘«—§—Yˆê. ‹CŠÇ‹·ó‚É‚æ‚éŒJ‚è•Ô‚·‹C“¹Š´õÇE–³‹C”x‚ɑ΂µ, NIPPV“±“ü‚Å“ü‰@‚Ì•p“x‚ªŒ¸­‚µ, •aó‚̉ü‘P‚ðŒ©‚½ˆê—á. ‘æ53‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï; 2017 Aug 20; ‹à‘ò.
    50. ”ª–ØMˆê, Ë“ckŠî, “ˆ”ö@’q, –xìT“ñ˜Y, ŽíŽsq’ˆ. ‘æ27‰ñ“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ï; 2017 Sep 2-3; ŽOd.
    51. ¬àVˆ»‰À, Ö“¡@—I, ‹{”ö¬–¾, Ö“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq, –سÆ, –F‘º’¼Ž÷. 22q11.2Œ‡Ž¸ÇŒóŒQ‚ɇ•¹‚µ‚½ƒtƒ@ƒ[Žl’¥ÇŒ^”x“®–¬•ÙŒ‡‘¹A¶”x“®–¬ŒÇ—§Ç‚̈ê—á. ‘æ45‰ñ–k—¤¬Ž™zŠÂŠíŠw‰ï; 2017 Sep 9; ‹à‘ò.
    52. ”ª–ØMˆê, ŽíŽsq’ˆ, ¼àVƒŽq, ¼“c@“µ, —щÀ“ÞŽq, ‚–؉€”ü, ‰±–{çŽj. •xŽRˆã—ÃŒ—‚É‚¨‚¯‚鬎™ˆã—ÓIƒPƒAŽÀKŒ¤C‰ï‚Ì[ŽÀ‚É‚Þ‚¯‚Ä‚ÌŽæ‚è‘g‚Ý‚Æ•xŽRŒ§‚É‚¨‚¯‚édÇSgáŠQŽ™(ŽÒ)‚Ö‚Ì’nˆæŽx‰‡‘̧\’z‚ɂ‚¢‚Ä. ‘æ43‰ñdÇSgáŠQŽ™Šw‰ï; 2017 Sep 29-30; å‘ä.
    53. –q–{—D”ü, ’––”’qŽÀ, ìú±—TŽq, “c‘ºŒ«‘¾˜Y, ‹g“cär. Bayley“û—cŽ™”­’BƒXƒP[ƒ‹III‚ð—p‚¢‚½‹É’áo¶‘ÌdSGAŽ™‚Ì3ÎŽž_ŒoŠw“I—\Œã. ‘æ62‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2017 Oct 12-14; ‘å‹{.
    54. ìú±—TŽq, ’––”’qŽÀ, “c‘ºŒ«‘¾˜Y, –q–{—D”ü, ‹g“cär. Šç–ÊEŠáâ|“àŒŒŠÇŽî‚ɑ΂µƒvƒƒvƒ‰ƒmƒ[ƒ‹“à•ž—Ö@‚ðs‚Á‚½‹É’áo¶‘ÌdŽ™‚Ì1—á. ‘æ62‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2017 Oct 12-14; ‘å‹{.
    55. ¬àVˆ»‰À, ‰ª•”^Žq, ‹{”ö¬–¾, âV“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq, –سÆ, –F‘º’¼Ž÷. ‰EŽº’áŒ`¬‚ÆSŽº’†•”•ÂÇ«”ì‘åŒ^S‹ØÇ‚ð‡•¹‚µ‚½¬Ž™‚̈ê—á. ‘æ26‰ñ“ú–{¬Ž™S‹ØŽ¾Š³Šw‰ï; 2017 Oct 14; ‘q•~.
    56. œA–ìŒbˆê, Žðˆä••F, ¬àVˆ»‰À, ”¨—R‹IŽq, ¼“c’¼“¿, ‰ª•”^Žq, ‹{”ö¬–¾, âV“¡˜a—R, –F‘º’¼Ž÷, ¼“c®Ž÷, Žs“c•™Žq. MYH7ˆâ“`Žq•ÏˆÙ‚ÆCD36ˆâ“`Žq•ÏˆÙ‚ªŒ©‚¢‚¾‚³‚ꂽS‹Øãk–§‰»áŠQ‚̈ê—á. ‘æ26‰ñ“ú–{¬Ž™S‹ØŽ¾Š³Šw‰ï; 2017 Oct 14; ‘q•~.
    57. ‰ª•”^Žq, œA–ìŒbˆê, ‹{”ö¬–¾, ’‡‰ª‰pK, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq, –؉ºkŽj, ‚èˆê˜N. ìè•a‹}«Šú‚É‚¨‚¯‚élong noncoding RNA‚Ì”­Œ»‰ðÍ. ‘æ37‰ñ“ú–{ìè•aŠw‰ïEŠwpW‰ï; 2017 Oct 27-28; “Œ‹ž.
    58. ‘«—§—zŽq, ”óŒû@Žû, ’†—ÑŒºˆê, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ”ÂàVŽõŽq, ‘«—§—Yˆê, ŽsŠÛ’q_, ¡ˆää‰p. ¬Ž™‚Ì‹C“¹ˆÙ•¨Ž–ŒÌ—\–h‚ÉŠÖ‚·‚é•êe‚Ì’mŽ¯‚ɉe‹¿‚ð—^‚¦‚éˆöŽqD‘æ50‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2017 Nov 10-11; “Œ‹ž.
    59. ”ª–ØMˆê, ‘«—§—Yˆê, •Ä“c“N–ç, ¬Ÿº³ŽŸ, “¡“cC•½. •xŽRŽs‚Ì’nˆæƒNƒŠƒjƒbƒN‚É‚¨‚¯‚é“û—cŽ™‚̌ċzŠíƒEƒCƒ‹ƒXŠw“I’²¸ ‘æ‚Q•ñ. ‘æ50‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2017 Nov 10-11; “Œ‹ž.
    60. œA–ìŒbˆê, Žðˆä••F, ¬àVˆ»‰À, ”¨—R‹IŽq, ¼“c’¼“¿, ‰ª•”^Žq, ‹{”ö¬–¾, âV“¡˜a—R, –F‘º’¼Ž÷, ¼“c®Ž÷, Žs“c•™Žq. A novel MYH7 and CD36 gene variants in a fetus with left ventricular noncompaction; crosstalk between beta myosin heavy chain and fatty acid translocase deteriorates heart failure after surgical intervention. “ú–{l—Þˆâ“`Šw‰ï‘æ62‰ñ‘å‰ï; 2017 Nov 15-18; _ŒË.
    61. ˆÉ“¡–õ“T. ‹³ˆçƒZƒ~ƒi[u¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2017`–ò•¨—Ö@‚̃|ƒCƒ“ƒgF’·ŠúŠÇ—‚Ì–ò•¨—Ö@‚̉ü’ù`‰½‚ª•Ï‚í‚Á‚½‚Ì‚©A•Ï‚¦‚½‚Ì‚©H`. ‘æ54‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2017 Nov 18-19; ‰F“s‹{.
    62. ˆÉ“¡–õ“T, ‘ê‘ò‘ô–¤, ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uJPGL2017‰ü’ù”Å@ƒL[ƒGƒbƒZƒ“ƒXF’·ŠúŠÇ—‚ÉŠÖ‚·‚é–ò•¨—Ö@. ‘æ54‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2017 Nov 18-19; ‰F“s‹{.
    63. ‘«—§—zŽq, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ”ÂàVŽõŽq, ‘«—§—Yˆê. u•ÛˆçŠ‚É‚¨‚¯‚éƒAƒŒƒ‹ƒM[‘ΉžƒKƒCƒhƒ‰ƒCƒ“vŒã5”NŠÔ‚Ì•xŽRŒ§“à‚Ì•ÛˆçŽ{Ý‚É‚¨‚¯‚霋ŽH‘Ήž‚̕ω». ‘æ54‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2017 Nov 18-19; ‰F“s‹{.
    64. ˆÉ“¡–õ“T, ‰º‘º^‹B, –Ø‘ºŒõ–¾, ‘«—§—Yˆê. Food protein induced enterocolitis syndrome (FPIES) ‚Ì•‰‰×ŽŽŒ±Ž{sŽž‚ÌŒoŽž“IƒTƒCƒgƒJƒCƒ“ƒvƒƒtƒ@ƒCƒ‹. ‘æ54‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2017 Nov 18-19; ‰F“s‹{. (—DG‰‰‘èÜ)
    65. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ‘«—§—zŽq, ’†—ÑŒºˆê, ”óŒû@Žû, •£àV—³–ç, ŽRŒ³ƒŽq, ‘ºãIŒ[, ‚”ö@Š², ‘«—§—Yˆê. ƒGƒsƒyƒ“Žg—p‚̃^ƒCƒ~ƒ“ƒO‚Ì—‰ð“x‚ÉŠÖ‚·‚é’²¸`1”NŒã‚Ì•]‰¿`D‘æ54‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2017 Nov 18-19; ‰F“s‹{.
    66. ¼–ì³’m, ŒÜ\—’—²•v, ‘«—§—YˆêD—Õ°“IŽ¡–ü‚ÉŽŠ‚Á‚½šb‘§¬Ž™—á‚É‚¨‚¯‚é‹C“¹‰ß•q«EŒÄ‹z‹@”\‚ÌŒŸ“¢D‘æ54‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2017 Nov 18-19; ‰F“s‹{. (Å—DG‰‰‘èÜ)
    67. œA–ìŒbˆê, ‹{”ö¬–¾, ‰ª•”^Žq, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq, ”¨—R‹IŽq, ¼“c®Ž÷. ‰ï’·—v–]‰‰‘èu¬Ž™S‹ØŽ¾Š³‚Æ•s®–¬v‘æ22‰ñ“ú–{¬Ž™S“dŠw‰ïŠwpW‰ï; 2017 Nov 24-25; “¿“‡.
    68. ꎓ¡@—I, –쑺ŒbŽq, ’Þ@_”V, ‘«—§—Yˆê, ìè—TŽq, ‹g“cär, •Ÿ“cD, Ý“cK‘¾˜Y. ŒŒ—F•aB•ÛˆöŽÒ”D•w‚ÌoŽYŒoŒ±@-ŽY•wl‰È, ŒŒ‰t“à‰È, ¬Ž™‰È, –ƒŒ‰È, –òÜ•”‚É‚æ‚é˜AŒg. ‘æ321‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2017 Dec 10; ‹à‘ò.

    2016”N

  • ’˜‘
    1. Hirono K, Ichida F. Kawasaki Disease: Current Understanding of Mechanism and Evidence-based Treatment. Saji B.T., Newburger J.W., Burns J.C., Takahashi M. (Eds.), 2016. Evidences of endothelial damage in acute stage.; p335-40. Springer, Japan.
    2. Hiraiwa A, Ibuki K, Watanabe K, Matsui M, Yoshimura N, Ichida F. -The growth of the brain- edited by Matsui M, Oishi K, Yamashita A. Aichi: Ichiryusyobou; 2016 Neurodevelopmental outcomes in children with congenital heart disease. How humans evolved supersize brains. p11-8.
    3. Kawasaki Y, Matsui M, Yoshida. T. -The growth of the brain- edited by Matsui M, Oishi K, Yamashita A. Aichi: Ichiryusyobou; 2016 Neurodevelopmental outcomes in children with congenital heart disease. Early Assessment of brain by MRImaging segmentation in small-for-gestational-age infants. P2-5.
    4. ‘«—§—Yˆê. ƒAƒŒƒ‹ƒM[ƒ}[ƒ`‚ð’f‚ ?ƒKƒCƒhƒ‰ƒCƒ“€‹’‚É‚æ‚éŠg‘å—\–h- rì_ˆê•Ò. ‘åã: ˆã–òƒWƒƒ[ƒiƒ‹; 2016. ƒoƒCƒIƒ}[ƒJ[iFeNO‚ðŠÜ‚Þj‚É‚æ‚èšb‘§”­Ç‚Í—\’m‚Å‚«‚é‚©H; p101-6.
    5. ‘«—§—Yˆê. ‘‡¬Ž™ˆã—ÃJƒ“ƒpƒjƒA ê–åˆã‚ª“š‚¦‚éƒAƒŒƒ‹ƒM[Ž¾Š³ Q&A. “cŒ´‘ì_•Ò. “Œ‹ž: ’†ŽR‘“X; 2016. ¬Ž™‚Ìšb‘§‚ŃŠƒ‚ƒfƒŠƒ“ƒO‚Í‹N‚±‚è‚Ü‚·‚©H‹z“üƒXƒeƒƒCƒh‚̓Šƒ‚ƒfƒŠƒ“ƒO—}§‚É—LŒø‚Å‚·‚©H; p78-9.
    6. ‘«—§—YˆêD¡“ú‚ÌŽ¡—ÃŽwj 2016”N“x”ÅDŽRŒû“O, –kŒ´Œõ•v•Ò. “Œ‹ž: ˆãŠw‘‰@; 2016. ¬Ž™‚Ì‚©‚ºÇŒóŒQDp1404-6.
    7. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj-2017”N”Å. ŽRŒû“O, –kŒ´Œõ’j•Ò. “Œ‹ž: ˆãŠw‘‰@; 2017. SŽ¾Š³‚ð‚à‚“û—cŽ™‚Ì“úí¶Šˆ‚ÌŠÇ—‚ÆŽw“±. P1360-1.
    8. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj-2017”N”Å. ŽRŒû“O, –kŒ´Œõ’j•Ò. “Œ‹ž: ˆãŠw‘‰@; 2017. SŽ¾Š³Š³ŽÒ‚Ì”DPEoŽY‚Ì“K‰žEŠÇ—. P429.
    9. Žs“c•™Žq.ŠwZS‘ŸŒŸf‚̃KƒCƒhƒ‰ƒCƒ“i2016”N”Åj“ú–{zŠÂŠíŠw‰ïE“ú–{¬Ž™zŠÂŠíŠw‰ï‡“¯ƒKƒCƒhƒ‰ƒCƒ“. “Œ‹ž: ˆê”ÊŽÐ’c–@l“ú–{zŠÂŠíŠw‰ï; 2016. S‹ØÇ, S‹Ø‰Š‚ÌŠÇ—. p57-60.
    10. ‹g“cär. ‚±‚±‚Ü‚ÅŽg‚¦‚éV¶Ž™E¬Ž™‚̃pƒ‹ƒXƒIƒLƒVƒƒgƒŠ. ×–ì@–ΕÒ. ‘åã: ƒƒfƒBƒJo”Å; 2016 ‡–°–ò‚ðŽg‚Á‚½ˆ’uEŒŸ¸Žž; p112-8.
    11. ŽíŽsq’ˆ, ‹{˜e—˜’j. ƒ|ƒPƒbƒg”ŃJƒ‰[“à‰ÈŠw. –å˜e@F, ‰iˆä—ÇŽO•Ò. “Œ‹ž: ¼‘º‘“X; 2016. Œ´”­«–Ɖu•s‘SÇŒóŒQ@1D‰t«–Ɖu•s‘S‚ðŽå‚Æ‚·‚鎾Š³. P1321-3.
    12. ¬àVˆ»‰À, Žs“c•™Žq. SƒGƒR[ƒnƒ“ƒhƒuƒbƒN@S•s‘S. ’|’†@Ž•Ò. ‹ž“s: ‹à–F“°; 2016. S‹Øãk–§‰»áŠQ. P219-26.
    13. ¬àVˆ»‰À, Žs“c•™Žq. S‘Ÿ‚ðŽç‚é. S‘Ÿ•a‚Ì‚±‚Ç‚à‚ðŽç‚ée‚̉ï•Ò. “Œ‹ž: Œõ—zƒƒfƒBƒA; 2016. pŒã‹N‚±‚肤‚é–â‘è‚Æ“à‰È“IŽ¡—Ã.S‘Ÿ•a‚ÌŽ¡—Ã: p155-61.
    14. ¬àVˆ»‰À, Žs“c•™Žq. S‘Ÿ‚ðŽç‚é. S‘Ÿ•a‚Ì‚±‚Ç‚à‚ðŽç‚ée‚̉ï•Ò. “Œ‹ž: Œõ—zƒƒfƒBƒA; 2016. “úí¶Šˆ. æ“V«SŽ¾Š³‚Æ”­’BáŠQ; p186-90.
    15. ˆÉ“¡–õ“T. ‘‡¬Ž™ˆã—ÃJƒ“ƒpƒjƒAFê–åˆã‚ª“š‚¦‚éƒAƒŒƒ‹ƒM[Ž¾Š³Q&A. “cŒ´‘ì_•Ò. “Œ‹ž: ’†ŽR‘“X; 2016. ƒAƒiƒtƒBƒ‰ƒLƒV[‚Ìf’f‚ƉŠúŽ¡—Ẫ|ƒCƒ“ƒg‚ÍH: p228-31.
    16. “cŒû‰ë“o, Žs“c•™Žq. ¬Ž™‚̈â“`Šw“IŒŸ¸Ef’fEƒJƒEƒ“ƒZƒŠƒ“ƒO@ŽÀ‘HƒP[ƒXƒtƒ@ƒCƒ‹. ‰œŽRŒÕ”V, ŽR–{rŽŠ•Ò. @ “Œ‹ž: f’f‚ÆŽ¡—ÃŽÐ; 2016. ƒ[ƒtƒ@ƒŠƒ“‚ÌŽ¡—ÃE“Š—^—Ê—\‘ª. p163-5.
  • Œ´’˜
    1. Hirono K, Hata Y, Miyao N, Nakaoka H, Saito K, Ibuki K, Watanabe K, Ozawa S, Higuma T, Yoshimura N, Nishida N, Ichida F. Anomalous origin of the right coronary artery evaluated with multidetector computed tomography and its clinical relevance. J Cardiol. 2016 Sep; 68(3): 196-201.
    2. Saito K, Nakaoka H, Takasaki I, Hirono K, Yamamoto S, Kinoshita K, Miyao N, Ibuki K, Ozawa S, Watanabe K, Bowles NE, Ichida F. MicroRNA-93 may control vascular endothelial growth factor A in circulating peripheral blood mononuclear cells in acute Kawasaki disease. Pediatr Res. 2016 Sep; 80(3): 425-32.
    3. Miyazaki A, Oguri A, Ichida F. Non-high-density lipoprotein cholesterol as a cardiovascular risk screening tool in children. Pediatr Int. 2016 Jun; 58(6): 439-44.
    4. Hashimoto I, Watanabe K, Ichida F. Right to Left Ventricular Diameter Ratio ?0.42 is the Warning Flag for Suspecting Atrial Septal Defect in Preschool Children: Age- and Body Surface Area-Related Reference Values Determined by M-Mode Echocardiography. Pediatr Cardiol. Apr; 37(4): 704-13.
    5. Kodo K, Ong SG, Jahanbani F, Termglinchan V, Hirono K, InanlooRahatloo K, Ebert AD, Shukla P, Abilez OJ, Churko JM, Karakikes I, Jung G, Ichida F, Wu SM, Snyder MP, Bernstein D, Wu JC. iPSC-derived cardiomyocytes reveal abnormal TGF-ƒÀ signalling in left ventricular non-compaction cardiomyopathy. Nat Cell Biol. 2016 Oct; 18(10): 1031-42.
    6. Yoshida K, Sasaki M, Adachi Y, Itazawa T, Odajima H, Saito H, Akasawa A. Factors associated with the severity of childhood rhinoconjunctivitis. Allergol Int. 2016 Apr; 65(2): 166-71.
    7. Sato K, Sato Y, Nagao M, Shimojo N, Yoshihara S, Adachi Y, Kameda M, Terada A, Fujisawa T; Best ACT Investigators. Development and validation of asthma questionnaire for assessing and achieving best control in preschool-age children. Pediatr Allergy Immunol. 2016 May; 27(3): 307-12.
    8. Kanatani KT, Hamazaki K, Inadera H, Sugimoto N, Shimizu A, Noma H, Onishi K, Takahashi Y, Itazawa T, Egawa M, Sato K, Go T, Ito I, Kurozawa Y, Konishi I, Adachi Y, Nakayama T; Japan Environment & Children's Study Group. Effect of desert dust exposure on allergic symptoms: A natural experiment in Japan. Ann Allergy Asthma Immunol. 2016 May; 116(5): 425-430.e7
    9. Hosoki K, Itazawa T, Boldogh I, Sur S. Neutrophil recruitment by allergens contribute to allergic sensitization and allergic inflammation . Curr Opin Allergy Clin Immunol. 2016 Feb; 16(1): 45-50.
    10. Hosoki K, Boldogh I, Aguilera-Aguirre L, Sun Q, Itazawa T, Hazra T, Brasier AR, Kurosky A, Sur S. Myeloid differentiation protein 2 facilitates pollen- and cat dander-induced innate and allergic airway inflammation. J Allergy Clin Immunol. 2016 May; 137(5): 1506-1513.e2.
    11. Kobayashi T, Fuse S, Sakamoto N, Mikami M, Ogawa S, Hamaoka K, Arakaki Y, Nakamura T, Nagasawa H, Kato T, Jibiki T, Iwashima S, Yamakawa M, Ohkubo T, Shimoyama S, Aso K, Sato S, Saji T; Z Score Project Investigators. A new Z score curve of the coronary arterial internal diameter using the lambda-mu-sigma method in a pediatric population. J Am Soc Echocardiogr. 2016 Aug; 29(8): 794-801.e29.
    12. Matsuura H, Ichida F, Saji T, Ogawa S, Waki K, Kaneko M, Tahara M, Soga T, Ono Y, Yasukochi S. Clinical features of acute and fulminant myocarditis in children - 2nd Nationwide survey by Japanese society of pediatric cardiology and cardiac surgery. Circ J. 2016 Oct 25; 80(11): 2362-8.
    13. Okuma Y, Suda K, Nakaoka H, Katsube Y, Mitani Y, Yoshikane Y, Ichida F, Matsushita T, Shichino H, Shiraishi I, Abe J, Hiroe M, Yoshida T, Imanaka-Yoshida K. Serum Tenascin-C as a novel predictor for risk of coronary artery lesion and resistance to intravenous immunoglobulin in Kawasaki disease - A multicenter retrospective study. Circ J. 2016 Oct 25; 80(11): 2376-81.
    14. Ochiai R, Kato H, Akiyama N, Ichida F, Yao A, Inuzuka R, Niwa K, Shiraishi I, Nakanishi T. Nationwide survey of the transfer of adults with congenital heart disease from pediatric cardiology departments to adult congenital heart disease centers in Japan. Circ J. 2016 Apr 25; 80(5): 1242-50.
    15. Gaynor JW, Stopp C, Wypij D, Andropoulos DB, Atallah J, Atz AM, Beca J, Donofrio MT, Duncan K, Ghanayem NS, Goldberg CS, Hovels-Gurich H, Ichida F, Jacobs JP, Justo R, Latal B, Li JS, Mahle WT, McQuillen PS, Menon SC, Pemberton VL, Pike NA, Pizarro C, Shekerdemian LS, Synnes A, Williams I, Bellinger DC, Newburger JW. Impact of operative and postoperative factors on neurodevelopmental outcomes after cardiac operations. Ann Thorac Surg. 2016 Sep; 102(3): 843-9.
    16. Hata Y, Kinoshita K, Mizumaki K, Yamaguchi Y, Hirono K, Ichida F, Takasaki A, Mori H, Nishida N. Postmortem genetic analysis of sudden unexplained death syndrome under 50 years of age: A next-generation sequencing study. Heart Rhythm. 2016 Jul; 13(7): 1544-51.
    17. Akashi K, Mezawa H, Tabata Y, Atsuta J, Tokuda R, Kawada Y, Kitamura T, Murasugi H, Ito H, Tabata M, Shirao K, Sato S, Nishimura H, Fujiwara M, Masuda K, Arakawa H, Adachi Y, Yoshihara S, Fujisawa T, Katsunuma T. Optimal step-down approach for pediatric asthma controlled by salmeterol/fluticasone: A randomized, controlled trial (OSCAR study). Allergol Int. 2016 Jul; 65(3): 306-11.
    18. Nakamura S, Watanabe N, Yoshimura N, Ozawa S, Hirono K, Ichida F, Taguchi M. A model analysis for dose-response relationship of warfarin in Japanese children: An introduction of the SIZE parameter. Drug Metab Pharmacokinet. 2016 Jun; 31(3): 234-41.
    19. Hachiya A, Motoki N, Akazawa Y, Matsuzaki S, Hirono K, Hata Y, Nishida N, Ichida F, Koike K. Left ventricular non-compaction revealed by aortic regurgitation due to Kawasaki disease in a boy with LDB3 mutation. Pediatr Int. 2016 Aug; 58(8): 797-800.
    20. Sasaki M, Yoshida K, Adachi Y, Furukawa M, Itazawa T, Odajima H, Saito H, Hide M, Akasawa A. Environmental factors associated with childhood eczema: Findings from a national web-based survey. Allergol Int. 2016 Oct; 65(4): 420-424.
    21. Kimura M, Ito Y, Tokunaga F, Meguro T, Shimomura M, Morishita H, Seto S. Increased C-reactive protein and fever in Japanese infants with food protein-induced enterocolitis syndrome. Pediatr Int. 2016 Sep; 58(9): 826-30.
    22. ˜a“c‘ñ–ç,@”ÂàVŽõŽq,@à_“¹”ü‹I,@”óŒû@Žû,@ˆÉ“¡–õ“T,@’†—ÑŒºˆê,@‰ª•””üŒb,@‘«—§—zŽq,@‘«—§—Yˆê.@¬Ž™ƒAƒŒƒ‹ƒM[«•@‰Š‚ÌdÇ“x‚È‚ç‚Ñ‚ÉÇó‚Ì’ö“x‚Ì•]‰¿‚É‚¨‚¯‚évisual analog scale‚Ì—L—p«. ¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ @2016 30: 642-50.
    23. ‹{@ˆêŽu, “c’‡çH, “c’†•ü”ü. Šw—îŠú”­’BáŠQE’m“IáŠQŽ™‚Ì“ñŽŸáŠQ‡•¹‚ÌŒŸ“¢. ‚Æ‚â‚Ü”­’B•ŸŽƒŠw”N•ñ. 2016 Jul 7:23-98.
    24. X‚±‚¸‚¦, ìú±—TŽq, –q–{—D”ü, ’|‘º‹žŽq, “c‘ºŒ«‘¾˜Y, ‹g“cär. HLAR‘Ì‚É‚æ‚Á‚ÄŒŒ¬”’ቺ‚ª‘J‰„‚µ‚½V¶Ž™“¯Ží–Ɖu«ŒŒ¬”ÂŒ¸­Ç‚̈ê—á. “ú–{ŽüŽYŠúV¶Ž™ˆãŠw‰ïŽGŽ 2016 Dec 52(4): 1220-3.
  • Ç—á•ñ
    1. Yoshida Y, Hirono K, Nakamura K, Suzuki T, Hata Y, Nishida N. A novel ACTC1 gene mutation in a young boy with left ventricular noncompaction and arrhythmias. Heart Rhythm Case Report 2016 2: 92?7.
    2. ꎓ¡@—I, ¼“c’¼“¿, –쑺ŒbŽq, ‘«—§—Yˆê, ‹àŒ“O˜a. ‹}«œ‘«”’ŒŒ•aiAML M0j‚Éæs‚µ‚½œ‘“÷Žî‚Ì1—á. “ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ïŽGŽ@2016 53(3): 300-4.
    3. ‘ŠJË•½, ¶…ŠÑl, –x]’åŽu, ’†’Ø‹v”T, ŽÂ茒‘¾˜Y, ‘剮®Žq, ¯Ži‘×O. ƒrƒj[ƒ‹‘܂̈ÙH‚É‚æ‚è’°•ÂÇ‚ð”­Ç‚µ‚½Ž©•ÂÇ‚Ì1—á. ¬Ž™‰È—Õ° 2016 July 69(7): 1243-7.
  • ‘à
    1. Ichida F. Management and treatment of hypertrophic cardiomyopathy in children. Guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy. Circ J 2016 80:753-74.
    2. Katsunuma T, Adachi Y, Miura K, Teramoto T, Fujisawa T, Ohya Y, Futamura M, Imai T, Kondo N. Care of children with allergic diseases following major disasters. Pediatr Allergy Immunol. 2016 Jun; 27(4): 425.
    3. ‘«—§—Yˆê. ŠÂ‹«‚ÆŽq‚Ç‚à‚̃AƒŒƒ‹ƒM[. Žq‚Ç‚à‚ÌŒ’N‰ÈŠw 2016 16(1): 7-11.
    4. ‘«—§—Yˆê. ƒAƒŒƒ‹ƒM[Ž¾Š³‚Ì‚·‚ׂÄF“ûŽ™Šú‚Ìšb‘§‚Æšb–Â. “ú–{ˆãŽt‰ïŽGŽ@2016 June 145: S170-1.
    5. ‘«—§—Yˆê. Ž„‚ÌŽ¡—Ã@¬Ž™‰È@ƒGƒrƒfƒ“ƒX‚ÉŠî‚¢‚½¬Ž™šb‘§‚Ì’·ŠúŠÇ—. ƒAƒŒƒ‹ƒM[‚Ì—Õ° 2016 May 36(5): 473-5.
    6. ‘«—§—Yˆê. “ÁWu¬Ž™“úíf—Âł»‚Ì–ò‚ðŽg‚¤‚Æ‚«EŽg‚¤‚ׂ«‚Å‚È‚¢‚Æ‚«F‹CŠÇŽxšb‘§‚ƃXƒeƒƒCƒh“à•ž–òv. ¬Ž™‰È 2016 57(13):1092-3.
    7. ‘«—§—Yˆê. “ÁWu¬Ž™“úíf—Âł»‚Ì–ò‚ðŽg‚¤‚Æ‚«EŽg‚¤‚ׂ«‚Å‚È‚¢‚Æ‚«F‹CŠÇŽxšb‘§‚Æ‹z“üƒXƒeƒƒCƒh–òv. ¬Ž™‰È 2016 57(13):1590-1.
    8. ‘«—§—Yˆê. ƒg[ƒ^ƒ‹ƒPƒA‚ð‚ß‚´‚·ƒAƒŒƒ‹ƒM[f—ÃF¬Ž™ƒAƒŒƒ‹ƒM[Ž¾Š³‚Ì“Á’¥‚Æ’ˆÓ“_D“ú–{“à‰ÈŠw‰ïŽGŽ 2016 105:1952-7.
    9. ‘«—§—Yˆê. “ÁWu¬Ž™ƒAƒŒƒ‹ƒM[Ž¾Š³‚ÌV’mŽ¯F˜@Žq‚Ç‚à‚̃AƒŒƒ‹ƒM[‚Í‚Ç‚ñ‚Ç‚ñ•Ï‰»‚µ‚Ä‚¢‚év. ƒAƒŒƒ‹ƒM[E–Ɖu 2016 Mar 23(4): 483-6.
    10. œA–ìŒbˆê, Žs“c•™Žq. –«SŽ¾Š³. S‹ØÇ. ¬Ž™‰È—Õ°2016 May 69(4): 617-22.
    11. œA–ìŒbˆê, Žs“c•™Žq. ¶ŽºS‹Øãk–§‰»áŠQ‚ð‚ǂ̂悤‚Éf’f‚·‚é‚©. Heart View 2016. Feb 20(2): 121-31.
    12. ’†—ÑŒºˆê. ƒCƒ“ƒpƒ‹ƒXƒIƒVƒƒƒgƒŠ[iIOSj‚Ì“Á’¥‚Æ—Õ°‰ž—p. “ú–{¬Ž™ŒÄ‹zŠíŠw‰ïŽGŽ 2016 27: 58-62.
    13. ¬àVˆ»‰À, Žs“c•™Žq. ŠwZS‘ŸŒŸf‚ð—Õ°‚ɶ‚©‚·. ŒÄ‹z‚ÆzŠÂ2016 7: 718-24.
    14. ¬àVˆ»‰À, Žs“c•™Žq. S•s‘S‚ƃÀŽÕ’f–ò.u¬Ž™“úíf—Âł»‚Ì–ò‚ðŽg‚¤‚Æ‚«EŽg‚¤‚ׂ«‚Å‚È‚¢Žžv. ¬Ž™‰È2016 57(13): 1636-7.
    15. ˆÉ“¡–õ“T. ¬Ž™ƒAƒŒƒ‹ƒM[Ž¾Š³‚̃tƒFƒmƒ^ƒCƒv. ƒAƒŒƒ‹ƒM[E–Ɖu 2016 Mar 23(4): 494-501.
    16. ¼“c’¼“¿, ΉHàV‰f”ü, ‘q‹´K–ç, Œã“¡Œ¤½, ²“¡—F‹I. ¬Ž™×‹Û«’°‰Š‚ð‹^‚Á‚½‚Æ‚«‚ÉR‹Û–ò‚ð“Š—^‚·‚é‚©? ¬Ž™‰È—Õ° 69(2): 291-5.
    17. ìè—TŽq, ‹g“cär. ”sŒŒÇE‘–Œ‰ŠE”x‰Š.yŽüŽYŠúˆãŠw•KC’mŽ¯(‘æ8”Å)zV¶Ž™•Ò (Part V)`V¶Ž™. ŽüŽYŠúˆãŠw 2016 46(‘): 619-21.
    18. ’––”’qŽÀ, ‹g“cär. GBSŠ´õÇ.yŽüŽYŠúˆãŠw•KC’mŽ¯(‘æ8”Å)zV¶Ž™•Ò (Part V)`V¶Ž™. ŽüŽYŠúˆãŠw 2016 46(‘): 622-4.

  • 2016”NŠw‰ï•ñ
    1. Itazawa T, Hosoki K, Boldogh I, Sur S. Cat Dander Extract Requires Myd88 to Induce Innate Neutrophil Recruitment, and Allergic Sensitization and Allergic Airway Inflammation. 72th Annual Meeting of American Academy of Allergy, Asthma and Clinical Immunology; 2016 Mar 4-7; Los Angels, USA.
    2. Saito K, Mayhew C, Stanton L, Towbin JA, Purevjav E. Generation of induced pluripotent stem cells from Epstein-Barr Virus immortalized lymphoblastoid cell lines using Episomal vectors. The Experimental Biology 2016 Meeting; 2016 Apr 2-6; San Diego, USA.
    3. Hirono K, Takasaki A, Hata Y, Okabe M, Nakaoka H, Ibuki K, Ozawa S, Nishida N, Ichida F. Clinical features and prognosis of pediatic patients with left ventricular noncompaction. European society for cardiology congress 2016; 2016 Aug 26-30; Rome.
    4. Adachi Y. Environmental factors and allergy in children. Joint Congress of Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) and Asia Pacific Association of Pediatric Allergy, Respirology & Immunology (APAPARI) 2016; 2016 Oct 16-20; Kuala Lumpur, Malaysia. (Invited Speech)
    5. Ichida F. Clinical features of left ventricular noncompaction: long-term clinical course and genetic background. The 6th APPCS; 2016 22; Shanghai. (Invited Lecture)
    6. Nakaoka H, Hirono K, Okabe M, Miyao N, Saito K, Ibuki K, Ozawa S, Takahashi K, Ichida F. Endothelial microparticles modulate vasculitis during the acute phase of Kawasaki Disease. The 89th Scientific sessions of AHA 2016; 2016 Nov 12-16; New Orleans, USA. (CVDY Outstanding research award)
    7. Hirono K, Wang C, Hata Y, Takasaki A, Ozawa S, Nakaoka H, Okabe M, Miyao N, Saito K, Nishida N, Ichida F. Long-term prognosis of the pediatric patients with Left Ventricular Noncompaction. 2nd International Congress of Cardiomyopathies and Heart Failure 2016; 2016 Dec 2-4; Kyoto.
    8. ‘ŠJË•½, ’‡‰ª²’qŽq, “c’†•ü”ü, “c’‡çH, ‹{@ˆêŽu, ŽíŽsq’ˆ, ‘«—§—Yˆê. R‚Ä‚ñ‚©‚ñ–ò‚ª‘tŒ÷‚µ‚½ŽüŠú«šq“fÇ‚Ì“ûŽ™—á. ‘æ69‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï; 2016 Feb 7; ‹à‘ò.
    9. ŽíŽsq’ˆ, àF’JLŽq. ¬Ž™”]Ž€Ž–—á‚ɑ΂µ‚Ä’·‹——£”À‘—‚ðs‚Á‚½ˆê—á. ‘æ43‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï; 2016 Feb 12-14; _ŒË.
    10. ŽíŽsq’ˆ, àF’JLŽq. OTCˆã–ò•i‚ÉŠÜ‚Ü‚ê‚éƒWƒqƒhƒƒRƒfƒCƒ“‚̈Ùí‘ãŽÓ‚É‹Nˆö‚µ‚½¬Ž™ƒIƒsƒIƒCƒh’†“Å. ‘æ43‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï; 2016 Feb 12-14; _ŒË.
    11. ¬àVˆ»‰À, ‹{”ö¬–¾, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, œA–ìŒbˆê, Žs“c•™Žq. ‘ÙŽ™Šú‚©‚ç’ÇÕ‚µAo¶Œã‘Šú‚ÉŠO‰È“IØœ‚ðs‚Á‚½‰E–[“àŒŒŠÇŽî‚̈ê—á. ‘æ22‰ñ‘ÙŽ™S‘Ÿ•aŠw‰ï; 2016 Feb 19-20; “Œ‹ž.
    12. ’‡‰ª²’qŽq, ìú±—TŽq, –ؗ•Žq, ’––”’qŽÀ, –q–{—D”ü, ‹g“cär, ‘«—§—Yˆê. CPK‚Ì㸂©‚炃JƒtƒFƒCƒ“ŒŒÇ‚ª”»–¾‚µ‚½‘ŽYŽ™‚̈ê—á. ‘æ316‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2016 Mar 13; •xŽR.
    13. Hirono K, Hata Y, Takasaki A, Miyao N, Nakaoka H, Ibuki K, Ozawa S, Nishida N, Ichida F. Clinical and genetic characteristics in the fetal patients with left ventricular noncompaction. ‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï; 2016 Mar 18-20; å‘ä.
    14. ŽíŽsq’ˆ, “c’†•ü”ü, ûüè–ƒ”ü, âV“¡@—I, ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€u‘I‘ðŽˆ’ñŽ¦‚̈Ӌ`‚Æ•‹yŒ[”­Šˆ“®F6Ζ¢–ž”]Ž€‰º‘ŸŠí’ñ‹Ÿ‚ÌŒoŒ±‚©‚çl‚¦‚é‘I‘ðŽˆ’ñŽ¦‚̈Ӌ`vD‘æ49‰ñ“ú–{—Õ°tˆÚAŠw‰ï; 2016 Mar 23-25; •ÄŽq.
    15. ‘«—§—Yˆê. ‘‡ƒVƒ“ƒ|ƒWƒEƒ€uŽq‹Ÿ‚̊‹«‚ÆŒ’N‚ðl‚¦‚é -ƒGƒRƒ`ƒ‹’²¸‚ÉŠú‘Ò‚·‚邱‚Æ-FŽq‚Ç‚à‚̊‹«‚ƃAƒŒƒ‹ƒM[v. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    16. ŽíŽsq’ˆ, ’ÒŒûŠì‘ã—², ‚‹´Œ¦‘ã. ‚±‚Ç‚à‚Ì”]Ž€‰º‘ŸŠí’ñ‹ŸŒoŒ±3Ž{Ý‚É‚¨‚¯‚éî•ñ‚Ì‹¤—L‚Æ–â‘è‰ðŒˆ‚ÉŒü‚¯‚Ä‚Ì’ñŒ¾. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    17. ŽíŽsq’ˆ, ¼ŽR˜aF, ˆäoŒ’‘¾˜Y, ‘¾“c–M—Y, ´…’¼Ž÷, ŽR”¨‰À“Ä, ”~Œ´@ŽÀ, ŽsìŒõ‘¾˜Y, ‹Êˆä@_, Ž›ˆä@Ÿ. “ú–{¬Ž™‰ÈŠw‰ï”ŬŽ™‹~‹}‘h¶ƒR[ƒXiŠJ”­’†jƒR[ƒX‚Ì–ÚŽw‚·ƒRƒ“ƒZƒvƒg(ˆÄ). ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    18. ’––”’qŽÀ, ìú±—TŽq, ¬‰Y@Ž, “c‘ºŒ«‘¾˜Y, –q–{—D”ü, ‹g“cär, ‘«—§—Yˆê. ‰Á‰·‰ÁŽ¼‚—¬—Ê•@ƒJƒjƒ…[ƒŒ‚ÌŽg—p‚ÅÝ‘îˆÚs‚Å‚«‚½–«”xŽ¾Š³‚Ì1—á. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    19. ’‡‰ª²’qŽq, “c’†•ü”ü, ‘ŠJãÄ•½, Ž›‰ºV‘¾˜Y, “ú”ä‘å—º, ¼ˆä@—I, •z‘º°, ŽíŽsq’ˆ, ‘«—§—Yˆê. OTCˆã–ò•i‚Ì“K³Žg—pŒã‚ɃIƒsƒIƒCƒh’†“Å‚ÉŽŠ‚Á‚½—Ž™—á. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    20. ‘ŠJË•½, “c’†•ü”ü, ’‡‰ª²’qŽq, ‹{@ˆêŽu, ŽíŽsq’ˆ, ‘«—§—Yˆê. R‚Ä‚ñ‚©‚ñ–ò‚ª‘tŒ÷‚µ‚½ŽüŠú«šq“fÇ‚Ì“ûŽ™—á. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    21. ‘ºã«Œ[, ¼“c’¼“¿, ’†’Ø‹v”T, ŽíŽsq’ˆ, –쑺ŒbŽq, ‘«—§—Yˆê. ‹}Œƒ‚Ȉӎ¯áŠQ‚ðŒ_‹@‚É”­Œ©‚³‚ꂽ‹}«’P‹…«”’ŒŒ•a(M5a)‚Ì1—á. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    22. ›“c^–ç, ˆÉ“¡–õ“T, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. ƒ}ƒJƒ_ƒ~ƒAƒiƒbƒc‚É‚æ‚éƒAƒiƒtƒBƒ‰ƒLƒV[‚̬Ž™—á. -ƒiƒbƒc—ÞƒAƒŒƒ‹ƒM[‚Ìf’fEŠÇ—‚ɂ‚¢‚Ä‚ÌlˆÄ-. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    23. rˆä”ü•ä, ˜a“c‘ñ–ç, ŽíŽsq’ˆ, ˆÀì@“µ, ›“c^–ç, ’†—ÑŒºˆê, ‘«—§—Yˆê, ’ß“cŽu, ’·’Jì‹v–í. ŒÀ‹Ç«”’”çǂɇ•¹‚µ‚½dLjô“ª“ǂ̈ê—á. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    24. ´…@”V, “c‘ºŒ«‘¾˜Y, ¬‰Y@Ž, ’––”’qŽÀ, ìè—TŽq, –q–{—D”ü, ‹g“cär, ‘«—§—Yˆê. ‘ÙŽ™f’f‚³‚ꂽæ“V«‰E”xŒ‡‘¹Ç‚Ì1—á. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    25. ‘ŠJË•½, “c’†•ü”ü, •½Šâ–¾Žq, “n•Ó—S‹I, ‘q–{@’, “¡–Ø–õŽq, “c’‡çH, ‹{@ˆêŽu, ‘«—§—Yˆê. ‚—tŽ_ŒŒÇ‚ð”F‚ß‚½d“x¸_‰^“®”­’B’x‰„‚Ì—Ž™—á. ‘æ58‰ñ“ú–{¬Ž™_ŒoŠw‰ï; 2016 June 3-5; “Œ‹ž.
    26. ”ª–ØMˆê, ŒÜ\—’“o, ”¨èŠì–F, ‰ª•”@Œh, ‘ºãIŒ[, Ë“ckŠî, “ˆ”ö@’q, ‘«—§—Yˆê, ‚–؉€, —щÀ“ÞŽq, ‰±–{çŽj. •xŽRŽs‚É‚¨‚¯‚鬎™ˆã—ÓIƒPƒAŽÀ‹ZŒ¤C‰ï‚ɂ‚¢‚Ä. ‘æ1•ñ. ‘æ27‰ñ“ú–{¬Ž™‰Èˆã‰ï‘‰ïƒtƒH[ƒ‰ƒ€; 2016 June 11-12; •ÄŽq.
    27. –xìT“ñ˜Y, ’†“ˆ“ÖŽq, Ž®¯WŽq, •½Šâ–¾Žq, ’‡‰ª‰pK, ¬‰Y@Ž, ’†’Ø‹v”T, ”óŒû@Žû, ‹{@ˆêŽu, ŽR“cŒbŽq, ˆ¢•Û@Ä, ’†—ÑŒºˆê, “¡“cC•½, ŽíŽsq’ˆ, ŒÜ\—’“o. •xŽR¬Ž™‰Šúf—ÃR[ƒX(TOPƒR[ƒX)‚ÌŠJ”­‚ÆŠˆ“®•ñ. ‘æ7‰ñ“ú–{ƒvƒ‰ƒCƒ}ƒŠEƒPƒA˜A‡Šw‰ï; 2016 June 11-12; “Œ‹ž.
    28. ˆÉ“¡–õ“T, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. H•¨ƒAƒŒƒ‹ƒM[(Šî‘b@‚»‚Ì‚Ù‚©) Œ{—‘ƒAƒŒƒ‹ƒM[Š³ŽÒ‚É‚¨‚¯‚éŒ{—‘RŒ´“ÁˆÙ“I§Œä«T×–E‚ÌŒŸo•û–@‚ÌŠm—§. ‘æ65‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2016 June 17-19; “Œ‹ž.
    29. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ”óŒû@Žû, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. ¬Ž™‹CŠÇŽxšb‘§‚ÌŽ¡—ÃEŠÇ— ƒAƒŒƒ‹ƒM[«•@‰Š‚É‚æ‚鬎™‹CŠÇŽxšb‘§‚Ö‚Ì‹Gß–ˆ‚̉e‹¿. ‘æ65‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2016 June 17-19; “Œ‹ž.
    30. ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, –F‘º’¼Ž÷. S–[’†ŠuŒ‡‘¹Ç(ASD)‚ɑ΂·‚éŒo”ç“I•Â½p‚ÌŒoŒ±‚Æ“–‰@‚É‚¨‚¯‚鬎™ASDŽ¡—Â̌»ó. ‘æ132‰ñ“ú–{zŠÂŠíŠw‰ï–k—¤’n•û‰ï; 2016 June 26; ‹à‘ò.
    31. “‡—DŽq, ˜a“c‘ñ–ç, ŽíŽsq’ˆ. dLjô“ª“ǂɑ΂µ‚Ä High-flow nasal cannula —Ö@‚ð—p‚¢‚½q‹ó”À‘—. ‘æ30‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï; 2016 July 1-2; å‘ä.
    32. œA–ìŒbˆê, Žs“c˜HŽq. ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“FŠwZS‘ŸŒŸf‚̈Ӌ`FŠeSŽ¾Š³–ˆ‚̃AƒEƒgƒJƒ€‚©‚ç’T‚é. uS‹ØÇv. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    33. œA–ìŒbˆê. ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€F¬Ž™zŠÂŠí—̈æ‚É‚¨‚¯‚éiPS×–E‚ð—p‚¢‚½Œ¤‹†‚ÌŒ»ó.uS‹ØÇv. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    34. ˆÉŒ\“ñ˜Y, ‹{”ö¬–¾, ’‡‰ª‰pK, âV“¡˜a—R, ¬àVˆ»‰À, œA–ìŒbˆê, –F‘º’¼Ž÷, Žs“c•™Žq. æ“V«SŽ¾Š³Ž™‚ÌŠw“¶Šú’m”\Žw”‚Æ“û—cŽ™Šú‚Ì”­’BŽw”‚ÌŠÖŒW. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    35. ¬àVˆ»‰À, ‹{”ö¬–¾, ˆÉŒ\“ñ˜Y, œA–ìŒbˆê, Žs“c•™Žq, ¼”ö’C˜N, “úŒG’qŒ›, –F‘º’¼Ž÷. ‘”xÖ¬ŠÒ—¬ˆÙíA”xÖ¬•ÂÇ‚ð‡•¹‚µ‚½¶S’áŒ`¬‚ɑ΂µA’iŠK“IŽèp‚ðs‚¢2SŽºC•œ‚É“ž’B‚µ‚½ˆê—á. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    36. ’‡‰ª‰pK, ‰ª•”^Žq, ‹{”ö¬–¾, ˆÉŒ\“ñ˜Y, âV“¡˜a—R, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. ìè•a‹}«Šú‚É‚¨‚¯‚錌ŠÇ“à”ç×–E—R—ˆ‚ÌŒŒŠÇ”÷¬—±Žq(EMPs)‚Ì–ðŠ„.@‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    37. ‰ª•”^Žq, ‹{”ö¬–¾, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. MDCTŒŸ¸‚ª—L—p‚Å‚ ‚Á‚½‰EŠ¥“®–¬‹NŽnˆÙí‚Ì3Žèp—á. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    38. ‹{”ö¬–¾, ‰ª•”^Žq, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. ¬Ž™SŽ¾Š³‚ɑ΂·‚éƒgƒ‹ƒoƒvƒ^ƒ“‚ÌŽg—pŒoŒ±‚Æ—LŒø«AˆÀ‘S«‚ÌŒŸ“¢. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    39. ꎓ¡@—I, ‹{”ö¬–¾, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. ‘ÙŽ™•p”‚Å”­Œ©‚³‚êA¶Œã•p”Ž¡—Âɓïa‚µ‚½S–[•p”(AT)‡•¹–[ŽºƒŠƒGƒ“ƒgƒŠ[«•p”(AVRT)‚̈ê—á. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    40. ‹´–{ˆè•v, ˆÉŒ\“ñ˜Y. 3DƒGƒR[ƒf[ƒ^‚©‚ç‚Ì3D printing‚ÉŒü‚¯‚½ŽŽ‚Ý. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    41. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê, ŽÄ“c@K, ”óŒû@Žû,@•£àV—³–ç, ŽRŒ³ƒŽq, ‘ºãIŒ[,@”öã—mˆê, ‚”ö@Š², à_“¹”ü‹I. ƒAƒhƒŒƒiƒŠƒ“Ž©ŒÈ’ŽËŠí(ƒGƒsƒyƒ“R)‚Í“KØ‚ÉŽg—p‚Å‚«‚é‚©? ?Š³ŽÒE•ÛŒìŽÒ‚ɑ΂·‚é‘Ζʒ²¸‚©‚ç?. ‘æ36‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2016 July 10; •xŽR.
    42. ”ª–ØGŽq, ’‡‰ª²’qŽq, ˜a“c‘ñ–ç, “c’†•ü”ü, ŽíŽsq’ˆ, ‘«—§—Yˆê. ˆÓŽ¯áŠQ‚ª‘J‰„‚µ‚½DravetÇŒóŒQ‚̈ê—á. ‘æ36‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2016 July 10; •xŽR.
    43. ‹g“cär. ƒVƒ“ƒ|ƒWƒEƒ€uNCPR2015‚Ì•ÏX“_‚Æ‚±‚ê‚Ü‚Å‚Ì“ú–{‚Å‚ÌŽÀÑ ƒgƒŒ[ƒjƒ“ƒOƒTƒCƒg‚ðŽ‚½‚È‚¢Œ§‚Å‚ÌNCPRuK‰ï‚ÌŽ–‹Æ‚ÌŒ»ó‚Æ–â‘è“_v. ‘æ52‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2016 Jul 16-18;•xŽR.
    44. ìè—TŽq, ’‡‰ª²’qŽq, –ؗ•Žq, ’––”’qŽÀ, –q–{—D”ü, ‹g“cär. CPK㸂ðŒ_‹@‚É‚ƒJƒtƒFƒCƒ“ŒŒÇ‚Æf’f‚µ‚½‘ŽYŽ™‚̈ê—á. ‘æ52‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2016 July 16-18; •xŽR.
    45. “c‘ºŒ«‘¾˜Y, ŽR–{’¼Š°, ’©“c—T‹M, ›@ÊŽq, ŠâŒ©—TŽq, Œ´“c–¾‰À, ‘å¼@‘, “c’†—TŽq, ŽsꔎK. ƒKƒ“ƒVƒNƒƒrƒ‹‚É‚æ‚鎡—Âð—v‚µ‚½Œã“V«ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠ´õÇ‚Ì’´’áo¶‘ÌdŽ™2Ç—á. ‘æ52‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2016 July 16-18; •xŽR.
    46. ’––”’qŽÀ, “c‘ºŒ«‘¾˜Y, ’‡‰ª²’qŽq, ìè—TŽq, –q–{—D”ü, ‹g“cär. ’è—Ê“I’´‰¹”g–@‚Å‘ª’肵‚½‘ŽYŽ™‚Ìœ—Ê. ‘æ52‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2016 July 16-18; •xŽR.
    47. ’‡‰ª²’qŽq, –ؗ•Žq, ìú±—TŽq, ’––”’qŽÀ, –q–{—D”ü, ‹g“cär. –¢nŽ™–Ô–ŒÇ‚ƶŒã1‚©ŒŽŠÔ‚Ì‘Ìd‘‰Á‚ÌŠÖ˜A. ‘æ52‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2016 July 16-18; •xŽR.
    48. ‘«—§—Yˆê. ƒCƒuƒjƒ“ƒOƒVƒ“ƒ|ƒWƒEƒ€uRIgER‘̗Ö@‚Ì¡Œã‚̃KƒCƒhƒ‰ƒCƒ“‚ł̈ʒu‚¯‚ðl‚¦‚éFRIgER‘̗Ö@‚Ì¡Œã‚̃KƒCƒhƒ‰ƒCƒ“‚ł̈ʒu‚¯v. ‘æ33‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï; 2016 July 16-17; å‘ä.
    49. ‘«—§—zŽq, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—Yˆê. ƒOƒ‹ƒp[ƒ‹19S‚É‚æ‚鬔žƒAƒŒƒ‹ƒM[F“–‰È‚É‚¨‚¯‚é¬l”­Ç—á‚Æ”äŠr‚µ‚½¬Ž™—á‚Ì“Á’¥. ‘æ33‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï; 2016 July 16-17; å‘ä.
    50. ’‡‰ª²’qŽq, –ؗ•Žq, ìú±—TŽq, ’––”’qŽÀ, –q–{—D”ü, ‹g“cär. –¢nŽ™–Ô–ŒÇ‚ƶŒã1‚©ŒŽŠÔ‚Ì‘Ìd‘‰Á‚ÌŠÖ˜A. ‘æ52‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; July 16-18; •xŽR.
    51. ‹v•ÛŸ”VCìú±—TŽqCˆÉ“Œ‰ë”üC’––”’qŽÀC“c‘ºŒ«‘¾˜YC–q–{—D”üC‹g“cär. MRSA‹ÛŒŒÇ‚É•¹”­‚µ‚½èò•”“î•”‘gDŠ´õÇ‚Ì‘ŽYŽ™—á. ‘æ52‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï; 2016 Aug 21; Šò•Œ.
    52. ”ª–ØMˆê, ŒÜ\—’“o, ‘ºãIŒ[, Ë“ckŠî, “ˆ”ö@’q, ŽíŽsq’ˆ, ‘«—§—Yˆê. •xŽRŽsŽžŠÔŠO¬Ž™‹~‹}‘Ήž‚Ö‚Ì20”NŠÔ‚Ì„ˆÚ‚ƬŽ™‰Èˆã‚̬Ž™‰Šú•]‰¿Œ¤CƒR[ƒX‚Ö‚ÌŽæ‚è‘g‚݂ɂ‚¢‚Ä. ‘æ26‰ñ“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ï; Aug 27-28; ì.
    53. ¬‰Y@Ž, ŒÜ\—’“o, ŽíŽsq’ˆ, “¡“cC•½, ‹{@ˆêŽu, –xìT“ñ˜Y, ˆ¢•Û@Ä, ŽR“cŒbŽq, ”óŒû@Žû, ‹à“c@®, ’†—ÑŒºˆê, ’†’Ø‹v”T, ’‡‰ª‰pK, •½Šâ–¾Žq, –x]’åŽu, Ž®¯ÍŽq, ’†“ˆ“ÖŽq. •xŽR¬Ž™‰Šúf—ÃR[ƒX(TOPƒR[ƒX)‚ÌŠJ”­‚ÆŠˆ“®•ñ. ‘æ26‰ñ“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ï; Aug 27-28; ì.
    54. ŽíŽsq’ˆ, ‚‹´Œ¦‘ã. ‚±‚Ç‚à‚Ì”]Ž€‰º‘ŸŠí’ñ‹ŸŒoŒ±3Ž{Ý‚É‚¨‚¯‚é–â‘è“_‚Ì‹¤—L‚Æ¡Œã‚̉ۑè. ‘æ52‰ñ“ú–{ˆÚAŠw‰ï; 2016 Sep 29-Oct 1; “Œ‹ž.
    55. ’‡‰ª‰pK, œA–ìŒbˆê, ‰ª•”^Žq, ‹{”ö¬–¾, ˆÉŒ\“ñû¶, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq. ìè•a‹}«Šú‚É‚¨‚¯‚錌ŠÇ“à”ç×–E—R—ˆ‚ÌŒŒŠÇ”÷¬—±Žq(EMPs)‚Ì–ðŠ„. ‘æ36‰ñ“ú–{ìè•aŠw‰ï; 2016 Sep30-Oct1; ‰¡•l.
    56. ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, •Ä“c“¿Žq, •Ä“c@“N, Ö“¡@Ž , ’†“ˆ—²•F. –UŒŸ‚ÄJ—¼SŽº‚ÉüˆÛ‰»‚ÆΊD‰»‚ð”F‚ß‘ÙŽ™S‹Øãk–§‰»áŠQ‚©J‹^‚í‚ꂽˆê—á. ‘æ25‰ñ“ú–{¬Ž™S‹ØŽ¾Š³Šw‰ï; 2016 Oct 8; “Œ‹ž.
    57. œA–ìŒbˆê, ‰¤@ô, ‰ª•”^Žq, ‹{”ö¬–¾, ’‡‰ª‰pK, ˆÉŒ\“ñû¶, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq. S‹Øãk–§‰»áŠQ‚̬Ž™Š³ŽÒ‚É‚¨‚¯‚é—\Œã - S‘Ÿ’´‰¹”gŒŸ¸‚ÌŠÏ“_‚©‚ç ?.‘æ25‰ñ“ú–{¬Ž™S‹ØŽ¾Š³Šw‰ï; 2016 Oct 8; “Œ‹ž.
    58. ‘«—§—Yˆê. ƒCƒuƒjƒ“ƒOƒVƒ“ƒ|ƒWƒEƒ€ušb‘§ƒGƒ“ƒhƒ^ƒCƒv‚ÆŽ¡—ÃF‘½—l«‚ðl—¶‚µ‚½¬Ž™šb‘§‚Ì’·ŠúŠÇ—v. ‘æ53‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2016 Oct 8-9; ŒQ”n.
    59. ˆÉ“¡–õ“T. ƒVƒ“ƒ|ƒWƒEƒ€uV¶Ž™E“ûŽ™Á‰»ŠÇƒAƒŒƒ‹ƒM[‚Ì•a‘ԉ𖾂ւ̃Aƒvƒ[ƒ`FV¶Ž™E“ûŽ™Á‰»ŠÇƒAƒŒƒ‹ƒM[‚̃tƒFƒmƒ^ƒCƒvE—Õ°‘œv. ‘æ53‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2016 Oct 8-9; ŒQ”n.
    60. ˆÉ“¡–õ“T, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. H•¨ƒAƒŒƒ‹ƒM[‚Ì‘¦ŽžŒ^—U”­Çó‚É‚¨‚¯‚édÇ“x•]‰¿@ƒAƒiƒtƒBƒ‰ƒLƒV[ƒKƒCƒhƒ‰ƒCƒ“‚ÌdÇ“x•ª—Þ‚ÉŠî‚­ƒAƒhƒŒƒiƒŠƒ“‹Ø“÷’ŽË‚Ì“K³Žg—p‚ɂ‚¢‚Ä. ‘æ53‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2016 Oct 8-9; ŒQ”n.
    61. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê, ŽÄ“c K, ”óŒû Žû, •£àV—³–ç, ŽRŒ³ƒŽq, ‘ºãIŒ[, ”öã —mˆê, ‚”ö@Š², à_“¹”ü‹I. ƒGƒsƒyƒ“Ĉ•ûŽž‚ÌŽè‹Z”\—Í‚¨‚æ‚ÑŽ©ŒÈ’ŽË‚Ì“K؂ȃ^ƒCƒ~ƒ“ƒO‚Ì—‰ð“x‚ð•]‰¿‚·‚邽‚߂̃c[ƒ‹‚Ìì¬. ‘æ53‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2016 Oct 8-9; ŒQ”n.
    62. ‘«—§—Yˆê. ‰ï’·u‰‰uƒAƒŒƒ‹ƒM[‚©‚猩‚½¬Ž™‚̌ċzŠíŽ¾Š³v. ‘æ49‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2016 Oct 28-29; •xŽR.
    63. ‘«—§—zŽq, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—Yˆê, ŽsŠÛ’q_, ¡ˆää‰p, ã“cN‹v, ‰¤@N‰ë, ”óŒû¹F. •xŽRŒ§‚É‚¨‚¯‚é2Ζ¢–žŽ™‚Ì•ÛŒìŽÒ‚Ì‹C“¹ˆÙ•¨‚ÌŽ–ŒÌ—\–h‚ɂ‚¢‚Ä‚Ì’mŽ¯‚ÉŠÖ‚·‚é’²¸?2010”N‚Æ‚Ì”äŠr?. ‘æ49‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2016 Oct 28-29; •xŽR.
    64. ’––”’qŽÀ, ìè—TŽq, “c‘ºŒ«‘¾˜Y, –q–{—D”ü, ‹g“cär, ‘«—§—Yˆê. Ý‘î‰Á‰·‰ÁŽ¼‚—¬—Ê•@ƒJƒjƒ…[ƒŒ‚Å‘Þ‰@‚µ‚¦‚½–«”xŽ¾Š³‚Ì1—á. ‘æ49‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2016 Oct 28-29; •xŽR.
    65. ”ª–ØMˆê, ‘«—§—Yˆê. •xŽRŽs‚Ì’nˆæƒNƒŠƒjƒbƒN‚É‚¨‚¯‚é“û—cŽ™‚̌ċzŠíƒEƒCƒ‹ƒXŠw“I’²¸‚©‚炱‚Ç‚à‚Ì‚©‚ºÇŒóŒQ‚ðl‚¦‚é. ‘æ49‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2016 Oct 28-29; •xŽR.
    66. ¼–ì³’m, ‘«—§—Yˆê, ŒÜ\—’—²•v. ŽvtŠú‚É‚¨‚¯‚é”ì–žó‘Ô‚Ì„ˆÚ‚ƬŽ™šb‘§‚Ì—Õ°Œo‰ßE‹C“¹‰ß•q«‚Æ‚ÌŠÖ˜A‚ɂ‚¢‚Ä. ‘æ49‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2016 Oct 28-29; •xŽR.
    67. ‘ºã«Œ[, ‘ŠJË•½, “c’†•ü”ü, ŽíŽsq’ˆ, ‘«—§—Yˆê. ¬Ž™ƒGƒ`ƒŒƒ“ƒOƒŠƒR[ƒ‹’†“łɑ΂µ‚ÄŒŒ‰t“§Í‚ƃzƒƒsƒ][ƒ‹‚Ì•¹—p‚ª—LŒø‚Å‚ ‚Á‚½ˆê—á. ‘æ44‰ñ“ú–{‹~‹}ˆãŠw‰ï; 2016 Nov 17-19; “Œ‹ž.
    68. –q–{—D”ü, ’––”’qŽÀ, ìú±—TŽq, “c‘ºŒ«‘¾˜Y, ‹g“cär. •ê‘Ì—r…”÷¶•¨”|—{Œ‹‰Ê‚ÆV¶Ž™–«”xŽ¾Š³”­ÇƒŠƒXƒN‚Æ‚ÌŠÖ˜A. ‘æ61‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2016 Dec 1-3; ‘åã.
    69. ìú±—TŽq, –q–{—D”ü, ’––”’qŽÀ, “c‘ºŒ«‘¾˜Y, –q–{—D”ü, ‹g“cär. ‹É’áo¶‘ÌdŽ™‚É‚¨‚¯‚é3DMRI‚ð—p‚¢‚½”]—e—Ê‚Æ“ªˆÍ‚ÌŠÖ˜A«. ‘æ61‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2016 Dec 1-3; ‘åã.
    70. “c‘ºŒ«‘¾˜Y, ’––”’qŽÀ, ìú±—TŽq, –q–{—D”ü, ‹g“cär. ƒ‰ƒ{‚ÌŒ©–{ŽsF’è—Ê“I’´‰¹”g–@‚ð—p‚¢‚½‘ŽYŽ™‚Ìœ—Ê‘ª’è/3ŽŸŒ³MRI‚ð—p‚¢‚½”]’è—Ê•]‰¿‚Æ_ŒoŠw“I”­’B. ‘æ61‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2016 Dec 1-3; ‘åã.
    71. ”ª–ØGŽq, ¬àVˆ»‰À, ’‡‰ª‰pK, ꎓ¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq. ‚΂¿Žw‚ðŒ_‹@‚É”­Œ©‚³‚ꂽ”x“®Ã–¬á‘‚Ì‚P—á. ‘æ318‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2016 Dec 12; ‹à‘ò.
    72. –쑺ŒbŽq, ’Þ@_”V, ¯–쌰G, ‹àŒ“O˜a, •è–M˜a, •l“cG—Y, •“c@•q. “–‰@‚ÅŒoŒ±‚µ‚½’†•_Œo”ñ’èŒ^ŠïŒ`Žî—l/ƒ‰ƒuƒhƒCƒhŽîá‡iAT/RTj‚Ì3—á. ‘æ58‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ïŠwpW‰ï; 2016 Dec 15-17; “Œ‹ž.

    2015”N

  • ’˜‘
    1. ‘«—§—Yˆê. ‚æ‚­‚í‚©‚éŽq‚Ç‚à‚Ìšb–Âf—ÃKƒCƒh. “¿ŽRŒ¤ˆê•Ò. “Œ‹ž: f’f‚ÆŽ¡—ÃŽÐ; 2015. ‹C“¹ˆÙ•¨; p45-9.
    2. ‘«—§—Yˆê. ‚æ‚­‚í‚©‚éŽq‚Ç‚à‚Ìšb–Âf—ÃKƒCƒh. “¿ŽRŒ¤ˆê•Ò. “Œ‹ž: f’f‚ÆŽ¡—ÃŽÐ; 2015. ‹z“ü—Ö@; p111-7.
    3. ‘«—§—Yˆê. ‚æ‚­‚í‚©‚éŽq‚Ç‚à‚Ìšb–Âf—ÃKƒCƒh. “¿ŽRŒ¤ˆê•Ò. “Œ‹ž: f’f‚ÆŽ¡—ÃŽÐ; 2015. ƒGƒLƒXƒp[ƒgƒAƒCƒYF2TŠÔ‘O‚Ƀs[ƒiƒbƒc‚ðH‚ׂĂނ¹‚½Žq‚Ç‚à‚ª”­”M‚Æšb–‚ð”­Ç‚µ‚½ê‡A‚·‚®ê–å•a‰@‚ÉЉ‚ׂ«‚©H; p170.
    4. ‘«—§—Yˆê. ¡“ú‚̬Ž™Ž¡—ÃŽwj‘æ16”Å. ‘åŠÖ••F‘¼•Ò. “Œ‹ž: ˆãŠw‘‰@; 2015. ‹CŠÇŽxšb‘§@”­ì‚ÌŽ¡—Ã. p302-4.
    5. ‘«—§—Yˆê. 34th ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒX@‹CŠÇŽxšb‘§‚Æ‚»‚ÌŽü•Ó ?ŋ߂̘b‘è-.‘«—§@–ž‘¼•Ò.@“Œ‹ž: ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXo”Å; 2015. ¬Ž™ŒyÇšb‘§‚É‚¨‚¯‚éICSŠÔŒ‡“Š—^‚Ì¥”ñFCON‚Ì—§ê‚©‚ç; p7-9.
    6. ‘«—§—Yˆê. uŒÄ‹zvƒGƒbƒZƒ“ƒVƒƒƒ‹ƒYƒGƒbƒZƒ“ƒVƒƒƒ‹ƒY ?ŒÄ‹zŠíŽ¾Š³‚̃sƒbƒgƒtƒH[ƒ‹-.•Ÿ’n‹`”V•, Š€Œ´@‚•Ò. “Œ‹ž: ˆê”ÊŽÐ’c–@l ŒÄ‹zŒ¤‹†; 2015. “û—cŽ™šb‘§. p102-5.
    7. ‘«—§—Yˆê. ¡“ú‚ÌŽ¡—ÃŽwj 2015”N“x”ÅDŽRŒû@“O, –kŒ´Œõ•v•Ò. “Œ‹ž: ˆãŠw‘‰@; 2015. ¬Ž™‚Ì‚©‚ºÇŒóŒQD p1288-9.
    8. Žs“c•™Žq. ¡“ú‚Ìf’fŽwji‘æ7”Åj. ‹ààVˆê˜YE‰iˆä—ÇŽO•Ò. “Œ‹ž: ˆãŠw‘‰@; 2015. ‘¾ŒÛƒoƒ`Žw; p250-1.
    9. Žs“c•™Žq. ¡“ú‚̬Ž™Ž¡—ÃŽwj‘æ16”Å. ‘åŠÖ••F‘¼•Ò. “Œ‹ž: ˆãŠw‘‰@; 2015. S“à–ŒüˆÛ’e«Ç; p525-6.
    10. Žs“c•™Žq. ƒlƒ‹ƒ\ƒ“¬Ž™‰ÈŠw@Œ´’˜‘æ19”Å. ŒÜ\—’—²‘¼•Ò. “Œ‹ž: ƒGƒ‹ƒ[ƒrƒAEƒWƒƒƒpƒ“; 2015. S‹Ø‚ÆS–Œ‚ÌŽ¾Š³; p1890-1900.
    11. Žs“c•™Žq. ¬læ“V«SŽ¾Š³ƒp[ƒtƒFƒNƒgƒKƒCƒh. Ô–Ø’õ“ñAˆÉ“¡@_•Ò. “Œ‹ž: •¶Œõ“°; 2015. ¬læ“V«SŽ¾Š³‚Ì‘SgŠÇ—@3.¸_ES—Šw“IƒAƒvƒ[ƒ`; p252-5.
    12. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj 2015”N“x”ÅDŽRŒû@“O, –kŒ´Œõ•v•Ò. “Œ‹ž: ˆãŠw‘‰@; 2015. SŽ¾Š³‚ðŽ‚ÂŽ™“¶E¶“k‚ÌŠwZŠÇ—‰º‚Å‚ÌŽæ‚舵‚¢•û; p1410-3.
    13. ‹g“cär. ‚æ‚­‚í‚©‚éV¶Ž™‚ÌŒŒ‰tƒKƒX: ŽüŽYŠúƒXƒ^ƒbƒt‚Ì‚½‚ß‚Ì. ×–ì–Ît•Ò. ‘åã: ƒƒfƒBƒJo”Å; 2015.ŒŒ‰tƒKƒX‘ª’è‚ÉŽg—p‚·‚é‹@Ší‚Æ•ªÍŒ‹‰Ê‚ÌŒ©•û‚ð’m‚낤!; p90-6.
    14. ”ÂàVŽõŽq, ‘«—§—Yˆê. ¬Ž™‰È—Õ°ƒsƒNƒVƒX‡D”N‘ã•ÊƒAƒŒƒ‹ƒM[Ž¾Š³‚ւ̑Ήž. ŒÜ\—’—²AŠC˜VàVŒ³G•Ò. “Œ‹ž: ’†ŽR‘“X; 2015. “ûŽ™šb‘§‚Ì’·ŠúŠÇ—; p110-3.
    15. ”ÂàVŽõŽq. ¡“ú‚̬Ž™Ž¡—ÃŽwj‘æ16”Å. ‘åŠÖ••F‘¼•Ò. “Œ‹ž: ˆãŠw‘‰@; 2015. –³‹C”x, ’†—tÇŒóŒQ; p422-4.
    16. ŽíŽsq’ˆ. Žq‚Ç‚à‚ð‚ ‚¸‚©‚él‚Ì‚½‚ß‚Ì‹~–½ƒ}ƒjƒ…ƒAƒ‹. “ú–{¬Ž™‘h¶Œ¤‹†‹@\, ŽíŽsq’ˆŠÄC. “Œ‹ž: ŠwŒ¤ƒƒfƒBƒJƒ‹GŽÐ; 2015.
    17. ˆÉŒ\“ñ˜Y, Žs“c•™Žq. Annual reviewzŠÂŠí2015. ¬Žºˆê¬, ²’n@•×‘¼•Ò. “Œ‹ž: ’†ŠOˆãŠwŽÐ; 2015. æ“V«SŽ¾Š³Ž™‚Ì”]zŠÂ‚Æ‚»‚ÌŒã‚̬Ž™Šú‚Ì‚ŽŸ‹@”\”­’B;p248-57.
    18. ˆÉŒ\“ñ˜Y, Žs“c•™Žq. ƒi[ƒX‚Ì“à‰ÈŠw. ²’n@•×‘¼•Ò. “Œ‹ž: ’†ŠOˆãŠwŽÐ; 2015. æ“V«SŽ¾Š³ ‘å“®–¬•Ù‹·óA‘å“®–¬kóÇAƒAƒCƒ[ƒ“ƒƒ“ƒQƒ‹ÇŒóŒQAƒtƒ@ƒ[Žl’¥ÇA‘匌ŠÇ“]ˆÊÇ; p391-4.
    19. ”óŒû@Žû, ‘«—§—Yˆê. uŒÄ‹zvƒGƒbƒZƒ“ƒVƒƒƒ‹ƒYƒGƒbƒZƒ“ƒVƒƒƒ‹ƒY ?ŒÄ‹zŠíŽ¾Š³‚̃sƒbƒgƒtƒH[ƒ‹-.•Ÿ’n‹`”V•, Š€Œ´@‚•Ò. “Œ‹ž: ˆê”ÊŽÐ’c–@l ŒÄ‹zŒ¤‹†; 2015. ¬Ž™‚É‚¨‚¯‚é‹C“¹ˆÙ•¨Dp150-3.
  • Œ´’˜
    1. Hirono K and Ichida F. Utility of TNF-ƒ¿ as a biomarker and the possibility of anti-TNF-ƒ¿ therapy for Kawasaki Diseases. Pediat Therapeut 2015; 5: 257.
    2. Nishida N, Yang X, Takasaki I, Imai K, Kato K, Inoue Y, Imamura T, Miyashita R, Kato F, Yamaide A, Mori M, Saito S, Hara J, Adachi Y, Miyawaki T, Kanegane H. Dysgammaglobulinemia assciated with a hypomorphic XIAP mutation. J Invest Allerg Clin 2015; 25(3): 205-13.
    3. Tamura K, Ikutani M, Yoshida T, Tanaka-Hayashi A, Yanagibashi T, Inoue R, Nagai Y, Adachi Y, Miyawaki T, Takatsu K, Mori H. Increased production of intestinal immunoglobulins in Syntenin-1-deficient mice. Immunobiology. 2015 May; 220(5):597-604.
    4. Hoshino A, Okuno Y, Migita M, Ban H, Yang X, Kiyokawa N, Adachi Y, Kojima S, Ohara O, Kanegane H. X-Linked Agammaglobulinemia Associated with B-Precursor Acute Lymphoblastic Leukemia. J Clin Immunol. 2015 Feb;35(2):108-11.
    5. Watanabe K, Hashimoto I, Ibuki K, Okabe M, Kaneda H, Ichida F. Evaluation of Right Ventricular Function Using Single-Beat Three-Dimensional Echocardiography in Neonate. Pediatr Cardiol. 2015 Jun;36(5):918-24.
    6. Inomata S, Yoshida T, Koura U, Tamura K, Hatasaki K, Imamura H, Mase D, Kigawa M, Adachi Y, Inadera H. Effect of preterm birth on growth and cardiovascular disease risk at school age. Pediatr Int. 2015 Dec; 57(6): 1126-30.
    7. Yang X, Nishida N, Zhao Z, Kanegane H. Advances inunderstanding the pathogenesis of Epstein-barr virus-assosiated lymphoproliferative disorders. Iran J Allergy Asthma Immunol 2015 Oct 14: 462-471.
    8. Nomura Y, Momoi N, Hirono K, Hata Y, Takasaki A, Nishida N, Ichida F. A novel MYH7 gene mutation in a fetus with left ventricular noncompaction. Can J Cardiol. 2015 Jan;31(1):103.e1-3.
    9. Takahiro R, Nakamura S, Kohno H, Yoshimura N, Nakamura T, Ozawa S, Hirono K, Ichida F, Taguchi M. Contribution of CYP3A Isoforms to Dealkylation of PDE5 Inhibitors: A Comparison between Sildenafil N-Demethylation and Tadalafil Demethylenation. Biol Pharm Bull. 2015;38(1):58-65.
    10. Kato T, Crestani E, Kamae C, Honma K, Yokosuka T, Ikegawa T, Nishida N, Kanegane H, Wada T, Yachie A, Ohara O, Morio T, Notarangelo LD, Imai K, Nonoyama S. RAG1 Deficiency May Present Clinically as Selective IgA Deficiency. J Clin Immunol. 2015 Apr;35(3):280-8.
    11. Heresco-Levy U, Durrant AR, Ermilov M, Javitt DC, Miya K, Mori H. Clinical and electrophysiological effects of D-serine in a schizophrenia patient positive for anti-N-methyl-D-aspartate receptor antibodies. Biol Psychiatry. 2015 Mar 15;77(6):e27-9.
    12. Gaynor JW, Stopp C, Wypij D, Andropoulos DB, Atallah J, Atz AM, Beca J, Donofrio MT, Duncan K, Ghanayem NS, Goldberg CS, Hovels-Gurich H, Ichida F, Jacobs JP, Justo R, Latal B, Li JS, Mahle WT, McQuillen PS, Menon SC, Pemberton VL, Pike NA, Pizarro C, Shekerdemian LS, Synnes A, Williams I, Bellinger DC, Newburger JW; International Cardiac Collaborative on Neurodevelopment (ICCON) Investigators. Neurodevelopmental outcomes after cardiac surgery in infancy. Pediatrics. 2015 May;135(5):816-25.
    13. Kuroda M, Shimizu M, Inoue N, Ikeno I, Nakagawa H, Yokoi A, Niida Y, Konishi M, Kaneda H, Igarashi N, Yamahana J, Taneichi H, Kanegane H, Ito M, Saito S, Furuichi K, Wada T, Nakagawa M, Yokoyama H, Yachie A. Serum tau protein as a marker of disease activity in enterohemorrhagic Escherichia coli O111-induced hemolytic uremic syndrome. Neurochem Int. 2015 Jun-Jul;85-86:24-30.
    14. Iwaki R, Higuma T, Ichida F, Yoshimura N. Follow-Up of Persistent Tracheal Stenosis After Surgery for a Double Aortic Arch. World J Pediatr Congenit Heart Surg. 2015 Jul;6(3):458-61.
    15. Sasaki M, Yoshida K, Adachi Y, Furukawa M, Itazawa T, Odajima H, Saito H, Akasawa A. Factors associated with asthma control in children: findings from a national web-based survey. Pediatr Allergy Immunol. 2014 Dec; 25(8): 804-9.
    16. Kimura M, Meguro T, Ito Y, Tokunaga F, Hashiguchi A, Seto S. Close positive correlation between the lymphocyte response to hen ggg white and house dust mites in Infants with atopic dermatitis. Int Arch Allergy Immunol 2015 166: 161-9.
    17. Uda S, Matsui M, Tanaka C, Uematsu A, Miura K, Kawana I, Noguchi K: Normal development of human brain white matter from infancy to early adulthood: a diffusion tensor imaging study. Dev Neurosci. 2015 37: 182-194.
    18. Tanaka-Arakawa MM, Matsui M, Tanaka C, Uematsu A, Uda S, Miura K, Sakai T, Noguchi K: Developmental changes in the corpus callosum from infancy to early adulthood: A structural magnetic resonance imaging study. PLoS One 2015 10(3): e0118760.
    19. ŽíŽsq’ˆ. Šó­_ŒoŠ´õÇ ’°ŠÇoŒŒ«‘å’°‹ÛŠ´õÇ‚É‚æ‚é‹}«”]Ç‚Ì•a‘Ô‚ÆŽ¡—Ãí—ª. NEUROINFECTION 2015 20: 34-39.
    20. ˆÉ“¡–õ“T, X‰º‰p–¾, ‰º‘º^‹B, “¿‰iˆè, –Ú•ŒhÍ, £ŒËŽk˜Y, –Ø‘ºŒõ–¾DŒ{—‘ƒAƒŒƒ‹ƒM[Š³ŽÒ‚Ì•‰‰×ŽŽŒ±—U”­Çó‚ÉŠî‚­ŠK‘w•ÊƒNƒ‰ƒXƒ^[‰ðÍ. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 2015 29: 270-7.
  • Ç—á•ñ
    1. Hoshino A, Nomura K, Hamashima T, Isobe T, Seki M, Hiwatari M, Yoshida K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Takita J, Kanegane H. Aggressive transformation of anaplastic large cell lymphoma with increased number of ALK-translocated chromosomes. Int J Hematol. 2015 Feb;101(2):198-202.
    2. Yang X, Hoshino A, Taga T, Kunitsu T, Ikeda Y, Yasumi T, Yoshida K, Wada T, Miyake K, Kubota T, Okuno Y, Muramatsu H, Adachi Y, Miyano S, Ogawa S, Kojima S, Kanegane H. A Female Patient with Incomplete Hemophagocytic Lymphohistiocytosis Caused by a Heterozygous XIAP Mutation Associated with Non-Random X-Chromosome Inactivation Skewed Towards the Wild-Type XIAP Allele. J Clin Immunol. 2015 Apr;35(3):244-8.
    3. Kawasaki Y, Makimoto M, Nomura K, Hoshino A, Hamashima T, Hiwatari M, Nakazawa A, Takita J, Yoshida T, Kanegane H. Neonatal acute megakaryoblastic leukemia mimicking congenital neuroblastoma. Clin Case Rep. 2015 Mar;3(3):145-9.
    4. Koura U, Horikawa S, Okabe M, Kawasaki Y, Makimoto M, Mizuta K, Yoshida T. Successful treatment of hemochromatosis with renal tubular dysgenesis in a preterm infant. Clin Case Rep. 2015 Aug;3(8):690-3.
    5. –쑺ŒbŽq, ¯–쌰G, ‰ª“cˆÀO, ŽRè@“O, âV“¡Ÿ•F, ×ì@•à, ‹àŒ“O˜a. • ’ÉE•Ö”é‚ð‰”­Çó‚Æ‚µ‚½¬Ž™‘å’°‚ª‚ñ‚Ì1—á. ¬Ž™‰È 2015 56(6): 863-7.
    6. –xìT“ñ˜Y, ‹{”ö¬–¾, ìè—TŽq, –q–{—D”ü, ‹g“cär, ‘«—§—Yˆê. ˜˜]Ò’ÅÇŒóŒQ‚É”º‚Á‚½˜ƒwƒ‹ƒjƒA. “ú–{¬Ž™‰ÈŠw‰ïŽ@2015 July 119(7): 1118-1123.
  • ‘à
    1. ‘«—§—YˆêDPro/Con Ž†ã“¢˜_@‹z“üƒXƒeƒƒCƒh–ò‚ÌŠÔŒ‡“Š—^‚Ì¥”ñ‚ɂ‚¢‚Ä Con‚Ì—§ê‚©‚çDšb‘§ 2015 28(1): 88-90.
    2. ‘«—§—Yˆê. ¬Ž™‹CŠÇŽxšb‘§‚̃tƒFƒmƒ^ƒCƒv‚ÆŽ¡—Ãí—ª. ƒAƒŒƒ‹ƒM[E–Ɖu 2015 22:1562-7.
    3. ‘«—§—Yˆê. ¬Ž™‹CŠÇŽxšb‘§ƒKƒCƒhƒ‰ƒCƒ“iJPGLj‚ÌÄ•]‰¿‚Æ“W–]FŠCŠO‚̃KƒCƒhƒ‰ƒCƒ“‚©‚ç‚Ý‚½JPGL‚ÌÄ•]‰¿‚Æ“W–]. ƒAƒŒƒ‹ƒM[EŒÄ‹z 2015 22:1088-96.
    4. ‘«—§—Yˆê. ì—p‹@˜‚©‚çl‚¦‚é–ò•¨—Ö@Fšb‘§. ¬Ž™‰È@56(3): 279-84.
    5. ‘«—§—Yˆê. ¬Ž™ŒÄ‹zŠíŽ¾Š³‚ð‚ ‚È‚Ç‚é‚ÈIFŒ©’¼‚·‚ׂ«–òÜiƒeƒIƒtƒBƒŠƒ“»ÜARƒqƒXƒ^ƒ~ƒ“–òj ¬Ž™‰Èf—à 2015 July 78(7): 953-8.
    6. ‘«—§—Yˆê. ƒtƒFƒmƒ^ƒCƒv•ª—Þ‚Æ‘Šú‰î“ü. “ú–{¬Ž™ŒÄ‹zŠíŠw‰ïŽ 2015 26(1): 116-9.
    7. ‘«—§—Yˆê. ŋ߂̬Ž™‹CŠÇŽxšb‘§f—Ã@‚æ‚è‚æ‚¢ƒRƒ“ƒgƒ[ƒ‹ƒŒƒxƒ‹‚ð–ÚŽw‚µ‚ÄD•xŽR‘åŠwˆãŠw‰ïŽ 2015 25: 50-3.
    8. ‘«—§—Yˆê, ”óŒû@Žû. Ž¾Š³‚©‚ç‚Ý‚é‰æ‘œf’f‚Ìi‚ß•ûE“Ç‚Ý•ûF‹C“¹ˆÙ•¨D¬Ž™‰Èf—Ã(‘) 2015 78:s111-5.
    9. ‘«—§—Yˆê, ‹à’J‹v”üŽq. ‰©»‚ƃAƒŒƒ‹ƒM[DƒAƒŒƒ‹ƒM[‚Ì—Õ°. 2015 35: 1043-6.
    10. Žs“c•™Žq. Žá”NŽÒ‚Ì”ì‘åŒ^S‹ØÇ‚Æ‚»‚ÌŠÓ•ÊŽ¾Š³. ŒÄ‹z‚ÆzŠÂ 2015 63:173-8.
    11. Žs“c•™Žq. S‹Øãk–§‰»áŠQ‚Ìf’f–@w¬Ž™zŠÂŠíf—Â̂¢‚Üx ¬Ž™“à‰È 2015 2: 220-4.
    12. Žs“c•™Žq. S‹Ø‰ŠES–Œ‰ŠwŽ„‚̈•û2015x ¬Ž™‰È—Õ° 2015 68: 637-43.
    13. Žs“c•™Žq. S‹Øãk–§‰»áŠQ@S‘Ÿ 2015 47: 637-44.
    14. ‹g“cär. V¶Ž™•Ò@³ŠúŽYŽ™‚Ì”ñ‹Ù’£«‹C‹¹‚ÌŽ¡—Â͂ǂ¤‚·‚é‚©? ŽüŽYŠúˆãŠw 2015 45(3): 337-9.
    15. ‹g“cär, –q–{—D”ü. ƒsƒ“ƒ|ƒCƒ“ƒg¬Ž™ˆã—Ã@V‚µ‚¢Ž¾Š³ŠT”O‚ÆŠÇ—‚ÌŒ©’¼‚µ@Late pretermŽ™‚Ì–â‘è“_. ¬Ž™“à‰È 2015 47(3): 371-4.
    16. –q–{—D”ü. NICU‘Þ‰@Œã‚̃tƒHƒ[ƒAƒbƒvƒVƒXƒeƒ€. ¬Ž™‰È 56(10): 1617-24.
    17. ”ÂàVŽõŽq. šb‘§Š³Ž™‚Ö‚Ì‹z“üŽw“±‚̃|ƒCƒ“ƒg. ¬Ž™‰È 2015 July 56(7)1001-7.
    18. œA–ìŒbˆê, Žs“c•™Žq. ”ì‘åŒ^S‹ØÇ—Þ‰Ž¾Š³i“Á’èS‹ØÇjŒÄ‹z‚ÆzŠÂ 2015 63: 631-6.
    19. ‰ª“c–ƒ‘ã, –Ζì—R‹M, ‹g“cär. šM“ûó‘Ô. ƒyƒŠƒlƒCƒ^ƒ‹ƒPƒA 34(7): 690-3.

  • 2015”NŠw‰ï•ñ
    1. Hirono K, Nakaoka H, Ibuki K, Ozawa S, Ichida F. The role of BMP10 during differentiating cardiomyocyte derived from iPSCs. ;2015 Jan 13-
    2. Nakaoka H, Hirono K, Ibuki K, Ozawa S, Ichida F. Increased circulating endothelial microparticles in the acute phase of Kawasaki Disease. 11th International Kawasaki Disease Symposium; 2015 Feb 3-6; Hawaii.
    3. Itazawa T, Hamamichi M, Higuchi O, Nakabayashi M, Okabe Y, Adachi SA, Adachi Y. Clinical usefulness of visual analogue scale to monitor symptoms of allergic rhinitis in children. 71th Annual Meeting of American Academy of Allergy, Asthma & Immunology; 2015 Feb 20-24; Houston, USA.
    4. Kusabiraki S., Watanabe Y., Taneichi H., Tanaka T., Tanaka C., Miya K., Mori H., Adachi Y. A case of boy with anti-NMDAR encephalitis treated with additional high-dose corticosteroid therapy.
    5. Ichida F. Insights into etiology and pathogenesis of childhood cardiomyopathy. The 5th Congress of the Asia Pacific Pediatric Cardiology Society; 2014 Mar. 7-9; New Delhi. (invited Lecture)
    6. Higuchi O, Itazawa T, Adachi YS, Hamamichi M, Nakabayashi M, Ito Y, Wada T, Yamamoto J, Murakami G, Adachi Y. Component-specific IgE and IgG4 levels in milk allergy children tolerated baked milk products. XXIV World Allergy Congress; 2015 Oct 14-17; Seoul, Korea.
    7. Nakaoka H, Hirono K, Takasaki I, Yamamoto S, Kinoshita K, Takasaki A, Miyao N, Saito K, Ibuki K, Ozawa S, Ichida F. Increased circulating endothelial microparticles in the acute phase of Kawasaki Disease. The 88th Scientific sessions of AHA 2015; 2015 Nov 7-11; Orlando, Florida, U.S.A.
    8. Takasaki A, Ozawa S, Miyao N, Nakaoka H, Ibuki K, Hirono K, Yoshimura N, Ichida F. Clinical Features and Prognosis of Patients with Left Ventricular Noncompaction Cardiomyopathy: A Comparison between Infantile and Juvenile Types. The 88th Scientific sessions of AHA 2015; 2015 Nov 7-11; Orlando, Florida, U.S.A.
    9. •½Šâ–¾Žq, 쇔ü•ä, ’·‰ªvG, ‘q–{@’, “c’†•ü”ü, ‹{@ˆêŽu, ŽíŽsq’ˆ, ‘«—§—Yˆê, ’‡‰ª²’qŽq, ”óŒû@Žû. BickerstaffŒ^”]Š²”]‰Š‚Æl‚¦‚ç‚ꂽ‚PΗŽ™—á. ‘æ67‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï; 2015 Feb 1; ‹à‘ò.
    10. ŽíŽsq’ˆ. ’°ŠÇoŒŒ«‘å’°‹Û”]Ç‚É‚¨‚¯‚éƒoƒCƒ^ƒ‹ƒTƒCƒ“‚̕ω». ‘æ42‰ñ“ú–{W’†Ž¡—ÈãŠw‰ï; Feb 9-11; “Œ‹ž.
    11. ¬àVˆ»‰À, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, œA–ìŒbˆê, Žs“c•™Žq, –q–{—D”ü, ‹g“cär, •Ä“c@“N, ꎓ¡@Ž . ‘ÙŽ™Šú‚ɉES•s‘S‚É‚Ä‹C•t‚©‚ꂽ¶ŽºS‹Øãk–§‰»áŠQ‚Ì3—á. ‘æ21‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŠw‰ïŠwpW‰ï; Feb 13; “Œ‹ž.
    12. ‘q–{@’, •½Šâ–¾Žq, ‘ŠJË•½, “n•Ó—S‹I, “c’†•ü”ü, “c’‡çH, ‹{@ˆêŽu, ‘«—§—Yˆê. ‰ß‹Ž5”NŠÔi2009`2014”Nj‚É“–‰È‚ÅŽ¡—Âðs‚Á‚½ÛHáŠQŠ³ŽÒ‚ɂ‚¢‚Ä. ‘æ313‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2015 March 8; ‹à‘ò.
    13. ŽíŽsq’ˆ, ŒÜ\—’“o, “¡“cC•½, ‹{@ˆêŽu, –xìT“ñ˜Y, ˆ¢•Û@Ä, ŽR“cŒbŽq, ”óŒû@Žû, ‹à“c@®, ’†—ÑŒºˆê, ’†’Ø‹v”T, ¬‰Y@Ž, ’‡‰ª‰pK, •½Šâ–¾Žq, Ž®¯ÍŽq. •xŽR¬Ž™‰Šúf—ÃiTOPjƒR[ƒX‚ÌŠJ”­. ‘æ118‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2015 Apr 17-19; ‘åã.
    14. •l“¹”ü‹I, ”ÂàVŽõŽq, ‰ª•””üŒb, ”óŒû@Žû, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. ŒoŒûH•¨•‰‰×ŽŽŒ±‚É‚æ‚é—U”­Çó‚ÌdÇ“x‚Æ“ÁˆÙ“IIgER‘̉¿‚¨‚æ‚Ñ‘•‰‰×—Ê‚Æ‚ÌŠÖŒW. ‘æ118‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2015 Apr 17-19; ‘åã.
    15. ‘ŠJË•½, ¶…ŠÑl, –x]’åŽu, ’†’Ø‹v”T, ŽÂ茒‘¾˜Y, ¯Ži‘×O. ƒrƒj[ƒ‹Žè‘܂̈ÙH‚É‚æ‚é’°•ÂÇ‚ð”­Ç‚µ‚½Ž©•ÂÇ‚Ì‚P—á. ‘æ118‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2015 Apr 17-19; ‘åã.
    16. Hirono K, Takasaki A, Hata Y, Nakaoka H, Ibuki K, Ozawa S, Sekine M, Yoshimura N, Nishida N, Ichida F. Sarcomere gene mutations in the patients with left ventricular noncompaction. ‘æ79‰ñ“ú–{zŠÂŠíŠw‰ï; 2015 Apr 24-26; ‘åã.
    17. ˜a“c‘ñ–ç, ”ÂàVŽõŽq, •l“¹”ü‹I, ”óŒû@Žû, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê. ¬Ž™ƒAƒŒƒ‹ƒM[«•@‰Š‚ÌÇ󃂃jƒ^ƒŠƒ“ƒO‚É‚¨‚¯‚éVAS(visual analog scale)‚Ì—L—p«. ‘æ64‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2015 May 26-28; “Œ‹ž.
    18. ˆÉ“¡–õ“TAX‰º‰p–¾A‰º‘º^‹BA“¿‰iˆèA–Ú•ŒhÍA£ŒËŽk˜YA–Ø‘ºŒõ–¾DŒ{—‘ƒAƒŒƒ‹ƒM[Š³ŽÒ‚É‚¨‚¯‚éŠK‘w“IƒNƒ‰ƒXƒ^[‰ðÍ‚É‚æ‚éÁ‰»ŠÇƒAƒŒƒ‹ƒM[—lƒtƒFƒmƒ^ƒCƒv‚Ì“¯’è. ‘æ64‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2015 May 26-28; “Œ‹ž.
    19. ˆÉ“¡–õ“TAX‰º‰p–¾A“¿‰iˆèA–Ú•ŒhÍA£ŒËŽk˜YA–Ø‘ºŒõ–¾D5΂ŎÀŽ{‚µ‚½‹“û•‰‰×ŽŽŒ±‚Å”sŒŒÇ—lÇó‚ð’悵‚½Á‰»ŠÇƒAƒŒƒ‹ƒM[.. ‘æ64‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2015 May 26-28; “Œ‹ž.
    20. •½Šâ–¾Žq, “c’†•ü”ü, ‘q–{@’, ‹{@ˆêŽu, ŽíŽsq’ˆ, ‘«—§—Yˆê. Žá”N«“Á”­«ŠÖ߉Š‚̉Á—Ã’†‚ɬ”]•a•Ï‚𔺂¤‰Â‹t«”]—À–c‘å•”•a•Ï‚ð—L‚·‚éŒyÇ”]‰ŠE”]ÇiM‚dRSj‚ð”­Ç‚µ‚½ˆê—á. ‘æ57‰ñ“ú–{¬Ž™_ŒoŠw‰ï; 2015 May 28-30; ‘åã.
    21. “c’†•ü”ü, ‹{@ˆêŽu, ‘ŠJË•½, •½Šâ–¾Žq, “n•Ó—S‹I, ‘q–{@’, “¡–Ø–õŽq, “c’‡çH, ‘«—§—Yˆê, Vˆä“c—v. PNKPˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚½¬“ªÇ‚̈ê’jŽ™—á. ‘æ57‰ñ“ú–{¬Ž™_ŒoŠw‰ï; 2015 May 28-30; ‘åã.
    22. ŽíŽsq’ˆ. ƒ[ƒNƒVƒ‡ƒbƒvu¬Ž™‹~–½‹~‹}‚ÌŒ»ó‚Æ“W–]v’n•û‚É‚¨‚¯‚éd“ĬŽ™f—Ņ̃?Šë‹@“IW’cŠ´õ‚©‚ç‚ÌlŽ@. ‘æ18‰ñ“ú–{—Õ°‹~‹}ˆãŠw‰ï; June 4-6; •xŽR.
    23. ŽíŽsq’ˆ, âV“¡@—I, ûüú±–ƒ”ü, “c’†•ü”ü, ‘«—§—Yˆê. ¬Ž™I––Šúˆã—Âɂ¨‚¢‚Ä•K—v‚È‚±‚Æ`”]Ž€‰º’·‹——£”À‘—‚ÌŒoŒ±‚ð’Ê‚µ‚Ä` ‘æ29‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï; 2015 June 12-13; ‘å‹{.
    24. âV“¡@—I, ûüú±–ƒ”ü, “c’†•ü”ü, ŽíŽsq’ˆ, ‘«—§—Yˆê. “ûŽ™dǃ~ƒIƒNƒƒj[‚Ä‚ñ‚©‚ñ‚É‚¨‚¯‚éR‚¯‚¢‚ê‚ñ–ò‚Ì‘I‘ð. ‘æ29‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï; 2015 June 12-13; ‘å‹{.
    25. Ž›‰ºV‘¾˜Y, ¼ˆä@—I, ‘ŠJË•½, ’‡‰ª²’qŽq, “c’†•ü”ü, ŽíŽsq’ˆ, ‘«—§—Yˆê, ²‹vŠÔ—FŽq, H‰ª’¼Ž÷, ŒKŽR’¼–ç. L”͂ɂ킽‚é”]Ö¬“´ŒŒð‚ð”F‚ß‚½ƒx[ƒ`ƒFƒbƒg•a‚̈ê—á. ‘æ314‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2015 June 14; ‹à‘ò.
    26. ‘«—§—zŽq, ˜a“c‘ñ–ç, •l“¹”ü‹I, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ”ÂàVŽõŽq, ‘«—§—Yˆê. ƒs[ƒiƒbƒcƒAƒŒƒ‹ƒM[‚É‚¨‚¯‚éŠeŽíƒRƒ“ƒ|[ƒlƒ“ƒg‚ɑ΂·‚é“ÁˆÙ“IIgER‘Ì‚ÌŒŸ“¢. ‘æ32‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï; 2015 June 20-21; ‰¡•l.
    27. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uŠÂ‹«‰˜õ‚ÌŒ»ó‚Æ‘ÎôF‰©»‚ɂ‚¢‚Äv ‘æ46‰ñ“ú–{E‹ÆEŠÂ‹«ƒAƒŒƒ‹ƒM[Šw‰ï; 2015 July 3-4; “Œ‹ž.
    28. ‹g“cär, “c‘ºŒ«‘¾˜Y, â“c“Þ, ìè—TŽq, –q–{—D”ü. NICU“à‚É‚¨‚¯‚éƒJƒ“ƒKƒ‹[ƒPƒA‚̕ꎙ‚ւ̉e‹¿. -‘Á‰tƒAƒ~ƒ‰[ƒ[‚É‚æ‚é•]‰¿- ‘æ51‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2015 July 10-12; •Ÿ‰ª.
    29. â“c“Þ, “c‘ºŒ«‘¾˜Y, ìè—TŽq, –q–{—D”ü, ‹g“cär, “ñ’J@•, ”¨èŠì–F. 18ƒgƒŠƒ\ƒ~[Ž™‚ÌÝ‘îˆÚs‚ÉŠÖ‚·‚錟“¢. ‘æ51‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2015 July 10-12; •Ÿ‰ª.
    30. ’·‰ªvG, â“c“Þ, “c‘ºŒ«‘¾˜Y, ìè—TŽq, –q–{—D”ü, ‹g“cär. ‹}«Šú‚ɕꎙŠÔ—AŒŒÇŒóŒQ‚Æ‚ÌŠÓ•Ê‚ª¢“ï‚Å‚ ‚Á‚½Diamond-Blackfan•nŒŒ‚Ì1—á. ‘æ51‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2015 July 10-12; •Ÿ‰ª.
    31. X‚±‚¸‚¦,@’|‘º‹žŽq, ìè—TŽq, –q–{—D”ü, “c‘ºŒ«‘¾˜Y, ‹g“cär, ˆÉ“¡ŽÀ, •Ä“c@“N. ŒŒ¬”’ቺ‚ª‘J‰„‚µ‚½HLAR‘Ì‚É‚æ‚éV¶Ž™“¯Ží–Ɖu«ŒŒ¬”ÂŒ¸­Ç‚̈ê—á. ‘æ51‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2015 July 10-12; •Ÿ‰ª.
    32. ‘ŠJË•½, “c’†•ü”ü, “c’‡çH, ‹{@ˆêŽu, ‘«—§—Yˆê. DownÇŒóŒQ‚É”º‚¤ÇŒó«WestÇŒóŒQ‚Ì6—á‚É‚¨‚¯‚é‰uŠw“IŒŸ“¢. ‘æ8‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï“ŒŠCE–k—¤’n•û‰ï; 2015 July 11; •xŽR.
    33. ˆÉ“¡–õ“T, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, à_“¹”ü‹I, ”‘òŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê. •xŽR‘åŠw‚É‚¨‚¯‚éŒoŒû–Ɖu—Ö@‚ðŽ{s‚µ‚Ä‚¢‚鎙‚ÌŒo‰ß‚ɂ‚¢‚Ä. ‘æ34‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2015 July 12; ‚‰ª.
    34. œA–ìŒbˆê, ”¨—R‹IŽq, ‹{”ö¬–¾, ’‡‰ª‰pK, ‚è–ƒ”ü, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, ¼“c®Ž÷, Žs“c•™Žq. ‘ÙŽ™ŠúEV¶Ž™Šú”­Ç‚̶ŽºS‹Øãk–§‰»áŠQ‚É‚¨‚¯‚é—Õ°ˆâ“`Šw“IŒŸ“¢. ‘æ51‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï 2015 July 16-18; “Œ‹ž.
    35. ’‡‰ª‰pK, œA–ìŒbˆê, ‚è–ƒ”ü, ‹{”ö¬–¾, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, Žs“c•™Žq. ìè•a‹}«Šú‚É‚¨‚¯‚錌ŠÇ“à”ç×–E—R—ˆ‚ÌŒŒŠÇ”÷¬—±Žq(EMPs)‚Ì–ðŠ„. ‘æ51‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2015 July 16-18; “Œ‹ž.
    36. ˆÉŒ\“ñ˜Y, ’‡‰ª‰pK, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. Ž©Œ±—á3Ç—á‚©‚猩‚½V¶Ž™S‹Øãk–§‰»áŠQ‚Ì—Õ°“I“Á’¥. ‘æ51‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï 2015 July 16-18; “Œ‹ž.
    37. ‰ª•”^Žq, ‹´–{ˆè•v, “n•Óˆê—m, 㨌hˆê˜Y, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. ìè•a‹}«Šú‚É‚¨‚¯‚éIVIGŽ{s‘OŒã‚ÌIgG’l‚ÆŽ¡—ÃŒø‰Ê‚ÌŒŸ“¢. ‘æ51‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï 2015 July 16-18; “Œ‹ž.
    38. ‘«—§—Yˆê. ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u¬Ž™šb‘§‚É‚¨‚¯‚é‹z“üƒXƒeƒƒCƒh–ò‚̈ʒu‚¯v. ‘æ25‰ñ“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ï 2015 Aug 22-23; å‘ä.
    39. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uƒƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚Æšb‘§“‰»F¬Ž™”ì–ž‚Æšb‘§“‰»v. ‘æ25‰ñ‘Ûšb‘§“ú–{E–kƒAƒWƒA•”‰ï 2015 Sep 3-4; ‰¡•l.
    40. Žs“c•™Žq. ƒVƒ“ƒ|ƒWƒEƒ€ ’j—‹¤“¯ŽQ‰æ„iƒ_ƒCƒoƒVƒeƒC\‚ÌŽæ‚è‘g‚Ý. •xŽR‘åŠw‚É‚¨‚¯‚é—«Œ¤‹†ŽÒŽx‰‡‚Æ’j—‹¤“¯ŽQ‰æ‚ÌŽæ‚è‘g‚Ý. “ú–{ƒZƒ‰ƒ~ƒbƒN‹¦‰ï‘æ28‰ñH‹GƒVƒ“ƒ|ƒWƒEƒ€ 2015 Sep 17; •xŽR.
    41. Žs“c•™Žq. ƒVƒ“ƒ|ƒWƒEƒ€@zŠÂŠíˆã—ÃŒ»ê‚Å‚Ì’j—‹¤“¯ŽQ‰æ‚ð‚ǂ̂悤‚Éi‚ß‚é‚©H ƒ[ƒNƒ‰ƒCƒtƒoƒ‰ƒ“ƒX‚ðŽx‚¦‚é`•xŽR‘åŠw‚Å‚ÌŽæ‚è‘g‚Ý`. ‘æ63‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï 2015 Sep 18-20; ‰¡•l.
    42. ŽíŽsq’ˆ. 6Ζ¢–ž”]Ž€‰º‘ŸŠí’ñ‹Ÿ‚ÌŒoŒ±‚©‚çl‚¦‚éŽq‚Ç‚à‚ÌI––Šúˆã—Ã. ‘æ51‰ñ“ú–{ˆÚAŠw‰ï 2015 Oct 1-3; ŒF–{.
    43. –q–{—D”ü. ƒVƒ“ƒ|ƒWƒEƒ€ •xŽRŒ§‚É‚¨‚¯‚鬎™Ý‘îˆã—Â̌»ó‚ƉۑèF¬Ž™Ý‘îˆã—ÃG‘—‚èo‚·‘¤‚ÌŒ»ó‚Æ–â‘è“_. ‘æ54‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï. 2015 Oct 4; •xŽR.
    44. Ž›‰ºV‘¾˜Y, ¼ˆä@—I, ‘ŠJË•½, ’‡‰ª²’qŽq, “c’†•ü”ü, ŽíŽsq’ˆ, ‘«—§—Yˆê, ²‹vŠÔ—FŽq, H‰ª’¼Ž÷, ŒKŽR’¼–ç. L”Í‚È”]Ö¬“´ŒŒð‚ð’悵‚½ŒŒŠÇŒ^ƒx[ƒ`ƒFƒbƒg•a‚̈ê—á. ‘æ25‰ñ“ú–{¬Ž™ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï; 2015 Oct 9-11; ‹à‘ò.
    45. ’‡‰ª‰pK, œA–ìŒbˆê, ‚èˆê˜N, ŽR–{½Žm, ‚è–ƒ”ü, ‹{”ö¬–¾, ˆÉŒ\“ñ˜Y, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq. ìè•a‹}«Šú‚É‚¨‚¯‚錌ŠÇ“à”ç×–E—R—ˆ‚ÌŒŒŠÇ”÷¬—±Žq (EMPs) ‚Ì–ðŠ„. ‘æ35‰ñ“ú–{ìè•aŠw‰ï 2015 Oct 9-10; Ž­Ž™“‡.
    46. ‹{”ö¬–¾, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. ‰“ŠuŠú‚É‘½”­«‚Ì‹‘å––½“®–¬áŽ‚¨‚æ‚Ñ‹‘劥“®–¬áŽ‚ª”F‚ß‚ç‚ꂽ•s‘SŒ^ìè•a‚̈ê—á. ‘æ35‰ñ“ú–{ìè•aŠw‰ï 2015 Oct 9-10; Ž­Ž™“‡.
    47. ‰ª•”^Žq, ‹´–{ˆè•v, ²‹vŠÔ—FŽq, “n•Óˆê—m, 㨌hˆê˜Y, ’‡‰ª‰pK, œA–ìŒbˆê, Žs“c•™Žq. ìè•a‹}«Šú‚É‚¨‚¯‚é IVIG ‘OŒã‚ÌŒŒ´ IgG ‚̕ω»‚ÆŽ¡—Ô½‰ž«‚ÌŒŸ“¢. ‘æ35‰ñ“ú–{ìè•aŠw‰ï 2015 Oct 9-10; Ž­Ž™“‡.
    48. ‹g“cär, â“c“Þ, “c‘ºŒ«‘¾˜Y, ìè—TŽq, –q–{—D”ü, “ñ’J•, ”¨èŠì–F. Ý‘îˆã—ÂֈÚs‚Å‚«‚½18ƒgƒŠƒ\ƒ~[Ž™‚ɂ‚¢‚Ä‚ÌŒŸ“¢. “ú–{l—Þˆâ“`Šw‰ï‘æ60‰ñ‘å‰ï 2015 Oct 14-17; “Œ‹ž.
    49. ‘«—§—Yˆê. ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u“û—cŽ™šb–‚ɂ¨‚¯‚郃CƒRƒgƒŠƒGƒ“Žó—e‘ÌhR–ò‚Ì–ðŠ„v. ‘æ48‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï 2015 Oct 23-24; ‘q•~.
    50. ’†—ÑŒºˆê.@ƒVƒ“ƒ|ƒWƒEƒ€u”x‹@”\ŒŸ¸ —‰ð‚ð[‚ß‚ÄŠˆ—p‚·‚邽‚ß‚ÉFƒCƒ“ƒpƒ‹ƒXƒIƒVƒƒƒgƒŠ[iIOSj‚Ì“Á’¥‚Æ—Õ°‰ž—pv. ‘æ48‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï 2015 Oct 23-24; ‘q•~.
    51. ”óŒû@Žû, ’‡‰ª²’qŽq, ‰ª•”^Žq, ²‹vŠÔ—FŽq, ¬ìŽŸ˜Y, 㨌hˆê˜Y, ¡‘º”Ž–¾, ŒE“c”Ž“¹, ’†—ÑŒºˆê, ‘«—§—Yˆê.@–³ä°–ŒŒ^ƒCƒ“ƒtƒ‹ƒGƒ“ƒU‹Û‚É‚æ‚èdÇ”x‰Š‚ð‹N‚±‚µ‚½‚Pƒ–ŒŽŽ™‚Ì2Ç—á.@‘æ48‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï 2015 Oct 23-24; ‘q•~.
    52. –q–{—D”ü, ’|‘º‹žŽq, ¬‰Y@Ž, â“c“Þ, ìè—TŽq, “c‘ºŒ«‘¾˜Y, ‹g“cär. ‹U«’°•ÂÇ‚ð’悵‚½æ“VŒ^‹Ø‹­’¼«ƒWƒXƒgƒƒtƒB[‚Ì’´’áo¶‘ÌdŽ™—á. ‘æ60‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ïŠwpW‰ï 2015 Oct 23-25; ·‰ª.
    53. œA–ìŒbˆê, ”¨—R‹IŽq, “ˆäL, ˆ¼‘ò@‰q, ˆ¢•”•S‡Žq, ’ÒˆäM”V, —Ñ@ŠÂ, âŒû•½”n, ˆ¢•”’‰˜N, ‹{”ö¬–¾, ‚è–ƒ”ü, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, ¼“c®Ž÷, Žs“c•™Žq. TAZˆâ“`Žq•ÏˆÙ‚𔺂¤¶ŽºS‹Øãk–§‰»áŠQ‚Ì—Õ°ˆâ“`Šw“IŒŸ“¢. ‘æ24‰ñ¬Ž™S‹ØŽ¾Š³Šw‰ïŠwpW‰ï 2015 Oct 24; ‘åã.
    54. ûüú±–ƒ”ü, ¬àVˆ»‰À, ‹{”ö¬–¾, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, œA–ìŒbˆê, Žs“c•™Žq. ¶ŽºS‹Øãk–§‰»áŠQ‚Ì“ûŽ™”­Ç—á‚ÆŽá”N”­Ç—á‚Ì—Õ°‘œ‚ÌŒŸ“¢. ‘æ24‰ñ¬Ž™S‹ØŽ¾Š³Šw‰ïŠwpW‰ï 2015 Oct 24; ‘åã.
    55. ‘«—§—Yˆê. ‹³ˆçƒZƒ~ƒi[u¬Ž™šb‘§@?‘ŠúŽ¡—Éî“ü‚ª‚à‚½‚ç‚·‚à‚Ì‚Æ‚ÍH-v ‘æ52‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï 2015 Nov 21-22; “Þ—Ç.
    56. Higuchi O, Itazawa T, Adachi YS, Hamamichi M, Nakabayashi M, Ito Y, Wada T, Yamamoto J, Murakami G, Adachi Y. Component-specific IgE and IgG4 in milk allergy children performed oral baked milk-containing food challenge. ‘æ52‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï 2015 Nov 21-22; “Þ—Ç.
    57. Ž›‰ºV‘¾˜Y, ”ÂàVŽõŽq, ’†—ÑŒºˆê, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, à_“¹”ü‹I, ‘«—§—zŽq, “c“ˆ’¼Æ, ‘«—§—Yˆê. ¬”ž‚¨‚æ‚уÖ-5ƒOƒŠƒAƒWƒ““ÁˆÙ“IIgER‘̉A«‚Å‚ ‚Á‚½¬”žˆË‘¶«‰^“®—U”­ƒAƒiƒtƒBƒ‰ƒLƒV[‚Ì1—á. ‘æ52‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï 2015 Nov 21-22; “Þ—Ç.
    58. –쑺ŒbŽq, ¼“c’¼“¿, ‘«—§—Yˆê, ‹àŒ“O˜a, ’Ø“c‰ëm, ‰““¡ˆê•½, ‹gè’qˆê. ‰ºˆô“ªŒ´”­‹Øã”çŠà‚Ì2Î’jŽ™—á. ‘æ57‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ïŠwpW‰ï 2015 Nov 27-29; ŽR—œ.
    59. ´…@”V, “c‘ºŒ«‘¾˜Y, ¬‰Y@Ž, ’––”’qŽÀ, ìè—TŽq, –q–{—D”ü, ‹g“cär, ‘«—§—Yˆê. ‘ÙŽ™f’f‚³‚ꂽæ“V«‰E”xŒ‡‘¹Ç‚Ì1—á. ‘æ315‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï 2015 Dec 13; ‹à‘ò.
    60. ”ª–ØMˆê, Ë“ckŠî, “ˆ”ö@’q, –xìT“ñ˜Y, ŽíŽsq’ˆ. ’nˆæ¬Ž™‰È‚É‚¨‚¯‚鬎™‰Šú‹~‹}Œ¤C‚Ö‚Ì‚Æ‚è‚­‚Ý[¬Ž™‹}•Ï‘Ήž@•]‰¿”FŽ¯ˆÀ’艻ƒvƒƒOƒ‰ƒ€(PEARS)‚Ì‘ÌŒ±‚ð’Ê‚µ‚ÄŠw‚ñ‚¾‚±‚Æ[. ‘æ315‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï 2015 Dec 13; ‹à‘ò.
    61. ¬‰Y@Ž, ŽíŽsq’ˆ, ‹{@ˆêŽu, ’†—ÑŒºˆê, ’†’Ø‹v”T, ’‡‰ª‰pK, •½Šâ–¾Žq, ŒÜ\—’“o, “¡“cC•½, –xìT“ñ˜Y,@ˆ¢•ÛÄ, Ž®¯ÍŽq, ’†“ˆ“ÖŽq, ŽR“cŒbŽq, ”óŒû@Žû, ‹à“c@®, –x]’åŽu. •xŽR¬Ž™‰Šúf—ÃR[ƒX(TOPƒR[ƒX)‚ÌŠJ”­‚ÆŠˆ“®•ñ. ‘æ315‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï 2015 Dec 13; ‹à‘ò.

    2014”N

  • ’˜‘
    1. ‘«—§—YˆêD¬Ž™Ž¾Š³f—Â̂½‚ß‚Ì•a‘Ô¶—1Dw¬Ž™“à‰Èxw¬Ž™ŠO‰Èx•ÒWˆÏˆõ‰ï‹¤•Ò. “Œ‹ž: ˆãŠw‘‰@; 2014D‹¹–Œ‰ŠD81-83.
    2. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj2014”N”Å. •ŸˆäŽŸ–•Ò. “Œ‹ž: ˆãŠw‘‰@; 2014. æ“V«SŽ¾Š³‚Ì’áŽ_‘f”­ì. 1246-7.
    3. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj2014”N”Å. •ŸˆäŽŸ–•Ò. “Œ‹ž: ˆãŠw‘‰@; 2014. æ“V«SŽ¾Š³i“à‰Èj. 411-2.
    4. Žs“c•™Žq. RSƒEƒCƒ‹ƒXŠ´õÇ‚˜ƒpƒŠƒrƒYƒ}ƒuData Book. “í“c@‘•Ò. ‘åã: ƒƒf²ƒJƒ‹ƒrƒ…[ŽÐ; 2014. ƒpƒŠƒrƒYƒ}ƒu“Š—^‚̈Ӌ`@¬Ž™zŠÂŠí‰È‚Ì—§ê‚©‚ç. 50-1.@
    5. Žs“c•™Žq. ¬Ž™‰Èf—Ãu¬Ž™‚ÌŽ¡—ÃŽwjvˆä“c”ŽK•Ò. “Œ‹ž: f’f‚ÆŽ¡—ÃŽÐ; 2014. ”ì‘åŒ^S‹ØÇ. 369-70.
    6. Žs“c•™Žq. ¬Ž™‰Èf—Ãu¬Ž™‚ÌŽ¡—ÃŽwjvˆä“c”ŽK•Ò. “Œ‹ž: f’f‚ÆŽ¡—ÃŽÐ; 2014. Šg’£Œ^S‹ØÇ. 371-2.
    7. Žs“c•™Žq. æ“V«SŽ¾Š³. ’†àV@½•Ò. “Œ‹ž: ƒƒf²ƒJƒ‹ƒrƒ…[ŽÐ; 2014. Šg’£Œ^S‹ØÇ. 378-84.
    8. Žs“c•™Žq. æ“V«SŽ¾Š³. ’†àV@½•Ò. “Œ‹ž: ƒƒf²ƒJƒ‹ƒrƒ…[ŽÐ; 2014. ”ì‘åŒ^S‹ØÇ. 385-96.
    9. Žs“c•™Žq. æ“V«SŽ¾Š³. ’†àV@½•Ò. “Œ‹ž: ƒƒf²ƒJƒ‹ƒrƒ…[ŽÐ; 2014. S‹Øãk–§‰»áŠQ. 397-403.
    10. Žs“c•™Žq. ¬Ž™“à‰È‘Š§†@•a‘Ô¶—‚h. ŒÜ\—’—²‘¼•Ò. “Œ‹ž: “Œ‹žˆãŠwŽÐ; 2014. FS‹Øãk–§‰»áŠQ. 432-7.
    11. Žs“c•™Žq. ¬læ“V«SŽ¾Š³. ’O‰HŒöˆê˜Y•Ò. “Œ‹ž: ƒƒf²ƒJƒ‹ƒrƒ…[ŽÐ; 2014. ˆâ“`ŽqˆÙíAõF‘̈Ùí. 8-12.
    12. œA–ìŒbˆê, Žs“c•™Žq. ìè•a‚Ì‚·‚ׂÄ. Έä³_•Ò, “Œ‹ž: ’†ŽR‘“X; 2014. ƒCƒ“ƒtƒŠƒLƒVƒ}ƒu—Ö@. 112-5.
    13. “n•Óˆê—m, Žs“c•™Žq. ‚í‚©‚è‚â‚·‚¢“à‰ÈŠwi‘æ4”Åj. ˆä‘º—T•v‘¼•Ò. “Œ‹ž: •¶Œõ“°; 2014. æ“V«SŽ¾Š³@zŠÂŠíŽ¾Š³. 118-28.
  • Œ´’˜
    1. Kanegane H, Imai K, Yamada M, Takada H, Ariga T, Bexon M, Rojavin M, Hu W, Kobayashi M, Lawo JP, Nonoyama S, Hara T, Miyawaki T. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases. J Clin Immunol. 2014 Feb; 34(2): 204-11.
    2. Hirono K, Sekine M, Shiba N, Hayashi S, Nakaoka H, Ibuki K, Saito K, Watanabe K, Ozawa S, Higuma T, Yoshimura N, Kitajima I, Ichida F. N-terminal pro-brain natriuretic peptide as a predictor of reoperation in children with surgically corrected tetralogy of Fallot. Circ J 2014 Feb 25; 78(3): 693-700.
    3. Hirono K, Ibuki K, Tomita H. Percutaneous catheter aspiration thrombectomy for the occluded stents of pulmonary artery in children with single ventricle physiology after fontan surgery. Catheter Cardiovasc Interv. 2014 Dec 1;84(7):1153-6.
    4. Miya K, Takahashi Y, Mori H. Anti-NMDAR autoimmune encephalitis. Brain Dev. 2014 Sep; 36(8): 645-52.
    5. Yoshida T, Takasaki I, Kanegane H, Inomata S, Ito Y, Tamura K, Makimoto M, Saito S, Yoshimoto Y, Miyawaki T. Intrauterine growth restriction modifies gene expressionprofiling in cord blood. Pediatr Int. 2014 Aug; 56(4): 559-65.
    6. Hoshino A, Shimizu M, Matsukura H, Sakaki-Nakatsubo H, Nomura K, Miyawaki T, Kanegane H. Allogeneic Bone Marrow transplantation appears to ameliorate IgA nephropathy in a patient with X-linked thrombocytopenia. J Clin Immunol. 2014 Jan; 34(1): 53-7.
    7. Hoshino A, Imai K, Ohshima Y, Yasutomi M, Kasai M, Terai M, Ishigaki K, Morio T, Miyawaki T, Kanegane H. Pneumothorax in patients with severe combined immunodeficiency. Pediatr Int. 2014 Aug; 56(4): 510-4.
    8. Yoshida K, Adachi Y, Sasaki M, Furukawa M, Itazawa T, Hashimoto K, Odajima H, Akasawa A. Test-retest reliability of the International Study of Asthma and Allergies in Childhood questionnaire for a web-based survey. Ann Allergy Asthma Immunol. 2014 Feb; 112(2): 181-2.
    9. Wada T, Kanegane H, Ohta K, Katoh F, Imamura T, Nakazawa Y, Miyashita R, Hara J, Hamamoto K, Yang X, Filipovich AH, Marsh RA, Yachie A. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine. 2014 Jan; 65(1): 74-8.
    10. Hata Y, Mori H, Tanaka A, Fujita Y, Shimomura T, Tabata T, Kinoshita K, Yamaguchi Y, Ichida F, Kominato Y, Ikeda N, Nishida N. Identification and characterization of a novel genetic mutation with prolonged QT syndrome in an unexplained postoperative death. Int J Legal Med. 2014 Jan; 128(1): 105-15.
    11. Horino S, Sasahara Y, Sato M, Niizuma H, Kumaki S, Abukawa D, Sato A, Imaizumi M, Kanegane H, Kamachi Y, Sasaki S, Terui K, Ito E, Kobayashi I, Ariga T, Tsuchiya S, Kure S. Selective expansion of donor-derived regulatory T cells after allogeneic bone marrow transplantation in a patient with IPEX syndrome. Pediatr Transplant. 2014 Feb; 18(1): E25-30.
    12. Kanatani KT, Okumura M, Tohno S, Adachi Y, Sato K, Nakayama T. Indoor particle counts during Asian dust events under everyday conditions at an apartment in Japan. Environ Health Prev Med. 2014 Jan; 19(1): 81-8.
    13. Kanatani KT, Adachi Y, Sugimoto N, Noma H, Onishi K, Hamazaki K, Takahashi Y, Ito I, Egawa M, Sato K, Go T, Kurozawa Y, Inadera H, Konishi I, Nakayama T. Birth cohort study on the effects of desert dust exposure on childrenfs health: protocol of an adjunct study of the Japan Environment & Childrenfs Study. BMJ Open 2014; 4: e004863
    14. Takanashi J, Taneichi H, Misaki T, Yahata Y, Okumura A, Ishida YI, Miyawaki T, Okabe N, Sata T, Mizuguchi M. Clinical and radiologic features of encephalopathy during 2011 E coli O111 outbreak in Japan. Neurology. 2014 Feb 18; 82(7): 564-72.
    15. Kobayashi S, Taki T, Nagoshi H, Chinen Y, Yokokawa Y, Kanegane H, Matsumoto Y, Kuroda J, Horiike S, Nishida K, Taniwaki M. Identification of novel fusion genes with 28S ribosomal DNA in hematologic malignancies. Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: Report of the Japan Histiocytosis Study Group.Int J Oncol. 2014 Apr; 44(4): 1193-8.
    16. Shimizu M, Kuroda M, Inoue N, Konishi M, Igarashi N, Taneichi H, Kanegane H, Ito M, Saito S, Yachie A. Extensive serum biomarker analysis in patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine. 2014 Mar; 66(1): 1-6.
    17. Horie A. Ishida K, Shibata K, Taguchi M, Ozawa A, Hirono K, Ichida F, Hashimoto Y. Pharmacokinetic variability of flecainide in younger Japanese patients and mechanisms for renal excretion and intestinal absorption. Biopharm Drug Dispos. Apr; 35(3): 145-53.
    18. Kinoshita K, Komatsu T, Nishide K, Hata Y, Hisajima N, Takahashi H, Kimoto K, Aonuma K, Tsushima E, Tabata T, Yoshida T, Mori H, Nishida K, Yamaguchi Y, Ichida F, Fukurotani K, Inoue H, Nishida N. A590T mutation in KCNQ1 C-terminal helix D decreases IKs channel trafficking and function but not Yotiao interaction. J Mol Cell Cardiol. 2014 Jul; 72: 273-80.
    19. Yamaguchi Y, Nishide K, Kato M, Hata Y, Mizumaki K, Kinoshita K, Nonobe Y, Tabata T, Sakamoto T, Kataoka N, Nakatani Y, Ichida F, Mori H, Fukurotani K, Inoue H, Nishida N. Glycine/Serine Polymorphism at Position 38 Influences KCNE1 Subunit's Modulatory Actions on Rapid and Slow Delayed Rectifier K+ Currents. Circ J 2014 Feb 25; 78(3): 610-8.
    20. Mitani Y, Ohta K, Ichida F, Nii M, Arakaki Y, Ushinohama H, Takahashi T, Ohashi H, Yodoya N, Fujii E, Ishikura K, Tateno S, Sato S, Suzuki T, Higaki T, Iwamoto M, Yoshinaga M, Nagashima M, Sumitomo N. Circumstances and Outcomes of Out-Of-Hospital Cardiac Arrest in Elementary and Middle School Students in the Era of Public-Access Defibrillation. Circ J 2014 Feb 25; 78(3): 701-7.
    21. Kogawa K, Sato H, Asano T, Ohga S, Kudo K, Morimoto A, Ohta S, Wakiguchi H, Kanegane H, Oda M, Ishii E. Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: Report of the Japan Histiocytosis Study Group. Pediatr Blood Cancer. 2014 Jul; 61(7): 1257-62.
    22. Murakami Y, Honjo S, Odajima H, Adachi Y, Yoshida K, Ohya Y, Akasawa A. Exercise-induced wheezing among Japanese pre-school children and pupils. Allergol Int. 2014 Jun; 63(2): 251-9.
    23. Yabal M, Muller N, Adler H, Knies N, Gros CJ, Damgaard RB, Kanegane H, Ringelhan M, Kaufmann T, Heikenwalder M, Strasser A, Gros O, Ruland J, Peschel C, Gyrd-Hansen M, Jost PJ. XIAP Restricts TNF- and RIP3-Dependent Cell Death and Inflammasome Activation. Cell Rep. 2014 Jun; 7(6): 1796-808.
    24. Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, Jones D, Nishida N, Miyawaki T, Bertoli LF, Sanders SK, Honjo K. The Long Elusive IgM Fc Receptor, FcƒÊR. J Clin Immunol. 2014 Jul; 34 Suppl 1: 35-45.
    25. Bowles NE, Arrington CB, Hirono K, Nakamura T, Ngo L, Wee YS, Ichida F, Weis JH. Kawasaki disease patients homozygous for the rs12252-C variant of interferon-induced transmembrane protein-3 are significantly more likely to develop coronary artery lesions. Mol Genet Genomic Med. 2014 Jul; 2(4): 356-61.
    26. Tabata T, Yamaguchi Y, Hata Y, Ichida F, Mori H. Modification of KCNH2-Encoded cardiac potassium channels by KCNE1 polymorphism. Circ J. 2014 Aug 25; 78(9): 2331.
    27. van Zelm MC, Bartol SJ, Driessen GJ, Mascart F, Reisli I, Franco JL, Wolska-Kusnierz B, Kanegane H, Boon L, van Dongen JJ, van der Burg M. Human CD19 and CD40L deficiencies impair antibody selection and differentially affect somatic hypermutation. J Allergy Clin Immunol. 2014 Jul; 134(1): 135-144.e7
    28. Igarashi T, Ito S, Sako M, Saitoh A, Hataya H, Mizuguchi M, Morishima T, Ohnishi K, Kawamura N, Kitayama H, Ashida A, Kaname S, Taneichi H, Tang J, Ohnishi M; Study group for establishing guidelines for the diagnosis and therapy of hemolytic uremic syndrome. Guidelines for the management and investigation of hemolytic uremic syndrome. Clin Exp Nephrol. 2014 Aug; 18(4): 525-57.
    29. Hamasaki Y, Kohno Y, Ebisawa M, Kondo N, Nishima S, Nishimuta T, Morikawa A, Aihara Y, Akasawa A, Adachi Y, Arakawa H, Ikebe T, Ichikawa K, Inoue T, Iwata T, Urisu A, Ohya Y, Okada K, Odajima H, Katsunuma T, Kameda M, Kurihara K, Sakamoto T, Shimojo N, Suehiro Y, Tokuyama K, Nambu M, Fujisawa T, Matsui T, Matsubara T, Mayumi M, Mochizuki H, Yamaguchi K, Yoshihara S. Japanese pediatric guideline for the treatment and management of bronchial asthma 2012.@Pediatr Int. 2014 Aug; 56(4): 441-50.
    30. Kato M, Saitsu H, Murakami Y, Kikuchi K, Watanabe S, Iai M, Miya K, Matsuura R, Takayama R, Ohba C, Nakashima M, Tsurusaki Y, Miyake N, Hamano S, Osaka H, Hayasaka K, Kinoshita T, Matsumoto N. PIGA mutations cause early-onset epileptic encephalopathies and distinctive features. Neurology. 2014 May 6; 82(18): 1587-96.
    31. Kohno H, Ichida F, Hirono K, Ozawa S, Yoshimura N, Nakamura T, Akita C, Ishida K, Taguchi M. Plasma Concentrations of Tadalafil in Children With Pulmonary Arterial Hypertension. Ther Drug Monit. 2014 Oct; 36(5): 576-83.
    32. Yoshida K, Adachi Y, Sasaki M, Furukawa M, Itazawa T, Hashimoto K, Odajima H, Akasawa A. Time-dependent variation in the responses to the Web-based ISAAC questionnaire. Ann Allergy Asthma Immunol. 2014 Nov; 113(5): 539-43.
    33. Katagiri M, Miya K, Matsui M. Difficulty of crossmodal processing in individuals with autism spectrum disorders: An audio-visual gap/overlap paradigm studyDRes Autism Spectrum Disorders 2014; 8: 424-31.
    34. Aguilar C, Lenoir C, Lambert N, Begue B, Brousse N, Canioni D, Berrebi D, Roy M, Gerart S, Chapel H, Schwerd T, Siproudhis L, Schappi M, Al-Ahmari A, Mori M, Yamaide A, Galicier L, Neven B, Routes J, Uhlig HH, Koletzko S, Patel S, Kanegane H, Picard C, Fischer A, Bensussan NC, Ruemmele F, Hugot JP, Latour S. Characterization of Crohn disease in X-linked inhibitor of apoptosis-deficient male patients and female symptomatic carriers. J Allergy Clin Immunol. 2014 Nov;134(5):1131-41.
    35. Igarashi A, Kanegane H, Kobayashi M, Miyawaki T, Tsutani K. Cost-Minimization Analysis of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients With Primary Immunodeficiency. Clin Ther. 2014 Nov 1;36(11):1616-24.
    36. Sasaki M, Yoshida K, Adachi Y, Furukawa M, Itazawa T, Odajima H, Saito H, Akasawa A. Factors associated with asthma control in children: findings from a national web-based survey. Pediatr Allergy Immunol. 2014 Dec;25(8):804-9.
    37. ‘«—§—zŽq, ‰ª•””üŒb, ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, •£àV—³–ç, ŽRŒ³ƒŽq, ‚”ö@Š², ”öã—mˆê, ‘ºãIŒ[, ‘«—§—Yˆê.@ •ÛˆçŽ{Ý‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨œ‹Ž‘Ήž‚Ì10”NŠÔ‚̕ω»- •xŽRŒ§‚É‚¨‚¯‚镽¬13”N“x‚Æ18”N“x’²¸‚Æ‚Ì”äŠr-@“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@2014 28(5): 806-13.
    38. ŽíŽsq’ˆ, ˜ZŽÔ@’, ‘¾“c–M—Y, ¬¼“¹—Y, ‰œ‘º²‹v, ‚—œˆê, …Œû@‰ë, ‹{˜e—˜’j. ’°ŠÇoŒŒ«‘å’°‹ÛO111W’cŠ´õ‚É‚¨‚¯‚éŠë‹@‘Ήž. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ. 2014;118(7): 1103-1108.
    39. •½Šâ–¾Žq, ˜a“c‘ñ–ç, ’†’Ø‹v”T, ŽÂ茒‘¾˜Y, ‹{˜e—˜’j, ‘«—§—Yˆê. ŠÈˆÕ…“¹‚ð‰î‚µ‚½Yersinia enterocolitica Š´õÇ‚ÌW’c”­¶.“ú–{¬Ž™‰ÈŠw‰ïŽ@2014; 118(12): 1738-1741.
    40. Αº–šŽq, ŽR“c‘½Žq, ŽR“c‚ ‚·‚©, ‹àŒ“O˜a. Žq‹Ÿ‚ƉƑ°‚Ì–Úü‚Ål‚¦‚½ƒvƒŒƒCƒ‹[ƒ€ì¬‚Ì‹L˜^. ¬Ž™‰È. 2014;@55(4): 443-8.
    41. •x“c@‰p, ŽRŠÝ³–¾, Žs“c•™Žq, â–{ŠìŽO˜Y, ò“c’¼ŒÈ, žwŠ_‚Žj, “yˆä¯ŽO˜Y, ˆÀ‰Í“à ãà, Šâ–{^—, ˆ¼àV@‰q. ¬Ž™zŠÂŠíê–åˆã§“x‚É‚¨‚¯‚éC—ûŽ{ÝEŽ{ÝŒQ‚Ì”NŽž•ñ:2011,2012”N•ñ‚Ì‚Ü‚Æ‚ß. ¬Ž™zŠÂŠíŠw‰ïŽGŽ@2014; 30: 431-5.
  • Ç—á•ñ
    1. Kawasaki Y, Makimoto M, Nomura K, Hoshino A, Hamashima T, Hiwatari M, Nakazawa A, Takita J, Yoshida T, Kanegane H. Neonatal acute megakaryoblastic leukemia mimicking congenital neuroblastoma. Clinical Case Reports 2014; DOI: 10.1002/ ccr3.183.
    2. Koura U, Sakaki-Nakatsubo H, Otsubo K, Nomura K, Oshima K, Ohara O, Wada T, Yachie A, Imai K, Morio T, Miyawaki T, Kanegane H. Successful treatment of systemic cytomegalovirus infection in severe combined immunodeficiency using allogeneic bone marrow transplantation followed by adoptive immunotherapy.@ J Investig Allergol Clin Immunol. 2014; 24(3): 200-2.
    3. Hoshino A, Nomura K, Kanegane H. Graft versus tumor effect against neuroblastoma: a case report with long-term survival and a review of the literature. J Hematopoietic cell Transplantation 2014 3(3): 93-96.
    4. Hoshino A, Nomura K, Noguchi K, Kanegane H. Relapsed leukemia without peripheral blood abnormalities and clinical symptoms detected on MRI. Pediatr Int. 2014 Oct; 56(5): 798.
    5. Yamagami K, Miyashita T, Nakamura T, Shirano M, Nakamura T, Kameda K, Nishijima M, Imanishi M, Yang X, Kanegane H. Campylobacter fetus Bacteremia with Purulent Pleurisy in a Young Adult with Primary Hypogammaglobulinemia. Intern Med. 2014; 53(11): 1221-5.
    6. Hata Y, Kinoshita K, Miya K, Hirono K, Ichida F, Yoshida K, Nishida N. An autopsy case of infantile-onset vanishing white matter disease related to an EIF2B2 mutation (V85E) in a hemizygous region. Int J Clin Exp Pathol. 2014 May; 7(6): 3355-62.
    7. Miyatake S, Koshimizu E, Hayashi YK, Miya K, Shiina M, Nakashima M, Tsurusaki Y, Miyake N, Saitsu H, Ogata K, Nishino I, Matsumoto N. Deep sequencing detects very-low-grade somatic mosaicism in the unaffected mother of siblings with nemaline myopathy. Neuromuscul Disord. 2014 Jul; 24(7): 642-7.
    8. Mizawa M, Makino T, Norisugi O, Hara H, Shimizu K, Nomura K, Kanegane H, Nojima T, Shimizu T. Primary cutaneous Ewing sarcoma following metastasis to the bone and lymph nodes. Br J Dermatol. 2014 Sep; 171(3): 660-2.
    9. ¬‰Y@Ž, –xìT“ñ˜Y, ìè—TŽq, –q–{—D”ü, ‘«—§—Yˆê, ‹g“cär. –Ú‚ÅŒ©‚鬎™‰È. Autopsy imaging‚Åf’f‚µ‚½cerebro-costo-mandibular syndrome‚Ì1—á. ¬Ž™‰È 2014 Sep; 55(10): 1365-6.
    10. ”öèO“T, –sŽq, ŽíŽsq’ˆ, “¹‹ïL_, —Ñ@“ÄŽu. —¼Šá‚Ì‹}Œƒ‚ÈŽ‹—͒ቺ‚ð‚«‚½‚µ,ƒXƒeƒƒCƒhŽ¡—Âɂæ‚è‰ü‘P‚ð‚Ý‚½Ž‹Œð³‰Š‚Ì1—á. —Õ°Šá‰È2014; 68: 545-51.
  • ‘à
    1. ‘«—§—YˆêDƒvƒƒRƒ“ƒfƒBƒx[ƒg2@ICSŠÔŒ‡“Š—^‚Ì¥”ñ Con‚Ì—§ê‚©‚çD “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 2014; 28(1): 75-80.
    2. ‘«—§—YˆêD‹C“¹Š´õ‚Æ“û—cŽ™Šú‚Ìšb–ÂDƒ`ƒƒƒCƒ‹ƒhƒwƒ‹ƒX 2014; 17: 244-7.
    3. ‘«—§—YˆêD¬Ž™‚É‚¨‚¯‚é‹z“üƒXƒeƒƒCƒh—Ö@‚ÌV“WŠJ`‹z“üƒXƒeƒƒCƒhŠÔŒ‡‹z“ü‚ÌŒ»ó‚Æ«—ˆ“W–]D‹z“ü—Ö@ 2014; 6: 54-8.
    4. ‘«—§—Yˆê. ƒAƒŒƒ‹ƒM[ƒ}[ƒ`‚©‚ç‚Ý‚½šb‘§‚Ö‚Ì‘Šú‰î“üD¬Ž™‰È 2014; 55: 1463-7.
    5. ‘«—§—YˆêD¬Ž™‹CŠÇŽxšb‘§‚Æ•@‰Š‚ÌŠÖŒWD“ú–{¬Ž™Ž¨•@ˆôA‰ÈŠw‰ï‰ïŽ 2014; 35(3): 222-5.
    6. ‘«—§—Yˆê. ‹CŠÇŽxšb‘§Ž¡—ẪXƒeƒbƒvƒ_ƒEƒ“DAir 2014 13(3): 4-5.
    7. ‘«—§—Yˆê, “¡àV—²•v. ЊQŽž‚Ì‚±‚Ç‚à‚̃AƒŒƒ‹ƒM[Ž¾Š³‘Ήžƒpƒ“ƒŒƒbƒg. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@2014; 27(5): 739-42.
    8. ‘«—§—Yˆê, ‹à’J‹v”üŽq. ¬Ž™šb‘§‚Æ‘å‹C‰˜õDRespiratory Trends@2014; 4:16-7.
    9. ‘«—§—Yˆê, ”óŒû@Žû. One airway, one disease‚Æšb–ÂŽ¾Š³‚ÌV‚µ‚¢•ª—ÞD¬Ž™‰ÈŠwƒŒƒNƒ`ƒƒ[@2014; 4:467-73.
    10. ‘«—§—Yˆê, ”óŒû@Žû, ŽsŠÛ’q_, ¡ˆää‰p, ã“cN‹v, ‰¤@N‰ë, ”óŒû¹F, ìèˆê‹P, ‘¾“c–M—Y, ”ª–ØMˆê. ¬Ž™‚É‚¨‚¯‚é‹C“¹ˆÙ•¨Ž–ŒÌ—\–h‚É‚Þ‚¯‚ÄDŠO—ˆ¬Ž™‰È 2014; 17: 81-5.
    11. ‘«—§—YˆêA‹à’J‹v”üŽqD‹CŠÇŽxšb‘§‚ÌŽ©‘R—ð‚ƃAƒEƒgƒOƒ[F”­ÇE‘ˆ«‚É‚¨‚¯‚é‘å‹C‰˜õE—±Žq󕨎¿‚Ì–ðŠ„Dšb‘§ 2014; 27: 152-6.
    12. Ichida F. Cardiovascular Events in Pregnancy With Hypertrophic Cardiomyopathy. Circ J. 2014 Sep 25; 78(10): 2386-7.
    13. Žs“c•™Žq. Cardiomyopathy: progress in diagnosis and treatments. Topics: II. Secondary cardiomyopathy; 5. Noncompaction of the ventricular myocardium. “ú–{“à‰ÈŠw‰ïŽGŽ. 2014; Feb 10; 103(2): 327-35.
    14. Žs“c•™Žq. æ“V«SŽ¾Š³Ž™‚̸__Œo”­’B. zŠÂŠí“à‰È. 2014; 75: 100-6.
    15. Žs“c•™Žq. æ“V«SŽ¾Š³Ž™‚̸__Œo”­’B.@“ú–{¬Ž™‰ÈŠw‰ïŽ. 2014; 118: 1181-9.
    16. Žs“c•™Žq. æ“V«SŽ¾Š³Ž™‚Ì‚ŽŸ”]‹@”\áŠQ. “ú–{—Õ°–ƒŒŠw‰ïŽGŽ. 2014; 34: 674-83.
    17. Žs“c•™Žq. S‹Øãk–§‰»áŠQ. S‘Ÿà’c‹•ŒŒ«SŽ¾Š³ƒZƒ~ƒi[@S‘Ÿ. 2014; 46: 1177-84.
    18. Žs“c•™Žq. æ“V«SŽ¾Š³Ž™‚̸__Œo”­’B. “ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŽGŽ. 2014; 50: 1174-6.
    19. ‹àŒ“O˜a. dÇŠ´õÇ‚ÉR‹Û–òˆÈŠO‚É‚Ç‚ñ‚ÈŽ¡—Ö@‚ª‚ ‚é‚©H. ¬Ž™Š´õ–Ɖu 2014; 25(4): 456-7.
    20. ‹àŒ“O˜a. –Ɖu•s‘SÇ‚É‚¨‚¯‚銴õÇ‚Ì—\–h. ¬Ž™‰È—Õ° 2014; 67(4): 695-700.
    21. ‹àŒ“O˜a. ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“•â[—Ö@?Ã’»Ü‚Ɣ牺’»Ü. ¬Ž™“à‰È 2014; 45(10): 1504.
    22. ‹àŒ“O˜a. R‘Ì•s‘S‚Æ’†•_ŒoŠ´õÇ. Neuroinfection 2014; 19(1): 103-7.
    23. ‹àŒ“O˜a.@‘¢ŒŒ•s‘S‚ð‡•¹‚·‚錴”­«–Ɖu•s‘SÇ.@“ú–{¬Ž™ŒŒ‰t‚ª‚ñŠw‰ïŽ@2014; 46(10): 1504.
    24. ‹àŒ“O˜a. Œ´”­«–Ɖu•s‘Sǂɇ•¹‚·‚鎩ŒÈ‰ŠÇ«Ž¾Š³@?‰ŠÇ«’°Ž¾Š³ƒ‚ƒfƒ‹‚Æ‚µ‚Ä?@“ú–{¬Ž™‰ÈŠw‰ïŽ@2014;118(11): 1588-94.
    25. ‹àŒ“O˜a. ŒÌ ‹{˜e—˜’j涂ðŽÃ‚ñ‚Å. ¬Ž™Š´õ–Ɖu 2014;26(2):345-6.
    26. ”ÂàVŽõŽq. ¬Ž™‚ÌŽ¡—ÃŽwjuŠPšuEšb–ÂvD¬Ž™‰Èf—à 2014; 77suppl: 10-3.
    27. ”ÂàVŽõŽq. ‹CŠÇŽxšb‘§D‚±‚Ç‚àƒPƒA 2014; 9: 16-20.
    28. ŽíŽsq’ˆ. ’°ŠÇoŒŒ«‘å’°‹ÛO111W’cŠ´õ‚É‚¨‚¯‚鬎™dÇ—á‚Ì“Á’¥‚Æ‚»‚Ì‘Îô. ¬Ž™‰È 2014; 55(7): 1017-25.
    29. ŽíŽsq’ˆ, ‹àŒ“O˜a. ’°ŠÇoŒŒ«‘å’°‹ÛŠ´õÇ‚ÌŽ¡—ÂÆW’cŠ´õ‚©‚çŠw‚Ô‚à‚Ì. Š´õÇ“à‰È 2014; 2(2): 195-202.
    30. ŽíŽsq’ˆ, ‘¾“c–M—Y. ¬Ž™‚ÌŽ¡—ÃŽwj ‹~‹}ê–Ê‚É‚¨‚¯‚鉊ú‘Ήž “M…. ¬Ž™‰Èf—à 2014; 77(‘) 85-7.
    31. ‘«—§—zŽq, ‘«—§—Yˆê. ¬Ž™‚ÌŽ¡—ÃŽwj ‹C“¹ˆÙ•¨D¬Ž™‰Èf—à 2014; 77suppl: 427-9.
    32. ¼“c’¼“¿, ‹àŒ“O˜a. –Ɖu•s‘SÇ‚ð‹^‚¤‚Æ‚«‚̉ŠúŒŸ¸. ¬Ž™“à‰È 2014; 46(10): 1449-53.
    33. ”ª–ØMˆê, –xìT“ñ˜Y, ŽíŽsq’ˆ. ¬Ž™‹~‹}ˆã—Â̎æ‚è‘g‚݂ɂ‚¢‚Ä@?‘‡¬Ž™‰Èˆã‹³ˆç‚Ì‚È‚©‚Å?. •xŽRŽsˆãŽt‰ï‰ï•ñ@2014; 523(10): 15-6.

  • 2014”NŠw‰ï•ñ
    1. Itazawa T, Higuchi O, Ito Y, Okabe Y, Adachi SA, Adachi Y, Ito K, Ebisawa M. Risk of oral food challenges in children ?a prospective multicenter study-. 70th Annual Meeting of American Academy of Allergy, Asthma & Immunology; 2014 Feb.28-May. 4; San Diego, CA, USA.
    2. Ichida F: Insights into etiology and pathogenesis of childhood cardiomyopathy. The 5th Congress of the Asia Pacific Pediatric Cardiology Society; 2014 Mar. 7-9; New Delhi. (invited Lecture)
    3. Ichida F: Genetic Abnormalities in Myocardial Development&Ventricular Noncompaction. The Korean Cardiology-Related Societies Joint Scientific Congress ; 2014 April 18-19 ; Gwangju, Korea. (invited Lecture)
    4. Ichida F: Pulmonary Hypertension in Adult Congenital Heart Disease. The Korean Cardiology-Related Societies Joint Scientific Congress ; 2014 April 18-19; Gwangju, Korea. (invited Lecture)
    5. Kanegane H. Symposium XLP (X-Linked Lymphoproliferative Syndrome) and EB-Virus infection. PAS/ASPR Joint Meeting ; 2014 May 3-6; Vancouver, Canada. (invited Lecture)
    6. Yang X, Kunitsu T, Ikeda Y, Taga T, Wada T, Yachie A, Yasumi T, Heike T, Kaneganee H. Female patient with X-linked lymphoproliferative syndrome type 2 caused by extremely skewed inactivation of X-chromosome. PAS/ASPR Joint Meeting ; 2014 May 3-6; Vancouver, Canada.
    7. Hirono K, Nakaoka H, Ibuki K, Ozawa S, Ichida F. BMP10 involved in the induction of left ventricular noncompaction via BMP receptors . 10th International BMP Conference; 2014 Sep 16-20; Berlin.
    8. Nishida N, Yang X, Hoshino A, Kanegane H. Inflammatory bowel disease in Japanese patients with XIAP deficiency. The 16th Biennial Meeting of the European Society for Immunodeficiencies; 2014 Oct 29-Nov 1; Prague, Czech Republic.
    9. Kanegane H. Symposium First XLP Session. Whole exome sequencing reveals atypical phenotype of X-linked lymphoproliferative syndrome. A symposium for researchers and clinicians on XLP WAS. : 2014 Nov 3-4; London.
    10. Takasaki A, Hata Y, Hirono K, Nakaoka H, Ibuki K, Ozawa S, Yoshimura N, Nishida N, Ichida F. Sarcomere gene mutations in left ventricular noncompaction. The 87th Scientific sessions of AHA 2014; 2014 Nov 15-19; Chicago.
    11. Hashimoto I, Watanabe K, Ibuki K, Ichida F. Feasibility of single beat three-dimensional echocardiography for analysis of right ventricular systolic function in neonatal heart. The 87th Scientific sessions of AHA 2014; 2014 Nov 15-19; Chicago.
    12. ˆÉŒ\“ñ˜Y, ’‡‰ª‰pK, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, ‘«—§—Yˆê. ‚—¬—Ê‚Ì‘ÌÖ¬‘¤•›ŒŒs˜H(ŠÌÖ¬-‰E–[)‚ɑ΂µ‚Ästriker Target detachable coil‚ð—p‚¢‚½double catheter technique‚É‚æ‚éÇðp‚ðŽ{s‚µ‚½TCPCŒã’PSŽºÇ‚Ì1—á. ‘æ25‰ñ“ú–{Pediatric Interventional CardiologyŠw‰ï; 2014 Jan 22-24; ¼–{.
    13. —k@žF, ¼“c’¼“¿, ‹àŒ“O˜a, ‡ˆä‹v”üŽq, _茒m, ‹g“cŒ’ˆê, ¬ì½Ži, ‘哇Fˆê, ‘º¼Gé, ‰œ–ì—F‰î, ¬“‡¨“ñ, ‹{–ì@Œå. X˜A½ƒŠƒ“ƒp‘BÇŒóŒQƒ^ƒCƒv1‚Ì‚P‰ÆŒn‚É‚¨‚¯‚郃‚ƒŠ[T×–E‚Ì‘Ì×–E•ÏˆÙ. ‘æ7‰ñ“ú–{–Ɖu•s‘SÇŒ¤‹†‰ï; 2014 Jan 25; •Ÿ‰ª.
    14. “n•Ó—S‹I, –x]’åŽu, “c’†•ü”ü, ‹{@ˆêŽu, ‘«—§—Yˆê. SCN1Aˆâ“`ŽqŒŸ¸‚ªŽ¡—Õûj‚ÌŒˆ’è‚É—L—p‚Å‚ ‚Á‚½“‚Ä‚ñ‚©‚ñ‚̈ê—á. ‘æ65‰ñ¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï; 2014 Feb 2; ‹à‘ò.
    15. —k@žF. X-linked hypogammaglobulinemia associated with somatically reverted memory T cell in a family with X-linked lymphoproliferative syndrome type 1. ‘æ3‰ñ¬Ž™–Ɖu•s‘SƒZƒ~ƒi[; 2014 Feb 7; ‹à‘ò.
    16. ¬àVˆ»‰À, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, œA–ìŒbˆê, Žs“c•™Žq. ‘Ù”Õ•«‡ŒŒŠÇƒŒ[ƒU[‹ÃŒÅpŒã‚ɉESŒn‡•¹Ç‚𗼎™‚É”F‚ß‚½‘o‘ÙŠÔ—AŒŒÇŒóŒQ‚Ì‘o‘Ù—á. ‘æ20‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŠw‰ïŠwpW‰ï; 2014 Feb 14-15; •l¼.
    17. “c’†•ü”ü, ‹{@ˆêŽu, “n•Ó—S‹I, “c’‡çH, ‘«—§—Yˆê. ŒoŠÇ‰h—{Ž{s’†‚ÌdÇSgáŠQŽ™iŽÒj‚É‚¨‚¯‚錌’†ƒJƒ‹ƒjƒ`ƒ“”Z“x‚Ì„ˆÚ‚Æ—Õ°Çó‚Æ‚ÌŠÖ˜A‚ÉŠÖ‚·‚錟“¢. ‘æ310‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2014 Mar 9; ‹à‘ò.
    18. ‘ŠJË•½, ¬‰Y@Ž, “c’†•ü”ü, ”óŒû@Žû, “c’‡çH, ‹{@ˆêŽu, ‘«—§—Yˆê. ¸_‰^“®”­’B’x‰„‚ð‹^‚í‚ꂽ‚ªA‹Ø¶ŒŸ‚æ‚èUllrichŒ^æ“V«‹ØƒWƒXƒgƒƒtƒB[‚Æf’f‚³‚ꂽˆê—á. ‘æ310‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2014 Mar 9; ‹à‘ò.
    19. ¯–쌰G, ŽíŽsq’ˆ, –쑺ŒbŽq, ‹àŒ“O˜a, ’†’Ø‹v”T, ‘å’ØŒc•ã, ‹{˜e—˜’j. “–‰@‚É‚¨‚¯‚錴”­«–Ɖu•s‘Sǂɑ΂·‚铯Ží‘¢ŒŒŠ²×–EˆÚA¬Ñ. ‘æ310‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2014 Mar 9; ‹à‘ò.
    20. ‹àŒ“O˜a. ƒŒƒNƒ`ƒƒ[uEBƒEƒCƒ‹ƒXŠÖ˜AƒŠƒ“ƒp‘BÇ‚ÌV“WŠJv. ‘æ23‰ñEBƒEƒCƒ‹ƒXŠ´õÇŒ¤‹†‰ï; 2014 March 16; “Œ‹ž.
    21. ‹àŒ“O˜a. ‹³ˆçu‰‰uŒ´”­«–Ɖu•s‘Sǂɇ•¹‚·‚鎩ŒÈ‰ŠÇv ‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –¼ŒÃ‰®.
    22. ‹àŒ“O˜a. ‹³ˆçƒZƒ~ƒi[uŒ´”­«–Ɖu•s‘Sǂɑ΂·‚é”牺’—p–ƉuƒOƒƒuƒŠƒ“IgPro20(HizentraR)‚Ì—LŒø«‚ƈÀ‘S«‚ɂ‚¢‚Äv ‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –¼ŒÃ‰®.
    23. ”ÂàVŽõŽq, ’†—ÑŒºˆê, ”óŒû@Žû, •l“¹”ü‹I, ‰ª•””üŒb, ‘«—§—zŽq, ˆÉ“¡_–¾, ŠC˜VàVŒ³G, ‘«—§—Yˆê. H•¨ƒAƒŒƒ‹ƒM[‚ɑ΂·‚éŒoŒû•‰‰×ŽŽŒ±‚Ì‘S‘’²¸.‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –¼ŒÃ‰®.
    24. “n•Ó—S‹I, •½Šâ–¾Žq, –xìT“ñ˜Y, ”ÂàVŽõŽq, ‹{@ˆêŽu, ‹g“cär, ‰Á“¡ŒõL, ‘ºã—ÇŽq, ‘«—§—Yˆê. PIGAˆâ“`Žq•ÏˆÙ‚É‚æ‚鑽”­¬ŠïŒ`A“«‚Ä‚ñ‚©‚ñ‚ð‚«‚½‚µ‚½’jŽ™—á. ‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –¼ŒÃ‰®.
    25. •½Šâ–¾Žq, ˜a“c‘ñ–ç, ’†’Ø‹v”T, ŽÂ茒‘¾˜Y, ‹{˜e—˜’j, ‘«—§—Yˆê. ŠÈˆÕ…“¹‚ð‰î‚µ‚½Yersinia enterocolitica O:8Š´õÇ‚ÌW’c”­¶.‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –¼ŒÃ‰®.
    26. ‹{”ö¬–¾, •½Šâ–¾Žq, ˜a“c ‘ñ–ç, ‘q–{@’, ’†’Ø‹v”T, ŽÂ茒‘¾˜Y, ‘«—§—Yˆê. äXŠÇ–ü‡•s‘S‚É‚æ‚é‹}«äX‰Š‚É’×ᇫ‘å’°‰Š‚𕹔­‚µ‚½ˆê—á. ‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –¼ŒÃ‰®.
    27. ‰ª•”^Žq, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, ‘«—§—Yˆê, •½–쟋v. Ö¬ŠÇŠJ‘¶Ç‚ɑ΂µ‚ÄŠO‰È“IŽ¡—Âðs‚Á‚½21trisomy‚Ì1—á. ‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –¼ŒÃ‰®.
    28. —k@žF, ‚–س–«, ‹e’r‰ëŽq, ‰¡“cr•½, ¬’rŒ’ˆê, ‘º¼Gé, ¬“‡¨“ñ, ‹àŒ“O˜a. NRAS‘Ì×–Eƒ‚ƒUƒCƒN•ÏˆÙ‚É‚æ‚鎩ŒÈ–Ɖu«ƒŠƒ“ƒp‘BÇŒóŒQ—lŽ¾Š³‚Ì‚P—á. ‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –¼ŒÃ‰®.
    29. ‹{è‚ ‚ä‚Ý, ¬ŒIˆºŽq, ’·’J“c—Sˆê, Žs“c•™Žq. ¬Ž™¶ŠˆKŠµ•aŒ’f‚É‚¨‚¯‚énon-HDL ƒRƒŒƒXƒeƒ[ƒ‹‚Ì—L—p«D‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –¼ŒÃ‰®.
    30. ‘«—§—YˆêDƒVƒ“ƒ|ƒWƒEƒ€u“û—cŽ™šb‘§‚É‚¨‚¯‚éICS‚̈ʒu•t‚¯‚ÌÄlv”ŠO‘‚É‚¨‚¯‚éi“û—cŽ™‚ɑ΂·‚éjICS‚̈ʒu•t‚¯. ‘æ26‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï; 2014 May 9-11; ‹ž“s.
    31. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‚‹´@–L, ŽO‰YŽŽu, ŠC˜VàVŒ³G, ㌴—R”üŽq, ˆÉ“¡_–¾, ‹T“c@½, Šì‘½‘º“N˜N, “í–Ú˜a‘ã, Žè’˃ˆê˜Y. ŒoŒûH•¨•‰‰×ŽŽŒ±‚É‚æ‚édÇ‚Ì—U”­Çó‚Æ“ÁˆÙ“IIgER‘̉¿‚ÌŠÖŒW. ‘æ26‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï; 2014 May 9-11; ‹ž“s.
    32. ‘«—§—Yˆê. “Á•Êu‰‰u‹z“üƒXƒeƒƒCƒh‚ð‚Ç‚¤Žg‚¤H¬Ž™šb‘§Ž¡—ÂÌStandard Care‚Æ‚ÍHvPediatric Expert Speakers Forum in Kobe; 2014 May 18: _ŒË.
    33. Žs“c•™Žq. “Á•Êu‰‰@æ“V«SŽ¾Š³pŒã‚Ì”­’BáŠQ‚ÆS—“I–â‘è. “Œ‹ž‚½‚ÜS‘Ÿ•a‚ÌŽq‚Ç‚à‚ðŽç‚é‰ïŽs–¯ŒöŠJuÀ; 2014 May 18; ‰¡•l.
    34. ‘ŠJË•½, “n•Ó—S‹I, ŽíŽsq’ˆ, “c’†•ü”ü, “c’‡çH, ‹{@ˆêŽu, X@Žõ, ‘«—§—Yˆê. ƒXƒeƒƒCƒhƒpƒ‹ƒX—Ö@‚Ì”½•œ‚ª—LŒø‚Å‚ ‚Á‚½RNMDAŽó—e‘ÌR‘Ì—z«•Ó‰Œn”]‰Š‚Ì11Î’jŽ™—á. ‘æ56‰ñ“ú–{¬Ž™_ŒoŠw‰ï; 2014 May 29-31; •l¼.
    35. Žs“c•™Žq. ¬læ“V«SŽ¾Š³‚Æê–åˆã§“x. ‘æ10‰ñ¬læ“V«SŽ¾Š³ƒZƒ~ƒi[; 2014 May 31; “Œ‹ž.
    36. ‘«—§—YˆêDƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™ƒAƒŒƒ‹ƒM[Ž¾Š³ up to dateFšb‘§v. ‘æ9‰ñ“ú–{¬Ž™Ž¨•@ˆôA‰ÈŠw‰ï; 2014 June 6-7; •l¼.
    37. ˆÉŒ\“ñ˜Y, ’‡‰ª‰pK, ¬àVˆ»‰À, œA–ìŒbˆê, –سÆ, “úŒG’qŒ›, –F‘º’¼Ž÷, ‘«—§—Yˆê, Žs“c •™Žq. Ý‘îNIPPV‚ª—LŒø‚¾‚Á‚½æ“V«SŽ¾Š³‚ɇ•¹‚µ‚½‹CŠÇŽx‹·ó‚Ì3Ç—á. ‘æ32‰ñ¼“ú–{¬Ž™zŠÂŠíHOTŒ¤‹†‰ï; 2014 June 7; ‘åã.
    38. ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, ¼”ö’C˜N, “úŒG’qŒ›, –F‘º’¼Ž÷. BASŒã‚àS–[ŠÔŒð’Ê‚ª–R‚µ‚­A¶Žº—¬“üáŠQ‚ª‹^‚í‚ꎡ—Õûj‚Ì‘I‘ð‚É“ïa‚·‚銮‘S‘匌ŠÇ“]ˆÊA’áo¶‘ÌdŽ™‚̈ê—á. ‘æ23‰ñ¬Ž™zŠÂŠíƒJƒ“ƒtƒ@ƒŒƒ“ƒX; 2014 June 7; ‹ž“s.
    39. œA–ìŒbˆê, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, Žs“c•™Žq, ”¨—R‹IŽq, ¼“c®Ž÷, ¬Š_Ž –L, •Ÿ›¸‹³ˆÌ. V¶Ž™Šú‚ÉS•s‘S‚É‚Ä”­Ç‚µƒTƒ‹ƒRƒƒAˆâ“`Žq‚Ì“ñd•ÏˆÙˆÙí‚ð”F‚ß‚½¶ŽºS‹Øãk–§‰»áŠQ‚̈ê—á. ‘æ311‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2014 June 8; •Ÿˆä.
    40. ”ª–ØMˆê, ŒÜ\—’“o, ”¨èŠì–F, ‰ª•”@Œh, ‘ºã”ü–çŽq, ‘ºãIŒ[, “ˆ”ö@’q, ‘«—§—Yˆê. •xŽRŽs‚É‚¨‚¯‚鬎™ˆã—ÓIƒPƒAEÝ‘îˆã—Öâ‘è‚Ö‚ÌŽæ‚è‘g‚݂ɂ‚¢‚Ä. ‘æ25‰ñ“ú–{¬Ž™‰Èˆã‰ï‘‰ï; 2014 June 14-15; ·‰ªD
    41. Žs“c•™Žq. “Á•Êu‰‰@S‹Øǂ̃gƒsƒbƒNƒX`SƒGƒR[‚©‚番ŽqƒŒƒxƒ‹‚̈Ùí‚ð’T‚é`. ‘æ40‰ñ’´‰¹”gŒŒ—¬Œ¤‹†‰ï; 2014 June 28; “Œ‹ž.
    42. ‘«—§—YˆêDŽs–¯ŒöŠJuÀu¬Ž™‚º‚ñ‘§v‘æ31‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï; 2014; June 28-29; –¼ŒÃ‰®.
    43. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‚‹´@–L, ŽO‰YŽŽu, ŠC˜VàVŒ³G, ㌴—R”üŽq, ˆÉ“¡_–¾, ‹T“c@½, Šì‘½‘º“N˜Y, “í–Ú˜a‘ã, Žè’˃ˆê˜Y. ŒoŒûH•¨•‰‰×ŽŽŒ±‚É‚æ‚é—U”­Çó‚ÌdÇ“x‚Æ•‰‰×ŽŽŒ±’†Ž~Žž‚Ì‘•‰‰×—Ê‚ÌŠÖŒW. ‘æ31‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï; 2014; June 28-29; –¼ŒÃ‰®.
    44. œA–ìŒbˆê, –쑺‘׋v, ”¨—R‹IŽq, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, “ˆäL, ¼“c®Ž÷, Žs“c•™Žq, ‘«—§—Yˆê. ‘ÙŽ™Šú‚ÉS•s‘S‚ðŒ_‹@‚É”­Œ©‚³‚ꂽMYH7ˆâ“`Žq•ÏˆÙ‚ð—L‚·‚鶎ºS‹Øãk–§‰»áŠQ‚̈ê—á. ‘æ50‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2014 July 3-5; ‰ªŽR.
    45. ˆÉŒ\“ñ˜Y, ’‡‰ª‰pK, ¬àVˆ»‰À, œA–ìŒbˆê, –سÆ, “úŒG’qŒ›, Žs“c•™Žq, ‘«—§—Yˆê, –F‘º’¼Ž÷. –³äBÇŒóŒQ‚̸_”­’B•]‰¿‚ðŠÜ‚ß‚½Ž¡—ìтƗ\Œã‚ÌŒŸ“¢. ‘æ50‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2014 July 3-5; ‰ªŽR.
    46. ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, “n•Óˆê—m, –سÆ, “úŒG’qŒ›, –F‘º’¼Ž÷, ‘«—§—Yˆê, Žs“c•™Žq. MYH7ˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚½¶ŽºS‹Øãk–§‰»áŠQ‚¨‚æ‚ÑSŽº’†ŠuŒ‡‘¹‚𔺂¤EbsteinŠïŒ`‚ÌŽo’í—á. ‘æ50‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2014 July 3-5; ‰ªŽR.
    47. ‰ª•”^Žq, “n•Óˆê—m, ‹à“c@®, ‹´–{ˆè•v, ŽR’J”ü˜a, ‹{@ˆêŽu. ‚Ä‚ñ‚©‚ñ‚ð‡•¹‚µ‚½‹U«•›bó‘B‹@”\’ቺÇ(PHP)‡TŒ^‚Ì—Ž™—á. ‘æ32‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2014 July 6; •xŽR.
    48. —L‘ò@—I, ûüú±–ƒ”ü, “c’†•ü”ü, ŽíŽsq’ˆ, ¬àVˆ»‰À, Žs“c•™Žq, ‘«—§—Yˆê. ìè•a”N’·Ž™—á‚É‚¨‚¯‚é—Õ°‘œ‚¨‚æ‚ÑŽ¡—Ãí—ª. ‘æ32‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2014 July 6; •xŽR.
    49. ’·‰ªvG, ¼“c’¼“¿, –쑺ŒbŽq, ‹àŒ“O˜a, ‘«—§—Yˆê. ”牺’»Ü‚É‚æ‚é–ƉuƒOƒƒuƒŠƒ“•â[—Ö@‚𓱓ü‚µ‚½R‘ÌŽY¶•s‘Sǂ̈ê—á. ‘æ32‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2014 July 6; •xŽR.
    50. ‹{@ˆêŽu, ‘ŠJË•½, ‘q–{@’, “c’†•ü”ü, “¡–Ø–õŽq, “c’‡çH, ‘«—§—Yˆê. ƒCƒ“ƒtƒ‹ƒGƒ“ƒUœëŠ³Œã‚É”­ì‚ªÁŽ¸‚µ‚½“‚Ä‚ñ‚©‚ñ‚Ì1—á. ‘æ8‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï“ŒŠC–k—¤’n•û‰ï; 2014 July 12; ɪ.
    51. Žs“c•™Žq. ‹³ˆçu‰‰@æ“V«SŽ¾Š³Ž™‚̸__Œo”­’B. ‘æ50‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï; 2014 July 13-15; ç—t.
    52. –xìT“ñ˜Y, ¬‰Y Ž, •Ÿ“cD, ìú±—TŽq, –q–{—D”ü, ‹g“cär, …“ckˆê. ”A׊nj`¬•s‘S‚ð‡•¹‚µ‚½V¶Ž™ƒwƒ‚ƒNƒƒ}ƒg[ƒVƒX‚Ì’áo¶‘ÌdŽ™—á. ‘æ50‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï; 2014 July 13-15; ç—t.
    53. ìè—TŽq, –q–{—D”ü, ¯–쌰G, à_“‡@ä, –쑺ŒbŽq, ‘ê“c‡Žq, ’†àV‰·Žq, ‹g“cär, ‹àŒ“O˜a. o¶Žž‚æ‚è”­Ç‚µ‚½RBM15-MKL1ƒLƒƒ‰ˆâ“`Žq—z«‹}«œ‘«”’ŒŒ•a. –k—¤¬Ž™ŒŒ‰t§˜b‰ï; 2014 July 12; ‹à‘ò.
    54. ‘«—§—YˆêDƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[uŠÂ‹«ˆöŽq‚ƃAƒŒƒ‹ƒM[”­ÇE‘ˆ«v‘æ24‰ñ‘Ûšb‘§Šw‰ï “ú–{E–kƒAƒWƒA•”‰ï; 2014; July 18-19; –¼ŒÃ‰®.
    55. ‘«—§—Yˆê. ¬Ž™ŒyÇšb‘§‚É‚¨‚¯‚éICSŠÔŒ‡“Š—^‚Ì¥”ñ Con‚Ì—§ê‚©‚ç. ‘æ34‰ñ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒX; 2014 July 26-27; ‹ž“s.
    56. Ž›‰ºV‘¾˜Y, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, ‘«—§—Yˆê, “¡“cC•½, Žs“c•™Žq, ’†¼•q—Y. WilliamsÇŒóŒQ‚É“Á’¥“I‚ÈSŒŒŠÇ•a•Ï‚Ì‚Ý‚ð—L‚µELNˆâ“`Žq‚Ì1‰–Šî•ÏˆÙ‚ð”F‚ß‚½1—á. ‘æ50‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï; 2014 Aug 10; ¼–{.
    57. ꎓ¡@—I, ¼“c’¼“¿, –쑺ŒbŽq, ‹àŒ“O˜a, ‘«—§—Yˆê.@’°–ŒŠÔƒŠƒ“ƒp߉Š‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚½è÷—±‹…“÷Žî‚Ì’jŽ™—á. ‘æ50‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï; 2014 Aug 10; ¼–{.
    58. ŽíŽsq’ˆ. ƒVƒ“ƒ|ƒWƒEƒ€Šó­_ŒoŠ´õÇu’°ŠÇoŒŒ«‘å’°‹ÛŠ´õÇ‚É‚æ‚é‹}«”]Ç‚Ì•a‘Ô‚ÆŽ¡—Ãí—ªv. ‘æ19‰ñ“ú–{_ŒoŠ´õÇŠw‰ï‘‰ïŠwpW‰ï‘æ26‰ñ“ú–{_Œo–ƉuŠw‰ïŠwpW‰ï; 2014 Sep 4; ‹à‘ò.
    59. ˆÉŒ\“ñû¶, X‚±‚¸‚¦, ’‡‰ª‰pK, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, –سÆ, “úŒG’qŒ›, –F‘º’¼Ž÷. o¶’¼Œã‚É‹@”\«”x“®–¬•Â½‚ð’悵‚½S‹Øãk–§‰»áŠQ‚Ì‚P—á. ‘æ42‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ï; 2014 Sep 13; ‹à‘ò.
    60. ‘«—§—Yˆê. u¬Ž™šb‘§ ÅV‚Ì’mŒ©vSymposium for Pediatrics 2014; 2014 Sep 21; “Œ‹ž.
    61. ¼“c’¼“¿. ƒ[ƒNƒVƒ‡ƒbƒv@‰ŠÇ«’°Ž¾Š³‚ð’æ‚·‚錴”­«–Ɖu•s‘SÇ. ‘æ42‰ñ“ú–{—Õ°–ƉuŠw‰ï; 2014 Sep 25-27; “Œ‹ž.
    62. ‘«—§—Yˆê. u¬Ž™‹CŠÇŽxšb‘§‚̉uŠw‚Æ‚»‚Ìf’fv. Asthma Begins in Childhood; 2014 Sep 27-28; ‘å’Ã.
    63. ‹{@ˆêŽu, ‘ŠJË•½, “n•Ó—S‹I, ‘q–{@’, “c’†•ü”ü, “¡–Ø–õŽq, “c’‡çH, ‘«—§—Yˆê. Š´õ‚ðŒ_‹@‚É”­ì‚ªÁŽ¸‚µ‚½“‚Ä‚ñ‚©‚ñ‚Ì3—á. ‘æ48‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï; 2014 Oct 2-3; “Œ‹ž.
    64. ”ÂàVŽõŽq, ˜a“c‘ñ–ç, ŽÂ茒‘¾˜Y, ‹à“c@®, X@‰ë—º, ‘«—§—Yˆê. ƒgƒVƒŠƒYƒ}ƒu’†Ž~Œã‚Ì‘½ŠÖߌ^Žá”N«“Á”­«ŠÖ߉Š‚ÌÄ”R‚ɑ΂µ‚ăgƒVƒŠƒYƒ}ƒu’PÜ‚É‚ÄŽ¡—ÃÄŠJ‚µ‚½ˆê—á. ‘æ24‰ñ¬Ž™ƒŠƒEƒ}ƒ`Šw‰ï; 2014 Oct 3-5; å‘ä.
    65. ‘«—§—Yˆê. ‹³ˆçu‰‰u¬Ž™šb‘§‚Ì—\Œãv ‘æ32‰ñŒÄ‹zŠíE–ƉuƒVƒ“ƒ|ƒWƒEƒ€; 2014 Oct 4; “Œ‹ž.
    66. “c’†•ü”ü, •lè@Œi, éì”ü‰À, ˆÉ“¡ŽÀ, ‘«—§—Yˆê, ˆîŽ›G–M. ƒGƒRƒ`ƒ‹’²¸iŽq‚Ç‚à‚ÌŒ’N‚Ɗ‹«‚ÉŠÖ‚·‚é‘S‘’²¸j‚©‚ç‚Ý‚½•xŽRŒ§‚É‚¨‚¯‚éˆçŽ™‚ÌŒ»ó. ‘æ53‰ñ•xŽR¬Ž™•ÛŒ’Šw‰ï; 2014 Oct 5; •xŽR.
    67. ŽíŽsq’ˆ. ƒVƒ“ƒ|ƒWƒEƒ€`¬Ž™S‘ŸˆÚA‚ð‚¢‚©‚É„i‚·‚é‚©`u6Ζ¢–ž¬Ž™ƒhƒi[‚ÌŠÇ—‚ðŒoŒ±‚µ‚Äv. ‘æ23‰ñ“ú–{¬Ž™S‹ØŽ¾Š³Šw‰ï; 2014 Oct 11; “Œ‹ž.
    68. œA–ìŒbˆê, ‚è–ƒ”ü, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, Žs“c•™Žq. ¶ŽºS‹Øãk–§‰»áŠQ‚É‚¨‚¯‚éƒTƒ‹ƒRƒƒAˆâ“`Žq•ÏˆÙ‚̉ðÍ. ‘æ23‰ñ“ú–{¬Ž™S‹ØŽ¾Š³Šw‰ï; 2014 Oct 11; “Œ‹ž.
    69. ŽíŽsq’ˆ. ’°ŠÇoŒŒ«‘å’°‹ÛŠ´õÇ‚É‚¨‚¯‚é—Õ°Çó‚ƃoƒCƒ^ƒ‹ƒTƒCƒ“‚ÌŒŸ“¢. ‘æ46‰ñ“ú–{¬Ž™Š´õÇŠw‰ï; 2014 Oct 18-19; “Œ‹ž.
    70. ¼“c’¼“¿, ¯–쌰G, ‘«—§—Yˆê, ‹àŒ“O˜a, “n•Ó—S‹I, ’†—ÑŒºˆê, r–Ø—ˆ‘¾, ¼‘º—Ǭ, ˜a“c‘׎O, ’J“à]ºG.@Œ´ˆö•s–¾‚ÌIgAŒ‡‘¹Ç‚Æ‚µ‚ătƒHƒ[‚³‚ꂽ activated PI3K-ƒÂ syndrome ‚̈ê—á. ‘æ46‰ñ“ú–{¬Ž™Š´õÇŠw‰ï; 2014 Oct 18-19; “Œ‹ž.
    71. “n•Ó—S‹I, –x]’åŽu, •½Šâ–¾Žq, ŽíŽsq’ˆ, ”ÂàVŽõŽq, Žs“c•™Žq, ‘«—§—Yˆê. Human metapneumovirusŠ´õ‚ðŒ_‹@‚É”­Ç‚µ‚½dÇmethicillin-resistant Staphylococcus aureus”x‰Š‚̈ê—á. ‘æ46‰ñ“ú–{¬Ž™Š´õÇŠw‰ï; 2014 Oct 18-19; “Œ‹ž.
    72. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€u“û—cŽ™šb‘§“û—cŽ™šb‘§‚Ì‚æ‚è—Ç‚¢f—Âð–ÚŽw‚µ‚ÄFƒtƒFƒmƒ^ƒCƒv•ª—Þ‚Æ‘Šú‰î“üv‘æ47‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2014 Oct 24-25; “Œ‹ž.
    73. —L‘ò@—I, ”ÂàVŽõŽq, “c’†•ü”ü, ‚è–ƒ”ü, ‹à“c@®, ’Ø“c‰ëm, Žç–{—ÏŽq, ‘«—§—Yˆê. ‹z‹C«šb–‚̌´ˆöŒŸõ‚É‚æ‚é‰æ‘œf’f‚É‚ÄŒŒŠÇŽî‚ª‹^‚í‚ꂽ‰ºˆô“ªŽîᇂÌ1—á. ‘æ47‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2014 Oct 24-25; “Œ‹ž.
    74. ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, ‘«—§—Yˆê, Žs“c•™Žq. ”­Ç‘Šú‚©‚犥“®–¬Šg’£‚ð”F‚ß‹‘劥“®–¬áŽ‚ðŒ`¬‚µ‚½ìè•a‚Ì2—á. ‘æ34‰ñ“ú–{ìè•aŠw‰ï; 2014 Oct 31-Nov 1; “Œ‹ž.
    75. ‰ª•”^Žq, –x]’åŽu,“n•Ó—S‹I,’‡‰ª‰pK,“c‘ºŒ«‘¾˜Y,¼“c’¼“¿,ˆÉŒ\“ñ˜Y,¬àVˆ»‰À,ŽíŽsq’ˆ,œA–ìŒbˆê,‹àŒ“O˜a,Žs“c•™Žq,‘«—§—Yˆê. ìè•a‹}«Šú‚ÉŒ`Ž¿×–E‘‘½Ç‚ð”F‚ß‚½IVIGŽ¡—Õs‰ž‚Ì‚P—á. ‘æ34‰ñ“ú–{ìè•aŠw‰ï; 2014 Oct 31-Nov 1; “Œ‹ž.
    76. ŽíŽsq’ˆ, ûüú±–ƒ”ü, âV“¡@—I, “c’†•ü”ü, ‘«—§—Yˆê. ‰Æ‘°‚ÌŠó–]‚ɉˆ‚Á‚½¬Ž™”]Ž€Š³ŽÒŠÇ—‚Ì‚ ‚è•û. ‘æ18‰ñ–k—¤¬Ž™‹~‹}W’†Ž¡—ÃŒ¤‹†‰ï; 2014 Nov 8; ‹à‘ò.
    77. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uŠÂ‹«‚ƃAƒŒƒ‹ƒM[F“ú–{‚É‚¨‚¯‚鉩»‚ÌŒ’N‚ւ̉e‹¿v. ‘æ51‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2014 Nov 8-9; Žl“úŽs.
    78. Adachi Y, Kanatani TK. Symposium gEnvironment and Allergy: Effects of Asian dust on respiratory health in Japanh ‘æ51‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2014 Nov 8-9; Žl“úŽs.
    79. ”ÂàVŽõŽq, ”óŒû@Žû, à_“¹”ü‹I, ’†—ÑŒºˆê, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê. ¬Ž™ƒAƒŒƒ‹ƒM[«•@‰Š¬Ž™ƒAƒŒƒ‹ƒM[«•@‰Š‚ÌdÇ“x•]‰¿‚É‚¨‚¯‚éVAS‚Ì—L—p«. ‘æ51‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; Nov 2014 8-9; Žl“úŽs.
    80. ¼–ì³’mA‘«—§—YˆêAŒÜ\—’—²•vD¬Ž™šb‘§‚ÌŒo‰ß‚ƌċCˆêŽ_‰»’‚‘f‚È‚ç‚Ñ‚É‹C“¹‰ß•q«‚ÌŠÖ˜A«‚ɂ‚¢‚Ä. ‘æ51‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; Nov 2014 8-9; Žl“úŽs.
    81. ŽíŽsq’ˆ. ’°ŠÇoŒŒ«‘å’°‹ÛO111W’cŠ´õ‚É‚¨‚¯‚éŠë‹@‘Ήž‚ÆIT‚ÌŠˆ—p. “ú–{—·sˆãŠw‰ï‘æ7‰ñ“Œ‹ž‘å‰ï; 2014 Nov 16. “Œ‹ž.
    82. ‘«—§—Yˆê. “Á•Êu‰‰u‹³ˆçŒ»ê‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[‚ւ̑Ήžv‘æ61‰ñ“ú–{ŠwZ•ÛŒ’Šw‰ï: 2014 Nov 15; ‹à‘ò.
    83. –쑺ŒbŽq, ¯–쌰G, ŽRè@“O, ‰ª“cˆÀO, âV“¡Ÿ•F, ×ì@•à, ‹àŒ“O˜a. ‘å’°‚ª‚ñ‚Ì11Î’jŽ™—á. ‘æ56‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ï; 2014 Nov 28-30; ‰ªŽR.
    84. ꎓ¡@—I, ¼“c’¼“¿, –쑺ŒbŽq, ‹àŒ“O˜a, ‘«—§—Yˆê. • o“àƒŠƒ“ƒpߎ‚ð”F‚ß‚½œ‘“÷Žî‚ªæs‚µ‚½‹}«œ‘«”’ŒŒ•a(AML M0)‚̈ê—á. ‘æ56‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ï; 2014 Nov 28-30; ‰ªŽR.
    85. ”ÂàVŽõŽq, •l“¹”ü‹I, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê. ƒAƒŒƒ‹ƒM[«•@‰Š‡•¹‚Ì‹CŠÇŽxšb‘§Ž™‚É‚¨‚¯‚é•@‰ŠÇó‚Æšb‘§ƒRƒ“ƒgƒ[ƒ‹ó‘Ô‚¨‚æ‚ьċz‹@”\‚Æ‚ÌŠÖŒW. ‘æ41‰ñ–k—¤ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï; 2014 Dec 6; ‹à‘ò.
    86. Žs“c•™Žq. Žs–¯ŒöŠJuÀ S‘Ÿ“Ë‘RŽ€‚©‚çg‚ðŽç‚éF•s®–¬‚ð—‰ð‚µ‚悤. Žq‹Ÿ‚ÌS‘Ÿ“Ë‘RŽ€@Œú˜J¬‰ÈŒ¤”ï•â•“«Ž¾Š³Ž•žŒ¤‹†Ž–‹Æu“Á”­«S‹ØÇ‚ÉŠÖ‚·‚é’²¸Œ¤‹†”ÇvŽåÓú–{zŠÂŠíŠw‰ï–k—¤Žx•”; 2014 Dec 7; •xŽR.
    87. ‘«—§—YˆêD ƒVƒ“ƒ|ƒWƒEƒ€uŽq‚Ç‚à‚Æ‘å‹CFŠÂ‹«‚ÆŽq‚Ç‚à‚̃AƒŒƒ‹ƒM[v ‘æ16‰ñ“ú–{Žq‚Ç‚àŒ’N‰ÈŠw‰ïŠwp‘å‰ï; 2014 Dec 13-14; ‹ž“s.
    88. ”ÂàVŽõŽq, ˜a“c‘ñ–ç, ‹à“c@®, ŽÂ茒‘¾˜Y, –xìT“ñ˜Y, ‘«—§—Yˆê. ¶•¨Šw“I»Ü‚𓱓ü‚µ‚½‘½ŠÖߌ^Žá”N«“Á”­«ŠÖ߉Š‚ɑ΂µ‚ÄDrug free‚ðŽŽ‚Ý‚½2Ç—á. ‘æ312‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2014 Dec 14; •xŽR.
    89. ‰ª•”^Žq, “n•Óˆê—m, ‹à“c@®, ‹´–{ˆè•v, ŽR’J”ü˜a, ‹{@ˆêŽu, ‹{X‰Á•áŽq, ´…³Ž÷. Œ¾ŒêáŠQ‚ÉTRH—Ö@‚ªŒø‰Ê“I‚Å‚ ‚Á‚½human metapneumovirus(hMPV)Š´õŠÖ˜A”]Ç‚Ì—Ž™—á. ‘æ312‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2014 Dec 14; •xŽR.
    90. âV“¡@—I, “c’†•ü”ü, X‚±‚¸‚¦, •½Šâ–¾Žq, ‚è–ƒ”ü, ‘q–{@’, ‹{@ˆêŽu, ‘«—§—Yˆê, Vˆä“c—v. ‘Šúf’f‚ÉŽŠ‚Á‚½“ûŽ™dǃ~ƒIƒNƒƒj[‚Ä‚ñ‚©‚ñ‚̈ê—á. ‘æ312‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2014 Dec 14; •xŽR.

    2013”N

  • ’˜‘
    1. ‘«—§—Yˆê. ¬Ž™šb‘§‚Ì”­Ç‹@˜. “Œ“c—L’q‘¼•Ò. “Œ‹ž: ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXo”Å; 2013. 32th˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒX. šb‘§Ž¡—Â̎c‚³‚ꂽ‰Û‘è; 3-6.
    2. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj2013”Å. ŽRŒû@“O‘¼•Ò. “Œ‹ž: ˆãŠw‘‰@; 2013. SŽ¾Š³‚ð‚à‚“û—cŽ™‚Ì“úí¶Šˆ‚ÌŠÇ—‚ÆŽw“±; 1184-5.
    3. Žs“c•™Žq. ŽüŽYŠúˆãŠw@43(‘). “í“c@‘‘¼•Ò. “Œ‹ž: “Œ‹žˆãŠwŽÐ; 2013. S‹ØÇ@ŽüŽYŠú‚̉摜f’f; 426-30.
    4. ”óŒû@Žû, ‘«—§—Yˆê. ‹C“¹ˆÙ•¨‚É‚æ‚éŠP. ‘«—§@–ž‘¼•Ò. “Œ‹ž: ‘‡ˆãŠwŽÐ; 2013. ’·ˆø‚­ŠP‚ÌŽ¡—ÃŽwj; 145-9.
    5. ¼“c’¼“¿, ‹àŒ“O˜a. ¬Ž™Š´õǃ}ƒjƒ…ƒAƒ‹. “ú–{¬Ž™Š´õÇŠw‰ï•Ò. “Œ‹ž: “Œ‹žˆãŠwŽÐ; 2012. ƒRƒƒiƒEƒCƒ‹ƒX, ƒuƒjƒAƒEƒCƒ‹ƒX, JCƒEƒCƒ‹ƒX, ƒvƒŠƒIƒ“; 548-61.
  • Œ´’˜
    1. Itazawa T, Adachi Y, Ito Y, Higuchi O, Mochizuki H, Shimojo N, Inoue T. Aerosol characteristics of admixture of budesonide inhalation suspension with a beta2-agonist, procaterol. Allergol Int. 2013 Mar;62(1):131-5.
    2. Higuchi O, Adachi Y, Adachi YS, Taneichi H, Ichimaru T, Kawasaki K. Mothers' knowledge about foreign body aspiration in young children. Int J Pediatr Otorhinolaryngol. 2013 Jan;77(1):41-4.
    3. Higuchi O, Adachi Y, Itazawa T, Ito Y, Yoshida K, Ohya Y, Odajima H, Akasawa A, Miyawaki T. Rhinitis has an association with asthma in school children. Am J Rhinol Allergy. 2013 Jan;27(1):e22-5.
    4. Ito Y, Adachi Y, Yoshida K, Akasawa A. No association between serum vitamin D status and the prevalence of allergic diseases in Japanese children. Int Arch Allergy Immunol. 2013;160(2):218-20.
    5. Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, Sanada M, Park MJ, Terui K, Suzuki H, Kon A, Nagata Y, Sato Y, Wang R, Shiba N, Chiba K, Tanaka H, Hama A, Muramatsu H, Hasegawa D, Nakamura K, Kanegane H, Tsukamoto K, Adachi S, Kawakami K, Kato K, Nishimura R, Izraeli S, Hayashi Y, Miyano S, Kojima S, Ito E, Ogawa S. Corrigendum: The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013 Nov 25;45(12): 1293-99.
    6. Marsh RA, Rao K, Satwani P, Lehmberg K, Muller I, Li D, Kim MO, Fischer A, Latour S, Sedlacek P, Barlogis V, Hamamoto K, Kanegane H, Milanovich S, Margolis DA, Dimmock D, Casper J, Douglas DN, Amrolia PJ, Veys P, Kumar AR, Jordan MB, Bleesing JJ, Filipovich AH. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood. 2013 Feb 7;121(6):877-83.
    7. Ishida K, Fukao M, Watanabe H, Taguchi M, Miyawaki T, Matsukura H, Uemura O, Zhang Z, Unadkat JD, Hashimoto Y. Effect of salt intake on bioavailability of mizoribine in healthy Japanese males. Drug Metab Pharmacokinet 2013;28(1):75-80.
    8. Chang B, Gorbea C, Lezin G, Li L, Shan L, Sakai N, Kogaki S, Otomo T, Okinaga T, Hamaoka A, Yu X, Hata Y, Nishida N, Yost HJ, Bowles NE, Brunelli L, Ichida F. 14-3-3ƒÃ gene variants in a Japanese patient with left ventricular noncompaction and hypoplasia of the corpus callosum. Gene. 2013 Feb 15;515(1):173-80.
    9. Yoshida K, Adachi Y, Akashi M, Itazawa T, Murakami Y, Odajima H, Ohya Y, Akasawa A. Cedar and cypress pollen counts are associated with the prevalence of allergic diseases in Japanese schoolchildren. Allergy. 2013 Jun;68(6):757-63.
    10. Morimoto A, Shimazaki C, Takahashi S, Yoshikawa K, Nishimura R, Wakita H, Kobayashi Y, Kanegane H, Tojo A, Imamura T, Imashuku S; Japan LCH Study Group. Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group. Int J Hematol. 2013 Jan;97(1):103-8.
    11. Shimizu M, Kanegane H, Wada T, Motoyoshi Y, Morio T, Candotti F, Yachie A. Aberrant glycosylation of IgA in Wiskott-Aldrich syndrome and X-linked thrombocytopenia. J Allergy Clin Immunol. 2013 Feb;131(2):587-90.e1-3.
    12. Katsunuma T, Fujisawa T, Nagao M, Akasawa A, Nomura I, Yamaoka A, Kondo H, Masuda K, Yamaguchi K, Terada A, Ikeda M, Nishioka K, Adachi Y, Kurihara K. Effects of transdermal tulobuterol in pediatric asthma patients on long-term leukotriene receptor antagonist therapy: results of a randomized, open-label, multicenter clinical trial in Japanese children aged 4-12 years. Allergol Int. 2013 Mar;62(1):37-43.
    13. Ohga S, Kang D, Kinjo T, Ochiai M, Doi T, Ishimura M, Kayamori Y, Urata M, Yamamoto J, Suenobu SI, Kanegane H, Ikenoue T, Shirahata A, Hara T. Paediatric presentation and outcome of congenital protein C deficiency in Japan. Haemophilia. 2013 May;19(3):378-84.
    14. Kamae C, Nakagawa N, Sato H, Honma K, Mitsuiki N, Ohara O, Kanegane H, Pasic S, Pan-Hammarstrom Q, van Zelm MC, Morio T, Imai K, Nonoyama S. Common variable immunodeficiency classification by quantifying T-cell receptor and immunoglobulin ƒÈ-deleting recombination excision circles. J Allergy Clin Immunol. 2013 May;131(5):1437-40.e5.
    15. Toki T, Kanezaki R, Kobayashi E, Kaneko H, Suzuki M, Wang R, Terui K, Kanegane H, Maeda M, Endo M, Mizuochi T, Adachi S, Hayashi Y, Yamamoto M, Shimizu R, Ito E. Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome. Blood. 2013 Apr 18;121(16):3181-4.
    16. Wada T, Muraoka M, Yokoyama T, Toma T, Kanegane H, Yachie A. Cytokine profiles in children with primary Epstein-Barr virus infection. Pediatr Blood Cancer. 2013 Jul;60(7):E46-8.
    17. Sakazaki H, Niwa K, Nakazawa M, Saji T, Nakanishi T, Takamuro M, Ueno M, Kato H, Takatsuki S, Matsushima M, Kojima N, Ichida F, Kogaki S, Kido S, Arakaki Y, Waki K, Akagi T, Joo K, Muneuchi J, Suda K, Lee HJ, Shintaku H. Clinical features of adult patients with Eisenmenger's syndrome in Japan and Korea. Int J Cardiol. 2013 Jul 15;167(1):205-9.
    18. Torii Y, Kimura H, Ito Y, Hayakawa M, Tanaka T, Tajiri H, Yoto Y, Tanaka-Taya K, Kanegane H, Nariai A, Sakata H, Tsutsumi H, Oda M, Yokota S, Morishima T, Moriuchi H; Japanese Society for Pediatric Infectious Diseases. Clinicoepidemiologic status of mother-to-child infections: a nationwide survey in Japan. Pediatr Infect Dis J. 2013 Jun;32(6): 699-701.
    19. Nagai K, Ochi F, Terui K, Maeda M, Ohga S, Kanegane H, Kitoh T, Kogawa K, Suzuki N, Ohta S, Ishida Y, Okamura T, Wakiguchi H, Yasukawa M, Ishii E. Clinical characteristics and outcomes of chediak-Higashi syndrome: a nationwide survey of Japan. Pediatr Blood Cancer. 2013 Oct;60(10):1582-6.
    20. Matsuhisa H, Yoshimura N, Higuma T, Misaki T, Onuma Y, Ichida F, Oshima Y, Okita Y. Ventricular septal dysfunction after surgical closure of multiple ventricular septal defects. Ann Thorac Surg. 2013 Sep;96(3):891-7.
    21. Ito Y, Kimura H, Torii Y, Hayakawa M, Tanaka T, Tajiri H, Yoto Y, Tanaka-Taya K, Kanegane H, Nariai A, Sakata H, Tsutsumi H, Oda M, Yokota S, Morishima T, Moriuchi H; Japanese Society for Pediatric Infectious Diseases. Risk factors for poor outcome in congenital cytomegalovirus infection and neonatal herpes on the basis of a nationwide survey in Japan. Pediatr Int. 2013 Oct;55(5):566-71.
    22. Mori D, Ranawaka U, Yamada K, Rajindrajith S, Miya K, Perera HK, Matsumoto T, Dassanayake M, Mitui MT, Mori H, Nishizono A, Soderlund-Venermo M, Ahmed K. Human bocavirus in patients with encephalitis, Sri Lanka, 2009-2010. Emerg Infect Dis. 2013 Nov;19(11):1859-62.
    23. Kobayashi K, Miya K, Akiyama T, Endoh F, Oka M, Yoshinaga H, Ohtsuka Y. Cortical contribution to scalp EEG gamma rhythms associated with epileptic spasms. Brain Dev. 2013 Sep;35(8):762-70.
    24. Kanatani KT, Slingsby BT, Mukaida K, Kitano H, Adachi Y, Haefner D, Nakayama T. Translation and Linguistic Validation of the Allergy-CONTROL-ScoreTM for Use in Japan. Allergol Int. 2013 Sep; 62(3): 337-41.
    25. ŽíŽsq’ˆ, ¬¼“¹—Y, ŒÜ\—’“o, ‹à“c@®, ¼‘q—TŠì, ¬‘qˆê«, •“c•¶l, ’J“à]ºG, ‹{˜e—˜’j. •xŽR‚ð’†S‚Æ‚µ‚½’°ŠÇoŒŒ«‘å’°‹ÛO111W’cŠ´õ. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ. 2013;117(9): 1409-15.
    26. ‘«—§—zŽq, ”óŒû@Žû, ŽíŽsq’ˆ, ‘«—§—Yˆê, ŽsŠÛ’q_, ¡ˆää‰p, ã“cN‹v, ‰¤@N‰ë, ”óŒû¹F, ìèˆê‹P. “û—cŽ™‚Ì‹C“¹ˆÙ•¨Ž–ŒÌ—\–h‚Ì‚½‚ß‚Ì•ÛŒ’Žt‚É‚æ‚éŽw“±‚ÉŠÖ‚·‚é’²¸. “ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ïŽ. 2013;23(2): 147-54.
    27. ¡‘º’¼l, —§Œ³ç”¿, ‘«—§—Yˆê, ‘ºãIŒ[, •£àV—³–ç, ‹gŒ´d”ü, ’†—ÑŒºˆê, ÔàV@W, ”öã—mˆê, ŸÀr—Y. ŒyÇ/’†“™ÇŽ‘±Œ^“û—cŽ™šb‘§‚ɑ΂·‚é’á—p—ʃuƒfƒ\ƒjƒh‹z“ü—pŒœ‘÷‰t‚Ì’·ŠúŠÇ—Œø‰Ê. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ. 2013;117(4): 732-9.
    28. ‘O“c@, ŒÃ’JŠìK, ˆîˆä@Œc, ¬ŒŠT“ñ, Š–ì_Ž÷, 㻌õ—T, ¼— —Ts, ¼‰ª—Ú”üŽq, X@Ž•F, {“cŒ›Ž¡, ”Ñ“‡³‹I, ’rŒ´@‘, ‘å–ØŠ°¶, ‹àŠÛ@_, “c“àé¶, ’†“‡O“¹, ¼Œ´‰h‹N, à_‰ªŒšé, ‘ŸºNM, –x•ÄmŽu, “ˆäL, ˆÀ“cŒª“ñ, ‰¡àV³l, VŠ_‹`•v, Žs“c•™Žq, ¬–ìˆÀ¶, ¬ŽRk‘¾˜Y, •]Œ“Ži, ¬—ÑrŽ÷, é”ö–M—², ”’Î@Œö, ’†ì‰ë¶, –쑺—Tˆê, ‘è’¼Ž÷, ‘ºã’q–¾, ˆÀ‰Í“àãà, ˆÀ“c“ŒŽn“N, ’†¼•q—Y, ŽRŠÝŒhK, “ú–{¬Ž™zŠÂŠíŠw‰ïSŒŒŠÇŽ¾Š³‚̈â“`Žq‰uŠwˆÏˆõ‰ï. ƒ`ƒAƒm[ƒ[«æ“V«SŽ¾Š³‚É‚¨‚¯‚é”]”^ᇂ̉uŠw@“ú–{¬Ž™zŠÂŠíŠw‰ïSŒŒŠÇŽ¾Š³‚̈â“`Žq‰uŠwˆÏˆõ‰ï@•½¬20”N“x-22”N“xŒ¤‹†‰Û‘è•ñ. “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ. 2013;29(5): 236-42.
  • Ç—á•ñ
    1. Kanegane H, Taneichi H, Nomura K, Wada T, Yachie A, Imai K, Ariga T, Santisteban I, Hershfield MS, Miyawaki T. Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency. Pediatr Transplant. 2013 Feb;17(1):E29-32.
    2. Nomura K, Hoshino A, Miyawaki T, Hama A, Kojima S, Kanegane H. Neutropenia and myeloid dysplasia in a patient with delayed-onset adenosine deaminase deficiency. Pediatr Blood Cancer. 2013 May;60(5):885-6.
    3. Adachi YS, Itazawa T, Okabe Y, Higuchi O, Ito Y, Adachi Y. A case of mite-ingestion-associated exercise- induced anaphylaxis mimicking wheat-dependent exercise-induced anaphylaxis. Int Arch Allergy Immunol. 2013;162(2):181-3.
    4. Otsubo K, Nomura K, Miyawaki T, Kanegane H. Nocturnal enuresis as a first manifestation of acute lymphoblastic leukemia. Pediatr Int. 2013 Feb;55(1):126-7.
    5. Otsubo K, Sakaki-Nakatsubo H, Taneichi H, Nomura K, Miyawaki T, Tokoro M, Kanegane H. Giardiasis in a patient undergoing chemotherapy for retinoblastoma and acute myelogenous leukemia. Pediatr Int 2013 Aug;55(4):524-7.
    6. Yang X, Miyawaki T, Kanegane H. Lymphoproliferative disorders in immunocompromised individuals and therapeutic antibodies for treatment. Immunotherapy. 2013 Apr;5(4):415-25.
    7. Yang X, Kanegane H, Miyawaki T. Progress of diagnosis and treatment of X-linked inhibitor of apoptosis deficiency. Zhonghua Er Ke Za Zhi. 2012 Jun;50(6):428-30.
    8. Lee YW, Yang EA, Kang HJ, Yang X, Mitsuiki N, Ohara O, Miyawaki T, Kanegane H, Lee JH. Novel mutation of IL2RG gene in a Korean boy with X-linked severe combined immunodeficiency. J Investig Allergol Clin Immunol. 2013;23(1):65-7.
    9. Hisata S, Sakaguchi H, Kanegane H, Hidaka T, Ichinose M, Kojima S, Nukiwa T, Ebina M. A Novel Missense Mutation of DKC1 In Dyskeratosis Congenita With Pulmonary Fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013 Nov 25;30(3):221-5.
    10. ˆÉ“¡–õ“T, “c‘ºŒ«‘¾˜Y, “n•Ó—S‹I, ‹{@ˆêŽu, ‹{˜e—˜’j. ’ZŠú‹L‰¯áŠQ‚Ì‚Ý‚ð’悵‚½RNMDAŽó—e‘ÌR‘Ì—z«•Ó‰Œn”]Ç‚Ì—Ž™—á. ¬Ž™‰È—Õ° 2013;66(3): 499-504.
    11. •½Šâ–¾Žq, âV“¡˜a—R, ¬àVˆ»‰À, “n•Óˆê—m, œA–ìŒbˆê, Žs“c•™Žq, ‹{˜e—˜’j, –F‘º’¼Ž÷, ¬‰Y@Ž, “¡“cC•½, “ñ’J@•, ”¨èŠì–F. dǶS•s‘S‚ɑ΂µAƒoƒ‹[ƒ“S–[’†Šu—ôŠJp‚ðŽ{s‚µ‹~–½‚µ“¾‚½V¶Ž™S‹Ø‰Š‚Ì1—á. “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ. 2013;29(3): 149-55.
    12. ’‡‰ª²’qŽq, ŽíŽsq’ˆ, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j. Š°‰ð“±“ü—Ö@‘Šú‚É”dŽí«ŒŒŠÇ“à‹ÃŒÅ‚ð”­Ç‚µ‚½‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚̈ê—á. “ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ïŽGŽ. 2013;50(4): 615-8.
  • ‘à
    1. Obuchi M, Adachi Y, Takizawa T, Sata T. Influenza A(H1N1)pdm09 virus and asthma. Front Microbiol. 2013 14;4:307.
    2. ‘«—§—Yˆê. ¬Ž™‚̔얞‚Æšb‘§. ƒAƒŒƒ‹ƒM[E–Ɖu 2013;20(11):1601-07.
    3. ‘«—§—Yˆê. dÇšb‘§‚ÌŽ¡—Ã. ƒAƒŒƒ‹ƒM[E–Ɖu 2013;20(9): 1325-30.
    4. ‘«—§—Yˆê, â–{—´—Y, à_è—Y•½. ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2012(‘æ10Í)@‹z“ü‹@Ší‚Æ‚»‚ÌŽg‚¢•û. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ. 2013;27(2): 196-9.
    5. ‘«—§—Yˆê, ”óŒû@Žû, ŽsŠÛ’q_, ¡ˆää‰p, ã“cN‹v, ‰¤@N‰ë, ”óŒû¹F, ìèˆê‹P, ‘¾“c–M—Y, “ú–{¬Ž™ŒÄ‹zŠíŠw‰ï‹C“¹ˆÙ•¨—\–hƒ[ƒLƒ“ƒOƒOƒ‹[ƒv. ¬Ž™‚É‚¨‚¯‚é‹C“¹ˆÙ•¨Ž–ŒÌ@Œ»ó‚Æ‚»‚Ì—\–h‚É‚Þ‚¯‚Ä. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ 2013;117(9): 1396-402.
    6. ‘«—§—Yˆê. ‹C“¹‰ß•q«ŽŽŒ±. ¬Ž™“à‰È 2013;45(5): 967-9.
    7. ‘«—§—Yˆê. ê–åˆã‚Ì‚½‚߂̃AƒŒƒ‹ƒM[ŠwuÀ: ‹CŠÇŽxšb‘§(¬Ž™)‚̃oƒCƒIƒ}[ƒJ[. ƒAƒŒƒ‹ƒM[ 2013;62(2): 124-30.
    8. ‘«—§—Yˆê. ‚æ‚èˆÀ‘S‚ȬŽ™Ž•‰Èˆã—Âð‹‚ß‚Ä. ¬Ž™‰Èˆã‚Ì—§ê‚©‚ç?‚±‚Ç‚à‚Ì‹C“¹“àˆÙ•¨‚ÉŠÖ‚·‚é—\–h‚ƑΉž–@?D¬Ž™Ž•‰È—Õ°. 2013;18: 32-8.
    9. ‘«—§—Yˆê. •@‰Š‡•¹¬Ž™šb‘§‚ÌŽ¡—Ã. —Õ°–ƉuEƒAƒŒƒ‹ƒM[‰È. 2013;60: 530-4.
    10. ‘«—§—Yˆê. “û—cŽ™šb‘§‚ÆVirus-induced wheeze. “ú–{¬Ž™ˆã‰ï•ñ. 2013;45: 28-30.
    11. ‘«—§—Yˆê. Œ¤‹†‚ÌŽü•Ó‚©‚çul‚Æ‚Ìo‰ï‚¢‚Ì’†‚ÅvŒÄ‹z 2013; 32: 671-2.
    12. Žs“c•™Žq. y‚í‚©‚éS“d}-•a‘Ô‚É”—‚é”»“ǂ̃Rƒcz S‹ØÇŽ¾Š³A‚»‚Ì‘¼@S‹ØÇ. ¬Ž™‰Èf—Ã. 2013;76(11): 1732-8.
    13. Žs“c•™Žq. ƒnƒCƒŠƒXƒNŽ™‚Ö‚ÌRSƒEƒBƒ‹ƒXŠ´õ—\–h. “ú–{ˆãŽ–V•ñ 2013;4676:31-5.
    14. Žs“c•™Žq. ‘æ114‰ñˆãŠwuÀ ‘ål‚É‚È‚è‚ä‚­ŒN‚½‚¿‚Ö`æ“V«SŽ¾Š³‚Æ”­’BáŠQ@S‘Ÿ‚ð‚Ü‚à‚é. ‘S‘S‘Ÿ•a‚ÌŽq‹Ÿ‚ðŽç‚é‰ï‰ïŽ 2013; 594:14-7.
    15. ‹àŒ“O˜a, ‹{˜e—˜’j. y—‰ð‚µ‚Äo‚»‚¤@¬Ž™‚ÌŒŸ¸-ƒI[ƒ_[EŽè‹ZE‰ðŽßz –ƉuEƒAƒŒƒ‹ƒM[EŠ´õÇ@–Ɖu’S“–×–E‹@”\ˆÙ팟¸(ƒŠƒ“ƒp‹…). ¬Ž™‰Èf—à 2013;76(‘): 180-5.
    16. ‹àŒ“O˜a. ŒJ‚è•Ô‚·’†Ž¨‰Š‚©‚牽‚ðl‚¦‚Ü‚·‚©H ¬Ž™Ž¨•@ˆôA‰È. 2013;34(2): 283-8.
    17. ”ÂàVŽõŽq. ƒAƒŒƒ‹ƒM[Ž¾Š³‚ÌŽ¡—Öòi10j@¬Ž™‰È—̈æ@’·ŽžŠÔì—p«ƒÀ2ŽhŒƒ–ò. ƒAƒŒƒ‹ƒM[E–Ɖu@2013G20i12j1875-1881.
    18. ŽíŽsq’ˆ:yŒŒð«”÷¬ŒŒŠÇÇ(TMA:TTP/HUS)‚ÌÅV’mŒ©zTMA‚Æ”]Ç‚Ì–â‘è. t‚Æ“§Í. 2013;74(6): 1063-8.
    19. ŽíŽsq’ˆ:yŒŒð«”÷¬ŒŒŠÇÇ(TMA:TTP/HUS)‚ÌÅV’mŒ©z‘“àŽ–—á. t‚Æ“§Í. 2013;74(6): 1087-90.
    20. ŽíŽsq’ˆ. ’°ŠÇoŒŒ«‘å’°‹ÛŠ´õÇ‚ÉŠÖ˜A‚µ‚½‹}«”]Ç‚Ì•a‘Ô‚ÆŽ¡—Ã`‚¦‚Ñ‚·H’†“ÅŽ–Œ‚ÌŒoŒ±‚©‚ç`. ƒƒfƒBƒJƒ‹’©“ú; 2013 Aug 34-35.
    21. œA–ìŒbˆê, Žs“c•™Žq. yƒƒ“ƒ‰ƒ“ƒNã‚̬Ž™‚Ì—Õ°ŒŸ¸-•a‘Ô¶—‚ÉŠî‚­‘I‚Ñ•ûEl‚¦•û-zzŠÂAŒÄ‹zŠíŒnŽ¾Š³‚Ì—Õ°ŒŸ¸@S•s‘S. ¬Ž™‰ÈŠwƒŒƒNƒ`ƒƒ[. 2013;3(2): 397-402.
    22. ¯–쌰G, ‹àŒ“O˜a. y’m‚Á‚Ä‚¨‚«‚½‚¢ÅV‚̖Ɖu•s‘SÇ•ª—Þ-f’f‚©‚玡—Â܂Åz •a‘Ô@–Ɖu’²ßáŠQ@Ž©ŒÈ–Ɖu«ƒŠƒ“ƒp‘BÇŒóŒQ, ‰Æ‘°«ŒŒ‹…æÃHƒŠƒ“ƒp‘gD‘‘½ÇŒóŒQ‚È‚Ç. ¬Ž™‰Èf—Ã. 2013;76(3): 425-30.
    23. ¯–쌰G, ‹àŒ“O˜a: yŒŒ‹…æÃHÇŒóŒQ‚Ì•a‘Ô‚Æf—ÂÌV“WŠJz X-linked lymphoproliferative syndrome(XLP)/ signaling-lymphocytic-activation-molecule-associated protein(SAP)‚Ì•a‘Ô. ŒŒ‰tƒtƒƒ“ƒeƒBƒA. 2013;23(1): 33-40.
    24. –{ŠÔŒ’ˆê, ¡ˆäk•ã, ‹àŒ“O˜a, –ìXŽRŒbÍ. MonoMACÇŒóŒQ (GATA2ˆÙíÇ). —Õ°–Ɖu?ƒAƒŒƒ‹ƒM[‰È 2013; 60(4): 439-46.
    25. “n糌’ˆê˜Y, X“ˆ’B–ç, ‹àŒ“O˜a. yŒŒ‰tÇŒóŒQ(‘æ2”Å)-‚»‚Ì‘¼‚ÌŒŒ‰tŽ¾Š³‚ðŠÜ‚ß‚Ä-z ‘¢ŒŒŠ²×–EˆÙí@Ķ•s—Ç«•nŒŒ@æ“V«“Á”­«Ä¶•s—Ç«•nŒŒ@Shwachman-DiamondÇŒóŒQ. “ú–{—Õ°. 2013; •ÊûŒŒ‰tÇŒóŒQ‘æ2”Å:24-7.
    26. ’†‘º—˜”ü, ‘«—§—Yˆê, ‘ºãIŒ[, ’J“à]ºG, ‘哈—E¬, áÁ‹|Œõ•¶, –k—¤¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃŒ¤‹†‰ï. Pediatric Asthma Support System‚Ì“±“ü‚É‚æ‚éƒKƒCƒhƒ‰ƒCƒ“‚ɉˆ‚Á‚½¬Ž™‹CŠÇŽxšb‘§Ž¡—Â̄i. ¬Ž™‰È—Õ°. 2013;66(6): 1079-90.

  • 2013”NŠw‰ï•ñ
    1. Adachi Y, Yoshida K, Itazawa T, Ohya Y, Odajima H, Akasawa H, Miyawaki T. Relationship between ARIA and ISAAC questionnaires regarding to the classification and severity of rhinitis in school children. 69th Annual Meeting of American Academy of Allergy, Asthma & Immunology; 2013 Feb 22-26; San Antonio, USA.
    2. Kanegane H. Epstein-Barr virus-associated lymphoproliferative disorders. ASPR-PSM 2013; 2013 May 9-12; Malaysia. (invited lecture)
    3. Kanegane H. Immunomodulatory therapy for lymphoproliferative disorders. ASPR-PSM 2013; 2013 May 9-12; Malaysia. (invited lecture)
    4. Itazawa T, Okabe Y, Ito Y, Higuchi O, Adachi SY, and Adachi Y. Impulse oscillometry is more sensitive to bronchodilator response than spirometry in children with asthma. 2013 Annual international congress co-sponsored by Korean Academy of Asthma, Allergy and Clinical Immunology and Korean Academy of Pediatric Allergy and Respiratory Disease; 2013 May 10-11; Seoul, Korea.
    5. Itazawa T, Adachi Y, Ito K, Ebisawa M. Severe reaction during oral food challenges in children in a prospective study. Asian Pacific Congress of Allergy, Asthma and Clinical Immunology; 2013 Nov 14-17; Taipei, Taiwan.
    6. œA–ìŒbˆê, ¬‰Y@Ž, â“c“Þ, ”óŒû@Žû, âV“¡˜a—R, “n•Óˆê—m, Žs“c•™Žq. ”x–ì‚É‚Ñ‚Ü‚ñ«Œ‹ß•a•Ï‚ð”F‚ß‚½ìè•a‚Ì‚P—á. ‘æ5‰ñ–k—¤ìè•aŒ¤‹†‰ï; 2013 Jan 22; ‹à‘ò.
    7. ˆÉŒ\“ñ˜Y, ¼”ö‹vŽÀ‘ã, “¡‰ª‘׶, ‰Á“¡‰·Žq, à_–{“Þ‰›, –F–{@A‹à@¬ŠC, –ž‰º‹IŒb, V‹³Šî, “c’†–õ•F, ¬–ìˆÀ¶. Œo”ç“I”x“®–¬Œ`¬p‚É‚¨‚¯‚é’´‚ˆ³ƒoƒ‹[ƒ“‚Æ‚ˆ³ƒoƒ‹[ƒ“‚Æ‚Ì”äŠr. ‘æ24‰ñ“ú–{Pediatric Interventional CardiologyŠw‰ïŠwpW‰ï; 2013 Jan 24; ˆ¤•Q.
    8. ¯–쌰G, ‹àŒ“O˜a, —k@žF, ‹{˜e—˜’j, ”º@‰pŽ÷, ‰E“c¹G, ‹´ˆä‰ÀŽq, Xˆä‰pˆê, ´‰ÍMŒh. ƒŠƒ“ƒpŒnŽîá‡‚ð‡•¹‚µ‚½X˜A½–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì2—á. ‘æ6‰ñ“ú–{–Ɖu•s‘SÇŒ¤‹†‰ï; 2013 Jan 26; “Œ‹ž.
    9. ’‡‰ª‰pK, “n•Óˆê—m, âV“¡˜a—R, ¬àVˆ»‰À, “n•Óˆê—m, œA–ìŒbˆê, Žs“c•™Žq, ‹{˜e—˜’j, ²“¡@Œ[, “¡“cC•½, ”¨èŠì–F. S–[’†ŠuŒ‡‘¹‚Æ•”•ª”xÖ¬ˆÙ퇕¹‚Ì”x“®–¬«”x‚ŒŒˆ³‚ɑ΂µ‚ÄA”xŒŒŠÇŠg’£–ò‚Ì‘½Ü•¹—p—Ö@‚ª‘tŒ÷‚µ‚½2ΗŽ™—á. ‘æ19‰ñ“ú–{¬Ž™”xzŠÂŒ¤‹†‰ï; 2013 Feb 2; “Œ‹ž.
    10. ‘«—§—Yˆê. ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u¬Ž™ƒAƒŒƒ‹ƒM[«•@‰Š ¬Ž™‰È‚Ì—§ê‚©‚çv. ‘æ31‰ñ“ú–{Ž¨•@ˆôA‰È–ƉuƒAƒŒƒ‹ƒM[Šw‰ï; 2013 Feb 7-9; ‘q•~.
    11. ¯–쌰G, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j. “¯Žíœ‘ˆÚAŒã‚É•”•ªŠ°‰ð‚Ì‚Ü‚Ü–³Ž¡—ÂŒ·Šú¶‘¶‚µ‚Ä‚¢‚é_Œo‰è×–EŽî‚̈ê—á. ‘æ35‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï; 2013 Mar 7-9; ‹à‘ò.
    12. –쑺ŒbŽq, ‹àŒ“O˜a, ŽíŽsq’ˆ, ‹{˜e—˜’j, ’Â@–LŽj, ˆÉ’B—mŽŠ. _Œo‰èŽî‚ÌŽ¡—Ê֘Aœ‘ˆÙŒ`¬ÇŒóŒQ‚ɑ΂·‚铯ŽíœˆÚAŒãA–«•Âǫ׋CŠÇŽx‰Š‚ɑ΂µA—¼‘¤¶‘Ì”xˆÚA‚ðŽ{s‚µ‚½¬Ž™—á. ‘æ35‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï; 2013 Mar 7-9; ‹à‘ò.
    13. ‘ŠJË•½, ‹{@ˆêŽu, ‹{˜e—˜’j. •xŽR‘åŠw¬Ž™‰È‚ÅŒoŒ±‚µ‚½‰ß‹Ž‚T”NŠÔ‚ÌWestÇŒóŒQ‚ɂ‚¢‚ẲuŠw“IŒŸ“¢. ‘æ307‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï; 2013 Mar 10; ‹à‘ò.
    14. ŽíŽsq’ˆ. •ª–ì•ÊƒVƒ“ƒ|ƒWƒEƒ€2@¬Ž™‚Ì‹}«”]‰ŠE”]ÇuEHEC”]Çv. ‘æ116‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2013 Apr 19-21; L“‡.
    15. ŽíŽsq’ˆ, ”ÂàVŽõŽq, ‹{˜e—˜’j. “–‰@‚É‚¨‚¯‚éƒOƒŠ[ƒtƒPƒA‚Ì‘æˆê•à.`ƒOƒŠ[ƒtƒJ[ƒh‚Ì–ðŠ„‚É‚Â‚¢‚Ä`. ‘æ116‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2013 Apr 19-21; L“‡.
    16. “n•Óˆê—m, Ö“¡˜a—R, Žs“c•™Žq, ‹{˜e—˜’j, Šâéûé”n, “úŒG’qŒ›, –F‘º’¼Ž÷. TCPCp’¼Œã‚©‚猌ðŒ`¬‚µASŠO“±ŠÇ•ÂÇ‚ð‚«‚½‚µ‚½3—á. ‘æ116‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2013 Apr 19-21; L“‡.
    17. ‘«—§—zŽq, ”óŒûŽû, ”ÂàVŽõŽq, ŽíŽsq’ˆ, ‘«—§—Yˆê, ‹{˜e—˜’j, ŽsŠÛ’q_, ìèˆê‹P. •ÛˆçŽ{Ý‚É‚¨‚¯‚é‹C“¹Ž–ŒÌ—\–h‚Ì‚½‚ß‚ÌŽæ‚è‘g‚Ý‚ÌŒ»ó. ‘æ116‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2013 Apr 19-21; L“‡.
    18. –xìT“ñ˜Y, ‹{”ö¬–¾, ìú±—TŽq, –q–{—D”ü, ‹g“cär, ‹{˜e—˜’j. ˜˜]Ò’ÅÇŒóŒQ‚̈ê—á. ‘æ116‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2013 Apr 19-21; L“‡.
    19. ‘ŠJË•½, âV“¡˜a—R, “n•Óˆê—m, œA–ìŒbˆê, ‘«—§—Yˆê, Žs“c•™Žq, ‹{˜e—˜’j, ”ª–ØMˆê. LMNAˆâ“`Žq•ÏˆÙ‚𔺂¤æ“V«‹ØƒWƒXƒgƒƒtƒB[‚Ì—Ž™‚É‚¨‚¯‚éS•s‘S‚ÌŒo‰ß. ‘æ116‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2013 Apr 19-21; L“‡.
    20. ’Þ@_”V, “c’†•ü”ü, ‰ª•”^Žq, ŽíŽsq’ˆ, ”ÂàVŽõŽq, ‹{˜e—˜’j. ‹”MŠÂ‹«‰º‚É‚¨‚¯‚é‰ß“x‚̉^“®‚É‚æ‚艡–ä‹Ø—Z‰ðÇ‚ð‚«‚½‚µ‚½‚P—á. ‘æ116‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2013 Apr 19-21; L“‡.
    21. ‘ŠJË•½, –x]’åŽu, ¬‰Y@Ž, “n•Ó—S‹I, ”óŒû@Žû, ‹{@ˆêŽu, ŽíŽsq’ˆ. ¬Ž™‚É‚¨‚¯‚é”ñƒwƒ‹ƒyƒX«‹}«•Ó‰Œn”]‰Š(RNMDAŽó—e‘ÌR‘Ì—z«—á) ‚ɑ΂·‚鎡—Ãí—ª. ‘æ15‰ñ–k—¤¬Ž™‹~‹}?W’†Ž¡—ÃŒ¤‹†‰ï; 2013 May 11; ‹à‘ò.
    22. ‘«—§—Yˆê. ‘‡ƒAƒŒƒ‹ƒM[ˆãˆç¬ƒR[ƒXFšb‘§”­ì‚ւ̑Ήži¬Ž™j. ‘æ25‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïtŠú—Õ°‘å‰ï; 2013 May 11-12; ‰¡•l.
    23. ”ÂàVŽõŽq, ”óŒû@Žû, ‘«—§—Yˆê, ‹g“cKˆê, ŒÃì^‹|, ¬“c“ˆ”Ž, Ö“¡”Ž‹v, ÔàV@W. ƒEƒFƒu’²¸‚ð—p‚¢‚½Šw“¶‚É‚¨‚¯‚éARIAiallergic rhinitis and its impact on asthmajŽ¿–â•[‚̑Ó–«‚ÉŠÖ‚·‚錟“¢D‘æ25‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïtŠú—Õ°‘å‰ï; 2013 May 11-12; ‰¡•l.
    24. ‘«—§—zŽq, ”óŒû@Žû, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j. ¬”žˆË‘¶«‰^“®—U”­ƒAƒiƒtƒBƒ‰ƒLƒV[‚ª‹^‚í‚ꂽ‚¨D‚ÝÄ‚«ƒAƒiƒtƒBƒ‰ƒLƒV[‚Ì1—áD‘æ25‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïtŠú—Õ°‘å‰ï; 2013 May 11-12; ‰¡•l.
    25. ”óŒû@Žû, ”ÂàVŽõŽq, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j, –q–ì‹P•F, ´…’‰“¹. Žs”Ì‚Ì‘‡Š´–`–ò‚Å‹}«”Ä”­«”­]Œ^”^ávÇ‚ð”­Ç‚µ‚½—Ž™—áD‘æ25‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïtŠú—Õ°‘å‰ï; 2013 May 11-12; ‰¡•l.
    26. Žs“c•™Žq. “Á•Êu‰‰@‘ål‚É‚È‚è‚ä‚­ŒN‚½‚¿‚Ö`SŽ¾Š³Ž™‚Ì”­’BáŠQ‚ɂ‚¢‚Ä`‘S‘S‘Ÿ•a‚ÌŽq‚Ç‚à‚ðŽç‚é‰ï@‹ž“sŽx•”u‰‰‰ï; 2013 May 12; ‹ž“s.
    27. ¯–쌰G, –쑺ŒbŽq, ‹àŒ“O˜a. ƒrƒ“ƒNƒŠƒXƒ`ƒ““Š—^‚ª‘tŒø‚µ‚½Kasabach-MerrittÇŒóŒQ‚̈ê—á. ‘æ6‰ñ–k—¤ƒwƒ‚ƒtƒBƒŠƒA§˜b‰ï; 2013 May 18; ‹à‘ò.
    28. Kanegane H, Yang X, Nishida N, Hoshino A, Miyawaki T. Clinical and genetic characterization of X-linked lymphoproliferative syndrome in Japan. The 4th JSH International symposium 2013; 2013 May 24-25; Ehime, Japan.
    29. Hoshino A, Kanegane H, Yang X, Ban H, Migita M, Kiyokawa N, Miyawaki T. B-precursor acute lymphoblastic leukemia in a patient with X-linked agammaglobulinemia. The 4th JSH International symposium 2013; 2013 May 24-25; Ehime, Japan.
    30. ”ÂàVŽõŽq, ‰ª•””üŒb, ”óŒû@Žû, ‘«—§—zŽq, ‘«—§—Yˆê. ŒÄ‹z‹@”\‚ª—ÇD‚Å‚ ‚鬎™‹CŠÇŽxšb‘§‚É‚¨‚¯‚éŒÄ‹C’†ˆêŽ_‰»’‚‘f‚̈Ӌ`. ‘æ30‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï; 2013 June 8-9;ˆïéD
    31. ‘«—§—zŽq, ”óŒû@Žû, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê. •xŽRŒ§“à‚Ì•ÛˆçŽ{Ý‚É‚¨‚¯‚霋ŽH‘Ήž‚Ì5”NŠÔ‚̕ω». ‘æ30‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï; 2013 June 8-9;ˆïéD
    32. ‹àŒ“O˜a. ƒVƒ“ƒ|ƒWƒEƒ€u’†Ž¨‰Š‚ɑ΂·‚é•Û‘¶—Ö@AŽèp—Ö@‚Ì‘I‘ðvŒJ‚è•Ô‚·’†Ž¨‰Š‚©‚牽‚ðl‚¦‚Ü‚·‚©H ‘æ8‰ñ“ú–{¬Ž™Ž¨•@ˆôA‰ÈŠw‰ï; 2013 June 20-21; ‘O‹´.
    33. ”ÂàVŽõŽq, ‰ª•””üŒb, ˆÉ“¡–õ“T, ”óŒû@Žû, ‘«—§—zŽq, ‘«—§—Yˆê. ‹CŠÇŽxšb‘§¬Ž™‚̉‹t«ŽŽŒ±‚É‚¨‚¯‚éImpulse Oscillometry System‚Ì—L—p«‚ÉŠÖ‚·‚錟“¢. ‘æ107‰ñ —Õ°ŒÄ‹z¶—Œ¤‹†‰ïŠwpW‰ï; 2013 June 22;“Œ‹ž.
    34. ¼‘q—TŠì, ‹{@ˆêŽu, ’·X–œ—¢Žq. ‘Ï“œ”\ˆÙíAt”X–EAõF‘̈Ùí‚𔺂¤Dandy-Walker variant‚Ì—Ž™—á. ‘æ48‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï; 2013 June 28-29; “¿“‡.
    35. Žs“c•™Žq. “Á•Êu‰‰@æ“V«SŽ¾Š³‚É‚¨‚¯‚é”xŒŒŠÇŠg’£–ò‚ÌŒø‰Ê. ‘æ49‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï; 2013 July 11-13; “Œ‹ž.
    36. œA–ìŒbˆê, âV“¡˜a—R, “n•Óˆê—m, ¬àVˆ»‰À, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, Žs“c•™Žq, –F‘º’¼Ž÷, Dirk Foel. ƒtƒHƒ“ƒ^ƒ“Žèp“K‰žŠ³ŽÒ‚É‚¨‚¯‚éƒGƒ“ƒhƒZƒŠƒ“‚Ì“®‘Ô. ‘æ49‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï; 2013 July 11-13; “Œ‹ž.
    37. ’‡‰ª‰pK, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, ¬àVˆ»‰À, œA–ìŒbˆê, ‘«—§—Yˆê, Žs“c•™Žq. LMNAˆâ“`Žq•ÏˆÙ‚𔺂¤æ“V«‹ØƒWƒXƒgƒƒtƒB[‚Ì—Ž™‚É‚¨‚¯‚éS•s‘S‚ÌŒo‰ß. ‘æ49‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï; 2013 July 11-13; “Œ‹ž.
    38. ˆÉŒ\“ñ˜Y, ¼”ö‹v”ü‘ã, “¡‰ª‘׶, ‰Á“¡‰·Žq, ²“¡Œc‰î, à_–{“Þ‰›, –F–{ , ‹à ¬ŠC, –ž‰º‹IŒb, V‹³Šî, ¬–ìˆÀ¶. Žá”NŠú‘å“®–¬•Ù‹t—¬‚ɑ΂·‚éŽèp“K‰ž•]‰¿‚̃pƒ‰ƒ_ƒCƒ€ƒVƒtƒg `Œo‹¹•ÇSƒGƒR[+SŒŒŠÇ‘¢‰e‚©‚çCS‘ŸMRI+ŒoH“¹SƒGƒR[ŒŸ¸‚Ö`. ‘æ49‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï; 2013 July 11-13; “Œ‹ž.
    39. ˆÉŒ\“ñ˜Y, ’‡‰ª‰pK, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. ”xŒŒŠÇŠg’£Ü‚ÅŒo‰ßŠÏŽ@‚µ‚½ASD-PAH‚̈ê—á.‘æ4‰ñPH-CHDƒNƒŠƒjƒJƒ‹ƒJƒ“ƒtƒ@ƒŒƒ“ƒX; 2013 July 20; ‘åã.
    40. ‘«—§—Yˆê, ŽsŠÛ’q_, ¡ˆää‰p, ã“cN‹v, ‰¤@N‰ë, ”óŒû¹F, ìèˆê‹P, ”ª–ØMˆê. ¬Ž™‚É‚¨‚¯‚é‹C“¹ˆÙ•¨Ž–ŒÌ—\–h‚É‚Þ‚¯‚Ä Ž–ŒÌ‚âŒ[”­Šˆ“®‚ÌŽÀ‘Ô. ‘æ23‰ñ“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ï; 2013 Aug 31-Sep 1; •Ÿ‰ª.
    41. ‘«—§—Yˆê, ŽsŠÛ’q_, ¡ˆää‰p, ã“cN‹v, ‰¤@N‰ë, ”óŒû¹F, ìèˆê‹P, ‘¾“c–M—Y, ”ª–ØMˆê. ¬Ž™‚É‚¨‚¯‚é‹C“¹ˆÙ•¨Ž–ŒÌ—\–h‚É‚Þ‚¯‚Ä Œ[”­—pƒpƒ“ƒtƒŒƒbƒgì¬. ‘æ23‰ñ“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ï; 2013 Aug 31-Sep 1; •Ÿ‰ª.
    42. ‘«—§—Yˆê. u“û—cŽ™šb‘§‚É‚¨‚¯‚éŋ߂̘b‘èv‘æ4‰ñPediatric Asthma Regional Seminar; 2013 Sep 7; å‘ä.
    43. ‘ºãIŒ[, ‚”ö@Š², ”öã—mˆê, ’†—ÑŒºˆê, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹g“cär. ŠJ‹Æˆã‚Ås‚¤H•¨ŒoŒû•‰‰×ŽŽŒ±‚ÌŒŸ“¢. ‘æ16‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï; 2013 Sep 14; •xŽR.
    44. ìè—TŽq, –q–{—D”ü, ¬‰Y@Ž, “c‘ºŒ«‘¾˜Y, –xìT“ñ˜Y, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹g“cär. “–‰@‚ÅŒoŒ±‚µ‚½V¶Ž™ƒ~ƒ‹ƒNƒAƒŒƒ‹ƒM[‚Ì3—á. ‘æ16‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï; 2013 Sep 14; •xŽR.
    45. ˆÉŒ\“ñ˜Y, ’‡‰ª‰pK, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, –سÆ, “úŒG’qŒ›, –F‘º’¼Ž÷, –F–{@. S‘ŸÄ“¯Šú—Ö@ƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚ðs‚Á‚½‚“xS•s‘S‚ð‡•¹‚µ‚½GlennŽèpŒãA‘å“®–¬k󕡇‚̈ê—á. ‘æ41‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ï; 2013 Sep 14; ‹à‘ò.
    46. ¬‰Y@Ž, â“c“Þ, ”óŒû@Žû, œA–ìŒbˆê, ‹àŒ“O˜a, Žs“c•™Žq, ‹{˜e—˜’j. ”x–ì‚É‚Ñ‚Ü‚ñ«Œ‹ß•a•Ï‚ð”F‚ß‚½•s‘SŒ^ìè•a‚Ì9‚©ŒŽ—Ž™—á. ‘æ33‰ñ“ú–{ìè•aŠw‰ï; 2013 Sep 27-28, •xŽR.
    47. œA–ìŒbˆê, ‰ª•”^Žq, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, Žs“c•™Žq, ¬Š_Ž –L, •Ÿ›¸‹³ˆÌ. ƒÀŽÕ’f–ò“Š—^‚É‚æ‚èS•s‘S‚ª‘ˆ«‚µ‚½¶ŽºS‹Øãk–§‰»áŠQ‚̈ê—á. ‘æ22‰ñ“ú–{¬Ž™S‹ØŽ¾Š³Šw‰ï; 2013 Oct 5; ‘åã.
    48. ‹àŒ“O˜a. ƒVƒ“ƒ|ƒWƒEƒ€uˆâ“`ŽqˆÙí‚Æ_ŒoŠ´õÇvR‘Ì•s‘SÇ‚Æ’†•_ŒoŠ´õÇ. ‘æ18‰ñ“ú–{_ŒoŠ´õÇŠw‰ï; 2013 Oct 10-12; ‹{è.
    49. Hoshino A, Nomura K, Noguchi K, Kotani T, Nakagawa N, Kanegane H. A case of relapsed APL without peripheral blood abnormalities and clinical symptoms detected by MRI. ‘æ75‰ñ“ú–{ŒŒ‰tŠw‰ï; 2013 Oct 10-13; ŽD–y.
    50. Žs“c•™Žq. ƒVƒ“ƒ|ƒWƒEƒ€f—Ņ̃FŠw‰ï‚ÌŽæ‚è‘g‚Ý‚ÌŒ»ó@“ú–{zŠÂŠíŠw‰ï‚æ‚è@ŠwpˆÏˆõ‰ï@¬læ“V«SŽ¾Š³•”‰ï‚ÌÝ—§. ‘æ9‰ñ¬læ“V«SŽ¾Š³ƒZƒ~ƒi[; 2013 Oct 19; ‘åã.
    51. ‘«—§—Yˆê. ƒXƒ|ƒ“ƒT[ƒhƒZƒ~ƒi[uHow to challenge and influence to the prognosis of childhood asthma: strategies and perspecitivev‘æ50‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2013 Oct 19-20; ‰¡•l.
    52. ‘«—§—Yˆê. ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u¬Ž™‹CŠÇŽxšb‘§Ž¡—à ƒXƒeƒbƒvƒ_ƒEƒ“‚ÆŽ¡—Ã’†Ž~‚Ì–ÚˆÀv‘æ50‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2013 Oct 19-20; ‰¡•l.@
    53. ‘«—§—Yˆê. Pro ConuICS‚ÌŠÔŒ‡“Š—^FCon‚Ì—§ê‚©‚çv‘æ50‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2013 Oct 19-20; ‰¡•l.
    54. ‘«—§—zŽq, ”ÂàVŽõŽq, ‰ª•””üŒb, •l“¹”ü‹I, ”óŒû@Žû, •£àV—³–ç, ŽRŒ³ƒŽq, ‚”ö@Š², ”öã—mˆê, ‘ºãIŒ[, ‘«—§—Yˆê. ƒ}ƒtƒBƒ“‚ð—p‚¢‚½’´‰Á”M“û•‰‰×ŽŽŒ±‚Ì—L—p«‚ɂ‚¢‚Ä. ‘æ50‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2013 Oct 19-20; ‰¡•l.
    55. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‚‹´@–L, ŽO‰YŽŽu, ŠC˜VàVŒ³G, ㌴—R”üŽq, ˆÉ“¡_–¾, ‹T“c@½, Šì‘½‘º“N˜N, “í–Ú˜a‘ã, Žè’˃ˆê˜Y. ‘S‘‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[‚ɑ΂·‚éŒoŒûH•¨•‰‰×ŽŽŒ±‚É‚æ‚é—U”­Çó‚ÉŠÖ‚·‚é‘S‘’²¸. ‘æ50‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2013 Oct 19-20; ‰¡•l.
    56. ”ÂàVŽõŽq. ˆê”ʈãƒZƒ~ƒi[uf—ØAŒg‚̃^ƒCƒ~ƒ“ƒOF‹CŠÇŽxšb‘§v ‘æ50‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2013 Oct 19-20; ‰¡•l.
    57. ‰ª•”^Žq, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, œA–ìŒbˆê, Žs“c•™Žq. “«ìè•a‚ɑ΂µ‚ÄIVIG‚¨‚æ‚уVƒNƒƒXƒ|ƒŠƒ“•¹—p—Ö@‚ª—LŒø‚Å‚ ‚Á‚½2—á. ‘æ13‰ñ•xŽR¬Ž™zŠÂŠíŒ¤‹†‰ï; 2013 Oct 25; •xŽR.
    58. ‹àŒ“O˜a. ICDuK‰ïu–Ɖu•s‘SÇŠ³ŽÒ‚É‚¨‚¯‚銴õ‘Îôv ‘æ45‰ñ“ú–{¬Ž™Š´õÇŠw‰ï; 2013 Oct 26-27; ŽD–y.
    59. ŽíŽsq’ˆ. ƒVƒ“ƒ|ƒWƒEƒ€uEHEC O111W’cŠ´õŽ–—á‚É‚¨‚¯‚éŒoŒ±‚©‚ç?EHEC”]ǂƬŽ™‰Èˆã‚É‚æ‚éŠë‹@‘Ήž?v ‘æ45‰ñ“ú–{¬Ž™Š´õÇŠw‰ï; 2013 Oct 26-27; ŽD–y.
    60. “n•Ó—S‹I, –x]’åŽu, •½Šâ–¾Žq, ŽíŽsq’ˆ, ”ÂàVŽõŽq, Žs“c•™Žq: human metapneumovirusŠ´õ‚ðŒ_‹@‚É”­Ç‚µ‚½dÇ methicillin-resistant Staphylococcus aureus ”x‰Š‚̈ê—á. ‘æ45‰ñ“ú–{¬Ž™Š´õÇŠw‰ï; 2013 Oct 26-27; ŽD–y.
    61. ¬‰Y@Ž, â“c“Þ, ”óŒû@Žû, ‹àŒ“O˜a, ‹{˜e—˜’j. ”x–ì‚É‚Ñ‚Ü‚ñ«Œ‹ß•a•Ï‚ð”F‚ß‚½•s‘SŒ^ìè•a‚Ì‚X‚©ŒŽ—Ž™—á. ‘æ45‰ñ“ú–{¬Ž™Š´õÇŠw‰ï; 2013 Oct 26-27; ŽD–y.
    62. Žs“c•™Žq. V¶Ž™ŠJSpŒã‚Ì‚ŽŸ”]‹@”\áŠQ. “ú–{—Õ°–ƒŒŠw‰ï‘æ33‰ñ‘å‰ï; 2013 Nov 1-3; ‹à‘ò.iµ‘Òu‰‰j
    63. ŽíŽsq’ˆ, œA–ìŒbˆê, ˆÉŒ\“ñ˜Y, ¬‰Y@Ž, Žs“c•™Žq, ‘«—§—Yˆê. “–‰È‚É‚¨‚¯‚édǬŽ™Š³ŽÒ‚Ì’·‹——£”À‘—. ‘æ16‰ñ–k—¤¬Ž™‹~‹}EW’†Ž¡—ÃŒ¤‹†‰ï; 2013 Nov 2; ‹à‘ò.
    64. ‘«—§—Yˆê. “Á•Êu‰‰u¬Ž™‚É‚¨‚¯‚éone airway, one diseasev“ú–{ƒAƒŒƒ‹ƒM[‹¦‰ï“Œ–kŽx•”Šwpu‰‰‰ï; 2013 Nov 2; å‘äD
    65. ‹àŒ“O˜a, –쑺ŒbŽq, ¯–쌰G. “–‰È‚É‚¨‚¯‚é•a“˜AŒg‚É‚æ‚錌—F•af—Ã. ‘æ8‰ñ–k—¤ƒwƒ‚ƒtƒBƒŠƒAƒZƒ~ƒi[; 2013 Nov 9; ‹à‘ò.
    66. ’†—ÑŒºˆê, ¼“c’¼“¿, ’Þ@_”V, “n•Ó—S‹I, ˆÉ“¡–õ“T, ‘«—§—Yˆê, –쌴@~, ¬—Ñ~“ñ. ‘æ27‰ñ“ú–{¬Ž™Ž‰Ž¿Œ¤‹†‰ï; 2013 Nov 9-10; •Ÿˆä.
    67. ‘«—§—Yˆê. “Á•Ê•ñu‹C“¹ˆÙ•¨`Ž–ŒÌ‚ðŒ¸‚ç‚·‚½‚ß‚É`v‘æ46‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2013 Nov 22-23; ²‰ê.
    68. ›“c^–ç, ”ÂàVŽõŽq, •½Šâ–¾Žq, “c’†•ü”ü, ‘«—§—Yˆê. •ÂÇ«‡–°Žž–³ŒÄ‹zÇŒóŒQ‚Æ”»’f‚³‚ê‚Ä‚¢‚½ŠoÁáŠQ‚Æl‚¦‚ç‚ê‚éƒ_ƒEƒ“ǂ̈ê—á. ‘æ46‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2013 Nov 22-23; ²‰ê.
    69. ¼–ì³’m, ‘«—§—Yˆê, ŒÜ\—’—²•v. ¬Ž™šb‘§‚É‚¨‚¯‚é—\–h“IŽ¡—Â̑Šú‰î“ü‚Ì—LŒø«‚ÉŠÖ‚·‚錟“¢ -ŽvtŠú‚É‚¨‚¯‚é”­ì󋵂â‹C“¹‰ß•q«‚Ì„ˆÚ‚ւ̉e‹¿‚ɂ‚¢‚Ä-. ‘æ46‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2013 Nov 22-23; ²‰ê.
    70. ‹àŒ“O˜a. ƒ[ƒNƒVƒ‡ƒbƒvu–Ɖu•s‘SÇv‘æ41‰ñ“ú–{—Õ°–ƉuŠw‰ï; 2013 Nov 27-29; ‰ºŠÖ.
    71. ‘«—§—Yˆê. ‹³ˆçu‰‰uŠÂ‹«ˆöŽq‚ƃAƒŒƒ‹ƒM[”­ÇE‘ˆ«v ‘æ63‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï; 2013 Nov 28-30; “Œ‹ž.
    72. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚é––½‹C“¹‚Ìd—v«F––½‹C“¹•a•Ï‚ð•W“I‚Æ‚µ‚½‹z“ü—Ö@v‘æ63‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï; 2013 Nov 28-30; “Œ‹ž.
    73. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uƒAƒŒƒ‹ƒM[Ž¾Š³ƒKƒCƒhƒ‰ƒCƒ“FTotal Allergist‚Æ‚µ‚Ă̬Ž™ƒAƒŒƒ‹ƒM[f—Ãv‘æ63‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï; 2013 Nov 28-30; “Œ‹ž.
    74. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uƒAƒŒƒ‹ƒM[ƒ}[ƒ` up to date ¬Ž™‚©‚ç¬l‚Ü‚ÅF¬Ž™‹CŠÇŽxšb‘§‚ƃAƒŒƒ‹ƒM[ƒ}[ƒ`v‘æ63‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï; 2013 Nov 28-30; “Œ‹ž.
    75. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‚‹´@–L, ŽO‰YŽŽu, ŠC˜VàVŒ³G, ㌴—R”üŽq, ˆÉ“¡_–¾, ‹T“c@½, Šì‘½‘º“N˜Y, “í–Ú˜a‘ã, Žè’˃ˆê˜Y. ‘S‘‚É‚¨‚¯‚éŒoŒûH•¨•‰‰×ŽŽŒ±‚É‚æ‚é—U”­Çó‚ÉŠÖ‚·‚é‘OŒü‚«’²¸. ‘æ63‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï; 2013 Nov 28-30; “Œ‹ž.
    76. ‹àŒ“O˜a. ƒVƒ“ƒ|ƒWƒEƒ€u‘¢ŒŒ•s‘S‚ð‡•¹‚·‚é–Ɖu•s‘SÇv‘æ55‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ï; 2013 Nov 29-Dec 1; •Ÿ‰ª.
    77. ‹àŒ“O˜a. Meet The Expartu–Ɖu•s‘S‚ð‡•¹‚·‚é–Ɖu•s‘SÇv ‘æ55‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ï; 2013 Nov 29-Dec 1; •Ÿ‰ª.
    78. –쑺ŒbŽq, ¯–쌰G, ‹àŒ“O˜a, ã–ì@–õ, ÎàV@L: —‘‘ƒ¬nŠïŒ`Žî‚É”­¶‚µ‚½Œ´Žn_ŒoŠOãó—t«Žîá‡(primitive neuroectodermal tumor: PNET)‚̈ê—á. ‘æ55‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ï; 2013 Nov 29-Dec 1; •Ÿ‰ª.
    79. ‘«—§—zŽq, à_“¹”ü‹I, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê. ‚¨D‚ÝÄ‚«‚É‚æ‚鬔žˆË‘¶«‰^“®—U”­ƒAƒiƒtƒBƒ‰ƒLƒV[‚ª‹^‚í‚ꂽ1—á. ‘æ40‰ñ–k—¤ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï; 2013 Dec 7; ‹à‘òD
    80. ‹{@ˆêŽu, “n•Ó—S‹I, “c’†•ü”ü, “c’‡çH, ‘«—§—Yˆê, ìè‘‘å, ‰œ‘º’ql, ’†¼@½. •s“oZ‚ð”wŒi‚Æ‚µ‚Ä‚ÌŠwK•sU‚Ìd—v«. ‘æ31‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2013 Dec 8; •xŽR.
    81. ”ÂàVŽõŽq. ‚PŒ^“œ”A•aŠ³ŽÒ‚̉h—{ŠÇ—ƒXƒLƒ‹ƒAƒbƒv‚ð–ÚŽw‚µ‚Ä. “ú–{•a‘Ô‰h—{Šw‰ï•½¬25”N“x“ŒŠCE–k—¤’n‹æǗጟ“¢‰ï; 2013 Dec 8;@•xŽR.

    2012”N

  • ’˜‘
    1. Žs“c•™ŽqF‚ŒŒˆ³Ç. u¡“ú‚̬Ž™Ž¡—ÃŽwj‘æ15”Åv ‘åŠÖ••F‘¼•Ò, ˆãŠw‘‰@, “Œ‹ž, 495-496, 2012.
    2. Žs“c•™ŽqF’m‚Á‚Ä‚¨‚«‚½‚¢“à‰ÈÇŒóŒQ. “à‰È@109Šª6†‘‘å†@BarthÇŒóŒQ, “ì]“°, “Œ‹ž, 1037-1038, 2012.
    3. Žs“c•™ŽqFVES‘Ÿ•af—Ãvƒ‰ƒNƒeƒCƒXƒVƒŠ[ƒY18.@¬l‚É‚È‚Á‚½æ“V«SŽ¾Š³. ŽÐ‰ï“I–â‘è.VŠ_‹`•vA[’J—²•Ò, •ªŒõ“°, “Œ‹ž, 152-156, 2012.
    4. ‘«—§—Yˆê: ׋CŠÇŽx‰ŠDu¬Ž™‰Èf—ÃEŽ¡—ÃŽwjv‰““¡•¶•v•Ò, ’†ŽR‘“X, “Œ‹ž, 502-505, 2012.
    5. ‹àŒ“O˜a: Œ´”­«–Ɖu•s‘SÇ. u¡“ú‚̬Ž™Ž¡—ÃŽwj‘æ15”Åv ‘åŠÖ••F‘¼•Ò, ˆãŠw‘‰@, “Œ‹ž, 282-283, 2012.
    6. ‹àŒ“O˜a: -–Ɖu•s‘SÇ-@4.–Ɖu’²ßáŠQ.u¬Ž™‚Ì”­”MA to Z-f’fŽ¡—ÂÌTips‚ÆPitfalls-v Œ´@Žõ˜Y•Ò, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 174-177, 2012.
    7. ‹àŒ“O˜a: 4.X˜A½ƒŠƒ“ƒp‘BÇŒóŒQ(XLP).uŽ©ŒÈ‰ŠÇ«Ž¾Š³?Ž©‘R–Ɖu•s‘SÇ‚Æ‚»‚̋߉Ž¾Š³v, ‹ß“¡’¼ŽÀA•½‰Ær’j•Ò, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 163-165, 2012.
    8. ‹àŒ“O˜a: Case 15. X˜A½ƒŠƒ“ƒp‘BÇŒóŒQ(XLP).uŽ©ŒÈ‰ŠÇ«Ž¾Š³?Ž©‘R–Ɖu•s‘SÇ‚Æ‚»‚̋߉Ž¾Š³v, ‹ß“¡’¼ŽÀA•½‰Ær’j•Ò, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 230-232, 2012.
    9. ŽíŽsq’ˆ, ‹{˜e—˜’j: Œ´”­«–Ɖu•s‘SÇŒóŒQ.@1D‰t«–Ɖu•s‘S‚ðŽå‚Æ‚·‚鎾Š³DuƒJƒ‰[”Å@“à‰ÈŠwv–å˜e@F, ‰iˆä—ÇŽO•Ò, ¼‘º‘“X, “Œ‹ž, 1321-1323, 2012.
    10. ¼“c’¼“¿, ‹{˜e—˜’j: -–Ɖu•s‘SÇ-@2.Žå‚Æ‚µ‚ÄR‘Ì•s‘S‚ðŽ¦‚·Ž¾Š³.u¬Ž™‚Ì”­”MA to Z-f’fŽ¡—ÂÌTips‚ÆPitfalls-v Œ´@Žõ˜Y•Ò, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 160-166, 2012.
    11. ¼“c’¼“¿, ‹àŒ“O˜a: ƒRƒƒiƒEƒCƒ‹ƒX, ƒuƒjƒAƒEƒCƒ‹ƒX, JCƒEƒCƒ‹ƒX, ƒvƒŠƒIƒ“. u¬Ž™Š´õǃ}ƒjƒ…ƒAƒ‹v,@“ú–{¬Ž™Š´õÇŠw‰ï•Ò, “Œ‹žˆãŠwŽÐ, “Œ‹ž, 548-561, 2012.
  • Œ´’˜
    1. Kanegane H., Yang X., Zhao M., Yamato K., Inoue M., Hamamoto K., Kobayashi C., Hosono A., Ito Y., Nakazawa Y., Terui K., Kogawa K., Ishii E., Sumazaki R., and Miyawaki T.: Clinical features and outcome of X-linked lymphoproliferative syndrome type1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis. Pediat Allergy Immunol 23: 488-493, 2012.
    2. Tanaka C, Matsui M, Uematsu A, Noguchi K, Miyawaki T. Developmental Trajectories of the Fronto-Temporal Lobes from Infancy to Early Adulthood in Healthy Individuals. Dev Neurosci. 2012;34(6):477-87.
    3. Miya K., Shimojima K., Sugawara M., Shimada S., Tsuri H., Harai-Tanaka T., Nakaoka S., Kanegane H., Miyawaki T., and Yamamoto T.: A de novo interstitial deletion of 8p11.2 including ANK1 identified in a patient with spherocytosis, psychomotor developmental delay, and distinctive facial features. Gene 506: 146-149, 2012.
    4. Harai T., Inoue R., Fujita Y., Tanaka A., Horio M., Hashimoto K., Hongou K., Miyawaki T., and Mori H.: Decreased susceptibility to seizures induced by pentylenetetrazole in serine racemase knockout mice. Epilepsy Res 102: 180-187, 2012.
    5. Higuchi O., Adachi Y., Itazawa T., Ito Y., Ohya Y., Odajima H., Akasawa A., and Miyawaki T.: Relationship between rhinitis and nocturnal cough in school children. Pediatr Allergy Immunol 23: 562-566, 2012.
    6. Higuchi O., Okabe M., Yoshida T., Fathy M., Saito S., Miyawaki T, and Nikaido T.: Stemness of human wharton's jelly mesenchymal cells is maintained by floating cultivation. Cell Reprogram 14: 448-455,, 2012.
    7. Okabe Y., Adachi Y., Itazawa T., Yoshida K., Ohya Y., Akasawa A., and Miyawaki T.: Association between obesity and asthma in Japanese preschool children. Pediatr Allergy Immunol 23: 550-555, 2012.
    8. Otsubo K., Horie S., Nomura K., Miyawaki T., Abe A., and Kanegane H.: Acute promyelocytic leukemia following aleukemic leukemia cutis harboring NPM/RARA fusion gene. Pediatr Blood Cancer 59: 959-960, 2012.
    9. Ibuki K., Watanabe K., Yoshimura N., Kakimoto T., Matsui M., Yoshida T., Origasa H., and Ichida F.: The improvement of hypoxia correlates with neuroanatomic and developmental outcomes: Comparison of midterm outcomes in infants with transposition of the great arteries or single-ventricle physiology. J Thorac Cardiovasc Surg 143: 1077-1085, 2012.
    10. Yang X., Wada T., Imadome K., Nishida N., Mukai T., Fujiwara M., Kawashima H., Kato F., Fujiwara S., Yachie A., Zhao X., Miyawaki T., and Kanegane H.: Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2. Herpesviridae 3: 1, 2012.
    11. Yang X., Kanegane H., Nishida N., Imamura T., Hanamoto K., Miyashita R., Imai K., Nonoyama S., Sanayama K., Yamaide A., Kato F., Nagai K., Ishii E., van Zelm MC., Latour S., Zhao XD., and Miyawaki T.: Clinical and Genetic Characteristics of XIAP Deficiency in Japan. J Clin Immunol 32: 411-420, 2012.
    12. Yang X., Kanegane H., Miyawaki T., and Zhao Z.: Progress of diagnosis and treatment of X-linked inhibitor of apoptosis deficiency. Chin J Pediatr 50: 428-430, 2012.
    13. Onouchi Y., Ozaki K., Burns JC., Shimizu C., Terai M., Hamada H., Honda T., Suzuki H., Suenaga T., Takeuchi T., Yoshikawa N., Suzuki Y., Yasukawa K., Ebata R., Higashi K., Saji T., Kemmotsu Y., Takatsuki S., Ouchi K., Kishi F., Yoshikawa T., Nagai T., Hamamoto K., Sato Y.,Honda A., Kobayashi H., Sato J., Shibuta S., Miyawaki M., Oishi K., Yamaga H., Aoyagi N., Iwahashi S., Miyashita R., Murata Y., Sasago K., Takahashi A., Kamatani N., Kubo M., Tsunoda T., Hata A., Nakamura Y., Tanaka T; Japan Kawasaki Disease Genome Consortium, Abe J., Kobayashi T., Arakawa H., Ichida F., Nomura Y., Miura M., Ikeda K., Hara T., Fukazawa R., Ogawa S., Hamaoka K. ; US Kawasaki Disease Genetics Consortium, Newburger JW., Baker AL., Rowley AH., Shulman ST., Melish ME., Mason WH., Takahashi M., Tremoulet AH.: A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet 44: 517-521, 2012.
    14. Kobayashi T., Saji T., Otani T., Takeuchi K., Nakamura T., Arakawa H., Kato T., Hara T., Hamaoka K., Ogawa S., Miura M., Nomura Y., Fuse S., Ichida F., Seki M., Fukazawa R., Ogawa C., Furuno K., Tokunaga H., Takatsuki S., Gara S., Morikawa A; on behalf of the RAISE study group investigators.: Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. LANCET 379: 1613-1620, 2012.
    15. Honda F., Kano H., Kanegane H., Nonoyama S., Kim ES., Lee ES., Takagi M., Mizutani S., and Morio T.: The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol 13: 369-378, 2012.
    16. Chida A., Shintani M., Yagi H., Fujiwara M., Kojima Y., Sato H., Imamura S., Yokozawa M., Onodera N., Horigome H., Kobayashi T., Hatai Y., Nakayama T., Fukushima H., Nishiyama M., Doi S., Ono Y., Yasukouchi S., Ichida F., Fujimoto K., Ohtsuki S., Teshima H., Kawano T., Nomura Y., Gu H., Ishiwata T., Furutani Y., Inai K., Saji T., Matsuoka R., Nonoyama S., and Nakanishi T.: Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers. Am J Cardiol 110: 586-593, 2012.
    17. Uchiyama T., Yoshimura K., Kaneko K., Nemoto S., Ichida F., Hata Y., and Nishida N.: Surgical repair of left ventricular noncompaction in a patient with a novel mutation of the Myosin heavy chain 7 gene. Tohoku J Exp Med 228: 301-304, 2012.
    18. Yamanaka K., Higuma T., Watanabe K., Okada Y., Ichida F., and Yoshimura N. : Congenital sternal cleft. J Pediatr Surg 47: 2143-2145, 2012.
    19. Shimizu M., Kuroda M., Sakashita N., Konishi M., Kaneda H., Igarashi N., Yamahana J., Taneichi H., Kanegane H., Ito M., Saito S., Ohta K., Taniguchi T., Furuichi K., Wada T., Nakagawa M., Yokoyama H., and Yachie A.: Cytokine profiles of patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine 60: 694-700, 2012.
    20. Momoi N., Chang B., Takeda I., Aoyagi Y., Endo K., and Ichida F.: Differing clinical courses and outcomes in two siblings with Barth syndrome and left ventricular noncompaction. Eur J Pediatr 171: 515-520, 2012.
    21. Otsuka H., Arimura T., Abe T., Kawai H., Aizawa Y., Kubo T., Kitaoka H., Nakamura H., Nakamura K., Okamoto H., Ichida F., Ayusawa M., Nunoda S., Isobe M., Matsuzaki M., Yoshinori LD., Fukuda K., Sasaoka T., Izumi T., Ashizawa N., and Kimura A.: Prevalence and distribution of sarcomeric gene mutations in Japanese patients with familial hypertrophic cardiomyopathy. Circ J 76: 453-461, 2012.
    22. Kawamura M., Kusano A., Furuya A., Hanai N., Tanigaki H., Tomita A., Horiguchi A., Nagata K., Itazawa T., Adachi Y., Okabe Y., Miyawaki T., and Kohno H.: New sandwich-type enzyme-linked immunosorbent assay for human MxA protein in a whole blood using monoclonal antibodies against GTP-binding domain for recognition of viral infection. J Clin Lab Anal 26: 174-183, 2012.
    23. Oshima K., Nagase T., Imai K., Nonoyama S., Obara M., Mizukami T., Nunoi H., Kanegane H., Kuribayashi F., Amemiya S., and Ohara O.: A dual reporter splicing assay using Halo Tag-containing proteins. Curr Chem Genomics 6: 27-37, 2012.
    24. Shimada S., Miya K., Oda N., Watanabe Y., Kumada T., Sugawara M., Shimojima K., and Yamamoto T.: An unmasked mutation of EIF2B2 due to submicroscopic deletion of 14q24.3 in a patient with vanishing white matter disease. Am J Med Genet A 158: 1771-1777, 2012.
    25. ˆÉ“¡–õ“T, ‘«—§—zŽq, ”óŒû@Žû, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§’·ŠúŠÇ—‚É‚¨‚¯‚éƒXƒeƒbƒvƒ_ƒEƒ“Žž‚̌ċCˆêŽ_‰»’‚‘f‚É‚æ‚鑈«‚Ì—\‘ª‚ÉŠÖ‚·‚錟“¢. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 26: 258-265, 2012.
    26. ‹{@ˆêŽu, ‚è–ƒ”ü, âV“¡˜a—R, ”‘òŽõŽq, 㨌hˆê˜Y, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: V¶Ž™?“ûŽ™‚ւ̃rƒ^ƒ~ƒ“K—\–h“Š—^‚ÉŠÖ‚·‚é•ÛŒìŽÒ‚̈ӎ¯’²¸. “ú–{¬Ž™‰ÈŠw‰ïŽ116F1554-1557, 2012.
  • Ç—á•ñ
    1. Matsukura H., Ibuki K., Nomura K., Higashiyama H., Takasaki A., Miyawaki T., Aikawa A., and Kanegane H.: Intracranial calcification in a uremic infant with Wilmsf tumor in a solitary kidney. CEN Case Rep 1: 86-89. 2012.
    2. Nakaoka H., Kanegane H., Taneichi H., Miya K., Yang X., Nomura K., Takezaki S., Yamada M., Ohara O., Kamae C., Imai K., Nonoyama S., Wada T., Yachie A., Hershfield MS., Ariga T., and Miyawaki T.: Delayed onset adenosine deaminase deficiency associated with acute disseminated encephalomyelitis. Int J Hematol 95: 692-696, 2012.
    3. Yamanaka K., Yoshimura N., Higuma T., and Ichida F.: Pseudoaneurysm following percutaneous balloon angioplasty for aortic arch recoarctation after the Norwood procedure. Gen Thorac Cardiovasc Surg 60: 305-307, 2012.
    4. Kanazawa Y., Asai M., Adachi Y., Yoshida T., Itazawa T., Shimao A., Inomata T., Abe H., and Watanabe Y.: Retropharyngeal abscess in a neonate: A case report and literature review. Int J Pediatr Otorhi 7: 115-118, 2012.
    5. Mohammadzadeh I., Yeganeh M., Aghamohammadi A., Parvaneh N., Behniafard N., Abolhassani H., Tabassomi F., Hemmat M., Kanegane H., Miyawaki T., Ohara O., and Rezaei N.: Severe primary antibody deficiency due to a novel mutation of micro heavy chain. J Investig Allergol Clin Immunol 22: 78-79, 2012.
    6. ”ÂàVŽõŽq, ’†’Ø‹v”T, ‹{@ˆêŽu, ŽíŽsq’ˆ, ‘«—§—Yˆê, a’JLŽq, ‹{˜e—˜’j: ”x‰Š‚ðŒ_‹@‚É‹}«ŒÄ‹z‹‡”—ÇŒóŒQ‚ÉŽŠ‚èAˆêŽ_‰»’‚‘f‹z“ü‚𓱓ü‚µ‚½3—á. “ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ïŽGŽ 23: 21-28, 2012.
    7. ¯–쌰G, ‹àŒ“O˜a, ¼“c’¼“¿, –쑺ŒbŽq, ‘å‰ê³ˆê, ‹{˜e—˜’j: R‹Û–ò“Š—^‚É‚æ‚莡–ü‚µ“¾‚½Ä”­«ŠÌ”^á‡‚ð‡•¹‚µ‚½–«“÷‰èŽîǂ̈ê—á. ¬Ž™Š´õ–Ɖu 24: 175-179, 2012.
    8. “¹–ì~Žq, ’†oË‘ã, ²’|ˆÉ’ÃŽq, ¼–ìŽåáÁ, ˆÀ‘º@•q, –F‘º’¼Ž÷, –쑺ŒbŽq, ‹àŒ“O˜a: dÇ•¡‡–Ɖu•s‘SÇ2—á‚É‚¨‚¯‚铯Žíœ‘×–EˆÚAŒã‚̃LƒƒŠƒYƒ€‰ðÍ. “ú–{—AŒŒ×–EŽ¡—Êw‰ïŽ 58: 704-709, 2012.
  • ‘à
    1. Žs“c•™Žq: “ÁW@¬Ž™–«Ž¾Š³‚̶ŠˆŽw“±?Å‹ß‚Ì’mŒ©‚©‚ç?@4. –«SŽ¾Š³ 3) S‹ØÇ. ¬Ž™‰È—Õ° 65: 709-717, 2012.
    2. Žs“c•™Žq: ¬læ“V«SŽ¾Š³‚Í’N‚ªf‚é‚Ì‚©`zŠÂŠí“à‰È‚ƬŽ™zŠÂŠí‰È‚̃Rƒ‰ƒ{ƒŒ[ƒVƒ‡ƒ“‚Ì•K—v«`. S‘Ÿ@4: 1-2, 2012.
    3. Žs“c•™Žq: ‘ål‚É‚È‚è‚ä‚­ŒN‚½‚¿‚Ö`æ“V«SŽ¾Š³‚Ì_Œo”­’B—\Œã`. “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ28: 293-294, 2012.
    4. Žs“c•™Žq: æ“V«SŽ¾Š³‚ÌŽüŽYŠúŠÇ—ƒAƒbƒvƒf[ƒg`æ“V«SŽ¾Š³‚ւ̃pƒŠƒrƒYƒ}ƒu“Š—^`. ŽüŽYŠúˆãŠw 10: 1349-1351, 2012.
    5. Žs“c•™Žq: Ž„‚̃‚ƒ`ƒx[ƒVƒ‡ƒ“ u‘f°‚炵‚¢’‡ŠÔ‚Æ‹¤‚ÉŒ³‹C‚É‚È‚Á‚½Žq‚Ç‚à‚ª‚É‚Á‚±‚è΂¤uŠÔ‚ðŒ©‚é‚½‚ß‚Év@Fetal & Neonatal Medicine 4: 47-49, 2012.
    6. ‘«—§—Yˆê: ¬Ž™šb‘§Ž¡—Âɂ¨‚¯‚é‹z“üƒXƒeƒƒCƒh–òFV‚½‚ÈŽg—p•û–@. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 26: 80-84, 2012.
    7. ‘«—§—Yˆê: ‹z“üƒXƒeƒƒCƒhÜ–òƒAƒhƒIƒ“‚̃|ƒCƒ“ƒg. ¬Ž™‰Èf—à 75: 1707-1712, 2012.
    8. ‘«—§—Yˆê: ‹z“üƒfƒoƒCƒXi‹z“üŠí?ƒXƒy[ƒT[j‚ÌŽí—Þ‚ÆŽg‚¢•û. šb‘§ 25: 153-157, 2012.
    9. ‘«—§—Yˆê, â–{—´—Y, à_è—Y•½: ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2012‚ɂ‚¢‚Ä -‹z“ü—Ö@FƒfƒoƒCƒX‚Æ‚»‚ÌŒø‰Ê“I‚ÈŽg‚¢•û-DƒAƒŒƒ‹ƒM[E–Ɖu 19: 730-737, 2012.
    10. ‘«—§—Yˆê, ‹´–{ŒõŽi: “Œ“ú–{‘åkЂƃAƒŒƒ‹ƒM[Ž¾Š³FŽx‰‡Šˆ“®•ñ ”íÐŽ™‚Ö–hƒ_ƒj‚Ê‚¢‚®‚é‚Ý‚ð‘—‚éƒvƒƒWƒFƒNƒgDƒAƒŒƒ‹ƒM[E–Ɖu 19: 566-570, 2012.
    11. ‘«—§—Yˆê: ‰Æ’ë‚Ì’†‚ł̓Rƒ“ƒvƒ‰ƒCƒAƒ“ƒXH “ú–{¬Ž™“šb‘§?ƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ïŽ 10: 267-268, 2012.
    12. ‘«—§—Yˆê: ¬Ž™‚ðŽæ‚芪‚­”–â‘èFЊQŽž‚Ìšb‘§‚ð‚Í‚¶‚ß‚Æ‚·‚éƒAƒŒƒ‹ƒM[Ž¾Š³‚ÌŽ¡—ÃEŠÇ—D AIR 11: 6-7, 2012.
    13. ‘«—§—Yˆê: ‰ïˆõ‚©‚çu‚ ‚܂肪‚ñ‚΂ç‚È‚¢‚Å‚­‚¾‚³‚¢v. “ú–{¬Ž™‰Èˆã‰ï•ñ 57: 119-120, 2012.
    14. ‘«—§—Yˆê: •ÛˆçŠ‚É‚¨‚¯‚éƒAƒŒƒ‹ƒM[‘ΉžƒKƒCƒhƒ‰ƒCƒ“‚ɂ‚¢‚Ä. ˆã•ñ‚Æ‚â‚Ü 1557: 10-11, 2012.
    15. ‹àŒ“O˜a: R‘ÌŽY¶•s‘SÇ‚É‚¨‚¯‚é—Õ°ˆâ“`Šw. “ú–{ˆâ“`ƒJƒEƒ“ƒZƒŠƒ“ƒOŠw‰ïŽ 33: 55-61, 2012.
    16. ‹àŒ“O˜a: “ÁW@¬Ž™–«Ž¾Š³‚̶ŠˆŽw“±?Å‹ß‚Ì’mŒ©‚©‚ç?@9. ŒŒ‰t?–ƉuŽ¾Š³ 3) Œ´”­«–Ɖu•s‘SÇ. ¬Ž™‰È—Õ° 65: 819-824, 2012.
    17. ‹àŒ“O˜a, ŽíŽsq’ˆ, ‹{˜e—˜’j: ’°ŠÇoŒŒ«‘å’°‹ÛO111‚ÌW’c”­¶‚©‚çŠw‚ñ‚¾‚±‚Æ. ¬Ž™Š´õ–Ɖu 24: 215-222, 2012.
    18. ‹àŒ“O˜a, –쑺ŒbŽq: ¬Ž™‚ª‚ñ‚̃g[ƒ^ƒ‹ƒPƒA‚ð‚ß‚´‚µ‚Ä. •xŽRŽsˆãŽt‰ï•ñ 490: 26-31, 2012.
    19. ”ÂàVŽõŽq: ƒAƒŒƒ‹ƒM[‘Š’kŽºQ&Au¬Ž™‰È@šb‘§‚ª‹^‚í‚ꂽê‡A‘Šú‚ÉŽ¡—ÂðŠJŽn‚µ‚½•û‚ªŽ©‘R—ð‚Í—Ç‚¢‚Å‚·‚©Hv@ƒAƒŒƒ‹ƒM[‚Ì—Õ° 32: 369, 2012.
    20. ŽíŽsq’ˆ: `ƒI[ƒo[ƒrƒ…[`•xŽREHEC/O111ƒAƒEƒgƒuƒŒƒCƒN‚©‚ç‚Ý‚½ƒŠƒRƒ“ƒrƒiƒ“ƒgƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“»Ü‚É‚¨‚¯‚é‰Â”\«. Thrombosis Medicine 2: 302-305, 2012.
    21. ”ª–ØMˆê, ‹{@ˆêŽu: ŠO—ˆ¬Ž™‰È‚É‚¨‚¯‚é”­’BáŠQ‚ւ̃Aƒvƒ[ƒ`. ŠO—ˆ¬Ž™‰È 15: 173-179, 2012.
    22. ¯–쌰G, ‹àŒ“O˜a: Ž©ŒÈ–ƉuƒŠƒ“ƒp‘BÇŒóŒQ. ¬Ž™“à‰È 44(‘): 236-237,@2012.
    23. ¼è‘½ç‘ã, ¼ˆäŽOŽ}, Žs“c•™Žq: ACHD‚ÌS—Šw“I“Á’¥‚ÆS—“IƒPƒA. Heart 12: 71-78, 2012.
    24. ‹ß“¡’¼ŽÀ, Ž›–{‹M‰p, ¼ˆä‰iŽq, ‰Á“¡‘Pˆê˜Y, Ôâ@“O, ÔàV@W, ˆÉ“¡_–¾, ‘«—§—Yˆê, ¡ˆäF¬, ‘å–îKO, ŸÀr—Y, “ì•”Œõ•F, “¡àV—²•v, “ñ‘º¹Ž÷, ¼ˆä–Ò•F, ŽO‰YŽŽu, Xì‚Ý‚«: “Œ“ú–{‘åkÐFˆã—ÃŽx‰‡‚ÌÝ‚è•ûFƒAƒŒƒ‹ƒM[Š³Ž™‚ւ̑Ήž. “ú–{¬Ž™‰Èˆã‰ï•ñ 43: 57-62, 2012.
    25. ‹ß“¡’¼ŽÀ, Ž›–{‹M‰p, ¼ˆä‰iŽq, ‰Á“¡‘Pˆê˜Y, Ôâ@“O, ÔàV@W, ˆÉ“¡_–¾, ‘«—§—Yˆê, ¡ˆäF¬, ‘å–îKO, ŸÀr—Y, “ì•”Œõ•F, “¡àV—²•v, “ñ‘º¹Ž÷, ¼ˆä–Ò•F, ŽO‰YŽŽu, Xì‚Ý‚«: “Œ“ú–{‘åkЂƃAƒŒƒ‹ƒM[Ž¾Š³FŽx‰‡Šˆ“®•ñ “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï‚Æ‚µ‚Ä‚ÌŽæ‘g‚Ý. ƒAƒŒƒ‹ƒM[E–Ɖu 19: 572-576, 2012.
    26. ‹à’J‹v”üŽq, ‘«—§—Yˆê: ‰©»‚̬Ž™šb‘§‚É—^‚¦‚é‰e‹¿. ƒAƒŒƒ‹ƒM[‚Ì—Õ° 32: 996-1001, 2012.

  • 2012”NŠw‰ï•ñ
    1. Adachi Y.: Aproach to anaphylaxis and anaphylactic shock. Paediatric Asthma and Allergy Workshop in Myanmar. 2012, 1, 26-27, Yangon, Myanmar.
    2. Adachi Y.: Management of asthma: acute and long term. Paediatric Asthma and Allergy Workshop in Myanmar. 2012, 1, 26-27, Yangon, Myanmar.
    3. Adachi Y., Okabe Y., Itazawa T., Yoshida K., Ohya Y., Odajima H., Akasawa A., Miyawaki T.: Impact of rhinitis on asthma in Japanese children. American academy of Allergy Asthma & Immunology 2012 Annual meeting, 2012, 3, 2-6, Orlando, U.S.A.
    4. Kanegane H.: Lesson learned from Epstein-Barr virus. 2012 The Korean society of pediatrics infectious disease, 2012, 5, 20, Seoul. (Invited Lecture)
    5. Ichida F., Brunelli L., Bowles NE., Sakai N., Hamaoka A., and Yost HJ.: The scaffold adapter protein 14-3-3 is involved in human left ventricular noncompaction. 2012 Pediatric Academic Societies Annual Meeting, 2012, 4.28- 5.1, Boston, U.S.A.
    6. Miyawaki T., Kanegane H., Imai K., Yamada M., Takada H., Nonoyama S., Ariga T., Bexon M., Rojavin M., Kobayashi M., and Hara T.: Efficacy and safety of Hizentra, a subcutaneous immune globulin, in Japanese patients with primary immunodeficiency diseases. The 15th Biennial Meeting of the European Society of Immunodeficiencies, 2012, 10, 3-6, Florence, Italy.
    7. Kanegane H., Nomura K., Hoshino A.,and Miyawaki T.: Neutropenia and myeloid dysplasia in a patient with late-onset adenosine deaminase deficiency. The 15th Biennial Meeting of the European Society of Immunodeficiencies, 2012, 10, 3-6, Florence, Italy.
    8. Nishida N., Yang X., Kanegane H., Sanayama K., Goi K., Sugita K., Kato K., and Miyawaki T.: X-linked Dysgammaglobulinemia caused by hypomorphic XIAP mutation. The 15th Biennial Meeting of the European Society of Immunodeficiencies, 2012, 10, 3-6, Florence, Italy.
    9. Kanegane H.: X-linked dysgammaglobulin caused by hypomorphic XIAP mutation. A conference for medical research on X-linked lymphoproliferative disease 2012, 2012, 10, 8, London.
    10. Kanegane H., Yang X., Nishida N., Ishii E., and Miyawaki T.: Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) and type2 (XIAP deficiency) in Japan. 28th Annual meeting of the Histiocyte society, 2012, 10, 10-12, London.
    11. Yoshida T., Takasaki I., Kanegane H., Inomata S., Ito Y., Tamura K., Makimoto M., Saito S., and Miyawaki T.: Gene expression profiling in umbilical cord blood from small for gestational age neonates indicates prediction of adult diseases. The 3rd International Congress of Union of European Neonatal & Perinatal Societies, 2012, 11, 14-17, Porto, Portugal.
    12. Tamura K, Igarashi N., Futatani T., Yoshida T., and Miyawaki T.: Hypernatremia and body weight loss in exclusively breast-fed neonates. The 3rd International Congress of Union of European Neonatal & Perinatal Societies, 2012, 11, 14-17, Porto, Portugal.
    13. Ichida F., Chang B, Gorbea C., Lezin G., Sakai N., Kogaki S., Otomo T., Okinaga T., Hata Y., Nishida N., Yost J., Bowles NE., and Brunelli L.: 14-3-3ƒÃ gene variants in left ventricular noncompaction and hypoplasia of the corpus callosum. The 85th Scientific sessions of AHA 2012, 2012, 11, 16-20, Los Angels, U.S.A.
    14. Hashimoto I., Nakagawa H., Shibata K., Kaneda, H. Saito K., Watanabe K., Ozawa S. Ichida F., and Yoshimura N.: Complementary relationship of right ventricular contraction between longitudinal and radial directions. The 85th Scientific sessions of AHA 2012, 2012, 11, 16-20, Los Angels, U.S.A.
    15. —k@žF, ‹àŒ“O˜a, ‹{˜e—˜’j, Zhao X., Jiang L.: A boy with recurrent skin abcess and respiratory tract infection: a novel immunodeficiency? . ‘æ5‰ñ“ú–{–Ɖu•s‘SÇŒ¤‹†‰ï, 2012, 1, 21, “Œ‹ž.
    16. ¯–쌰G, ‹àŒ“O˜a, ‘å’ØŒc•ã, ¼‘q—TŠì, ‹{˜e—˜’j: œ‘ˆÚAŒã‚Ét‘gD‚̉ü‘P‚ð”F‚ß‚½X˜A½«ŒŒ¬”ÂŒ¸­Ç‡IgAtǂ̈ê—á. ‘æ5‰ñ“ú–{–Ɖu•s‘SÇŒ¤‹†‰ï, 2012, 1, 21, “Œ‹ž.
    17. ¯–쌰G, “¡“cˉ›, –쑺ŒbŽq, ‹àŒ“O˜a, ‘å’ØŒc•ã, ‹{˜e—˜’j, ÎàV@L, ã–ì@–õ: —‘‘ƒŒ´”­PNET‚Ì‚P—á. ‘æ35‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ï, 2012, 2, 4, ‹à‘ò.
    18. ¯–쌰G, “n•Ó—S‹I, –xìT“ñ˜Y, ‹àŒ“O˜a, ‹{˜e—˜’j, X@‰ë—º: ƒŒƒCƒm[Œ»Û‚Ì‚Ý‚ª‘J‰„‚µ‚Ä‚¢‚鬇«Œ‹‡D•a‚Ì‚P—á. ‘æ35‰ñ–k—¤¬Ž™ƒŠƒEƒ}ƒ`Œ¤‹†‰ï, 2012, 2, 18, ‹à‘ò.
    19. ‹àŒ“O˜a, ˜`@˜a”ü, ˆäã‰ë”ü, •l–{˜aŽq, ¬—ÑçŒb, ז숟Žq, ˆÉ“¡”\´, ’†‘ò—mŽO, ƈäŒN“T, Žqì˜aG, ΈäžÄˆê, ‹{˜e—˜’j: X˜A½ƒŠƒ“ƒp‘BÇŒóŒQƒ^ƒCƒv1(SAPŒ‡‘¹Ç)‚ɑ΂·‚é‘¢ŒŒŠ²×–EˆÚA. ‘æ34‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï, 2012, 2, 24-25, ‘åã.
    20. –쑺ŒbŽq, ŽíŽsq’ˆ, ‹àŒ“O˜a, —L‰ê@³, ‹{˜e—˜’j: œ‘”ñ”j‰ó“I‘Oˆ’u‚É‚ÄHLAˆê’v“¯–E‚æ‚蓯Žíœ‘ˆÚA‚ðs‚Á‚½’x”­Œ^ADAŒ‡‘¹Ç‚Ì1—á. ‘æ34‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï, 2012, 2, 24-25, ‘åã.
    21. ŽíŽsq’ˆ, ‹{˜e—˜’j: ’ጌ“œ¨‡Œã‚Ɉӎ¯áŠQA‹Ø—͒ቺ‚ÌÄ”R‚ð”F‚ß‚½ÛHáŠQ‚Ì1—á. ‘æ39‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï, 2012, 2.28-3.1, ç—t.
    22. ŽíŽsq’ˆ: ’°ŠÇoŒŒ«‘å’°‹ÛO-111W’cŠ´õ‚Ì—Õ°‘œ. ‘æ51‰ñŠ´õ«’°‰ŠŒ¤‹†‰ï, 2012, 3, 10, “Œ‹ž.
    23. —k@žF, ¼“c’¼“¿, ‹{˜e—˜’j, ‹àŒ“O˜a, ˜a“c‘׎O, ’J“à]ºG, ¡—¯Œªˆê, “¡Œ´¬‰x: Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-assosiated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2. ‘æ21‰ñEBƒEƒCƒ‹ƒXŠ´õÇŒ¤‹†‰ï, 2012, 3, 17, “Œ‹ž.
    24. ¯–쌰G, –x]’åŽu, ‘å’ØŒc•ã, ŽíŽsq’ˆ, ‹àŒ“O˜a, ‹{˜e—˜’j: ŠÌŽî‘åAŠÌ‹@”\áŠQ‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚½ŠÌŒ^“œŒ´•a‚Ì1—á. ‘æ304‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï, 2012, 3, 11, ‹à‘ò.
    25. ŽíŽsq’ˆ, –x]’åŽu, –쑺ŒbŽq, ‹àŒ“O˜a, ¬¼“¹—Y, ŽR“cŒbŽq, ‘¾“c–M—Y, ’J“à]ºG, ˜ZŽÔ@’, ‹{˜e—˜’j:’°ŠÇoŒŒ«‘å’°‹ÛO-111W’cŠ´õ‚É‚¨‚¯‚é‹}«”]ǂ̃AƒEƒgƒuƒŒƒCƒN‘Ήž. ‘æ115‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2012, 4, 20-22, •Ÿ‰ª.
    26. ‘«—§—zŽq, ”óŒû@Žû, ‘«—§—Yˆê, ‹{˜e—˜’j, ŽsŠÛ’q_: “û—cŽ™‚Ì‹C“¹ˆÙ•¨Ž–ŒÌ‚ð—\–h‚·‚邽‚ß‚Ì•ÛŒ’Žt‚É‚æ‚éŽw“±‚ÉŠÖ‚·‚é’²¸. ‘æ115‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2012, 4, 20-22, •Ÿ‰ª.
    27. —k@žF, ¼“c’¼“¿,‹àŒ“O˜a, ‹{˜e—˜’j: ‘æ115‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2012, 4, 20-22, •Ÿ‰ª.
    28. ’‡‰ª²’qŽq, “c’†•ü”ü, ’‡‰ª‰pK, ”ÂàVŽõŽq, ŽÄ“c@K, ’Ô¦áÁˆê, ‹{˜e—˜’j: ‹}«ƒoƒ‹ƒvƒŽ_’†“łɑ΂µL-ƒJƒ‹ƒjƒ`ƒ““Š—^‚ðs‚Á‚½‚PÎ’jŽ™—á. ‘æ115‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2012, 4, 20-22, •Ÿ‰ª.
    29. ‰ª•”^Žq, “c’†•ü”ü, –x]’åŽu, ‹{@ˆêŽu, ‹g“cär, “ñ’J@•, ‹{˜e—˜’j: “–‰@‚ÅŒoŒ±‚µ‚½ƒVƒgƒŠƒ“Œ‡‘¹Ç‚Ì2—á. ‘æ115‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2012, 4, 20-22, •Ÿ‰ª.
    30. Žs“c•™Žq: “Á•Êu‰‰uS‹Øãk–§‰»áŠQ‚Ì—Õ°v. ‘æ48‰ñH“cŒ§zŠÂŠíŽ¾Š³Ž¡—ÃŒ¤‹†‰ï, 2012, 5, 11, H“c.
    31. ”óŒû@Žû, ŽíŽsq’ˆ, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ‹C“¹ˆÙ•¨‚ɑ΂·‚é•ÛŒìŽÒ‚Ì”FŽ¯‚ÆŽ–ŒÌ—\–h‚Ì‚½‚ß‚Ì•ÛŒ’Žw“±‚ÉŠÖ‚·‚é’²¸. ‘æ13‰ñ–k—¤¬Ž™‹~‹}?W’†Ž¡—ÃŒ¤‹†‰ï, 2012, 5, 12, ‹à‘ò.
    32. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‚É‚¨‚¯‚éã‹C“¹E‰º‹C“¹‰ŠÇFŽ¡—ÂÌl‚¦•ûv ‘æ24‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2012, 5, 12-13, ‘åã.
    33. ‘«—§—YˆêDƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“‚ÉŠî‚¢‚½Ž¡—ÃFƒKƒCƒhƒ‰ƒCƒ“‚Ì”äŠrv ‘æ24‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2012, 5, 12-13, ‘åã.
    34. ”ÂàVŽõŽq, ”óŒû@Žû, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ŒoŒû•‰‰×ŽŽŒ±‚ŃAƒiƒtƒBƒ‰ƒLƒV[ƒVƒ‡ƒbƒN‚ð’悵‚½—‘ƒAƒŒƒ‹ƒM[‚ɑ΂µ‚Ä‹}‘¬ŒoŒû–Ɖu—Ö@‚𓱓ü‚µ‚½ˆê—á. ‘æ24‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2012, 5, 12-13, ‘åã.
    35. ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹g“cKˆê, ‘å–îKO, ¬“c“ˆ”Ž, ÔàV@W, ‹{˜e—˜’j: —cŽ™‚É‚¨‚¯‚é”ì–ž‚Æšb‘§‚ÌŠÖŒW‚É‚¨‚¯‚é‹@˜‚ÌŒŸ“¢. ‘æ24‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2012, 5, 12-13, ‘åã.
    36. ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ”öã—mˆê, ‘«—§—Yˆê, ‹{˜e—˜’j: Ž…‹›ìŽs‚É‚¨‚¯‚é10”NŠÔ‚̬Ž™‹CŠÇŽxšb‘§“ü‰@Š³ŽÒ‚Ì„ˆÚ?ƒNƒ‰ƒXƒ^[•ªÍ‚ð—p‚¢‚½ƒvƒƒtƒ@ƒCƒ‹‰ð͂ɂ‚¢‚Ä?. ‘æ24‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2012, 5, 12-13, ‘åã.
    37. ‹{@ˆêŽu, “c’†•ü”ü, X@Žõ, ‹{˜e—˜’j: ”­”M‚ðŒ_‹@‚És“®ˆÙ킪‘ˆ«‚µARNMDAŽó—e‘ÌR‘Ì‚ª—z«‚Å‚ ‚Á‚½L”Ä«”­’BáŠQ‚̈ê—á. ‘æ54‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2012, 5, 17-19, ŽD–y.
    38. “c’†•ü”ü, ‹{@ˆêŽu, ‘q–{@’, “¡–Ø–õŽq, “c’‡çH, ‹{˜e—˜’j: ƒXƒeƒƒCƒh’ïR«‘SgŒ^dÇ‹Ø–³—Íǂɑ΂µ‚ă^ƒNƒƒŠƒ€ƒX‚𓱓ü‚µ‚½‚P—á. ‘æ54‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2012, 5, 17-19, ŽD–y.
    39. —k@žF, ‹àŒ“O˜a, ¼“c’¼“¿, ‹{˜e—˜’j, ¯‰Á«Œá, ‰Á“¡•¶‘ã, ™Œ´–ÎF, “àŠƒˆÀŽq: Ž©ŒÈ–Ɖu«—nŒŒ«•nŒŒ‚ð‡•¹‚µ‚½V¶Ž™”­Ç“œ”A•a‚Ì1 —á. ‘æ33‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2012, 5, 24, •xŽR.
    40. ‘«—§—Yˆê: JPGL2012 ‰ü’ù‚Ì—v“_F’·ŠúŠÇ—. ‘æ4‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[Ž¾Š³ƒtƒH[ƒ‰ƒ€, 2012, 6, 2, ‹ž“s.
    41. “c’†•ü”ü, ‹{@ˆêŽu, ‘ŠJË•½, â“c“Þ, ”óŒû@Žû, ”ÂàVŽõŽq, ‹{˜e—˜’j: WestÇŒóŒQ”­Ç‚ðŒ_‹@‚É”­Œ©‚³‚ꂽMenkes•a‚Ì1—á. ‘æ305‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï, 2012, 6, 10, •Ÿˆä.
    42. ”ÂàVŽõŽq, ”óŒû@Žû, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚¨‚¯‚éƒAƒŒƒ‹ƒM[«•@‰Š‚Ì•aŒ^‚Æšb‘§‚̃Rƒ“ƒgƒ[ƒ‹ó‘ÔAŒÄ‹z‹@”\‚ÌŠÖŒW. ‘æ29‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï, 2012, 6, 14-15, ‘åã.
    43. ’†—ÑŒºˆê, “c‘ºŒ«‘¾˜Y, ˆÉ“¡–õ“T, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: H•¨ƒAƒŒƒ‹ƒM[‚Æ‚µ‚Ä‘½•i–Ú‚ÌH•¨‚ð’·Šú‚Éœ‹Ž‚³‚ê‚Ä‚¢‚½Sˆö«šq“f‚̈ꗎ™—á. ‘æ29‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï, 2012, 6, 14-15, ‘åã.
    44. ŽíŽsq’ˆ: ¬Ž™‚É‚¨‚¯‚éEHEC O111W’cŠ´õ‘Ήž`‹Ù‹}ƒ[ƒŠƒ“ƒOƒŠƒXƒg‚ÆLˆæ”À‘—`. ‘æ20‰ñ“ú–{W’†Ž¡—ÈãŠw‰ï“ŒŠC–k—¤’n•û‰ïƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“‡T, 2012, 6, 23, •xŽR.
    45. ¼‘q—TŠì, ‚è–ƒ”ü, ‹{˜e—˜•v, ‘Šì@Œú: ¶‘Ìt‘ŸˆÚA‚W”NŒã‚É“Ë‘R‚Ì’`”’”A‚ð”F‚ß‚½ˆê—á. ‘æ47‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï, 2012, 6, 29-30, “Œ‹ž.
    46. ‹{”ö¬–¾, ¯–쌰G, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ´…³Ž÷: Chronic recurrent multifocal osteomyelitis (CRMO) ‚Æ‚ÌŠÓ•Êf’f‚ð—v‚µ‚½‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚Ì’jŽ™—á. –k—¤¬Ž™ŒŒ‰t§˜b‰ï, 2012, 6, 30, ‹à‘ò.
    47. ꎓ¡@—I, ¬‰Y@Ž, ”óŒû@Žû, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: “î•”‘gDˆ««ŽîᇂƂ̊ӕʂɋꗶ‚µ‚½‹ØüˆÛŽîÇimyofibromatosisj‚Ì‚P—á. ‘æ28‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï, 2012, 7, 1, •xŽR.
    48. “n•Óˆê—m, ’‡‰ª‰pK, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq, ’†ˆäG˜a, “úŒG’qŒ›, –F‘º’¼Ž÷: ƒtƒ@ƒ[Žl’¥ÇpŒãŠ³ŽÒ‚̶Žº‹@”\áŠQ ?QRSŽžŠÔ‰„’·‚ª‚µ‚ß‚·‚à‚Ì-. ‘æ48‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2012, 7, 5-7, ‹ž“s.
    49. âV“¡˜a—R, ¬àVˆ»‰À, “n•Óˆê—m, Žs“c•™Žq, ‹{˜e—˜’j, ’†ˆäG˜a, “úŒG’qŒ›, –F‘º’¼Ž÷, ˆÀ‘º@•q, Š£‚ ‚â‚Ì, “¡àV’m—Y: ƒtƒHƒ“ƒ^ƒ“pŒãŒo‰ß‚É”º‚¤ŠÌ‘@ˆÛ‰»ƒ}[ƒJ[‚̕ω»‚ÆŽ¡—Ẩ”\«. ‘æ48‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2012, 7, 5-7, ‹ž“s.
    50. ’‡‰ª‰pK, “n•Óˆê—m, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq, ’†ˆäG˜a, “úŒG’qŒ›, –F‘º’¼Ž÷: 64—ñMDCT‚ð—p‚¢‚½SŽº“à\‘¢•]‰¿. ‘æ48‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2012, 7, 5-7, ‹ž“s.
    51. Žs“c•™Žq: ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u‚à‚¤‚·‚®‘ål‚ɂȂ邱‚Ç‚à‚½‚¿‚Öv ‘æ48‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2012, 7, 5-7, ‹ž“s.
    52. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€u‹z“ü—Ö@‚̃sƒbƒgƒtƒH[ƒ‹‚ðl‚¦‚é ?¬Ž™-v. ‘æ35‰ñ‹z“ü—Ö@Œ¤‹†‰ï, 2012, 7, 14, “Œ‹ž.
    53. ’†—ÑŒºˆê, ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ”óŒû@Žû, •£àV—³–ç, ‰ª•””üŒb, ŽRŒ³ƒŽq, ˆÉ“Œ“¹•v, ”öã—mˆê, ‘«—§—zŽq, ‚”ö@Š², ‘ºãIŒ[, ¼–ì³’m, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚Ì‹z“ü—Ö@‚ɂ‚¢‚Ä‚Ì’mŽ¯‚ÆŽÀŽ{󋵂Ɋւ·‚é’²¸. ‘æ35‰ñ‹z“ü—Ö@Œ¤‹†‰ï, 2012, 7, 14, “Œ‹ž.
    54. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€ušb‘§Ž¡—ÂɎc‚³‚ꂽ‰Û‘èF¬Ž™šb‘§‚Ì”­Ç‹@˜v. ‘æ32‰ñ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒX, 2012, 7, 28-29, ‹ž“s.
    55. ‘«—§—Yˆê: “Á•Êu‰‰u¬Ž™šb‘§‚É‚¨‚¯‚éƒtƒFƒmƒ^ƒCƒvv. ‘æ40‰ñ¼“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2012, 8, 19-20, •Ÿ‰ª.
    56. ’Þ@_”V, ‹{˜e—˜’j, –xìT“ñ˜Y, ‘å“´—R‹IŽq, “ˆ”öˆ»Žq, –q–{—D”ü, ‹g“cär: NO‹z“ü—Ö@‚ª’˜Œø‚µ‚½’´’áo¶‘ÌdŽ™‚Ì2—á. ‘æ48‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï, 2012, 8, 26, •Ÿˆä.
    57. Žs“c•™Žq: “Á•Êu‰‰uV¶Ž™ŠJSpŒã‚Ì‚ŽŸ”]‹@”\áŠQv “ú–{¬Ž™–ƒŒŠw‰ï‘æ18‰ñŠwpW‰ï, 2012, 9, 2, “È–Ø.
    58. Žs“c•™Žq: “Á•Êu‰‰uS‹Øãk–§‰»áŠQ‚Ì—Õ°v ‘æ6‰ñŽ­Ž™“‡¬Ž™zŠÂŠíŒ¤‹†‰ï, 2012, 9, 8, Ž­Ž™“‡.
    59. ”óŒû@Žû, ˆÉ“¡–õ“T, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ‰uŠwŒ¤‹†‚©‚ç‚Ý‚½One Airway One disease‚ɂ‚¢‚Ä. ‘æ15‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2012, 9, 8, •xŽR.
    60. ‘«—§—zŽq, ‰ª•””üŒb, ”ÂàVŽõŽq, ”óŒû@Žû, ‚”ö@Š², ”öã—mˆê, ‘ºãIŒ[, ‘«—§—Yˆê, ‹{˜e—˜’j: •xŽRŒ§‚Ì•ÛˆçŽ{Ý‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚霋ŽH‘Ήž‚ÌŽÀ‘Ô. ?•½¬13”NA18”N“x’²¸‚Æ‚Ì”äŠr- ‘æ15‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2012, 9, 8, •xŽR.
    61. ’‡‰ª‰pK, ‘ŠJË•½, âV“¡˜a—R, “n•Óˆê—m, œA–ìŒbˆê, Žs“c•™Žq, ‹{˜e—˜’j: Lamin A/C ˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚½”ñ•ŸŽRŒ^ƒƒƒVƒ“—z«‹ØƒWƒXƒgƒƒtƒB[‚̈ê—á. ‘æ40‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ï, 2012, 9, 8, ‹à‘ò.
    62. ”ÂàVŽõŽq: ƒVƒ“ƒ|ƒWƒEƒ€u‚È‚Å‚µ‚±ƒVƒ“ƒ|ƒWƒEƒ€ ?—«Œ¤‹†ŽÒŽx‰‡‚ðl‚¦‚é?v. ‘æ49‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï@2012, 9, 15-16, ‘åã.
    63. ”ÂàVŽõŽq: ƒVƒ“ƒ|ƒWƒEƒ€uV‚µ‚¢•]‰¿•û–@FŒÄ‹CNOAIOSA‹C“¹‰ß•q«‚ɂ‚¢‚Ä?v. ‘æ49‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï@2012, 9, 15-16, ‘åã.
    64. ‘«—§—Yˆê: ƒCƒuƒjƒ“ƒOƒVƒ“ƒ|ƒWƒEƒ€ušb‘§ƒKƒCƒhƒ‰ƒCƒ“ world-wideF¬Ž™šb‘§ƒKƒCƒhƒ‰ƒCƒ“‚Ì‘Û”äŠrv. ‘æ49‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï@2012, 9, 15-16, ‘åã.
    65. ‘«—§—Yˆê, ˆäãšæ–Î, ‰ºð’¼Ž÷, –]ŒŽ”Ž”V: “û—cŽ™šb‘§‚É‚¨‚¯‚éƒuƒfƒ\ƒjƒh‹z“ü—pŒœ‘÷‰t“±“üŽž‚ɃvƒƒJƒeƒ[ƒ‹‰–Ž_‰–…˜a•¨‹z“ü‰t‚Ƃ̬‡‰t‚ð‹z“ü‚·‚邱‚Æ‚Ì—L—p«‚ƈÀ‘S«‚ÌŒŸ“¢. ‘æ49‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï@2012, 9, 15-16, ‘åã.
    66. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‚‹´@–L, ŽO‰YŽŽu, ŠC˜VàVŒ³G, ㌴—R”üŽq, ˆÉ“¡_–¾, ‹T“c@½, Šì‘½“c“N˜N, “í–Ú˜a‘ã, Žè’˃ˆê˜Y: ‘S‘‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[‚ɑ΂·‚éŒoŒûH•¨•‰‰×ŽŽŒ±‚ÌŽÀ‘Ô’²¸. ‘æ49‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï@2012, 9, 15-16, ‘åã.
    67. ‘«—§—zŽq, ‰ª•””üŒb, ”ÂàVŽõŽq, ”óŒû@Žû, ‚”ö@Š², ”öã—mˆê, ‘ºãIŒ[, ‘«—§—Yˆê, ‹{˜e—˜’j: •xŽRŒ§“à‚Ì•ÛˆçŽ{Ý‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚霋ŽH‘Ήž‚ɂ‚¢‚Ä‚Ì’²¸. ‘æ49‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï@2012, 9, 15-16, ‘åã.
    68. ’†—ÑŒºˆê, ”ÂàVŽõŽq, ˆÉ“¡–õ“T, •£àV—³–ç, ŽRŒ³ƒŽq, ã–ì—zŽq, ˆÉ“¡“¹•v, ”öã—mˆê, ‚”ö@Š², ‘ºãIŒ[, ¼–ì³’m, ŒÜ\—’—²•v, ‘«—§—Yˆê, ‹{˜e—˜’j: šb‘§Ž™‚È‚ç‚Ñ‚É‚»‚̉Ƒ°‚É‚¨‚¯‚é‹z“üŽè‹Z‚Ì’mŽ¯‚ÉŠÖ‚·‚é’²¸. ‘æ49‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï@2012, 9, 15-16, ‘åã.
    69. ¯–쌰G, ‹{”ö¬–¾, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ×ì@•à, ‰ª“cˆÀO, ŽRè@“O, âV“¡Ÿ•F: Žá”N«‘å’°‚ª‚ñ‚̈ê—á. ‘æ36‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ï, 2012, 9, 15, ‹à‘ò.
    70. Žs“c•™Žq: ƒ‚[ƒjƒ“ƒOƒŒƒNƒ`ƒƒ[uS‹Øãk–§‰»áŠQ‚Ìf—Ãv ‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ï,@2012, 9, 16, ‹à‘ò.
    71. ¯–쌰G, ‹àŒ“O˜a, ‘哈—E¬, Ί_ŒiŽq, Š}ˆä³Žu, ¯ŽiNŠ°, ‹g“c@^, ‹à“c@áÁ, Ž›ˆä@Ÿ, ¡ˆäk•ã, X”ö—FG, ‹{˜e—˜’j: dǖƉu•s‘SÇ‚É‚¨‚¯‚éƒjƒ…[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚Æ‹C‹¹‚ɂ‚¢‚Ä. ‘æ3‰ñŠÖ“Œb‰z–Ɖu•s‘SÇŒ¤‹†‰ï, 2012, 9, 22, “Œ‹ž.
    72. ”ÂàVŽõŽq, ”óŒû@Žû, ‘«—§—Yˆê, ‹{˜e—˜’j, óˆä³Žk, –F‘º’¼Ž÷: ECMO‰º‚Å‚Ì‹C“¹ˆÙ•¨“Eop‚É‚æ‚è‹~–½‚µ“¾‚½‹CŠÇŽxˆÙ•¨‚̈ꗎ™—á. ‘æ45‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï, 2012, 9, 28-29, ˆ®ì.
    73. ‘«—§—zŽq, ”óŒû@Žû, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: •xŽRŒ§‚Ì•ÛˆçŽ{Ý‚É‚¨‚¯‚é‹C“¹ˆÙ•¨Ž–ŒÌ—\–h‚Ì‚½‚ß‚ÌŽæ‚è‘g‚Ý‚ÌŒ»ó. ‘æ45‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï, 2012, 9, 28-29, ˆ®ì.
    74. ”ÂàVŽõŽq, ”óŒû@Žû, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‚É‚¨‚¯‚éƒAƒŒƒ‹ƒM[«•@‰Š‚Ì•aŒ^•Ê‚ÌdÇ“x‚Æšb‘§‚̃Rƒ“ƒgƒ[ƒ‹ó‘ÔAŒÄ‹z‹@”\‚ÌŠÖŒW. ‘æ20‰ñ—Õ°šb‘§Œ¤‹†‰ï, 2012, 10, 6, ‹à‘ò.
    75. ŽíŽsq’ˆ:•xŽRŒ§‚É‚¨‚¯‚éEHEC O111W’cŠ´õŽ–—á`—Õ°‚©‚ç‚ÌŽ‹“_`D‘æ95‰ñ“ú–{׋ۊw‰ïŠÖ“ŒŽx•”‘‰ï, 2012, 10, 12, “Œ‹ž.
    76. ¼‘q—TŠì, –쑺ŒbŽq, ‹àŒ“O˜a: •ÐtŒ´”­WilmsŽîᇑS“Eop‚É‚æ‚è‰i‘±“It’uŠ·—Ö@‚ð—v‚µA¬”]‚Ɉي«ÎŠD‰»‚ð”F‚ß‚½—Ž™—á. ‘æ65‰ñ϶‰ïŠw‰ï, 2012, 10, 13-14, ‹ž“s.
    77. ‘«—§—Yˆê: “Á•Êu‰‰uÅV‚̬Ž™šb‘§‚Ì‚Ý‚©‚½ -•@Çó‚Æ‚ÌŠÖŒW‚ðŠÜ‚ß-v. ‘æ190‰ñ•ºŒÉŒ§Ž¨•@ˆôA‰Èˆã‰ï—Õ°§˜b‰ï, 2012, 10, 14, _ŒË.
    78. Nomura K., Hoshino A., Kanegane H., and Miyawaki T.: Neutropenia and myeloid dysplasia in a patient with late-onset adenosine deaminase deficiency. ‘æ74‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï, 2012, 10, 19-21, ‹ž“s.
    79. ‹{”ö¬–¾, ’Þ@_”V, ‹{˜e—˜’j, –xìT“ñ˜Y, ìè—TŽq, “ˆ”öˆ»Žq, –q–{—D”ü, ‹g“cär: DŽ_‹…‘‘½Ç‚ð‡•¹‚µ‚½dÇTAM‚̈ê—á. ‘æ26‰ñ–k—¤ŽüŽYŠú?V¶Ž™Œ¤‹†‰ï, 2012, 10, 21, ‹à‘ò.
    80. ‹´–{ˆè•v, ŽÄ“c@K, ’†ì—TN, ã–ì—zŽq, ‹à“c@®, –쑺‰ÀO, œA–ìŒbˆê, Žs“c•™Žq: ˆÉ“¡”’”Á‚ɇ•¹‚µ‚½SŽº’†ŠuŒ‡‘¹Ç‚ªpŒãŠg’£Œ^S‹ØÇ‚Éi“W‚µ‚½’jŽ™—á. ‘æ21‰ñ“ú–{S‹ØÇŽ¾Š³Šw‰ïŠwpW‰ï, 2012, 10, 26, “Œ‹ž.
    81. Žs“c•™Žq: “Á•Êu‰‰uæ“V«SŽ¾Š³‚É‚¨‚¯‚é”xŒŒŠÇŠg’£–ò‚ÌŒø‰Ê`ƒtƒHƒ“ƒ^ƒ“zŠÂ‚ð’†S‚É`v ‘å㬎™‚o‚gƒtƒH[ƒ‰ƒ€, 2012, 11, 10, ‘åã.
    82. ‹àŒ“O˜a: ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u¬Ž™ŒŒ‰t?Žîᇈã‚É’m‚Á‚Ä‚à‚ç‚¢‚½‚¢–Ɖu•s‘SÇv ‘æ53‰ñ“ú–{¬Ž™ŒŒ‰t?‚ª‚ñŠw‰ï, 2011, 11, 27, ‘O‹´.
    83. ‘«—§—Yˆê: ê–åˆã§“xŒöŠJ“¢˜_‰ïF–]‚Ü‚µ‚¢ê–åˆã‚ð–ÚŽw‚µ‚Ä ?¬Ž™‰ÈŒ¤C‚ɂ‚¢‚Ä-. ‘æ62‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2012, 11.29-12.1, ‘åã.
    84. ”ÂàVŽõŽq, ”óŒû@Žû, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚̃AƒŒƒ‹ƒM[«•@‰ŠÇó‚ƌċz‹@”\‚ÌŠÖŒW‚É‚¨‚¯‚é’·ŠúŠÇ—–ò‚̉e‹¿-. ‘æ62‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2012, 11.29-12.1, ‘åã.
    85. ”óŒû@Žû, ”ÂàVŽõŽq, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹g“cKˆê, ‘å–îKO, ¬“c“ˆ”Ž, ÔàV@W, ‹{˜e—˜’j: —cŽ™‚É‚¨‚¯‚éƒAƒŒƒ‹ƒM[«•@‰Š‚Ìšb‘§Çó‚ւ̉e‹¿-. ‘æ62‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2012, 11.29-12.1, ‘åã.
    86. ˆÉ“¡–õ“T, ”ÂàVŽõŽq, ’†—ÑŒºˆê, •£àV—³–ç, ŽRŒ³ƒŽq, ‘«—§—Yˆê, ‹g“cKˆê, ÔàV@W, ‹{˜e—˜’j: “ú–{‚̬Šw¶‚É‚¨‚¯‚錌´ƒrƒ^ƒ~ƒ“D’l‚ƃAƒŒƒ‹ƒM[Ž¾Š³—L•a—¦‚ÌŠÖ˜A«-. ‘æ62‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2012, 11.29-12.1, ‘åã.
    87. Žs“c•™Žq: “Á•Êu‰‰uƒtƒHƒ“ƒ^ƒ“zŠÂ‚É‚¨‚¯‚é”xŒŒŠÇŠg’£–ò‚ÌŽ¡—ÃŒø‰Ê.v ‘æ6‰ñç—tæ“V«SŽ¾Š³PAHŒ¤‹†‰ï, 2012, 11, 27, ç—t.
    88. ¯–쌰G, ‹àŒ“O˜a, Yang X., ’†”ö•ü•½, ‰Á“¡Œ[•ã, “¡ŽR@‘, ‚‹´Š°‹g, ¡‘ºr•F, ΈäžÄˆê, ‹{˜e—˜’j: ŽŸŽq‚Ì”­Ç‚ðŒ_‹@‚Ɉâ“`Žqf’f‚ÅŽ€ˆö‚ÌŠm’肵‚½‰Æ‘°«ŒŒ‹…æÃH«ƒŠƒ“ƒp‘gD‹…Ç‚Ì2—á. ‘æ54‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ï, 2012, 11.30-12.2, ‰¡•l.
    89. ¯–쌰G, ŽíŽsq’ˆ, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ŽR“c•ü”ü, ŽR˜H˜aF, –x@šæ¬, ’ßàV³m: Ä”­ALL‚ɑ΂·‚é”ñŒŒ‰ŽÒŠÔ“¯ŽíˆÚAŒã‚É‘å‘Úœ’P“ÆÄ”­‚ð‚«‚½‚µ‚½ˆê—á. ‘æ54‰ñ“ú–{¬Ž™ŒŒ‰t?‚ª‚ñŠw‰ï, 2012, 11.30-12.2, ‰¡•l.
    90. ˆÉ“¡–õ“T, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‚É‚¨‚¯‚錌’†ƒrƒ^ƒ~ƒ“D”Z“x‚ƃAƒŒƒ‹ƒM[Ž¾Š³—LÇ—¦‚ÌŠÖŒW. ‘æ39‰ñ–k—¤ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2012, 12, 15, ‹à‘ò.

    2011”N

  • ’˜‘
    1. Žs“c•™Žq: SŽ¾Š³‚ð‚à‚ÂŽ™“¶E¶“k‚ÌŠwZŠÇ—‰º‚ł̈µ‚¢•û@w¡“ú‚ÌŽ¡—ÃŽwjx2011@ŽRŒû@“O‘¼•ÒAˆãŠw‘‰@, “Œ‹ž, 1174-1177, 2011.
    2. Žs“c•™Žq: ¬Ž™S•s‘S‚ƈâ“`Ž¾Š³@wS‘ŸˆÚAx¼“c@ôŠÄC, “ú–{S‘ŸˆÚAŒ¤‹†‰ï•Ò, ƒVƒ…ƒvƒŠƒ“ƒK[EƒWƒƒƒpƒ“, “Œ‹ž, 393-397, 2011.
    3. ‘«—§—Yˆê: ‚¢‚šb‘§‚Æf’f‚·‚é‚Ì‚Å‚·‚©D¬Ž™“à‰È•Êûu¬Ž™‚Ìf—Â̂µ‚©‚½vŒÜ\—’—²•Ò, “Œ‹žˆãŠwŽÐ, “Œ‹ž, 495-497, 2011.
    4. ‘«—§—Yˆê: “û—cŽ™‚Ì‹z“üƒXƒeƒƒCƒhiICSj‚Ì“K³Žg—p‚ɂ‚¢‚Ä‹³‚¦‚ĉº‚³‚¢.u¬Ž™šb‘§‚Ì‚±‚±‚ª’m‚肽‚¢ Q&AvŸÀr—Y•Ò, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 49-51, 2011.
    5. ‘«—§—Yˆê: šb‘§‚Ì”­ÇˆöŽq‚Æ‘ˆ«ˆöŽqDu30th ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒX@2010”N‚É‚¨‚¯‚é‹CŠÇŽxšb‘§‚Ì‘S‚Äv‘«—§@–ž, X캜A, HŽRˆê’j, ‘å“c@Œ’, “Œ“c—L’q•Ò, ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXo”Å, “Œ‹ž, 23-28, 2011.
    6. ‹àŒ“O˜a: ˆÕŠ´õA–Ɖu•s‘S. ¬Ž™‰È—Õ°ƒsƒNƒVƒXuÇó•ÊŒŸ¸‚Ì‘I‚Ñ•û?i‚ß•ûvŒÜ\—’—²‘•ÒW, ’†ŽR‘“X, “Œ‹ž, 112-115, 2011.
    7. ‹àŒ“O˜a: Shwachman-DiamondÇŒóŒQ. “ú–{—ÕକÊûuäX‘ŸÇŒóŒQ@‚»‚Ì‘¼‚ÌäX‘ŸŽ¾Š³‚ðŠÜ‚ß‚Äv”’’¹ŒhŽq•ÒW, “ú–{—Õà¬, ‘åã, 65-68, 2011.
    8. ‹àŒ“O˜a: æ“V«–Ɖu•s‘SÇ. uŒŒ‰tê–åˆãƒeƒLƒXƒgv“ú–{ŒŒ‰tŠw‰ï•ÒW, “ì]“°, “Œ‹ž, 340-343, 2011.
    9. ‹àŒ“O˜a, ‘å’ØŒc•ã, –쑺ŒbŽq: –Ɖu•s‘SŠÖ˜AƒŠƒ“ƒp‘B«Ž¾Š³. u¬Ž™‚ª‚ñf—Ãnƒ“ƒhƒuƒbƒNv–x•”ŒhŽO•Ò, ˆã–òƒWƒƒ[ƒiƒ‹ŽÐ, ‘åã, 414-419,@2011.
    10. ”ÂàVŽõŽq: ‰Æ‘°‚⊳Ž™‚Ö‚ÌICS‚Ìà–¾‚ɂ‚¢‚Ä‹³‚¦‚ĉº‚³‚¢Du¬Ž™šb‘§‚Ì‚±‚±‚ª’m‚肽‚¢ Q&AvDŸÀr—Y•Ò, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 64-68, 2011.
    11. œA–ìŒbˆê, Žs“c•™Žq: EBM‚Ɋ‚­“«ìè•a‚ÌŽ¡—Ãí—ªFƒCƒ“ƒtƒŠƒLƒVƒ}ƒuŽ¡—ÂƂ»‚̃ƒJƒjƒYƒ€wEBM¬Ž™Ž¾Š³‚ÌŽ¡—ÃxŒÜ\—’—²ŠÄC, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 154-157, 2011.
    12. “n•Óˆê—m, Žs“c•™Žq: wƒi[ƒX‚̬Ž™‰ÈŠwx²’n@•×‘¼•Ò, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 384-387, 2011.
    13. “n•Óˆê—m, Žs“c•™Žq: –[Žº’†ŠuŒ‡‘¹Ç@w‚±‚Ç‚àƒPƒA10.11ŒŽ†x“ú‘Œ¤, –¼ŒÃ‰®, 34-37, 2011.
    14. ”óŒû@Žû, ‘«—§—Yˆê: ‹C“¹ˆÙ•¨Du‚±‚Ç‚à‚ÌŠPšu f’fƒKƒCƒhƒuƒbƒNvƒjƒ…[ƒƒyƒvƒ^ƒCƒhŒ¤‹†‰ï•Ò, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 83-85, 2011.
    15. ˆÉ“¡–õ“T, ‘«—§—Yˆê: ŠPšuAšb–ÂA”x‰¹‚̈Ùí. ¬Ž™‰È—Õ°ƒsƒNƒVƒX24uÇó•ÊŒŸ¸‚Ì‘I‚Ñ•û?i‚ß•ûvŒÜ\—’—²‘•ÒW, ’†ŽR‘“X, “Œ‹ž, 92-95, 2011.
    16. ˆÉ“¡–õ“T, ‘«—§—Yˆê: ŒÄ‹zŠí‚ÉŠÖ‚·‚éfŽ@i–âfAŽ‹fA’®fj‚Å’ˆÓ‚·‚é“_‚Í‚È‚ñ‚Å‚·‚©. ¬Ž™“à‰È•Êûu¬Ž™‚Ìf—Â̂µ‚©‚½vŒÜ\—’—²•Ò, “Œ‹žˆãŠwŽÐ, “Œ‹ž, 129-131, 2011.
    17. ¬àVˆ»‰À, Žs“c•™Žq: zŠÂŠíŽ¾Š³@æ“V«SŽ¾Š³Aw¬Ž™—Õ°‰h—{ŠwxŽ™‹Ê_Žq‘¼•Ò, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 294-298, 2011.
  • Œ´’˜
    1. Nomura K., Kanegane H., Otsubo K., Wakiguchi H., Noda Y., Kasahara Y., and Miyawaki T.: Autoimmune lymphoproliferative syndrome mimicking chronic active Epstein-Barr virus infection. Int J Hematol 93: 760-764, 2011.
    2. Okabe Y., Itazawa T., Adachi Y., Yoshida K., Ohya Y., Odajima H., Akasawa A., and Miyawaki T.: Association of overweight with asthma symptoms in Japanese school children. Pediatr Int 53: 192-198, 2011.
    3. Ito Y., Adachi Y., Itazawa T., Okabe Y., Adachi YS., Higuchi O., Katsumuma T., and Miyawaki T.: Association between the results of the childhood asthma control test and objective parameters in asthmatic children. J Asthma 48: 1076-1080, 2011.
    4. Otsubo K., Kanegane H., Kamachi Y., Kobayashi I., Tsuge I., Imaizumi M., Sasahara Y., Hayakawa A., Nozu K., Iijima K., Ito S., Horikawa R., Nagai Y., Takatsu K., Mori H., Ochs H.D., and Miyawaki T.: Identification of FOXP3-negative regulatory T-like(CD4+CD25+CD127low) cells in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Clin Immunol 141: 111-120, 2011.
    5. Zhao M., Kanegane H., Kobayashi C., Nakazawa Y., Ishii E., Kasai M., Terui K., Gocho Y., Imai K., Kiyasu J., Nonoyama S., and Miyawaki T.: Early and rapid detection of X-linked lymphoproliferative syndrome with SH2D1A mutations by flow cytometry. Cytometry Part B- Clin Cytom 80B: 8-13, 2011.
    6. Chang B., Nishizawa T., Furutani M., Fujiki A., Tani M., Kawaguchi M., Ibuki K., Hirono K., Taneichi H., Uese K., Onuma Y., Bowles N.E., Ichida F., Inoue H., Matsuoka R., and Miyawaki T.: Identification of novel TPM1 mutation in a family with left ventricular noncompaction and sudden death. Mol Genet Metab 102: 200-206, 2011.
    7. Booth C., Gilmour K.C., Veys P., Gennery A.R., Slatter M.A., Chapel H., Heath P.T., Steward C.G., Smith O., O'Meara A., Kerrigan H., Mahlaoui N., Cavazzana-Calvo M., Fischer A., Moshous D., Blanche S., Schmid J.P., Latour S., Saint-Basile G., Albert M., Notheis G., Rieber N., Stahm B., Ritterbusch H., Lankester A., Hatwig N.G., Meyts I., Plebani A., Soresina A., Finocchi A., Pignata C., Cirillo E., Bonanomi S., Peters C., Kalwak K., Pasic S., Sedlacek P/. Jazbec J., Kanegane H., Nichols K.E., Hanson I.C., Kapoor N., Haddad E., Cowan M., Choo S., Smart J., Arkwright P.D., and Gaspar H.B.: X-linked lymphoproliferative due to SAP/SH2D1A deficiency: amulticenter study on the manifestations, management and outcome of the disease. Blood 117: 53-62, 2011.
    8. Schmid J.P., Canioni D., Moshous D., Touzot F., Mahlaoui N., Hauck F., Kanegane H., Lopez-Granados E., Mejstrikova E., Pellier I., Galicier L., Galambrun C., Barlogis V., Bordigoni P., Fourmaintraux A., Hamidou M., Dabadie A., Deist F., Haerynck F., Ouachee-Chardin M., Rohrlich P., Stephan J-L., Lenoir C., Rigaud S., Lambert N., Milili M., Schiff C., Chapel H., Picard C., Basile G.S., Blanche S., Fischer A., and Latour S.: Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP dificiency) versus type 2(XLP-2/XIAP deficiency). Blood 117: 1522-1529, 2011.
    9. Imamura M., Kawai T., Okada S., Izawa K., Takachi T., Iwabuchi H., Yoshida S., Hosokai R., Kanegane H., Yamamoto T., Umezu H., Nishikomori R., Heike T., Uchiyama M., and Imai C.: Disseminated BCG infection mimicking metastatic nasopharyngeal carcinoma in immunodeficient child with a novel hypomorphic NEMO mutation. J Clin Immunol 31 : 802-810, 2011.
    10. Ishimura M., Takada H., Doi T., Imai K., Sasahara Y., Kanegane H., Nishikomori R., Morio T., Heike T., Kobayashi M., Ariga T., Tsuchiya S., Nonoyama S., Miyawaki T., and Hara T.: Nationwide survey of patients with primary immunodeficiency disease in Japan. J Clin Immunol 31 : 968-976, 2011.
    11. Futamura M., Ohya Y., Akashi M., Adachi Y., Odajima H., Akiyama K., and Akasawa A.: Age-related prevalence of allergic diseases in Tokyo schoolchildren. Allergol Int 60: 509-515, 2011.
    12. Taguchi M., Ichida F., Hirono K., Miyawaki T., Yoshimura N., Nakamura T., Akita C., Nakayama T., Saji T., Kato Y., Horiuchi I., and Hashimoto Y.: Pharmacokinetics of Bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. Drug Metab Pharmacokinet 26: 280-287, 2011.
    13. Kato Y., Ichida F., Saito K., Watanabe K., Hirono K., Miyawaki T., Yoshimura N., Horiuchi I., Taguchi M., and Hashimoto Y.: Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug Metab Pharmacokinet 26: 295-299, 2011.
    14. Nakagawa N., Imai K., Kanegane H., Sato H., Yamada M., Kondoh K., Okada S., Kobayashi M., Agematsu K., Takada H., Mitsui N., Oshima K., Ohara O., Suri D., Rawat A., Singh S., Pan-Hammarstrome Q., Hammarstrome L., Reinhard S., Ariga T., Hara T., Miyawaki T., and Nonoyama S.: Quantification of k-deleting recombination excision circles in Guthrie cards for the identification of early B-cell maturation defects. J Allergy Clin Immunol 128: 223-225, 2011.
    15. Tadaki H., Saitsu H., Kanegane H., Miyake N., Imagawa T., Kikuchi M., Hara R., Kaneko U., Kishi T., Miyamae T., Nishimura A., Doi H., Tsurusaki Y., Sakai H., Yokota S., and Matsumoto N.: Exonic deletion of CASP10 in a patient presenting with systemic juvenile idiopathic arthritis, but not with autoimmune lymphoproliferative syndrome type IIa. Int J Immunogenet 38: 287-293, 2011.
    16. Arai T., Zhao M., Kanegane H., Zelm M.C. Futatani T., Yamada M., Ariga T., Ochs H.D., Miyawaki T., and Oh-ishi T.: Genetic analysis of contagious X-chromosome deletion syndrome encompassing the BTK and TIMM8A genes. J Hum Genet 56: 577-582, 2011.
    17. Morimoto A., Shioda Y., Imamura T., Kanegane H., Sato T., Kudo K., Nakagawa S., Nakadate H., Tauchi H., Hama A., Yasui M., Nagatoshi Y., Kinoshita A., Miyaji R., Anan T., Yabe M., and Kamizono J. for the LCH committee, the Japanese pediatric leukemia/lymphoma study group.: Nationwide survey of bisphosphonate therapy for children with reactivated langerhans cell histiocytosis in Japan. Pediatr Blood Cancer 56:110-115, 2011.
    18. Taga T., Shimomura Y., Horikoshi Y., Ogawa A., Itoh M., Okada M., Ueyama J., Higa T., Watanabe A., Kanegane H., Iwai A., Saikawa Y., Kogawa K., Yamanaka J., and Tsurusawa M.: Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeroid leukemia: Report from the Japanese children's cancer and leukemia study group (CCLSG) AML 9805 down study. Pediatr Blood Cancer 57: 36-40, 2011.
    19. Yamaguchi M., Fujimura K., Kanegane H., Toga-Yamaguchi H., Chopra R., and Okamura N.: Mislocalization or low expression of mutated Shwachman-Bodian-Diamond syndrome protein. Int J Hematol 94: 54-62, 2011.
    20. Fujioka T., Kawashima H., Nishimata S., Ioi H., Takekuma K., Hoshika A., kanegane H., and Miyawaki T.: Atypical case of X-linked agammaglobulinemia diagnosed at 45 years of age. Pediatr Int 53: 611-612, 2011.
    21. Ohta H, Miyashita E, Hirata I, Matsumura R, Yoshida H, Hashii Y, Higashiura T, Yasumi T, Murata Y, Heike T, Yang X, Kanegane H, Ohara O, and Ozono K.: Hematopoietic stem cell transplantation with reduced intensity conditioning from a family haploidentical donor in an infant with familial hemophagocytic lymphohistiocytosis. Int J Hematol 94: 285-290, 2011.
    22. Kawakami C., Inoue A., Takitani K., Kanegane H., Miyawaki T., and Tamai H.: X-linked agammaglobulinemia complicated with endobronchial tuberculosis. Acta Paediatr 100: 466-468, 2011.
    23. Mori M., Kawashiri M., Hayashi T., Konnno T., Hayashi K., Ino H., Yoshimura T., Okeie K., Ichida F., Shigeyuki T., Watanabe G., and Yamagishi M.: Cardiac papillary fibroelastoma originated from atrial side of mitral valve leaflet. J Echocardiogr 9 : 156-157,2011.
    24. ”ÂàVŽõŽq, ‘«—§—zŽq, ‰ª•””üŒb, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: ¬Ž™šb‘§ƒRƒ“ƒgƒ[ƒ‹ƒeƒXƒgiChildhood Asthma Control Test: C-ACTj‚Ì—L—p«‚Æ–â‘è“_. “ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ïŽ 9: 30-35, 2011.
    25. â讓¿A’O‰HŒöˆê˜Y, ã–ì—Ï•F, ‚ŽºŠîŽ÷, ’†¼•q—Y, ‰Á“¡@‹Ï, ¼“‡³‹C, ¬“‡“Þ”üŽq, Žs“c•™Žq, ¬Š_Ž –L, éŒË²’mŽq, VŠ_‹`•v, Ô–Ø’õŽ¡, é”ö–M—², {“cŒ›Ž¡, ’†àV@½, ²’n@•×: –{–M‚É‚¨‚¯‚éEisenmengerÇŒóŒQ¬l—á‚ÌŒŸ“¢. ¬Ž™zŠÂŠíŠw‰ïŽGŽ 27: 121-131, 2011.
  • Ç—á•ñ
    1. Yang X., Wang J., Kanegane H., Miyawaki T., Zhao K.: Genetic and proteinic analysis of a Chinese boy with X-linked lymphoproliferative disease and his maternal relatives. Chinese J Pediatr 49: 416-420, 2011.
    2. Hamidah A., Renna M., Halim A.R.A., Ibrahim S., Eguchi M., Zarina A.L., Norazlin A.N., Iamal R., and Kanegane H.: Successful treatment of very large congenital infantile fibrosarcoma. Pediatr Int 53: 768-770, 2011.
    3. Ukeba-Terashita Y., Saita Y., Ito Y., Kanegane H., Kimura H., and Kobayashi I.: Chronological changes in Epstein-Barr virus genome and subsets of peripheral mononuclear cells in a case of HLH. Open J Pediatr 1: 30-33, 2011.
    4. Kawakami C., Inoue A., Kakitani K., Kanegane H., Miyawaki T., and Tamai H.: X-linked agammaglobulinemia complicated with endobronchial tuberculosis. Acta Paediatr 100: 466-468, 2011.
    5. –쑺ŒbŽq, ‹{’n@[, ‘å’ØŒc•ã, ‹àŒ“O˜a, “y‰®–M•F, ׈ä@‘n, ‹{˜e—˜’j: ƒpƒ‰ƒtƒBƒ“•ï–„”÷¬ŒŸ‘Ì‚©‚çƒLƒƒ‰ˆâ“`Žq‚ðŒŸo‚µ“¾‚½’†“ªŠWâ|Œ´”­–E‘ƒŒ^‰¡–ä‹Ø“÷Žî‚̈ê—á. ¬Ž™‚ª‚ñ@48: 310-314, 2011.
    6. ‚è–ƒ”ü, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ƒGƒLƒmƒRƒbƒNƒX‚Æ‚ÌŠÓ•Ê‚É‹ê—¶‚µ‚½ŠÌ•gŠ´õÇ‚Ì‚P—Ž™—á. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ@115: 1781-1785, 2011.
    7. ’|j—fm, ãp@—T“Ä, V쬓N, ÎàV@Œb, ‹{è—ÇŽ÷, Šâ“c“ÖŽq, –x@šæ¬, ’ßàV³m, ˆÀ“¡ˆèŽq, ‹àŒ“O˜a: —cŽ™Šú‚ÉŒ©“¦‚³‚ê‚Ä‚µ‚Ü‚Á‚½X˜A½–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì‚P—á. ¬Ž™‰È—Õ° 64: 61-65, 2011.
    8. –xìT“ñ˜Y, ŒÜ\—’“oF‹}«¬Ž™•Ð–ƒáƒ‚ð’悵‚½ƒCƒ“ƒtƒ‹ƒGƒ“ƒU”]Ç‚Ì‚P—Ž™—áD¬Ž™‰È—Õ° 64: 255-260, 2011.
    9. –xìT“ñ˜Y, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ‰Â‹t«”]—À–c‘å•”•a•Ï‚𔺂Á‚½ toxic shock syndrome ‚Ì‚P—á. ¬Ž™Š´õ–Ɖu 23: 141-147, 2011.
    10. ‚è–ƒ”ü, ‹g“cär, “¡–Ø–õŽq, ’––”’qŽÀ, ˆÉŒ\“ñ˜Y, “nç³’qŽq, œAìTˆê˜Y, •l“cG—Y, •è–M˜a, ‹{˜e—˜’j: ½ãèpŒã‚É”]Žº“àoŒŒ‚ð”­Ç‚µ‚½ Late preterm ‚̈êãO–Ñ–Œ«‘o‘Ù—á. ¬Ž™‰È—Õ°@64: 2412-2416, 2011.
  • ‘à
    1. ‹{˜e—˜’j: ‚Æ‚à‚ ‚ê@‚ЂƂÂ@‚ЂƂÂ. ¬Ž™‰È—Õ° 64: 56-59, 2011.
    2. ‹{˜e—˜’j: Why we get sick?. ƒAƒŒƒ‹ƒM[?–Ɖu 18: 7, 2011.
    3. ‹{˜e—˜’j: æ“V«–Ɖu•s‘Sǂɂ‚¢‚Ä. •êŽq•ÛŒ’‹¦‰ïŽu‚Ó‚½‚Îv 75: 28-34, 2011.
    4. Žs“c•™Žq: zŠÂŠí•a—1 1.S‹ØŽ¾Š³ 2)¶ŽºS‹Øãk–§‰»áŠQ. •a—‚Æ—Õ° 29: 149-153, 2011.
    5. ‘«—§—Yˆê: ƒAƒŒƒ‹ƒM[Ž¾Š³‚Ìf’f‚ÆŽ¡—ẪsƒbƒgƒtƒH[ƒ‹ -¬Ž™šb‘§-. ƒAƒŒƒ‹ƒM[‚Ì—Õ°@31: 1048-1051, 2011.
    6. ‘«—§—Yˆê, ŸÀr—Y: ЊQŽž‚É‚¨‚¯‚éšb‘§?ƒAƒŒƒ‹ƒM[Š³Ž™‚ւ̑Ήž‚Æ–â‘è“_. [“Œ“ú–{‘åkЂł̕ñ‚Æ¡Œã‚Ö‚Ì’ñŒ¾[@5. ‘Ήžƒpƒ“ƒtƒŒƒbƒg(1)‚Í‚¶‚ß‚É. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 25: 739-741, 2011.
    7. ‘«—§—Yˆê, “¡àV—²•v: ЊQŽž‚É‚¨‚¯‚éšb‘§?ƒAƒŒƒ‹ƒM[Š³Ž™‚ւ̑Ήž‚Æ–â‘è“_. [“Œ“ú–{‘åkЂł̕ñ‚Æ¡Œã‚Ö‚Ì’ñŒ¾[@5. ‘Ήžƒpƒ“ƒtƒŒƒbƒg(2)šb‘§. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 25: 742-745, 2011.
    8. ‘«—§—Yˆê: •Ûˆç‚Ìê‚É‚¨‚¯‚éƒAƒŒƒ‹ƒM[Ž¾Š³Ž™‚ւ̑Ήž.“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ïŽ 9: 263-264, 2011.
    9. ‘«—§—Yˆê: ‹CŠÇŽxšb‘§‚̃tƒFƒmƒ^ƒCƒv. ¬Ž™‰È 52: 1807-181, 2011.
    10. ‹àŒ“O˜a, ‘å’ØŒc•ã, ‹{˜e—˜’j: §Œä«T×–E‚ɈÙí‚ð—L‚·‚錴”­«–Ɖu•s‘S. ‰ŠÇ‚ƖƉu 19: 210-216, 2011.
    11. ‹àŒ“O˜a: X˜A½ƒŠƒ“ƒp‘BÇŒóŒQ-SAPŒ‡‘¹Ç‚ÆXIAPŒ‡‘¹Ç. ˆãŠw‚Ì‚ ‚ä‚Ý 238: 1058-1064, 2011.
    12. ”ÂàVŽõŽq: šb‘§f—Âɂ¨‚¯‚鬎™‚̌ċz‹@”\ŒŸ¸. ¬Ž™‰È 52: 1013-1020, 2011.
    13. Hirono K, Ichida F: Possible new role of vascular endothelial growth factor-d during the acute phase of kawasaki disease. Circ J. 75:1324-1325, 2011.
    14. œA–ìŒbˆê, Žs“c•™Žq: ìè•aŒŒŠÇ‰Š‚Ì•a‘Ô. “ÁW/ìè•a‚Ì”–â‘è. zŠÂŠí“à‰È 69: 399-406, 2011.
    15. ŽíŽsq’ˆ, ‹{˜e—˜’j: ‚—p—ʖƉuƒOƒƒuƒŠƒ“—Ö@. “ú–{—Õ° 69: 515-519, 2011.
    16. “n•Óˆê—m, Žs“c•™Žq: V¶Ž™ŠúS‘ŸŽèpŒã‚̸_‰^“®”­’B. ¬Ž™‰È 50: 219-223, 2011.
    17. “n•Óˆê—m, Žs“c•™Žq: S‹Ø‰ŠwÇŒóEŽ¾Š³ŒQ•Ê‚Ì—Õ°ŒŸ¸‚Ìi‚ß•ûx¬Ž™‰Èf—Ã@74(‘): 289-292, 2011.
    18. “n•Óˆê—m, Žs“c•™Žq: w¬Ž™‚Ìf—Â̂µ‚©‚½[‚ ‚È‚½‚Ì‹^–â‚É“š‚¦‚Ü‚·xVIII.Ž¾Š³•Ê‚Ìf—Ã@7.zŠÂŠíŽ¾Š³iV¶Ž™E“ûŽ™Šúj4)RSƒ‚ƒmƒNƒƒi[ƒ‹R‘Ì‚Ì“K‰ž‚ð‹³‚¦‚Ä‚­‚¾‚³‚¢@¬Ž™“à‰È 43(‘): 610-611, 2011.
    19. ‰ª•””üŒb, ‘«—§—Yˆê: ¬Ž™šb‘§Ž¡—Âɂ¨‚¯‚é‹z“üŽw“±. ‹z“ü—Ö@ 3: 58-62, 2011.
    20. ‰ª•””üŒb: Q&A Žq‹Ÿ‚Å‚àA”ì–ž‚Æšb‘§‚ÍŠÖŒW‚ª‚ ‚è‚Ü‚·‚©. ƒAƒŒƒ‹ƒM[‚Ì—Õ°@31: 10, 2011.
    21. ¬àVˆ»‰À, Žs“c•™Žq: S‘ŸŒŸf‚̈Ӌ`‚ÆŽÀÛ. ¬Ž™‰È—Õ° 64: 1451-1462, 2011.
    22. ¬àVˆ»‰À, Žs“c•™Žq: æ“V«SŽ¾Š³‡•¹Ž™‚̃tƒHƒ[ƒAƒbƒv‚Å‚Ì’ˆÓ“_. ŽüŽYŠúˆãŠw 41: 1380-1382, 2011.
    23. ˆÉ“¡–õ“T, ‘«—§—zŽq, ”óŒû@Žû, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ŒÄ‹z‚ÉŠÖ‚·‚éfŽ@i–âfAŽ‹fA’®fj‚Å’ˆÓ‚·‚é“_‚Í‚È‚ñ‚Å‚·‚©. ¬Ž™“à‰È 43(‘): 129-131, 2011.
    24. ‘å’ØŒc•ã, ‹àŒ“O˜a,‹{˜e—˜’j: ƒAƒŒƒ‹ƒM[Ž¾Š³‚ƖƉu’²ß(Treg×–E) ¬Ž™‰È 52: 879-887, 2011.
    25. ¼“c’¼“¿, ‹àŒ“O˜a: –Ɖu•s‘SÇŒóŒQiHIVŠ´õÇ‚ðŠÜ‚Þj. ¬Ž™‰È—Õ°@64: 2597-2602, 2011.
    26. Š`–{‘½ç‘ã, Žs“c•™Žq: æ“V«SŽ¾Š³‡•¹Ž™‚̸__Œo”­’B—\Œã@“ÁW/How to Follow-up Q & A-ƒtƒHƒ[ƒAƒbƒv‚̃Rƒc‚·‚ׂċ³‚¦‚Ü‚·@ŽüŽYŠúˆãŠw@41: 1383-1385, 2011.

  • 2011”NŠw‰ï•ñ
    1. Adachi Y., Itazawa T., Adachi YS., Ito Y., Okabe Y., Yoshida K., Ohya Y., Odajima H., Akasawa A., and Miyawaki T.: Association of Obesity with Asthma in Japanese Preschool Children. 67th Annual Meeting of American Academy of Allergy, Asthma & Immunology, 2011, 3, 19-22, San Francisco, USA.
    2. Itazawa T., Adachi Y., YAdachi YS., Ito Y., Okabe Y., Yoshida K., Ohya Y., Odajima H., Akasawa A., and Miyawaki T.: Association of Body Composition with Asthma Control in Japanese Preschool Children. 67th Annual Meeting of American Academy of Allergy, Asthma & Immunology, 2011, 3, 19-22, San Francisco, USA.
    3. Hashimoto I., Saitou K., Ibuki K., Ozawa S., and Ichida F.: New index-pulmonary vascular index-for evaluation of pulmonary flow resistance in congenital heart disease. i2 summit, American College of Cardiology, 2011, 4, 4, New Orleans.
    4. Ichida F.: Genetic basis of noncompaction cardiomyopathy. 2011 Pediatric Academic Societies and Asian Society for Pediatric Research, 2011, 4, 30-5.1, Denver (U.S.A). (invited lecture)
    5. Kanegane H.: SAP and XIAP deficiency in hemophagocytic lymphohistiocytosis. 2011 Pediatric Academic Societies and Asian Society for Pediatric Research, 2011, 4, 30-5.1, Denver (U.S.A). (invited lecture)
    6. Saito K., Takasaki I., Hirono K., Ibuki K., Watanabe K., Bowles NE., Ichida F., and Miyawaki T.: MicroRNAs may control mRNA in circulating PBMCs during the acute phase of Kawasaki disease. The 45th Annual meeting for the association for European pediatric cardiology, 2011, 5, 20, Granada, Spain.
    7. Ichida F., Hata Y., Chang B., Ozawa S., Saito K., Ibuki K., Watanabe K., and Nishida N.: Genetic basis of left ventricular noncompaction. European Society of Cardiology Congress 2011, 2011, 8, 28, Paris.
    8. Yoshida T., Takasaki I, Kanegane H., Inomata S., Shimao A., Ito Y., Saito S., and Miyawaki T.: Identification of predictive makers for adult heart disease from gene expression profiling of cord blood. . 6th Recent advances in neonatal medicine an international symposium, 2011, 10, 2-4, Wurzburg, Germany.
    9. Inomata S., Yoshida T., Shimao A., Hatasaki K., Imamura H., and Miyawaki T.: The relationship between preterm birth and the risk factors for cardiovascular diseases in schoolchildren. 6th Recent advances in neonatal medicine an international symposium, 2011, 10, 2-4, Wurzburg, Germany.
    10. Ichida F., Hata Y., Chang B., Ozawa S., Saito K., Ibuki K., Watanabe K., Hirono K., Nishida N., Bowles NE., and Miyawaki T.: Genetic basis of left ventricular noncompaction. The 84th Scientific sessions of AHA 2011, 2011, 11, 13-15, Orlando, U.S.A.
    11. Ibuki K., Watanabe K., Yoshimura N., Kakimoto T., Matsui M., Saito K., Ozawa S., Hirono K., Yoshida T., Noguchi K., and Ichida F.: The improvement of hypoxia correlates with neuroanatomical and developmental outcomes in infants with transposition of the great arteries or single ventricle physiology. The 84th Scientific sessions of AHA 2011, 2011, 11, 13-15, Orlando, U.S.A.
    12. Saito K., Ozawa S., Inui A., Fujisawa T., Yasumura S., Sumi S., Ibuki K., Watanabe K., Ichida F., Yoshimura N., and Miyawaki T.: Type IV collagen 7S and hyaluronic acid predict the early stage of liver cirrhosis in patients after Fontan procedure The 84th Scientific sessions of AHA 2011, 2011, 11, 13-15, Orlando, U.S.A.
    13. “n•Óˆê—m, Ö“¡˜a—R, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, Žs“c•™Žq, ŽR’†ŸO, “úŒG’qŒ›, –F‘º’¼Ž÷: TRUFILL DCS ORBIT Detachable Coil‚ÌŽg—pŒoŒ±. ‘æ22‰ñ“ú–{Pediatric Interventional CardiologyŠw‰ï, 2011, 1, 20, ‰ªŽR.
    14. —k@žF, ‹àŒ“O˜a, ‹{˜e—˜’j, ¡‘ºr•F, •l–{˜aŽq, ‹{‰º—¥Žq: Clinical and genetic analysis of XIAP deficiency in Japan. ‘æ4‰ñ“ú–{–Ɖu•s‘SÇŒ¤‹†‰ï, 2011, 1, 22, •Ÿ‰ª.
    15. ’‡‰ª‰pK, ŽíŽsq’ˆ, ‹àŒ“O˜a, ‹{˜e—˜’j, ’|èrˆê˜Y, ŽR“c‰ë•¶, —L‰ê@³, M.S.Hershfield: –{–M‰‚Ì’x”­Œ^ADAŒ‡‘¹Ç‚Ì‚P—á. ‘æ4‰ñ“ú–{–Ɖu•s‘SÇŒ¤‹†‰ï, 2011, 1, 22, •Ÿ‰ª.
    16. –쑺ŒbŽq, ‘å’ØŒc•ã,‹àŒ“O˜a, ‹{’n@[, “y‰®–M•F, ׈ä@‘n, ÎàV@L, ‹{˜e—˜’j: ƒpƒ‰ƒtƒBƒ“•ï–„”÷¬ŒŸ‘Ì‚©‚çƒLƒƒ‰ˆâ“`Žq‚ðŒŸo‚µ“¾‚½’†“ªŠWâ|Œ´”­–E‘ƒŒ^‰¡–ä‹Ø“÷Žî‚̈ê—á. ‘æ11‰ñ“ú–{‰¡–ä‹Ø“÷ŽîŒ¤‹†ƒOƒ‹[ƒvŒ¤‹†‰ï, 2011, 1, 29, “Œ‹ž.
    17. ‘å’ØŒc•ã, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ÎàV@L, ‹{’n@[, “y‰®–M•F, ׈ä@‘n: ƒpƒ‰ƒtƒBƒ“•ï–„”÷¬ŒŸ‘Ì‚©‚çƒLƒƒ‰ˆâ“`Žq‚ðŒŸo‚µ“¾‚½’†“ªŠWâ|Œ´”­–E‘ƒŒ^‰¡–ä‹Ø“÷Žî‚̈ê—á. ‘æ33‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ï, 2011, 2, 11, ‹à‘ò.
    18. ŽíŽsq’ˆ: ŒJ‚è•Ô‚·”xoŒŒ‚É‚æ‚è’·Šú’ÁÃ‚ð‹­‚¢‚ç‚ꂽS‘©Œ^S‹ØÇ‚Ì7ΗŽ™—á. ‘æ38‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï, 2011,2,24-26, ‰¡•l.
    19. ŽíŽsq’ˆ: ’°ŠÇoŒŒ«‘å’°‹Û(EHEC)W’cŠ´õ‚É‹Nˆö‚µ‚½‹}«”]Ç‘½”­—á‚ւ̑Ήž`˜g‘g‚Ý‚ð‰z‚¦‚½˜AŒg‚Ìd—v«`.‘æ11‰ñ–k—¤¬Ž™‹~‹}?W’†Ž¡—ÃŒ¤‹†‰ï, 2011, 5, 14, ‹à‘ò.
    20. ŽíŽsq’ˆ, ™ŽR–¾Žq, ‹{˜e—˜’j: ¬Ž™‰Èˆã‚É‚¨‚¯‚éЊQˆã—Â̂ ‚è•û‚Ƃ͉½‚©. ‘æ11‰ñ–k—¤¬Ž™‹~‹}?W’†Ž¡—ÃŒ¤‹†‰ï, 2011, 5, 14, ‹à‘ò.
    21. –xìT“ñ˜Y, ŽíŽsq’ˆ: •xŽRŒ§‚ł̉ߋŽ10”N‚É‚¨‚¯‚é“ûŽ™CPAÇ—á”À‘—‚ÌŒ»ó. ‘æ11‰ñ–k—¤¬Ž™‹~‹}?W’†Ž¡—ÃŒ¤‹†‰ï, 2011, 5, 14, ‹à‘ò.
    22. ‘«—§—Yˆê: ŒöŠJÀ’k‰ï Šî’²u‰‰u¬Ž™‰È‚©‚猩‚½ One Airway, One Diseasev. ‘æ23‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2011, 5, 14-15, ç—t.
    23. ”ÂàVŽõŽq, ‘«—§—Yˆê, ˆÉ“¡’¼, ‰ºð’¼Ž÷, “¡àV—²•v, Šâ“c@—Í, ‹{˜e—˜’j: ŒoŒû•‰‰×ŽŽŒ±‚ŃAƒiƒtƒBƒ‰ƒLƒV[ƒVƒ‡ƒbƒN‚ð’悵‚½—‘ƒAƒŒƒ‹ƒM[‚̈ꗎ™—á. ‘æ23‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2011, 5, 14-15, ç—t.
    24. ˆÉ“¡–õ“TA‰ª•””üŒbA”ÂàVŽõŽqA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’j: ¬Ž™šb‘§‚É‚¨‚¯‚é”x‹@”\ (FEV1,FEV1/FVC, FEF25-75) ‚ƃRƒ“ƒgƒ[ƒ‹ƒŒƒxƒ‹‚Æ‚ÌŠÖŒW.. ‘æ23‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2011, 5, 14-15, ç—t.
    25. ‹{@ˆêŽu, Œ´ˆä•ü”ü, “¡–Ø–õŽq, ‘q–{@’, –{‹½˜a‹v, ‹{˜e—˜’j: Šá‰È“IˆÙí‚Å”­Œ©‚³‚ꂽSepto-Optic Dysplasia‚Ì2“ûŽ™—á. ‘æ53‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2011, 5, 26-28, ‰¡•l.
    26. Œ´ˆä•ü”ü, ‹{@ˆêŽu, ‘q–{@’, “¡–Ø–õŽq, “c’‡çH, ‹{˜e—˜’j: V¶Ž™Šú‚ɗΓàá‚Å”­Ç‚µ‚½_ŒoüˆÛŽîÇ1Œ^‚Ì1—á. ‘æ53‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2011, 5, 26-28, ‰¡•l.
    27. –{‹½˜a‹v, ‹{@ˆêŽu, Œ´ˆä•ü”ü, “¡–Ø–õŽq, “c’‡çH, ‘q–{@’, ‹{˜e—˜’j: ¬Ž™–Ɖu«’†•_ŒoŽ¾Š³‚Ì—Õ°@Å‹ß‚Ìi•à —n˜A‹ÛŠ´õŠÖ˜A«¸__ŒoŽ¾Š³‚Ì—Õ°‘œ‚¨‚æ‚уŠƒ\ƒKƒ“ƒOƒŠƒIƒVƒhR‘Ì‚Ì—z«—¦. ‘æ53‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2011, 5, 26-28, ‰¡•l.
    28. –쑺ŒbŽq, ‘å’ØŒc•ã, ‹àŒ“O˜a, ‹{˜e—˜’j: ƒTƒCƒ‚ƒOƒƒuƒŠƒ““Š—^21‚©ŒŽŒã‚ÉŠ°‰ð‚ª“¾‚ç‚ꂽdÇŒ^AA (RCC) ‚Ì‚P—á. ‘æ18‰ñ¬Ž™Ä¶•s—Ç«•nŒŒŽ¡—ÃŒ¤‹†‰ï, 2011, 5, 28, –¼ŒÃ‰®.
    29. ŽíŽsq’ˆ:‚±‚Ç‚à‚Ì”­”M‚ ‚ꂱ‚ê`‰Šú‘Ήž‚ð’†S‚É`.Žs–¯ŒöŠJuÀ •a‹C‚̃VƒOƒiƒ‹, 2011, 5, 28, •xŽR.
    30. ”ÂàVŽõŽq, ‰ª•””üŒb, ”óŒû@Žû, ˆÉ“¡–õ“T, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ƒXƒpƒCƒƒƒgƒŠ[‚ɂČċz‹@”\—ÇD‚Æ”»’f‚³‚ꂽšb‘§¬Ž™‚É‚¨‚¯‚éimpulse oscillation systemiIOSj‚ð—p‚¢‚½‹C“¹‰Â‹t«‚ÌŒŸ“¢. ‘æ28‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï, 2011, 6, 4-5, ‰¡•l.
    31. ŽíŽsq’ˆ, ˜a“c‘ñ–ç, ‹{˜e—˜’j: ’ጌ“œ¨‡‚É‚Ä‹~‹}”À‘—‚³‚ꂽBMI 7.8‚ÌdÇÛHáŠQ—Ž™‚É‚¨‚¯‚éŠÇ—ŒoŒ±. ‘æ25‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï, 2011,6,10-11, “Œ‹ž.
    32. ™ŽR–¾Žq, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, ¬àVˆ»‰À, Žs“c•™Žq, ‹{˜e—˜’j, ¬‰Y@Ž, “¡“cC•½, “ñ’J@•: ‘m–X•Ù‹t—¬‚É‚æ‚é”xÖ¬‚¤‚ÁŒŒ‚ɑ΂µ‚ăoƒ‹[ƒ“S–[—ôŠJp‚ðŽ{s‚µA‹~–½‚µ“¾‚½V¶Ž™S‹Ø‰Š‚Ì‚P—á. ‘æ302‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï, 2011, 6, 12, •Ÿˆä.
    33. ’‡‰ª²’qŽq, Œ´ˆä•ü”ü, ’‡‰ª‰pK, ”ÂàVŽõŽq, ‹{˜e—˜’j: ƒoƒ‹ƒuƒŽ_’†“Å‚É‚æ‚éis«ˆÓŽ¯áŠQ‚ð”F‚ß‚½‚PÎ’jŽ™—á. ‘æ302‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï, 2011, 6, 12, •Ÿˆä.
    34. ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ”óŒû@Žû, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‚Ì‹CŠÇŽxšb‘§‚É‚¨‚¯‚éIOSiimpulse oscillation systemj‚Ì—L—p«‚ɂ‚¢‚ÄD‘æ14‰ñ–k—¤¬Ž™šb‘§Œ¤‹†‰ï, 2011, 6, 18, ‹à‘ò.
    35. âV“¡˜a—R, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, “n•Óˆê—m, Žs“c•™Žq, ‹{˜e—˜’j, ‰Á“¡—I–ç, “cŒû‰ë“o, –x“àˆÐ²’j, ‹´–{ª–ç, –F‘º’¼Ž÷: “ú–{læ“V«SŽ¾Š³Š³Ž™‚É‚¨‚¯‚éƒ[ƒtƒ@ƒŠƒ“•K—v“Š—^—Ê‚ÉŠÖ‚·‚éVKORC1‚̈â“`Žq‘½Œ^‚̉e‹¿‚ɂ‚¢‚Ä. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    36. âV“¡˜a—R, ¬àVˆ»‰À, Š£‚ ‚â‚Ì, “¡‘ò’m—Y, ˆÀ‘º@•q, Šp@dŠì, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, Žs“c•™Žq, –F‘º’¼Ž÷, ‹{˜e—˜’j: @ƒtƒHƒ“ƒ^ƒ“pŒã‚ÌŠÌüˆÛ‰»‚ÉŠÖ‚µ‚Ä4Œ^ƒRƒ‰[ƒQƒ“7S‚¨‚æ‚уqƒAƒ‹ƒƒ“Ž_‚Ì‘Šú”­Œ©ƒ}[ƒJ[‚Æ‚µ‚Ä‚Ì—L—p«. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    37. ¬àVˆ»‰À, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, Žs“c•™Žq, ‹{˜e—˜’j: ¬Ž™æ“V«SŽ¾Š³‚É”º‚¤”x‚ŒŒˆ³‚ւ̃^ƒ_ƒ‰ƒtƒBƒ‹‚ÌŽg—pŒoŒ±. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    38. ˆÉŒ\“ñ˜Y, âV“¡˜a—R, Š`–{‘½ç‘ã, ¬àVˆ»‰À, “n•Óˆê—m, ‹g“cär, Žs“c•™Žq, ‹{˜e—˜’j, “úŒG’qŒ›, –F‘º’¼Ž÷, ¼ˆäŽOŽ}: æ“V«SŽ¾Š³Ž™‚É‚¨‚¢‚Ä’áŽ_‘fŒŒÇ‚̉ü‘P‚Í”]‚̬’·‚Æ”­’B—\Œã‚ð‰ü‘P‚·‚é`Š®‘S‘匌ŠÇ“]ˆÊÇ‚Æ’PSŽºÇ‚Ì’†Šú—\Œã‚Ì”äŠr`. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    39. ‹{è‚ ‚ä‚Ý, ¬ŒIˆºŽq, ’·’J“c—Sˆê, Žs“c•™Žq: ¬Ž™‚ÌHŒã‚É‚¨‚¯‚éƒgƒŠƒOƒŠƒZƒŠƒh’l‚¨‚æ‚ÑLDLƒRƒŒƒXƒeƒ[ƒ‹ŒvŽZ’l‚Ì•]‰¿. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    40. ‹´–{ˆè•v, ¬àVˆ»‰À, Žs“c•™Žq: ŠwZS‘Ÿ•aŒŸf‚ÅŒ©‚‚©‚éPVCÇ—á‚ÌSƒGƒR[‚É‚æ‚éŒ`‘Ô“I“Á’¥. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    41. ™ŽR–¾Žq, “n•Óˆê—m, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, Žs“c•™Žq, “¡“cC•½, “ñ’J@•: ‘m–X•Ù‹t—¬‚É‚æ‚é”xÖ¬‚¤‚ÁŒŒ‚É‚½‚¢‚µ‚ăoƒ‹[ƒ“S–[—ôŠJp‚ðŽ{s‚µA‹~–½‚µ“¾‚½V¶Ž™S‹Ø‰Š‚Ì‚P—á. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    42. ’‡‰ª‰pK, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, “n•Óˆê—m, Žs“c•™Žq, ‹{˜e—˜’j, ŽR’†ŸO, ‘å‚TŒá, “úŒG’qŒ›, –F‘º’¼Ž÷: ’á—p—ʃAƒ~ƒIƒ_ƒƒ“‚ª—LŒø‚Å‚ ‚Á‚½¬Ž™“«•s®–¬3—á‚ÌŒoŒ±. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    43. ŽíŽsq’ˆ: ’°ŠÇoŒŒ«‘å’°‹Û(EHEC)Š´õ‚É‚æ‚é‹}«‰óŽ€«”]ǂ̉摜ŠŒ©. ‘æ26‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2011,7,10, •xŽR.
    44. ”ª–ØMˆê, ‹{ˆêŽu, ŽíŽsq’ˆ: ’°ŠÇoŒŒ«‘å’°‹ÛO-111 ƒEƒCƒ‹ƒXŠ´õ‚É”F‚ß‚ç‚ꂽ‹}«‰óŽ€«”]ǂ̉摜ŠŒ©‚Ì„ˆÚ‚ɂ‚¢‚Ä@•½¬23”N•xŽRŒ§‚Å”F‚ß‚ç‚ꂽO-111ŠÖ˜A”]Ç‚Ì“ÁˆÙ‚ȉ摜ŠŒ©‚ðf’f‚·‚邽‚ß‚É. ‘æ26‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2011,7,10, •xŽR.
    45. –쑺ŒbŽq, –x]’åŽu, ŽíŽsq’ˆ, ‹{˜e—˜’j, ¼‘q—TŠì: ’°ŠÇoŒŒ«‘å’°‹ÛO-111 ƒXƒeƒƒCƒhƒpƒ‹ƒX—Ö@‚ðs‚Á‚½HUS‚Ì1—á. ‘æ26‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2011,7,10, •xŽR.
    46. ’––”’qŽÀ, ‹g“cär, ”¨èŠì–F, ¡‘º”Ž–¾, ‹{˜e—˜’j: Šw“¶Œ’f‚ð—p‚¢‚½‘ŽYŽ™‚ƶŠˆKŠµ•aƒŠƒXƒNˆöŽq‚ÉŠÖ‚·‚錟“¢. ‘æ47‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï, 2011, 7, 10-12, ŽD–y.
    47. Š`–{‘½ç‘ã, ‹g“cär, ‹{˜e—˜’j: ‘ŽYŽ™‚Ì”­’BŽx‰‡‚É‚¨‚¯‚éƒxƒCƒŠ[“û—cŽ™”­’BŒŸ¸(‘æ3”Å)‚Ì—L—p«‚ÌŒŸØ. ‘æ47‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï, 2011, 7, 10-12, ŽD–y.
    48. ŽíŽsq’ˆ: ’°ŠÇoŒŒ«‘å’°‹Û(EHEC)W’cŠ´õ‚É‹Nˆö‚µ‚½‹}«”]Ç‘½”­—á‚ւ̑Ήž`˜g‘g‚Ý‚ð‰z‚¦‚½˜AŒg‚Ìd—v«`.‘æ15‰ñ’°ŠÇoŒŒ«‘å’°‹ÛŠ´õÇŒ¤‹†‰ï,2011,7,15-16, ‘åã.(µ‘Òu‰‰)
    49. âV“¡˜a—R, ‚èˆê˜N, œA–ìŒbˆê, “n•Óˆê—m, ¬àVˆ»‰À, Žs“c•™Žq, ‹{˜e—˜’j:‹}«Šúìè•a‚Ì—¬ŒŒ’†––½ŒŒ’PŠj‹…×–E‚É‚¨‚¯‚éƒ}ƒCƒNƒRNA‚É‚æ‚émRNA‚Ì”­Œ»§Œä‚̉”\«. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï, 2011, 8, 3-4, ‰¡•l.
    50. ‘«—§—Yˆê: ¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚é‹}«”­ìŠÇ—. ‘æ5‰ñ‘Š–ÍŒ´—Õ°ƒAƒŒƒ‹ƒM[ƒZƒ~ƒi[, 2011, 8, 5-7, ‰¡•l.
    51. âV“¡˜a—R, “n•Óˆê—m, ¬àVˆ»‰À, Žs“c•™Žq, ‹{˜e—˜’j:“«ìè•a‚ɑ΂·‚éƒVƒNƒƒXƒ|ƒŠƒ“A‚ÌŒø‰Ê‚¨‚æ‚Ñì—p‹@˜‚ÌŒŸ“¢. ‘æ15‰ñìè•aŽ¡—ç˜b‰ï, 2011, 8, 14, “Œ‹ž.
    52. ‘«—§—Yˆê: ‹³ˆçƒZƒ~ƒi[u“û—cŽ™šb‘§‚Ìf’f‚ÆŽ¡—Ãv‘æ114‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï, 2011, 8, 12-14, “Œ‹ž.
    53. ŽíŽsq’ˆ, Œ´ˆä•ü”ü, ‹{˜e—˜’j: Š´õŒ¹‚Æ‚µ‚ÄŽº“àŽ”ˆç‚̃PƒdƒƒŠƒNƒKƒ‚ª‹^‚í‚ꂽSalmonella poonaŠ´õÇ‚Ì“ûŽ™—á. ‘æ114‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï, 2011, 8, 12-14, “Œ‹ž.
    54. âV“¡˜a—R, ‚èˆê˜N, “n•Óˆê—m, ¬àVˆ»‰À, Žs“c•™Žq, ‹{˜e—˜’j: ‹}«Šúìè•a‚Ì—¬ŒŒ’†––½ŒŒ’PŠj‹…×–E‚É‚¨‚¯‚éƒ}ƒCƒNƒRNA‚É‚æ‚émRNA‚Ì”­Œ»§Œä‚̉”\«`miR-93‚É‚æ‚éVEGFA‚̧Œä`. ‘æ114‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï, 2011, 8, 12-14, “Œ‹ž.
    55. ™ŽR–¾Žq, “n•Ó—S‹I, ‘å’ØŒc•ã, ŽíŽsq’ˆ, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ‹CŠÇˆ³”r‚ð‚«‚½‚µ‚½“ûŽ™_Œo‰èŽî‚Ì2—á. ‘æ114‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï, 2011, 8, 12-14, “Œ‹ž.
    56. ’‡‰ª‰pK, ŽíŽsq’ˆ, ‹àŒ“O˜a, ’|èrˆê˜Y, ŽR“c‰ë•¶, —L‰ê@³, ‹{˜e—˜’j: –{–M‰‚Ì’x”­Œ^ADAŒ‡‘¹Ç‚̈ê—á. ‘æ114‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï, 2011,8,12-14, “Œ‹ž.
    57. ’‡‰ª²’qŽq, ”óŒû@Žû, ‘«—§—Yˆê, ‹{˜e—˜’j, ŽsŠÛ’qG, aŒû’BO, ¡ˆää‰p, ã“cN‹v, ”óŒû¹F, ìú±ˆê‹P: •xŽRŒ§‚É‚¨‚¯‚é2Ζ¢–žŽ™‚Ì•êe‚É‚¨‚¯‚鬎™‚Ì‹C“¹ˆÙ•¨‚ɂ‚¢‚Ä‚Ì’mŽ¯‚ÉŠÖ‚·‚é’²¸. ‘æ114‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï, 2011,8,12-14, “Œ‹ž.
    58. ’Þ@_”V, ‹{@ˆêŽu, Œ´ˆä•ü”ü, ’‡‰ª²’qŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ‰º“‡Œ\Žq, ŽR–{rŽŠ: ƒAƒŒƒCCGH‚É‚æ‚賊m‚ÉŒ‡Ž¸•”ˆÊ‚𓯒肵‚½‚W”ÔõF‘Ì•”•ªŒ‡Ž¸‚̈ê—á. ‘æ47‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï, 2011, 8, 21, –¼ŒÃ‰®.
    59. “ˆ”öˆ»Žq, ’––”’qŽÀ, ”óŒû@Žû, ‹g“cär, ‹{˜e—˜’j: ’°ŠÇoŒŒ«‘å’°‹ÛŠ´õ‚É”º‚¤HUS”­Ç•ê‘Ì‚æ‚è‹Ù‹}’鉤؊J‚Åo¶‚µ‚½‘ŽYŽ™. ‘æ47‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï, 2011, 8, 21, –¼ŒÃ‰®.
    60. ”ÂàVŽõŽq, ‘«—§—zŽq, ‰ª•””üŒb, ”óŒû@Žû, ˆÉ“¡–õ“T, ‘«—§—Yˆê, ‹{˜e—˜’j: “–‰È‚É‚¨‚¯‚é—‘ƒAƒŒƒ‹ƒM[‚ɑ΂·‚é‹}‘¬ŒoŒû–Ɖu—Ö@‚ÌŒoŒ±. ‘æ14‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2011, 9, 3, •xŽR.
    61. “n•Óˆê—m, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq, ’†ˆäG˜a, “úŒG’qŒ›, –F‘º’¼Ž÷: 64—ñMDCT‚ð—p‚¢‚½SŽº“à\‘¢•]‰¿. ‘æ39‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ï, 2011, 9, 10, •Ÿˆä.
    62. ¬àVˆ»‰À, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, Žs“c•™Žq, ’†ˆäG˜a, “úŒG’qŒ›, –F‘º’¼Ž÷: ¬Ž™æ“V«SŽ¾Š³‚É”º‚¤”x‚ŒŒˆ³Ç‚ւ̃AƒhƒVƒ‹ƒJ‚ÌŽg—pŒoŒ±. ‘æ1‰ñ–k—¤¬Ž™PAHŒ¤‹†‰ï, 2011, 9, 16, ‹à‘ò.
    63. ‹àŒ“O˜a: ƒ~ƒjƒŒƒNƒ`ƒƒ[u–Ɖu•s‘Sǂ̃XƒNƒŠ[ƒjƒ“ƒOŒŸ¸‚ÆV‚½‚ɉÁ‚í‚Á‚½Ž¾Š³‚ɂ‚¢‚Äv, ‘æ2‰ñŠÖ“Œb‰z–Ɖu•s‘SÇŒ¤‹†‰ï, 2011, 9, 18, “Œ‹ž.
    64. Αº–šŽq, ‹àŒ“O˜a, ŽR“c‘½Žq: Š³Ž™?‰Æ‘°‚Ì–Úü‚ðl‚¦‚½ƒvƒŒƒCƒ‹[ƒ€‚­‚è. ‘æ11‰ñ’†•”¬Ž™‚ª‚ñƒg[ƒ^ƒ‹ƒPƒAŒ¤‹†‰ï, 2011, 10, 1, –¼ŒÃ‰®.
    65. ŽíŽsq’ˆ: •xŽR‘åŠw•t‘®•a‰@‚É‚¨‚¯‚é‹s‘Ò—\–h‚Ö‚ÌŽæ‚è‘g‚Ý. ‘æ50‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï, 2011,10,2, •xŽR.
    66. ‹{@ˆêŽu, ‘«—§—zŽq, ‘«—§—Yˆê, ’·”ü’q‘ã, ‹{˜e—˜’j: V¶Ž™E“ûŽ™‚É‚¨‚¯‚éƒrƒ^ƒ~ƒ“K2ƒVƒƒbƒv—\–h“Š—^‚ɑ΂·‚é•ÛŒìŽÒ‚̈ӎ¯’²¸. ‘æ50‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï, 2011, 10, 2, •xŽR.
    67. Œ´ˆä•ü”ü, ‹{@ˆêŽu, ‘q–{@’, “¡–Ø–õŽq, “c’‡çH, ‹{˜e—˜’j, –{‹½˜a‹v: ƒoƒ‹ƒvƒŽ_ƒiƒgƒŠƒEƒ€“Š—^’†‚ÉFanconiÇŒóŒQ‚¨‚æ‚уJƒ‹ƒjƒ`ƒ“Œ‡–RÇ‚ð‚«‚½‚µ‚½‚R—á. ‘æ45‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï, 2011, 10, 6-7, VŠƒ.
    68. ‹{@ˆêŽu, Œ´ˆä•ü”ü,‘q–{@’, –{‹½˜a‹v, ”ª–ØMˆê, ‹{˜e—˜’j: “‚Ä‚ñ‚©‚ñ‚É‚¨‚¯‚élevetiracetam‚ÌŽ¡—ÃŒø‰Ê‚ÌŒŸ“¢. ‘æ45‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï, 2011, 10, 6-7, VŠƒ.
    69. ‚è–ƒ”ü, –쑺ŒbŽq, –x]’åŽu, ‹àŒ“O˜a, ‹{˜e—˜’j, ŒÃŽs@Œb, æ™@—, ´…’‰“¹, –쓇F”V: ”畆Œ´”­ Ewing/PET‚̈ê—á. ‘æ34‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ï, 2011, 10, 8, ‹à‘ò.
    70. ‘«—§—Yˆê: ‹³ˆçƒZƒ~ƒi[u¬Ž™ŒÄ‹zŠíŽ¾Š³‚Ì‹~‹}f—à -‹C“¹ˆÙ•¨-v ‘æ44‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï, 2011, 10, 15-16, ‰F“s‹{.
    71. ‘«—§—zŽq, ”óŒû@Žû, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ‹C“¹ˆÙ•¨Ž–ŒÌ—\–h‚Ì‚½‚ß‚Ì•ÛŒìŽÒ‚ɑ΂·‚é•ÛŒ’Žw“±‚ÉŠÖ‚·‚é’²¸. ‘æ44‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï, 2011, 10, 15-16, ‰F“s‹{.
    72. ‚è–ƒ”ü, ”ÂàVŽõŽq, “ˆ”öˆ»Žq, ’––”’qŽÀ, ‘«—§—Yˆê, ‹{˜e—˜’j, óˆä³Œp: ¶ŒãŠÔ‚à‚È‚­‚æ‚è‹z‹C«šb–‚ð”F‚ß‚½ˆôŒã”^ᇂÌV¶Ž™—á. ‘æ44‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï, 2011, 10, 15-16, ‰F“s‹{.
    73. ’––”’qŽÀ,“ˆ”öˆ»Žq, ‹g“cär, ‹{˜e—˜’j, •ÄàV—‰Â, ˆî“cvŽOŽq, âV“¡@Ž , ŽR“c’O: ‘ÙŽ™Šú‚æ‚葽”­‚·‚éœÜ‚ð”F‚ßA“ûŽ™Šú‘Šú‚æ‚èƒrƒXƒtƒHƒXƒtƒHƒl[ƒgŽ¡—ÂðŠJŽn‚µ‚½œŒ`¬•s‘S‚̈ê—á. ‘æ25‰ñ–k—¤ŽüŽYŠú?V¶Ž™Œ¤‹†‰ï, 2011, 10, 16, ‹à‘ò.
    74. Nomura K., Kanegane H., Horie S., Otsubo K., Abe A., and Miyawaki T.: Acute promyelocytic leukemia originating from leukemia cutis associated with cutaneous mastocytosis. ‘æ73‰ñ“ú–{ŒŒ‰tŠw‰ï, 2011, 10, 14-16, –¼ŒÃ‰®.
    75. Yoshida K., Toki T., Park MJ., Nagata Y., Wang R., Shiraishi Y., Sanada M., Nagasaki M., Miyano S., Kanegane H., Kawakami K., Koji K., Kojima S., Hayashi Y., Ito E., and Ogawa S.: Ehole exome analysis of transient abnormal myelopoiesis(TAM) and AMKL with Down syndrome. ‘æ73‰ñ“ú–{ŒŒ‰tŠw‰ï, 2011, 10, 14-16, –¼ŒÃ‰®.
    76. ŽíŽsq’ˆ,Žá™‰ë_,‰œŽ›@Œh,‘¾“c–M—Y,˜ZŽÔ@’,Z“c@—º:ƒ†ƒbƒPÛH‚É‚æ‚é’°ŠÇoŒŒ«‘å’°‹ÛW’cŠ´õ‚É‹Nˆö‚µ‚½‹}«”]Ç‘½”­—á‚ւ̑Ήž. ‘æ39‰ñ“ú–{‹~‹}ˆãŠw‰ï, 2011,10,18-20, “Œ‹ž.
    77. “n•Óˆê—m, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq, ’†ˆäG˜a, “úŒG’qŒ›, –F‘º’¼Ž÷: BTƒVƒƒƒ“ƒgŒo—R‚Å”x“®–¬ƒoƒ‹[ƒ“Šg’£p‚ðŽ{s‚µ‚½5—á‚Ì‚Ü‚Æ‚ß. ‘æ11‰ñ•xŽR¬Ž™zŠÂŠíŒ¤‹†‰ï, 2011, 10, 28, •xŽR.
    78. Okabe Y., Higuchi O., Itazawa T., Adachi Y., Ito Y., Yoshida K., Ohya Y., Odajima H., Akasawa A., and Miyawaki T.: Rhinitis is a risk factor for asthma in Japanese school children. Joint Congress of Asia Pacific Association of Pediatric Allergy, Respirology & Immunology and 48th Annual Meeting of Japanese Society of Pediatric Allergy and Clinical Immunology, 2011, 10, 28-30, Fukuoka.
    79. Adachi Y.: Symposium gBronchial Asthma Long-term ManagementhInhaled corticosteroid in the management of childhood asthma. Joint Congress of Asia Pacific Association of Pediatric Allergy, Respirology & Immunology and 48th Annual Meeting of Japanese Society of Pediatric Allergy and Clinical Immunology, 2011, 10, 28-30, Fukuoka.
    80. ”ÂàVŽõŽq: ƒVƒ“ƒ|ƒWƒEƒ€uV‚µ‚¢ƒoƒCƒIƒ}[ƒJ[ŒÄ‹CNOF‰Â”\«‚ÆŒÀŠE‚ðl‚¦‚é -ŒÄ‹CNO‘ª’è‚É‚æ‚éšb‘§Ž¡—ƒjƒ^ƒŠƒ“ƒO-v ‘æ48‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïA‘æ16‰ñƒAƒWƒA‘¾•½—m¬Ž™ƒAƒŒƒ‹ƒM[ŒÄ‹zŠí–ƉuŠw‰ï‡“¯Šwp‘å‰ï, 2011, 10, 28-30, •Ÿ‰ª.
    81. ‘«—§—Yˆê, ŽO‰YŽŽu, Xì‚Ý‚«, Ôâ@“O, ŽRŒûiŽq, —é–؇‘¢, ‹´–{ŒõŽi, ŸÀr—Y, Ž›–{‹M‰p, ‹ß“¡’¼ŽÀ: “Œ“ú–{‘åkЂŔíЂµ‚½‚±‚Ç‚à‚Ö‚Ìu–hƒ_ƒj‚Ê‚¢‚®‚é‚Ýv‚ð‘—‚éƒvƒƒWƒFƒNƒg‚ÌŒŸØD‘æ48‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïA‘æ16‰ñƒAƒWƒA‘¾•½—m¬Ž™ƒAƒŒƒ‹ƒM[ŒÄ‹zŠí–ƉuŠw‰ï‡“¯Šwp‘å‰ï, 2011, 10, 28-30, •Ÿ‰ª.
    82. ‘«—§—zŽq, ‰ª•””üŒb, ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, •£àV—³–ç, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™šb‘§‚̃Rƒ“ƒgƒ[ƒ‹ó‘Ô•]‰¿‚É‚¨‚¯‚éÅ‘åŒÄ‹C’†ŠÔ—¬—ÊiFEF25-75j‚Ì—Õ°“IˆÓ‹`. ‘æ48‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïA‘æ16‰ñƒAƒWƒA‘¾•½—m¬Ž™ƒAƒŒƒ‹ƒM[ŒÄ‹zŠí–ƉuŠw‰ï‡“¯Šwp‘å‰ï, 2011, 10, 28-30, •Ÿ‰ª.
    83. ‹àŒ“O˜a: ‹³ˆçu‰‰@’°ŠÇoŒŒ«‘å’°‹ÛO111‚ÌW’c”­¶‚©‚çŠw‚ñ‚¾‚±‚Æ. ‘æ43‰ñ“ú–{¬Ž™Š´õÇŠw‰ï, 2011, 10, 29-30, ‰ªŽR.
    84. ”óŒû@Žû, ‰ª•””üŒb, ‘«—§—zŽq, ”ÂàVŽõŽq, ’†—ÑŒºˆê, •£àV—³–ç, ŽRŒ³ƒŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: šb‘§Ž™‚É‚¨‚¯‚é•@Çó‚Æšb‘§ƒRƒ“ƒgƒ[ƒ‹ó‘ÔA”x‹@”\AŒÄ‹CˆêŽ_‰»’‚‘f‚Æ‚ÌŠÖŒW. ‘æ61‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwpW‰ï, 2011, 11, 10-12, “Œ‹ž.
    85. ”ÂàVŽõŽq, ‰ª•””üŒb, ”óŒû@Žû, ˆÉ“¡–õ“T, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: šb‘§ƒRƒ“ƒgƒ[ƒ‹‚ª—ÇD‚ÈŽ™‚É‚¨‚¯‚éŒÄ‹C’†ˆêŽ_‰»’‚‘f‚Æ”x‹@”\‚̕ω». ‘æ61‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwpW‰ï, 2011, 11, 10-12, “Œ‹ž.
    86. ‹g“cär, “ˆ”öˆ»Žq, ’––”’qŽÀ, ‹{˜e—˜’j, •Ä“c@“N: w‚ ‚©‚¿‚á‚ñ‹äŠy•”x‚É‚æ‚éˆãŠw¶‚Ö‚ÌEarly Exposure. ‘æ56‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ï, 2011, 11, 13-15, “Œ‹ž.
    87. ‹g“cär, ’––”’qŽÀ, “ˆ”öˆ»Žq,‹{˜e—˜’j: ä`‘ÑŒŒˆâ“`Žq”­Œ»‚©‚ç‚Ý‚½¶ŠˆKŠµ•a”­Ç—\’mƒ}[ƒJ[‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ56‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ï, 2011, 11, 13-15, “Œ‹ž.
    88. “ˆ”öˆ»Žq, ’––”’qŽÀ, ‹g“cär, ‹{˜e—˜’j: ¶Œã‚Ü‚à‚È‚­‚æ‚èšb–‚ð”F‚ß‚½ˆôŒã”^ᇂÌ1—á. ‘æ56‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ï, 2011, 11, 13-15, “Œ‹ž.
    89. ”ÂàVŽõŽq, ‰ª•””üŒb, ”óŒû@Žû, ˆÉ“¡–õ“T, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: šb‘§¬Ž™‚É‚¨‚¯‚éImpulse Oscillometry System (IOS)‚ð—p‚¢‚½‹C“¹‰Â‹t«‚ÌŒŸ“¢. ‘æ19‰ñ—Õ°šb‘§Œ¤‹†‰ï, 2011, 11, 19, ‘åã.
    90. Žs“c•™Žq, ²’n@•×, Š–ì_Ž÷, ¬ìrˆê, ’†¼•q—Y: ‰ä‚ª‘‚̬Ž™ŠúS‹ØŽ¾Š³‚Ì•p“x`‰ß‹Ž‚U”NŠÔ‚̊󭎾Š³’²¸‚©‚ç`. ‘æ20‰ñ“ú–{¬Ž™S‹ØŽ¾Š³Šw‰ïŠwpW‰ï, 2011, 11, 19, “Œ‹ž.
    91. ‹àŒ“O˜a: uƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[v¬Ž™ŒŒ‰t?Žîᇈã‚É’m‚Á‚Ä‚à‚ç‚¢‚½‚¢–Ɖu•s‘SÇ. ‘æ53‰ñ“ú–{¬Ž™ŒŒ‰t?‚ª‚ñŠw‰ï, 2011, 11, 27, ‘O‹´.
    92. Αº–šŽq,‹àŒ“O˜a, ŽR“c‘½Žq: Š³Ž™?‰Æ‘°‚Ì–Úü‚ðl‚¦‚½ƒvƒŒƒCƒ‹[ƒ€‚­‚è. ‘æ53‰ñ“ú–{¬Ž™ŒŒ‰t?‚ª‚ñŠw‰ï, 2011, 11, 25-27, ‘O‹´.
    93. ‰ª•””üŒb, ”óŒû@Žû, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‚É‚¨‚¯‚é•@‰Š‚ªšb‘§‚É‹y‚Ú‚·‰e‹¿. ‘æ38‰ñ–k—¤ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2011, 12, 3, ‹à‘ò.
    94. ¯–쌰G, “¡“cˉ›, ¼“c’¼“¿, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ‘å“í´•¶: PCR–@‚É‚Ä”^`‚©‚ç׋ÛDNA‚ðŒŸo‚µ‚¦‚½ŠÌ”^ᇇ•¹–«“÷‰èŽîǂ̈ê—á. ‘æ19‰ñH×–E‹@”\ˆÙíÇŒ¤‹†‰ï, 2011, 12, 3, “Œ‹ž.

    2010”N

  • ’˜‘
    1. Žs“c•™ŽqF”ì‘åŒ^S‹ØÇDu¬Ž™‚ÌŽ¡—ÃŽwjv‰ª@–¾CŸÀr—YCŠÖŒûiˆê˜YC‚‹´®l•ÒCf’f‚ÆŽ¡—ÃŽÐC“Œ‹žC349-350, 2010D
    2. Žs“c•™ŽqFŠg’£Œ^S‹ØÇDu¬Ž™‚ÌŽ¡—ÃŽwjv‰ª@–¾CŸÀr—YCŠÖŒûiˆê˜YC‚‹´®l•ÒCf’f‚ÆŽ¡—ÃŽÐC“Œ‹žC351-352, 2010.
    3. Žs“c•™ŽqFS‹Ø‰Š.u¬Ž™‚ÌŽ¡—ÃŽwjv‰ª@–¾CŸÀr—YCŠÖŒûiˆê˜YC‚‹´®l•ÒCf’f‚ÆŽ¡—ÃŽÐC“Œ‹žC353-354, 2010D
    4. “n•Óˆê—mCŽs“c•™ŽqF¬læ“V«SŽ¾Š³CSŽº’†ŠuŒ‡‘¹DuzŠÂŠíŒ¤Cƒm[ƒgv‰iˆä—ÇŽO•ÒCf’f‚ÆŽ¡—ÃŽÐC“Œ‹žC632-634, 2010D
    5. ‘«—§—YˆêF¬Ž™‚Ì”x‰ŠDu¡“ú‚ÌŽ¡—ÃŽwj2010”N”Å|Ž„‚Í‚±‚¤Ž¡—µ‚Ä‚¢‚évŽRŒû@“OC–kŒ´Œõ•vC•ŸˆäŽŸ–î•ÒCˆãŠw‘‰@C“Œ‹žC1097-1098, 2010D
    6. ‘«—§—YˆêF“û—cŽ™šb‘§‚ÌŠÓ•Êf’fDu29th ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒX@šb‘§‚Ìf’f‚ÆŽ¡—Âɂ¨‚¯‚é–â‘è“_v‘«—§@–žCX캜ACHŽRˆê’jC‘å“c@Œ’C“Œ“c—L’q•ÒCƒ‰ƒCƒtƒTƒCƒGƒ“ƒXo”ÅC“Œ‹žC108-115, 2010D
  • Œ´’˜
    1. Hirono K., Yoshimura N., Taguchi M., Watanabe K., Nakamura T., Ichida F., and Miyawaki T.: Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery. J Thorac Cardiov Surg, 140: 346-351, 2010.
    2. Otsubo K. , Kanegane H., Eguchi M., Eguchi I.M., Tamura K., Nomura K., Abe A., Ishii E., and Miywaki T.: ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia. Cancer Genet Cytogen, 202: 22-26, 2010.
    3. Chang B., Momoi N., Shan L., Mitomo M., Aoyagi Y., Endo K., Takada I., Chen R., Xing Y., Yu X., Watanabe A., Yoshida T., Kanegane H., Tsubata S., Bowles N.E., Ichida F., Miyawaki T., Noncompaction study collaborators: Gonadal mosaicism of a TAZ (G4.5) mutation in a Japanese family with Barth syndrome and left ventricular noncompaction. Mol Genet Metab, 100: 198-203, 2010.
    4. Matsuzaki T., Matsui M., Ichida F., Nakazawa J., Hattori A., Yoshikosi K., Miyazaki M., Fujii M., Hagino I., Kagisaki K., and Yagihara T.: Neurodevelopment in 1-year-old Japanese infants after congenital heart surgery. Pediatr Int, 52: 420-427, 2010.
    5. Ito Y., Adachi Y., Itazawa T., Okabe Y., Adachi S.Y., Katsunuma T., and Miyawaki T.: Comparison of exhalation time methods (6 sec vs. 10 sec) of a hand-held exhaled nitric oxide analyzer. Pediatr Pulmonol, 45: 1005-1008, 2010.
    6. Kuramoto T., Daikoku T., Yoshida Y., Takemoto M., Oshima K., Eizuru Y., Kanda Y., Miyawaki T., and Shiraki K.: Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir. J Pharmacol Exp Ther 333: 816-821, 2010.
    7. Matsuhisa H., Yoshimura N., Niimi H., and Ichida F.: Open-heart surgery in an infant with heterozygous factor VII deficiency. Interact Cardiovasc Thorac Surg, 10: 1037-1038, 2010.
    8. Makino T., Horikawa S., Hongo K., Ichida F., Furuichi M., Ueda C., Miyawaki T., and Shimizu T.: Livedo racemosa presenting with congenital fibromuscular dysplasia. Br J Dermatol, 163: 1362-1364, 2010.
    9. Kanezaki R., Toki T., Terui K., Xu G., Wang R., Shimada A., Hama A., Kanegane H., Kawkami K., Endo M., Hasegawa D., Kogawa K., Adachi S., Ikeda Y., Iwamoto S., Taga T., Kosaka Y., Kojima S., Hayashi Y., and Ito E.: Down syndrome and GATA1 mutations in trasient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood, 116: 4631-4638, 2010.
    10. Imamura T., Sato T., Shiota Y., Kanegane H., Kudo K., Nakagawa S., Nakadate H., Tauchi H., Kamizono J., and Morimoto A.: Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan. Int J Hematol, 91: 646-651, 2010.
    11. Yoshinaga M., Takahashi H., Shinomiya M., Miyazaki A., Kuribayashi N., and Ichida F.: Impact of having one cardiovascular risk factor on other cardiovascular risk factor levels in adolescents. J Atheroscler Thromb, 17: 1167-1175, 2010.
    12. Tsurusawa M., Shimomura Y., Asami K., Kikuta A., Watanabe A., Horikoshi Y., Matsushita T., Kanegane H., Ohta S., Iwai A., Mugishima H., and Koizumi S.: Long-term results of the Japanese childhood cancer and leukemia study group studies 811, 841, 874 and 911 on chilohood acute lymphoblastic leukemia. Leukemia, 24: 335-344, 2010.
    13. Toga A., Wada T., Sakakibara Y., Mase S., Araki R., Tone Y., Toma T., Kurokawa T., Yanagisawa R., Tamura K., Nishida N., Taneichi H., Kanegane H., and Yachie A.: Clinical significance of cloned expansion and CD5 down-regulation in Epstein-barr virus (EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis. J Infect Dis, 201: 1923-1932, 2010.
    14. Sekine T., Konno M., Sasaki S., Moritani S., Miura T., Wong WS., Nishio H., Nishiguchi T., Ohuchi MY., Tsuchiya S., Matsuyama T., Kanegane H., Ida K., Miura K., Harita Y., Hattori M., Horita S., Igarashi T., Saito H., and Kunishima S.: Patients eith Epstein-Fechtner syndromes owing to MYH9 R702 mutation develop progressive proteinuric renal disease. Kidney Int, 78: 207-214, 2010.
    15. Kondo N., Nishimura T., Nishima S., Morikawa A., Aihara Y., Akasaka T., Akasawa A., Adachi Y., Arakawa H., Ikarashi T., Ikebe T., Inoue T., Iwata T., Urisu A., Ebisawa M., Ohya Y., Okada K., Odajima H., Katsunuma T., Kameda M., Kurihara K., Kohno Y., Sakamoto T., Shimojo N., Suehiro Y., Tokuyama K., nambu M., hamasaki Y., Fujisawa T., Matsui T., Matsubara T., Mayumi M., Mukoyama T., Mochizuki H., Yamaguchi K., and Yoshihara S.: Japanease pediatric guidelines for the treatment and management of bronchial asthma 2008. Pediatr Int, 52: 319-326, 2010.
    16. Kanatani K., Isao I., Al-Delaimy W., Adachi Y., Mathews W., Ramsdell J., Toyama Asian Desert-Dust and Asthma Study Team.: Desert-dust exposure is associated with increased risk of asthma hospitalization in children. Am J Respir Crit Care Med, 182: 1475-1481, 2010.
    17. Taga T., Shimomura Y., Hori T., Horikoshi Y., Ogawa A., Itoh M., Watanabe A., Saikawa Y., Ueyama J., Hyakuna N., Chin M., Iizuka S., Miyake M., Iwai A., Kamitamari A., Kanegane H., Sato N., and Tsurusawa M.: A morphology-based approach for the treatment of children with acute myeloid leukemia: A report from the Japanease Children's Cancer and Leukemia Study Group AML 9805 study. Jpn J Pediatr Hematol, 24: 283-291, 2010.
    18. Yamaji K., Okamoto T., Yokota S., Watanabe A., Horikoshi Y., Asami K., Kikuta A., Hyakuna N., Saikawa Y., Ueyama J., Watanabe T., Okada M., Taga T., Kanegane H., Kogawa K., Chin M., Iwai A., Matsushita T., Shimomura Y., Hori T., Tsurusawa M., and Japanease Children's Cancer and Leukemia Study Group: Minimal residual disease-based augmented therapy in chilohood acute lymphoblastic leukemia: a report from the Japanease Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer 55: 1287-1295, 2010.
    19. Tamhankar P.M., Zhao M., Kanegane H., and Phadke S.R.:Identification of DKC1 gene mutation in an Indian patients. Indian J Pediatr 77: 310-312, 2010.
    20. Kawashima H., Kanegane H., Mori M., imanaka K., Shinjo M., Murata T., Kasahara Y., Taniguchi Y., Sugita K., and Miyawaki T.: Hyper IgD and periodic fever syndrome in Japan. “Œ‹žˆã‰È‘åŠwŽGŽC68: 235-238, 2010D
    21. ‰ª•””üŒb, ‘«—§—Yˆê, ”ÂàVŽõŽq, ’†—ÑŒºˆê, •£àV—³–ç, ŒÜ\—’—²•v, ‘ºãIŒ[, ”öã—mˆê, ‚”ö@Š², ‘«—§—zŽq, ‹{˜e—˜’j, ‘å–îKO, ¬“c“‡”Ž, ÔàV@W: “û—cŽ™šb‘§‚̉uŠw’²¸‚Ì‚½‚ß‚ÌŽ¿–â•\‚̑Ó–«‚ÉŠÖ‚·‚錟“¢. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@24: 705-712, 2010.
  • Ç—á•ñ
    1. Harai T. , Kanegane H., Ito Y., Saito M., Hongo K., and Miyawaki T.: Case of acute cerebellar ataxia associated with primary Epstein-Barr virus infection. Pediatr Int, 52: e178-e180, 2010.
    2. Zhao M. , Kanegane H., Ouchi K., Imamura T., latour S., and Miyawaki T.: A novel XIAP mutation in a Japanese boy with recurrent pancytopenia and splenomegaly. Haematologica, 95: 688-689, 2010.
    3. ‘å’ØŒc•ãC‹àŒ“O˜aC–쑺ŒbŽqC•l“cG—YCŒI–{¹‹IC“¹‹ïL_C“c’†k‘¾˜YC‹{˜e—˜’jF¼‰Ê‘Ìyolk sac tumor‚ÌŽ¡—ÃŒo‰ß’†‚Ƀp[ƒLƒ“ƒ\ƒ“ÇŒóŒQ‚ð”­Ç‚µ‚½’jŽ™—áD“ú–{¬Ž™ŒŒ‰tŠw‰ïŽGŽC24: 150-154, 2010D
    4. –xìT“ñ˜YC“c‘ºŒ«‘¾˜YC‰eŽR—²ŽiC“n•Óˆê—mC–{‹½˜a‹vCŽs“c•™ŽqC‹{˜e—˜’jF‘¢‰eCT‚É‚æ‚é3ŽŸŒ³Ä\’zŒŒŠÇ‰æ‘œ‚É‚æ‚èf’f‚µ‚½üˆÛ‹ØŒ`¬•s‘S‚Ì1“ûŽ™—áD“ú–{¬Ž™‰ÈŠw‰ïŽGŽC114: 1588-1591, 2010D
    5. –xìT“ñ˜YC”ÂàVŽõŽqC–Ø‘]Œ´ŒåC‹àŒ“O˜aC‹{˜e—˜’jFäX•ª”嫃gƒŠƒvƒVƒ“ƒCƒ“ƒqƒrƒ^[ˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚½‰Æ‘°«äX‰Š‚Ì1—áD“ú–{¬Ž™‰ÈŠw‰ïŽGŽC114: 1603-1607, 2010D
    6. å@‹v”TCˆÉŒ\“ñ˜YC’†—ÑŒºˆêCŽÂ茒‘¾˜YC‹àŒ“O˜aC‹{˜e—˜’jFŽ¨«…“ªÇ‚Ì1—áD“ú–{¬Ž™‰ÈŠw‰ïŽGŽC114: 1723-1728, 2010D
    7. âV“¡˜a—RC’Ô¦áÁˆêC‘ºãIŒ[C–{ŠÔˆê³F—ˆ‰@ŽžS”x’âŽ~6—á‚ÌŒŸ“¢‚¨‚æ‚ÑŽ€–SŽž‰æ‘œf’f‚ÌŒoŒ±D¬Ž™‰È—Õ°C63: 515-520, 2010D
    8. “c‘ºŒ«‘¾˜YC‹g“cärC–xìT“ñ˜YC“ŒŽROKCà_“‡@äCÎàV@LCˆÉ“¡ŽÀC“‡@—FŽqC•Ä“c@“NC‰–è—LGCâV“¡@Ž C‹{˜e—˜’jF‘Ù”Õ“àãO–ÑŠà‚É‚æ‚è‘ÙŽ™•ê‘ÌŠÔ—AŒŒÇŒóŒQ‚ð”­Ç‚µ‚½“ñãO–Ñ–Œ“ñ—r–Œ«‘o‘Ù‚Ì1—áDŽüŽYŠúˆãŠwC40: 273-276, 2010D
  • ‘à
    1. Žs“c•™ŽqFS‹Øãk–§‰»áŠQD“ú–{¬Ž™‰ÈŠw‰ïŽGŽC114: 1819-1828, 2010D
    2. Žs“c•™ŽqFS‹Ø‰Š,S–ŒŽ¾Š³‚Ìup to date ¶ŽºS‹Øãk–§‰»áŠQD¬Ž™“à‰ÈC42: 730-732, 2010D
    3. Žs“c•™ŽqFS‹Ø‰Š,S–Œ‰Š ƒtƒ[ƒ`ƒƒ[ƒg‚ł݂鎄‚̈•ûD¬Ž™‰È—Õ°C63: 623-628, 2010D
    4. Žs“c•™ŽqF‚±‚±‚Ü‚Å‚í‚©‚Á‚Ä‚¢‚鎩ŒÈR‘Ì‚ÆŽ©ŒÈ–ƉuŽ¾Š³@Šg’£Œ^S‹ØÇD¬Ž™‰Èf—ÃC73i‘j: 2201-2203, 2010D
    5. ‘«—§—YˆêF‹CŠÇŽxšb‘§‚Æ‚»‚̑ΉžD“ú–{¬Ž™‰ÈŠw‰ïŽGŽC114: 23-30, 2010D
    6. ‘«—§—YˆêF¬Ž™šb‘§‚É‚¨‚¯‚é‹z“üƒÀŽhŒƒ–ò‚ÌŽg‚¢•ûD¬Ž™‰ÈC51: 1273-1278, 2010D
    7. ‘«—§—YˆêF‹CŠÇŽxšb‘§@f—ÃKƒCƒhƒ‰ƒCƒ“‚̉ðàD¬Ž™‰È—Õ°C63: 2539-2543, 2010D
    8. ‘«—§—YˆêF¬Ž™dÇšb‘§‚Ì—Õ°D—Õ°–ƉuEƒAƒŒƒ‹ƒM[‰ÈC53: 179-183, 2010D
    9. ‘«—§—YˆêF“û—cŽ™šb‘§DŒÄ‹zC29: 1194-1198, 2010D
    10. ‹àŒ“O˜aC˜a“c‘׎OC–Ø‘º@GFEBƒEƒCƒ‹ƒXŠ´õÇD¬Ž™‰ÈC51: 554-555, 2010D
    11. ‹àŒ“O˜aCVˆä^—“ÞC’J“à]ºGF–«Šˆ“®«EBƒEƒCƒ‹ƒXŠ´õÇDƒ‚ƒ_ƒ“ƒƒfƒBƒAC56: 93-99, 2010D
    12. ‹{˜e—˜’jC‹àŒ“O˜aFŒ´”­«–Ɖu•s‘SÇ-–³‚Ü‚½‚Í’áƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ-@f’f‚ÆŽ¡—ÂÌV‚µ‚¢ƒgƒŒƒ“ƒhD“ú–{—Õà¬C68: 1197-1203, 2010D
    13. ‹àŒ“O˜aC‹{˜e—˜’jFæ“V«–Ɖu•s‘SÇ‚É‚¨‚¯‚é’áƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇDŒŒ‰tƒtƒƒ“ƒeƒBƒAC20: 1983-1989, 2010D
    14. ‹àŒ“O˜a: ‚ǂ̂悤‚È‚Æ‚«‚ɖƉu•s‘SÇ‚ð‹^‚¤‚©H ¬Ž™Š´õ–Ɖu 22: 417-419, 2010.
    15. –{‹½˜a‹vC‹{@ˆêŽuF¬Ž™“«‚Ä‚ñ‚©‚ñ‚ÌŽ©ŒÈ–Ɖu“I”wŒiD¬Ž™‰ÈC51:1749-1753, 2010D
    16. ”ÂàVŽõŽqF’á”N—‚É‚¨‚¯‚éŒÄ‹z‹@”\ŒŸ¸‚ÌŽÀŒ»‚ð–ÚŽw‚µ‚ÄD“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽC24: 389-396, 2010D
    17. ”ÂàVŽõŽqC‘«—§—YˆêFƒAƒŒƒ‹ƒM[Ž¾Š³‚Ɗ‹«ˆöŽq‚̉uŠwD—Õ°–ƉuEƒAƒŒƒ‹ƒM[‰ÈC53: 36-41, 2010D
    18. ”ÂàVŽõŽqC‘«—§—YˆêF¬Ž™šb‘§‚Ì‹}«‘ˆ«‚ɑ΂·‚鉊ú‘ΉžDƒAƒŒƒ‹ƒM[‚Ì—Õ°C30: 902-906, 2010D
    19. ”ÂàVŽõŽqFImpulse oscillometry system (IOS) ‚É‚æ‚é”x‹@”\‚Ì•]‰¿•û–@D“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ïŽGŽC21: 33-37, 2010D
    20. “n•Óˆê—mCŽs“c•™ŽqFV¶Ž™Šú‰ñfpŒã‚Ì”]‚ŽŸ‹@”\áŠQDFetal & Neonatal Medicine, 2: 40-44, 2010D
    21. ‘«—§—zŽqF‚Í‚¶‚Ü‚è‚̓`ƒŠ‚Ì’†D“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽC24: 401-408, 2010D
    22. ‘å’ØŒc•ãC‹àŒ“O˜aC¬—шê˜YC‹{˜e—˜’jFIPEXÇŒóŒQ‚ƃqƒgTreg×–EDJpn J Clin Immunol, 33: 196-206, 2010D
    23. ”óŒû@ŽûC‘«—§—YˆêF‚±‚ꂾ‚¯‚Í’m‚Á‚Ä‚¨‚«‚½‚¢‹C“¹Ž¾Š³‚ÌÅVf’fŒŸ¸–@@IV. š\á‚¥ŒŒ‰tŒŸ¸@ŒŒ‰t¥¶‰»ŠwŒŸ¸D¬Ž™‰Èf—ÃC73: 1763-1765, 2010D
    24. “c‘ºŒ«‘¾˜YC‹àŒ“O˜aC‹{˜e—˜’jFŽ©ŒÈ–Ɖu«ƒŠƒ“ƒp‘BÇŒóŒQD¬Ž™‰Èf—ÃC73: 2210-2214, 2010D
    25. à_è—Y•½CáÁ‹|Œõ•¶C‘«—§—YˆêF¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2008‰ðà@ƒKƒCƒhƒ‰ƒCƒ“‚ð‚Ç‚¤“Ç‚Þ‚©g‘æ10Í@¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚é‹z“ü‹@Ší‚Æ‚»‚ÌŽg‚¢•û"D“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽC24: 241-246, 2010D

  • 2010”NŠw‰ï•ñ
    1. Miyawaki T., and Kanegane H.: Early recognition of primary immunodeficiency diseases by flow cytometry. 13th Asian Pacific Congress of Pediatrics, 2009, 10, 10-14, China. (Invited lecture)
    2. Kanegane H.: Flow cytometric diagnosis of XLP1 and 2. The world's first conference on X-linked lymphoproliferative disease, 2010, 2, 15, London.
    3. Adachi Y., Itazawa T., Matsuno M., Adachi YS., Ito Y., Okabe Y., Akasawa A., and Miyawaki T.: Association of obesity with lung function of symptom-free asthmatic children. 66th Annual Meeting of American Asthma Allergy & Immunology, 2010, 2, 26-3, 2, New Orleans, LA, USA.
    4. Itazawa T., Adachi Y., Matsuno M., Adachi YS., Ito Y., Okabe Y., Akasawa A., and Miyawaki T.: Association of obesity with asthma control in childhood asthma. 66th Annual Meeting of American Asthma Allergy & Immunology, 2010, 2, 26-3, 2, New Orleans, LA, USA.
    5. Ichida F.: Left ventricular noncompaction, Genetic clinical features and genetic background. 6th Krea-Japan-China Forum, 2010, 3, 27, Soeul. (Invited lecture)
    6. Kanegane H., Koura U., Sakaki H., Otsubo K., Nomura K., Morio T., Wada T., Yachie A., Oshima K., Ohara O., and Miyawaki T.: T-B+NK+ severe combined immunodeficiency caused by a common gamma chain deficiency. 2010 First American Primary Immune Deficiency National Conference, 2010, 5, 20-23, Philadelphia, USA.
    7. Ichida F: Left ventricular noncompaction, Genetic clinical features and genetic background. The 44th Annual Meeting of AEPC, 2010, 5, 28, Innsbruck. (Invited lecture)
    8. Ichida F. : Genetics and manifestations of Noncompaction. APPCS Panel Discussion, 2010, 7, 7, Chiba.
    9. Saito K., Hirono K., Ibuki K., Watanabe K., Ozawa S., Ichida F., Miyawaki T., and Yoshimura N.: NT-pro-BNP is sensitive to latent chronic heart failure in congenital heart disease. APPCS Panel Discussion, 2010, 7, 7, Chiba.
    10. Saito K., Hirono K., Ibuki K., Kanegane H., Ichida F., Miyawaki T., and Kemmotsu Y.: S100 proteins could not be suppressed by infliximab treatment in refractory Kawasaki disease. APPCS Panel Discussion, 2010, 7, 7, Chiba.
    11. Ibuki K., Saito K., Hirono K., Yoshimura N., Taguchi M., Watanabe K., Nakamura T., Ichida F., and Miyawaki T.: Bosentan induces clinical and hemodynamic improvement in candidates for right heart bypass surgery. APPCS Panel Discussion, 2010, 7, 7, Chiba.
    12. Kanegane H., Otsubo K., Yang X., Kamachi Y., Kobayashi I., and Miyawaki T.: Identification of FOXP3-negative regulatory T-like (CD127dimCD25+CD4+) cells in patients with IPEX. 14th Meeting of the European Society for Immunodeficiencies, 2010, 10, 6-9, Turkey .
    13. Ichida F., Chang B., TNishizawa T., Furutani M., Fujiki A., Tani M., KawaguchiM., Ibuki K., Hirono K., Bowles N.E., and Matsuoka R.: Identification of a novel TPM1 mutation in a family with left ventricular noncompaction and sudden death. The 83th Scientific Sessions of AHA 2010, 2010, 11, 13-17, Chicago.
    14. Saito K., Takasaki I., Hirono K., Ibuki K., Watanabe K., Bowles N.E., Ichida F., and Miyawaki T.: MicroRNAs may control MRNA networks in circulating PBMCs during the acute phase of Kawasaki disease. The 83th Scientific Sessions of AHA 2010, 2010, 11, 13-17, Chicago.
    15. “n•Óˆê—mCˆÉŒ\“ñ˜YCâV“¡˜a—RCœA–ìŒbˆêCŽs“c•™ŽqC–F‘º’¼Ž÷F‚“x‹·ó•a•Ï‚ɑ΂·‚é’´‚‘ψ³ƒoƒ‹[ƒ“CONQUEST‚Ì—LŒø«D‘æ21‰ñ“ú–{Pediatric Interventional Cardiology (JPIC) Šw‰ïŠwpW‰ïC2010, 1, 21-23, ɪD
    16. ˆÉŒ\“ñ˜YCâV“¡˜a—RC“n•Óˆê—mCœA–ìŒbˆêCŽs“c•™ŽqCŽR’†ŸOC‘å‚TŒáC“úŒG’qŒ›C–F‘º’¼Ž÷C•x“c@‰pFTCPCpŒã‚Ì”x“®–¬ƒXƒeƒ“ƒg“àŒŒð«•Âǂɑ΂µCƒJƒe[ƒeƒ‹‚É‚æ‚錌ð‹zˆøœ‹Ž‚ðs‚Á‚½2Ç—áD‘æ21‰ñ“ú–{Pediatric Interventional Cardiology (JPIC) Šw‰ïŠwpW‰ïC2010, 1, 21-23, ɪD
    17. ¬‰Y@ŽCå@‹v”TC‘å’ØŒb•ãC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jC•õŠÝŽu’ÃŽqCX”ö—FGC˜a“c‘׎OC’J“à]ºGC‘哈GˆêC¬Œ´@ŽûF“¯Žíœ‘ˆÚA‚É‚Ä‹~–½‚µ‚¦‚½dǃTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠ´õLJ•¹dÇ•¡‡–Ɖu•s‘SÇ‚Ì1—áD‘æ3‰ñ“ú–{–Ɖu•s‘SÇŒ¤‹†‰ïC2010, 1, 30, “Œ‹žD
    18. ‘å’ØŒc•ãC‹àŒ“O˜aF‰Eèò•”ŒðŠ´_Œoߌ´”­ALK—z«_Œo‰èŽî‚Ì3‚©ŒŽ—Ž™—áD‘æ5‰ñJNBSG‘‰ïC2010, 1, 31, “Œ‹žD
    19. ‘«—§—YˆêFJPGL2008‚ÆŽÀ’n—Õ°‚Æ‚ÌGAP‚ðŒŸØ‚·‚é|f’fEŠÇ—‚Ì‚½‚ß‚ÌŒŸ¸‚ÉŠÖ‚·‚éGAP|D‘æ18‰ñ¬Ž™—Õ°–ò—EƒAƒŒƒ‹ƒM[E–ƉuŒ¤‹†‰ïC2010, 1, 30-31, ŽOdD
    20. œA–ìŒbˆêCˆÉŒ\“ñ˜YCâV“¡˜a—RC“n•Óˆê—mCŽs“c•™ŽqC‹{˜e—˜’jCŽR’†ŸOC‘å‚TŒáC“úŒG’qŒ›C–F‘º’¼Ž÷F”x‚ŒŒˆ³‚ð—L‚·‚é‰ESƒoƒCƒpƒXŽèp“K‰ž¢“ï—á‚ɑ΂·‚éƒ{ƒZƒ“ƒ^ƒ“‚Ì—L—p«D‘æ16‰ñ“ú–{¬Ž™”xzŠÂŒ¤‹†‰ïC2010, 2, 6, “Œ‹žD
    21. å@‹v”TC¬‰Y@ŽC‘å’ØŒc•ãC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jFlHŒÄ‹zŠÇ—‰º‚Å“¯Žíœ‘ˆÚA‚ðs‚Á‚½‘SgƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠ´õLJ•¹dÇ•¡‡–Ɖu•s‘SÇ‚Ì1—áD‘æ32‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïC2010, 2, 19-20, •l¼D
    22. ‘å’ØŒc•ãCå@‹v”TC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jF”ñŠ°‰ðó‘Ô‚ÅHLA”¼‡’vŒŒ‰ƒhƒi[‚©‚ç––½ŒŒŠ²×–EˆÚA‚ðs‚Á‚½AMLC—¼‘¤–Ô–Œ‰èŽî‚Ìd•¡‚ª‚ñ‚Ì—Ž™—áD‘æ32‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïC2010, 2, 19-20, •l¼D
    23. “n•Ó—S‹IC‹{@ˆêŽuC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jC‰ª“cˆÀOCŽRè@“OCŽO‰Y³‹`Cã–ì—zŽqC’B@GŽ÷CŽÄ“c“NŽuC‘ŽRG–¾CŒKŒ´@‹­C‚‹´’å‰ÀC•Ÿ–{‘׋KC‰Í–ì”üKCˆÉìœA“¹C–؉º‰p—ŽqC–©@GC–쓇F”VC‰ª“c’¼Ž÷C–xàV@“OCÒì@‘¾F•af˜AŒgCWŠw“IŽ¡—Âɂæ‚芰‰ð‚ÉŽŠ‚Á‚½• o“à”j—ô‚µ‚½ŠÌ‰èŽî‚̈ê—áD‘æ31‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ïC2010, 2, 27, ‹à‘òD
    24. Hirono K., Saito K., Ibuki K., Watanabe K., Ichida F., and Miyawaki T.: Cyclosporin improves coronary artery lesions and inflammation via down regulation of calcineurin-NFAT signaling in refractory Kawasaki disease. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ïEŠwpW‰ïC2010, 3, 5-7, ‹ž“sD
    25. ‘åÀ–FŽqC¼‹vO“TC–F‘º’¼Ž÷C“n•Óˆê—mC¬àVˆ»‰ÀCœA–ìŒbˆêCŽs“c•™ŽqC‹{˜e—˜’jF³í¬Ž™¶Žº‹ÇŠ•Ç‰^“®“Á«FƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚ð—p‚¢‚½•]‰¿D‘æ74‰ñ“ú–{zŠÂŠíŠw‰ïEŠwpW‰ïC2010, 3, 5-7, ‹ž“sD
    26. ‹àŒ“O˜aC‹{˜e—˜’jFX-linked lymphoproliferative disease: An update. ‘æ20‰ñEBƒEƒCƒ‹ƒXŠ´õÇŒ¤‹†‰ïC2010, 3, 6, “Œ‹žD
    27. ‘å“àˆêFC¡‘ºr•FC”[’J^—R”üC‹àŒ“O˜aCæâ@”ü›PC‹{˜e—˜’jC׈ä@‘nFXIAPŒ‡‘¹ÇiX˜A½ƒŠƒ“ƒp‘B2Œ^j‚Ì1—áD‘æ6‰ñŒŒ‹…æÃHÇŒóŒQŒ¤‹†‰ïC2010, 3, 6, “Œ‹žD
    28. ‘«—§—YˆêFƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u“û—cŽ™šb‘§‚ÆVirus-induced wheezev@‘æ9‰ñ‹ãBŠO—ˆ¬Ž™‰ÈŒ¤‹†‰ïC2010, 3, 14, ‹{èDiµ‘Òu‰‰j
    29. ¼è‘½ç‘ãFƒVƒ“ƒ|ƒWƒEƒ€uæ“V«SŽ¾Š³‚Ì”­’B‚ÉS—Šw‚͉½‚ª‚Å‚«‚é‚Ì‚©|“ûŽ™Šú”­’B‚Ì—lŽqv@‘æ21‰ñ“ú–{”­’BS—Šw‰ïŠwpW‰ïC2010, 3, 26, _ŒËD
    30. “n•Ó—S‹IC‘å’ØŒc•ãC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jF‹z‹C«šb–‚𔺂¤ŒÄ‹z¢“ï‚𗈂½‚µ‚½cŠuŽîᎂ̓ûŽ™—áD‘æ5‰ñ•xŽRERƒtƒH[ƒ‰ƒ€C2010, 4, 9, •xŽRD
    31. Žs“c•™ŽqF•ª–ì•ÊƒVƒ“ƒ|ƒWƒEƒ€@–ƉuƒOƒƒuƒŠƒ“•s‰ž—á‚ɑ΂·‚éRƒTƒCƒgƒJƒCƒ“—Ö@D‘æ113‰ñ“ú–{¬Ž™‰ÈŠw‰ïC2010, 4, 23-25, ·‰ªD
    32. ‹àŒ“O˜aCŠ—’r‹g˜NC‹{˜e—˜’jF‚킪‘‚ÌIPEXÇŒóŒQ‚Ì—Õ°“I¥–ƉuŠw“I“Á’¥D‘æ113‰ñ“ú–{¬Ž™‰ÈŠw‰ïC2010, 4, 23-25, ·‰ªD
    33. ”~ìŒåŽiC“n•Óˆê—mCœA–ìŒbˆêCŽs“c•™ŽqC‹{˜e—˜’jCd“cFMCã–{–õ‰îC•Ÿ“cW–çCŠ}Œ´ŒQ¶Fƒ`ƒAƒm[ƒ[‚ðŒ_‹@‚Éæ“V«–å–¬Œ‡‘¹ÇEŠÌ”xÇŒóŒQ‚Æf’f‚µ¶‘̊̈ÚA‚ðŽ{s‚µ‚½1—áD‘æ113‰ñ“ú–{¬Ž™‰ÈŠw‰ïC2010, 4, 23-25, ·‰ªD
    34. ”ÂàVŽõŽqC¼–ì³’mCˆÉ“¡–õ“TC‰ª•””üŒbC‘«—§—zŽqC‘«—§—YˆêCÔàV@WC‹{˜e—˜’jF”ì–ž‚ª¬Ž™šb‘§‚̃Rƒ“ƒgƒ[ƒ‹ó‘Ô‚â”x‹@”\‚É‹y‚Ú‚·‰e‹¿D‘æ113‰ñ“ú–{¬Ž™‰ÈŠw‰ïC2010, 4, 23-25, ·‰ªD
    35. ¼è‘½ç‘ãCŽs“c•™ŽqC¼ˆäŽOŽ}FpŒãæ“V«SŽ¾Š³Ž™‚Ì_Œo”­’B“I’·Šú—\ŒãD‘æ113‰ñ“ú–{¬Ž™‰ÈŠw‰ïC2010, 4, 23-25, ·‰ªD
    36. ‘«—§—YˆêFƒe[ƒ}ŠÙ@Šw‰ïƒAƒ[ušb‘§Ž¡—Âɂ¨‚¯‚éRLT–ò‚Ì–ðŠ„v@‘æ22‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ïC2010, 5, 8-9, ‹ž“sD
    37. ‘«—§—YˆêFƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€u“ûŽ™šb‘§‚ÆŠ´õ|“û—cŽ™šb‘§‚Ìf’f@ƒRƒc‚ƃsƒbƒgƒtƒH[ƒ‹|v@‘æ22‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ïC2010, 5, 8-9, ‹ž“sD
    38. ‘ºã—mŽqC¬“c“ˆ”ŽC‘«—§—YˆêC‹g“cKˆêC‘å–îKOCÔàV@WF¬Ž™‚É‚¨‚¯‚é‰^“®—U”­šb‘§‚ÌŽÀ‘ÔD‘æ22‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ïC2010, 5, 8-9, ‹ž“sD
    39. ”ÂàVŽõŽqC‘«—§—YˆêC‹g“cKˆêC‘å–îKOC¬“c“ˆ”ŽCÔàV@WC‹{˜e—˜’jF—cŽ™‚É‚¨‚¯‚é‘ÌŠi‚ƃAƒŒƒ‹ƒM[Ž¾Š³‚ÌŠÖŒWD‘æ22‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ïC2010, 5, 8-9, ‹ž“sD
    40. ˆÉ“¡–õ“TC”ÂàVŽõŽqC‰ª•””üŒbC”óŒû@ŽûC’†—ÑŒºˆêC•£àV—³–çC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jF¬Ž™—pšb‘§ƒRƒ“ƒgƒ[ƒ‹ƒeƒXƒg‚Å‹qŠÏ“I‚ȃRƒ“ƒgƒ[ƒ‹ó‘Ô‚ð‚Ç‚±‚Ü‚Å•]‰¿‚Å‚«‚é‚©D‘æ22‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ïC2010, 5, 8-9, ‹ž“sD
    41. ‘«—§—zŽqC”ÂàVŽõŽqC‰ª•””üŒbCˆÉ“¡–õ“TC‘«—§—YˆêC‹{˜e—˜’jFH•¨ƒAƒŒƒ‹ƒM[Ž™‚É‚¨‚¯‚镉‰×ŽŽŒ±Œã‚Ìœ‹ŽH‰ðœ‚ÌŒ»óD‘æ31‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ¤‹†‰ïC2010, 5, 13, •xŽRD
    42. ‘åÀ–FŽqC¼‹vO“TC–F‘º’¼Ž÷C“n•Óˆê—mC¬àVˆ»‰ÀCœA–ìŒbˆêCŽs“c•™ŽqC‹{˜e—˜’jF2DƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚émultiple VSDpŒã‚Ì‚Ë‚¶‚ê‚Æ‚Ù‚Ç‚¯‚Ì•]‰¿D‘æ21‰ñ“ú–{SƒGƒR[}Šw‰ïC2010, 5, 13-15, ŽD–yD
    43. Žs“c•™ŽqFæ“V«SŽ¾Š³‚É‚¨‚¯‚é”x‚ŒŒˆ³‚ÌŽ¡—ÃD“ޗǬŽ™æ“V«SŽ¾Š³ƒZƒ~ƒi[C2010, 5, 15, “Þ—ÇDiµ‘Òu‰‰j
    44. ŽíŽsq’ˆCœA–ìŒbˆêCˆÉŒ\“ñ˜YC¬‰Y@ŽC–x‰ªzŽqCVŽðŠì”ü‘ãCŽs“c•™ŽqC‹{˜e—˜’jF¬Ž™ŠCŠO”À‘—‚É‚¨‚¯‚é–â‘è“_‚ÌlŽ@D‘æ10‰ñ–k—¤¬Ž™‹~‹}EW’†Ž¡—ÃŒ¤‹†‰ïC2010, 5, 15, ‹à‘òD
    45. ‹{@ˆêŽuC–{‹½˜a‹vC‹{˜e—˜’jF“ªŠW“àãó×–EŽîᇂ̒†•_Œo‡•¹Ç‚ÉŠÖ‚·‚錟“¢D‘æ52‰ñ“ú–{¬Ž™_ŒoŠw‰ï‘‰ïC2010, 5, 20-22, •Ÿ‰ªD
    46. –{‹½˜a‹vC“¡–Ø–õŽqCŒ´ˆä•ü”üC“c’‡çHC‹{@ˆêŽuC‹{˜e—˜’jF“Á”­«‚Ä‚ñ‚©‚ñ‚Ì”F’m‹@”\D‘æ52‰ñ“ú–{¬Ž™_ŒoŠw‰ï‘‰ïC2010, 5, 20-22, •Ÿ‰ªD
    47. ŽíŽsq’ˆFƒCƒ“ƒtƒ‹ƒGƒ“ƒUAiH1N1j2009Š´õ‚É‚¨‚¯‚é‘Šúf’fƒ}[ƒJ[‚Æ‚µ‚Ä‚ÌMxA’`”’‘ª’è‚̈Ӌ`D‘æ24‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ïC2010, 5, 28-29, ‹ž“sD
    48. ‘«—§—zŽqC”ÂàVŽõŽqC‰ª•””üŒbCˆÉ“¡–õ“TC‘«—§—YˆêC‹{˜e—˜’jFH•¨ƒAƒŒƒ‹ƒM[Ž™‚É‚¨‚¯‚镉‰×ŽŽŒ±Œã‚Ìœ‹ŽH‰ðœ‚ÌŒ»óD‘æ27‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ïC2010, 5, 29-30, “Œ‹žD
    49. ‘«—§—YˆêFƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u“û—cŽ™šb‘§‚ƃA[ƒŠ[ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“v@‘æ27‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ïC2010, 5, 29-30, “Œ‹žD
    50. ‘åÀ–FŽqC¼‹vO“TC–F‘º’¼Ž÷C“n•Óˆê—mC¬àVˆ»‰ÀCœA–ìŒbˆêCŽs“c•™ŽqC‹{˜e—˜’jFƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚émultiple VSDp‘OŒã‚̬Ž™‹ÇŠ•Ç‰^“®‚Ì”äŠrD“ú–{’´‰¹”gˆãŠw‰ï‘æ83‰ñŠwpW‰ïC2010, 5, 29-31, ‹ž“sD
    51. Œ´ˆä•ü”üC‘q–{@’C“¡–Ø–õŽqC‹{@ˆêŽuCŠÛŽRŒ³ËCóˆä³ŽkC–{‹½˜a‹vF“–‰@‚ÅŽ{s‚µ‚½ˆô“ª‹CŠÇ•ª—£p‚ɂ‚¢‚Ä‚ÌŒŸ“¢D‘æ299‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ïC2010, 6, 13, •ŸˆäD
    52. ‹{@ˆêŽuCÔ‰H@’C“¡–Ø–õŽq,‘«—§—zŽqC‹{˜e—˜’jF‚¯‚¢‚ê‚ñ‚ðŒ_‹@‚É”­Œ©‚³‚ꂽƒrƒ^ƒ~ƒ“DŒ‡–R«’áƒJƒ‹ƒVƒEƒ€ŒŒÇ‚Ì1Î’jŽ™—áD‘æ299‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ïC2010, 6, 13, •ŸˆäD
    53. Žs“c•™ŽqFS‹Øãk–§‰»áŠQ‚Ì—Õ°i“Á•Êu‰‰jD‘æ71‰ñ–k—¢zŠÂŠí§˜b‰ïC2010, 6, 24, _“ÞìDiµ‘Òu‰‰j
    54. “n•Óˆ»‰ÀCÖ“¡˜a—RCˆÉŒ\“ñ˜YC“n•Óˆê—mCœA–ìŒbˆêC㨌hˆê˜YCŽs“c•™ŽqC‹{˜e—˜’jF¶ŽºS‹Øãk–§‰»áŠQ‚Ì—Õ°‘œ‚ÌŒŸ“¢|“û—cŽ™”­Ç—á‚ÆŽá”N”­Ç—á‚Ì‘Šˆá|iYIAŽóÜjD‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—tD
    55. Žs“c•™ŽqFƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[uRSV infection in Congenital heart diseasevæ“V«SŽ¾Š³‚ÆRSVŠ´õÇD‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—tD
    56. “n•Óˆê—mCˆÉŒ\“ñ˜YCâV“¡˜a—RCŽs“c•™ŽqC‹{˜e—˜’jCŽR’†ŸOC“úŒG’qŒ›C–F‘º’¼Ž÷C¬àVˆ»‰ÀF“à‘ŸöˆÊÇŒóŒQ‚ɇ•¹‚·‚é‹CŠÇŒ`‘ÔˆÙí‚̉e‹¿|MDCT‚ð—p‚¢‚½‹CŠÇ‚ÌŒ`‘Ô•]‰¿|D‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—tD
    57. ˆÉŒ\“ñ˜YCœA–ìŒbˆêC‘åÀ–FŽqC¬‰Y@ŽCâV“¡˜a—RC“n•Óˆê—mCŽíŽsq’ˆCŽs“c•™ŽqC‹{˜e—˜’jFdÇS•s‘SŠ³ŽÒ‚É‚¨‚¯‚éŠCŠOq‹ó”À‘—Žž‚ÌS‹@”\‚̕ω»D‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—tD
    58. ‹´–{ˆè•vCã–ì—zŽqC¼‰Y‰ÂjC‹à“c@®CˆÉŒ\“ñ˜YCâV“¡˜a—RC‘åÀ–FŽqCŽs“c•™ŽqC‹{˜e—˜’jFDeformed Ventricle‚ð—L‚·æ“V«SŽ¾Š³‚ɑ΂·‚éS‹@”\•]‰¿D‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—tD
    59. ¼è‘½ç‘ãCŽs“c•™ŽqC¼ˆäŽOŽ}C–F‘º’¼Ž÷F“ûŽ™‘Šú‚ÉŠJSp‚ðŽ{s‚³‚ꂽæ“V«SŽ¾Š³Ž™‚ÌAŠwŽž”F’m‹@”\D‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—t.
    60. ¼è‘½ç‘ãC¼ˆäŽOŽ}CŽs“c•™ŽqC–F‘º’¼Ž÷CŽsì@”£C”ª–ØŒ´rŽFV¶Ž™E“ûŽ™ŠJSpŒã‚̸_E‰^“®”­’B‚ÌŒpŽž“I•]‰¿D‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—tD
    61. ‘åÀ–FŽqC¼‹vO“TC–F‘º’¼Ž÷CâV“¡˜a—RCˆÉŒ\“ñ˜YC¬àVˆ»‰ÀC“n•Óˆê—mCœA–ìŒbˆêC‹´–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jFmultiple VSD‚¨‚æ‚ÑVSD2Œ^pŒã‚̶Žº‹ÇŠ•Ç‰^“®‚Ì”äŠr@2DƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚ð—p‚¢‚½•]‰¿D‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—tD
    62. âV“¡˜a—RF“«ìè•a‚ɑ΂·‚éƒVƒNƒƒXƒ|ƒŠƒ“A‚ÌŒø‰Ê‚¨‚æ‚Ñì—p‹@˜‚ÌŒŸ“¢D‘æ14‰ñìè•aŽ¡—ç˜b‰ïC2010, 7, 9, ç—tD
    63. ŽíŽsq’ˆC‹{@ˆêŽuC”ÂàVŽõŽqC–{‹½˜a‹vC‹àŒ“O˜aC‘«—§—YˆêC‹{˜e—˜’jF“–‰È‚ÅŒoŒ±‚µ‚½dǃCƒ“ƒtƒ‹ƒGƒ“ƒUAiH1N1j2009Š´õÇ‚Æ•xŽRŒ§‚É‚¨‚¯‚é‘Îô‚ðU‚è•Ô‚Á‚ÄD‘æ25‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ïC2010, 7, 11, ‚‰ªD
    64. ™ŽR–¾ŽqC‘å’ØŒc•ãC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jC•l“cG—YCŒI–{¹‹IFNeoadjuvant chemotherapy ‚ðs‚Á‚½ AT/RT‚̈ê—áD‘æ9‰ñ¬Ž™”]Žîᇎ¡—ÃŒ¤‹†‰ïC2010, 7, 17, ‘åãD
    65. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€g2010”N‚É‚¨‚¯‚é‹CŠÇŽxšb‘§‚Ì‚·‚ׂÄ"ušb‘§‚Ì”­ÇˆöŽq‚Æ‘ˆ«ˆöŽqi‰q¶‰¼à‚ðŠÜ‚Þjv@‘æ30‰ñ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒXC2010, 7, 31-8, 1, ‹ž“sDiµ‘Òu‰‰j
    66. ‘«—§—YˆêF‹CŠÇŽxšb‘§‚Ì‹}«”­ì‚ÌŽ¡—ÃD‘æ4‰ñ‘Š–ÍŒ´ƒAƒŒƒ‹ƒM[ƒZƒ~ƒi[C2010, 8, 8, ‰¡•lD
    67. ŽíŽsq’ˆC–x]’åŽuC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jC’Â@–LŽjCˆÉ’B—mŽŠF‘¢ŒŒŠ²×–EˆÚAŒã‚ɇ•¹‚µ‚½•Âǫ׋CŠÇŽx‰Š‚ɑ΂µ‚Ä—¼‘¤¶‘Ì”xˆÚA‚ðŽ{s‚µ‚½15Î’jŽ™—áD‘æ46‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ïC2010, 8, 22, ‹à‘òD
    68. ’‡‰ª‰pKC“n•Óˆê—mCâV“¡˜a—RCˆÉŒ\“ñ˜YC¬àVˆ»‰ÀCœA–ìŒbˆêCŽíŽsq’ˆC‹{@ˆêŽuCŽs“c•™ŽqC‹{˜e—˜’jC‚è–ƒ”üC㨌hˆê˜YFS”x’âŽ~‚©‚ç‘h¶‚µ“¾‚½S‘©Œ^S‹Øǂ̈ê—áD‘æ46‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ïC2010, 8, 22, ‹à‘òD
    69. ¼è‘½ç‘ãCˆÉŒ\“ñ˜YCâV“¡˜a—RC¬àVˆ»‰ÀC“n•Óˆê—mCŽs“c•™ŽqC–F‘º’¼Ž÷Fæ“V«SŽ¾Š³Ž™‚̸_‰^“®”­’BD‘æ38‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ïC2010, 8, 28, ‹à‘òD
    70. ”ÂàVŽõŽqC‰ª•””üŒbC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jF–{–M¬Ž™‚É‚¨‚¯‚éšb‘§‚Ɣ얞‚ÌŠÖŒWD‘æ13‰ñ•xŽR¬Ž™ƒAƒŒƒ‹ƒM[Œ¤‹†‰ïC2010, 9, 4, •xŽRD
    71. ™ŽR–¾ŽqC‘å’ØŒc•ãC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jCÎàV@LC‘ê“c‡ŽqF‰Eèò•”ŒðŠ´_Œoߌ´”­ALK—z«_Œo‰èŽîstageE‚Ì“ûŽ™—áD‘æ32‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ïC2010, 9, 11, ‹à‘òD
    72. Kanegane H., Zhao M., and Miyawaki T: Clinical and genetic characteristics of X-linked lyomphoproliferative diagnosed in Japan. ‘æ72‰ñ“ú–{ŒŒ‰tŠw‰ïC2010, 9, 24-26, ‰¡•lD
    73. Otsubo K., Kanegane H., Eguchi M., Ishimae M., Nomura K., Abe A., Ishii Eiichi and Miyawaki T.: A TEL-ARNT fusion in a boy with T lymphoblastic leukemia. ‘æ72‰ñ“ú–{ŒŒ‰tŠw‰ïC2010, 9, 24-26, ‰¡•lD
    74. Žs“c•™ŽqF¬Ž™Šú‚ÌS‹ØÇ|ŋ߂̘b‘è|D‘æ6‰ñ_“Þ쬎™zŠÂŠíŒ¤‹†‰ïC2010, 9, 25, _“ÞìDiµ‘Òu‰‰j
    75. Žs“c•™ŽqF¶ŽºS‹Øãk–§‰»áŠQ‚Ì—Õ°D“Œ–M‘åŠw’nˆæ˜AŒgŠwpW‰ïMeet the ExpertsC2010, 10, 1, “Œ‹žDiµ‘Òu‰‰j
    76. å@‹v”TC”~ìŒåŽiCˆÉ“¡–õ“TCŽÂ茒‘¾˜YC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jFÝ‘îƒ^[ƒ~ƒiƒ‹ƒPƒA‚ðŽ{s‚µ‚½15Α‰èŽî‚Ì—Ž™—áD‘æ10‰ñ’†•”‚ª‚ñƒg[ƒ^ƒ‹ƒPƒAŒ¤‹†‰ïC2010, 10, 2, –¼ŒÃ‰®D
    77. ¼è‘½ç‘ãC‹g“cärC“ñ’J•C¼ˆäŽOŽ}CˆÉŒ\“ñ˜YC“n•Óˆê—mCŽs“c•™ŽqFBayley“û—cŽ™”­’BŒŸ¸‚É‚æ‚é”­’B•]‰¿‚Æ‚»‚Ì—LŒø«F‘æ49‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ïC2010, 10, 3, •xŽRD
    78. ˆÉŒ\“ñ˜YC‘åÀ–FŽqCâV“¡˜a—RC¬àVˆ»‰ÀC“n•Óˆê—mCŽíŽsq’ˆCŽs“c•™ŽqC‹{˜e—˜’jFdÇS•s‘SŠ³Ž™‚É‚¨‚¯‚éŠCŠOq‹ó”À‘—Žž‚ÌS‹@”\‚̕ω»D‘æ29‰ñ“ú–{S‘ŸˆÚAŒ¤‹†‰ïŠwpW‰ïC2010, 10, 9, “Œ‹žD
    79. ŽíŽsq’ˆCŽá™‰ë_CHœA‹I“lŽiC—L“ˆ‘ñ˜YC‰œŽ›@ŒhF¬Ž™ŠCŠO”À‘—‚ÌŽÀÛ‚Æ–â‘è“_‚ÌlŽ@D‘æ38‰ñ“ú–{‹~‹}ˆãŠw‰ïC2010, 10, 9-11, “Œ‹žD
    80. Žs“c•™ŽqF“Á•Ê”­Œ¾uIVNG•s‰ž—á‚ɑ΂·‚鎡—ÃvƒƒgƒR[ƒ‹`ƒCƒ“ƒtƒŠƒLƒVƒ}ƒu—Ö@‚Ì–â‘è“_‚Æ“K³Žg—p`v@‘æ30‰ñ“ú–{ìè•aŠw‰ïEŠwpW‰ïC2010, 10, 10-11, ‹ž“sD
    81. ꎓ¡˜a—RC‚èˆê˜NCˆÉŒ\ŽŸ˜YC¬àVˆ»‰ÀC“n•Óˆê—mCœA–ìŒbˆêCƒj[ƒ‹ƒ{[ƒŒƒXCŽs“c•™ŽqC‹{˜e—˜’jFìè•a‹}«Šú‚Ì’PŠj‹…×–E‚É‚¨‚¯‚éCƒ}ƒCƒNƒRNA‚É‚æ‚émRNA‚Ì”­Œ»§Œä‚̉”\«‚ɂ‚¢‚ÄD‘æ30‰ñ“ú–{ìè•aŠw‰ïEŠwpW‰ïC2010, 10, 10-11, ‹ž“sD
    82. ’‡‰ª²’qŽqCꎓ¡˜a—RCˆÉŒ\“ñ˜YC¬àVˆ»‰ÀC“n•Óˆê—mCŽs“c•™ŽqC‹{˜e—˜’jC“úŒG’qŒ›C[Œ´ˆêWC–F‘º’¼Ž÷Fìè•aŒã‹}«S‹Ø[Ç‚É‚æ‚èŒ`¬‚³‚ꂽ¶ŽºáŽ‚ɑ΂µCŠ¥“®–¬ƒoƒCƒpƒXp‚ƶŽºŒ`¬p‚ðŽ{s‚µ‚½5Î’jŽ™—áD‘æ30‰ñ“ú–{ìè•aŠw‰ïEŠwpW‰ïC2010, 10, 10-11, ‹ž“sD
    83. –x]’åŽuCꎓ¡˜a—RCˆÉŒ\“ñ˜YC“n•Óˆê—mCŽíŽsq’ˆCŽs“c•™ŽqC‹{˜e—˜’jC“úŒG’qŒ›C–F‘º’¼Ž÷FFontanpŒã‘Šú‚Éìè•a‚ð”­Ç‚µ‚½ˆê—áD‘æ30‰ñ“ú–{ìè•aŠw‰ïEŠwpW‰ïC2010, 10, 10-11, ‹ž“sD
    84. ‹{@ˆêŽuC‚è–ƒ”üC–x]’åŽuC“n•Ó—T‹IC‘q–{@’CŒ´ˆä•ü”üC“¡–Ø–õŽqC–{‹½˜a‹vC‹{˜e—˜’jFTopiramate‚Ì“Š—^‚ðŒ_‹@‚É“Ë”­«‚Ì‹»•±ó‘Ô‚ªoŒ»‚·‚é‚悤‚É‚È‚Á‚½ŠOŒã‚Ä‚ñ‚©‚ñ‚̈ê—áD‘æ44‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ïC2010, 10, 14-15, ‰ªŽRD
    85. ˆÉ“¡–õ“TC”ÂàVŽõŽqC‘«—§—YˆêC‹{˜e—˜’jF¬Ž™—pšb‘§ƒRƒ“ƒgƒ[ƒ‹ƒeƒXƒgiC-ACTj‚É‚æ‚Á‚Ä‹qŠÏ“I‚ȃRƒ“ƒgƒ[ƒ‹ó‘Ô‚Í•]‰¿‰Â”\‚©H@‘æ18‰ñ—Õ°šb‘§Œ¤‹†‰ïC2010, 10, 16, “Œ‹žD
    86. ‹g“cärC’––”’qŽÀC“ˆ”öˆ»ŽqCˆîâ@~CâV“¡@Ž C‹{˜e—˜’jFSGAŽ™ä`‘ÑŒŒ‚É‚¨‚¯‚éˆâ“`Žq”­Œ»‚Ì–Ô—…“I‰ð͂ɂ‚¢‚ÄD‘æ24‰ñ–k—¤ŽüŽYŠú¥V¶Ž™Œ¤‹†‰ïC2010, 10, 17, ‹à‘òD
    87. Adachi Y.: Clinical aspects of severe asthma in children. The 3rd Asthma Meeting in Tokyo, 2010, 10, 23, Tokyo.
    88. ”ÂàVŽõŽqC‚è–ƒ”üC‹{@ˆêŽuC‘«—§—YˆêC‹{˜e—˜’jFƒCƒ“ƒtƒ‹ƒGƒ“ƒUƒEƒCƒ‹ƒXAiH1N1jŠ´õ‚̉ñ•œŠú‚É”­Œ©‚³‚ꂽPlastic Bronchitis‚̈ê—áD‘æ43‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ïC2010, 10, 29-30, •Ÿ‰ªD
    89. –x]’åŽuCŽíŽsq’ˆC”ÂàVŽõŽqC‘«—§—YˆêC‹{˜e—˜’jC“n•Ó—S‹IF‹CŠÇ“à‘}ŠÇ‚É‚Ä‹~–½‚µ“¾‚½dǃNƒ‹[ƒvÇŒóŒQ‚Ì1—áD‘æ43‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ïC2010, 10, 29-30, •Ÿ‰ªD
    90. ‘«—§—zŽqC”óŒû@ŽûC”ÂàVŽõŽqC‘«—§—YˆêC‹{˜e—˜’jCaŒû’BOCŽsŠÛ’q_C¡ˆää‰pCã“cN‹vC”óŒû¹FCìèˆê‹PF•xŽRŒ§‚É‚¨‚¯‚é2Ζ¢–žŽ™‚Ì•ÛŒìŽÒ‚É‚¨‚¯‚é‹C“¹ˆÙ•¨‚ÌŽ–ŒÌ—\–h‚ɂ‚¢‚Ä‚Ì’mŽ¯‚ÉŠÖ‚·‚é’²¸D‘æ43‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ïC2010, 10, 29-30, •Ÿ‰ªD
    91. ”ÂàVŽõŽqCˆÉ“¡–õ“TC‰ª•””üŒbC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jF¬Ž™‚É‚¨‚¯‚éšb‘§ƒRƒ“ƒgƒ[ƒ‹‚ÉŠÖ‚·‚é–âf•[iC-ACT, JPACj‚ÌŒ‹‰Ê‚Æ‹qŠÏ“IŽw•W‚ÌŠÖŒWD‘æ37‰ñ–k—¤šb‘§Œ¤‹†‰ïC2010, 11, 20, ‹à‘òD
    92. ‰ª•””üŒbC”ÂàVŽõŽqC‘«—§—YˆêC‹g“cKˆêC¬“c“ˆ”ŽC‘å–îKOCÔàV@WC‹{˜e—˜’jF4-5ÎŽ™‚É‚¨‚¯‚é”ì–ž‚Æšb‘§‚ÌŠÖŒWD‘æ60‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ïC2010, 11, 25-27, “Œ‹žD
    93. ”ÂàVŽõŽqCˆÉ“¡–õ“TC‰ª•””üŒbC”óŒû@ŽûC’†—ÑŒºˆêC•£àV—³–çC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jFŽ¿–â•[‚Ōċz‹@”\‚ðŠÜ‚ß‚½¬Ž™šb‘§‚̃Rƒ“ƒgƒ[ƒ‹ó‘Ô‚Í•]‰¿‰Â”\‚©D‘æ60‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ïC2010, 11, 25-27, “Œ‹žD
    94. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€u–¾‚ç‚©‚É‚È‚è‚‚‚ ‚é“‰»ˆöŽqC‚È‚º“‰»‚·‚é‚Ì‚©H|”ì–ž|v@ƒAƒXƒsƒŠƒ“•s‘ÏÇE“«šb‘§Œ¤‹†‰ï2010C2010, 11.27, “Œ‹žD
    95. ‚è–ƒ”üC”ÂàVŽõŽqC‘«—§—YˆêC‹{˜e—˜’jFƒGƒLƒmƒRƒbƒNƒX‚Æ‚ÌŠÓ•Ê‚É‹ê—¶‚µ‚½ŠÌ•gŠ´õǂ̈ꗎ™—áD‘æ42‰ñ“ú–{¬Ž™Š´õÇŠw‰ïC2010, 11, 27-28, å‘äD
    96. ”ÂàVŽõŽqC’†—ÑŒºˆêC‰ª•””üŒbC‘«—§—YˆêC‹{˜e—˜’jF¬Ž™‚Ì”­”M«Ž¾Š³‚É‚¨‚¯‚錌’†ƒvƒƒJƒ‹ƒVƒgƒjƒ“‚ÆMxA’`”’‚Ì‘ª’è‚̈Ӌ`D‘æ42‰ñ“ú–{¬Ž™Š´õÇŠw‰ïC2010, 11, 27-28, å‘äD
    97. ‘«—§—YˆêFƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u¬Ž™‹CŠÇŽxšb‘§‚ÌŠÇ—‚̃Rƒc|Šw“¶ŠúŽ¡—Âð’†S‚É|v@‘æ47‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2010, 12, 4-5, ‰¡•lD
    98. ‘«—§—zŽqCˆÉ“¡–õ“TC‰ª•””üŒbC”ÂàVŽõŽqCŽRŒ³ƒŽqC’†—ÑŒºˆêC•£àV—³–çC‘«—§—YˆêC‹{˜e—˜’jFŒÄ‹CˆêŽ_‰»’‚‘f”Z“x‘ª’èŠíCNIOX MINO‚Í6•bƒ‚[ƒh‚Å‚à’P‰ñ‘ª’è‚Å—Ç‚¢‚Ì‚©H@‘æ47‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2010, 12, 4-5, ‰¡•lD
    99. ”ÂàVŽõŽqC‰ª•””üŒbC”óŒû@ŽûC‘«—§—YˆêC‹g“cKˆêC‘å–îKOC¬“c“ˆ”ŽCÔàV@WC‹{˜e—˜’jFšb‘§—cŽ™i4-5Îj‚̃Rƒ“ƒgƒ[ƒ‹ó‘Ô‚Æ‘ÌŠi‚ÌŠÖŒWD‘æ47‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2010, 12, 4-5, ‰¡•lD
    100. ˆÉ“¡–õ“TC‰ª•””üŒbC”ÂàVŽõŽqC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jF‹CŠÇŽxšb‘§ŠÇ—‚É‚¨‚¯‚éƒXƒeƒbƒvƒ_ƒEƒ“‚ÅFeNO‚Í‘ˆ«‚ð—\‘ª‚Å‚«‚é‚©H@‘æ47‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2010, 12, 4-5, ‰¡•lD
    101. Žs“c•™ŽqF“Á•Êu‰‰@S‹Øãk–§‰»áŠQ‚Ì—Õ°D‘æ7‰ñ‚’m¬Ž™zŠÂŠíEìè•aŒ¤‹†‰ïC2010, 12, 9, ‚’mDiµ‘Òu‰‰j
    102. Žs“c•™ŽqF“Á•Êu‰‰@S‹Øãk–§‰»áŠQ‚Ì—Õ°D‘æ4‰ñˆ¤•Q”­’BS‘Ÿ•aŒ¤‹†‰ïC2010, 12, 11, ¼ŽRDiµ‘Òu‰‰j
    103. ¼“c’¼“¿C‹àŒ“O˜aC‹{˜e—˜’jF’·ŠúŠÔR‹Û–ò“Š—^‚É‚æ‚Á‚ÄŽ¡–ü‚µ‚¦‚½ŠÌ”^ᇇ•¹–«“÷‰èŽîǂ̈ê—áD‘æ18‰ñH×–E‹@”\ˆÙíÇŒ¤‹†‰ïC2010, 12, 11, “Œ‹žD
    104. ”ÂàVŽõŽqCŒ´ˆä•ü”üC˜a“c‘ñ–çC’‡‰ªGKCˆÉ“¡–õ“TC‰ª•””üŒbC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jF‹}‘¬ŒoŒû–Ɖu—Ö@‚𓱓ü‚µ‚½—‘ƒAƒŒƒ‹ƒM[‚Ì2Ç—áD‘æ300‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ïC2010, 12, 12, ‹à‘òD
    105. Š`–{‘½ç‘ãC‹g“cärC“ñ’J@•C¼ˆäŽOŽ}CˆÉŒ\“ñ˜YCâV“¡˜a—RC“n•Óˆê—mC¬àVˆ»‰ÀCŽs“c•™ŽqFBayley“û—cŽ™”­’BŒŸ¸‚É‚æ‚é”­’B•]‰¿D‘æ300‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ïC2010, 12, 12, ‹à‘òD
    106. –쑺ŒbŽqC‘å’ØŒc•ãC‹àŒ“O˜aC‹{’n@[C“y‰®–M•FC׈ä@‘nC‹{˜e—˜’jF^ŽìŽî«’†Ž¨‰Š‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚½’†“ªŠWâ|Œ´”­‰¡–ä‹Ø“÷Žîi–E‘ƒŒ^j‚̈ê—áD‘æ52‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ïC2010, 12, 17-19, ‘åãD
    107. ™ŽR–¾Žq,‘å’ØŒc•ãC–쑺ŒbŽqC ‹àŒ“O˜aCÎàV@LC‘ê“c‡ŽqC‹{˜e—˜’jF‰Eèò•”ŒðŠ´_Œoߌ´”­‚Ì ALK—z«_Œo‰èŽî‚Ì“ûŽ™‚Ì1Ç—áD‘æ52‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ïC2010, 12, 17-19, ‘åãD

    2009”N

  • ’˜‘
    1. ‹{˜e—˜’j: –Ɖu•s‘S.uV—Õ°“à‰ÈŠwv,ŠÑ˜a•q”Ž‘¼•Ò, ˆãŠw‘‰@, “Œ‹ž, 1514-1519, 2009.
    2. ‹{˜e—˜’j: 16Í. Œ´”­«–Ɖu•s‘S. u–ƉuŠwƒCƒ‰ƒXƒgƒŒƒCƒeƒbƒh‘æ7”Åv, ‚’ùŽu‘¼ŠÄ–ó, “ì]“°, “Œ‹ž, 299-310, 2009.
    3. Žs“c•™Žq: SŽ¾Š³‚ð‚à‚“û—cŽ™‚Ì“úí¶Šˆ‚ÌŠÇ—‚ÆŽw“±. ŽRŒû@“O‘¼•ÒAw¡“ú‚ÌŽ¡—ÃŽwj@2009”N”Åx, ˆãŠw‘‰@, 1003-100 , 2009.
    4. Žs“c•™Žq: SŽG‰¹. V¶Ž™E“ûŽ™•Ò.ŽüŽYŠú‘Š’k318, ŽüŽYŠúˆãŠw‘Š§† 39F512-514, 2009.
    5. ‘«—§—Yˆê: ƒAƒŒƒ‹ƒM[‚̊‹«ˆöŽq. u–Ɖu‹@\§Œä‚Ì—‰ð‚ƃAƒŒƒ‹ƒM[”­Ç‚̃ƒJƒjƒYƒ€v@’†¼Œ›Ži‘¼•Ò, —r“yŽÐ, “Œ‹ž, 170-175, 2009.
    6. ‘«—§—Yˆê, ˆÉ“¡–õ“T, ‹{˜e—˜’j: ‹CŠÇŽxšb‘§. ‰ŠÇEĶˆãŠwŽ–“TD¼“‡jŽ¡‘¼•Ò,’©‘q‘“X, “Œ‹ž, 256-259, 2009.
    7. ‹àŒ“O˜a: ‚SÍ@–ƉuEƒAƒŒƒ‹ƒM[EäPŒ´•a. u}‰ð¬Ž™‰Èv, ‹v•Û“cŒ’•v‘¼•Ò, ‹à–F“°, ‹ž“s, 95-134, 2009.
    8. œA–ìŒbˆêAŽs“c•™ŽqFƒCƒ“ƒtƒŠƒLƒVƒ}ƒu—Ö@. uìè•a‚Ì‚·‚ׂÄv, Έä³_‘¼•Ò, ƒAƒNƒ`ƒ…ƒAƒ‹¬Ž™‰È, ’†ŽR‘“X, “Œ‹ž, 112-115, 2009.
    9. ”ÂàVŽõŽq, ‘«—§—Yˆê: “ûŽ™šb‘§‚Ì’·ŠúŠÇ—. ¬Ž™‰È—Õ°ƒsƒNƒVƒXEu”N‘ã•Ê¬Ž™ƒAƒŒƒ‹ƒM[«Ž¾Š³‚ւ̑ΉžvDŒÜ\—’@—²•Ò, ’†ŽR‘“X, “Œ‹ž, 110-113, 2009.
    10. “n•Óˆê—m, Žs“c•™Žq:æ“V«SŽ¾Š³pŒã‚̸_‰^“®”­’B. Annual Review zŠÂŠí, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 278-283,2009.
  • Œ´’˜
    1. Watanabe K., Uese K., Higuchi O., Futatani T., Yoshimura N., Nakamura T., and Ichida F.: Three-dimensional computed tomographic findings of bilateral tracheal bronchus. Pediatr Cardiol 30: 87-88, 2009.
    2. Watanabe K., Matsui M., Matsuzawa J., Tanaka C.11, Noguchi K., Yoshimura N., Hongo K., Ishiguro M., Wanatabe S., Hirono K., Uese K., Ichida F., Origasa H., Nakazawa J., Oshima Y., Miyawaki T., Matsuzaki T., Yagihara T, Bilker W., and Gur RC.: Impaired neuroanatomic development in infants with congenital heart disease. J Thorac Cardiov Surg 137: 146-153, 2009.
    3. Hirono K., Konishi T., Origasa H., Ichida F., and Miyawaki T.: Echocardiographic and electrocardiographic analyses of patients with severe motor and intellectual disabilities. Heart Vessels 24: 46-53, 2009.
    4. Hirono K., Kemmotsu Y., Wittkowski H., Foell D., Saito K., Ibuki K., Watanabe K., Watanabe S., Uese K., Kanegane H., Origasa H., Ichida F., Roth J., Miyawaki T., and Saji T.: Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 65: 696-701, 2009.
    5. Hirono K., Miura M., Kanegane H., Miyamoto M., Okada Y., Yamazaki T., Yoshimura N., Ichida F., Ito E., and Miyawaki T.: Hepatocyte growth factor in transient myeloproliferative disorder of Down syndrome. Pediatr Int 51: 754-755, 2009.
    6. Saito K., Ibuki K., Yoshimura N., Hirono K., Watanabe S., Watanabe K., Uese K., Yasukouchi S., Ichida F., and Miyawaki T.: Cardiac resynchronization therapy in a 3-year-old girl with isolated noncompaction of the left ventricle and narrow QRS complex. Circ J 73: 2173-2177, 2009.
    7. Watanabe S., Hashimoto I., Saito K., Watanabe K., Hirono K., Uese K., Ichida F., Saito S., Miyawaki T., Niemabb P., and Sahn D.J.: Characterization of ventricular myocardial performance in the fetus by tissue doppler imaging. Circ J 73: 943-947,2009.
    8. Higuchi O., Adachi Y., Ichimaru T., Asai M., and Kawasaki K.: Foreign body aspiraion in children: A nationwide survey in Japan. Int J Pedia Otorhinolaryngol 73: 659-661, 2009.
    9. Ito Y., Adachi Y., Makino T., Higashiyama H., Fuchizawa T., Shimizu T., and Miyawaki T.: Expansion of FOXP3-positive CD4+CD25+ T cells associated with disease activity in atopic dermatitis. Ann Allerg Asthma Immun 103: 160-165, 2009.
    10. Morinishi Y., Imai K., Nakagawa Noriko., Sato H., Horiuchi K., Ohtsuka Y., Kaneda Yumi., Taga T., Hisakawa H., Miyaji R., Endo M., Oh-ishi T., Kamachi Y., Akahane K., Kobayashi C., Tsuchida M., Morio T., Sasahara Y., Kumaki S., Ishigaki K., Yoshida M., Urabe T., Kobayashi N., Okimoto Y., Reichenbach J., Hashii Y., Tsuji Y., Kogawa K., Yamaguchi S., Kanegane H., Miyawaki T., Yamada M., Ariga T., and Nonoyama S.: Identification of severe combined immunodeficiency by T-cell receptor excision circles quantification using neonatal guthrie cards. J Pediatr 155: 829-833, 2009.
    11. Nanki T., Takada K., Komano Y., Morio T., Kanegane H., Nakajima A., Lipsky P.E., and Miyasaka N.: Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 11: R149, 2009.
    12. Neil E. B., Hirono K., Yu X., and Ichida F.: Parvoviral Genomes are not present in endothelial cells of Kawasaki disease patients who develop coronary artery lesions. Pediatr Infect Dis J 28: 345, 2009.
    13. Horiuchi I., Mori Y., Taguchi M., Ichida F., Miyawaki T., and Hashimoto Y.: Mechanisms responsible for the altered pharmacokinetics of bosentan: Analysis utilizing rats with bile duct ligation-induced liver dysfunction. Biopharm Drug Dispos 30: 326-333, 2009.
    14. Yoshimura N., Matsuhisa H., Otaka S., Kitahara J., Murakami H., Uese K., Ichida F., and Misaki T.: Surgical management of multiple ventricular septal defects: the role of the felt sandwich technique. J Thorac Cardiovasc Surg 137: 924-928, 2009.
    15. Dougu N., Joho S., Shan L., Shida T., Matsuki A., Uese K., Hirono K., Ichida F., Tanaka K., Nishino I., and Inoue H.: Novel LAMP-2 mutation in a family with Danon disease presenting with hypertrophic cardiomyopathy. Circ J 73: 376-380, 2009.
    16. Keerthikumar S., Raju R., Kandasamy K., Hijikata A., Ramabadran S., Balakrishnan L., Ahmed M., Rani S., Selvan LD., Somanathan DS., Ray S., Bhattacharjee M., Gollapudi S., Ramachandra YL., Bhadra S., Bhattacharyya C., Imai K., Nonoyama S., Kanegane H., Miyawaki T., Pandey A., Ohara O., and Mohan S.: RAPID: Resource of Asian primary immunodeficiency diseases. Nucleic Acids Res. 37: D863-D867, 2009.
    17. Aghamohammadi A., Cheraghi T., Rezaei N., Kanegane H., Abdollahzede S., Talaei-KhoeiM., Heidari G., Zandieh F., Moin M., and Miyawaki T.: Neutropenia associated with x-linked agammaglobulinemia in an Iranian referral center. Iran J Allergy Asthma Immunol 8: 43-47,2009.
    18. Wang Y., Kanegane H., Wang X., Han X., Zhang Q., Zhao S., Yu Y., Wang J., and Miyawaki T.: Mutation of the BTK Gene and clinical feature of X-linked agammaglobulinemia in Mainland China. J Clin Immunol 29 : 352-356, 2009.
    19. Kojima N., Ohya Y., Futamura M., Akashi M., Odajima H., Adachi Y., and Akasawa A.: Exercise-induced asthma is associated with impaired quality of life among children with asthma in Japan. Allergol Int 58:187-192, 2009.
    20. Fujiwara M., Miyamoto S., Iguchi K., Matsunaka T., Sakashita H., Tsuruyama T., Kanegane H., Marusawa H., Nakase H., and Chiba T.: Acute Epstein-Barr virus infection presenting as severe gastroenteritis without infectious mononucleosis-like manifestations. Clin J Gastroenterol, 2: 398-403, 2009.
    21. “n•Óˆ»‰À, Ö“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, œA–ìŒbˆê, 㨌hˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j: ¶ŽºS‹Øãk–§‰»áŠQ‚Ì—Õ°‘œ‚ÌŒŸ“¢|“û—cŽ™”­Ç—á‚ÆŽá”N”­Ç—á‚Ì‘Šˆá|.“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ@25: 16-22, 2009.
    22. ‹{è‚ ‚ä‚Ý, ‹g‰i³•v, [“‡‹u–ç, •½“c–rŽq, ¼‘º˜aŽq, Žs“c•™Žq, ‚‹´Gl: ‚Z¶‚̶ŠˆKŠµ•a—\–hŒŸf. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ 113: 1687-1694, 2009.
    23. ”ª–ØMˆêC‹{@ˆêŽuC–{‹½˜a‹vCŒÜ\—’“oF¬Ž™‚̃Cƒ“ƒtƒ‹ƒGƒ“ƒUŠ´õ‚É”º‚¤‚¹‚ñ–Ï‚¨‚æ‚Ñ“ÁˆÙ‚È_ŒoÇó‚ɂ‚¢‚Ä|‚”M‚¹‚ñ–Ï‚¨‚æ‚шӎ¯•Ï—e‚𗈂½‚·•a‘Ԃɂ‚¢‚Ä|D’¹Žæ—Õ°‰ÈŠwC2: 63-71, 2009D
    24. ‹{è‚ ‚ä‚Ý, ‹g‰i³•v, ŽÂ‹{³Ž÷, “c’†—TŽ¡, ŒI—ÑLˆê, ˆÉ“¡‘P–ç, Žs“c•™Žq, ‚‹´Gl: ‚Z¶‚ð‘ÎÛ‚Æ‚µ‚½ƒƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€—\–hŒ’f-Ž­Ž™“‡Œ§Eç—tŒ§E•xŽRŒ§‚É‚¨‚¯‚錟fŒ‹‰Ê‚Ì”äŠr- ”ì–žŒ¤‹†15: 217-221, 2009.
    25. ’J“à]ºG, áÁ‹|Œõ•¶, ‘«—§—Yˆê, ’†‘º—˜”ü:•ÛŒìŽÒƒAƒ“ƒP[ƒg‚É‚æ‚é–k—¤’n‹æ‚É‚¨‚¯‚鬎™‹CŠÇŽxšb‘§f—Â̎À‘Ô’²¸.“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 23: 103-112, 2009.
    26. ’ßàV³m, ‘½‰ê@’, –x‰z‘×—Y, ¬ì@~, ‹e“c@“Ö, ‹àŒ“O˜a, ‰ª“c‰ë•F, •S–¼L”V, ’Â@Šî–¾, Šâˆä’©K, “n•Ó@V, “n•Ó@—Í, ‰º‘º•Ûl, ‘哇Fˆê, ¬Ž™Šà”’ŒŒ•aŒ¤‹†ƒOƒ‹[ƒv: —\–h“I“ªŠWÆŽË‚ðÈ‚¢‚½ ALLŒ^Ž¡—ÂðŽó‚¯‚½59—á‚̬Ž™ƒŠƒ“ƒp‰è‹…«ƒŠƒ“ƒpŽî‚Ì—\Œã-CCLSG-NHL960—Õ°ŽŽŒ±‚Ì•ñ-. “ú–{¬Ž™ŒŒ‰tŠw‰ïŽGŽ 23: 244-250, 2009.
    27. ‹´‘º—T–ç, –ì’Ê°‘å, _“cˆÇŽq, ‘ì@», ’|“‡‘×O, ‹àŒ“O˜a, ‹{˜e—˜’j, ”Ñ“‡ˆê½, ¼”ö‰ë•¶: IPEX ÇŒóŒQ‚ÆtŽ¾Š³. “ú–{¬Ž™t‘ŸŠw‰ïŽ 22: 131-135, 2009.
  • Ç—á•ñ
    1. Kanegane H., Nomura K., Abe A., Makino T., Ishizawa S., Shimizu T., Naoe T., and Miyawaki T.: Spontaneous regression of aleukemic cutis harboring a NPM/RARA fusion gene in an infant with cutaneous mastosytosis. Int J Hematol 89: 86-90, 2009.
    2. Kanegane H., Nakano T., Shimono Y., Zhao M., and Miyawaki T.: Pneumocytis jiroveci pneumonia as a an atypical presentation of X-linked agammaglobulinemia. Int J Hematol 89: 716-717, 2009.
    3. Sakaki H., Kanegane H., Nomura K., Goi K., Sugita K., Miura M., Ishii E., and Miyawaki T: Early lineage switch in an infant acute lymphoblastic leukemia. Int J Hematol 90: 653-655, 2009.
    4. Saito K., Ibuki K., Yoshimura N., Hirono K., Watanabe S., Watanabe K., Uese K., Yasukouchi S., Ichida F., and Miyawa T. : Successful cardiac resynchronization therapy in a 3-year-old girl eith isolated left ventricular non-compaction and narrow QRS complex -A case report - . Circ J 73: 2173-2177,2009.
    5. Matsuhisa H., Yoshimura N., Kitahara J., Otaka S., Ichida F., Funada H., and Misaki T.: An infected pseudoaneurysm following a modified Blalock-Taussig shunt. Interact Cardiovasc Thorac Surg. 8: 108-110, 2009.
    6. Imashuku S., Azuma N., Kanegane H., and Kasahara Y.: M-protein-positive chronic Epstein-barr virus infection: features mimicking HIV-1 infection. Int J Hematol 90: 235-238, 2009.
    7. Kawakami C., Inoue A., Koh M., Takitani K., Kanegane H., Miyawaki T., and Tamai H.: Three brothers of X-kinked agammaglobulinemia; the relation between phenotype and neutropenia. Int J Hematol 90: 117-119 2009.
    8. “c‘ºŒ«‘¾˜Y, ‹àŒ“O˜a, ¼“c’¼_, å@‹v”T, –쑺ŒbŽq, –ö‘ò@—´, ˜a“c‘׎O, ’J“à]ºG, ‹{˜e—˜’j: Epstein-BarrƒEƒCƒ‹ƒXŠÖ˜AŒŒ‹…æÃH«ƒŠƒ“ƒp‘gD‹…Ç‚Q—á‚É‚¨‚¯‚é–ƉuŠw“I¥ƒEƒCƒ‹ƒXŠw“I‰ðÍ. “ú–{¬Ž™ŒŒ‰tŠw‰ïŽGŽ 23: 360-365, 2009.
    9. ¼‰ª@—C㌴@—²C‹{@ˆêŽuC–쑺ŒbŽqC‹àŒ“O˜aCŠp“c‰ë•FC—é–Ø“¹—YF¼‰Ê‘Ì•”germinoma‚ÌŽ¡—Ã’†‚É‹}«ö—ó‘Ô‚ðŒJ‚è•Ô‚µ‚½ˆê—áD¸_‰ÈC15: 482-487, 2009D
    10. ‹àŒ“çt, ‘«—§—Yˆê, Žs“c•™Žq: QT‰„’·ÇŒóŒQ‚ð‡•¹‚µ‚½‹CŠÇŽxšb‘§2Ç—á‚É‚¨‚¯‚éFluticasone propionate - salmeterol combination‚Ì—L—p«. Progress in Medicine 29: 1815-1821, 2009.
    11. ¼ŒG‰pŽ¡, ŽRŠÝ“ÄŽŠ, ‰PˆäVŽ¡, ŽR“cŒj‘¾˜Y, ŽR–{’—T, ‹g“cär, ‹àŒ“O˜a: 3D-CT‚ª³Šm‚Èœ•a•Ï‚Ì”cˆ¬‚É—L—p‚Å‚ ‚Á‚½½œ“ªŠWˆÙŒ`¬Ç‚Ì‚P—á. ¬Ž™‰È—Õ°@62: 511-515, 2009.
  • ‘à
    1. Ichida F.: Left ventricular noncompaction.@Circ J. 73 : 19-26, 2009.
    2. Žs“c•™Žq: NoncompactionS‹Øãk–§‰»áŠQ. ‰Á–Θ_•¶‚ɑ΂·‚éEditorial Comment S‘Ÿ 41: 166-167, 2009.
    3. Žs“c•™Žq: Danon•a‚É‚¨‚¯‚éS‹ØÇ@™]˜_•¶‚ɑ΂·‚éEditorial Comment S‘Ÿ 41: 419-21, 2009.
    4. Žs“c•™ŽqFNoncompactionS‹Øãk–§‰»áŠQ@S‘ŸHEART's Selection 3
    5. ‘«—§—Yˆê: ƒGƒfƒBƒgƒŠƒAƒ‹uð“ú‚Ü‚Å‚Ì펯‚ÍA¡“ú‚Ì”ñ펯Hv@“ú–{¬Ž™“šb‘§ƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ïŽ 7: 189-190, 2009.
    6. ‘«—§—Yˆê: ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2008‚̉ü’ù“_ -‹}«”­ì‘Ήž-D“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ïŽ 7: 238-241, 2009.
    7. ‘«—§—Yˆê: ƒXƒeƒƒCƒh{’·ŽžŠÔì—p«ƒÀ2ŽhŒƒ–ò‡ÜŽg—p‚Ì“K‰ž. ¬Ž™“à‰È 41: 1457-1461, 2009.
    8. ‘«—§—Yˆê: ‚º‚ñ‚»‚­‚̉uŠw‚Æ—\Œã. ƒ`ƒƒƒCƒ‹ƒhƒwƒ‹ƒX 12: 398-401, 2009.
    9. ‘«—§—Yˆê: ƒƒCƒRƒgƒŠƒGƒ“hR–ò‚Ì’PܗÖ@‚Æ•¹—p—Ö@DƒAƒŒƒ‹ƒM[E–Ɖu 16: 812-818, 2009.
    10. ‘«—§—Yˆê: “ûŽ™šb‘§‚Ì‹}«”­ì‚Æ’·ŠúŠÇ—‚ւ̑ΉžD¬Ž™‰È 50: 551-557, 2009.
    11. ‘«—§—Yˆê: V‚µ‚¢ƒKƒCƒhƒ‰ƒCƒ“‚ª‘E‚ß‚é“û—cŽ™šb‘§‚ÌŽ¡—Ãí—ª. Pediatric Allergy for Clinicians 13: 64-68, 2009.
    12. ‘«—§—Yˆê: ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2008‰ü’ù‚É‚¨‚¯‚é’ˆÓ“_ -‹}«”­ì‚ւ̑Ήž‚ɂ‚¢‚Ä-DPediatric Allergy for Clinicians 13: 18-22, 2009.
    13. ‘«—§—Yˆê: ƒAƒŒƒ‹ƒM[‚Ɗ‹«ˆöŽq. ŽÀŒ±ˆãŠw 27: 3366-3371, 2009.
    14. ‹àŒ“O˜a: V¶Ž™‚É‚¨‚¯‚é–Ɖu‹@”\‚Æ‚»‚Ì”­’B. “ú–{ŽY•wl‰ÈEV¶Ž™ŒŒ‰tŠw‰ïŽ 18: 155-164, 2009.
    15. ‹àŒ“O˜a, ‹{˜e—˜’j: Duncan•a(X˜A½ƒŠƒ“ƒp‘BÇŒóŒQ). ¬Ž™‰Èf—à 72(‘): 256, 2009.
    16. ‹àŒ“O˜a, ‹{˜e—˜’j: autoimmune lymphoproliferativeÇŒóŒQ. ¬Ž™‰Èf—à 72(‘): 400, 2009.
    17. ‹àŒ“O˜a: bare lymphocyteÇŒóŒQ. ¬Ž™‰Èf—à 72(‘): 401, 2009.
    18. ‹àŒ“O˜a, æâ@”ü“ß, ‹{˜e—˜’j: –³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ. ¬Ž™‰È50: 1134-1139, 2009.
    19. ‹àŒ“O˜a, äç‰êŽq, ‹{˜e—˜’j: –Ɖu•s‘SÇ‚Ì FACS ‚É‚æ‚éŠÈˆÕf’f–@. —Õ°ŒŸ¸@53: 541-546, 2009.
    20. –{‹½˜a‹v: ’†SE‘¤“ª•”‚Éž™”g‚ðŽ‚—ǫ¬Ž™‚Ä‚ñ‚©‚ñ. ¬Ž™“à‰È 41: 435-43, 2009.
    21. ”ÂàVŽõŽq, ‘«—§—Yˆê: JPGL2008‚̉ü’ù‚ÉŠÖ‚µ‚Ä -‰¢•Ä‚̃KƒCƒhƒ‰ƒCƒ“‚Æ”ä‚ׂ½“Á’¥-.šb‘§ 22: 17-22, 2009.
    22. ”ÂàVŽõŽq: šb‘§‚Ì•a‘Ô•]‰¿F‹C—¬§ŒÀ. “ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ïŽ@20: 38-42, 2009.
    23. “n•Óˆê—m, Žs“c•™Žq: V¶Ž™ŠúS‘ŸŽèpŒã‚̸_‰^“®”­’B.¬Ž™‰È 50: 219-223, 2009.
    24. ˆÉ“¡–õ“T, ‘«—§—Yˆê: ‹CŠÇŽxšb‘§‚Ìf’f@f’f‚É‚¨‚¯‚é–âf‚ÆfŽ@–@‚ÌŠî–{D¬Ž™“à‰È 41:1388|1392, 2009.
    25. ²’n@•×, —é–ØŒ[”V, Žs“c•™Žq, ¬—Ñ@“O: ìè•a‹}«ŠúŽ¡—ÂÌÅ‘Oü. Pharma Medica 27: 167-175, 2009.
    26. ŽsŠÛ’q_, ‘«—§—Yˆê: ‘S‘’²¸‚©‚ç‚Ý‚½¬Ž™‚Ì‹CŠÇE‹CŠÇŽxˆÙ•¨‚Ìf’f‚ÆŽ¡—Ã. ¬Ž™‰È 50: 2073-2077, 2009.

  • 2009”NŠw‰ï•ñ
    1. Ichida F.: Left ventricular noncompaction. Recent advances in the cardiovascular treatment. Chungam National University-Toyama University Joint International Symposium, 2009, 2, 6, Daejeon, Korea.
    2. Adachi Y., Okabe Y., Itazawa T., Adachi Y.S., Miyawaki T., Odajima H., Ohya Y., and Akazawa A.: Validity of a questionnaire for diagnosis of asthma in younger children. 65th Annual Meeting of American Academy of Allergy & Immunology, 2009, 3, 13-17, Washington, DC, USA.
    3. Ichida F., Xing Y., Shan L., Chen R., Watanabe S., Tsubata S., Neil E.B., and Jeffrey A.T.: Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. 5th World Congress of Pediatric Cardiology and Cardiac Surgery. 2009, 6, 22, Cairns, Australia.
    4. Watanabe S., Saito K., Ibuki K., Watanabe K., Hirono K., Uese K., Ichida F., and Miyawaki T.: Clinical features of left ventricular noncompaction in infants and children. 5th World Congress of Pediatric Cardiology and Cardiac Surgery. 2009, 6, 22, Cairns, Australia.
    5. Watanabe K., Matsui M., Yoshimura N., Hirono K., Ichida F., Ohshima Y., Matsuzaki T., and Yagihara T.: Impaired neuroanatomic development in infants with congenital heart disease. 5th World Congress of Pediatric Cardiology and Cardiac Surgery. 2009, 6, 22, Cairns, Australia.
    6. Ibuki K., Hirono K., Saito K., Watanabe K., Watanabe S., Ichida F., and Miyawaki T.: Combination therapy of bosentan, beraprost and HOT improve pulmonary artery hypertension related to congenital heart disease in contraindications for right heart bypass surgery. 5th World Congress of Pediatric Cardiology and Cardiac Surgery. 2009, 6, 22, Cairns, Australia.
    7. Saito K., Hirono K., Ibuki K., Kanegane H., Ichida F., and Miyawaki T.: S100 proteins could not be suppressed by infliximab treatment in refractory Kawasaki disease. 5th World Congress of Pediatric Cardiology and Cardiac Surgery. 2009, 6, 22, Cairns, Australia.
    8. Hirono K., Ibuki K., Saito K., Watanabe K., Watanabe S., Ichida F., and Miyawaki T.: NT-pro-BNP is sensitive to latent chronic heart failure in the patients with single ventricle physiology and Tetralogy of Fallot. 5th World Congress of Pediatric Cardiology and Cardiac Surgery. 2009, 6, 22, Cairns, Australia.
    9. Hirono K., Kemmotsu Y., Toho, Saito K., Ibuki K., Kanegane H., Ichida F., Saji T., and Miyawaki T.: S100 proteins could not be suppressed by infliximab treatment in refractory Kawasaki disease. American Heart Association, Basic Cardiovascular Sciences Conference 2009, 2009, 7, 20, Las Vegas. USA.
    10. Adachi Y.: Japanese Pediatric Asthma Guideline 2008. The 2nd asthma meeting in Tokyo, 2009, 10, 3, Tokyo.
    11. Miyawaki T.: early recognition of primary immunodeficiency disease by flow cytometry. 13th Asian pacific congress of pediatrics, 2009. 10, 14-18, Shanghai, China.
    12. œA–ìŒbˆê, “n•Óˆê—m, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, “n粈»‰À, 㨌hˆê˜Y, –F‘º’¼Ž÷, Žs“c•™Žq, ‹{˜e—˜’j: ¶S’áŒ`¬ÇŒóŒQ‚̶”x“®–¬‹·ó‚ɑ΂µ‚ÄAƒtƒHƒ“ƒ^ƒ“ŽüpŠú‚ɃXƒeƒ“ƒg—¯’up‚ðs‚Á‚½3—á. ‘æ20‰ñ“ú–{Pediatric Interventional CardiologyŒ¤‹†‰ï, 2009, 1, 16, “Œ‹ž.
    13. ‹àŒ“O˜a, ‘q–{@’, –쑺ŒbŽq, ‹{˜e—˜’j, ‹g–ì“Ä”Í, ¼‘q—TŠì: t‰Š‚ð‡•¹‚µ‚½X˜A½–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì‚Q—á. ‘æ‚Q‰ñ“ú–{–Ɖu•s‘SŒ¤‹†‰ï, 2009, 1, 31, “Œ‹ž.
    14. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€uƒAƒŒƒ‹ƒM[Ž¾Š³‘‡f—Âð–ÚŽw‚µ‚Ä -ƒsƒbƒgƒtƒH[ƒ‹‚̉ñ”ð-A¬Ž™‰È‚Ì—§ê‚©‚çv@‘æ17‰ñ“ú–{¬Ž™—Õ°–ò—EƒAƒŒƒ‹ƒM[–ƉuŒ¤‹†‰ï, 2009, 1.31-2.1, ‰F“s‹{.
    15. å@‹v”T, –쑺ŒbŽq, ‹àŒ“O˜a, ‘å’ØŒc•ã, ˜a“c‘׎O, ‹{˜e—˜’j: ‘½Ê‚ȇ•¹Ç‚𔺂Á‚½X˜A½ŒŒ¬”ÂŒ¸­ÇŠ³ŽÒ‚ɑ΂·‚é”ñŒŒ‰ŽÒŠÔ“¯Žíœ‘ˆÚA. ‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï, 2009, 2, 5-6, ŽD–y.
    16. –{‹½˜a‹v, ‘q–{@’, ‰eŽR—²Ži, ‹{˜e—˜’j: Pallister-KillianÇŒóŒQ‚̈ê—á. ‘æ55‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï, 2009, 2, 8,‹à‘ò.
    17. ‘q–{@’, Œ´ˆä•ü”ü, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, –{‹½˜a‹v, ”ª–ØMˆê, ‹{˜e—˜’j: ƒyƒjƒVƒŠƒ“G“Š—^Œã¸_Çó‚ÌŒy‰õ‚ª‚Ý‚ç‚ꂽPANDAS‚̈ê—á. ‘æ55‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï, 2009, 2, 8,‹à‘ò.
    18. ¼è‘½ç‘ã, Žs“c•™Žq, “n•Óˆê—m, –F‘º’¼Ž÷, ¼ˆäŽOŽ}: “û—cŽ™‚Ìî“®”­’B. ‘æ‚U‰ñCREST—̈æ“àŒ¤‹†•ñ‰ï@2009, 3, 20, ‘åã.
    19. ‹àŒ“O˜a, ‘ºã@ƒ, “›ˆä”ü, íŽRKˆê, ÎàV@L, –쑺ŒbŽq, ‹{˜e—˜’j: ¬lƒ‰ƒ“ƒQƒ‹ƒnƒ“ƒX×–E‘gD‹…Ç‚Ì‚Q—á. ‘æ28‰ñLCHŒ¤‹†‰ï 2009, 3, 28, ‘åã.
    20. Žs“c•™Žq: Šî’²u‰‰uæ“V«SŽ¾Š³pŒã‚̸__Œo”­’BvD‘æ39‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï, 2009, 4, 22, •xŽR.
    21. ¼è‘½ç‘ã, Žs“c•™Žq, –F‘º’¼Ž÷, ŽOè‘ñ˜Y, ¼ˆäŽOŽ}, ”ª–ØŒ´rŽ: V¶Ž™E“ûŽ™ŠúŠJSpŒãŠ³Ž™‚ÌAŠwŽž”F’m‹@”\D‘æ39‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï, 2009, 4, 22, •xŽR.
    22. ‘«—§—Yˆê: ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u“û—cŽ™šb‘§‚ÌŽ¡—Ãí—ª`ƒKƒCƒhƒ‰ƒCƒ“‚Í‚Ç‚¤•Ï‚í‚Á‚½‚©Hv@‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    23. ‹àŒ“O˜a: ƒVƒ“ƒ|ƒWƒEƒ€u–Ɖu•s‘SÇ‚Æ—\–hÚŽív‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    24. ”ÂàVŽõŽq, ‰ª•””üŒb, ‘«—§—zŽq, ˆÉ“¡–õ“T, ‘«—§—Yˆê, ‹{˜e—˜’j: ŒÄ‹CNO”Z“x‚©‚ç‚Ý‚½šb‘§¬Ž™‚É‚¨‚¯‚éMS-IOS‚Ì—Õ°“IˆÓ‹`. ‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    25. œA–ìŒbˆê, “n•Óˆê—m, ˆÉŒ\“ñ˜Y, Ö“¡˜a—R, ‘å‚TŒá, –kŒ´~ˆê˜Y, ¼‹vO“T, –F‘º’¼Ž÷, Žs“c•™Žq, ‹{˜e—˜’j: æ“V«SŽ¾Š³‚É‚¨‚¯‚éNT-pro BNP‚Ì—L—p«. ‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    26. ¼è‘½ç‘ã, Žs“c•™Žq, ¼ˆäŽOŽ}, “n•Óˆê—m, ”‹–춒j, ”ª–ØŒ´rŽ: Bayley“û—cŽ™”­’BŒŸ¸i‘æ‚Q”Åj‚ð—p‚¢‚½æ“V«SŽ¾Š³Ž™‚Ì_Œo”­’B•]‰¿. ‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    27. ‹{è‚ ‚ä‚Ý, ‹g‰i³•v, ŽÂ‹{³Ž÷, “c’†—TŽ¡, ŒI—ÑLˆê, Žs“c•™Žq, ‚‹´Gl: Ž­Ž™“‡Œ§Eç—tŒ§E•xŽRŒ§‚Ì‚Z¶‚É‚¨‚¯‚鶊ˆKŠµ•b—\–hŒŸfŒ‹‰Ê‚Ì’nˆæ·. ‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    28. ‹{è‚ ‚ä‚Ý, ‹g‰i³•v, [“‡‹u–ç, Žs“c•™Žq, ‚‹´Gl: •xŽRŒ§‚ÌT‚Z¶‚É‚¨‚¯‚鶊ˆKŠµ•a—\–hŒŸfŒ‹‰Ê‚Ì«·‚¨‚æ‚ѶŠˆKŠµ‚Æ‚ÌŠÖ˜A. ‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    29. ‘q–{@’, ‹àŒ“O˜a, –쑺ŒbŽq, ¼‘q—TŠì, ‹{˜e—˜’j: X˜A½–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚ɇ•¹‚µ‚½Ž‘±«’á•â‘ÌŒŒÇ«t‰Š. ‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    30. –{‹½˜a‹v, ‘q–{@’, “¡–Ø–õŽq, Œ´ˆä•ü”ü, ‹{@ˆêŽu, ‰eŽR—²Ži, ‹{˜e—˜’j: —n˜A‹ÛŠ´õ‚É”º‚¤ƒgƒEƒŒƒbƒgáŠQ‚ɂ‚¢‚Ä. ‘æ51‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2009, 5, 28-30, ’¹Žæ.
    31. “¡–Ø–õŽq, ‘q–{@’, Œ´ˆä•ü”ü, ‹{@ˆêŽu, ‰eŽR—²Ži, –{‹½˜a‹v, ‹{˜e—˜’j: AD/HD‚Ö‚ÌCPT(‚à‚®‚ç[‚¸)‚É‚æ‚é•]‰¿. ‘æ51‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2009, 5, 28-30, ’¹Žæ.
    32. Œ´ˆä•ü”ü, ‘q–{@’, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, –{‹½˜a‹v, ‹{˜e—˜’j: ”ñ“ÁˆÙ“I‚ÈŒo‰ß‚ð‚½‚Ç‚Á‚½PANDAS‚̈ê—á. ‘æ51‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2009, 5, 28-30, ’¹Žæ.
    33. ‰eŽR—²Ži, ‘q–{@’, Œ´ˆä•ü”ü, “¡–Ø–õŽq, ‹{@ˆêŽu, –{‹½˜a‹v, ‹{˜e—˜’j: ‰ß‹Ž5”NŠÔ‚ÉŒoŒ±‚µ‚½HHV-6”]‰Š‚Ì5—á. ‘æ51‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2009, 5, 28-30, ’¹Žæ.
    34. ‘q–{@’, Œ´ˆä•ü”ü, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, –{‹½˜a‹v, ‹{˜e—˜’j: Ý‘îŒÄ‹zŠÇ—‚ÉŠÖ‚·‚éˆêlˆÄ. ‘æ51‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2009, 5, 28-30, ’¹Žæ.
    35. “n•Ó—S‹I, ‰eŽR—²Ži, ‘q–{@’, Œ´ˆä•ü”ü, “¡–Ø–õŽq, ‹{@ˆêŽu, –{‹½˜a‹v, ‹{˜e—˜’j: ‘½Ê‚È•sˆÓ‰^“®‚ð’悵‚½”ñƒwƒ‹ƒyƒX”]‰Š‚̈ê—á. ‘æ51‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2009, 5, 28-30, ’¹Žæ.
    36. ¬‰Y@Ž, å@‹v”T, ‘å’ØŒc•ã, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠ´õÇ‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚½X˜A½dÇ•¡‡–Ɖu•s‘SÇ‚Ì“ûŽ™—á. ‘æ30‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2009, 5, 28, •xŽR.
    37. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2008‚̉ü’ù—v“_ -‹}«”­ì‘Ήž-v@‘æ26‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï, 2009, 5, 30-31, •Ÿ‰ª.
    38. ‘«—§—Yˆê, ”ÂàVŽõŽq, ‰ª•””üŒb, ˆÉ“¡–õ“T, ‘«—§—zŽq, ‹{˜e—˜’j: dÇšb‘§Ž™‚É‚¨‚¯‚éƒtƒ‹ƒ`ƒJƒ]ƒ“{ƒZƒŒƒxƒ“ƒg‡Ü‚ÌŽg—pŒoŒ±. ‘æ26‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï, 2009, 5, 30-31, •Ÿ‰ª.
    39. ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ‘ºãIŒ[, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚é”ì–ž‚ÆdÇ“x‚ÉŠÖ‚·‚錟“¢D‘æ26‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï, 2009, 5, 30-31, •Ÿ‰ª.
    40. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€udÇšb‘§‚Ì•a‘Ô‚ÆŠ³ŽÒ‚É—D‚µ‚¢Ž¡—ÂƂ»‚ÌŠJ”­ -¬Ž™“«šb‘§‚Ì—Õ°-v ‘æ21‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2009, 6, 4-6, Šò•Œ.
    41. ˆÉ“¡–õ“T, ”óŒû@Žû, ‰ª•””üŒb, ”‘òŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚éŒÄ‹CˆêŽ_‰»’‚‘f’l‚ɉe‹¿‚ð‹y‚Ú‚·ˆöŽq‚ÌŒŸ“¢. ‘æ21‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2009, 6, 4-6, Šò•Œ.
    42. ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ‹g“cKˆê, ‘å–îKO, ¬“c“ˆ”Ž, ÔàV@W, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚¨‚¯‚é”ì–ž‚ƌċz‹@”\‚ÉŠÖ‚·‚錟“¢. ‘æ21‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2009, 6, 4-6, Šò•Œ.
    43. ‰ª•””üŒb, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, •£àV—³–ç, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§‚̃Rƒ“ƒgƒ[ƒ‹ó‘Ԃɑ΂·‚é•@‰ŠÇó‚̉e‹¿. ‘æ21‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2009, 6, 4-6, Šò•Œ.
    44. Žs“c•™Žq: ‹³ˆçu‰‰u”x‚ŒŒˆ³:Å‹ß‚ÌŽ¡—ƒ·ŠúŒø‰Êv. ‘æ3‰ñ¬læ“V«SŽ¾Š³ƒZƒ~ƒi[, 2009, 6, 6, “Œ‹ž.
    45. âV“¡˜a—R, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, “n•Óˆê—m, œA–ìŒbˆê, 㨌hˆê˜Y, ‹àŒ“O˜a, Žs“c•™Žq, ‹{˜e—˜’j: “«ìè•a‚ɑ΂µ‚ăVƒNƒƒXƒ|ƒŠƒ“A‚ª‘tŒø‚µ‚½3Ç—á. ‘æ23‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï, 2009, 6, 28, •xŽR.
    46. ¬‰Y@Ž, “c‘ºŒ«‘¾˜Y, ‘å’ØŒc•ã, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ‘½”­‚·‚铪ŠW“àoŒŒ‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚½‹}«‘Oœ‘«”’ŒŒ•aiAPLj‚Ì1—á. ‘æ23‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï, 2009, 6, 28, •xŽR.
    47. ‹{è‚ ‚ä‚Ý, ‹g‰i³•v, ŽÂ‹{³Ž÷, ‚‹´Gl, •½“c–rŽq, Žs“c•™Žq: ‚‰ª‚Z¶ŠˆKŠµ•a—\–hŒŸfŒ‹‰ÊE‘æŽl•ñ Ž­Ž™“‡Œ§¥ç—tŒ§‚Z¶‚Æ‚Ì”äŠr. ‘æ23‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï, 2009, 6, 28, •xŽR.
    48. ‹{@ˆêŽu, “n•Ó—S‹I, –{‹½˜a‹v, ‹{˜e—˜’j: Œo‰ß’†‚ɶ‰E·‚Ì‚ ‚é‹­’¼”­ì‚ð”F‚ß‚½Ž¸—§ƒ~ƒIƒNƒƒj[‚Ä‚ñ‚©‚ñ‚̈ê—á. ‘æ2‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï’†•”E–k—¤’n•û‰ï, 2009, 7, 11, –¼ŒÃ‰®.
    49. –쑺ŒbŽq, ¬‰Y@Ž, ‘å’ØŒc•ã, å@‹v”T, ‹àŒ“O˜a: ”ñŠ°‰ðó‘Ô‚ÅHLA•s“K‡ŒŒ‰ƒhƒi[‚©‚ç––½ŒŒŠ²×–EˆÚA‚ðs‚Á‚½AML M4,—¼‘¤–Ô–Œ‰è×–EŽîd•¡‚ª‚ñ‚Ì—Ž™—á. ‘æ5‰ñCCLSG‰Ä‹GƒZƒ~ƒi[, 2009, 7, 5, ” ª.
    50. ‹àŒ“O˜a, ¬‰Y@Ž, å@‹v”T, ‘å’ØŒc•ã, –쑺ŒbŽq, ‹{˜e—˜’j: lHŒÄ‹zŠÇ—‰º‚Å“¯Žíœ‘ˆÚA‚ðs‚Á‚½‘SgƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠ´õLJ•¹dÇ•¡‡–Ɖu•s‘Sǂ̈ê—á. ‘æ5‰ñCCLSG‰Ä‹GƒZƒ~ƒi[, 2009, 7, 5, ” ª.
    51. –xìT“ñ˜Y, ‰eŽR—²Ži, –쑺ŒbŽq, ‹{˜e—˜’j: ‰Â‹t«”]—À–c‘å•”•a•Ï‚𔺂Á‚½ toxic shock syndrome‚̈ê—á. ‘æ12‰ñ•xŽR¬Ž™Š´õ–ƉuŒ¤‹†‰ï, 2009, 7, 11, •xŽR.
    52. œA–ìŒbˆê, —Ñ@Žj˜N, ˆÉŒ\“ñ˜Y, Ö“¡˜a—R, “n•Óˆê—m, “n•Óˆ»‰À, –k“‡@ŒM, ˆäã@”Ž, Žs“c•™Žq, ‹{˜e—˜’j: ¬Ž™‚É‚¨‚¯‚éƒzƒ‹ƒ^[S“d}ŒŸ¸‚É‚æ‚éQTŽžŠÔ‚ÌŒŸ“¢. ‘æ45‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï, 2009, 7, 15, _ŒË.
    53. “n•Óˆê—m, ˆÉŒ\“ñ˜Y, Ö“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq, ¼è‘½ç‘ã, ‹{˜e—˜’j, ‘å‚TŒá, –kŒ´~ˆê˜Y, –F‘º’¼Ž÷, ¼ˆäŽOŽ}: “ûŽ™‘Šú‚ÉŠJSp‚ðŽ{s‚³‚ꂽæ“V«SŽ¾Š³Ž™‚Ì”]—e—ÊApŒã”­’B‚̉“ŠuŠú•]‰¿D‘æ45‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï, 2009, 7, 15, _ŒË.
    54. “n•Óˆê—m, ˆÉŒ\“ñ˜Y, Ö“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq, ‹{˜e—˜’j, ‘å‚TŒá, –kŒ´~ˆê˜Y, ¼‹vO“T, –F‘º’¼Ž÷: “à‘ŸöˆÊÇŒóŒQ‚É”º‚¤‹CŠÇ•a•Ï‚Ìp‘O•]‰¿‚ɑ΂·‚éMDCT‚Ì—LŒø«. ‘æ45‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï, 2009, 7, 15, _ŒË.
    55. “n•Óˆ»‰À, Ö“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, œA–ìŒbˆê, Žs“c•™Žq, ‹{˜e—˜’j, –F‘º’¼Ž÷, ˆÀ‘º@•q: ƒtƒHƒ“ƒ^ƒ“pŒãÇ—á‚É‚¨‚¯‚éŠÌ‘@ˆÛƒ}[ƒJ[‚Ì—LŒø«. ‘æ45‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï, 2009, 7, 15, _ŒË.
    56. ¼è‘½ç‘ã, ”‹–춒j, Œ®èNŽ¡, ”ª–ØŒ´rŽ: V¶Ž™E“ûŽ™ŠúŠJSpŒã‚̉^“®”­’B‚ɉe‹¿‚ð‹y‚Ú‚·”ˆöŽq. ‘æ45‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï, 2009, 7, 15, _ŒË.
    57. ¬‰Y@Ž, ‘å’ØŒc•ã, ‹{@ˆêŽu, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j, óˆä³Žk: ‹}‘¬‚ÈŒo‰ß‚Ōċz•s‘S‚ÉŽŠ‚Á‚½plastic bronchitis‚Ì1—á. ‘æ45‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï, 2009, 8, 23, –¼ŒÃ‰®.
    58. ˆÉ“¡–õ“T, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚¨‚¯‚éŒÄ‹CˆêŽ_‰»’‚‘fiFeNOj‚Ì‘ª’è‚Ɖe‹¿‚ð‹y‚Ú‚·ˆöŽq‚ɂ‚¢‚Ä. ‘æ12‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2009, 9, 12, •xŽR.
    59. “n•Óˆê—m, ˆÉŒ\“ñ˜Y, Ö“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq, –س–ç, ŽR’†ŸO, ‘å‚TŒá, “úŒG’qŒ›, –F‘º’¼Ž÷: TCPCŽ{sŽž‚ɃXƒeƒ“ƒg‚ð—¯’u‚µ‚½‚ªA•ÂÇ‚ÉŽŠ‚Á‚½¶”x“®–¬‚ɑ΂µ‚ÄŒŒðœ‹Ž—Ö@‚ðŽ{s‚µÄŠJ’ʂ𓾂½ŽOë•Ù•Â½(EB)‚Ì‚P—á. ‘æ37‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ï, 2009, 9, 19, ‹à‘ò.
    60. –{‹½˜a‹v, “¡–Ø–õŽq, Œ´ˆä•ü”ü, “c’‡çH, ‹{ˆêŽu, ‹{˜e—˜’j: “Á”­«‚Ä‚ñ‚©‚ñ‚Ì”F’m‹@”\‚ÌŒŸ“¢. ‘æ43‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï, 2009, 10, 22-23, O‘O.
    61. Žs“c•™Žq: “Á•Êu‰‰ (S‹Øãk–§‰»áŠQ‚Ì—Õ°( ‘æ18‰ñŠÖ“Œ¬Ž™S‹ØŽ¾Š³Œ¤‹†‰ï, 2009, 10, 3, “Œ‹ž.
    62. Ö“¡˜a—R, œA–ìŒbˆê, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, “n•Óˆê—m, 㨌hˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j: ƒVƒNƒƒXƒ|ƒŠƒ“A‚ð“Š—^‚µ‚½“«ìè•a3Ç—á‚É‚¨‚¯‚éƒTƒCƒgƒJƒCƒ“‚ÌŒŸ“¢. ‘æ29‰ñ“ú–{ìè•aŠw‰ï, 2009, 10, 17,–¼ŒÃ‰®.
    63. ”ÂàVŽõŽq: ƒ[ƒNƒVƒ‡ƒbƒvu¬Ž™‚Ì”x‹@”\‚̃Xƒ^ƒ“ƒ_[ƒh -IOS‚É‚æ‚é”x‹@”\‚Ì•]‰¿•û–@-v. ‘æ42‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï, 2009, 10, 17-18, ‚è.
    64. ”ÂàVŽõŽq, ‹{@ˆêŽu, å@‹v”T, ŽíŽsq’ˆ, ‘«—§—Yˆê, ‹{˜e—˜’j: ”x‰Š‚ðŒ_‹@‚ÉdÇ‹}«ŒÄ‹z•s‘S‚ÉŽŠ‚Á‚½Ž™‚ɑ΂·‚éˆêŽ_‰»’‚‘f‹z“ü—Ö@‚Ì“±“ü. ‘æ42‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï, 2009, 10, 17-18, ‚è.
    65. ’†—ÑŒºˆê, ˆÉ“¡–õ“T, ”óŒû@Žû, •£àV—³–ç, ”ÂàVŽõŽq, ‘«—§—Yˆê, –F‘º’¼Ž÷, ‹{˜e—˜’j: “–‰È‚É‚¨‚¯‚éæ“V«‹CŠÇ‹·óÇ—á‚ÌŒŸ“¢. ‘æ42‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï, 2009, 10, 17-18, ‚è.
    66. Kanegane H., Zelm M.C.V., Agematsu K., Sekiguchi T., Arai T., Oishi T., and Miyawaki T.: Clinical and immunological characteristics of CD19 deficiency. ‘æ71‰ñ“ú–{ŒŒ‰tŠw‰ï, 2009, 10, 23-25, ‹ž“s.
    67. Nomura K., Kanegane H., Tamura K., Nishida M., Kuramoto T., Sakaki H., yanagisawa R., Wada T., Yachie A., and Miyawaki T.: Immunological and viological analysis of EB virus-associated hemophagocytic lymphohistiocytosis. ‘æ71‰ñ“ú–{ŒŒ‰tŠw‰ï, 2009, 10, 23-25, ‹ž“s.
    68. “n•Ó—S‹I, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, “n•Óˆê—m, œA–ìŒbˆê, Žs“c•™Žq, –F‘º’¼Ž÷, ‹{˜e—˜’j: CRT‚ðŽ{s‚µ‚½“ûŽ™Šú”­ÇS‹Øãk–§‰»áŠQ‚Ì1—á`SˆÚA‚ÉŒü‚¯‚Ä`. ‘æ9‰ñ•xŽR¬Ž™zŠÂŠíŒ¤‹†‰ï, 2009, 10, 23, •xŽR.
    69. ”ÂàVŽõŽq, ¼–ì³’m, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ÔàV@W, ‹{˜e—˜’j: ¬Ž™‚Ìšb‘§‚É‚¨‚¢‚Ĕ얞‚Å‚ ‚邱‚Æ‚ªƒRƒ“ƒgƒ[ƒ‹ó‘Ԃɉe‹¿‚·‚é. ‘æ59‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2009, 10, 29-31, H“c.
    70. ¼–ì³’m, ŒÜ\—’—²•v, ”ÂàVŽõŽq, ‘«—§—Yˆê, ÔàV@W, ‘ºãIŒ[, ‹{˜e—˜’j: ¬Ž™šb‘§‚É‚¨‚¢‚Ĕ얞‚Å‚ ‚邱‚Æ‚ª‹C“¹‰ß•q«‚â”x‹@”\‚ɉe‹¿‚·‚é. ‘æ59‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2009, 10, 29-31, H“c.
    71. –xìT“ñ˜Y, ‰eŽR—²Ži, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ‰Â‹t«”]—À–c‘å•”•a•Ï‚𔺂Á‚½ Toxic shock syndrome‚̈ê—á. ‘æ41‰ñ“ú–{¬Ž™Š´õÇŠw‰ï, 2009, 11, 14-15, •Ÿˆä.
    72. ‹àŒ“O˜a, ’†–ì‹MŽi, ‰º–ì‹gŽ÷, æâ@”ü›P, ‹{˜e—˜’j: ƒjƒ…[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚ð‡•¹‚µ‚½X˜A½–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚̈ê—á. ‘æ41‰ñ“ú–{¬Ž™Š´õÇŠw‰ï, 2009, 11, 14-15, •Ÿˆä.
    73. ‘å’ØŒc•ã, ]Œû^—Žq, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: t(1;12)(q21;p13)‚𔺂Á‚½T×–E«‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚É‚¨‚¯‚éƒLƒƒ‰ˆâ“`Žq‰ðÍ. ‘æ51‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2009, 11, 27-29, ç—t.
    74. ¬‰Y@Ž,‘å’ØŒc•ã,–쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ‘½”­‚·‚铪ŠW“àoŒŒ‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚½‹}«‘Oœ‘«”’ŒŒ•a(APL)‚̈ê—á. ‘æ51‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2009, 11, 27-29, ç—t.
    75. ˆÀ“c²’qŽq, ŽíŽsq’ˆ, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: Š°‰ð“±“ü—Ö@‘Šú‚ÉDIC‚ð‡•¹‚µ‚½ALL‚̈ê’jŽ™—á. ‘æ51‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2009, 11, 27-29, ç—t.
    76. Žs“c•™Žq: “Á•Êu‰‰uS‹Øãk–§‰»áŠQ‚Ì—Õ°v. ‘æ48‰ñVŠƒS•s‘SŒ¤‹†‰ï, 2009, 11, 26, VŠƒ.
    77. ‘«—§—zŽq, ”ÂàVŽõŽq, ‰ª•””üŒb, ˆÉ“¡–õ“T, ‘«—§—Yˆê, ‹{˜e—˜’j: •‰‰×ŽŽŒ±Œã‚Éœ‹Ž‰ðœ‚ðs‚Á‚½H•¨ƒAƒŒƒ‹ƒM[Ç—á‚ÌŒo‰ß. ‘æ36‰ñ–k—¤ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2009, 11, 28,‹à‘ò.
    78. ‘«—§—Yˆê: ƒKƒCƒhƒ‰ƒCƒ“ŒöŠJ“¢˜_‰ïušb‘§Ž¡—ẪOƒŒ[ƒ][ƒ“‚ðŒŸØ‚·‚é -“û—cŽ™šb‘§‚Ì“K³f—Ã-v. ‘æ46‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2009, 12, 5-6, •Ÿ‰ª.
    79. ‘«—§—Yˆê: ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u¬Ž™šb‘§Ž¡—Âɂ¨‚¯‚é‹z“üƒÀŽhŒƒ–ò‚̈ʒu‚¯v. ‘æ46‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2009, 12, 5-6, •Ÿ‰ª.
    80. ”ÂàVŽõŽq, ‰ª•””üŒb, ‘«—§—zŽq, ˆÉ“¡–õ“T, ”óŒû@Žû, ’†—ÑŒºˆê, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚¨‚¯‚éŒÄ‹C’†ˆêŽ_‰»’‚‘fieNOj‘ª’è‚Æ‹C“¹‰Â‹t«‚ÌŠÖŒW. ‘æ46‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2009, 12, 5-6, •Ÿ‰ª.
    81. ‘«—§—zŽq, ”ÂàVŽõŽq, ‰ª•””üŒb, •£àV—³–ç, ŽRŒ³ƒŽq, ‚”ö@Š², ”öã—mˆê, ‘ºãIŒ[, ‘«—§—Yˆê, ‹{˜e—˜’j: H•¨ƒAƒŒƒ‹ƒM[Ž™‚É‚¨‚¢‚Ä•‰‰×ŽŽŒ±Œã‚Éœ‹Ž‰ðœ‚ðs‚Á‚½Ç—á‚ÌŒo‰ß‚ɂ‚¢‚Ä. ‘æ46‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2009, 12, 5-6, •Ÿ‰ª.
    82. ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹g“cKˆê, ¬“c“ˆ”Ž, ‘å–îKO, ÔàV@W, ‹{˜e—˜’j: ‰ä‚ª‘‚̬Ž™‚É‚¨‚¯‚é‘ÌŠi‚Æšb‘§‚Æ‚ÌŠÖŒW. ‘æ46‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2009, 12, 5-6, •Ÿ‰ª.
    83. ˆÉ“¡–õ“T, ”ÂàVŽõŽq, ‰ª•””üŒb, ‘«—§—Yˆê, ŽRŒ³ƒŽq, •£àV—³–ç, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚¨‚¯‚éŒÄ‹CˆêŽ_‰»’‚‘f‚Ì‘ª’莞ŠÔ‚ÉŠÖ‚·‚錟“¢. ‘æ46‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2009, 12, 5-6, •Ÿ‰ª.
    84. ‹{@ˆêŽu, ˆÉŒ\“ñ˜Y, ‹{˜e—˜’j: Ž…‹›ì‘‡•a‰@‚É‚¨‚¯‚é10”NŠÔ‚̬Ž™“ü‰@Š³ŽÒ”‚Ì„ˆÚD‘æ24‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï, 2009, 12, 13,•xŽR.
    85. å@‹v”T, ”~ìŒåŽi, ˆÉ“¡–õ“T, ŽÂ茒‘¾˜Y, –쑺ŒbŽq, ‹àŒ“O˜a, ŒI–{¹‹I: Ý‘îƒ^[ƒ~ƒiƒ‹ƒPƒA‚ðŽ{s‚µ‚½ŒoŒ±‚ð’Ê‚µ‚Ä. ‘æ24‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï, 2009, 12, 13,•xŽR.
    86. ‚è–ƒ”ü, ‹{@ˆêŽu, ²“¡Š²“Þ, âV“¡˜a—R, ”‘òŽõŽq, ‹{˜e—˜’j: ƒrƒ^ƒ~ƒ“KŒ‡–R‚É‚æ‚铪ŠW“àoŒŒ‚ð‚«‚½‚µ‚½“ûŽ™—áD‘æ24‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï, 2009, 12, 13,•xŽR.

    2008”N

  • ’˜‘
    1. Aghamohammadi A., Lougaris V., Plebani A., Miyawaki T. Anne Durandy., and Hammarstrom L.: Chapter 3 Predominantly antibody deficiencies. uPrimary immunodeficiency diseasesv, Rezaei N., Aghamohammadi A., Notarangelo L.D. eds., Springer, Berlin Heidelberg, 97-130, 2008.
    2. Žs“c•™Žq: S‹Ø‰Š.w¬Ž™‰ÈŠwx ‘æ3”Å, ˆãŠw‘‰@,“Œ‹ž, 1110-1112, 2008.
    3. Žs“c•™Žq: ¬lŠú‚É‚È‚é‚Æ‹N‚±‚邱‚Æ\‚»‚Ì“Á’¥C•p“x\ˆâ“`D¬l‚Ìæ“V«SŽ¾Š³ƒKƒCƒhƒuƒbƒN, ’O‰HŒöˆê˜Y‘¼•Ò, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 138-142, 2008.
    4. Žs“c•™Žq: zŠÂŠíÇŒóŒQ@IIIi‘æ‚Q”Åj.V—̈æ•ÊÇŒóŒQƒVƒŠ[ƒYNo.6 VIII. S‹ØŽ¾Š³C¬Ž™ŠúS‹ØÇ, –îè‹`—Y‘¼•Ò, “ú–{—Õ°2008”N•Êû, “ú–{—Õ°ŽÐ, “Œ‹ž, 141-148,2008.
    5. Žs“c•™Žq: ”ì‘åŒ^S‹ØÇ, III zŠÂŠíŽ¾Š³, u¬Ž™Ž¾Š³f—Â̂½‚ß‚Ì•a‘Ô¶—1v, ¬Ž™“à‰ÈE¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï•Ò, “Œ‹žˆãŠwŽÐ, “Œ‹ž, 420-424, 2008.
    6. ‘«—§—Yˆê: DŽ_‹…«”x‰Š. u¬Ž™Ž¾Š³f—Â̂½‚ß‚Ì•a‘Ô¶—‚Pv, ¬Ž™“à‰ÈE¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï•Ò,“Œ‹žˆãŠwŽÐ, “Œ‹ž, 114-117, 2008.
    7. ‹àŒ“O˜a, æâ@”ü“ß, ‹{˜e—˜’j: BTKŒ‡‘¹Ç. ¬Ž™“à‰È‘Š§u¬Ž™Ž¾Š³f—Â̂½‚ß‚Ì•a‘Ô¶—‚Pv, ¬Ž™“à‰ÈE¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï•Ò, “Œ‹žˆãŠwŽÐ, “Œ‹ž, 1266-1270, 2008.
    8. ‘å’ØŒc•ã, ‹àŒ“O˜a, ‹{˜e—˜’j: X˜A½ƒŠƒ“ƒp‘B«Ž¾Š³. ¬Ž™“à‰È‘Š§u¬Ž™Ž¾Š³f—Â̂½‚ß‚Ì•a‘Ô¶—‚Pv, ¬Ž™“à‰ÈE¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï•Ò, “Œ‹žˆãŠwŽÐ, “Œ‹ž, 1322-1326, 2008.
    9. 㨌hˆê˜Y, Žs“c•™ŽqFæ“V«SŽ¾Š³@3.‘”xÖ¬ŠÒ—¬ˆÙí,•”•ª”xÖ¬ŠÒ—¬ˆÙí, ScimitarÇŒóŒQ. uu‹`˜^@¬Ž™‰ÈvƒƒWƒJƒ‹ƒrƒ…[ŽÐ, 454-455 ,2008.
    10. 㨌hˆê˜Y, Žs“c•™Žq: æ“V«SŽ¾Š³@10DS–[’†ŠuŒ‡‘¹. uu‹`˜^@¬Ž™‰ÈvƒƒWƒJƒ‹ƒrƒ…[ŽÐ, 472-473, 2008.
    11. 㨌hˆê˜Y, Žs“c•™Žq: Œã“V«SŽ¾Š³@3DS‹Ø‰Š,S–Œ‰Š. 4DS‹ØÇ.uu‹`˜^@¬Ž™‰ÈvƒƒWƒJƒ‹ƒrƒ…[ŽÐ, 500-505, 2008.
  • Œ´’˜
    1. Miya K., Inoue R., Takata Y., Abe M., Natsume R., Sakimura K., Hongou K., Miyawaki T., and Mori H.: Serine racemase is predominantly localized in neurons in mouse brain. J Comp Neurol 510: 641-654,2008.
    2. Taneichi H., Kanegane H., Sira M.M., Futatani T., Agematsu K., Sako M., Kaneko H., Kondo N., Kaisho T., and Miyawaki T.: Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia. Clin Immunol 126: 148-154, 2008.
    3. Futatani T., Nii E., Obata M., Ichida F., Okabe Y., Kanegane H., and Miyawaki T.: Molecular characterization of two novel VEGFR3 mutations in Japanese families with Milroy's disease. Pediatr Int 50: 116-118, 2008.
    4. Shan L., Makita N., Xing Y., Watanabe S., Futatani T., Ye F., Saito K., Ibuki K., Watanabe K., Hirono K., Uese K., Ichida F., Miyawaki T., Origasa H., Bowles N.E., and Towbin J.A.: SCN5A variants in Japanese patients with left ventricular noncompaction and arrhythmia. SCN5A variants in Japanese patients with left ventricular noncompaction and arrhythmia. Mol Genet Metab. 93: 468-474, 2008.
    5. Shan L., Dougu, N., Joho S., Shida T., Matsuki A., Uese K., Ichida F., Miyawaki T., Tanaka K., Inoue H: A novel LAMP-2 mutation in a family with hypertrophic cardiomyopathy: O-072. Pediatr Int 50:740, 2008.
    6. Tsurusawa M., Taga T., Horikoshi Y., Ogawa A., Kikuta A., Kanegane H., Matsushita T., Hyakuna N., Shimomura Y., Ohshima K; Lymphoma committee of Japanese childhood cancer and leukemia.: Favourable outcomes in children with diffuse large B-cell lymphoma treated by a short-term ALL-like regimen: a report on the NHL960 study from the Japanese childhood cancer and leukemia study group. Leuk Lymphoma 49: 734-739, 2008.
    7. Sato T., Toki T., Kanezaki R., Xu G., Terui K., Kanegane H., Miura M., Adachi S., Migita M., Morinaga S., Nakano T., Endo M., Kojima S., Kiyoi H., Mano H., and Ito E.: Functional analysis of JAK3 mutation in transient myeloproliferative disoder and acute megakaryoblastic leukaemia accompanying Down syndrome. Brit J Haematol 141: 681-688,2008.
    8. Shin D-M., Jo E-K., Kanegane H., Futatani T., Zhao M., Song C-H., Yamagishi A., and Miyawaki T.: Transcriptional regulatory defects in the first intron of Bruton's throsine kinase. Pediatr Int 50: 801-805, 2008.
    9. Shimada A., Kato M., Tamura K., Hirato J., Kanegane H., Takeuchi Y., Park MJ., Sotomatsu M., Hatakeyama S., Hayashi Y.: Hemophagocytis lymphohistiocytosis associated with uncontrolled inflammatory cytokinemia and chemokinemia was caused by systemic anaplastic large cell lymphoma: A case report and review of the literature. J Pediatr Hematol Oncol 30: 785-787, 2008.
    10. ‘«—§—Yˆê, ‘ºãIŒ[, ’†‘º—˜”ü, ’J“à]ºG, ‘哈—E¬, áÁ‹|Œõ•¶: ŠO—ˆ‚Å‚ÌŠÈ’P‚È–âf•[‚ƃ`ƒFƒbƒN•\‚𓱓ü‚·‚邱‚Æ‚É‚æ‚鬎™‹CŠÇŽxšb‘§ƒKƒCƒhƒ‰ƒCƒ“‚ɉˆ‚Á‚½Ž¡—Äi‚ÌŒø‰Ê. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 22: 369-378, 2008.
    11. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‘«—§—zŽq, ‰ª•””üŒb, ˆÉ“¡–õ“T, ”óŒû@Žû, ‹{˜e—˜’j:ƒCƒ\ƒvƒƒeƒm[ƒ‹Ž‘±‹z“ü—Ö@’†‚Ì™–¬”­Œ»‚ÉŠÖ‚·‚錟“¢. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@22: 349-356, 2008.
    12. ”óŒû@Žû, ‘«—§—Yˆê, óˆä³Žk: ƒs[ƒiƒbƒc‚É‚æ‚é‹CŠÇE‹CŠÇŽxˆÙ•¨. ¬Ž™ŠO‰È 40: 1230-1234, 2008.
    13. ŽsŠÛ’q_C”óŒû@ŽûC‘«—§—YˆêCóˆä³ŽkCìèˆê‹P: ¬Ž™‚É‚¨‚¯‚é‹CŠÇE‹CŠÇŽxˆÙ•¨‚Ì‘S‘’²¸?—\–hô‚Ì„i‚É‚Þ‚¯‚Ä?. “ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ïŽGŽ@19: 85-89,2008.
    14. ¼è‘½ç‘ã, ¼ˆäŽOŽ}, ’†àV@, Žs“c•™Žq, ”ª–ØŒ´rŽ: æ“V«SŽ¾Š³Ž™‚Ì‚ŽŸ”]‹@”\•]‰¿‚Æ‚µ‚ẴxƒCƒŠ[“û—cŽ™”­’BŽÚ“x“±“ü‚ÌŽŽ‚Ý. ”]‚Æ”­’B40: 308-312, 2008.
    15. ¼ìr˜Y, ²’n@•×, “‚àVŒ«—S, Ž›ˆä@Ÿ, Žs“c•™Žq, ’Ë–ì^–ç, ¬Š_Ž –L: ¬Ž™Šú”ì‘åŒ^S‹ØÇ‘S‘’²¸Œ‹‰Ê@“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 24: 572-574, 2008.
    16. —é–ØŒb”üŽq, ‘哈‹`”Ž, “y”ì‘P˜Y, ‘å‚TŒá, ‹´–{ˆè•v, Žs“c•™Žq, ‹{˜e—˜’j, ŽOè‘ñ˜Y 13ƒgƒŠƒ\ƒ~[‚Ü‚½‚Í18ƒgƒŠƒ\ƒ~[‚ɑ΂·‚éŠJSp‚ÌŒoŒ±. “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 24: 546-554, 2008.
  • Ç—á•ñ
    1. Kanegane H., Itazawa T., Saito M., Nishikomori R., Makino T., Shimizu T., Adachi Y., Nakahata T., and Miyawaki T.: A CIAS1 mutation in a Japanese girl with familial cold autoinflammatory syndrome. Eur J Pediatr 167: 245-247, 2008.
    2. Otubo K., Kanegane H., Nomura K., and Miyawaki T.: Atypical lymphoproliferative disorder in a patient with X-linked thrombocytopenia. Pediatr Bllod Cancer 51: 443-444,2008.
    3. Matsukura H., Fuchizawa T., Higuchi O., and Miyawaki T. : Gross hematuria as an unusual manifestation in minimal change nephrotic syndrome. Clin Nephrol 69 : 142-144, 2008.
    4. Fukushima K., Ueno Y., Kanegane H., Yamagiwa Y., Inoue J., Kido O., Nagasaki F., Kogure T., Kakazu E., Nakagome Y., Matsuda Y., Obara N., Kimura O., and Shimosegawa T.: A case of severe recurrent hepatitis with common variable immunodeficiency. A case of severe recurrent hepatitis with common variable immunodeficiency. Hepatol Res 38: 415-420, 2008.
    5. Tsuji Y., Kogawa K., Imai K., Kanegane H., Fujimoto J., and Nonoyama S.: Evans syndrome in a patient with Langerhans cell histiocytosis: possible pathogenesis of autoimmunity in LCH. Int J Hematol 87: 75-77, 2008.
    6. Hamidah A., Rashid R.A., Jamal R., Zhao M., and Kanegane H.: X-linked dyskeratosis congenital in Malaysia. Pediatr Blood Cancer 50: 432, 2008.
    7. Hamada H., Kurimoto M., Hayashi N., Nagai S., Kurosaki K., Nomoto K., Kanegene H., Nomura K., and Endo S.: Pilomyxoid astrocytoma in a patient presenting with fatal hemorrhage. J Neurosurg Pediatr 1: 244-246, 2008.
    8. ”ÂàVŽõŽq, ‹àŒ“O˜a, ‘«—§—Yˆê, ‹{˜e—˜’j, –q–ì‹P•F, ´…’‰“¹, Ä“¡@, ¼¬X—²‘¾: ‰Æ‘°«Š¦—⎩ŒÈ‰ŠÇÇŒóŒQ‚̈ê—á. ƒAƒŒƒ‹ƒM[‚Ì—Õ° 28: 221-225, 2008.
    9. Œ´ˆä•ü”ü, ŽíŽsq’ˆ, å@‹v”T, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ’˜–¾‚È—«‰»“û–[‚ð’悵‚½cŠu×–EŽîᇇ•¹ Klinefelter ÇŒóŒQ‚Ì‚P—á. “ú–{¬Ž™ŒŒ‰tŠw‰ïŽGŽ 22: 42-46, 2008.
    10. ˆÉ“¡G˜a, •£àV—³–ç, ’†“ˆˆ¤Žq, ‹{˜e—˜’j: ”w•”’É‚ðŒ_‹@‚É”­Œ©‚³‚ꂽŠÌŒÀ‹Ç«Œ‹ß«‰ßŒ`¬‚Ì10ΗŽ™—á. ¬Ž™‰Èf—Ã@71: 165-168, 2008.
    11. —é–ØŒb”üŽq, ‘哈‹`”Ž, “y”ì‘P˜Y, ‘å‚TŒá, ‹´–{ˆè•v, Žs“c•™Žq, ‹{˜e—˜’j, ŽOè‘ñ˜Y: 13ƒgƒŠƒ\ƒ~[‚Ü‚½‚Í18ƒgƒŠƒ\ƒ~[‚ɑ΂·‚éŠJSp‚ÌŒoŒ±.“ú–{¬Ž™zŠÂŠíŠw‰ïŽ 24: 38-46. 2008.
  • ‘à
    1. ‘«—§—Yˆê: MxA’`”’‚ðŽw•W‚Æ‚µ‚½¬Ž™ƒEƒCƒ‹ƒXŠ´õ‚Ìf’f. —Õ°‚ƃEƒCƒ‹ƒX 36: 257-262, 2008.
    2. ‘«—§—Yˆê, ˆÉ“¡–õ“T, ‹{˜e—˜’j: ƒAƒŒƒ‹ƒM[Ž¾Š³‚̧ŒäƒVƒXƒeƒ€.¬Ž™‰È 49: 1223-1228, 2008.
    3. ‘«—§—Yˆê, ‹{˜e—˜’j, ŽR“c‘½Žq: ¬Ž™‚Ì‹CŠÇŽx‰ŠC”x‰Š. ‚±‚Ç‚àƒPƒA 3: 82-86,2008.
    4. ‘«—§—Yˆê: ƒAƒŒƒ‹ƒM[f—Â̗Ž‚Æ‚µŒŠ(pit fall)@ƒKƒCƒhƒ‰ƒCƒ“‚Ì“K«Žg—p. ¬Ž™‰Èf—à 71:1209-1214,2008.
    5. ‘«—§—Yˆê: ‰ŠÇ«ƒTƒCƒgƒJƒCƒ“‚È‚Ç‚ð—p‚¢‚½Š´õÇ‚Ìf’f–@. ¬Ž™‰Èf—à 71: 37-42, 2008.
    6. ‘«—§—Yˆê: ŒoŒû‚ÌRƒAƒŒƒ‹ƒM[–ò‚Í‘½‚­‚ÌŽí—Þ‚ª‚ ‚è‚Ü‚·‚ªC‚ǂ̂悤‚ÉŽg‚¢•ª‚¯‚é‚Ì‚Å‚·‚©u–ò‚ÉŠÖ‚·‚é‘f–p‚È‹^–âv¬Ž™“à‰È 40: 335-337, 2008.
    7. ‹àŒ“O˜a: Š´õÇ‚©‚çæ“V«–Ɖu•s‘SÇ‚ðl‚¦‚éD¬Ž™Š´õ–Ɖu 20: 175-182,2008.
    8. ‹àŒ“O˜a, ‹{˜e—˜’j:Œ´”­«–Ɖu•s‘SÇ‚É‚¨‚¯‚é—Õ°Çó.¬Ž™‰È—Õ° 61: 1743-1749, 2008.
    9. ‹àŒ“O˜a, æâ@”ü“ß,‹{˜e—˜’j: ”º«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ.ƒAƒŒƒ‹ƒM[E–Ɖu 15: 1322-1328, 2008.
    10. ‹àŒ“O˜a, ‹{˜e—˜’j: –ƉuŽ¾Š³f—ÂÌi•à‚Æ“W–]. ¬Ž™‰Èf—à 71: 1973-1978, 2008.
    11. ‘å’ØŒc•ã, ‹àŒ“O˜a,‹{˜e—˜’j: æ“V«–Ɖu•s‘SÇ‚ÆEBV Š´õÇ. ŒŒ‰tEŽîá‡‰È 56: 272-280,2008.
    12. ÔàV@W, ¬“c“ˆ”Ž, ‘«—§—Yˆê, ‘å–îKO, –¾Î^K, ¬“ˆ‚È‚ÝŽq: ¬Ž™‹CŠÇŽxšb‘§‚̉uŠw. šb‘§ 21: 26-34, 2008.

  • 2008”NŠw‰ï•ñ
    1. Adachi Y., Okabe Y., Itazawa T., Adachi YS., Miyawaki T., Odajima H., Ohya Y., and Akazawa A.: Prevalence of, and risk factors for allergic diseases in 3-year-old children in Japan. 64th Annual Meeting of American Academy of Allergy & Immunology, 3, 14-18, 2008, Philadelphia, USA.
    2. Hirono K., Wittkowski H., Vogl T., Ibuki K., Saito K., Uese K., Ichida F., and Miyawaki T.: Reverse kinetics of circulating soluble receptor for advanced glycation end products (sRAGE) and its ligand S100A12 in acute Kawasaki disease. The 57th American College of Cardiology 08, 2008, 3, 31, Chicago.
    3. Miyawaki T.: Variable EBV infection situation in children. International workshop on Pediatric immunology, 2008, 10, 21-23, Chong-chin, China. (Invited Lecture)
    4. Hirono K., Saito K., Watanbe S., Higuchi O., Ibuki K., Uese K., Ichida F., Kanegane H., Miyawaki T., Kennmotsu Y., and Saji T.: The efficacy of infliximab treatment and dynamic changes of inflammatory cytokines in patients with refractory Kawasaki disease. The 4th International Kawasaki Disease Symposium, 2008, 4, 11, Taipei.
    5. Adachi Y.: gRole of beta2-agonists in the management of childhood asthmah, 16th Annual Meeting of Philippine Academy of Pediatric Pulmonologists and 8th National Meeting on Childhood Asthma, 2008, 5, 2, Baguio City, Philippines. (Invited Lecture)
    6. Ichida F.: Efficacy of Bosentan therapy in candidates for right heart bypass surgery. Panel discussion Challenges in the management of CHD-PAH@ 5th Scientific Symposium: Strategic Perception for PAH Management, 2008, 6, 8, Tokyo.
    7. Kanegene H., Yamada M., Zhao M., Futatani T., Oh-ishi T., Sakiyama Y., Ariga T., and Miyawaki T.: A Japanese patients with X-linked agammaglobulinemia and deafness caused by contiguous X-chromosome deletion including the BTK, TIMM8A, TAF7L, and DRP2 genes. The 13th meeting of the European Society for Immunodeficiencies, 2008, 10, 16-19, Netherlands.
    8. Hirono K, Ibuki K., Saito K., Watanabe K., Watanabe S., Ichida F., Miyawaki T., Yoshimura N., Akita C., and Nakamura T.: . Bosentan induces clinical and hemodynamic improvement in candidates for right heart bypass surgery. The 81th Scientific sessions 2008 American 2008, 11, 10, U.S.A.
    9. Kanegane H.: Flow cytometric diagnosis of primary immunodeficiency diseases. Symposium for PID in Asia, 2008, 12, 11-12, Yokohama.
    10. ‘å’ØŒc•ã, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: EBV”ñŠÖ˜AƒŠƒ“ƒpŽî‚ð”­Ç‚µ‚½X˜A½ŒŒ¬”ÂŒ¸­Ç‚Ì‚P’jŽ™—á. ‘æ1‰ñ“ú–{–Ɖu•s‘SŒ¤‹†‰ï, 2008, 1, 19,“Œ‹ž.
    11. œA–ìŒbˆê, ˆÉŒ\“ñ˜Y, Ä“¡˜a—R, “n•Óˆ»‰À, “n•Óˆê—m, 㨌hˆê˜Y, ‘å‚TŒá, ¼‹v‹v“T, –kŒ´~ˆê˜Y, –F‘º’¼Ž÷, Žs“c•™Žq, ‹{˜e—˜’j: ‰ESƒoƒCƒpƒXŽèp“K‰ž¢“ï—á‚ɑ΂·‚éCƒ{ƒZƒ“ƒ^ƒ“Cƒxƒ‰ƒvƒƒXƒgCÝ‘îŽ_‘f•¹—p—Ö@‚Ì—L—p«. ‘æ14‰ñ“ú–{¬Ž™”xzŠÂŒ¤‹†‰ï, 2008, 2, 2, “Œ‹ž.
    12. ‘«—§—Yˆê: ‹z“üƒXƒeƒƒCƒhŒœ‘÷‰t‚Ì•¬–¶“Á« -ƒlƒuƒ‰ƒCƒU[‚É‚æ‚é·ˆá-. ‘æ17‰ñ“’“cãƒJƒ“ƒtƒ@ƒŒƒ“ƒX, 2008, 2, 2-3, VŠƒ.
    13. Œ´ˆä•ü”ü, –{‹½˜a‹v, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ‹{˜e—˜’j: 9q34ÇŒóŒQ‚̈ê—á. ‘æ53‰ñ“ú–{¬Ž™_Œo–k—¤’n•û‰ï, 2008, 2, 10, ‹à‘ò.
    14. Œ´ˆä•ü”ü, ‹àŒ“O˜a, ˆÉ“¡–õ“T, ”ÂàVŽõŽq, –{‹½˜a‹v, ‹{˜e—˜’j, âV“¡–œ—¢Žq, ˆÉ“¡‰Ã‹K: EBƒEƒCƒ‹ƒXŠ´õ‚É”º‚¤‹}«¬”]‰Š‚Æl‚¦‚ç‚ꂽ‚P—á. ‘æ18‰ñEBƒEƒCƒ‹ƒXŠ´õÇŒ¤‹†‰ï, 2008, 3, 8, “Œ‹ž.
    15. ¼“c’¼“¿, å@‹v”T, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ’J“à]ºG, –ö‘ò@—´: VƒÀ3+CD8+T×–E‚̃Nƒ[ƒ“«‘B‚ð”F‚ß‚½EBƒEƒCƒ‹ƒXŠÖ˜AŒŒ‹…æÃHƒŠƒ“ƒp‘gD‹…ǂ̈ê—á. ‘æ18‰ñEBƒEƒCƒ‹ƒXŠ´õÇŒ¤‹†‰ï, 2008, 3, 8, “Œ‹ž.
    16. ‘«—§—Yˆê: V‚½‚ÈŽ¡—Öò‚ð‚ǂ̂悤‚ÉŽg‚¤‚Ì‚© -ƒuƒfƒ\ƒjƒh{ƒÀ2ŽhŒƒ–ò-. ‘æ18‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 4, 13, •Ÿ‰ª.
    17. Žs“c•™Žq: ƒVƒ“ƒ|ƒWƒEƒ€u‚q‚rƒEƒCƒ‹ƒXŠ´õ‚Ìf’f‚Æ—\–hŽ¡—Â̌ø‰Ê‚ðl‚¦‚év.æ“V«SŽ¾Š³‚ւ̃pƒŠƒrƒYƒ}ƒu‚ÌŒø‰Ê‚Æ–â‘è“_. ‘æ111‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2008, 4, 25-27, “Œ‹ž.
    18. ‹àŒ“O˜a: ƒVƒ“ƒ|ƒWƒEƒ€uŽ©ŒÈ–ƉuŽ¾Š³‚̈â“`ŽqˆÙív. ‘æ111‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2008, 4, 25-27, “Œ‹ž.
    19. ”ÂàVŽõŽq, ‘«—§—zŽq, ‰ª•””üŒb, ˆÉ“¡–õ“T, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚éImpulse Oscillometry System‚Ì—L—p«‚ÌŒŸ“¢. ‘æ111‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2008, 4, 25-27, “Œ‹ž.
    20. ‘«—§—zŽq, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j, ¬“c“ˆ”Ž, ‘å–îKO, ÔàV@W: •xŽRŒ§‚É‚¨‚¯‚é‚RÎŽ™‚̃AƒŒƒ‹ƒM[Ž¾Š³‚Ì”­Ç‚Ɗ‹«ˆöŽq‚ÌŠÖŒW‚ÉŠÖ‚·‚錤‹†. ‘æ111‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2008, 4, 25-27, “Œ‹ž.
    21. Žs“c•™Žq: ƒVƒ“ƒ|ƒWƒEƒ€uIVIG•s‰ž—á‚ɑ΂·‚éV‚½‚Ȃ鎡—Ãí—ªv.‚h‚u‚h‚f•s‰ž—á‚ɑ΂·‚éRƒTƒCƒgƒJƒCƒ“—Ö@. ‘æ12‰ñìè•aŽ¡—ç˜b‰ï, 2008, 4, 27, “Œ‹ž.
    22. –{‹½˜a‹v, Œ´ˆä•ü”ü, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ”ª–ØMˆê, ‹{˜e—˜’j: _Œo¸_Çó‚ð’悵‚½Š³ŽÒ‚É‚¨‚¯‚錌’†R”]R‘Ì@‘æ50‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2008, 5, 31, “Œ‹ž.
    23. ”ÂàVŽõŽq, ‘«—§—zŽq, ˆÉ“¡–õ“T, ”óŒû@Žû, ‰ª•””üŒb, •£‘ò—³–ç, ’†—ÑŒºˆê, ŽRŒ³ƒŽq, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: ”x‹@”\‘ª’肪‹êŽè‚ÈŽq‚Ç‚à‚É‚¨‚¯‚é‚æ‚賊m‚È‘ª’è‚ÌŽŽ‚Ý. ‘æ25‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï, 2008, 5.31-6.1, “Þ—Ç.
    24. ‘«—§—Yˆê: ƒCƒuƒjƒ“ƒOƒVƒ“ƒ|ƒWƒEƒ€u㉺‹C“¹Ž¾Š³‚ÌŽ•ž‚ÉŒü‚¯‚Ä -¬Ž™‹CŠÇŽxšb‘§‚̓‰»—vˆö‚Æ‚»‚̉ñ”ð-v ‘æ20‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2008, 6, 12-14, “Œ‹ž.
    25. ‘«—§—Yˆê, ”ÂàVŽõŽq, ‘«—§—zŽq, ŒÜ\—’—²•v, ‘ºãIŒ[, ”öã—mˆê, ‚”ö@Š², ’†—ÑŒºˆê, •£‘ò—³–ç, ‹{˜e—˜’j, ÔàV@W: “û—cŽ™šb‘§‰uŠw’²¸—pŽ¿–â•[‚̑Ó–«‚ÉŠÖ‚·‚錤‹†. ‘æ20‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2008, 6, 12-14, “Œ‹ž.
    26. ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ‰ª•””üŒb, ”óŒû@Žû, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ƒÀ2ŽhŒƒ–ò‹z“ü‚Ö‚Ì”½‰ž«‚©‚ç‚Ý‚½šb‘§¬Ž™‚É‚¨‚¯‚éMS-IOS‚Ì—Õ°“IˆÓ‹`. ‘æ20‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2008, 6, 12-14, “Œ‹ž.
    27. ‘«—§—zŽqCˆÉ“¡–õ“TC”óŒû@ŽûC‰ª•””üŒbC”ÂàVŽõŽqCŽRŒ³ƒŽqC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jDƒAƒjƒ[ƒVƒ‡ƒ“‚ð—p‚¢‚½ŒÄ‹C“®ì—U“±‚É‚æ‚é”x‹@”\‘ª’è‚Ì—L—p« ‘æ2•ñ@EasyOne‚ð—p‚¢‚Ä. ‘æ20‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2008, 6, 12-14, “Œ‹ž.
    28. ”ÂàVŽõŽq: ‹CŠÇŽxšb‘§Š³Ž™‚Ì•ÛŒìŽÒ‚ɑ΂·‚éˆÓŽ¯’²¸‚ÌŒ‹‰Ê. –k—¤¬Ž™šb‘§Ž¡—ÃŒ¤‹†‰ï, 2008, 6, 21, ‹à‘ò.
    29. ‘«—§—Yˆê: ¬Ž™‹CŠÇŽxšb‘§f—ÃKƒCƒhƒ‰ƒCƒ“‚ɉˆ‚Á‚½Ž¡—Â̂·‚·‚ß. –k—¤¬Ž™šb‘§Ž¡—ÃŒ¤‹†‰ï, 2008, 6, 21, ‹à‘ò.
    30. ‹àŒ“O˜a: ƒVƒ“ƒ|ƒWƒEƒ€uV¶Ž™‚̖Ɖu‹@”\‚Æ‚»‚Ì”­’B v‘æ18‰ñ“ú–{ŽY•wl‰ÈEV¶Ž™ŒŒ‰tŠw‰ï, 2008, 6, 27, ”Ž‘½.(µ‘Òu‰‰)
    31. Žs“c•™Žq: ƒVƒ“ƒ|ƒWƒEƒ€u¶ŠUæ“V«SŽ¾Š³@”DPEoŽY‚̈ãŠwS—ŽÐ‰ï“I–â‘è@æ“V«SŽ¾Š³‚ÍŒJ‚è•Ô‚·‚©? æ“V«SŽ¾Š³‚̉uŠwv.@‘æ44‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2008, 7, 2-4, •Ÿ“‡.
    32. Ichida F., Saji T., Nakazawa M., Oyama K., Harada K.: Efficacy and safety of anti-RS virus monoclonal antibody palivizumab for pediatric patients with congenital heart diseases.‘æ44‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2008, 7, 2-4, •Ÿ“‡.
    33. “n•Óˆê—m, Ε^—R”ü, ¼ˆäŽOŽ}, œA–ìŒbˆê, Žs“c•™Žq, ‹{˜e—˜’j, –F‘º’¼Ž÷, ”ª–ØŒ´rŽ, ¼è‘½ç‘ã: Bayley scale‚ð—p‚¢‚½“ûŽ™‘Šú‚ÉŠJSp‚ðŽ{s‚³‚ꂽŽ™‚Ì”­’B•]‰¿. ‘æ44‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2008, 7, 2-4, •Ÿ“‡.
    34. âV“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, “n•Óˆ»‰À, œA–ìŒbˆê, 㨌hˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j, –F‘º’¼Ž÷, ˆÀ‰Í“àãà: S‘ŸÄ“¯Šú—Ö@(CRT)‚ðŽ{s‚µ‚½narrow QRS complex‚̶ŽºS‹Øãk–§‰»áŠQ(LVNC)3ΗŽ™—áC–ñ2”NŠÔ‚ÌŒo‰ß.‘æ44‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2008, 7, 2-4, •Ÿ“‡.
    35. ˆÉŒ\“ñ˜Y, Ä“¡˜a—R, “n•Óˆ»‰À, “n•Óˆê—m, œA–ìŒbˆê, 㨌hˆê˜Y, Žs“c•™Žq, ‘å‚TŒá, ¼‹vO“T, –kŒ´~ˆê˜Y, ‹g‘º’¼Ž÷, ¼”ö‰Äl, ‹v•Û@ŽÀ: HOT‚ƃ{ƒZƒ“ƒ^ƒ““à•ž‚ŃtƒHƒ“ƒ^ƒ“Žèp‚É“ž’B‚µ‚½–³äBÇŒóŒQ‚Ì1—á. ‘æ44‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2008, 7, 2-4, •Ÿ“‡.
    36. ˆÉŒ\“ñ˜Y, âV“¡˜a—R, “n•Óˆê—m, “n•Óˆ»‰À, œA–ìŒbˆê, 㨌hˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j: “ú—î35‚É”­Ç‚µƒVƒNƒƒXƒ|ƒŠƒ“‚ª—LŒø‚Å‚ ‚Á‚½“«ìè•a‚Ì1—á. ‘æ44‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2008, 7, 2-4, •Ÿ“‡.
    37. Œ´ˆä•ü”ü, –{‹½˜a‹v, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ‹{˜e—˜’j: —n˜A‹ÛŠ´õ‚É”º‚¢‘½Ê‚ȸ__ŒoÇó‚ð’悵‚½—Ž™—á. ‘æ21‰ñ“ú–{¬Ž™‰ÈŠw‰È•xŽR’n•û‰ï, 2008, 7, 6, •xŽR.
    38. Œ´ˆä•ü”ü, –{‹½˜a‹v, “¡–Ø–õŽq, ‹{ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ‹{˜e—˜’j: 9q34ÇŒóŒQ‚̈ê—á. ‘æ1‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï’†•”E–k—¤’n•û‰ï, 2008, 7, 21, –¼ŒÃ‰®.
    39. ‰ª•””üŒb, ‘«—§—zŽq, ”ÂàVŽõŽq, ‚”ö@Š², ”öã—mˆê, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: ˆê”Ê‚ÌH•i‚ð—p‚¢‚½H•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éŠO—ˆ‚Å‚ÌH•¨•‰‰×ŽŽŒ±‚Ì—L—p«. ‘æ11‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Ž¾Š³Œ¤‹†‰ï, 2008, 9, 13, •xŽR.
    40. ‘«—§—Yˆê: ƒAƒŒƒ‹ƒM[Ž¾Š³‚É‚¨‚¯‚駌äƒVƒXƒeƒ€. ‘æ26‰ñƒtƒH[ƒ‰ƒ€‘n–ò, 2008, 9, 26, •xŽR.
    41. “c‘ºŒ«‘¾˜Y, ”ÂàVŽõŽq, ‘«—§—Yˆê, •“c•¶l, ŽO‰Y³‹`, ‹{˜e—˜’j: ‚Ñ–Ÿ«”x–EoŒŒÇŒóŒQ‚Ì1ΗŽ™—á. ‘æ41‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï, 2008, 10, 3-4, ”ŸŠÙ.
    42. ”óŒû@Žû, ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ‘«—§—Yˆê, ‹{˜e—˜’j: 2007”N“x“~‹G‚É“ü‰@‰Á—Âð—v‚µ‚½‹}«×‹CŠÇŽx‰Š10—á‚ÌŒŸ“¢. ‘æ41‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï, 2008, 10, 3-4, ”ŸŠÙ.
    43. ”ÂàVŽõŽq: ƒ[ƒNƒVƒ‡ƒbƒvušb‘§‚Ì•a‘Ô•]‰¿ -‹CŠÇŽxšb‘§¬Ž™‚É‚¨‚¯‚é‹C—¬§ŒÀ-v. ‘æ41‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï, 2008, 10, 3-4, ”ŸŠÙ.
    44. –{‹½˜a‹v: ƒVƒ“ƒ|ƒWƒEƒ€u”­’B«“Ç‚Ý‘‚«áŠQ‚Ì•a‘ԂƑΉžv. ‘æ47‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï, 2008, 10, 5, •xŽR.
    45. –{‹½˜a‹v: ƒVƒ“ƒ|ƒWƒEƒ€u“–‰È‚É‚¨‚¯‚éAD/HD‚ւ̑Ήžv. ‘æ1‰ñ•xŽRŒ§”­’BáŠQŒ¤‹†‰ï, 2008, 10, 5, •xŽR.
    46. ‘å’ØŒc•ã, å@‹v”T, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, Š@³Ž¡: –Ô–Œ‰èŽîC‹}«”’ŒŒ•a•¹”­Š³Ž™‚ɑ΂·‚鉻Šw—Ö@’†‚É”­Ç‚µ‚½ƒAƒ‹ƒWƒAŠ´õÇ‚Ì‚P—á. ‘æ70‰ñ“ú–{ŒŒ‰tŠw‰ï, 2008, 10, 10-12, ‹ž“s.
    47. “n•Óˆ»‰À, ‹{ˆêŽu, 㨌hˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j, –F‘º’¼Ž÷, ŽOè‘ñ˜Y, ÎàV@L, ¼ìr˜Y, Vatta Matteo.: S‹Ø“àΊD‰»‚𔺂Á‚½Œ´”­«S“à–ŒüˆÛ’e«ÇiEFEj‚Ì1—á. ‘æ17‰ñŠÖ“Œ¬Ž™S‹ØŽ¾Š³Œ¤‹†‰ï, 2008, 10, 11, “Œ‹ž.
    48. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‘ºãIŒ[, –k—¤¬Ž™šb‘§Ž¡—ÃŒ¤‹†‰ï: ŠO—ˆ‚Å‚ÌŠÈ’P‚È–âf•[‚ƃ`ƒFƒbƒN•\‚𓱓ü‚·‚邱‚Æ‚É‚æ‚鬎™‹CŠÇŽxšb‘§ƒKƒCƒhƒ‰ƒCƒ“‚ɉˆ‚Á‚½Ž¡—Äi‚ÌŒø‰Ê. ‘æ16‰ñ—Õ°šb‘§Œ¤‹†‰ï, 2008, 10, 18, “Œ‹ž.
    49. œA–ìŒbˆê, ŠÄ•¨@–õ, ˆÉŒ\“ñ˜Y, Ö“¡˜a—R, “n•Óˆê—m, “n•Óˆ»‰À, 㨌hˆê˜Y, ‹àŒ“O˜a, Žs“c•™Žq, ‹{˜e—˜’j, ²’n@•×: ƒCƒ“ƒtƒŠƒLƒVƒ}ƒuŽ¡—Âðs‚Á‚½“«ìè•a‚É‚¨‚¯‚éƒTƒCƒgƒJƒCƒ“‚Ì“®‘Ô. ‘æ28‰ñ“ú–{ìè•aŒ¤‹†‰ï, @2008, 10, 17-18, ŽD–y.
    50. –{‹½˜a‹v, Œ´ˆä•ü”ü, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ”ª–ØMˆê, ‹{˜e—˜’j: ‚Ä‚ñ‚©‚ñŠ³ŽÒ‚É‚¨‚¯‚éLysogangliosideR‘Ì‚Ì•Û—L—¦. ‘æ42‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï, 2008, 10, 18-19, “Œ‹ž.
    51. Œ´ˆä•ü”ü, –{‹½˜a‹v, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ‹{˜e—˜’j: WestÇŒóŒQ‚ð‡•¹‚µ‚½9q34Œ‡Ž¸ÇŒóŒQ‚̈ê—á. ‘æ42‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï, 2008, 10, 18-19, “Œ‹ž.
    52. ‰eŽR—²Ži, Œ´ˆä•ü”ü, –{‹½˜a‹v, “¡–Ø–õŽq, ‹{@ˆêŽu, “c’‡çH, ‹{˜e—˜’j: ”­ì«‰^“®—U”­«•‘“¥ƒAƒeƒg[ƒ[‚Ì5—á. ‘æ42‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï, 2008, 10, 18-19, “Œ‹ž.
    53. ¼‘q—TŠì, ‘q–{@’, ‹àŒ“O˜a, –쑺ŒbŽq, ‹{˜e—˜’j: X˜A½–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ(XLA)‚ɇ•¹‚µCŽ‘±«’á•â‘ÌŒŒÇ‚ð’悵‚½ƒƒTƒ“ƒMƒEƒ€‘B«t‰Š‚̈ê—á. ‘æ16‰ñ–k—¤tŽ¾Š³EŒŒ‰tò‰»—Ö@Œ¤‹†‰ï,2008, 10, 25, ‹à‘ò.
    54. “c‘ºŒ«‘¾˜Y, ¼“c’¼“¿, å@‹v”T, ‘å’ØŒc•ã, –쑺ŒbŽq, ‹àŒ“O˜a, –ö‘ò@—´, ’J“à]ºG, ‹{˜e—˜’j: EBƒEƒCƒ‹ƒXŠÖ˜AŒŒ‹…æÃH«ƒŠƒ“ƒp‘gD‹…Ç‚Ì‚Q—á. ‘æ50‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2008, 11, 14-16, ç—t.
    55. ‘«—§—Yˆê: “Á•Êu‰‰u¬Ž™‚Ì‹C“¹ˆÙ•¨ ?f’f‚ÆŽ¡—ÃC‚»‚µ‚Ä—\–h-v ‘æ33‰ñ“Œ“ú–{¬Ž™‰ÈŠw‰ï, 2008, 11, 23, _“Þì.
    56. ‘«—§—Yˆê: ƒCƒuƒjƒ“ƒOƒVƒ“ƒ|ƒWƒEƒ€u‹CŠÇŽxšb‘§‚ÌV‚½‚ÈŽ¡—Ãí—ª -¬Ž™‚É‚¨‚¯‚é‚æ‚è—Ç‚¢šb‘§Ž¡—Â̎À‘H-v ‘æ58‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2008, 11, 27-29, “Œ‹ž.
    57. ‘«—§—Yˆê: “Á•ÊƒVƒ“ƒ|ƒWƒEƒ€uƒAƒŒƒ‹ƒM[Ž¾Š³‚Ɗ‹«ˆöŽq‚̉uŠw ?Šˆàu‰q¶‰¼àv‚ÌŒoˆÜ‚ÆŒ»óŒŸØ?v ‘æ58‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2008, 11, 27-29, “Œ‹ž.
    58. ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ’†—ÑŒºˆê, ‘«—§—Yˆê, ‹{˜e—˜’j: šb‘§¬Ž™‚É‚¨‚¯‚éŒÄ‹CNO”Z“x‚ƌċz‹@”\‚Æ‚ÌŠÖŒW. ‘æ58‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2008, 11, 27-29, “Œ‹ž.
    59. ‘ºãIŒ[, ”óŒû@Žû, •£àV—³–ç, ”ÂàVŽõŽq, ‘«—§—Yˆê, ¬“c“ˆ”Ž: ¬Ž™šb‘§‚̉ƒë‚Å‚Ì”­ìŽž‚É‚¨‚¯‚éƒÀ2ŽhŒƒ–ò‚ÌŽg—p‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²¸. ‘æ58‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2008, 11, 27-29, “Œ‹ž.
    60. Žs“c•™Žq: ƒVƒ“ƒ|ƒWƒEƒ€u¶ŽºS‹Øãk–§‰»áŠQLeft ventricular noncompactionv. ‘æ30‰ñS‹Ø¶ŒŸŒ¤‹†‰ï, 2008, 11, 28, ŽOd.
    61. ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: šb‘§Ž™‚Ì‹C—¬§ŒÀ‘ª’è‚É‚¨‚¯‚éƒgƒsƒbƒNƒXD‘æ35‰ñ–k—¤ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2008, 12, 6, ‹à‘ò.
    62. “c‘ºŒ«‘¾˜Y, ‹g–{’q”ü, ”ÂàVŽõŽq, ‹{˜e—˜’j: ŒJ‚è•Ô‚·‹¹˜ˆ³”—œÜ‚Å”­Ç‚µ‚½œŒ`¬•s‘SÇ‚Ì“ûŽ™—á. ‘æ26‰ñ¬Ž™‘ãŽÓ«œŽ¾Š³Œ¤‹†‰ï, 2008, 12, 6, ‘åã.
    63. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2008 ‰ðà -‘ŠúŽ¡—Éî“ü‚ÌŒø‰Ê-v. ‘æ45‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2008, 12, 13-14, ‰¡•l.
    64. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‘ºãIŒ[, ’†‘º—˜”ü, ’|ƒm“à—TŽÀ, ’Óc‰p•v, ‘哈—E¬, ’J“à]ºG, áÁ‹|Œõ•¶, ‹{˜e—˜’j: ‹CŠÇŽxšb‘§Š³Ž™•ÛŒìŽÒ‚É‚¨‚¯‚é•a‘Ô‚Ì—‰ð“x‚ÆŽ¡—ÖڕW‚ÉŠÖ‚·‚é’²¸. ‘æ45‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2008, 12, 13-14, ‰¡•l.
    65. ‘«—§—zŽq, ”ÂàVŽõŽq, ‰ª•””üŒb, ˆÉ“¡–õ“T, ”óŒû@Žû, ŽRŒ³ƒŽq, ‚”ö@Š², ”öã—mˆê, ‘ºãIŒ[, ‘«—§—Yˆê, ‹{˜e—˜’j: •ÛˆçŽ{Ý‚Å‚ÌH•¨ƒAƒŒƒ‹ƒM[œ‹ŽH’ñ‹Ÿ‚É‚¨‚¯‚鉀Ž™‚Ö‚Ì”z—¶. ‘æ45‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2008, 12, 13-14, ‰¡•l.
    66. ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—zŽq, ŒÜ\—’—²•v, ‘ºãIŒ[, ”öã—mˆê, ‚”ö@Š², ’†—ÑŒºˆê, •£àV—³–ç, ‘«—§—Yˆê, ‹{˜e—˜’j, ÔàV@W: “û—cŽ™šb‘§‰uŠw’²¸—pŽ¿–â•[‚̑Ó–«‚ÉŠÖ‚·‚錤‹†@‘æ2•ñ@’·ŠúŠÇ—–ò‚ÌŽg—p‚ɂ‚¢‚ÄD‘æ45‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2008, 12, 13-14, ‰¡•l.

    2007”N

  • ’˜‘
    1. Shan L., Xing Y., Futatani T., Tsubata S., Watanabe S., Saito K., Watanabe K., Hirono K., Uese K., Ichida F., Miyawaki T., Bowles N.E., and Towbin J.A.: SCN5A variants in Japanese patients with left ventricular noncompaction and arrhythmia. future aspects of medical sciences and education gChallenge of integrated medical sciencesh Edited by Nadal-Ginard B and Takakura K. IREIIMS, Tokyo, 148-149, 2007.
    2. Žs“c•™Žq: S‹Ø‚Ì\‘¢‚ÆS‹ØÇ‚Ì•ªŽqˆãŠw.@u—Õ°S‘Ÿ”­¶Šwv,ŽRŠÝŒhK,”’ÎŒö•Ò,ƒƒWƒJƒ‹ƒrƒ…[ŽÐ,“Œ‹ž,195-202, 2007.
    3. Žs“c•™Žq: “ñŽŸ«S‹ØÇ‚ðŒ©‚Ì‚ª‚³‚È‚¢. ¶ŽºS‹Øãk–§‰»áŠQuVES‘Ÿ•af—Ãvƒ‰ƒNƒeƒBƒX 10@S‹ØÇ‚ðŽ¯‚éEf‚éEŽ¡‚·v. ˆé•”ŒõÍ‘¼•Ò, •¶Œõ“°, “Œ‹ž, 342-347, 2007.
    4. Žs“c•™Žq: æ“V«SŽ¾Š³Du‚í‚©‚è‚â‚·‚¢“à‰ÈŠw‰ü’ù‘æ3”Åvˆä‘º—T•v‘¼•Ò, •ªŒõ“°, “Œ‹ž, 150-162, 2007.
    5. ‘«—§—Yˆê: ‹z“üƒfƒBƒoƒCƒX‚Ì‘I‘ð MDI‚©DPI‚©…—n‰t‚©,uTHE 26th ROKKO CONFERENCED‹CŠÇŽxšb‘§‚Ì‚æ‚è‚æ‚¢Ž¡—Â̂½‚ß‚Év, ¬—Ñß—Y‘¼•Ò, 49-55, ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXo”Å, “Œ‹ž, 2007.
    6. ‹àŒ“O˜a, ‹{˜e—˜’j, ¡ˆäk•ã: æ“V«–Ɖu•s‘SÇ‚Ìf’f‚Ìi•à‚ÆEBM‚ÉŠî‚­Ž¡—Ö@‚ÌŽÀÛ‚ÍH,uEBM¬Ž™Ž¾Š³‚ÌŽ¡—ÃvŒÜ\—’—²‘¼•Ò, 351-353, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 2007.
    7. ‹àŒ“O˜a: ½œ“ªŠWˆÙŒ`¬Ç,uœŒn“Ž¾Š³ƒ}ƒjƒ…ƒAƒ‹v“ú–{®Œ`ŠO‰ÈŠw‰ï,¬Ž™®Œ`ŠO‰ÈˆÏˆõ‰ï•Ò,144-145,“ì]“°,“Œ‹ž,2007.
    8. 㨌hˆê˜Y, Žs“c•™Žq: ¶S•ÂÇ«Ž¾Š³DuŽüŽYŠú‚ÌÇŒóEf’fEŽ¡—Ãiƒr@ŽüŽYŠúˆãŠw‘æ37Šª‘Š§v, ŽüŽYŠúˆãŠw•ÒWˆÏˆõ‰ï•Ò, “Œ‹žˆãŠwŽÐ, 583-585, 2007.
    9. 㨌hˆê˜Y, Žs“c•™Žq: ƒ`ƒAƒm[ƒ[«SŽ¾Š³.uŽüŽYŠú‚ÌÇŒóEf’fEŽ¡—Ãiƒr@ŽüŽYŠúˆãŠw‘æ37Šª‘Š§v, ŽüŽYŠúˆãŠw•ÒWˆÏˆõ‰ï•Ò, “Œ‹žˆãŠwŽÐ, 597-582, 2007.
    10. ÔàV@W, ‘«—§—Yˆê, Šâ“c@—Í, ŒIŒ´˜aK, ¼–´“c•q”V, –]ŒŽ”Ž”V: ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒnƒ“ƒhƒuƒbƒN2007, X캜A, ¼ŠÔŽOŠ]ŠÄC, ‹¦˜aŠé‰æ, “Œ‹ž, 2007.
  • Œ´’˜
    1. Kanegane H., Agematsu K., Futatani T., Sira M.M., Suga K., Sekiguchi T., Zelm M.C., and Miyawaki T.: Novel mutation in a Japanese patient with CD19 deficiency. Genes Immun 8: 663-670, 2007.
    2. Fuchizawa T., Adachi Y., Ito Y., Higashiyama H., Kanegane H., Futatani T., Kobayashi I., Kamachi Y., Sakamoto T., Tsuge I., Tanaka H., Banham A.H., Ochs H.D., and Miyawaki T.: Developmental changes of FOXP3-expressing CD4+CD25+ regulatory T cells and their impairment in patients with FOXP3 gene mutations. Clin Immunol 125: 237-246, 2007.
    3. Matsukura H., Miya K., Arai M., Miyawaki T., and Inaba S.: Minimal change variants with mesangial IgA deposits. Clin Nephrol 68: 337-338, 2007.
    4. Matsukura H., Kida K., Miya K., Kanegane H., Arai M., and Miyawaki T.: Gross hematuria as a manifestation of membranous nephropathy. Clin Nephrol 68: 339-340, 2007.
    5. Hashimoto I., Uese K., Watanabe S., Watanabe K., Hirono K., Ichida F., and Miyawaki T.: Assessment of variables affecting velocity of left ventricle in healthy children. Pediatr Int 49: 305-309, 2007.
    6. Chen X., Origasa H., Kamibeppu K., Ichida F., and Varni J.A.: Reliability and validity of the pediatric quality of life inventory (PedsQL) short form-15 (SF15) generic core scales in Japan. Quality Life Res 16: 1239-1249, 2007.
    7. Imai K., Kanegane H., Kumaki S., Ariga T., Tsuchiya S., Morio T., Tsuji Y., Agematsu K., Takada H., Nonoyama S., and Miyawaki T.: Retrospective analysis of stem cell transplantations for severe combined immunodeficiency in Japan. Bone Marrow Transpl 39: S75-76, 2007.
    8. Arai A., Kitano A., Kanegane H., Miyawaki T., and Miura O.: Relapsing campylobacter coli bacteremia with reactive arthritis in a patient with X-linked agammaglobulinemia. Int Med 46: 605-609, 2007.
    9. Yoshihara T., Kobayashi M., Kikuta A., Kato K., Adachi N., Kikuchi A., Ishida H., Hirota Y., kuroda H., Nagatoshi Y., Inukai T., Koike K., Kigasawa H., Yagasaki H., Tokuda K., Kishimoto T., Nakano T., Fujita N., Goto H., Nakazawa Y., Kanegane H., Matsuzaki A., Osugi Y., Hasegawa D., Uoshima N., Nakamura K., Tsuchida M., Tanaka R., Eatanabe A., and Yabe H.: Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents. Int J Hematology 85: 246-255, 2007.
    10. Hirose Y., Ichida F., Oshima Y., and Yoshimura N.: Developmental status of young infants with congenital heart disease. Pediatr Int 49: 468-471, 2007.
    11. Amoras ALB., da Silva MTN., Zollner RL., Kanegane H., Miyawaki T., and Viela MMS.: Expression of Fc gamma and complement receptors in monocytes of X-linked agammaglobulinaemia and common variable immunodeficiency patients. Clin Exp Immunol 150: 422-428, 2007.
    12. Atarod L., Aghamohammadi A., Moin M., Kanegane H., Rezaei N., Rezaei K.K., Amirzagar A.A., Futatani T., and Miyawaki T.: Successful management of neutropenia in a patient with CD40 ligand deficiency bu immunoglobulin replacement therapy. Iran J Allergy Asthma Immunol 6: 37-40, 2007.
    13. Grebe S., Ichida F., Grabitz R., B?ltmann B., Heidemann S., and Kaisenberg C.S.V.: Reversed pulmonary artery flow in isolated noncompaction of the ventricular myocardium. Fetal Diagn Ther 22: 29-32, 2007.
    14. Wittkowski H., Hirono K., Ichida F., Vogl T., Ye F., Yanlin X., Saito K., Uese K., Miyawaki T., Viemann D., Roth J., and Foell D.: Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum 56: 4174-4181, 2007.
    15. ‘«—§—Yˆê, ˆäãšæ–Î, ‹´–{ŒõŽi, ‹ß“¡’¼ŽÀ, áÁ‹|Œõ•¶, X캜A, ¼ŠÔŽOŠ]: ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2005‚ª“ûŽ™šb‘§‚ÌŽ¡—ÃŒ»ê‚É—^‚¦‚½‚à‚Ì?‘æ15‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï‚ł̃Aƒ“ƒP[ƒg’²¸Œ‹‰Ê‚æ‚è?. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@21: 116|123, 2007.
    16. ‘«—§—zŽq, ’†—ÑŒºˆê, •£àV—³–ç, ‰ª•””üŒb, ”ÂàVŽõŽq, ‚”ö@Š², ŽRŒ³ƒŽq, ”öã—mˆê, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: •ÛˆçŽ{Ý‚Å‚ÌH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨œ‹Ž‘Ήž‚É‚¨‚¯‚é•Ï‰» ?•xŽRŒ§‚É‚¨‚¯‚镽¬13”N“x‚Æ18”N“x’²¸‚Ì”äŠr-. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ21: 305|310, 2007.
    17. ŽíŽsq’ˆ, Œ´ˆä•ü”ü, ‹{˜e—˜’j: ŠC…ƒpƒ“ƒc‚̃Cƒ“ƒi[ƒƒbƒVƒ…‚É‚æ‚鬎™‰AŒs•””畆‘¹‚Ì‚Q—á. ¬Ž™“à‰È@39: 527|530, 2007.
    18. óˆä³Žk, ‘«—§—Yˆê, ’†ì@”£, –Ø‘º@Š°, ”ÂàVŽõŽq, ˜a“c—Ï”V•, ˆÀ•”‰pŽ÷, •š–ØG², Ô”‹Ÿˆê, ˆÀ‘º²“s‹I, ›’Ï“úo•v, “n•Ós—Y: ¬Ž™‚Ì‹CŠÇE‹CŠÇŽxˆÙ•¨Ç—á‚ÌŒŸ“¢. “ú‹CH‰ï•ñ58: 64|70, 2007.
    19. –ö“à¹, ˆÉ“¡Šó”ü, ‰F‰Á]@i, ‹àŒ“O˜a, ‹{˜e—˜’j: D’†‹…Œ¸­‚𔺂Á‚½X˜A½–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚Ì‚P—á. —ÕବŽ™ˆãŠw@55: 37|40, 2007.
    20. œA£K”ü, ‹{–{çŽj, Žs“c•™Žq, –F‘º’¼Ž÷, ‘哈‹`”Ž: “ûŽ™Šú‚ÉŽèp‚ð—v‚·‚鎙‚Ì”­’B‚ÉŠÖ‚·‚錤‹†\‚PΔ¼‚É‚¨‚¯‚é”­’B‚Æ‚»‚ÌŠÖ˜A—vˆö\@¬Ž™•ÛŒ’Œ¤‹†@66: 75|82, 2007.
  • Ç—á•ñ
    1. Kanegane H., Watanabe S., Nomura K., Xu G., Ito E., and Miyawaki T.: Distinct clones are associated with the development of @transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome. Int J Hematol 86: 250-252, 2007.
    2. ˆÉ“¡G˜a, ŽíŽsq’ˆ, ¼‘q—TŠì, ‹{˜e—˜’j: ”x‰Š‡•¹‚ðŒ_‹@‚É”­Œ©‚³‚ꂽ—n˜A‹ÛŠ´õŒã‹}«Ž…‹…‘Ìt‰Š‚Ì‚QÇ—á. ¬Ž™‰È—Õ°@60: 323|330, 2007.
  • ‘à
    1. ‹{˜e—˜’j: ’áƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ. ŒŒ‰tƒtƒƒ“ƒeƒBƒA@17: 31|37, 2007.
    2. Žs“c•™Žq: ˆâ“`ŽqˆÙí‚É‚æ‚é•s®–¬‚ÆS‹ØŽ¾Š³|‚»‚Ì•a‘ÔŒ`¬‚Ì‹@˜‚ÆŽ¡—Ãí—ª\•ªŽqSŒŒŠÇ•a@8: 136|142, 2007.
    3. Žs“c•™Žq: æ“V«SŽ¾Š³‚Æ‚q‚rƒEƒBƒ‹ƒXŠ´õÇ. “~‚̃EƒBƒ‹ƒXŠ´õÇ. ¬Ž™‰Èf—Ã@70: 2249|2253, 2007.
    4. Žs“c•™Žq: ”ñŽèp‚̃`ƒAƒm[ƒ[Ž¾Š³‚̃PƒA,S‘ŸˆÈŠO‚ÌŽèp,–ƒŒ,Ž•‰ÈŽ¡—Ã,’m. ¬læ“V«SŽ¾Š³f—ÃKƒCƒhƒ‰ƒCƒ“(2006”N‰ü’ù”Å). Circulation J 71: SupplementVI, 2007.
    5. Žs“c•™ŽqFƒ`ƒAƒm[ƒ[,ÔŒŒ‹…‘‘½Ç‚̇•¹Ç. ¬læ“V«SŽ¾Š³f—ÃKƒCƒhƒ‰ƒCƒ“(2006”N‰ü’ù”Å). Circulation J 71: SupplementVI, 2007.
    6. ‘«—§—Yˆê: ¬Ž™‹CŠÇŽxšb‘§‚ÌŠ°‰ð‚ÆŽ¡—Ã. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@21: 271|280, 2007.
    7. ‘«—§—Yˆê: ’·ŠúŠÇ—‚Ì•ÏX‚ÆI—¹‚ð‚Ç‚¤‚·‚é‚© uƒfƒBƒx[ƒg “ûŽ™šb‘§vDƒAƒŒƒ‹ƒM[E–Ɖu 14: 1346|1352, 2007.
    8. ‘«—§—Yˆê: “ûŽ™‚Ìšb–Âf—à uŠO—ˆƒAƒŒƒ‹ƒM[f—ÃABCv ¬Ž™‰Èf—Ã@70: 1247|1252, 2007.
    9. ‹àŒ“O˜a: Š´õÇ‚Æ—\–hÚŽí. ¬Ž™Š´õ–Ɖu 19: 427|431, 2007.
    10. ‹àŒ“O˜a, å@‹v”T, –쑺ŒbŽq, ‹{˜e—˜’j, M“c@‹v: –Ɖu•s‘SÇ‚É‚Ý‚é^‹ÛŠ´õÇ‚Æ‚»‚Ì‘Îô?R^‹Û–ò‚ÌŽž‘ã?‰»Šw—Ö@‚̗̈æ@23: 411|415, 2007.
    11. ‹àŒ“O˜a, 㼈ê‰i, ‹{˜e—˜’j: Ž©ŒÈ‰ŠÇ«ÇŒóŒQ (autoinflammatory syndrome) ‚ƈâ“`ŽqˆÙí. ƒŠƒEƒ}ƒ`‰È 38: 370|379, 2007.
    12. ”ÂàVŽõŽq, ‘«—§—Yˆê: ¬Ž™‹CŠÇŽxšb‘§‚Ì‹}«”­ì‚ւ̑Ήž uƒvƒ‰ƒCƒ}ƒŠEƒPƒAˆã‚Ì‚½‚߂̬Ž™ƒAƒŒƒ‹ƒM[‚Ìf‚©‚½ ?ê–åˆãEŠwZˆãE‰Æ’ëˆã‚̘AŒg-v Ž¡—Ã@89: 1798|1804, 2007.
    13. •lè—Y•½, ˆäãšæ–Î, ‘«—§—Yˆê: ƒKƒCƒhƒ‰ƒCƒ“‚ð‚Ç‚¤“Ç‚Þ‚©u‘æ10Í ¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚é‹z“üŠí‹@‚Æ‚»‚ÌŽg‚¢•ûv“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 21: 235|239, 2007.

  • 2007”NŠw‰ï•ñ
    1. ItoY., Adachi Y., Itazawa T., Saito K., Uese K., Ichida F., and Miyawaki T.: Comorbidity of life-threatening arrhythmia in children with asthma. 63nd Annual Meeting of American Academy of Allergy & Immunology, 2007, 2, 23-27, San Diego,USA.
    2. Adachi Y.: Procaterol as Reliever and Controller in Pediatric Asthma, Pediatrics KOL symposium, 2007, 3, 4, Bali, Indonesia.(Invited Lecture)
    3. Watanabe S., Hashimoto I., Saito K., Watanabe K., Hirono K., Uese K., Ichida F., Sakai M., Saito S., Miyawaki T., Nieman P., and Sahn D.J.: Characterization of ventricular myocardial performance in fetus by tissue doppler imaging. The 56th scientific sessions of American college of cardiology, 2007, 3, 24-27, New Orleans, U.S.A.
    4. Shan L., Xing Y., Watanabe S., Futatani T., Tsubata S., Ye F., Saito K., Watanabe K., Hirono K., Uese K., Ichida F., Miyawaki T., Bowles N.E. and Towbin J.A. : SCN5A mutations in Japanese patients with left ventricular noncompaction and arrhythmia. The 56th scientific sessions of American college of cardiology, 2007, 3, 24-27, New Orleans, U.S.A.
    5. Adachi Y.: Role of beta2-agonists in the management of childhood asthma. The 4th Meeting of Taiwanese Society of Pediatric Pulmonology, 2007, 4, 15, Taipei, Taiwan. (Invited Lecture)
    6. Adachi Y.: Immunological Aspects in Childhood Asthma. 2007 Spring academic meeting of Taiwanese Society of Pediatric Allergy Asthma and Immunology , 2007, 4, 15, Kaohsiung, Taiwan. (Invited Lecture)
    7. Kanegane H.: X-linked lymphoproliferative syndrome in Japan. 3rd Hemophagocytic syndrome research meeting, 2007, 4, 1, Tokyo.
    8. Watanabe K., Matsui M., Ishiguro M., Matsuzaki T., Watanabe S., Hirono K., Uese K., Yoshimura N., Ichida F., and Miyawaki T.: Neuroanatomical development of infants undergoing heart surgery evaluated by quantitative three-dimentional magnetic resonance imaging. The 3rd Congress of Asian Society for Pediatric Research, 2007, 10, 6-8, Tokyo.
    9. Saito K., Ichida F., Ibuki K., Hirono K., Watanabe S., Uese K., Miyawaki T., Ohtaka S., Yoshimura N., and Yasukouchi S.: Cardiac resynchronization therapy in a 3-year-old girl with isolated left ventricular noncompaction and narrow QRS complex. The 3rd Congress of Asian Society for Pediatric Research, 2007, 10, 6-8, Tokyo.
    10. Ibuki K., Hirono K., Uese K., Saito K., Watanabe S., Watanabe K., Ichida F., Miyawaki T., Ohtaka S., Kitahara J., Murakami H., and Yoshimura N.: Efficacy of combination therapy of bosentan, beraprost and HOT in candidates for right heart bypass surgery. The 3rd Congress of Asian Society for Pediatric Research, 2007, 10, 6-8, Tokyo.
    11. Hirono K., Wittkowski H., Vogl T., Ibuki K., Saito K., Uese K., Ichida F., and Miyawaki T.: Reverse kinetics of circulating soluble receptor for advanced glycation end products (sRAGE) and its ligand S100A12 in acute Kawasaki disease. The 3rd Congress of Asian Society for Pediatric Research, 2007, 10, 6-8, Tokyo.
    12. Shan L., Dougu N., Joho S., Shida T., Matsuki A., Uese K., Ichida F., Miyawaki T., Tanaka K., and Inoue H.: A novel LAMP-2 mutation in a family with hypertrophic cardiomyopathy. The 3rd Congress of Asian Society for Pediatric Research, 2007, 10, 6-8, Tokyo.
    13. Itazawa T., Adachi Y., Mochizuki H., Shimojo N., Inoue T., Nishimuta T., Morikawa A., and Nishima S.: Aerosol characteristics of admixture of budesonide inhalation solution with beta2-agonist, procaterol. XX World Allergy Congress 2007, 2007, 12, 2-6, Bangkok, Thailand.
    14. 㨌hˆê˜Y, Ä“¡˜a—R, “n•Óˆ»‰À, “n•Óˆê—m, œA–ìŒbˆê, Žs“c•™Žq, ‘ºã”Ž‹v, –F‘º’¼Ž÷: ƒNƒŠƒbƒvœ‹Žp‚Ń`ƒAƒm[ƒ[‚ª‰ü‘P‚¹‚¸RV-PAƒVƒƒƒ“ƒg‚ɑ΂µ‚ăoƒ‹[ƒ“Ž¡—Âðs‚È‚Á‚½NorwoodpŒã‚Ì‚P—á. ‘æ18‰ñ“ú–{Pediatric Interventional CardiologyŒ¤‹†‰ïŠwpW‰ï, 2007, 1, 19|20, •Ÿ‰ª.
    15. ‘«—§—zŽq, ˆÉ“¡–õ“T, ”óŒû@Žû, ‰ª•””üŒb, ”ÂàVŽõŽq, ŽRŒ³ƒŽq, ‚”ö@Š², ”öã—mˆê, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: •ÛˆçŽ{Ý‚É‚¨‚¯‚éH•¨œ‹ŽŽwŽ¦‘‚ÍŠ®‘Sœ‹Ž‚©ŒÂ•Ê‘Ήž‚©@?•xŽRŒ§‚É‚¨‚¯‚éƒAƒ“ƒP[ƒg’²¸Œ‹‰Ê‚æ‚è?. ‘æ7‰ñH•¨ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2007, 1, 27, “Œ‹ž.
    16. –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ˆÀ‘º²“s‹I: ¶Ž¨‰º‘B•”‰¡–ä‹Ø“÷Žî,‚»‚ÌŒã‚ÌŒo‰ß?Ž¡—ÃI—¹‚RƒJŒŽŒã,¶è󕔃Šƒ“ƒpßÄ”­. ‘æ26‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ï, 2007, 2, 3, ‹à‘ò.
    17. Ä“¡˜a—R, “n•Óˆ»‰À, 㨌hˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j, ‘å‚TŒá, –kŒ´~ˆê˜Y, ‘ºã”Ž‹v, –F‘º’¼Ž÷, ‹v•Û@ŽÀ: ƒ{ƒZƒ“ƒ^ƒ“, ƒxƒ‰ƒvƒƒXƒg, HOT‚𕹗p‚µGlennŽèp‰Â”\‚Æ‚È‚Á‚½’PSŽº‚Ì‚WÎ’jŽ™—á. ‘æ13‰ñ“ú–{¬Ž™”xzŠÂŒ¤‹†‰ï, 2007, 2, 3, “Œ‹ž.
    18. ‹{@ˆêŽu, “¡–Ø–õŽq, Œ´ˆä•ü”ü, ‰eŽR—²Ži, “c’‡çH, –{‹½˜a‹v, ‹{˜e—˜’j: —Ç«“ûŽ™áz¹‚ÌŠù‰‚ð—L‚·‚éPKC‚̈ê—á. ‘æ51‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï, 2007, 2, 4, ‹à‘ò.
    19. ‘å’ØŒc•ã, å@‹v”T, ”óŒû@Žû, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ŠÛ’J‰xŽq, ²Ž¡”Ž•v: HLA3À•sˆê’v‚Ì•ƒ•ê‚©‚瓯Ží‘¢ŒŒŠ²×–EˆÚA‚ðs‚Á‚½monosomy7‚̈ꬎ™—á. ‘æ29‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï, 2007, 2, 16|17, •Ÿ‰ª.
    20. Ä“¡˜a—R, “n•Óˆ»‰À, 㨌hˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j, ‘å‚TŒá, –kŒ´~ˆê˜Y, ‘ºã”Ž‹v, –F‘º’¼Ž÷, ˆÀ‰Í“à‘: ¶ŽºS‹Øãk–§‰»áŠQ‚Ì‚RΗŽ™‚ɑ΂µ‚ÄS‘ŸÄ“¯Šú—Ö@iCRTj‚ðŽ{s‚µ‚½ŒoŒ±. ‘æ33‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ï, 2007, 2, 25, ‹à‘ò.
    21. å@‹v”T, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: “¯Žíœ‘ˆÚA‚ðŽ{s‚µ‚½ Diamond-Blackfan•nŒŒ‚̈ê—á. ‘æ289‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï, 2007, 3, 11, ‹à‘ò.
    22. Shan L., Xing Y., Watanabe S., Futatani T., Tsubata S., Ye F., Saito K., Watanabe K., Hirono K., Uese K., Ichida F., Miyawaki T., Bowles N.E., and Towbin J.A. : SCN5A mutations in Japanese patients with left ventricular noncompaction and arrhythmia. The 71 th@annual scientific meeting of the Japanese circulation society, 2007, 3, 15-17, Kobe.
    23. “¡–Ø–õŽq, Œ´ˆä•ü”ü, ‹{@ˆêŽu, ‰eŽR—²Ži, –{‹½˜a‹v, ‹{˜e—˜’j: ‚Ä‚ñ‚©‚ñ‚ÌWISC-‡V. ‘æ31‰ñ–k—¤‚Ä‚ñ‚©‚ñ§˜b‰ï, 2007, 3, 10, ‹à‘ò.
    24. ”ÂàVŽõŽq, ‘«—§—zŽq, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: ƒAƒjƒ[ƒVƒ‡ƒ“‚É‚æ‚éŒÄ‹C“®ì—U“±‘•’u•t‚«”x‹@”\‘ª’è‹@Ší‚Ì—L—p«. ‘æ10‰ñ–k—¤šb‘§Œ¤‹†‰ï, 2007, 3, 24, ‹à‘ò.
    25. ‹àŒ“O˜a, 㼈ê‰i, “ñ’J@•, M. M. Sira,, {‰êŒ’ˆê, ŠÖŒû—²“T, ‹{˜e—˜’j: CD19Œ‡‘¹‚É‚æ‚é’áƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì‚P—á. ‘æ30‰ñ“ú–{¬Ž™ˆâ“`Šw‰ï, 2007, 4, 19, ‹ž“s.
    26. ‹àŒ“O˜a: ƒ[ƒNƒVƒ‡ƒbƒvuŠ´õ‚ÆR‘ÌŽY§•s‘Sv‘æ110‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2007, 4, 20|22, ‹ž“s.
    27. ‹àŒ“O˜a, ”ÂàVŽõŽq, Ä“¡@, ¼¬X—²‘¾, ‹{˜e—˜’j: ‰Æ‘°«Š¦—⎩ŒÈ‰ŠÇÇŒóŒQ‚Ì‚P—á. ‘æ110‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2007, 4, 20|22, ‹ž“s.
    28. –쑺ŒbŽq, “n•Óˆ»‰À, ‹àŒ“O˜a, ˆÉ“¡‰x˜N, ‹{˜e—˜’j: TAM ‚ÆAMKL‚Ì”­Ç‚ɈقȂéGATA-1ˆâ“`Žq•ÏˆÙƒNƒ[ƒ“‚ªŠÖ—^‚µ‚½DownÇŒóŒQ‚Ì‚P—á. ‘æ110‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2007, 4, 20|22, ‹ž“s.
    29. œA–ìŒbˆê, âV“¡˜a—R, “n•Óˆ»‰À, ”óŒû@Žû, 㨌hˆê˜Y, Žs“c•™Žq, ‹àŒ“O˜a, ‹{˜e—˜’j: ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“•s‰žìè•a‚ɑ΂·‚éInfliximab‚Ì—LŒø«‚ƃTƒCƒgƒJƒCƒ“‚Ì“®‘Ô. ‘æ110‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2007, 4, 20|22, ‹ž“s.
    30. ‘«—§—zŽq, ˆÉ“¡–õ“T, ”óŒû@Žû, ’†—ÑŒºˆê, •£àV—³–ç, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: •ÛˆçŽ{Ý‚Å‚ÌH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨œ‹Ž‚ÌŽÀ‘Ô?•½¬13”N“x’²¸‚Æ‚Ì”äŠr?. ‘æ110‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2007, 4, 20|22, ‹ž“s.
    31. ‰ª•””üŒb, ŒE“c”Ž“¹, ‘ºãIŒ[, ŽO‰Y³‹`, ”öã—mˆê, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: Žs’†”x‰Š‚É‚¨‚¯‚éƒEƒCƒ‹ƒXŠ´õ‚Ì•p“x?––½ŒŒMxA’`”’”­Œ»‚ðŽw•W‚Æ‚µ‚Ä?. ‘æ110‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2007, 4, 20|22, ‹ž“s.
    32. Shan L., Dougu N., Joho S., Uese K., Hirono K., Watanabe S., Watanabe K., Saito Y., Ichida F., and Miyawaki T.: A novel LAMP-2 mutation in a family with hypertrophic cadiomyopathy. ‘æ110‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2007, 4, 20|22, ‹ž“s.
    33. ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ”óŒû@Žû, ’†—ÑŒºˆê, •£àV—³–ç, ‰ª•””üŒb, ŽRŒ³ƒŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚é•s®–¬‚ÌŒŸ“¢. ‘æ24‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï, 2007, 5, 26-27, “Œ‹ž.
    34. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹àŒ“O˜a, ‹{˜e—˜’j, –q–ì‹P•F: Š¦—âå@–ƒ]‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚½‰Æ‘°«Š¦—⎩ŒÈ‰ŠÇÇŒóŒQifamilial cold autoinflammatory syndromej‚̈ê—á. ‘æ28‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2007, 5, 31, •xŽR.
    35. ‹àŒ“O˜a: ƒVƒ“ƒ|ƒWƒEƒ€u’á‚Ü‚½‚Í–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚ɑ΂·‚é–ƉuƒOƒƒuƒŠƒ“•â[—Ö@v ‘æ55‰ñ“ú–{—AŒŒ×–EŽ¡—Êw‰ï, 2007, 5, 31|6, 2, –¼ŒÃ‰®.
    36. ‹{˜e—˜’j: EBƒEƒCƒ‹ƒXŠ´õ‚ƈâ“`«ƒŠƒ“ƒp‘BŽ¾Š³. ‘æ48‰ñ“ú–{—Õ°ƒEƒBƒ‹ƒXŠw‰ï, 2007, 6, 2|3, •xŽR.(µ‘Òu‰‰)
    37. ‘«—§—Yˆê, ’†—ÑŒºˆê, ‹{˜e—˜’j: ƒVƒ“ƒ|ƒWƒEƒ€uƒEƒCƒ‹ƒXŠ´õÇ‚Ìŋ߂̘b‘èvMxA’`”’‚ðŽw•W‚Æ‚µ‚½¬Ž™ƒEƒCƒ‹ƒXŠ´õÇ‚Ìf’f. ‘æ48‰ñ“ú–{—Õ°ƒEƒBƒ‹ƒXŠw‰ï, 2007, 6, 2|3, •xŽR.
    38. ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: Š¦—âå@–ƒ]‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚½‰Æ‘°«Š¦—⎩ŒÈ‰ŠÇÇŒóŒQifamilial cold autoinflammatory syndromej‚̈ê—á. ‘æ19‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2007, 6, 10|12, ‰¡•l.
    39. ‘«—§—zŽq, ˆÉ“¡–õ“T, •£‘ò—³–ç, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: “w—Í«ŒÄo‚ª•s\•ª‚Èšb‘§Ž™‚É‚¨‚¯‚éƒAƒjƒ[ƒVƒ‡ƒ“‚ð—p‚¢‚½ŒÄ‹C“®ì—U“±‚É‚æ‚é”x‹@”\‘ª’è‚Ì—L—p«. ‘æ19‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2007, 6, 10|12, ‰¡•l.
    40. ˆÉ“¡–õ“T, ”óŒû@Žû, ’†—ÑŒºˆê, ‰ª•””üŒb, ”ÂàVŽõŽq, ŽRŒ³ƒŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: MS-IOS‚É‚æ‚é”x‹@”\•]‰¿‚É‹y‚Ú‚·ŒÄ‹zƒpƒ^[ƒ“‚̉e‹¿. ‘æ19‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï, 2007, 6, 10|12, ‰¡•l.
    41. –쑺ŒbŽq, ‹àŒ“O˜a, “n•Óˆ»‰À, ¬ìŽŸ˜Y, “ñ’J@•, L–ìŒbˆê, ŽO‰Y³‹`, ˆÉ“¡‰x˜Y, ‹{˜e—˜’j: ŋߌoŒ±‚µ‚½ transient abnormal myelopoiesis ‚Ì‚T—á. ‘æ17‰ñ“ú–{ŽY•wl‰ÈEV¶Ž™ŒŒ‰tŠw‰ï, 2007, 6, 29-30, •xŽR.
    42. ‘å’ØŒc•ã, ¬ìŽŸ˜Y, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ®“c‰žŽq, ŽRŠÝ“ÄŽŠ, ‘“‡LŽ¡: ‹‘匌¬”‚Æè÷—±‹…••“ü‘Ì‚ð”F‚ß‚½ MYH9 ˆÙíǂ̈ê’jŽ™—á. ‘æ17‰ñ“ú–{ŽY•wl‰ÈEV¶Ž™ŒŒ‰tŠw‰ï, 2007, 6, 29-30, •xŽR.
    43. 㨌hˆê˜Y, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆ»‰À,@“n•Óˆê—m,@”óŒû@Žû,@œA–ìŒbˆê,@Žs“c•™Žq,@‹àŒ“O˜a,@‹{˜e—˜’j: “«ìè•a‚ɑ΂·‚éInfliximab‚Ì—LŒø«‚ÌŒŸ“¢. ‘æ43‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï, 2007, 7, 4|6, “Œ‹ž.
    44. ¼è‘½ç‘ã, Œ®èNŽ¡, ”‹–춒j, ”’ÎCˆê, ‰zŒã–ΔV, ”ª–ØŒ´rŽ, ’†àV@, ¼ˆäŽOŽ}, Žs“c•™Žq: ƒxƒCƒŠ[“û—cŽ™”­’BŒŸ¸‚ð—p‚¢‚½V¶Ž™ŠúE“ûŽ™ŠúŠJSppŒã”­’B•]‰¿. ‘æ43‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï, 2007, 7, 4|6, “Œ‹ž.
    45. “¡–Ø–õŽq, Œ´ˆä•ü”ü, ‹{@ˆêŽu, ‰eŽR—²Ži, –{‹½˜a‹v, ‹{˜e—˜’j: ‚Ä‚ñ‚©‚ñ‚Ì‚ŽŸ”]‹@”\‚̉ðÍ. ‘æ49‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2007, 7, 5|7, ‘åã.
    46. –{‹½˜a‹v, “¡–Ø–õŽq, Œ´ˆä•ü”ü, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ‹{˜e—˜’j: Ž©•ÂÇŠ³ŽÒ‚¨‚æ‚Ñ•êe‚ÌŒŒ’†R”]R‘̂̉ðÍ. ‘æ49‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2007, 7, 5|7, ‘åã.
    47. âV“¡–œ—¢Žq, ‹{˜e—˜’j: ‘S’E–т̸¸‚Å”­Œ©‚³‚ꂽBasedow•a‚Ì—Ž™—á. ‘æ43‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï, 2007, 9, 2, –¼ŒÃ‰®.
    48. ˆÉŒ\“ñ˜Y, œA–ìŒbˆê, 㨌hˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j, –F‘º’¼Ž÷, M“c@‹v, “n•Óˆê—m: BTƒVƒƒƒ“ƒgpŒãFallotŽl’¥Ç‚ɇ•¹‚µ‚½Š´õ«‹U«“®–¬áŽ‚̈ê—á. ‘æ34‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ï, 2007, 9, 8, ‹à‘ò.
    49. ¼è‘½ç‘ã, ¼ˆäŽOŽ}, ’†àV@, Žs“c•™Žq, ”ª–ØŒ´rŽ: S‘ŸŽèp‚ðŽó‚¯‚½‚PÎŽ™‚Ì”F’m‰^“®”­’B‚Æ“ü‰@‚É‚æ‚é•êŽq•ª—£‘ÌŒ±‚ÌŠÖ˜A\ƒxƒCƒŠ[“û—cŽ™”­’BŽÚ“x\‘æ‚Q”Å‚ð—p‚¢‚Ä[ ‘æ71‰ñ“ú–{S—Šw‰ï, 2007, 9, 18|20, “Œ‹ž.
    50. Œ´ˆä•ü”ü, –{‹½˜a‹v, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ’Ô¦Tˆê, ”ª–ØMˆê, Žs“c•™Žq, ‹{˜e—˜’j: 9q34ÇŒóŒQ‚̈ê—á. ‘æ52‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï, 2007, 9, 23, ‹à‘ò.
    51. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€hƒAƒŒƒ‹ƒM[«Ž¾Š³‚ÌÅV‚ÌŒ¤‹†‚©‚犳ŽÒ‹³ˆç‚Ü‚Åh uŽ¡—Â̎Š“K‰»,V‚µ‚¢Expert Panel‚©‚çv. ‘æ17‰ñ‹C“¹ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2007, 10, 7, “Œ‹ž.
    52. ‹{˜e—˜’j: æ“V«–Ɖu•s‘SÇ‚Æ’†•_ŒoŠ´õ. ‘æ12‰ñ“ú–{_ŒoŠ´õÇŠw‰ï, 2007, 10, 12|13, •Ÿ‰ª.(µ‘Òu‰‰)
    53. ”ÂàVŽõŽq, ‹àŒ“O˜a, ‘«—§—Yˆê, ‹{˜e—˜’j, âV“¡@, ¼¬X—²‘¾, ’†”¨—´r: Žá”N«“Á”­«ŠÖ߉Š‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚½‰Æ‘°«Š¦—⎩ŒÈ‰ŠÇÇŒóŒQ‚̈ê—á. ‘æ35‰ñ“ú–{—Õ°–ƉuŠw‰ï, 2007, 10, 19|20, ‘åã.
    54. ˆÉŒ\ˆê˜Y, œA–ìŒbˆê, 㨌hˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j: V¶Ž™“Á”­«SŽº•p”‚Ì1—á. ‘æ7‰ñ•xŽR¬Ž™zŠÂŠíŒ¤‹†‰ï, 2007, 10, 19,•xŽR.
    55. ˆÉ“¡G˜a, ˆÉ“ÞŽu”¿”ü, ‹g“cär, “ŒŽROK, “ñ’J@•, ‹{˜e—˜’j: —\’è’鉤؊J‚É‚Äo¶‚µ‚½‚É‚à‚©‚©‚í‚炸”­Ç‚µ‚½‘SgŒ^V¶Ž™ƒwƒ‹ƒyƒX‚Ì1—á. ‘æ21‰ñ–k—¤ŽüŽYŠúEV¶Ž™Œ¤‹†‰ï, 2007, 10, 21,‹à‘ò.
    56. Ä“¡˜a—R, ˆÉŒ\ˆê˜Y, œA–ìŒbˆê, 㨌hˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j, ‘å‚TŒá, –kŒ´~ˆê˜Y, –F‘º’¼Ž÷, ˆÀ‰Í“à‘: S‘ŸÄ“¯Šú—Ö@iCRTj‚ª—LŒø‚Å‚ ‚Á‚½ narrowQRS‚̶ŽºS‹Øãk–§‰»áŠQ‚É”º‚¤dÇS•s‘S‚Ì3ΗŽ™iCRTŒã1”N‚ÌŒo‰ßj. ‘æ16‰ñŠÖ“Œ¬Ž™S‹ØŽ¾Š³Œ¤‹†‰ï, 2007, 10, 27, “Œ‹ž.
    57. –{‹½˜a‹v, “¡–Ø–õŽq, Œ´ˆä•ü”ü, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ‹{˜e—˜’j: —\–hÚŽí‚É”º‚¤’†•_Œo‡•¹Ç. ‘æ41‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï, 2007, 11, 1|2, •Ÿ‰ª.
    58. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€gšb‘§Ž€ƒ[ƒ‚͉”\‚©H -Ž¡—ÂÌi•à‚ÆŒ»ó-h u“û—cŽ™‚Ìšb‘§v. ‘æ57‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2007, 11, 1|3, ‰¡•l.
    59. ‘«—§—Yˆê, ”ÂàVŽõŽq, –]ŒŽ”Ž”V, ‰ºð’¼Ž÷, ˆäãšæ–Î, ¼–´“c•q”V, XìœAº, ¼ŠÔŽOŠ]: ƒuƒfƒ\ƒjƒh‹z“üŒœ‘÷‰t‚ƃvƒƒJƒeƒ[ƒ‹‹z“ü‰t‚̬‡‚É‚æ‚镬–¶“Á«‚ւ̉e‹¿@‘æ‚P•ñƒWƒFƒbƒgŽ®ƒlƒuƒ‰ƒCƒU[. ‘æ57‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2007, 11, 1|3,‰¡•l.
    60. ”ÂàVŽõŽq, ‘«—§—zŽq, ˆÉ“¡–õ“T, ‰ª•””üŒb, ”óŒû@Žû, ‘«—§—Yˆê, ‹{˜e—˜’j, ‘ºãIŒ[: ¬Ž™šb‘§ƒRƒ“ƒgƒ[ƒ‹ƒeƒXƒgiChildhood Asthma Control TestFC-ACTj‚Ì—L—p«‚ÌŒŸ“¢. ‘æ57‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2007, 11, 1|3,‰¡•l.
    61. ˆÉ“¡–õ“T, –q–ì‹P•F, ‘«—§—Yˆê, “ŒŽROK, •£àV—³–ç, ´…’‰“¹, ‹{˜e—˜’j: ƒAƒgƒs[«”畆‰ŠŠ³ŽÒ‚É‚¨‚¢‚Ä––½«FOXP3—z«§Œä«T×–E‚ÍdÇ“x‚É‘ŠŠÖ‚µ‘‰Á‚·‚é. ‘æ57‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2007, 11, 1|3,‰¡•l.
    62. ŒÜ\—’—²•v, ˆÉ“Œ“¹•v, ¼–ì³’m, ‘ºãIŒ[, ‘«—§—Yˆê, ‘«—§—zŽq: “dŽqƒJƒ‹ƒe‚É‚æ‚é‹CŠÇŽxšb‘§’·ŠúŠÇ—‚ÌŽŽ‚Ý. ‘æ57‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2007, 11, 1|3,‰¡•l.
    63. ‰ª•””üŒb, ŒE“c”Ž“¹, ”öã—mˆê, ’†—ÑŒºˆê, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‚ÌŽs’†”x‰Š‚ɑ΂·‚鎡—ÕûjŒˆ’è‚É––½ŒŒMxA’`”’‘ª’è‚Í—L—p‚©. ‘æ39‰ñ“ú–{¬Ž™Š´õÇŠw‰ï, 2007, 11, 9|11, ‰¡•l.
    64. ”ÂàVŽõŽq, ‘«—§—zŽq, ‰ª•””üŒb, ˆÉ“¡–õ“T, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: ¬Ž™—pšb‘§ƒRƒ“ƒgƒ[ƒ‹ƒeƒXƒg‚©‚ç‚Ý‚½Impulse Oscillometry System‚Ì—L—p«. ‘æ40‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï, 2007, 11, 17|18, ‘åã.
    65. ”óŒû@Žû, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ƒWƒFƒbƒgŽ®‚È‚ç‚тɃƒbƒVƒ…Ž®ƒlƒuƒ‰ƒCƒU[‚É‚¨‚¯‚éƒvƒƒJƒeƒ[ƒ‹‹z“ü‰t‚Ì•¬–¶“Á«‚̈Ⴂ. ‘æ40‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï, 2007, 11, 17|18,‘åã.
    66. ˆÉ“¡G˜a, ˆÉ“ÞŽu”¿”ü, “ŒŽROK, ‹g“cär, “ñ’J@•, ‹{˜e—˜’j, ŽíŽsq’ˆ: ‘Ù“àŠ´õ‚ªŽ¦´‚³‚ꂽ—\’è’鉤؊J‚Åo¶‚ÌV¶Ž™‘SgŒ^’Pƒƒwƒ‹ƒyƒXŠ´õǂ̈ê—á. ‘æ52‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ï, 2007, 11, 24|26, ‚¼.
    67. ‹g“cärC“ñ’J@•C¬ìŽŸ˜Y, “ŒŽROK, ˆÉ“ÞŽu”¿”ü, ˆÉ“¡G˜a, ‹{˜e—˜’j: ‰“û’†‚ÌV‹K–Ɖu’²ßƒ^ƒ“ƒpƒNSyntenin-1‚Íä`‘ÑŒŒƒiƒC[ƒu‚a×–E‚ðIgAŽY¶×–E‚Ö‚Æ•ª‰»‚³‚¹‚é. ‘æ52‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ï, 2007, 11, 24|26, ‚¼.
    68. ˆÉ“¡–õ“T, ‘«—§—Yˆê, ”ÂàVŽõŽq, “ŒŽROK, ‹{˜e—˜’j, –q–ì‹P•F, ´…’‰“¹: ƒAƒgƒs[£”畆‰Š‚É‚¨‚¯‚駌ä«T×–E‚ÌŒŸ“¢. ‘æ34‰ñ–k—¤ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï, 2007, 12, 1, ‹à‘ò.
    69. ˆÉŒ\“ñ˜Y, âV“¡˜a—R, “n粈»‰À, “n•Óˆê—m, œA–ìŒbˆê, 㨌hˆê˜Y, Žs“c•™Žq, ‘å‚TŒá, ¼‹vO“T, –kŒ´~ˆê˜Y, –F‘º’¼Ž÷, ¼”ö‰Äl, ‹v•Û@ŽÀ: HOT‚ƃ{ƒZƒ“ƒ^ƒ““à•ž‚ŃtƒHƒ“ƒ^ƒ“Žèp‚É“ž’B‚µ‚½–³äBÇŒóŒQ‚Ì1—á. ‘æ25‰ñ¼“ú–{¬Ž™zŠÂŠíHOTŒ¤‹†‰ï, 2007, 12, 8, ‘åã.
    70. ‘«—§—Yˆê: ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“ ?“û—cŽ™šb‘§‚Ì’·ŠúŠÇ—‚ð’†S‚É-. ‘æ44‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2007, 12, 8|9, –¼ŒÃ‰®. (µ‘Òu‰‰)
    71. ‘«—§—Yˆê, ”ÂàVŽõŽq, ”óŒû@Žû, –]ŒŽ”Ž”V, ‰ºð’¼Ž÷, ˆäãšæ–Î, ¼–´“c•q”V, XìœAº, ¼ŠÔŽOŠ]: ƒuƒfƒ\ƒjƒh‹z“üŒœ‘÷‰t‚ƃvƒƒJƒeƒ[ƒ‹‹z“ü‰t‚̬‡‚É‚æ‚镬–¶“Á«‚ւ̉e‹¿@‘æ2•ñƒƒbƒVƒ…Ž®ƒlƒuƒ‰ƒCƒU[‚É‚¨‚¯‚錟“¢. ‘æ44‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2007, 12, 8|9, –¼ŒÃ‰®.
    72. ‘«—§—Yˆê, ‘ºãIŒ[, ’†‘º—˜”ü, ’J“à]ºG, ‘哈—E¬ ,áÁ‹|Œõ•¶: ŠO—ˆ‚Å‚ÌŠÈ’P‚È–âf•[‚𓱓ü‚·‚邱‚Æ‚É‚æ‚éšb‘§ƒKƒCƒhƒ‰ƒCƒ“‚É‘¥‚µ‚½Ž¡—Äi‚ÌŒø‰Ê. ‘æ44‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2007, 12, 8|9, –¼ŒÃ‰®.
    73. ‘«—§—zŽq, ”ÂàVŽõŽq, ‰ª•””üŒb, •£‘ò—³–ç, ŽRŒ³ƒŽq, ‚”ö@Š², ”öã—mˆê, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: H•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éˆê”Ê‚ÌH•i‚ð—p‚¢‚½H•¨•‰‰×ŽŽŒ±‚Ì—L—p«. ‘æ44‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2007, 12, 8|9, –¼ŒÃ‰®.
    74. ’†—ÑŒºˆê, –xìT“ñ˜Y, ‰eŽR—²Ži, ŽÂ茒‘¾˜Y, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ƒ`ƒIƒyƒ“ƒ^[ƒ‹Ã’Œã‚ɃAƒiƒtƒBƒ‰ƒLƒV[ƒVƒ‡ƒbƒN‚ð‚«‚½‚µ‚½1’jŽq—á. ‘æ44‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2007, 12, 8|9, –¼ŒÃ‰®.
    75. ŒÜ\—’—²•v, ˆÉ“Œ“¹•v, ¼–ì³’m, ‘ºãIŒ[, ‘«—§—Yˆê, ‘«—§—zŽq: “dŽqƒJƒ‹ƒe‚É‚æ‚é‹CŠÇŽxšb‘§Ž™‚Ì’·ŠúŠÇ—. ‘æ44‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2007, 12, 8|9, –¼ŒÃ‰®.
    76. ¼“c’¼“¿, ˆÉ“¡G˜a, “ŒŽROK, ‹{˜e—˜’j, ˆÉ“ÞŽu”¿”ü, ‹g“cär, “ñ’J@•, ‰ºàVLs: ‘ÙŽ™Šú‚æ‚è”]ŽºŠg‘å‚ðŽw“E‚³‚ê‚Ä‚¢‚½ZellwegerÇŒóŒQ‚Ì‚P—á. ‘æ291‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï, 2007, 12, 9, •xŽR.
    77. ‹{˜e—˜’j: R‘ÌŽY¶•s‘S‚É‚¨‚¯‚é–ƉuƒOƒƒuƒŠƒ“•â[—Ö@‚Ì‚ ‚炽‚È“WŠJ. ‘æ49‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2007, 12, 14|15, å‘ä. (µ‘Òu‰‰)
    78. –쑺ŒbŽq, ‹àŒ“O˜a, –q–ì‹P•F, ´…’‰“¹, ÎàV@L, ˆÀ•”–¾O, ’¼]’mŽ÷, ‹{˜e—˜’j: NPM/RARA‚ªŠÖ—^‚µ‚½ aleukemic leukemia cutis ‚̈ê—á. ‘æ49‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2007, 12, 14|15, å‘ä.
    79. ‘å’ØŒc•ã, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, –ö‘òGˆê˜Y, ŽíŽsq’ˆ: —¼Šá«–Ô–Œ‰è×–EŽî‚É‹}«œ‘«”’ŒŒ•a‚𕹔­‚µ‚½“ñdŠà‚Ì—Ž™—á. ‘æ49‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2007, 12, 14|15, å‘ä.
    80. å@‹v”T, Œ´ˆä•ü”ü, ”ÂàVŽõŽq, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ƒrƒ“ƒNƒŠƒXƒ`ƒ““Š—^‚ª’˜Œø‚µ‚½ Kasabach-Merritt ÇŒóŒQ‚Ì‚P—á. ‘æ49‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2007, 12, 14|15, å‘ä.

    2006”N

  • ’˜‘
    1. ‹{˜e—˜’jFŒŒ—F•a“™ŒŒ‰t–ƉuŽ¾Š³Cu¬Ž™–«Ž¾Š³ƒ}ƒjƒ…ƒAƒ‹v‰Á“¡’‰–¾ŠÄCC484-488Cf’f‚ÆŽ¡—ÃŽÐC“Œ‹žC2006.
    2. ‹{˜e—˜’jFŒ´”­«–Ɖu•s‘SÇDu¡“ú‚̬Ž™Ž¡—ÃŽwj‘æ14”Åv‘åŠÖ••F‘¼•ÒC225CˆãŠw‘‰@C“Œ‹žC2006.
    3. ‹{˜e—˜’jC‹àŒ“O˜aF’á‚Ü‚½‚Í–³ƒÁ-ƒOƒƒuƒŠƒ“ŒŒÇ. uÃ’—p–ƉuƒOƒƒuƒŠƒ“»Üƒnƒ“ƒhƒuƒbƒNvC³‰ª@“OŠÄCC30-37CƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐC‘åãC2006.
    4. Žs“c•™ŽqF¶ŽºS‹Øãk–§‰»áŠQDu¬Ž™Ž¾Š³‚Ìf’fŽ¡—Êæ‚R”Åvu¬Ž™“à‰Èvu¬Ž™ŠO‰Èv•ÒWˆÏˆõ‰ï‹¤•ÒC528-529C“Œ‹žˆãŠwŽÐC“Œ‹žC2006.
    5. Žs“c•™ŽqFŒÇ—§«S‹Øãk–§‰»áŠQDu¡“ú‚̬Ž™Ž¡—ÃŽwj‘æ14”Åv‘åŠÖ••F‘¼•ÒC387-388CˆãŠw‘‰@C“Œ‹žC2006.
    6. Žs“c•™ŽqF¶ŽºS‹Øãk–§‰»áŠQDu—Õ°S‘Ÿ•aŠwv¼è‰v“¿•ÎC402-403C•¶Œõ“°C“Œ‹žC2006.
    7. Žs“c•™ŽqFS‹ØÇDw¬Ž™‚ÌŽ¡—ÃŽwjx¬Ž™‰Èf—ÑŠ§†D‰q“¡‹`Ÿ‘¼•ÒC 379-381Cf’f‚ÆŽ¡—ÃŽÐC“Œ‹žC2006.
    8. Žs“c•™ŽqFŒÇ—§«S‹Øãk–§‰»áŠQ‚Ì”­¶‚Æf’fDwS‘Ÿ•af—Ãvƒ‰ƒNƒeƒBƒXxŒI—ÑK•v•ÒC182-185C•¶Œõ“°C“Œ‹žC2006.
    9. ‘«—§—YˆêFƒNƒ‹[ƒvÇŒóŒQDu¬Ž™Ž¾Š³‚Ìf’fŽ¡—Êæ‚R”Åvu¬Ž™“à‰Èvu¬Ž™ŠO‰Èv•ÒWˆÏˆõ‰ï‹¤•ÒC444-445C“Œ‹žˆãŠwŽÐC“Œ‹žC2006.
    10. ‘«—§—YˆêF‹}«‘ˆ«ŽžŽ¡—ÖòFƒeƒIƒtƒBƒŠƒ“EƒAƒ~ƒmƒtƒBƒŠƒ“Cu¬Ž™ƒAƒŒƒ‹ƒM[ƒVƒŠ[ƒYwšb‘§xvCŸÀr—Y•ÒC62-65Cf’f‚ÆŽ¡—ÃŽÐC“Œ‹žC2006.
    11. ‘«—§—YˆêFƒRƒ‰ƒ€FƒeƒIƒtƒBƒŠƒ“ˆ•ûŽž‚É•K—v‚Èe‚Ö‚Ìà–¾‚Ì‚µ‚©‚½Cu¬Ž™ƒAƒŒƒ‹ƒM[ƒVƒŠ[ƒYwšb‘§xvCŸÀr—Y•ÒC65Cf’f‚ÆŽ¡—ÃŽÐC“Œ‹žC2006.
    12. ‘«—§—YˆêFŽ„‚̈•ûâ³F‚VÎ ’·ŠúŠÇ—–ò‚ð‘—Ê‚µ‚Ä‚àÇ󂪂悭‚È‚ç‚È‚¢Cu¬Ž™ƒAƒŒƒ‹ƒM[ƒVƒŠ[ƒYwšb‘§xvCŸÀr—Y•ÒC104-105Cf’f‚ÆŽ¡—ÃŽÐC“Œ‹žC2006.
    13. ‘«—§—YˆêFŽ„‚̈•ûâ³F‚XÎ –«‚ÌŠPšu‚Æ•@•Â‚ð‘i‚¦‚Ä—ˆ‰@Cu¬Ž™ƒAƒŒƒ‹ƒM[ƒVƒŠ[ƒYwšb‘§xvCŸÀr—Y•ÒC133Cf’f‚ÆŽ¡—ÃŽÐC“Œ‹žC2006.
    14. ‘«—§—YˆêFušb‘§—\–hEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2006vC“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï ŠÄCC‹¦˜aŠé‰æC“Œ‹žC2006.
    15. ‘«—§—YˆêF•@•›•@o‰Š‚̇•¹CuTHE 25th ROKKO CONFERENCEDšb‘§‚Ì•a‘Ô‚ÆŽ¡—©‚ç‚Ý‚½¢‘ã“Ii”N—î“Ij“Á’¥vC¬—Ñß—Y‘¼•ÒC51-56Cƒ‰ƒCƒtƒTƒCƒGƒ“ƒXo”ÅC“Œ‹žC2006.
    16. ‘«—§—YˆêF¬Ž™‚Ì”x‰ŠCu¡“ú‚ÌŽ¡—ÃŽwj 2006”N”Å|Ž„‚Í‚±‚¤Ž¡—µ‚Ä‚¢‚év48”ÅCŽRŒû@“O‘¼•ÒC964-966CˆãŠw‘‰@C“Œ‹žC2006.
    17. ‹àŒ“O˜aC‹{˜e—˜’jFƒEƒCƒ‹ƒXŠ´õÇ. uƒlƒ‹ƒ\ƒ“¬Ž™‰ÈŠw‘æ17”ÅvC‰q“¡‹`ŸŠÄCC1051-1091CƒGƒ‹ƒ[ƒrƒAEƒWƒƒƒpƒ“C“Œ‹žC2005.
    18. ‹àŒ“O˜aC‹{˜e—˜’jF–ƉuŒn.u‚±‚ꂾ‚¯‚Í’m‚Á‚Ä‚¨‚«‚½‚¢.¬Ž™ˆã—Â̒mŽ¯vC•ÊŠ•¶—Y•ÒC21-25CU‹»ˆãŠwo”ÅŽÐC“Œ‹žC2006.
    19. ‹àŒ“O˜aCã“cˆç‘ãCΈäžÄˆêFHemophagocytic lymphohistiocytosis ‚É‚¨‚¯‚éƒp[ƒtƒHƒŠƒ“ˆâ“`ŽqˆÙí.uAnnual Review ŒŒ‰t 2006vC‚‹vŽj–›‘¼•ÒC178-187C’†ŠOˆãŠwŽÐC“Œ‹žC2006.
    20. ‹àŒ“O˜aFŒŒ—F•a“™ŒŒ‰t–ƉuŽ¾Š³Cu¬Ž™–«Ž¾Š³ƒ}ƒjƒ…ƒAƒ‹v‰Á“¡’‰–¾ŠÄCC 488-492C495-496f’f‚ÆŽ¡—ÃŽÐC“Œ‹žC2006.
    21. ‹àŒ“O˜aCæâ”ü›PF‚w˜A½ƒŠƒ“ƒp‘BÇŒóŒQDu¬Ž™Ž¾Š³‚Ìf’fŽ¡—Êæ‚R”Åvu¬Ž™“à‰Èvu¬Ž™ŠO‰Èv•ÒWˆÏˆõ‰ï‹¤•ÒC238C“Œ‹žˆãŠwŽÐC“Œ‹žC2006.
    22. ‹àŒ“O˜aF“`õ«’PŠjÇC–«Šˆ“®«EBƒEƒCƒ‹ƒXŠ´õÇDu¡“ú‚̬Ž™Ž¡—ÃŽwj‘æ14”Åv‘åŠÖ••F‘¼•ÒC252-253CˆãŠw‘‰@C“Œ‹žC2006.
    23. ‹àŒ“O˜aC‹{˜e—˜’jFEBV ‚ɑ΂·‚é–Ɖu‰ž“š. uƒwƒ‹ƒyƒXƒEƒCƒ‹ƒXŠwv“ú–{—Õ଑Š§C564-567C“ú–{—Õ଎ÐC‘åãC2006.
    24. –{‹½˜a‹vFŽüŠú«ŽlŽˆ–ƒáƒDu¬Ž™Ž¾Š³‚Ìf’fŽ¡—Êæ‚R”Åvu¬Ž™“à‰Èvu¬Ž™ŠO‰Èv•ÒWˆÏˆõ‰ï‹¤•ÒC784-785C“Œ‹žˆãŠwŽÐC“Œ‹žC2006.
  • Œ´’˜
    1. Adachi Y.S., Itazawa T., Nakabayashi M., Fuchizawa T., Okabe Y., Ito Y., Adachi Y., Murakami G., and Miyawaki T. : Safety and usefulness of a novel eMotion electric mesh nebulizer in children with asthma. Allergology Int 55: 167-171, 2006.
    2. Adachi Y.S., Adachi Y., Itazawa T., Yamamoto J., Murakami G., and Miyawaki T.: Ability of preschool children to use dry powder inhalers as evaluated by In-Check meter. Pediatr Int 48: 62-65, 2006.
    3. Itazawa T., Adachi Y., Nakabayashi M., Fuchizawa T., Murakami G., and Miyawaki T. : Theophylline metabolism in acute asthma with MxA-indicated viral infection. Pediatr Int 48: 54-57, 2006.
    4. Taneichi H., Kanegane H., Futatani T., Otsubo K., Nomura K., Sato Y., Hama A., Kojima S., Kohdera U., Nakano T., Hori H., Kawashima H., Inoh Y., Kamizono J., Adachi N., Osugi Y., Mizuno H., Hotta N., Yoneyama H., Nakashima E., Ikegawa S., and Miyawaki T. : Clinical and genetic analyses of presumed Shwachman-Diamond syndrome in Japan. Int J Hematol 84: 60-62, 2006.
    5. Hirono K., Foell D., Xing Y., Miyagawa T. S., Ye F., Ahlmann M., Vogl T., Futatani T., Chen R., Yu X., Watanabe K., Watanabe S., Tsubata S., Uese K., Hashimoto I., Ichida F., Nakazawa M., Roth J., and Miyawaki T. : Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease. J Am Coll cardiol 48: 1257-1264, 2006.
    6. Nakabayashi M., Adachi Y., Itazawa T., Okabe Y., Kanegane H., Kawamura M., Tomita A., and Miyawaki T.: MxA-Based recognition of viral illness in febrile children by a whole blood assay. Pediatr Res 60: 770-774, 2006.
    7. Xing Y., Ichida F., Matsuoka T., Isobe T., Ikemoto Y., Higaki T., Tsuji T., Haneda N., Kuwabara A., Chen R., Futatani T., Tsubata S., Watanabe S., Watanabe K., Hirono K., Uese K., Miyawaki T., Bowles K.R., Bowles N.E., and Towbin J.A. : Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. Mol Genet Metab 88 : 71-77, 2006.
    8. Aghamohammadi A., Fiorini M., Moin M., Parvaneh., Teimourian S., Yeganeh M., Goffi F., Kanegane H., Amirzargar A. A., Pourpak Z., Rezaei N., Salavati A., Pouladi N., Abdollahzade S., Notarangelo L.D., Miyawaki T., and Plebani A. : Ckinical, immunological and molecular characteristics of 37 Iranian patients with X-linked agammaglobulinemia. Int Arch Allegy Immunol. 141 : 408-414, 2006.
    9. Kanemoto N., Horigome H., Nakayama J., Ichida F., Xing Y., Buonadonna A. L., kanemoto K., and Gentile M.: Interstitial 1q43-q43 deletion with left ventricular noncompaction myocardium. Eur J Med Genet 49 : 247-253, 2006.
    10. Nakazawa M., Saji T., Ichida F., Oyama K., Harada K., and Kusuda S. : Guidelines for the use of palivizumab in infants and young children with congenital heart disease. Pediatr Int . 48 : 190-193, 2006.
    11. Kobayashi R., Ariga T., Nonoyama S., Kanegane H., Tsuchiya S., Morio T., Yabe H., Nagatoshi Y., Kawa K., Tabuchi K., Tsuchida M., Miyawaki T., and Kato S. : Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Brit J Haematol 135 : 362-366, 2006.
    12. Minegishi Y., Saito M., Morio T., Watanabe K., Agematsu K., Tsuchiya S., Takada H., Hara T., Kawamura N., Ariga T., Kaneko H., Kondo N., Tsuga I., Yachie A., Sakiyama Y., Iwata T., Bessho F., Ohishi T., Joh K., Imai K., Kogawa K., Shinohara M., Fujieda M., Wakiguchi H., Pasic S., Abinun M., Ochs H.D., Renner E.D., Jansson A., Belohradsky B.H., Metin A., Shimizu N., Mizutani S., Miyawaki T., Nonoyama S., and Karasuyama H.: Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25 : 745-755 , 2006.
    13. Grebe S., Ichida F., Grabitz R., B?ltmann B., Heidemann S., von Kaisenberg CS. : Reversed pulmonary artery flow in isolated noncompaction of the ventricular myocardium. Fetal Diagnosis and Therapy. 22: 29-32, 2006.
    14. Murakami H., Yoshimura N., Kitahara J., Otaka S., Ichida F., and Misaki T. : Collision of the caval flows caused early failure of the Fontan circulation. J Thorac Cardiovasc Surg. 132: 1235-1236, 2006.
    15. ˆÉ“¡–õ“TC‘«—§—zŽqC•£àV—³–çC”ÂàVŽõŽqC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jF‹CŠÇŽxšb‘§Ž™‚É‚¨‚¯‚éƒNƒŠƒbƒN‚Öƒ‰[iƒhƒ‰ƒCƒpƒEƒ_[Ž®‹z“üŠíj‚ð—p‚¢‚½Û‚Ì‹z‹C—¬‘¬‚ÌŒŸ“¢. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@20F160-165C2006.
    16. “y”ì‘P˜YC‘哈‹`”ŽC“‡’ÃeŽuCŽOè‘ñ˜YC‹´–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC“ñ’J@•FŽèpŽž‘Ìd2C500g–¢–ž‚Ìæ“V«SŽ¾Š³Š³ŽÒ‚ɑ΂·‚éŠO‰ÈŽ¡—Â̑I‘ð. “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ@22: 75-79C2006.
    17. –Ø‘º@G, ‰Í@Œh¢, ‘åÎ@•×, ‘O“c–¾•F, ‰ª‘º—²s, ‘å‰ê³ˆê, ‹àŒ“O˜a, X@‰ë—º, X–{@“N, X”ö—FG, ¡ˆä͉î, ‰ª–ì‘f•F, ’J“à]ºG, “y‰®@Ž , ˜eŒû@G: –«Šˆ“®«EBƒEƒCƒ‹ƒXŠ´õÇ‚Ì’·Šú—\Œã‚ɂ‚¢‚Ä. “ú–{¬Ž™‰ÈŠw‰ïŽ@110: 1578|1580, 2006.
  • Ç—á•ñ
    1. Matsukura H., Itoh Y., Kanegane H., Arai M., Miyawaki T., and Murakami G.: Acute tubulointerstitial nephritis : possible association with cytomegalovirus infection. Pediatr Nephrol 21 : 442-443, 2006.
    2. Honma T., Kanegane H., Shima T., Otsubo K., Nomura K., and Miyawaki T.: Neuroblastoma in an XYY male. Cancer Genet Cytogen 168 : 83-84, 2006.
    3. Otsubo K., Kanegene H., Nomura K., Ogawa J., and Miyawaki T.: Identification of a novel MYH9 mutation in a patient with May-Hegglin anomaly. Pediatr Blood Cancer. 47 : 968-969, 2006.
    4. Mitsui T., Tsukamoto N., Kanegane H., Agematsu K.,Sekigami T., Irisawa H., Saitoh T., Uchiumi H., Handa H., Matsushima T., Karasawa M., Murakami H., Miyawaki T., and Nojima Y. : X-linked agammaglobulinemia diagnosed in adulthhood: A case report. Int J Hematol 84 : 154-157, 2006.
    5. Yoshino A., Honda M., Kanegane H., Obata K., Matsukura H., Sakazume S., Katada Y., Miyawaki T., Ueda Y., and Nagai T.: Membranoproliferative glomerulonephritis in a patient with X-linked agammaglobulinemia. Pediatr Nephrol 21 : 36-38,2006.
    6. Yoshimura N., Murakami H., Otaka S., Watanabe K., Watanabe S., Uese K., Nomura K., Hashimoto I., Kanegane H., Ichida F., and Misaki T.: Open heart operration in a child with congential heart disease and hereditary spherocytosis. Circ J 70: 1655-1657 , 2006.
    7. Kawashima H., Ushio M., Aritaki K., Kashiwagi Y., Watanabe C., Nishimata S., Takekuma K., Hoshika A., Taneichi H., and Kanegane H.: Discordant endocrinopathy in a sibling with shwachman-diamond syndrome. J Trop Pediatr 52 : 445-447, 2006.
    8. Alangari A., Abobaker A., Kanegane H., and Miyawaki T.: X-linked lymphoproliferative disease associated with hypogammaglobulinemia and growth-hormone deficiency. Eur J Pediatr 165 : 165-167, 2006.
    9. ˆÉ“¡–õ“TC‘å’ØŒc•ãC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jFƒVƒ…ƒEŽ_ƒJƒ‹ƒVƒEƒ€Œ‹ÎÇ‚ð‡•¹‚µ‚½‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚Ì‚P—á. “ú–{¬Ž™ŒŒ‰tŠw‰ïŽ@20F30-33C 2006.
    10. ¼‰i‹M”VCŽR–{ŽŽqC‹{–{Œ’ŽuC’‡“‡‘å•ãC’؈䗴¶C”‹àV@iC•Ÿ“‡Œ[‘¾˜YC•àVGŒõC™“cŒ›ˆêC‹àŒ“O˜aC]ŒûŒõ‹»F—Δ^‹Û”sŒŒÇ‚Å”­Ç‚µ‚½D’†‹…Œ¸­Ç‚𔺂¤‚w˜A½–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚Ì‚P—á. “ú–{¬Ž™ŒŒ‰tŠw‰ïŽ@20F101-104C2006.
    11. ŠÖªŠîŽ÷C‚‹´³hC•l–ì‹GC‘å㌤“ñC”Ñ“c­OC–î•”‚Ý‚Í‚éC‘åã–ƒ—R—¢C‹àŒ“O˜aC‹{˜e—˜’jF”½•œ«’†Ž¨‰Š‚ɑ΂·‚ép‘OŒŸ¸‚©‚ç”­Œ©‚³‚ꂽ‚w˜A½–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ—á. Ž¨•@—Õ°@99F95-100C 2006.
    12. ¬¼”ŽŽjC”§¨’m‰ëC‚—œ–œ”üC–Øè‘P˜YC‹g“cärC‹àŒ“O˜aF½œ“ªŠWœˆÙŒ`¬Ç‚Ì‚P—á?’ág’·‚ɑ΂·‚é‚f‚g•â[—Ö@‚ÌŒø‰Ê‚àŠÜ‚ß‚Ä?@¬Ž™‰È—Õ°@59F1175-1179C 2006.
    13. ¬’r“¹–¾C‰Ÿ–¡˜a•vC㼈ê‰iC“ñ’J@•F¬Ž™Šú‚æ‚芴õ‚ðŒJ‚è•Ô‚µ28΂ʼn‚ß‚Äf’f‚³‚ꂽ‚PŒ^‚IgMÇŒóŒQ. —Õ°ŒŒ‰t 47F1377-1380C 2006.
  • ‘à
    1. ‹{˜e—˜’jFæ“V«–Ɖu•s‘SÇ‚Ìŋ߂̘b‘è. ŒŒ‰tƒtƒƒ“ƒeƒBƒA@16F529-531C 2006.
    2. Žs“c•™ŽqFS‹Øãk–§‰»áŠQ‚Æ•s®–¬D‘æ8‰ñ—Õ°S‘Ÿ•aƒtƒH[ƒ‰ƒ€ “ú–{S“d}Šw‰ïŽ@6:5-16C 2006.
    3. Žs“c•™ŽqFNoncompactionS‹Øãk–§‰»áŠQ@wS‘ŸxHEARTfs Selection 38 : 1020-1023C 2006.
    4. ‘«—§—YˆêF¬Ž™ƒAƒŒƒ‹ƒM[Šw‚ÌV‚µ‚¢“WŠJ@‚PÍ3. 3)¬Ž™‹CŠÇŽxšb‘§‚Ì‹}«”­ì. ¬Ž™‰È—Õ°@59(‘)F1283-1290C 2006.
    5. ‘«—§—YˆêF¬Ž™šb‘§‚Ì”­ìŽž‚̃Aƒ~ƒmƒtƒBƒŠƒ“‚ÌŽg‚¢•û‚ÍH@‚p•‚`‚Å‚í‚©‚éƒAƒŒƒ‹ƒM[Ž¾Š³@2: 463-465C 2006.
    6. ‘«—§—YˆêF¬Ž™šb‘§‚Ìf’f‚ÆŽ¡—ÃC¬Ž™šb‘§‚Ì‘Šúf’f‚Æ‚»‚̉ۑè. —Õ°–ƉuEƒAƒŒƒ‹ƒM[‰È 46: 483-487C 2006.
    7. ‘«—§—YˆêF“û—cŽ™‚Ìšb‘§Ž¡—Âɑ΂·‚éV‚½‚È“WŠJCƒlƒuƒ‰ƒCƒU[‚ð—p‚¢‚½‹z“üƒXƒeƒƒCƒh—Ö@. Pharma Medica 24: suppl 15-20C 2006.
    8. ‘«—§—YˆêFƒAƒŒƒ‹ƒM[Ž™CŽÐ‰ï‚ÅŽx‚¦‚é‚»‚Ì–¢—ˆ. “ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ïŽ 4: 144-149C 2006.
    9. ‘«—§—YˆêF¬Ž™‚Ì‘J‰„«ŠPšu‚ɑ΂·‚é’ÁŠPE‹Žá‚–ò‚ÌŽg‚¢•û. ¬Ž™‰Èf—à 69: 1503-1507C 2006.
    10. ‘«—§—YˆêFH•¨ƒAƒŒƒ‹ƒM[ Ž¡—Â̋³ˆçEŽw“±‚ɂ‚¢‚Ä. Topics in Atopy 5: 33-38C 2006D
    11. ‘«—§—YˆêF“ûŽ™šb‘§‚ÌŽÀ‘ÔCf’fCŽ¡—Ã. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 19 : 27-32C 2006.
    12. ‘«—§—Yˆê: ¬Ž™šb‘§‚Ì‘Šúf’f‚Æ‚»‚̉ۑè. —Õ°–ƉuEƒAƒŒƒ‹ƒM[‰È46: 483|487, 2006.
    13. ‘«—§—Yˆê: ƒNƒ‹[ƒvÇŒóŒQ. ¬Ž™“à‰È38(‘): 444|445, 2006.
    14. ‹àŒ“O˜aC“ñ’J@•C‹{˜e—˜’jFŒ´”­«–Ɖu•s‘SÇ‚Å“¯’肳‚ê‚Ä‚¢‚錴ˆöˆâ“`Žq.¬Ž™‰È@47F25-38C 2006.
    15. ‹àŒ“O˜aC‹{˜e—˜’jFŒ´”­«–Ɖu•s‘SÇ\ˆâ“`ŽqŽ¡—ÈȊO‚ÌŽ¡—Ã\. ¬Ž™‰Èf—Ã@69F251-253C 2006.
    16. ‹àŒ“O˜aC‹{˜e—˜’jF–ƉuƒOƒƒuƒŠƒ“•â[—Ö@‚ÌV‚½‚È“WŠJ. ŒŒ‰tƒtƒƒ“ƒeƒBƒA@16F601-607C 2006.
    17. ‹àŒ“O˜aF‚ǂ̂悤‚ÈŽž‚ɖƉu•s‘SÇ‚ð‹^‚¤‚©H@¬Ž™Š´õ–Ɖu 18F41-46C 2006.
    18. ‹àŒ“O˜aCæâ@”ü›PC‹{˜e—˜’jF‚w˜A½ƒŠƒ“ƒp‘BÇŒóŒQ‚É‚¨‚¯‚é Th1/Th2 ƒTƒCƒgƒJƒCƒ“ƒoƒ‰ƒ“ƒX. —Õ°–Ɖu@45F468-471C 2006.
    19. ‹àŒ“O˜aC‘å’ØŒc•ãC‹{˜e—˜’jF–Ɖu•só‘Ô‚Å‚ÌR‹Û–ò—Ö@?æ“V«–Ɖu•s‘SÇ.¬Ž™“à‰È@38F1203-1206C 2006.
    20. ‹àŒ“O˜aCæâ@”ü›PC‹{˜e—˜’jF‚w˜A½ƒŠƒ“ƒp‘B«Ž¾Š³. —Õ°‚ƃEƒCƒ‹ƒX@34F133-140C 2006.
    21. ‹àŒ“O˜a, æâ@”ü“ß: ‚w˜A½ƒŠƒ“ƒp‘BÇŒóŒQD¬Ž™“à‰È38(‘): 238, 2006.
    22. –{‹½˜a‹vF•KŒgI‚¯‚¢‚ê‚ñˆÓŽ¯áŠQy‚»‚ÌŽž‚Ç‚¤‚·‚éz‚¯‚¢‚ê‚ñ‚ÌŽ¡—ÂƊǗC‚¯‚¢‚ê‚ñ‚ÉŠÖ‚·‚é’mŽ¯C‚¯‚¢‚ê‚ñ‚ƊԈႦ‚â‚·‚¢¶—“I‰^“®CˆÙí‰^“®. ¬Ž™“à‰È 38F207-210C 2006.

  • 2006”NŠw‰ï•ñ
    1. Adachi Y.: Guest Lecture gA new Japanese guideline for asthma in childhoodh Early Intervention Meeting 2006, 2006,2, London.
    2. Adachi Y., Okabe Y., Itazawa T., Adachi YS., Nakabayashi M., Fuchizawa T., Miyawaki T., Odajima H.: Quality of life of children with allergic diseases. 62nd Annual Meeting of American Academy of Allergy, Asthma & Immunology,2006,3,Miami Beach,USA.
    3. Itazawa T., Adachi Y., Okabe Y., Adachi YS., Nakabayashi M., Harai T., Miya K., Uese K., and Miyawaki T. :. A child case of anaphylaxis to polyvinylpyrrolidone containing medicines. 62nd Annual Meeting of American Academy of Allergy, Asthma & Immunology,2006,3,Miami Beach,USA.
    4. Hirono K., Foell D., Xing Y., Miyagawa-Tomita S., Ye F., Watanabe K., Watanabe S., Uese K., Nakazawa M., Ichida F., Roth J., and Miyawaki T.: Dynamic changes of Myeloid-Related Protein (MRP)8/MRP14 positive circulating endothelial cells in patients with acute Kawasaki disease. The 70th Annual scientific meeting of the Japanese circulation society,3,2006,Nagoya.
    5. Shan L., Xing Y., Ye bF., Chen R., Tsuji T., Haneda N., Matsuoka T., Yu X., Tsubata S., Futatani T., Watanabe S., Watanabe K., Hirono K., Uese,K. Hamamichi Y., Hashimoto I., Ichida F., Miyawaki T., and Towin JA.: Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. The 70th Annual scientific meeting of the Japanese circulation society,2006,3,Nagoya.
    6. Adachi Y.FGuest Lecture gNew Concept of Beta2-agonists. Focus on Intrinsic Efficacyh, Scientific Meeting gNew Concept of Beta2-agonistsh ,2006,5,Jakarta & Surabaya,Indonesia.
    7. Kanegane H., Agematsu K., Futatani T., Suga K., Sekiguchi T., and Miyawaki T. : A novel CD19 deficiency in a Japanease patient with hypogammmagloblinemia. 2006 Primary Immunodeficiency diseases consortium conference,2006,6,San Francisco,U.S.A.
    8. Shan L., Ichida F., Xing Y., Chen R., Futatani T., Tsubata S., Watanabe S., Watanabe K., Hirono K., Uese K., Miyawaki T., Bowles KR,. Bowles NE., and Towbin JA.., etc. Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. Pediatric Heart Forum 2006, 2006,9,Shanghai,China.
    9. Kanegane H., Agematsu K., Futatani T., Suga K., Sekiguchi T., and Miyawaki T.: A novel CD19 deficiency in a Japanese patients with hypogammaglobulinemia. 12th meeting of the European society for immunodeficiencies,2006,10,Budapest,Hungary.
    10. Taneichi H., Kanegane H., Futatani T., and Miyawaki T. : Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia. 12th meeting of the European society for immunodeficiencies,2006,10,Budapest,Hungary.
    11. Aghamohammadi A., Kanegane H., Amizargar A.A., Pourpak Z., Rezaei N., Salavati A., Abdollahzade S., Notarangelo L.D., and Miyawaki T. : Molecular analysis in Iranian patients with antibody deficiency. 12th meeting of the European society for immunodeficiencies,2006,10,Budapest,Hungary.
    12. Zhao M., Kanegane H., Futatani T., and Miyawaki T. : Enhanced expression of SAP in CD45RO+CD8+ T cells and NK cells and its deficiency in X-linked lymphoproliferative disease. 12th meeting of the European society for immunodeficiencies,2006,10,Budapest,Hungary.
    13. Hirono K., Foell D., Xing Y., Miyagawa-Tomita S., Ye F., Watanabe K., Watanabe S., Uese K., Nakazawa M., Ichida F., Roth J., and Miyawaki T.: Dynamic change and pivotal role of Myeloid-Related Protein (MRP) 8 and MRP14 in acute Kawasaki disease. The 79th Scientific Sessions of American Heart Association,2006,11,Chicago.
    14. Ichida F., Watanabe K., Matsui M., Noguchi K., Yoshimura N., Oshima Y., Murakami H., Watanabe S., Hirono K., UeseK., Origsa H., Nakazawa J., Yagihara T., Bilker WB., and Gur RC. Neuroanatomical development of infants undergoing heart surgery evaluated bu quantitative three-dimensional magnetic resonance imaging. The 79th Scientific Sessions of American Heart Association,2006,11,Chicago.
    15. Shan L., Xing Y., Futatani T., Tsubata S., Watanabe S., Saito K., Watanabe K., Hirono K., Uese K., Ichida F., Miyawaki T.C Bowles NE., and Towbin JA. : SCN5A variant in Japanese patients with left ventricular noncompaction and arrhythmia. The 2nd IREIIMS Open Symposium,2006,12,Tokyo.
    16. Shan L., Xing Y., Watanabe S., Futatani T., Watanabe K., Hirono K., Uese K., Ichida F., Miyawaki T.C Bowles NE., and Towbin JA. : SCN5A variant in Japanese patients with left ventricular noncompaction and arrhythmia. The 2nd Congress of the Asian Society for Pediatric Research. 2006,12,Yokohama.(Young Investigatorfs Award 2006)
    17. Hirono K., Kobayashi Y., Mitani Y., Kaneda H., Okabe T., Miura M., Kameda K., Konishi T., Ichida F., and Miyawaki T.: CThe 2nd Congress of the Asian Society for Pediatric Research. 2006,12,Yokohama.
    18. Watanabe S., Hashimoto I., Saito K., Watanabe K., Uese K., Hirono K., Ichida F., Saito S., and Miyawaki T. : Characterization of ventricular myocardial performance in the fetus by tissue Doppler imaging. The 2nd Congress of the Asian Society for Pediatric Research. 2006,12,Yokohama.
    19. ‘«—§—YˆêF“Á•Êu‰‰u“û—cŽ™šb‘§‚Ì‹}«ŠúŽ¡—ƒ·ŠúŠÇ—v. Airway Forum 2006 in •ŸˆäC2006C1C•Ÿˆä.
    20. ‘«—§—zŽqC”ÂàVŽõŽqC‰ª•””üŒbCŽRŒ³ƒŽqC‚”ö@Š²C”öã—mˆêC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jF•ÛˆçŽ{Ý‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨œ‹ŽŽwŽ¦‘‚Ì—L—p«. ‘æ6‰ñH•¨ƒAƒŒƒ‹ƒM[Œ¤‹†‰ïC2006C1C“Œ‹ž.
    21. ‘«—§—YˆêF“Á•Êu‰‰uJPGL2005‚ÌŽå‚È•ÏX“_‚Æ¡Œã‚ÌŽ¡—ÓW–]v. ‹ž“s¬Ž™‰Èˆã‰ïŠwpu‰‰‰ïC2006C2C‹ž“s.
    22. ‘«—§—YˆêD“Á•Êu‰‰u“û—cŽ™šb‘§‚Ì‹}«ŠúŽ¡—ƒ·ŠúŠÇ—v. ¬Ž™šb‘§ƒtƒH[ƒ‰ƒ€ in SAPPOROC2006C2CŽD–yD
    23. –쑺ŒbŽqC‘å’ØŒc•ãC‹àŒ“O˜aC‹{˜e—˜’jCÎàV@LC•Ÿ‰ª‡–çCŽO‰Y³‹`F¶Ž¨‰º‘B•”‰¡–ä‹ØŽî‚̈ê—á. ‘æ24‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ïC2006C2.‹à‘ò.
    24. “n•Óˆ»‰ÀC‹´–{ˆè•vCÄ“¡˜a—RC“n•Óˆê—mCœA–ìŒbˆêC㨌hˆê˜YCŽs“c•™ŽqCÄ“¡Ž C‹{˜e—˜’jF‘gDƒhƒvƒ‰–@‚ð—p‚¢‚½‘ÙŽ™S‹@”\‚Ì•]‰¿. ‘æ12‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŒ¤‹†‰ïŠwpW‰ïC2006C2CŒyˆä‘ò.
    25. 㨌hˆê˜YC“n•Óˆê—mC“n•Óˆ»‰ÀCŽs“c•™ŽqFæ“V«SŽ¾Š³‚É‚¨‚¯‚é3DCT‚Ì—L—p«‚ÌŒŸ“¢. ‘æ31‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ïC2006C2C‹à‘ò.
    26. œA–ìŒbˆêCŽO’J—S‰îC‹à“c®C‰ª•”ŒhCŽO‰Y³‹`CX‰i‹¨ŽqCŽs“c•™ŽqFAccelerated idioventricular rhythm‚ð”F‚½‚ßV¶Ž™‚Ì‚P—á. ‘æ31‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ïC2006C2C‹à‘ò.
    27. –{‹½˜a‹vC‹{ˆêŽuC‰eŽR—²ŽiC“c’‡çHC‹{˜e—˜’jFR”]R‘Ì‚ª—z«‚¾‚Á‚½•sˆÓ‰^“®‚Ì4—á. ‘æ49‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ïC2006C2C‹à‘ò.
    28. ¬ìŽŸ˜YCÎŽRº•FC“ŒŽROKCœAìTˆê˜YCŽðˆä³—˜C“ñ’J@•C‘å¼N°CâV“¡@Ž C‹{˜e—˜’jF’´’áo¶‘ÌdŽ™‚Ì’°úE‚ɑ΂·‚éŠO‰È“IŽ¡—Ö@‚Ì‘I‘ð‚ɂ‚¢‚Ä. ‘æ9‰ñ•xŽRŒ§•êŽqˆã—ÃŒ¤‹†‰ïC2006C2C•xŽR.
    29. ‘«—§—YˆêFPro/Con uƒAƒŒƒ‹ƒM[«•@‰Š‚ÌŽ¡—ÂŚb‘§‚̃Rƒ“ƒgƒ[ƒ‹‚͉ü‘P‚·‚é‚©Hv@‘æ3‰ñŽOd‹C“¹ƒAƒŒƒ‹ƒM[Œ¤‹†‰ïC2006C3C’ÃD
    30. –{‹½˜a‹vC‹{@ˆêŽuC‰eŽR—²ŽiC“c’‡çHC‹{˜e—˜’jFHHV6”]‰Š‰ñ•œŠúˆÈ~‚Éáz¹‚ðŒJ‚è•Ô‚µ‚½2—á. ‘æ30‰ñ–k—¤‚Ä‚ñ‚©‚ñ§˜b‰ïC2006C3C‹à‘ò.
    31. ‰eŽR—²ŽiC‹{@ˆêŽuC–{‹½˜a‹vC‹{˜e—˜’jC‹T“cˆê”ŽC¬¼@“OFdÇSgáŠQŽ™iŽÒj‚ɑ΂·‚é”x“àƒp[ƒJƒbƒVƒ‡ƒ“ƒxƒ“ƒ`ƒŒ[ƒ^[‚Ì’ZŠúŽg—p—á.‘æ286‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ïC2006C3C‹à‘ò.
    32. ‘å’ØŒc•ãCŒ´ˆä•ü”üC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jCŒI–{¹‹IC‰““¡r˜YFÅ‹ß‚P”NŠÔ‚Å“–‰È‚ªŒoŒ±‚µ‚½”]ŽîᇂS—á.‘æ286‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ïC2006C3C‹à‘ò.
    33. ‘q–{@’CŒÜ\—’“oC’·‰«—DŽqC’†ŽR—SŽqC”öã—mˆêC”¨èŠì–FF‚a‚b‚fV–@iuŒ‹Šj—\–h–@v‰ü³j‚̉e‹¿‚Æ“–‰È‚Å‚ÌŽæ‚è‘g‚Ý.‘æ286‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ïC2006C3C‹à‘ò.
    34. ‹àŒ“O˜aC“ñ’J@•C{‰êŒ’ˆêCŠÖŒû—²Œ›C㼈ê‰iC‹{˜e—˜’jFCD19Œ‡‘¹‚É‚æ‚é–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ. ‘æ109“ú–{¬Ž™‰ÈŠw‰ïC2006C4C‹à‘ò.
    35. –쑺ŒbŽqC‘å’ØŒc•ãC‹àŒ“O˜aC‘«—§—YˆêC‹{˜e—˜’jFˆŸ‹}«‰óŽ€«ƒŠƒ“ƒp߉Š‚É‚¨‚¯‚é MxA ’`”’‚ÌŒŸ“¢. ‘æ109“ú–{¬Ž™‰ÈŠw‰ïC2006C4C‹à‘ò.
    36. ‰ª•””üŒbC”ÂàVŽõŽqC‘«—§—zŽqC’†—ÑŒºˆêC•£‘ò—³–çC‘«—§—YˆêC‹{˜e—˜’jC¬“c“ˆ@”ŽCÔàV@WF•xŽRŒ§‚É‚¨‚¯‚éISAACŽ¿–â•[‚ð—p‚¢‚½ƒAƒŒƒ‹ƒM[Ž¾Š³’²¸”üŒb@‘æ109“ú–{¬Ž™‰ÈŠw‰ïC2006C4C‹à‘ò.
    37. “n•Óˆê—mCŽs“c•™ŽqC‹{˜e—˜’jC¼ˆäŽOŽ}CΕ^—R”üC–F‘º’¼Ž÷C‘哈‹`”ŽC’†‘òC¼è‘½ç‘ãC”ª–ØŒ´rŽFV¶Ž™ŠúC“ûŽ™‘ŠúŽèp‚ðŽ{s‚³‚ꂽæ“V«SŽ¾Š³Ž™‚̸_‰^“®”­ç—\Œã. ‘æ109“ú–{¬Ž™‰ÈŠw‰ïC2006C4C‹à‘ò.
    38. “n•Óˆ»‰ÀC‹´–{ˆè•vC“n•Óˆê—mCœA–ìŒbˆêC㨌hˆê˜YCŽs“c•™ŽqC‹{˜e—˜’jCÖ“¡Ž F‘gDƒhƒvƒ‰–@‚ð—p‚¢‚½‘ÙŽ™S‹@”\‚Ì•]‰¿. ‘æ109“ú–{¬Ž™‰ÈŠw‰ïC2006C4C‹à‘ò.
    39. ‘å’ØŒc•ãC–쑺ŒbŽqC¬ìŽŸ˜YC‹àŒ“O˜aC‹{˜e—˜’jC®“c‰žŽqCŽRŠÝ“ÄŽŠF‹‘匌¬”‚Æè÷—±‹…••“ü‘Ì‚ð”F‚ß‚½ MYH9 ˆÙíǂ̈ê’jŽ™—á. ‘æ109“ú–{¬Ž™‰ÈŠw‰ïC2006C4C‹à‘ò.
    40. –{‹½˜a‹vC‹{ˆêŽuC‰eŽR—²ŽiC“c’‡çHCL–ìŒbˆêC‹{˜e—˜’j. ŒŒ’†R”]R‘Ì‚ª—z«‚ðŽ¦‚µ‚½“ÁˆÙ‚È”]‰ŠE”]ÇŒã‚Ä‚ñ‚©‚ñ‚Ì2—á. ‘æ109“ú–{¬Ž™‰ÈŠw‰ïC2006C4C ‹à‘ò.
    41. ‹àŒ“O˜aFƒVƒ“ƒ|ƒWƒEƒ€u’vŽ€« EB ƒEƒCƒ‹ƒXŠÖ˜AŽ¾Š³‚Ìf’f‚ÆŽ¡—Ã?‚w˜A½ƒŠƒ“ƒp‘B«Ž¾Š³v‘æ80“ú–{Š´õÇŠw‰ïC2006C4C “Œ‹ž.
    42. ‘«—§—YˆêF“Á•Êu‰‰uŽq‚Ç‚à‚ÌH•¨ƒAƒŒƒ‹ƒM[v. •½¬18”N“x•xŽR‰h—{Žm‰ï‘‰ïC2006C5C•xŽR.
    43. ‘«—§—YˆêF“Á•Êu‰‰u“û—cŽ™šb‘§‚Ìf’f‚ƬŽ™šb‘§ƒKƒCƒhƒ‰ƒCƒ“‚ÌŽæ‚舵‚¢‚ɂ‚¢‚Äv. ‘æ‚U‰ñ¬Ž™‰Èˆã‚Ì‚½‚ß‚Ìšb‘§ƒtƒH[ƒ‰ƒ€C2006C5C‘åã.
    44. ‘«—§—zŽqC”óŒû@ŽûCˆÉ“¡–õ“TC‰ª•””üŒbC”ÂàVŽõŽqC‘«—§—YˆêC‹{˜e—˜’jF¬Ž™‚É‚¨‚¯‚é‹CŠÇŽxšb‘§‚Æ•@‰Š‚ÌŠÖ˜A‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ27‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ¤‹†‰ïC2006C5C•xŽR.
    45. ‘«—§—zŽqC”óŒû@ŽûCˆÉ“¡–õ“TC”ÂàVŽõŽqCŽRŒ³ƒŽqC”öã—mˆêC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jF‹CŠÇŽxšb‘§Ž™‚É‚¨‚¯‚é•@•›•@o‰Š‚È‚ç‚тɃAƒŒƒ‹ƒM[«•@‰Š‚̇•¹—¦. ‘æ18‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ïC2006C5C“Œ‹ž.
    46. ‰ª•””üŒbC”ÂàVŽõŽqC‘«—§—zŽqC’†—ÑŒºˆêC•£‘ò—³–çC‘«—§—YˆêC‹{˜e—˜’jC¬“c“ˆ@”ŽCÔàV@WF•xŽRŒ§‚É‚¨‚¯‚éISAACŽ¿–â•[‚ð—p‚¢‚½ƒAƒŒƒ‹ƒM[Ž¾Š³’²¸. ‘æ18‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ïC2006C5C“Œ‹ž.
    47. ŒÜ\—’—²•vC¼–ì³’mCˆÉ“Œ“¹•vC‘ºãIŒ[C‘«—§—zŽqC‘«—§—YˆêF“–‰@ƒAƒŒƒ‹ƒM[ŠO—ˆ‚É‚¨‚¯‚é‹CŠÇŽxšb‘§Ž™‚Ì”N—î‘w•ÊƒvƒŠƒbƒNƒeƒXƒg—z«—¦‚ɂ‚¢‚Ä. ‘æ18‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ïC2006C5C“Œ‹ž.
    48. ‘«—§—YˆêF“Á•Êu‰‰u¬Ž™‹CŠÇŽxšb‘§Ž¡—Âɂ¨‚¯‚éŋ߂̘b‘èv. Î쌧¬Ž™‰Èˆã‰ïC2006C6C‹à‘ò.
    49. ‘«—§—YˆêF“Á•Êu‰‰uV‚µ‚¢¬Ž™‹CŠÇŽxšb‘§f—ẪRƒc‚Æ—Ž‚Æ‚µŒŠv. ‘æ4‰ñ¬Ž™šb‘§ƒtƒH[ƒ‰ƒ€in‘½–€C2006C6C“Œ‹ž.
    50. –{‹½˜a‹vCŒ´ˆä•ü”üC‹{@ˆêŽuC‰eŽR—²ŽiC“c’‡çHC”ª–ØMˆêC‚‹´K—˜C‹{˜e—˜’jF‚Ä‚ñ‚©‚ñ‚̖Ɖu“I”wŒi‚ÉŠÖ‚·‚錟“¢. ‘æ48‰ñ“ú–{¬Ž™_ŒoŠw‰ï2006C6C“Œ‹ž.
    51. ‹{@ˆêŽuC–{‹½˜a‹vC‰eŽR—²ŽiCŒ´ˆä•ü”üC”ª–ØMˆêC‚‹´K—˜C‹{˜e—˜’jF“ÁˆÙ‚È”]‰ŠE”]ÇŒã‚Ä‚ñ‚©‚ñ‚̈êŒQ‚É‚¨‚¯‚éR”]R‘Ì‚ÌŒŸ“¢. ‘æ48‰ñ“ú–{¬Ž™_ŒoŠw‰ï2006C6C“Œ‹ž.
    52. ‰eŽR—²ŽiC‹{@ˆêŽuC Œ´ˆä•ü”üC–{‹½˜a‹vC”ª–ØMˆêC‹{˜e—˜’jF—\–hÚŽíŒã‚É‚¯‚¢‚ê‚ñ‚ð’悵‚½2—á. ‘æ48‰ñ“ú–{¬Ž™_ŒoŠw‰ï2006C6C“Œ‹ž.
    53. Œ´ˆä•ü”üC–{‹½˜a‹vC‹{@ˆêŽuC ‰eŽR—²ŽiC•£‘ò—³–çC‹{˜e—˜’jFRamsay-Hunt ÇŒóŒQ‚É”][Ç‚ð”­Ç‚µ‚½ˆê—á. ‘æ48‰ñ“ú–{¬Ž™_ŒoŠw‰ï2006C6C“Œ‹ž.
    54. ‘«—§—YˆêF‰ï’·u‰‰uƒAƒŒƒ‹ƒM[Ž™CŽÐ‰ï‚ÅŽx‚¦‚é‚»‚Ì–¢—ˆv‘æ23‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï2006C6C •xŽR.
    55. ‰ª•””üŒbC”ÂàVŽõŽqC”óŒû@ŽûCˆÉ“¡–õ“TC‘«—§—zŽqC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jF‰ßŠ·‹CÇŒóŒQ‡•¹‚ÌdÇšb‘§Ž™‚Æ‚µ‚ÄЉ‚ꂽ2—á. ‘æ23‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï2006C6C •xŽR.
    56. ¼–ì³’mCˆÉ“Œ“¹•vC‹gZ@ºC‘«—§—YˆêCŒÜ\—’—²•vFŽ{Ý“ü‰@—Ö@‚ðs‚Á‚½šb‘§Ž™‚Ì‹C“¹‰ß•q«‚Ì„ˆÚ‚Æ—\Œã‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ23‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï2006C6C•xŽR.
    57. –{‹½˜a‹vF¬Ž™_ŒoŽ¾Š³‚̖Ɖu“I”wŒi. ‘æ235‰ñŒà¼¬Ž™‰ÈW’k‰ïC2006C6C•xŽR.
    58. ‘«—§—YˆêF“Á•Êu‰‰u“û—cŽ™šb‘§‚É‚¨‚¯‚銴õ‚Ì–ðŠ„v ‘æ45‰ñ‹žŽ —Õ°ƒAƒŒƒ‹ƒM[§’k‰ïC2006C7.29C‹ž“s.
    59. ‘«—§—YˆêF“Á•Êu‰‰u¬Ž™šb‘§‚Ìf’f‚ÆŽ¡—ÂƬŽ™ƒKƒCƒhƒ‰ƒCƒ“‚ɂ‚¢‚Äv “úˆã¶ŠU‹³ˆç‹¦—ÍuÀC2006C7C˜a‰ÌŽR.
    60. œA–ìŒbˆêC¬¼“OCŽs“c•™ŽqFdÇSgáŠQŽ™‚É‚¨‚¯‚éS“dŠw“I“Á’¥. ‘æ42‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïC2006C7C–¼ŒÃ‰®.
    61. “n•Óˆê—mC¼ˆäŽOŽ}CΕ^‹|C–F‘º’¼Ž÷C‘ºã”Ž‹vC“n•Óˆ»‰ÀC㨌hˆê˜YCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽC”ª–ØŒ´rŽFŠJSp‚ðŽ{s‚³‚ꂽæ“V«SŽ¾Š³Ž™‚Ì”­ç—\Œã\Bayley scale‚¨‚æ‚Ñ3D-MRI‚ð—p‚¢‚½”]—e—Ê‚Ì•]‰¿|. ‘æ42‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïC2006C7C–¼ŒÃ‰®.
    62. “n•Óˆ»‰ÀC‹´–{ˆè•vCÖ“¡˜a—RC“n•Óˆê—mCœA–ìŒbˆêC㨌hˆê˜YCŽs“c•™ŽqCÖ“¡Ž C‹{˜e—˜’jF‘gDƒhƒvƒ‰–@‚ð—p‚¢‚½‘ÙŽ™S¾k”\‚Ì•]‰¿. ‘æ42‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïC2006C7C–¼ŒÃ‰®.
    63. ’P —í’¾C‚µ‚ñ‰—ÔC“ñ’J•C’Ô¦áÁˆêC“n•Óˆ»‰ÀC“n•Óˆê—mCœA–ìŒbˆêC㨌hˆê˜YCŽs“c•™ŽqC‹{˜e—˜’jFSCN5A mutations in Japanese patients with left ventricular noncompaction. ‘æ42‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïC2006C7C–¼ŒÃ‰®.
    64. ¼è‘½ç‘ãC’†àV@C¼ˆäŽOŽ}CŽs“c•™ŽqCΕ^‹|CŠp@GHCâ–{ŠìŽO˜YC²–ìr“ñCà_˜e³DC‘O“c³MC”ª–ØŒ´rŽF¬Ž™ŠJSpŒã‚É‚¨‚¯‚é”­’B•]‰¿‚Æ‚µ‚Ä‚ÌBayley scale‚Ì“±“ü. ‘æ42‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïC2006C7C–¼ŒÃ‰®.
    65. Shan L.: Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. ‘æ‚V‰ñ¬Ž™SŒŒŠÇ•ªŽqˆãŠwŒ¤‹†‰ïC2006C7C–¼ŒÃ‰®.
    66. å ‹v”TC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jF“¯Žíœ‘ˆÚA‚ðs‚Á‚½Žá”N«œ‘’P‹…«”’ŒŒ•a‚Ì‚P—á. ‘æ11‰ñ•xŽR‘¢ŒŒŠ²×–EˆÚA§˜b‰ïC2006C7C•xŽR.
    67. ‹àŒ“O˜aC‘«—§—YˆêC‹{˜e—˜’jFƒNƒ‰ƒ~ƒWƒAEƒjƒ…[ƒ‚ƒjƒGŠ´õÇ‚Ì—Õ°‘œ.‘æ‚X‰ñ•xŽR¬Ž™Š´õ–ƉuŒ¤‹†‰ïC2006C7C •xŽR.
    68. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€g‹CŠÇŽxšb‘§‚Ì‚æ‚è‚æ‚¢Ž¡—Â̂½‚ß‚Éh u‹z“üƒfƒBƒoƒCƒX‚Ì‘I‘ðCMDI‚©DPI‚©ƒlƒuƒCƒU[‚©v ‘æ27‰ñ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒXC2006C8C‹ž“s.
    69. ‘«—§—YˆêF“Á•Êu‰‰u¬Ž™šb‘§Ž¡—Âɂ¨‚¯‚éƒÀ2ŽhŒƒ–ò‚̈ʒu‚¯v ‘æ13‰ñAllergy Forum in GunmaC2006C9C‘O‹´.
    70. –{‹½˜a‹vFƒ[ƒNƒVƒ‡ƒbƒvu¬Ž™“«‚Ä‚ñ‚©‚ñ‚ÌŽ©ŒÈ–Ɖu“I”wŒiv. ‘æ40‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï‘‰ïC2006C9C@@.
    71. Ö“¡˜a—RC“n•Óˆ»‰ÀC㨌hˆê˜YCŽs“c•™ŽqC”‘òŽõŽqC‘«—§—Y\C‹{˜e—˜’jCÎŒ´r“ñCF茒F‹CŠÇŽxšb‘§Ž¡—Ã’†?ŽhŒƒ–ò‹z“ü‚É‚æ‚èQT‰„’·ÇŒóŒQ‚ª”­Œ©‚³‚ꂽ[—á. ‘æ32‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ïC2006C9C‹à‘ò.
    72. “n•Óˆê—mCÄ“¡˜a—RC“n•Óˆ»‰ÀC㨌hˆê˜YCŽs“c•™ŽqFæ“V«SŽ¾Š³Ž™‚ɑ΂·‚éƒpƒŠƒrƒYƒ}ƒu“Š—^\ƒtƒ@[ƒXƒgƒV[ƒYƒ“‚ðU‚è•Ô‚Á‚Ä. ‘æ32‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ïC2006C9C‹à‘ò.
    73. L–ìŒbˆêFExpression of myeloid-related protein (MRP) 8 and MRP14 in patients with acute Kawasaki disease. ‘æ54‰ñ“ú–{S‘Ÿ•aŠw‰ïC2006C9CŽ­Ž™“‡(2006”N“xYIA—DGÜ).
    74. ‰ª•””üŒbC”ÂàVŽõŽqC‘«—§—zŽqC’†—ÑŒºˆêC•£‘ò—³–çC‘«—§—YˆêC‹{˜e—˜’jF•xŽRŒ§‚É‚¨‚¯‚鬎™ƒAƒŒƒ‹ƒM[Ž¾Š³’²¸. ‘æ9‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ¤‹†‰ïC2006C9C•xŽR.
    75. –쑺ŒbŽqCâV“¡˜a—RC‹àŒ“O˜aC‹{˜e—˜’jCŽO’J—S‰îC‹à“c@®CŽO‰Y³‹`F• •”ŽîᎂðŒ_‹@‚ÉŒ©‚‚©‚Á‚½_Œo‰è×–EŽî stage IVA ‚Ì1—á. ‘æ25‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ïC2006C9C‹à‘ò.
    76. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€uJPGL2005‚̉ü’ù‚ª“ûŽ™šb‘§‚ÌŽ¡—ÃŒ»ê‚É—^‚¦‚½‚à‚ÌCƒAƒ~ƒmƒtƒBƒŠƒ“’v ‘æ15‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[Œ¤‹†‰ïC2006C10C_ŒË.
    77. ‘«—§—YˆêF“Á•Êu‰‰u¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚éƒÀ2ŽhŒƒ–ò‚Ì“K³Žg—pv “ŒŽO‰Í¬Ž™‰Èˆã‰ïŠwpu‰‰‰ïC2006C10C–L‹´.
    78. ‘«—§—YˆêF“Á•Êu‰‰u“û—cŽ™šb‘§‚É‚¨‚¯‚éŋ߂̘b‘èv ‹ž“s•{•a‰@–òÜŽt‰ï•½¬18”N“xŠwpˆÏˆõ‰ïŠwpu‰‰‰ïC2006C10C‹ž“s.
    79. “n•Óˆ»‰ÀCÄ“¡˜a—RC㨌hˆê˜YC‹àŒ“O˜aCŽs“c•™ŽqC‹{˜e—˜’jFŠeŽíŽ¡—ÂɒïR«‚Ììè•a‚ɃVƒNƒƒXƒ|ƒŠƒ“A‚ª—LŒø‚Å‚ ‚Á‚½ˆê—á. @‘æ26‰ñ“ú–{ìè•aŒ¤‹†‰ï. 2006C10C‘åã.
    80. Ä“¡˜a—RC“n•Óˆ»‰ÀC“n•Óˆê—mCœA–ìŒbˆêC㨌hˆê˜YCŽs“c•™ŽqC‹{˜e—˜’jFƒÁƒOƒƒuƒŠƒ“‰ß•qÇ‚Ììè•aŽ™‚ɑ΂µ‚ÄInfliximabiRTNF|ƒ¿R‘Ìj‚ðŽg—p‚µ‚½ŒoŒ±. ‘æ26‰ñ“ú–{ìè•aŒ¤‹†‰ïC2006C10C‘åã.
    81. “n•Óˆ»‰ÀCÄ“¡˜a—RC㨌hˆê˜YCŽs“c•™ŽqC‘å‚TŒáC–F‘º’¼Ž÷C‘ºã”Ž‹vC–kŒ´~ˆê˜YCŽOè‘ñ˜YFŽŠ“KAV delay‚ÌÝ’è‚É‚æ‚èCS•s‘S‚̉ü‘P‚ð”F‚ß‚½¶S’áŒ`¬ÇŒóŒQCƒy[ƒXƒ[ƒJ[‘}“üŒã‚̈ê—á. •xŽR¬Ž™zŠÂŠíŠw‰ïC2006C10C•xŽR.
    82. ‘«—§—YˆêF“Á•Êu‰‰u“û—cŽ™šb‘§Ž¡—Âɂ¨‚¯‚éV‚µ‚¢“W–]v •½¬18”N“x•ŸˆäŒ§¬Ž™‰Èˆã‰ïŠwpW‰ïC2006C11C•Ÿˆä.
    83. ‘«—§—YˆêF“Á•Êu‰‰uƒAƒiƒtƒBƒ‰ƒLƒV[ƒVƒ‡ƒbƒN‚ÆC‚»‚̑Ήž‚ɂ‚¢‚Äv •½¬18”N“x•xŽRŒ§—{Œì‹³—@Šˆ“®Œ¤C‰ïC2006C11C•xŽR.
    84. ‘«—§—YˆêF“Á•Êu‰‰uŠwZ‚É‚¨‚¯‚éƒAƒŒƒ‹ƒM[Ž¾Š³‚ւ̑Ήžv Vì’n‹æ‚“™ŠwZ•ÛŒ’˜A—‹¦‹c‰ïC2006C11C‹›’Ã.
    85. ‘«—§—YˆêF“Á•Êu‰‰u¬Ž™‚É‚¨‚¯‚éOne airway, One disease‚Ìl‚¦•ûv ‘æ2‰ñŒQ”n‹C“¹Ž¾Š³Œ¤‹†‰ïC2006C11CŒQ”n.
    86. ‘«—§—YˆêF“Á•Êu‰‰u“ûŽ™šb‘§‚Ìf’f‚ÆŽ¡—Ã?ŋ߂̘b‘è?v ˆ¤’m¬Ž™ƒAƒŒƒ‹ƒM[u‰‰‰ïC2006C11C–¼ŒÃ‰®.
    87. ‘«—§—YˆêFƒCƒuƒjƒ“ƒOƒVƒ“ƒ|ƒWƒEƒ€gŒÄ‹zŠíŽ¾Š³‚ɑ΂·‚éV‚½‚Èf’f‚ւ̃Aƒvƒ[ƒ`hu“û—cŽ™šb‘§‚Ì‘Šúf’f‚É‚¨‚¯‚é‰Û‘èv. ‘æ56‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwpW‰ïC2006C11C“Œ‹ž.
    88. ˆÉ“¡–õ“TC”óŒû@ŽûC”ÂàVŽõŽqC‰ª•””üŒbC‘«—§—zŽqC‘«—§—YˆêCŽRŒ³ƒŽqC‘ºãIŒ[C‹{˜e—˜’jF’vŽ€“I•s®–¬‚ð‡•¹‚·‚é‹CŠÇŽxšb‘§Ž™‚ÌŠÇ—. ‘æ56‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwpW‰ïC2006C11C“Œ‹ž.
    89. ‘«—§—zŽqC’†—ÑŒºˆêC•£àV—³–çC”ÂàVŽõŽqC‚”ö@Š²C”öã—mˆêCŠžŒ´¹ŽqC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jF•ÛˆçŽ{Ý‚É‚¨‚¯‚éH•¨œ‹ŽŽwŽ¦‘‚Ì‚ ‚è•û?Š®‘Sœ‹Ž‚©ŒÂ•Ê‘Ήž‚©[. ‘æ56‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwpW‰ïC2006C11C“Œ‹ž.
    90. ŒÜ\—’—²•vC¼–ì³’mCˆÉ“Œ“¹•vC‘«—§—YˆêC‘«—§—zŽqC‘ºãIŒ[F“û—cŽ™‚É‚¨‚¯‚éˆê‰ß«šb–ÂC”ñƒAƒgƒs[Œ^šb‘§CƒAƒgƒs[Œ^šb‘§‚Ì‹C“¹‰ß•q«‚Ì”äŠrŒŸ“¢. ‘æ56‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwpW‰ïC2006C11C“Œ‹ž.
    91. ”óŒû@ŽûC‘«—§—YˆêCŽsŠÛ’q_Cóˆä³ŽkCìèˆê‹PFh‘è•ñu¬Ž™‚É‚¨‚¯‚é‹CŠÇE‹CŠÇŽxˆÙ•¨‚ÉŠÖ‚·‚é’²¸Œ‹‰Êv. ‘æ39‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ïC2006C11C“Œ‹ž.
    92. ‘ºãIŒ[CˆÉ“¡–õ“TC’Ô¦áÁˆêC–{ŠÔ@mC”ÂàVŽõŽqC㨌hˆê˜YC‘«—§—YˆêF2005/2006‚É‚¨‚¯‚éRSƒEƒCƒ‹ƒXŠ´õ‚Å‚Ì“ü‰@—á‚Ì—Õ°“IŒŸ“¢. ‘æ39‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ïC2006C11C“Œ‹ž.
    93. ‘«—§—YˆêF‹³ˆçƒZƒ~ƒi[u¬Ž™ŒÄ‹zŠíŽ¾Š³‚É‚¨‚¯‚郃CƒRƒgƒŠƒGƒ“Žó—e‘ÌhR–ò‚ÌÅV’mŒ©v. ‘æ43‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2006C11Cç—t.
    94. ”ÂàVŽõŽqC‰ª•””üŒbCˆÉ“¡–õ“TC”óŒû@ŽûC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jC‘ºãIŒ[C¼–ì³’mFƒCƒ\ƒvƒƒŒƒeƒm[ƒ‹Ž‘±‹z“ü—Ö@’†‚Ì™–¬”­Œ»‚ɂ‚¢‚Ä. ‘æ43‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2006C11Cç—t.
    95. ‘«—§—zŽqC’†—ÑŒºˆêC•£àV—³–çC‰ª•””üŒbC”ÂàVŽõŽqC‚”ö@Š²CŽRŒ³ƒŽqC”öã—mˆêC‘ºãIŒ[C‘«—§—YˆêC‹{˜e—˜’jF•xŽRŒ§‚Ì•ÛˆçŽ{Ý‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨œ‹Ž‚ÌŽÀ‘Ô’²¸|•½¬13”N“x‚Æ‚Ì”äŠr|. ‘æ43‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2006C11Cç—t.
    96. ŒÜ\—’—²•vC¼–ì³’mCˆÉ“Œ“¹•vC‘«—§—YˆêC‘«—§—zŽqC‘ºãIŒ[F“û—cŽ™‚É‚¨‚¯‚éˆê‰ß«šb–ÂC”ñƒAƒgƒs[Œ^šb‘§CƒAƒgƒs[Œ^šb‘§‚Ì—Õ°Œo‰ß‚Æ‹C“¹‰ß•q«‚Ì”äŠrŒŸ“¢. ‘æ43‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2006C11Cç—t.
    97. ŒÜ\—’—²•vC¼–ì³’mCˆÉ“Œ“¹•vC‘«—§—zŽqC‘«—§—YˆêC‘ºãIŒ[FŽ¼]•a•Ï‚ªæs‚µ‚½šb‘§‚Ææs‚µ‚È‚©‚Á‚½šb‘§‚Ì—Õ°Œo‰ß‚È‚ç‚Ñ‚É‹C“¹‰ß•q«‚Ì”äŠrŒŸ“¢. ‘æ43‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2006C11Cç—t.
    98. ‹àŒ“O˜aFƒVƒ“ƒ|ƒWƒEƒ€uŠî‘bŽ¾Š³‚ðŽ‚Š³Ž™‚ɑ΂·‚é—\–hÚŽí?Š´õÇ‚Æ—\–hÚŽív.‘æ38‰ñ“ú–{¬Ž™Š´õÇŠw‰ïC2006C11C‚’m.
    99. å@‹v”TC‹àŒ“O˜aC‹{˜e—˜’jCˆÉŒ\“ñ˜YC’†—ÑŒºˆêCŽÂ茒‘¾˜YFŽ¨«…“ªÇ‚̈ê—á.‘æ38‰ñ“ú–{¬Ž™Š´õÇŠw‰ïC2006C11C‚’m.
    100. ‹àŒ“O˜aF‹³ˆçu‰‰uæ“V«–Ɖu•s‘SÇ‚ÉŠÖ‚·‚éV‚µ‚¢˜b‘èv.‘æ48‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ïC2006C11C‘åã.
    101. ‘å’ØŒc•ãC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jF¼‰Ê‘Ìãó×–EŽîᇂ̎¡—ÃŒo‰ß’†‚Ƀp[ƒLƒ“ƒ\ƒ“ÇŒóŒQ‚ð”­Ç‚µ‚½ˆê’jŽ™—á. ‘æ48‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ïC2006C11C‘åã.
    102. å@‹v”TC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jC’†‘ò—mŽOC¬’rŒ’ˆêC¼“c˜a”VFԉ苅Œn×–E‚Ì‘‰Á‚ð”F‚ß‚½Žá”N«œ‘’P‹…«”’ŒŒ•a‚̈ê—á. ‘æ48‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ïC2006C11C‘åã.
    103. “ñ’J@•C ¬ìŽŸ˜YC ˆÉ“ÞŽu”¿”üC “ŒŽROKC ‹{˜e—˜’jFCDKN1C(p57kip2)ˆâ“`Žq•ÏˆÙ‚É‚æ‚éBeckwith-WiedemannÇŒóŒQ‚Ì‹É’áo¶‘ÌdŽ™—á. ‘æ51‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ïC2006C11C‘å‹{.
    104. ¼è‘½ç‘ãC’†àV@C¼ˆäŽOŽ}CŽs“c•™ŽqC”ª–ØŒ´rŽFBayley“û—cŽ™”­’BŽÚ“x‚É‚æ‚é”­’B¸’èi‚QjS‘ŸŽ¾Š³Ž™‚Ö‚Ì“K—p. ‘æ70‰ñ“ú–{S—Šw‰ïC2006C11C•Ÿ‰ª.
    105. ‘«—§—YˆêF‹³ˆçu‰‰u¬Ž™‚Ìšb‘§‚É‚¨‚¯‚é‹z“üƒfƒoƒCƒX‚ɂ‚¢‚Äv ‘æ6‰ñ•xŽRšb‘§Œ¤‹†‰ïC2006C12C•xŽR.
    106. Kanegane H., Agematsu K., Futatani T., Sira M., and Miyawaki T. : A novel CD19 deficiency in a Japanese patients with hypogammaglobulinemia. ‘æ36‰ñ“ú–{–ƉuŠw‰ï,2006,12,‘åã.
    107. ˆÉ“¡–õ“TC•£àV—³–çC“ŒŽROKC‘«—§—YˆêC‹àŒ“O˜aC‹{˜e—˜’jC¬—шê˜YC“c’†@Š®CŠ—’r‹g˜NFFOXP3—z«CD25+CD4+T×–E‚̬’·‚É”º‚¤•Ï‰»‚Æ FOXP3 ˆâ“`Žq•ÏˆÙ—á‚É‚¨‚¯‚éˆÙí. ‘æ36‰ñ“ú–{–ƉuŠw‰ïC2006C12C‘åã.
    108. ‹àŒ“O˜aC–쑺ŒbŽqC‹{˜e—˜’jF–«“÷‰èŽîǂɑ΂·‚éƒ{ƒŠƒRƒiƒ][ƒ‹‚ÌŽg—pŒoŒ±.‘æ18‰ñH×–E‹@”\ˆÙíÇŒ¤‹†‰ï. 2006C12C“Œ‹ž.
    109. ˆÉ“¡–õ“TC”óŒû@ŽûC”ÂàVŽõŽqC‰ª•””üŒbC‘«—§—YˆêF’vŽ€«•s®–¬‚ð‡•¹‚µ‚½¬Ž™‚É‚¨‚¯‚éšb‘§ŠÇ—. ‘æ14‰ñ—Õ°šb‘§Œ¤‹†‰ïC2006C12C‹à‘ò.
    110. ‘«—§—zŽqCˆÉ“¡–õ“TC”óŒû@ŽûC‰ª•””üŒbC”ÂàVŽõŽqC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jF•ÛˆçŽ{Ý‚Å‚ÌH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨œ‹Ž‚ÌŽÀ‘Ô|•½¬13”N“x’²¸‚Æ‚Ì”äŠr|. ‘æ33‰ñ–k—¤ƒAƒŒƒ‹ƒM[Œ¤‹†‰ïC2006C12C‹à‘ò.

    2005”N

  • ’˜‘
    1. ‹{˜e—˜’jFŒ´”­«–Ɖu•s‘SÇŒóŒQ.w¡“ú‚ÌŽ¡—ÃŽwj2005x@ŽRŒû“O‘¼•Ò,959,ˆãŠw‘‰@,“Œ‹ž,2005.
    2. Ichida F. : Novel gene mutations in patients with left ventricular noncompaction and evidence for genetic heterogeneity. Cardiovascular Development and Congenital Malformations. Edited by Artman M, Blackwell Futura,277-278, Oxford, UK,2005.
    3. Žs“c•™ŽqFS‘ŸŠO‰ÈKnack & Pitfalls.ŽY‰È,V¶Ž™‰È,¬Ž™‰È,ŠO‰È‚Ƃ̃Rƒ‰ƒ{ƒŒ[ƒVƒ‡ƒ“.‚–{áÁˆê•Ò,29-31,•¶Œõ“°,“Œ‹ž,2005.
    4. Žs“c•™ŽqFŒÇ—§«S‹Øãk–§‰»áŠQ.w¡“ú‚̬Ž™Ž¡—ÃŽwjx@‘æ14”Å,726,ˆãŠw‘‰@,“Œ‹ž,2005.
    5. Žs“c•™ŽqFVu–Ú‚ÅŒ©‚ézŠÂŠí•aƒVƒŠ[ƒYvwæ“V«SŽ¾Š³x@Šg’£Œ^S‹ØÇ,”ì‘åŒ^S‹ØÇ,ãk–§‰»áŠQ,359-367,ƒƒWƒJƒ‹ƒrƒ…[ŽÐ,“Œ‹ž,2005.
    6. ƒ^ƒ‰EƒEƒH[ƒJ[iŠÄC@‹{˜e—˜’jjFŽq‹Ÿ‚ÌŠ´õǃPƒA‹³–{.ŽY’²o”Å,“Œ‹ž,2005.
    7. ‹àŒ“O˜a,¼‘q—TŠì,–쑺ŒbŽq,‹{˜e—˜’jFƒŠƒ“ƒp‹…ƒTƒuƒZƒbƒg,‚m‚jŠˆ«,ŒŒ´–ƉuƒOƒƒuƒŠƒ“.u”’l‚©‚猩‚鬎™‚̬’·‚Æ”­’B.v–،p–«‘¼•Ò,47-55,‹àŒ´o”Å,“Œ‹ž,2005.
  • Œ´’˜
    1. Kanegane H., Kasahara Y., Okamura J., Hongo T., Tanaka R., Nomura K., Kojima S., and Miyawaki T.: Identification of DKC1 gene mutations in Japanese patients with X-linked dyskeratosis congenita. Brit J Haematol. 78: 130-133,2005.
    2. Kanegane H., Taneichi H., Nomura K., Futatani T., and Miyawaki T. : Severe neutropenia in Japanease patients with X-linked agammaglobulinemia. J Clin Immunol 25: 491-495,2005.
    3. Tabata Y., Villanueva J., Lee S.M., Zhang K., Kanegane H., Miyawaki T., Sumegi J., and Filipovich A.H. : Rapid detection of intracellular SH2D1A protein in cytoxic lymphocytes from patients with X-linked lymphoproliferative disease and their family members. Blood 105: 3066-3071,2005.
    4. Conley M.E., Broides A., Hemandez-Trujillo V., Howard V., Kanegane H., Miyawaki T., and Shurtleff S.A. : Genetic analysis of patients with defects in early B-cell development. Immunol Rev 78 : 130-133,2005.
    5. Viemann D., Strey A., Janning A., Jurk K., Klimmek K., Vogl T., Hirono K., Ichida F., Foell D., Kehrel B., Gerke V., Sorg C., and Roth J. : Myeloid-related protein 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood. 105: 2955-2962,2005.
    6. Yumura-Yagi K., Inoue M., Sakata N., Okamura T., Yasui M., Sawada A., Sato E., Chayama K., Endo C., Sasabe M., Miyamura T., Park Y.D., Nakano T., Inagaki J., Kishimoto T., Nomura K., Saito I., Hamada S., Nakano T., Hashii Y., and Kawa K.: Unrelated donor bone marrow transplantation for 100 pediatric patients : a single institutefs experience. Bone Marrow Transplant 36 : 307-313, 2005.
    7. Oshima Y., Doi Y., Misaki T., Ichida F. : Surgical repair of coronary sinus orifice atresia. Eur J Cardiothorac Surg. 27:351-352,2005.
    8. Wang XC., Wang Y., Kanegane H., Miyawaki T., and Yu YH. : Gene diagnosis of X-linked agammaglobulinemia. Zhonghua Er Ke Za Zhi 43: 449-452,2005.
    9. Okano M., Kawa K., Kimura H., Yachie A., Wakiguchi H., Maeda A., Imai S., Ohga S., Kanegane H., Tsuchiya S., Morio T., Mori M., Yokota S., and Imashuku S.: Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 80: 64-69,2005.
    10. Tanaka-Kitajima N., Sugaya N., Futatani T., Kanegane H., Suzuki C., Oshiro M., Hayakawa M., Futamura M., Morishima T., and Kimura H. : Ganciclovir therapy for congenital cytomegalovirus infection in six infants. Pediatr Infect Dis J 24: 782-785,2005.
    11. Taniuchi S., Masuda M., Fujii Y., Izawa K., Kanegene H., and Kobayashi Y. : The role of a mutation of the CXCR4 gene in WHIM syndrome. Haematologica 90: 1271-1272,2005.
    12. Taguchi M., Hongou K., Yagi S., Miyawaki T., Takizawa M., Aiba T., and Hashimoto Y. : Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients. Drug Metab. Pharmacokinet 20: 107-112,2005.
    13. ‹àŒ“O˜a,ŽíŽsq’ˆ,“ñ’J@•,‹{˜e—˜’jFIgGƒTƒuƒNƒ‰ƒX‘ª’è‚Ì—Õ°“I•K—v«‚ÌŒŸ“¢.“ú–{¬Ž™‰ÈŠw‰ïŽGŽ@109F16-21,2005.
    14. ŽíŽsq’ˆ,‹{–{—TŽq,–kì³M,’†—ÑŒºˆê,‹{˜e—˜’jFdÇSgáŠQŽ™iŽÒj‚É‚¨‚¯‚é”­”M‚ÌŠÓ•Êf’f`MxA’`”’‚ðŽw•W‚Æ‚µ‚Ä`.“ú–{dÇSgáŠQŠw‰ïŽ@30F93-997,2005.
    15. ’†àV@½,²’n@•×,Žs“c•™Žq,¬ŽRk‘¾˜Y,“í“c@‘,Œ´“cŒ’‰îFæ“V«SŽ¾Š³Ž™‚É‚¨‚¯‚éƒpƒŠƒrƒYƒ}ƒu‚ÌŽg—p‚ÉŠÖ‚·‚éƒKƒCƒhƒ‰ƒCƒ“.“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ@21F60-62,2005.
    16. œA£K”üCŽs“c•™ŽqC‘哈‹`”ŽF“ûŽ™Šú‚ÉS‘ŸŽèp‚ð—v‚·‚鎙‚Ì”­’B‚ÉŠÖ‚·‚錤‹†|“ûŽ™Šú‘O”¼‚É‚¨‚¯‚é”­’B‚Æ‚»‚ÌŠÖ˜A—vˆö|¬Ž™•ÛŒ’Œ¤‹†@64F669- 675,2005.
  • Ç—á•ñ
    1. Kanegane H., Ito Y., Ohshima K., Shichijo T., Tomimasu K., Nomura K., Futatani T., Sumazaki R., and Miyawaki T. : X-linked lymphoproliferative syndrome presenting with systemic lymphocytic vasculitis. Am J Hematol 78: 130-133,2005.
    2. Yoshida T., Kanegane H., Otsubo K., Nomura K., Hirokawa S., Tsuneyama K., Egawa H., and Miyawaki T. : Acute lymphoblastic leukemia after living donor liver transplantation. Pediatr Int 47: 579-582,2005.
    3. Igarashi N., Mugishima H., Sukegawa K., Kanegane H., and Yachie A. : 4 year follow-up of growth in a patient with Hunter disease who received unrelated bone marrow transplantation. Clin Pediatr Endocrinol 14: 19-24,2005.
    4. Satoh N., Koike T., Takato H., Fujiwara M., Emura I., and Kanegane H. : Fatal primary Epstein-Barr virus infection due to clonal CD8+ T-lymphocyte proliferation in an immunocompetent adult. Int J Hematol 82: 169-170,2005.
    5. Hoshino T., Kanegane H., Doki N., Irisawa H., Sakura T., Nojima Y., Miyawaki S., and Miyawaki T. : X-linked lymphoproliferative disease in an adult. Int J Hematol 82: 55-58,2005.
    6. ‘å’ØŒc•ãCŒÜ\—’“oC”¨èŠì–FFƒpƒ‹ƒ{B19ƒEƒCƒ‹ƒXŠ´õ‚ÉŠÖ˜A‚µ‚½‘½Ê‚È—Õ°‘œ‚ð’悵‚½3—á. ¬Ž™‰È—Õ°@58F225-228C2005.
    7. –{ŠÔ@m,å@‹v”T,”ÂàVŽõŽq,’†—ÑŒºˆê,•£àV—³–ç,‘«—§—zŽq,‘«—§—Yˆê,óˆä³Žk,‹{˜e—˜’jF‚È‚º‹C“¹ˆÙ•¨‚ªf’f‚³‚ê‚é‚Ü‚Å‚É’·ŽžŠÔ‚ð—v‚µ‚½‚Ì‚©|ƒs[ƒiƒbƒc‹zˆø‚Ì‚R¬Ž™—á‚ÌŒŸ“¢.“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ïŽGŽ 16: 21-26,2005.
  • ‘à
    1. Žs“c•™ŽqFS‹Øãk–§‰»áŠQ‚Æ•s®–¬.‘æ8‰ñ—Õ°S‘Ÿ•aƒtƒH[ƒ‰ƒ€,“ú–{S“d}Šw‰ïŽF26,2005.
    2. Žs“c•™ŽqFŒÇ—§«¶ŽºS‹Øãk–§‰»áŠQ‚Ƃ͉½‚Å‚·‚©H¬Ž™zŠÂŠíŽ¾Š³-‚»‚±‚ª’m‚肽‚¢Q&A.¬Ž™“à‰È37F1730-1732,2005.
    3. ‘«—§—Yˆê,ŒÜ\—’—²•vF¬Ž™‚̃AƒXƒsƒŠƒ“šb‘§. Topicws in Atopy 4:20-23,2005.
    4. ‹àŒ“O˜a,‹{˜e—˜’jFEBƒEƒCƒ‹ƒX‚Í‚w˜A½ƒŠƒ“ƒp‘BÇŒóŒQ(XLP)”­Ç‚É‚¢‚©‚ÉŠÖ‚í‚Á‚Ä‚¢‚é‚©.ŒŒ‰tƒtƒƒ“ƒeƒBƒA@15F85-92,2005.
    5. ‹àŒ“O˜a,‹{˜e—˜’jF”’l‚©‚猩‚鬎™‚̬’·‚Æ”­’B.ƒŠƒ“ƒp‹…ƒTƒuƒZƒbƒg.¬Ž™‰È@46F47-48,2005.
    6. ‹àŒ“O˜a,–쑺ŒbŽq,‹{˜e—˜’jF”’l‚©‚猩‚鬎™‚̬’·‚Æ”­’B.NKŠˆ«.¬Ž™‰È@46F49,2005.
    7. ‹àŒ“O˜a,‹{˜e—˜’jF”’l‚©‚猩‚鬎™‚̬’·‚Æ”­’B.ŒŒ´–ƉuƒOƒƒuƒŠƒ“.¬Ž™‰È@46F50,2005.
    8. –{‹½˜a‹v,“c’‡çH,”ª–ØMˆê,íŽRKˆê,‹{˜e—˜’jF—n˜A‹ÛŠ´õǂƬŽ™Ž©ŒÈ–ƉuŠÖ˜A«¸__ŒoŽ¾Š³.@¬Ž™‰È@46 : 563-569,2005.
    9. “ñ’J@•,‹àŒ“O˜a,‹{˜e—˜’jFæ“V«–Ɖu•s‘SÇŒóŒQ.“ú–{—Õ°@63(‘)F559-564,2005.
    10. ”ÂàVŽõŽq,‘«—§—YˆêF‹êí‚·‚éšb‘§‚Æ‚»‚Ì‘Îôu“û—cŽ™Šú‚Ìšb‘§v. šb‘§ 18 : 42-47,2005.
    11. ‹g“cär,‹àŒ“O˜aFRuntŠÖ˜A“]ŽÊˆöŽq‚Q(RUNX2).¶‘̂̉Ȋw@56F368-369,2005.
    12. ‘«—§—zŽq,‘«—§—Yˆê,‹{˜e—˜’jFH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨œ‹ŽŽwŽ¦‘쬂̎Ž‚Ý.ƒAƒŒƒ‹ƒM[‰È@19F348-354,2005.
    13. ‘«—§—zŽq,’†—ÑŒºˆê,•£àV—³–ç,”ÂàVŽõŽq,‘«—§—Yˆê,‘ºãIŒ[,‹{˜e—˜’jF•xŽRŒ§“଎™‰Èˆã‚É‚¨‚¯‚éšb‘§’·ŠúŠÇ—‚ɑ΂·‚éˆÓŽ¯’²¸|ƒAƒ“ƒP[ƒg’²¸‚É‚æ‚é‚T”NŠÔ‚̕ω»|¬Ž™‰È—Õ°@58F993-998,2005.
    14. ŽíŽsq’ˆ,‹àŒ“O˜aFæ“V«ŒŒ‹…Œ¸­Ç‚Ì•a‘Ô‚ÆŽ¡—Ã.7.ShwachmanÇŒóŒQ.ŒŒ‰tƒtƒƒ“ƒeƒBƒA15F429-435,2005.
    15. “n•Óˆê—m,Žs“c•™ŽqFæ“V«SŽ¾Š³‚É‚¨‚¯‚édÇRSƒEƒBƒ‹ƒXŠ´õÇ‚ÌŒoŒ±. RSV Actual Information 7 : 1-4, 2005.

  • 2005”NŠw‰ï•ñ
    1. Miyawaki T.: Primary immunodeficiencies inducing EBV-associated severe illnesses. The First International Congress of Immunodeficiency Disorders,2005,2,Teheran,Iran. (Invited Lecture)
    2. Adachi Y., Adachi YS., Nakabayashi M., Fuchizawa T., Itazawa T., Murakami G.,, and Miyawaki T.: Food allergic reactions in kindergartens in Japan. 61st Annual Meeting of American Academy of Allergy, Asthma & Immunology,2005,3,San Antonio, USA.
    3. Miyawaki T.FClinical and molecular features of congenital agammaglobulinemia. 2005 Shanghai International Pediatric Forum. 2005,6,Shanghai,China. (Invited Lecture)
    4. Ichida F., Xing Y., Chen R., Tsuji T., Haneda N., Matsuoka T., Isobe T., Kuwabara A., Higaki T., Ikemoto Y., Tsubata S., Futatani T., Watanabe S., Watanabe K., Hirono K., Uese K., Miyawaki T., Karla R. Bowles., and Neil E. Bowels. : Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. The 78th Scientific Sessions of American Heart Association,2005,11,Dallas,U.S.A.
    5. Nakabayashi M., Okabe Y., Fuchizawa T., Itazawa T., Adachi Y., Murakami G., and Miyawaki T. : A whole blood assay of MxA for diagnosis of viral infection in febrile children. 1st Congress of Asian Society for Pediatric Research,2005,11,Tokyo.
    6. Hirono K., Xing Y., Miyagawa-Tomita S., Futatani T., Watanabe K., Watanabe S., Tsubata S., Uese K., Hashimoto I., Ichida F., and Miyawaki T.: Profound expression of myeloid-related protein (MRP) 8 and MRP14 in Kawasaki disease. 1st Congress of Asian Society for Pediatric Research,2005,11,Tokyo.
    7. Mostafa S., Futatani T., OgawaJ., Kanegane H., and Miyawaki T. : Breast milk contains a novel factor promoting maturation of naive B cells into IgA-secreting cells. 1st Congress of Asian Society for Pediatric Research,2005,11,Tokyo.
    8. Xing Y., Chen R., Tsuji T., Haneda N., Matsuoka T., Isobe T., Kuwabara A., Higaki T., Ikemoto Y., Tsubata S., Futatani T., Watanabe S., Watanabe K., Hirono K., Uese K., Ichida F., Miyawaki T., Karla R. Bowles., and Neil E. Bowels. : Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. 1st Congress of Asian Society for Pediatric Research,2005,11,Tokyo.
    9. ‘«—§—zŽq,’†—ÑŒºˆê,•£‘ò—³–ç,”ÂàVŽõŽq,‚”ö@Š²,‘«—§—Yˆê,‘ºãIŒ[,‹{˜e—˜’jF•ÛˆçŽ{Ý‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨œ‹ŽŽwŽ¦‘쬂̎Ž‚Ý.‘æ‚T‰ñH•¨ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2005,1,“Œ‹ž.
    10. ‹{˜e—˜’jF(“Á•Êu‰‰)æ“V«–Ɖu•s‘Sǂ̊ȈÕf’f‚Æ—Õ°“I‘½—l«,‘æ8‰ñŠò•Œ¬Ž™Š´õǧ˜b‰ï,2005,‚P,Šò•Œ.
    11. ‹àŒ“O˜aF“Á•Êu‰‰uæ“V«–Ɖu•s‘SÇ‚Ìf‚©‚½v‘æ31‰ñ–k‹ãB¬Ž™ŒŒ‰tEŽîᇧ˜b‰ï,2005,1,–k‹ãB.
    12. ”óŒû@Žû,–쑺ŒbŽq,‹àŒ“O˜a,‹{˜e—˜’jFŒŒ‹…æÃHƒŠƒ“ƒp‘gD‹…Ç‚Ì“ûŽ™—á.‘æ9‰ñŒŒ‰tŽ¾Š³‚ƃTƒCƒgƒJƒCƒ“Œ¤‹†‰ï,2005,1,‹à‘ò.
    13. ˆÉ“¡–õ“T,–쑺ŒbŽq,‹àŒ“O˜a,‹{˜e—˜’j,ˆÀ‘º²“s‹I,‚‹´”Ž”V,íŽRKˆêF¶â¿œ“´Œ´”­‰¡–ä‹ØŽî stage 4 ‚Ì‚P—á.‘æ22‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ï,2005,2,‹à‘ò.
    14. –{‹½˜a‹v,‹{ˆêŽu,‰eŽR—²Ži,“c’‡çH,‹{˜e—˜’jF–ƉuCü—Ö@‚ªáz¹dÏ/ŒQ”­‚É‘tŒ÷‚µ‚½ÇŒó«‹ÇÝŠÖ˜A‚Ä‚ñ‚©‚ñ‚Ì‚R—á. ‘æ47‰ñ–k—¤¬Ž™_ŒoŠw‰ï,2005,2,‹à‘ò.
    15. Žs“c•™ŽqFS‹Øãk–§‰»áŠQ‚Æ•s®–¬.ƒtƒ@ƒCƒA[ƒTƒCƒhƒZƒ~ƒi[.The 69th Annual Scientific Meeting of the Japanese Circulation Society,2005,3,Yokohama.
    16. Xing Y., Ye F., Chen R., Tsuji T., Haneda N., Matsuoka T.,Yu X., Tsubata S., Futatani T., Watanabe S., Watanabe K., Hirono K., Uese K., Hamamichi Y., Hashimoto I., Ichida F., Miyawaki T., and Towin J.A. : Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. The 69th Annual Scientific Meeting of the Japanese Circulation Society,2005,3,Yokohama.
    17. –{‹½˜a‹v,‹{ˆêŽu,‰eŽR—²Ži,,“c’‡çH,‹{˜e—˜’jFƒ~ƒIƒNƒƒj|”­ì‚ðŒ_‹@‚É”­Œ©‚³‚ꂽDeVivo•ai‹^‚¢j‚̈ê—á. ‘æ29‰ñ–k—¤‚Ä‚ñ‚©‚ñŠw‰ï,2005,3,‹à‘ò.
    18. ‹àŒ“O˜a,‹{˜e—˜’j,‘Oì@Žü,¼’rˆê•F,ì–{@–LFƒJƒ“ƒWƒ_”sŒŒÇ‚ðŒJ‚è•Ô‚µ‚½ˆê—Ž™—á.‘æ16‰ñ•xŽR“«Ž¾Š³Š´õÇŒ¤‹†‰ï,2005,3,•xŽR.
    19. ‘«—§—zŽq,”‘òŽõŽq,’†—ÑŒºˆê,•£‘ò—³–ç,‘«—§—Yˆê,‹{˜e—˜’jFŠO—ˆ‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨•‰‰×ŽŽŒ±‚ÌŽÀÛ@|“ñd–ÓŒŸ–@‚ð’†S‚É|.‘æ26‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2005,3.17,•xŽR.
    20. –쑺ŒbŽq,“¡–Ø–õŽq,Œ´ˆä•ü”ü,å@‹v”T,ˆÉ“¡–õ“T,‹àŒ“O˜a,‹{˜e—˜’j,ˆÀ‘º²“s‹IF•›•@oŒ´”­ˆ««Žîᇂ̂R—á.‘æ283‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,2005,3,‹à‘ò.
    21. –{‹½˜a‹v,‹{@ˆêŽu,‰eŽR—²Ži,“c’‡çH,ŽR’J”ü˜a,”ª–ØMˆê,X@Žõ,íŽRKˆê,‹{˜e—˜’jFR”]R‘Ì‚ð—L‚·‚鬎™‚Ä‚ñ‚©‚ñ‚Ì—Õ°‘œ.‘æ108‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2005,4,“Œ‹ž.
    22. ‹àŒ“O˜a,“ñ’J@•,‹{˜e—˜’jFƒtƒ[ƒTƒCƒgƒƒgƒŠ[‚È‚ç‚тɈâ“`Žq‰ðÍ‚É‚æ‚é‚w˜A½–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ìf’f.‘æ108‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2005,4,“Œ‹ž.
    23. ”ÂàVŽõŽq,‘«—§—zŽq,’†—ÑŒºˆê,•£àV—³–ç,‘«—§—Yˆê,‚”ö@Š²,”öã—mˆê,‘ºãIŒ[,ŠC˜VàVŒ³G,‹{˜e—˜’jFH•¨ƒAƒŒƒ‹ƒM[‚ɑ΂·‚éŠO—ˆ‚Å‚ÌH•¨•‰‰×ŽŽŒ±‚̈À‘S«.‘æ108‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2005,4,“Œ‹ž.
    24. ’†—ÑŒºˆê,”ÂàVŽõŽq,•£àV—³–ç,ŽRŒ³ƒŽq,‘«—§—zŽq,‘«—§—Yˆê,ùŒ´²Žq,”öã—mˆê,‘ºãIŒ[,‹{˜e—˜’jF¬Ž™ƒEƒCƒ‹ƒXŠ´õÇ‚É‚¨‚¯‚é‘SŒŒ ELISA –@‚É‚æ‚é MxA ’`”’‘ª’è‚Ì—L—p«.‘æ108‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2005,4,“Œ‹ž.
    25. L–ìŒbˆê,“n•Óˆê—m,—t@”ò,ƒfƒCƒ‹ƒNƒtƒHƒGƒ‹,“n•Óˆ»‰À,㨌hˆê˜Y,‹´–{ˆè•v,’Ô¦ áÁˆê,Žs“c•™Žq,‹{˜e—˜’jFTNF-ƒ¿‚ÌŽhŒƒ‚É‚æ‚éMRP 8/MRP 14‚Ì“®‘Ô.‘æ108‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2005,4,“Œ‹ž.
    26. ˆÉ“¡–õ“T,–쑺ŒbŽq,‹àŒ“O˜a,‹{˜e—˜’jF”A˜HŒ‹Î‚ð‡•¹‚µ‚½‹}«ƒŠƒ“ƒp‹}«”’ŒŒ•a‚Ì‚P—á.‘æ108‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2005,4,“Œ‹ž.
    27. Xing Y., Chen R., Tsuji T., Haneda N., Matsuoka T., Isobe T., Kuwabara A., Higaki T., Ikemoto Y., Tsubata S., Futatani T., Watanabe S., Hirono K., Ichida F., Miyawaki T., and Neil E. Bowels. : Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity.‘æ108‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2005,4,“Œ‹ž.
    28. ‘«—§—zŽq,”‘òŽõŽq,’†—ÑŒºˆê,•£‘ò—³–ç,‘«—§—Yˆê,‚”ö@Š²,”öã—mˆê,‘ºãIŒ[,‹{˜e—˜’jF•ÛˆçŽ{Ý‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨œ‹ŽŽwŽ¦‘‚Ì쬂ɓ–‚½‚Á‚Ä‚Ì–â‘è“_.‘æ22‰ñ“ú–{“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï,2005,5,‘åã.
    29. ”‘òŽõŽq,‘«—§—zŽq,’†—ÑŒºˆê,•£‘ò—³–ç,‰ª•””üŒb,‘«—§—Yˆê,ŽRŒ³ƒŽq,”öã—mˆê,‘ºãIŒ[,‹{˜e—˜’jFƒƒbƒVƒ…Ž®ƒlƒuƒ‰ƒCƒU[iƒGƒ‚[ƒVƒ‡ƒ“j‚ƃRƒ“ƒvƒŒƒbƒT[Ž®ƒlƒuƒ‰ƒCƒU[iƒ^[ƒ{ƒWƒ…ƒjƒAj‚Ì”äŠrŒŸ“¢.‘æ22‰ñ“ú–{“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï,2005,5,‘åã.
    30. Žs“c•™ŽqFS‹Øãk–§‰»áŠQ‚Ì—Õ°.‘æ19‰ñ—Õ°’´‰¹”gƒZƒ~ƒi[,2005,6,“Œ‹ž.
    31. Žs“c•™ŽqFæ“V«SŽ¾Š³‚ÆRSƒEƒBƒ‹ƒXŠ´õÇ\ƒpƒŠƒrƒYƒ}ƒu‚Ì“K‰žƒKƒCƒhƒ‰ƒCƒ“.‘æ88‰ñ“ŒŠC¬Ž™zŠÂŠí’k˜b‰ï,2005,6,–¼ŒÃ‰®.
    32. ‘«—§—zŽq,”‘òŽõŽq,’†—ÑŒºˆê,•£‘ò—³–ç,‘«—§—Yˆê,”öã—mˆê,‘ºãIŒ[,‹{˜e—˜’jFƒƒbƒVƒ…Ž®ƒlƒuƒ‰ƒCƒU[,e-Motion‚ð—p‚¢‚½ƒÀ2ŽhŒƒ–ò‹z“ü‚É‚æ‚éS””‚ւ̉e‹¿.‘æ17‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,2005,6,‰ªŽR.
    33. ”‘òŽõŽq,’†—ÑŒºˆê,•£‘ò—³–ç,‰ª•””üŒb,‘«—§—zŽq,‘«—§—Yˆê,‹{˜e—˜’jF“\•tŒ^ƒÀ2ŽhŒƒ–ò‚ÌŒëŽg—p‚É‚æ‚Á‚Ä’†“Å‚ÉŽŠ‚Á‚½‚P“ûŽ™—á.‘æ17‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,2005,6,‰ªŽR.
    34. –쑺ŒbŽq,“¡–Ø–õŽq,Œ´ˆä•ü”ü,å@‹v”T,ˆÉ“¡–õ“T,‹àŒ“O˜a,‹{˜e—˜’j,ˆÀ‘º²“s‹IF•›•@oŒ´”­ˆ««Žîᇂ̂R—á.‘æ18‰ñ•xŽRŠàŽ¡—ç˜b‰ï,2005,6,•xŽR.
    35. –{‹½˜a‹v,‹{ˆêŽu,‰eŽR—²Ži,“c’‡çH,‹{˜e—˜’jF‘½Ê‚È”­ìÇó‚ð’悵‚½GLUT-1 deficiency syndrome‚̈ê—á.‘æ284‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,2005,6,•Ÿˆä.
    36. ‘«—§—YˆêFƒZƒ~ƒi[g˜aŠ¿–ò‚ÆÁ‰»ŠÇhu¬Ž™‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[‚ÌŒ»ó‚Ɖۑèv@‘æ26‰ñ˜aŠ¿–òŒ¤‹†Š“Á•ÊƒZƒ~ƒi[,2005,7,•xŽR.
    37. ”óŒû@Žû,”ÂàVŽõŽq,“¡–Ø–õŽq,‘«—§—Yˆê,‹{˜e—˜’jF•p‰ñ‚É–³ŒÄ‹z”­ì‚ðŒJ‚è•Ô‚µ‚½•S“úŠP‚̈ê—á.‘æ‚W‰ñ•xŽR¬Ž™Š´õ–ƉuŒ¤‹†‰ï,2005,7,•xŽR.
    38. “ñ’J@•,‘«—§—Yˆê,‹{˜e—˜’j,˜a“c’¼Ž÷FV¶Ž™ƒ}ƒXƒXƒNƒŠ[ƒjƒ“ƒOŒŸ¸‚ðŒ_‹@‚É”­Œ©‚³‚ꂽƒVƒgƒŠƒ“Œ‡‘¹Ç‚ÌV¶Ž™—á.‘æ15‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2005,7,•xŽR.
    39. Œ´ˆä•ü”ü,㨌hˆê˜Y,“n•Óˆ»‰À,“n•Óˆê—m,ŽíŽsq’ˆ,“¡–Ø–¾,Žs“c•™ŽqFPseudo VT‚ð”F‚ß,‚Žü”gƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Âðs‚Á‚½WPWÇŒóŒQ‚̈ê—á.‘æ15‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2005,7,•xŽR.
    40. ‹´–{ˆè•v,“n•Óˆ»‰À,㨌hˆê˜Y,Žs“c•™Žq,‹{˜e—˜’jF³í‘ÙŽ™S‚É‚¨‚¯‚鶉ES‹@”\. ‘æ41‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï,2005,7,“Œ‹ž.
    41. L–ìŒbˆê,“ñ’J@•,’C‰h—Ñ,“n•Óˆê—m,“n•Óˆ»‰À,’Ô¦áÁˆê,‹´–{ˆè•v,㨌hˆê˜Y,Žs“c•™Žq,‹{˜e—˜’jFìè•a‹}«Šú‚É‚¨‚¯‚é”’ŒŒ‹…’†myeloid-related-protein(MRP)8‚¨‚æ‚ÑMRP14‚̈â“`Žq”­Œ»‚ÌŒŸ“¢“®‘Ô. ‘æ41‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï,2005,7,“Œ‹ž.
    42. “n•Óˆ»‰À,“n•Óˆê—m,œA–ìŒbˆê,㨌hˆê˜Y,‹´–{ˆè•v,Žs“c•™Žq,‹{˜e—˜’jF¶ŽºS‹Øãk–§‰»áŠQ‚Ì—Õ°‘œ‚ÌŒŸ“¢|“ûŽ™”­Ç—á‚ÆŽá”N”­Ç—á‚Ì‘Šˆá\. ‘æ41‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï,2005,7,“Œ‹ž.
    43. “n•Óˆê—m,¼è‘½ç‘ã,“n•Óˆ»‰À,Žs“c•™Žq,‘哈‹`”Ž,L£K”ü,¼ˆäŽOŽ},’†ì,‹{˜e—˜’j,”ª–ØŒ´rŽFæ“V«SŽ¾Š³Ž™‚É‚¨‚¯‚é¸_‰^“®”­’B‚Ì•]‰¿|BayleyŽ®“û—cŽ™”­’BŒŸ¸“±“ü‚ÌŽŽ‚Ý|. ‘æ41‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï,2005,7,“Œ‹ž.
    44. Ä“¡˜a—R,ˆÉ“¡G˜a,“n•Óˆ»‰À,¬ìŽŸ˜Y,“ñ’J•,‹´–{ˆè•v,“y”ì‘P˜Y,‘哈‹`”Ž,Žs“c•™Žq,‹{˜e—˜’jF¶S’áŒ`¬ÇŒóŒQiHLHSj‚ð‡•¹‚µ‚½46XX, der(9)t(5;9)(q33.3;p22)‚Ì‘o‘Ù—á. ‘æ41‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï,2005,7,“Œ‹ž.
    45. ‹àŒ“O˜aFƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“uEBƒEƒCƒ‹ƒXŠÖ˜A T/NK ×–EƒŠƒ“ƒp‘B«Ž¾Š³.v‘æ12‰ñƒwƒ‹ƒyƒXŠ´õǃtƒH[ƒ‰ƒ€,2005,8,¬’M.
    46. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€gšb‘§‚Ì•a‘Ô‚ÆŽ¡—©‚ç‚Ý‚½¢‘ã“Ii”N—î“Ij“Á’¥huŠw“¶Šú@•›•@o‰Š‚Ƃ̇•¹v@‘æ26‰ñ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒX,2005,8,‹ž“s.
    47. ‘å’ØŒc•ã,–쑺ŒbŽq,‹àŒ“O˜a,‹{˜e—˜’jFŒÒŠÖß’É‚ðŽåÇó‚Æ‚µ,DIC‚È‚ç‚Ñ‚ÉäX‰Š‚ð‡•¹‚µ‚½‹}«’P‹…«”’ŒŒ•a‚Ì‚P—á.‘æ41‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2005,8,–¼ŒÃ‰®.
    48. ‰eŽR—²Ži,‹{@ˆêŽu,–{‹½˜a‹v,¼‘òƒŽq,ŽR’J”ü˜a,‹{˜e—˜’j,¬¼@“O,”ª–ØMˆêFäX‰Š‚É”º‚¤‚¯‚¢‚ê‚ñ‚ɑ΂µƒJƒ‹ƒoƒ}ƒ[ƒsƒ“‚ð“Š—^‚µ‚½Û”­],–³è÷—±‹…Ç‚ð’悵‚½‚P—á.‘æ41‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2005,8,–¼ŒÃ‰®.
    49. ‹{@ˆêŽu,ˆÉ“¡–õ“T,–{‹½˜a‹v,“ñ’J@•,‰eŽR—²Ži,‹{˜e—˜’jF‘½Ê‚È”­ìÇó‚ð’悵‚½ GLUT-1 deficiency syndrome ‚Ì‚P—á.‘æ41‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2005,8,–¼ŒÃ‰®.
    50. –{‹½˜a‹v,‹{@ˆêŽu,‰eŽR—²Ži,X@Žõ,‹{˜e—˜’jF”­Ç‚ɖƉu“I‹@˜‚ÌŠÖ—^‚ª„Ž@‚³‚ê‚éŠC”n•a•Ï‚ð—L‚·‚鬎™‚Ä‚ñ‚©‚ñ‚Ì‚Q—á.‘æ41‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2005,8,–¼ŒÃ‰®.
    51. Žs“c•™ŽqFæ“V«SŽ¾Š³‚ÆRSƒEƒBƒ‹ƒXŠ´õÇ\ƒpƒŠƒrƒYƒ}ƒu‚Ì“K‰žƒKƒCƒhƒ‰ƒCƒ“.‘æ30‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ï,2005,9,‹à‘ò.
    52. ”ÂàVŽõŽq,’†—ÑŒºˆê,‹{@ˆêŽu,Œ´ˆä•ü”ü,㨌hˆê˜Y,‘«—§—zŽq,‘«—§—Yˆê,‹{˜e—˜’jFƒAƒXƒxƒŠƒ“ƒhƒ‰ƒCƒVƒƒbƒv‚ÉŠÜ‚Ü‚ê‚éƒ|ƒŠƒrƒjƒ‹ƒsƒƒŠƒhƒ“iPVPj‚É‚æ‚éƒAƒiƒtƒBƒ‰ƒLƒV[‚Ì1—á.‘æ8‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2005,9,•xŽR.
    53. Žs“c•™ŽqF¬Ž™‚ÌS‘Ÿ«“Ë‘RŽ€. ‘æ22‰ñ“ú–{S“dŠw‰ïŠwpW‰ïŽs–¯ŒöŠJuÀ,2005,10,•xŽR.
    54. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€g¬Ž™šb‘§‚Ìf’f‚ÆŽ¡—Ãh u‘Šúf’f‚Æ‚»‚̉ۑè _“ûŽ™šb‘§‚ð’†S‚É-v.‘æ55‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2005,10,·‰ª.
    55. ”ÂàVŽõŽq,‘«—§—zŽq,‰ª•””üŒb,•£àV—³–ç,’†—ÑŒºˆê,‘«—§—Yˆê,‘ºãIŒ[,ŒÜ\—’—²•v,‹{˜e—˜’jFƒC[ƒW[ƒAƒYƒ}ƒvƒƒOƒ‰ƒ€—pƒAƒ“ƒP[ƒg‚Æ”x‹@”\‚Æ‚ÌŠÖŒW‚ÉŠÖ‚·‚錟“¢.‘æ55‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2005,10,·‰ª.
    56. ‘«—§—zŽq,‚”ö@Š²,ŽRŒ³ƒŽq,”öã—mˆê,‘«—§—Yˆê,‘ºãIŒ[,‹{˜e—˜’jF•ÛˆçŽ{Ý‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨œ‹ŽŽwŽ¦‘‚Ì—L—p«.‘æ55‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2005,10,·‰ª.
    57. ŒÜ\—’—²•v,¼–ì³’m,ˆÉ“Œ“¹•v,‘«—§—Yˆê,‘«—§—zŽq,‘ºãIŒ[FSpO2‚Í‹C“¹‰ß•q«ŽŽŒ±‚ÌŽw•W‚ƂȂ肦‚é‚©.‘æ55‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2005,10,·‰ª.
    58. –{‹½˜a‹v,‹{ˆêŽu,‰eŽR—²Ži,“c’‡çH,‹{˜e—˜’jFƒOƒ‹ƒR[ƒX—A‘—’S‘ÌŒ‡‘¹Ç‚Ì”]”gŠŒ©iÇ—á•ñj.‘æ39‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,2005,10, .
    59. “n•Óˆê—m,㨌hˆê˜Y,Ä“¡˜a—R,“n•Óˆ»‰À,œA–ìŒbˆê,Žs“c•™Žq,‹{˜e—˜’jF“®–¬áŽÁ‘ÞŒã,‰“ŠuŠú‚ÉΊD‰»‚É‚æ‚é—¼½œ‰º“®–¬Š®‘S•ÂÇ‚ð‚«‚½‚µ‚½1—á. ‘æ25‰ñ“ú–{ìè•aŒ¤‹†‰ï,2005,10,“Œ‹ž.
    60. Ä“¡˜a—R,‘å’ØŒc•ã,œA–ìŒbˆê,“n•Óˆê—m,“n•Óˆ»‰À,㨌hˆê˜Y,‹´–{ˆè•v,Žs“c•™Žq,‹{˜e—˜’j,’Ô¦áÁˆê,‘ºãIŒ[F‘¤•›ŒŒs‚Ì”­’B‘£i‚ðŠú‘Ò‚µ,ƒwƒpƒŠƒ“—Ö@‚ðŽŽ‚Ý‚½ìè•aŒãS‹Ø[Ç‚Ì“ûŽ™—á. ‘æ25‰ñ“ú–{ìè•aŒ¤‹†‰ï,2005,10,“Œ‹ž.
    61. “n•Óˆ»‰À,“n•Óˆê—m,œA–ìŒbˆê,㨌hˆê˜Y,Žs“c•™Žq,‹{˜e—˜’jFŒÇ—§«S‹Øãk–§‰»áŠQ‚Æ•s®–¬. ‘æ14‰ñŠÖ“ŒS‹ØŽ¾Š³Œ¤‹†‰ï,2005,10,“Œ‹ž.
    62. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€g¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2005h u“ûŽ™šb‘§‚ÌŽÀ‘ÔEf’fEŽ¡—Ãv@‘æ42‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2005,11,•Ÿˆä.
    63. ˆÉ“¡–õ“T,‘«—§—zŽq,•£‘ò—³–ç,”ÂàVŽõŽq,‘«—§—Yˆê,‘ºãIŒ[,‹{˜e—˜’jF‹CŠÇŽxšb‘§Ž™‚É‚¨‚¯‚éV‚µ‚¢ƒhƒ‰ƒCƒpƒEƒ_[‹z“üŠí‹ïƒNƒŠƒbƒNƒwƒ‰[‚ð—p‚¢‚½Û‚Ì‹z‹C—¬‘¬‚Ì‘ª’è.‘æ42‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2005,11,•Ÿˆä.
    64. ”ÂàVŽõŽq,’†—ÑŒºˆê,”óŒû@Žû,‰ª•””üŒb,ŽRŒ³ƒŽq,”öã—mˆê,‘«—§—Yˆê,‹{˜e—˜’jFƒ|ƒŠƒrƒjƒ‹ƒsƒƒŠƒhƒ“iPVPj‚É‚æ‚éƒAƒiƒtƒBƒ‰ƒLƒV[‚̈ê—á.‘æ42‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2005,11,•Ÿˆä.
    65. “n•Óˆ»‰À,“n•Óˆê—m,œA–ìŒbˆê,㨌hˆê˜Y,Žs“c•™Žq,‹{˜e—˜’jFŒÇ—§«S‹Øãk–§‰»áŠQ‚Æ•s®–¬. “ú–{¬Ž™S“dŠwŒ¤‹†‰ï,2005,11,VŠƒ.
    66. ”óŒû Žû,”ÂàVŽõŽq,’†—ÑŒºˆê,•£àV—³–ç,‘«—§—Yˆê,‹{˜e—˜’j,óˆä³Žk,‹v•ÛŽ›ŒPŽq,‰““¡@[,ŽRŠÝ“ÄŽŠFŠPšu‚Æšb–‚ðŒJ‚è•Ô‚µ,Congenital Lobar OverinflationiCLOj‚Æl‚¦‚ç‚ꂽˆê—á.‘æ38‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,2005,11,VŠƒ.
    67. ‹àŒ“O˜aFƒ~[ƒgƒUƒGƒLƒXƒp[ƒgu‚ǂ̂悤‚ÈŽž‚ɖƉu•s‘SÇ‚ð‹^‚¤‚©Hv‘æ37‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,2005,11,’Ã.
    68. –쑺ŒbŽq,‘å’ØŒc•ã,‹àŒ“O˜a,‹{˜e—˜’jF•›•@oŒ´”­ˆ««Žîᇂ̂R—á.‘æ21‰ñ“ú–{¬Ž™‚ª‚ñŠw‰ï,2005,‰F“s‹{.
    69. ‘å’ØŒc•ã,Š}Œ´‘Pm,˜eŒû@G,–ì“cKO,–쑺ŒbŽq,‹àŒ“O˜a,‹{˜e—˜’jŽ©ŒÈ–Ɖu«ƒŠƒ“ƒp‘BÇŒóŒQ type1a‚Æ–«Šˆ“®« EB ƒEƒCƒ‹ƒXŠ´õÇ.‘æ47‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2005,11,‰F“s‹{.
    70. Œ´ˆä•ü”ü,‹àŒ“O˜a,‘«—§—Yˆê,‹{˜e—˜’j.ƒNƒ‰ƒ~ƒWƒAEƒjƒ…[ƒ‚ƒjƒGIgMR‘Ì—z«—á‚Ì—Õ°“IŒŸ“¢.‘æ16‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2005,12,•xŽR.
    71. ”ÂàVŽõŽq,’†—ÑŒºˆê,‹{@ˆêŽu,Œ´ˆä•ü”ü,㨌hˆê˜Y,‘«—§—zŽq,‘«—§—Yˆê,‹{˜e—˜’j.ƒ|ƒŠƒrƒjƒ‹ƒsƒƒŠƒhƒ“iPVPj‚É‚æ‚éƒAƒiƒtƒBƒ‰ƒLƒV[‚Ì1—á.‘æ32‰ñ–k—¤ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2005,12,‹à‘ò.
    72. ”óŒû@Žû,”ÂàVŽõŽq,‘«—§—zŽq,‰ª•””üŒb,‘«—§—Yˆê,‘ºãIŒ[,‹{˜e—˜’j.¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚¨‚¯‚éƒC[ƒW[ƒAƒYƒ}ƒvƒƒOƒ‰ƒ€—pƒAƒ“ƒP[ƒgŒ‹‰Ê‚Æ”x‹@”\‚ÌŠÖŒW.‘æ13‰ñ—Õ°šb‘§Œ¤‹†‰ï,2005,12,•Ÿ‰ª.

    2004”N

  • ’˜‘
    1. ‹{˜e—˜’jA“ñ’J@•F–Ɖu•s‘SÇŒóŒQ‚ÌŽ¾Š³•ª—ÞB“à‰Èf—Âp•‚`‘æ39†A186-187A˜Z–@o”ÅŽÐA“Œ‹žA2004.
    2. Žs“c•™ŽqF¬Ž™‚É‚Ý‚ç‚ê‚éS–Œ‰Š‚ɂ‚¢‚ÄB¬Ž™‰Èf—ÃQ & AB1551-1552A˜Z–@o”ÅŽÐA“Œ‹žA2004.
    3. Žs“c•™ŽqFŠ´õ«S“à–Œ‰Š‚ɂ‚¢‚ÄB¬Ž™‰Èf—ÃQ & AB1552-1553A˜Z–@o”ÅŽÐA“Œ‹žA2004.
    4. ‹g“cär,ŠpŽŠˆê˜Y,‹àŒ“O˜aFDysplasia with predominant membranous bone involvement –Œ«œ‚ðN‚·œˆÙŒ`¬Ç|ŠTà.u–Ú‚ÅŒ©‚霌n“Ž¾Š³2004vˆÉ“¡•¶”V‘¼•Ò,182-184,“Œ‹žˆãŠwŽÐ,“Œ‹ž,2004.
    5. X@–ΘYA‹àŒ“O˜aAŠâŒŽŒ[ŽA‰Ÿ–¡˜a•vF‚»‚Ì‘¼‚Ì EBV ŠÖ˜A T/NK ƒŠƒ“ƒp‘B«Ž¾Š³BuÅVEˆ««ƒŠƒ“ƒpŽîƒAƒgƒ‰ƒXv‹e’r¹O‘¼•ÒA276-280A•¶Œõ“°A“Œ‹žA2004.
  • Œ´’˜
    1. Miyawaki T.: Primary immunodeficiencies inducing EBV-associated severe illness. Iranian J Allergy Asthma Immunol. 3: 51-57,2004.
    2. Hashimoto I., Hejmadi A., Li X., Jones M., Davis C. H., Swanson J.C., Schindera S. T., and Sahn D. J.: Tissue doppler-derived myocardial acceleration for evaluation of left ventricular diastolic function. J Am Coll Cardiol. 44 : 1459-1466,2004.
    3. Ogawa J., Sasahara A., Yoshida T., Sira M. M., Futatani T., Kanegane H., and Miyawaki T. : Role of transforming growth factor-ƒÀ in breast milk for initiation of IgA production in newborn infants. Early Hum Dev 77 : 67-75,2004.
    4. Ye F., Foell D., Hirono K., Vogl T., Futatani T., Rui C., Yu X., Watanabe S., Watanabe K., Uese K., Hashimoto I., Roth J., Ichida F., Miyawaki T. : Nautrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease. Am J Cardiol 94 : 840-844,2004.
    5. Yu X., Hirono K., Ichida F., Uese K., Rui C., Watanabe S., Watanabe K., Hashimoto I., Kumada T., Okada E., Terai M., Suzuki A., and Miyawaki T.: Enhanced iNOS expression in leukocytes and circulating endothelial cells is associated with the progression of coronary artery lesion in acute Kawasaki disease. Pediatr Res: 688-694,2004.
    6. Asghar A.., Parvaneh N., Kanegana H., Moin M., Amirzargar A.A., Farhoudi A., Pourpak Z., Movahedi M., Gharagozlou M., Rezaei N., Futatani T., and Miyawaki T.: Screening of the Bruton tyrosine kinase (BTK) gene mutations in 13 Iranian patients with presumed X-linked agammaglobulinemia. Iranian J Allergy, Asthma and Immunology. 3 : 175-179,2004.
    7. Takada H., Kanegane H., Nomura A., Yamamoto K., Ihara K., Takahashi Y., Tsukada S., Miyawaki T., and Hara T.: Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactiva-tion. Blood 103 : 185-187,2004.
    8. Harada S., Kamata Y., Ishii Y., Eda H., Kitamura R., Obayashi M., Ito S., Ban F., Kuranari J., Nakajima H., Kuze T., Hayashi M., Okabe N., Senpuku H., Miyasaka N., Nakamura Y., Kanegane H., and Yanagi K. : Maintenance of serum immunoglobulin G antibodies to Epstein-Barr virus (EBV) nuclear antigen 2 in healthy individuals from different age groups in a Japanease population with a high childhood incidence of asymptomatic primary EBV infection. Clin Diagn Lab Immun. 11 : 123-130,2004.
    9. Tsurusawa M., ChinM., Iwai A., Nomura K., Maeba H., Taga T., Higa T., Kuno T., Hori T., Muto A., and Yamagata M.: L-asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leckemia under asparaginase treatment. Cancer Chemoth Pharm 53 : 204-208,2004.
    10. Kenton AB., Sanchez X., Coveler KJ., Makar KA., Jimenez S., Ichida F., Murphy RT., Elliott PM., McKenna W., Bowles NE., Towbin JA., and Bowles KR.: Isolated left ventricular noncom-paction is rarely caused by mutations in G4.5, ƒ¿-dystrobrevin and FK binding protein-12. Mol Genet Metab. 82 : 162-166,2004.
    11. Li X., Jones M., Irvine T., Rusk RA., Mori Y., Hashimoto I., Von Ramm OT., Li J., Zetts A., Pemberton J., and Sahn DJ.: Real-time 3-dimensional echocardiography for quantification of the difference in left ventricular versus right ventricular stroke volume in a chronic animal model study: Improved results using C-scans for quantifying aortic regurgitation. J Am Soc Echocardiogr. 17 : 870-875,2004.
    12. Watanabe N., Kanegane H., Kinuya S., Shuke N., Yokoyama K., Kato H., Tomizawa G., Shimizu M., Funada H., and Seto H.: The radiotoxity of 131I therapy of thyroid cancer: Assessment by micronucleus assay of B lymphocytes. J Nucl Med : 608-611,2004.
    13. Yoshida R., Hasegawa T., Hasegawa Y., Nagai T., Kinoshita E., Tanaka Y., Kanegane H., Ohyama K., Onishi T., Hanew K., Okuyama T., Horikawa R., Tanaka T., and Ogata T.: Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. J Clin Endocr Metab. 89: 3359-3364,2004.
    14. Watanabe D., Ezoe S., Fujimoto M., Kimura A., Saito Y., Nagai H., Tachibana I., Matsumura I., Tanaka T., Kanegane H., Miyawaki T., Emi M., Kanakura Y., Kawase I., Naka T., and Kishimoto T.: Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Brit J Haematol. 426 : 726-735,2004.
    15. Jo E.K., Kook H., Uchiyama T., Hakozaki I., Kim Y.O., Song C.H., Park J.K., Kanegane H., Tsuchiya S., and Kumaki S.: Characterization of a novel nonsense mutation in the Interleukin-7 receptor ƒ¿ gene in a Korean patient with severe combined immunodeficiency. Int J Hematol . 80: 332-335,2004.
    16. Oshima Y., Koto K., Shimazu C., Misaki T., Ichida F., and Hashimoto I.: Cusp extension technique for bicuspid aortic valve in Turner-like stigmata. Asian Cardiovasc Thorac Ann.12 : 266-269,2004.
    17. Prakash K ., Li X., Hejmadi A., Hashimoto I., and Sahn DJ. : Determination of asymmetric cavity volumes using real-time three-dimensional echocardiography: an in vitro balloon model study. Echocardiography. 21:257-263,2004.
    18. ‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çAà_“¹”ü‹IA‰ª•””üŒbA”‘òŽõŽqA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jF•ÛˆçŽ{Ý‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨œ‹Ž‚ÌŽÀ‘Ô[•xŽRŒ§‚É‚¨‚¯‚é’²¸Œ‹‰Ê[B“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@18F100-107,2004.
    19. ”ÂàVŽõŽqA‘«—§—YˆêAˆÉ“Œ“¹•vA¼–ì³’mAŽRŒ³ƒŽqA‘ºãIŒ[AŒÜ\—’—²•vA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚éDSCG+Procaterol‚ÆDSCG’P“Æ‚Ì’èŠú‹z“ü—Ö@‚Ì’·ŠúŒø‰ÊB“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@18F571-577,2004.
    20. ŽO‰Y³‹`A㨌hˆê˜YA‘ºãIŒ[AûŠˆä³tAZ“c@—ºA‘«—§—YˆêA‹{˜e—˜’jF•xŽRŒ§‚É‚¨‚¯‚鬎™‹~‹}ˆã—Â̌»ó‚Æ–â‘è“_B“ú–{¬Ž™‰ÈŠw‰ïŽ@108F1234-1240,2004.
    21. ’†ì@”£A—Ñ@—²ˆêA‹{˜e—˜’jAŽ›àV·”NFƒNƒŠƒjƒJƒ‹EƒNƒ‰[ƒNƒVƒbƒv‚É‚¨‚¯‚éˆã—Ãî•ñ‹³ˆç‚ÌŒoŒ±`ƒRƒ“ƒsƒ…[ƒ^ƒŠƒeƒ‰ƒV[‚©‚çî•ñƒŠƒeƒ‰ƒV[‚ւ̃Vƒtƒg`ˆãŠw‹³ˆç@35F337-342,2004.
    22. ’†àV@½A’O‰HŒöˆê˜YA‹g‰i³•vAŽ›ˆä@ŸA‰zŒã–ΔVA“¡Œ´@‘ìA‘ºã’q–¾AŽs“c•™ŽqAé”ö–M—²A‰Hª“c‹IKAžwŠ_‚ŽjA—é–Ø@_A㑺GŽ÷AΘa“c–«•FA—§–ì@Ž A‹v•Û“cˆêŒ©A•Ÿ“‡—T”VA’Ë–ì^–çAX@‘PŽ÷Fæ“V«SŽ¾Š³‚É‚¨‚¯‚銴õ«S“à–Œ‰Š‚Ì—\–hAŽ¡—ÂɊւ·‚é‘S‘’²¸\‘æ2•ñ\@“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ@20F668-673,2004.
    23. ’†àV@½A²’n@•×AŽs“c•™ŽqA¬ŽRk‘¾˜YA“í“c@‘AŒ´“cŒ’‰îFæ“V«SŽ¾Š³Ž™‚É‚¨‚¯‚éƒpƒŠƒrƒYƒ}ƒu‚ÌŽg—p‚ÉŠÖ‚·‚éƒKƒCƒhƒ‰ƒCƒ“B“ú–{¬Ž™‰ÈŠw‰ïŽGŽ@108F1548-1551,2004.
    24. ŽíŽsq’ˆA‹àŒ“O˜aA“ñ’J@•A‹{˜e—˜’jF‚킪‘‚É‚¨‚¯‚é‚w˜A½–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚Ì—Õ°f’f‚ÉŠÖ‚·‚錟“¢B“ú–{¬Ž™‰ÈŠw‰ïŽGŽ@108F1118-1122,2004.
  • Ç—á•ñ
    1. Matsukura H., Kanegane H., Miya K., Ohtsubo K., Higuchi A., Tanizawa T., and Miyawaki T.: IgA nephropathy associated with X-linked thrombocytopenia. Am J Kidney Dis 43 : E7-E11,2004.
    2. Jo E.K., Kumaki S., Wei D., Tsuchiya S., Kanegane H., Song C.H., Noh H.A., Kim Y.O., Kim S.Y., Chung H.Y., Kim H.Y., and Kook H. : X-linked severe combined immunodeficiency syndrome : The first Korean case with ƒÁc chain gene mutation and subsequent genetic counseling. J Korean Med Sci 19 : 123-126,2004.
    3. Mikami T., Hayasaka S., Nagai Y., Yanagisawa S., Futatani T., and Takano Y. : Congenital corneal staphyloma associated with aphakia. J. Pediat. Ophth Strab 41 : 180-182,2004.
    4. ŽíŽsq’ˆAV’J®‹vA“¡“cC•½A“n•Ó@KAŒÜ\—’@“oA”¨èŠì–FF—A‰tŒ¸—Ê‚É”º‚Á‚Ēጌ“œ¨‡‚ð‚«‚½‚µ‚½_Œo«HŽv•sUÇ‚Ì‚P—áB¬Ž™‰È45F123-127,2004.
  • ‘à
    1. ‹{˜e—˜’jFƒAƒŒƒ‹ƒM[‘Š’kŽº‚p•‚`BƒAƒŒƒ‹ƒM[‚Ì—Õ°@24F406,2004.
    2. Žs“c•™ŽqFŒ¤Cˆã‚Ì‚½‚ß‚Ì‚æ‚­Œ©‚鎾Š³ABCuìè•av¬Ž™‰Èf—ÓÁW†,801-804,2004.
    3. Žs“c•™ŽqF¶ŽºS‹Øãk–§‰»áŠQu“ñŽŸ«S‹ØÇ\ŠÓ•Êf’f‚É•K—v‚È’mŽ¯\vHeart ViewA528-532,2004.
    4. ‘«—§—YˆêFšb‘§—li«j‹CŠÇŽx‰Š‚Æ‚ÍŽ¾Š³’PˆÊ‚©B¬Ž™“à‰È@36F545-548,2004.
    5. ‹àŒ“O˜a,‹{˜e—˜’jFŒ´”­«–Ɖu•s‘SÇ‚É‚¨‚¯‚é–ƉuˆÙí 1) X-linked lymphoproliferative disease.@ƒAƒŒƒ‹ƒM[E–Ɖu@11F1570-1575,2004.
    6. ‹àŒ“O˜aA‹{˜e—˜’jF”º«ƒŠƒ“ƒp‘B«Ž¾Š³iDuncanÇŒóŒQjBŒŒ‰tEŽîᇉÈ@48F357-365,2004.
    7. ‹àŒ“O˜aA–쑺ŒbŽqA‹{˜e—˜’jF‚d‚aƒEƒCƒ‹ƒXŠ´õÇB¬Ž™‰È@45F451-456,2004.
    8. ‹àŒ“O˜aA‹{˜e—˜’jFŽ©ŒÈ–Ɖu«ƒŠƒ“ƒp‘BÇŒóŒQB¬Ž™“à‰È@36F1600-1603,2004.
    9. ‹àŒ“O˜aA‹{˜e—˜’jFX-linked lymphopro-liferative disease. ƒAƒŒƒ‹ƒM[E–Ɖu@11F1570-1575,2004.
    10. ‹àŒ“O˜aA‹{˜e—˜’jFEBƒEƒCƒ‹ƒX‚Í‚w˜A½ƒŠƒ“ƒp‘BÇŒóŒQ(XLP)”­Ç‚É‚¢‚©‚ÉŠÖ‚í‚Á‚Ä‚¢‚é‚©BŒŒ‰tƒtƒƒ“ƒeƒBƒA@15F85-92,2004.
    11. “ñ’J@•A‹{˜e—˜’jFŒ´”­«–Ɖu•s‘SÇB—Õ°ŠÅŒì@30F985-988,2004.
    12. “ñ’J@•AŽíŽsq’ˆA‹{˜e—˜’jFƒ}ƒNƒƒtƒ@[ƒW‚Ì‹@”\‚ÆBtkB—Õ°–Ɖu@41F583-586,2004.
    13. “ñ’J@•,‹àŒ“O˜a,‹{˜e—˜’jF–Ɖu•s‘SÇ‚ð‹^‚¤‚̂͂ǂ̂悤‚È‚Æ‚«‚©.¬Ž™“à‰È@36F1702-1706,2004.
    14. ŽíŽsq’ˆA‹àŒ“O˜aA‹{˜e—˜’jF”º«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇiBTK Œ‡‘¹ÇjB¬Ž™“à‰È@36F1736-1739,2004.
    15. ‚“c‰pr,‹àŒ“O˜a,–쑺–¾•F,‹{˜e—˜’j,Œ´@Žõ˜YFNon-random X inactivation ‚É‚æ‚è—Ž™‚É”­¶‚µ‚½BTKŒ‡‘¹–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ.—Õ°–Ɖu@42F36-42,2004.

  • 2004”NŠw‰ï•ñ
    1. Adachi Y., Adachi YS., Itazawa T., Yamamoto J., Murakami G., and Miyawaki T.: Measurement of peak inspiratory flow rates with an in-check meter to identify preschool children's ability to use dry powder inhalers; diskus and turbuhaler. 61th anniversary meeting of American academy of allergy, asthma and immunology annual meeting,2004,3,San Francisco, USA.
    2. Hashimoto I., Barber J.B, Jones M., Li X., and Sahn DJ.: Regional spectrum of tissue doppler dereived myocardial acceleration during isovolumic relaxation and its relationship to peak filling. The 53th annual scientific session American college of cardiology,2004,3,New Orleans, U.S.A.
    3. Hashimoto I., Crispin HD., Lee J-S., Ichida F., Miyawaki T., and Sahn DJ.: Accuracy of RF field strain rate (elasticity) imaging : Studies using a calibrated physiologic contracting myocardial phantom. The 53th annual scientific session American college of cardiology,2004,3,New Orleans, U.S.A.
    4. Adachi Y.: Guideline asthma management and experience in Japan. The 20th national congress of allergy and immunology in ThailandA2004,4,Bangkok,Thailand.(Invited Lecture)
    5. Kanegane H., Futatani T., Wang Y., and Miyawaki T.: Nation-wide survey of X-linked agammaglobulinemia by flow cytometric and genetic analyses in Japan. 11th meeting for the European society for Immunodeficiencies,2004,10,Paris.
    6. Aghamohammadi A., Kanegane H., Mostafa M., Lida A., Ali-Akbar A., Kiara R-K., Futatani T., Nima R., and Miyawaki T. : Recurrent and persistant neutropenia in patient with X-linked hyper IgM syndrome. 11th meeting for the European society for Immunodeficiencies,2004,10,Paris.
    7. Ichida F., Ye F., Foell D., Vogl T., Hirono K., Watanabe S., Watanabe K., Uese K., Miyawaki T., and Roth J.: Neutrophil derived S100A12 is profoundly upregulated in early stage of acute Kawasaki disease. The 77th scientific sessions of American heart association,2004,11, New Orleans,U.S.A.
    8. Hirono K., Ye F., Foell D., Watanabe S., Watanabe K., Uese K., Ichida F., Miyawaki T., and Roth J.: Possible role of myeloid related protein(MRP)8 and MRP14 in progression of coronary artery lesions in acute Kawasaki disease. The 77th scientific sessions of American heart association,2004,11, New Orleans,U.S.A.
    9. “n•Óˆê—mA“n粈»‰ÀAL–ìŒbˆêA㨌hˆê˜YA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA‘å’ØŒc•ãA“ñ’J•A“y”ì‘P˜YA“‡’ÃeŽuA‘哈‹`”ŽAŽOè‘ñ˜YFpŒã‘Šú‚ÉŒJ‚è•Ô‚µŒo”ç“I‘å“®–¬•ÙŒ`¬p‚ðŽ{s‚µ‚½‘å“®–¬‹|—£’f‚Ì“ûŽ™—áB‘æ15‰ñ“ú–{Pedia-tric Interventional CardiologyŒ¤‹†‰ï,2004,1,“Œ‹ž.
    10. ‘«—§—zŽqA”ÂàVŽõŽqA‘«—§—YˆêA”öã—mˆêA‘ºãIŒ[A‹{˜e—˜’jF•xŽRŒ§‚É‚¨‚¯‚éˆãŽt‚É‚æ‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨œ‹ŽŽw“±‚ÌŽÀ‘ÔB‘æ4‰ñH•¨ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2004,1,“Œ‹ž.
    11. ˆÉŒ\“ñ˜YA‘q–{@’A“ŒŽROKA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAœAìTˆê˜YA“yŠò‘P‹IAˆê–ØŽ”VAÎàV@LFÅ‹ß“–‰È‚É‚ÄŒoŒ±‚µ‚½‹»–¡‚ ‚é_Œo‰è×–EŽî‚Ì‚Q—á|Ž©‘R‘Þk‚µ‚½ IVS ‚Ì‚P—á‚Æ Horner ’¥Œó‚ð‡•¹‚µ‚½‚P—á|B‘æ20‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ï,2004,2,‹à‘ò.
    12. ‹´–{ˆè•vF‘ÙŽ™•s®–¬‚Ì‘gDƒhƒvƒ‰[‚ƃXƒgƒŒƒCƒ“ƒŒƒCƒg‚É‚æ‚é•]‰¿B‘æ10‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŒ¤‹†‰ï,2004,2,“Þ—Ç.
    13. ŽRŒ³ƒŽqA’Ô¦áÁˆêA‘ºãIŒ[A–{ŠÔˆê³A–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAˆÉ“¡‰x˜NA¬’rŒ’ˆêFGATA-1 ˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚½ Down ÇŒóŒQ‡•¹ transient myeloproliferative disorder ‚̈ê—áB‘æ8‰ñŒŒ‰tŽ¾Š³‚ƃTƒCƒgƒJƒCƒ“Œ¤‹†‰ï,2004,2,‹à‘ò.
    14. “n粈»‰ÀA‹´–{ˆè•vA“n•Óˆê—mAœA–ìŒbˆêA㨌hˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jA‘哈‹`”ŽF‘gDƒhƒvƒ‰[–@‚ð—p‚¢‚½‘ÙŽ™¶ŽºŽûk”\‚Ì•]‰¿B‘æ10‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŒ¤‹†‰ï,2004,2,“Þ—Ç.
    15. Ä“¡˜a—RA‘哈‹`”ŽA“y”ì‘P˜YA“‡’ÃeŽuA‘å‚TŒáAŽOè‘ñ˜YA“n•Óˆê—mA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA‹g“cärA“ñ’J@•FIAA(type B) pŒã‚ÌASR‚ɑ΂µ‚ÄARossŽèp‚ðŽ{s‚µ‚½ CHARGEÇŒóŒQ‚Ì1—áB‘æ27‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ï,2004,2,‹à‘ò.
    16. ”‘òŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çAŽRŒ³ƒŽqA‘«—§—YˆêA‹{˜e—˜’jFšb‘§¬Ž™‚É‚¨‚¯‚é‹z‹C—¬‘¬‘ª’è|DPI“±“ü‚Ì‚½‚ß‚ÌŠî‘b“IŒŸ“¢|B‘æ25‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2004,2,•xŽR.
    17. Ye F., Ichida F., Hirono K., Watanabe S., Watanabe K., Uese K., Hashimoto I., Miyawaki T., Foell D., Vogl T., and Roth J. : Profound S100A12 expression in neutrophils in early stage of acute Kawasaki disease. The 68th annual scientific meeting of the Japanese circulation society,2004,3,Tokyo.
    18. Watanabe S., Hashimoto I., Watanabe K., Hirono K., Keiichiro K., Ichida F., Miyawaki T., and Sahn DJ. : Validation of myocardial accelera-tion during Isovolumic contraction as a non-invasive index of left ventricular contractility. The 68th annual scientific meeting of the Japanese circulation society,2004,3,Tokyo.
    19. ‘«—§—YˆêF¬Ž™šb‘§Ž¡—ÂɊւ·‚éƒAƒ“ƒP[ƒgB‘æ‚V‰ñ–k—¤šb‘§Œ¤‹†‰ï,2004,3,‹à‘ò.
    20. –{‹½˜a‹vA‹{@ˆêŽuA‰eŽR—²ŽiA“c’‡çHA¼‘òƒŽqAŠžŒ´¹ŽqA”ª–ØMˆêA‹{˜e—˜’jF—n˜A‹ÛŠ´õÇ‚ª”­Ç‚ÉŠÖ—^‚µ‚½‚ÆŽv‚í‚ê‚鬎™_Œo¸_Ž¾Š³B‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2004,4,‰ªŽR.
    21. ‹àŒ“O˜aA“ñ’J@•A‹{˜e—˜’jFIgG ƒTƒuƒNƒ‰ƒX‘ª’è‚Ì—Õ°“Iƒj[ƒhFƒAƒ“ƒP[ƒg’²¸‚É‚æ‚錟“¢B‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2004,4,‰ªŽR.
    22. ‹´–{ˆè•vA“n粈»‰ÀA“n•Óˆê—mA㨌hˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jFƒŠƒAƒ‹ƒ^ƒCƒ€‚RŽŸŒ³SƒGƒR[–@‚ð—p‚¢‚½¬Ž™æ“V«SŽ¾Š³‚ÌŒ`‘Ôf’fB‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï,2004,4,‰ªŽR.
    23. ”ÂàVŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—YˆêA”öã—mˆêA‘ºãIŒ[A‹{˜e—˜’jFƒxƒNƒƒƒTƒ]ƒ“‚Å‚ÌŽ¡—ÃŒø‰Ê‚ª\•ª‚Å‚È‚©‚Á‚½šb‘§¬Ž™‚ɑ΂·‚éƒtƒ‹ƒ`ƒJƒ]ƒ“‚Ì—LŒø«B‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï,2004,4,‰ªŽR.
    24. ”ª–ØMˆêA”ª–ØŽO˜YAŽíŽsq’ˆA–{‹½˜a‹vA‹{˜e—˜’jA¼‘q—TŠìA“¡àV—TŽqFƒAƒ“ƒP[ƒg’²¸‚©‚ç‚̃Cƒ“ƒtƒ‹ƒGƒ“ƒU‚ÉŠÖ‚·‚é‹~‹}ŠO—ˆf—Âɂ‚¢‚Ä‚ÌlŽ@B‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï,2004,4,‰ªŽR.
    25. “c’‡çHA¼‘òƒŽqA‹{@ˆêŽuA‰eŽR—²ŽiA–{‹½˜a‹vA”ª–ØMˆêA¼ˆäŽOŽ}A‹{˜e—˜’jF“û—cŽ™Šú‚©‚çŽvtŠú‚É‚¨‚¯‚錒픭’B”]‚Ì MRI ‚É‚æ‚錟“¢B‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï,2004,4,‰ªŽR.
    26. “n粈»‰ÀA‹´–{ˆè•vA“n•Óˆê—mAœA–ìŒbˆêA㨌hˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jADavid SahnF‘gDƒhƒvƒ‰[–@‚ð—p‚¢‚½“™—eŽûkŠúS‹Ø‰Á‘¬“x‚ͶŽºŽûk”\‚Ì”ñNP“IŽw•W‚Æ‚µ‚Ä—L—p‚©B‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï,2004,4,‰ªŽR.
    27. “n•Óˆê—mA‹´–{ˆè•vA“n•Ó ˆ»‰ÀAœA–ìŒbˆêA㨌hˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jB‰EŽºŽûk•]‰¿‚É‚¨‚¯‚éS‹Ø‰Á‘¬“x‘gDƒhƒvƒ‰[–@‚Ì—L—p«B‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï,2004,4,‰ªŽR.
    28. ˆÉŒ\“ñ˜YA“ŒŽROKA“¡–Ø–õŽqA‰eŽR—²ŽiArˆä”ü˜aŽqA–쑺ŒbŽqA‹àŒ“O˜aA¼‘q—TŠìA‹{˜e—˜’jF•Ðt–³Œ`¬‚É”­Ç‚µ‚½ Wilms Žîᇂ̈ê—áB‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï,2004,4,‰ªŽR.
    29. å@‹v”TA”ÂàVŽõŽqA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAˆÀ‘º²“s‹IAÎàV@LF•úŽËü—Ö@‹y‚Ñ DeVIC —Ö@‚ª—LŒø‚Å‚ ‚Á‚½ nasel NK/T cell lymphoma ‚Ì‚P—Ž™—áB‘æ14‰ñEBƒEƒCƒ‹ƒXŠ´õÇŒ¤‹†‰ï,2004,5,“Œ‹ž.
    30. ‹àŒ“O˜aA‹{˜e—˜’jA{–è@—ºF‚킪‘‚Ì‚w˜A½ƒŠƒ“ƒp‘BÇŒóŒQ‚Ì—Õ°“IˆÓ‹`B‘æ14‰ñEBƒEƒCƒ‹ƒXŠ´õÇŒ¤‹†‰ï,2004,5,“Œ‹ž.
    31. ‘«—§—zŽqA”ÂàVŽõŽqAà_“¹”ü‹IA‰ª•””üŒbA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jFH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨œ‹ŽŽwŽ¦‘쬂̎Ž‚Ý|•xŽRŒ§“à‚̈ãŽt‚ւ̃Aƒ“ƒP[ƒgŒ‹‰Ê|B‘æ16‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,2004,5,‘O‹´.
    32. ”‘òŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çAŽRŒ³ƒŽqA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jF¬Ž™‚É‚¨‚¯‚éšb‘§”­ìŽž‚Æ”ñ”­ìŽž‚Ì‹z‹C—¬‘¬‚ÌŒŸ“¢|DPI‚ÌŽg—p‚ÉŠÖ‚·‚éŠî‘b“IŒŸ“¢|B‘æ16‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,2004,5,‘O‹´.
    33. ŒÜ\—’—²•vA¼–ì³’mAˆÉ“Œ“¹•vA‘«—§—YˆêA‘«—§—zŽqA”öã—mˆêA‘ºãIŒ[Fƒ‚ƒ“ƒeƒ‹ƒJƒXƒg“Š—^‘OŒã‚É‚¨‚¯‚é‹C“¹‰ß•q«‚Ì•Ï“®‚ÉŠÖ‚·‚錟“¢B‘æ16‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,2004,5,‘O‹´.
    34. •£‘ò—³–çA”‘òŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêAŽRŒ³ƒŽqA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jFšb‘§Ž™‚ɑ΂·‚éƒhƒ‰ƒCƒpƒEƒ_[‹z“üŠíiDPIjŽg—p‚ÉŠÖ‚·‚éŠî‘b“IŒŸ“¢|”ñ”­ìŽž‚È‚ç‚Ñ‚É”­ìŽž‚Ì‹z‹C—¬‘¬|B‘æ21‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï,2004,6,‰F“s‹{.
    35. ‘«—§—YˆêF—Šw—Ö@‚É‚¨‚¯‚é¡Œã‚̉ۑèBƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚é—Šw—Ö@‚̃Rƒc‚Æ—Ž‚Æ‚µŒŠvB‘æ21‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï,2004,6,‰F“s‹{.
    36. “ñ’J@•AŽs“c•™ŽqA‹{˜e—˜’jFVEGFR3 ƒLƒi[ƒ[ƒhƒƒCƒ““à‚̃~ƒXƒZƒ“ƒX•ÏˆÙ‚É‚æ‚éˆâ“`«ƒŠƒ“ƒp•‚Žî(Milroy•a)‚̈ê‰ÆŒnB‘æ28‰ñ“ú–{ƒŠƒ“ƒpŠw‰ï‘‰ï,2004,6,•xŽR.
    37. “n粈»‰ÀA‹´–{ˆè•vA“n•Óˆê—mAœA–ìŒbˆêA㨌hˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jF‘gDƒhƒvƒ‰[–@‚ð—p‚¢‚½‘ÙŽ™S‹@”\‚̉ðÍB‘æ11‰ñ–k—¤zŠÂŠí’´‰¹”gŒ¤‹†‰ï,2004,6,‹à‘ò.
    38. ˆÉ“¡–õ“TA”ÂàVŽõŽqA–쑺ŒbŽqA‹àŒ“O˜aA‘«—§—YˆêA’J“à]ºGA‰¡“cr•½A‹{˜e—˜’jFƒŒƒCƒm[Œ»Û‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚½¬Ž™”畆‹Ø‰Š‚̈ê—áB‘æ41‰ñ–k—¤—Õ°–ƉuEǗጟ“¢Œ¤‹†‰ï,2004,7,‹à‘ò.
    39. ‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jADavid SahnFŽOŽŸŒ³‘gDƒhƒvƒ‰[–@‚ð—p‚¢‚½S‹Ø‘gD«ó‚Ì”»’èB‘æ40‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2004,7,“Œ‹ž.
    40. L–ìŒbˆêA—t@”òA“n•Óˆê—mA“n粈»‰ÀA㨌hˆê˜YA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jADirk Foell, Jahammes RothFìè•a‹}«Šú‚É‚¨‚¯‚éMRP 8/MRP 14‚Ì“®‘ÔB‘æ40‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2004,7,“Œ‹ž.
    41. “n粈»‰ÀA‹´–{ˆè•vA“n•Óˆê—mAœA–ìŒbˆêA㨌hˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jADavid SahnF‘gDƒhƒvƒ‰[–@‚ð—p‚¢‚½“™—eŽûkŠúS‹Ø‰Á‘¬“x‚ͶŽºŽûk”\‚Ì”ñNP“IŽw•W‚Æ‚µ‚Ä—L—p‚©B‘æ40‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2004,7,“Œ‹ž.
    42. “n•Óˆê—mA‹´–{ˆè•vA“n•Ó ˆ»‰ÀAœA–ìŒbˆêA㨌hˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jF‰EŽºŽûk•]‰¿‚É‚¨‚¯‚éS‹Ø‰Á‘¬“x‘gDƒhƒvƒ‰[–@‚Ì—L—p«B‘æ40‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2004,7,“Œ‹ž.
    43. Ä“¡˜a—RA‘哈‹`”ŽA“y”ì‘P˜YA–¼‘q—¢DAŽOè‘ñ˜YA‹´–{ˆè•vAŽs“c•™ŽqA‹g“cärA“ñ’J•A‹{˜e—˜’jF¶S’áŒ`¬ÇŒóŒQ‚ɑ΂µA“ñSŽºC•œ‚ðŽŽ‚Ý‚½‚P—áB‘æ40‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2004,7,“Œ‹ž.
    44. ˆÉ“¡–õ“TA”ÂàVŽõŽqA–쑺ŒbŽqA‹àŒ“O˜aA‘«—§—YˆêA‹{˜e—˜’jFƒŒƒCƒm[Œ»Û‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚½¬Ž™”畆‹Ø‰Š‚̈ê—áB‘æ40‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2004,8,Šò•Œ.
    45. å@‹v”TA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jFŒŒ¬”‘‘½‚𔺂Á‚½ monosomy 7‚̈ê—áB‘æ40‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2004,8,Šò•Œ.
    46. ‹àŒ“O˜aA–쑺ŒbŽqA“ñ’J@•A‹{˜e—˜’jF¬lŠú‚Éf’f‚³‚ꂽ‚w˜A½–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇB‘æ66‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ïE‘æ46‰ñ—Õ°ŒŒ‰tŠw‰ï‘‰ï,2004,9,‹ž“s.
    47. –쑺ŒbŽqA‹àŒ“O˜aAÎàV@LA‹{˜e—˜’jFNasal NK/T cell lymphoma ‚Ì‚Q—Ž™—áB‘æ66‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ïE‘æ46‰ñ—Õ°ŒŒ‰tŠw‰ï‘‰ï,2004,9,‹ž“s.
    48. ‘«—§—zŽqA”‘òŽõŽqA‘«—§—YˆêA‰Ÿ“cŠì”ŽA‹{˜e—˜’jFŒûoƒAƒŒƒ‹ƒM[ÇŒóŒQ‚Ì‚P’jŽ™—áB‘æ7‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2004,9,•xŽR.
    49. ”ÂàVŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—YˆêA‹{˜e—˜’jFdÇšb‘§“û—cŽ™2—á‚É‚¨‚¯‚éHFA-BDP‚ÌŽg—pŒoŒ±B‘æ‚P‰ñ•xŽRšb‘§–ò•¨Ž¡—ÃŒ¤‹†‰ï,2004,9,•xŽR.
    50. ‹´–{ˆè•vA“n•Óˆê—mA“n粈»‰ÀAL–ìŒbˆêA㨌hˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jF‘gDƒhƒbƒvƒ‰[–@‚ð—p‚¢‚½dÇS‹ØÇ‚ÌS‹@”\”»’èB‘æ21‰ñ“ú–{’´‰¹”gˆãŠw‰ï’†•”’n•û‰ï,2004,10,•xŽR.
    51. “n粈»‰ÀA‹´–{ˆè•vA“n•Óˆê—mAL–ìŒbˆêA㨌hˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jF‘gDƒhƒbƒvƒ‰[–@‚ð—p‚¢‚½¬Ž™‚É‚¨‚¯‚é“™—eŽûkŠúS‹Ø‰Á‘¬“x‰ðÍB‘æ21‰ñ“ú–{’´‰¹”gˆãŠw‰ï’†•”’n•û‰ï,2004,10,•xŽR.
    52. ”ÂàVŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—YˆêA‹{˜e—˜’jFdÇŽ‘±Œ^‚Ìšb‘§“û—cŽ™‚Q—á‚Ö‚ÌHFA-BDP“±“üŒoŒ±B‘æ12‰ñ—Õ°šb‘§Œ¤‹†‰ï,2004,10,L“‡.
    53. ‹àŒ“O˜aA“ñ’J@•A–쑺ŒbŽqA‹vŠÔ–ØŒåA“y‰®@Ž A–ìXŽRŒbÍA‹{˜e—˜’jFŒ´”­«–Ɖu•s‘SÇŒóŒQ‚̈â“`Žqf’f‚É‚¨‚¯‚é‘Û‹¦—ÍB‘æ36‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,2004,11,“Œ‹ž.
    54. –쑺ŒbŽqA‹àŒ“O˜aA“ñ’J@•A‹àŽq‰p—YA‹ß“¡’¼ŽÀA‹{˜e—˜’jFIgGƒTƒuƒNƒ‰ƒX‘ª’è‚Ì—Õ°“Iƒj[ƒh‚ÆIgGƒTƒuƒNƒ‰ƒXŒ‡‘¹Ç‚ÌŽÀ‘ÔB‘æ36‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,2004,11,“Œ‹ž.
    55. âV“¡˜a—RA“ŒŽROKA–쑺ŒbŽqA‹àŒ“O˜aA‘«—§—YˆêA‹{˜e—˜’jF‘lŒa•”Œ‹Šj«ƒŠƒ“ƒp߉Š‚Ì—cŽ™—áB‘æ36‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,2004,11,“Œ‹ž.
    56. ‘å’ØŒc•ãA‹{@ˆêŽuA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jFhistiocytosis ‚𔺂Á‚½cŠuŒ´”­ Germ cell tumor ‚̈ê’jŽ™—áB‘æ20‰ñ“ú–{¬Ž™‚ª‚ñŠw‰ï,2004,11,‹ž“s.
    57. ”óŒû@ŽûAˆÉŒ\ŽŸ˜YA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF—‘‰©”XŠà‚ð‡•¹‚µ‚½ Aicardi ÇŒóŒQ‚̈ê—áB‘æ20‰ñ“ú–{¬Ž™‚ª‚ñŠw‰ï,2004,11,‹ž“s.
    58. ‹àŒ“O˜aFƒ‚[ƒjƒ“ƒOƒŒƒNƒ`ƒƒ[u–Ɖu•s‘SÇvB‘æ46‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2004,11,‹ž“s.
    59. å@‹v”TA–쑺ŒbŽqA‹àŒ“O˜aA^•”@~‹{˜e—˜’jFŒŒ¬”‘‘½‚𔺂Á‚½ monosomy 7 ‚̈ê—áB‘æ46‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2004,11,‹ž“s.
    60. ‘«—§—YˆêF˜_‰ðuƒCƒ\ƒvƒƒeƒŒƒm[ƒ‹Ž‘±‹z“ü—Ö@‚̓AƒXƒv[ƒ‹‚©ƒvƒƒ^ƒm[ƒ‹‚©vB‘æ41‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2004,11,“Œ‹ž.
    61. ”ÂàVŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jFdÇšb‘§‚Ì“û—cŽ™‚É‚¨‚¯‚éHFA-BDP‚ÌŒø‰Ê|2—á‚ÌŽg—pŒoŒ±‚©‚çB‘æ41‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2004,11,“Œ‹ž.
    62. ‘«—§—zŽqAà_“¹”ü‹IA‰ª•””üŒbA”ÂàVŽõŽqA”öã—mˆêA‘«—§—YˆêAŠC˜VàVŒ³GA‹{˜e—˜’jFŠO—ˆ‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨•‰‰×ŽŽŒ±B‘æ41‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2004,11,“Œ‹ž.
    63. ¼–ì³’mAˆÉ“Œ“¹•vA‘«—§—YˆêAŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚é—\–h“IŽ¡—Â̑Šú“±“ü‚Ì—L—p«‚ɂ‚¢‚Ä‚ÌŒŸ“¢B‘æ41‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2004,11,“Œ‹ž.
    64. ŒÜ\—’—²•vA¼–ì³’mAˆÉ“Œ“¹•vA‘«—§—YˆêA‘«—§—zŽqA”öã—mˆêA‘ºãIŒ[FŽó“®‹i‰Œ‚ª¬Ž™šb‘§‚̌ċC’†CO”Z“xAŒÄ‹z‹@”\A‹C“¹‰ß•q«‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚ÄB‘æ41‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2004,11,“Œ‹ž.
    65. –{ŠÔ@mAå@‹v”TA”ÂàVŽõŽqA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—zŽqA‘«—§—YˆêAóˆä³ŽkA‹{˜e—˜’jFf’f‚³‚ê‚é‚Ü‚Å’·ŠúŠÔ‚ð—v‚µ‚½ƒs[ƒiƒc‚É‚æ‚é‹C“¹ˆÙ•¨‚Ì‚R—áD‘æ37‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,2004,11,“Œ‹ž.
    66. ”ÂàVŽõŽqAÄ“¡˜a—RA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jF”w•”’É‚Å”­Œ©‚³‚êA‚`ŒQ—n˜A‹ÛŠ´õ‚É‚æ‚é‚Æl‚¦‚ç‚ꂽ‘½”­«‰~Œ`”x‰Š‚̈ê—áB‘æ37‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,2004,11,“Œ‹ž.
    67. ŒÜ\—’—²•vA¼–ì³’mAˆÉ“Œ“¹•vA‘«—§—YˆêA‘«—§—zŽqA”öã—mˆêAŠžŒ´¹ŽqA‘ºãIŒ[FŠÔÚ‹i‰Œ‚ª¬Ž™šb‘§‚̌ċz‹@”\‚Æ‹C“¹‰ß•q«‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚ÄB‘æ54‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2004,11,‰¡•l.
    68. ”‘òŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—YˆêAŽRŒ³ƒŽqA‘ºãIŒ[A‹{˜e—˜’jF•xŽRŒ§“଎™‰Èˆã‚É‚¨‚¯‚éšb‘§Ž¡—Âɑ΂·‚él‚¦•û‚Ì‚T”NŠÔ‚ł̕ω»B‘æ54‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2004,11,‰¡•l.
    69. ‘«—§—zŽqA”ÂàVŽõŽqAà_“¹”ü‹IA‰ª•””üŒbA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jFH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨œ‹ŽŽwŽ¦‘쬂̎Ž‚Ý|•xŽRŒ§“à‚Ì•ÛˆçŽ{݂ւ̃Aƒ“ƒP[ƒgŒ‹‰Ê|B‘æ54‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2004,11,‰¡•l.
    70. ŽíŽsq’ˆA‹àŒ“O˜aA“ñ’J@•A‹{˜e—˜’jF‚w˜A½–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ—R—ˆŽ÷ó×–E‚É‚¨‚¯‚é Toll-like receptor ligands ‚ɑ΂·‚鉞“š«B‘æ34‰ñ“ú–{–ƉuŠw‰ï‘‰ï,2004,12,ŽD–y.
    71. Mostafa S., Yoshida T., Futatani T., Kanegane H., and Miyawaki T. : Human breast milk can promote class switching of neonatal naive B-cells into IgA-secreting cells. ‘æ34‰ñ“ú–{–ƉuŠw‰ï‘‰ï,2004,12,ŽD–y.
    72. ‘«—§—zŽqA”ÂàVŽõŽqA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jF“–‰ÈŠO—ˆ‚Å‚ÌH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•¨•‰‰×ŽŽŒ±‚ÌŽÀÛB‘æ31‰ñ–k—¤ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2004,12,‹à‘ò.

    2003”N

  • ’˜‘
    1. ‹{˜e—˜’jC”ª–ØMˆêFˆã—Õ¶‘ì¬ã‚Ì’ˆÓ“_‚RDf’f‘uƒRƒAEƒ[ƒeƒCƒVƒ‡ƒ“¬Ž™‰Èv^‹|Œõ•¶‘¼•ÒC8-9C‹à–F“°C“Œ‹žC2003.
    2. Žs“c•™ŽqFŒÇ—§«S‹Øãk–§‰»áŠQBu¡“ú‚̬Ž™‚ÌŽ¡—ÃŽwjv‘æ13”ÅC‘åŠÖ••F‘¼•ÒC364-365CˆãŠw‘‰@C“Œ‹žC2003.
    3. Žs“c•™ŽqF¬Ž™‚Ì•s®–¬Bu¡“ú‚ÌŽ¡—ÃŽwj 2003”N”ÅvCŽRŒû@“O‘¼•ÒC903-904CˆãŠw‘‰@C“Œ‹žC2003.
    4. Žs“c•™ŽqFŠî–{fŽ@–@B‹¹• •”uƒRƒAEƒ[ƒeƒCƒVƒ‡ƒ“¬Ž™‰ÈváÁ‹|Œõ•¶‘¼•ÒC52-55C‹à–F“°C“Œ‹žC2003.
    5. Žs“c•™ŽqF¶ŽºS‹Øãk–§‰»áŠQBuAnnual ReviewzŠÂŠí@2003v™‰º–õ˜Y‘¼•ÒC83-88C’†ŠOˆãŠwŽÐC“Œ‹žC2003.
    6. ‘«—§—YˆêF‹C“¹•W“I×–E‚É‹y‚Ú‚·‰ŠÇ‰ž“š‚Ì“Á’¥Bu}àF¬Ž™šb‘§‚Ì“Á’¥-•a‘Ô‚Æ–ò•¨—Ö@‚ð’†S‚É-vC¼ŠÔŽOŠ]‘¼•ÒC42-54CƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐC“Œ‹žC2003.
    7. ‘«—§—YˆêF¬Ž™‚É‚Ý‚ç‚ê‚é‹CŠÇŽxŠg’£Ç‚ɂ‚¢‚ÄBu¬Ž™‰Èf—Âp•‚`v’ǘ^‘æ37†CԒˇˆê‘¼•ÒC1420-1421C˜Z–@o”ÅŽÐC“Œ‹žC2003D
    8. ‘«—§—YˆêFÌŒŒBuƒRƒAEƒ[ƒe[ƒVƒ‡ƒ“@¬Ž™‰ÈvCáÁ‹|Œõ•¶‘¼•ÒC66-67C‹à–F“°C‹ž“sC2003D
    9. ‘«—§—YˆêF‹z“ü—Ö@BuƒRƒAEƒ[ƒe[ƒVƒ‡ƒ“@¬Ž™‰ÈvCáÁ‹|Œõ•¶‘¼•ÒC170-171C‹à–F“°C‹ž“sC2003D
    10. ‘«—§—YˆêF‹}«×‹CŠÇŽx‰ŠBu¡“ú‚̬Ž™Ž¡—ÃŽwjv13”ÅC‘åŠÖ••F‘¼•ÒC270-271CˆãŠw‘‰@C“Œ‹žC2003.
    11. ‘«—§—YˆêFdÇ‹CŠÇŽxšb‘§”­ì‚ɑ΂·‚éƒCƒ\ƒvƒƒeƒŒƒm[ƒ‹Ž‘±‹z“ü—Ö@‚ɂ‚¢‚ÄBu¬Ž™‰ÈŠO—ˆf—ẪRƒc‚Æ—Ž‚Æ‚µŒŠ‚P@¬Ž™šb‘§f—ÃvCX캜A•ÒC132-133C’†ŽR‘“XC“Œ‹žC2003.
    12. ‘«—§—YˆêFŠO—ˆ‚ÅŠÈ’P‚É‚Å‚«‚é”x‹@”\ŒŸ¸|ƒÀ2ŽhŒƒ–ò‚ɑ΂·‚锽‰ž«ŒŸ¸|Bu¬Ž™‰ÈŠO—ˆf—ẪRƒc‚Æ—Ž‚Æ‚µŒŠ‚P@¬Ž™šb‘§f—ÃvCX캜A•ÒC41-41C’†ŽR‘“XC“Œ‹žC2003D
    13. ‹àŒ“O˜aC‹{˜e—˜’jFŒ´”­«–Ɖu•s‘SÇŒóŒQBu“à‰ÈŠw‘攪”Åv™–{P–¾‘¼•ÒC1322-1327C’©‘q‘“XC“Œ‹žC2003.
    14. “ñ’J@•C‹{˜e—˜’jFV¶Ž™E¬Ž™•ÛŒ’‚W‘Ù“àŠ´õBuƒ_ƒCƒiƒ~ƒbƒN@ƒƒfƒBƒVƒ“‚Vv‰ºð•¶•‘¼•ÒC28¥23-28¥26C¼‘º‘“XCVŠƒC2003.
  • Œ´’˜
    1. Hashimoto I., Li X., Bhat A.H., Jones M., Zetts A. D., and Sahn D.J. : Myocardial strain rate is a superior method for evaluation of left ventricular subendocardial function compared with tissue doppler imaging. J Am Coll Cardiol 42 : 1574-1583,2003.
    2. Yoshida T., Kanegane H., Osato M., Yanagida M., Miyawaki T., Ito Y., and Shigesada K.: Functional analysis of RUNX2 mutations in cleidocranial dysplasia : novel insights into genotype-phenotype correlations. Blood Cell Mol Dis. 30: 184-193,2003.
    3. Itazawa T., Adachi Y., Okabe Y., Hamamichi M., Adachi Y. S., Toyoda M., Morohashi M., and Miyawaki T.: Developmental changes in interleukin-12-producing ability by monocytes and their relevance to allergic diseases. Clin Exp Allergy 33 : 525-530,2003.
    4. Foell D., Ichida F., Vogl T., Yu X., Chen R., Miyawaki T., Sorg C., and Roth J.: S100A12 (EN-RAGE) in monitoring Kawasaki disease. LANCET 361 : 1270-1272,2003.
    5. Yagi H., Furutani Y., Hamada H., Sasaki T., Asakawa S., Minoshima S., Ichida F., Joo K., Kimura M., Imamura S., Kamatani N., Momma K., Takao A., Nakazawa M., Shimizu N., and Matsuoka R.: Role of TBX1 in human del22q11.2 syndrome. LANCET 362 : 1366-1373,2003.
    6. Oyoshi MK., Nagata H., Kimura N., Zhang Y., Demachi A., Hara T., Kanegane H., Matsuo Y., Yamaguchi T., Morio T., Hirano A., Shimizu N., and Yamamoto K. : Preferential expansion of VƒÁ9-JƒÁP/VƒÂ2-JƒÂ3 ƒÁ-ƒÂ T cells in Nasal T-cell lymphoma and chronic active Epstein-Barr virus infection. Am J Pathol 162: 1629-1638,2003.
    7. Amoras AL., Kanegane H., Miyawaki T., and Vilela MM.: Defective Fc-, CR1- and CR3-mediated monocyte phagocytosis and chemotaxis in common variable immunodeficiency and X-linked agammaglobulinemia patients. J Investig Allergol Clin Immunol 13:181-188,2003.
    8. Kimura H., Morishima T., Kanegane H.,Ohga S., Hoshino Y., Maeda A., Imai S., Okano M., Morio T., Yokota S., Tsuchiya S., Yachie A., Imashuku S., Kawa K., Wakiguchi H., and Members of the Japanese association for research on Epstein-Barr virus and related diseases.: Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 187 : 527-533,2003.
    9. Gagliardi M.C., Finocchi A., Orlandi P., Cursi L., Cancrini C., Moschese V., Miyawaki T., and Rossi P. : Bruton's tyrosine kinase defect in dendritic cells from X-linked agammaglobulinae-mia patients does not influence their differenti-ation, maturation and antigen-presenting cell function. Clin Exp Immunol 133 : 115-122,2003.
    10. Jo EK., Wang Y., Kanegane H., Futatani T., Song CH., Park JK., Kim JS, Kim DS, Ahn KM., Lee SI., Park HJ., Hahn YS., Lee JH., and Miyawaki T.: Identification of mutations in the Bruton's tyrosine kinase gene, including a novel genomic rearrangements resulting in large deletion, in Korean X-linked agammaglobulinemia patients. J Hum Genet 48: 322-326,2003.
    11. Carnevali S., Mio T., Adachi Y., Spurzem J.R., StrizI., Romberger D.J., Illig M.,and Rennard. S.I.: Gamma radiation inhibits fibroblast-mediated collagen gel retraction. Tissue Cell 35: 459-69;2003.
    12. Li X., Jones M., Wang HF., Davies CH., Swanson JC., Hashimoto I., Rusk RA., Schindera ST., Barber BJ., and Sahn DJ. : Strain rate acceleration yields a better index for evaluating left ventricular contractile function as compared with tissue velocity acceleration during isovolumic contraction time: an in vivo study. J Am Soc Echocardiogr 16:1211-1216,2003.
    13. Miyazaki S., Tsuda H., Sakai M., Hori S., Sasaki Y., Futatani T., Miyawaki T., and Saito S.: Predominance of Th2-promoting dendritic cells in early human pregnancy decidua. J Leukocyte Biol 74: 514-522,2003.
    14. ¼–ì³’mCˆÉ“Œ“¹•vC‹gZ@ºC‘«—§—YˆêCŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§dÇ”­ì‚ɑ΂·‚éƒCƒ\ƒvƒƒeƒŒƒm[ƒ‹Ž‘±‹z“ü—Ö@@[dl‘Ì‚Æl‘Ì‚Ì”äŠrŒŸ“¢[B“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@17F115-121,2003.
    15. L£K”üCˆê–Ø”ü’qŽqCŽs“c•™ŽqC‘哈‹`”ŽFæ“V«SŽ¾Š³Ž™—Èçƒj[ƒY‚ÉŠÖ‚·‚錤‹†[‘æ1•ñFV‚µ‚¢ŽÚ“x‚ÌŠJ”­[“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ@19F14-19,2003.
    16. L£K”üCˆê–Ø”ü’qŽqCŽs“c•™ŽqC‘哈‹`”ŽFæ“V«SŽ¾Š³Ž™—Èçƒj[ƒY‚ÉŠÖ‚·‚錤‹†[‘æ2•ñFê–å‰Æ‚Æ•êe‚ª”cˆ¬‚·‚é—Èçƒj[ƒY‚Ì”äŠrŒŸ“¢[“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ@19F20-27, 2003.
    17. ’†àV@½C’O‰HŒöˆê˜YC‹g‰i³•vCŽ›ˆä@ŸC‰zŒã–ΔVC“¡Œ´@‘ìC‘ºã’q–¾CŽs“c•™ŽqCé”ö–M—²C‰Hª“c‹IKCžwŠ_‚ŽjC—é–Ø@_C㑺GŽ÷CΘa“c–«•FC—§–ì@Ž C‹v•Û“cˆêŒ©Fæ“V«SŽ¾Š³‚É‚¨‚¯‚銴õ«S“à–Œ‰Š‚Ì”­¶•p“xC—\–hCŽ¡—ÂɊւ·‚é‘S‘’²¸Ñ‘æ1•ñÑ“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ@19F117-122, 2003.
    18. ¼‰ª—Ú”üŽqC“ì‘ò@‹CHŒ³@Š]CŽs“c•™ŽqC‘¾“c”ªç—YC¬ìrˆêC¬–ìˆÀ¶C¬ŽRk‘¾˜YC•]Œ“ŽiC¬â˜a‹PC—¢Œ©Œ³‹`Cé”ö–M—²C£Œû³ŽjC‚‹´‰x˜YC’†ì‰ë¶C‰Hª“c‹IKC”nê@´C•Ÿd~ˆê˜YC‘O“c@C‘ºˆäFˆÀCX@ˆê”ŽCX@Ž•FC‹g‰i³•vCˆÀ“¡³•FF‰Æ‘°“à”­ÇSŒŒŠÇŽ¾Š³iSŽº’†ŠuŒ‡‘¹CS–[’†ŠuŒ‡‘¹Cƒtƒ@ƒ[Žl’¥ÇC“®–¬ŠÇŠJ‘¶j‚ÉŠÖ‚·‚é‰uŠw’²¸•ñ[1999”N8ŒŽ`2002”N7ŒŽ[@¬Ž™zŠÂŠíŠw‰ïŽGŽ@19F622-628, 2003.
    19. áÁ‹|Œõ•¶C‘哈—E¬C‹{˜e—˜’jC‚‹´OºC¬ò»ˆêF•a‰@¬Ž™‰È‹Î–±ˆã‚̋Ζ±ó‹µ‚Æ‚»‚̉ü‘P‚ɂ‚¢‚ÄB“ú–{¬Ž™‰ÈŠw‰ïŽ@107F85-92,2003.
  • Ç—á•ñ
    1. Kanegane H., Vielela MMS., Wang Y., Futatani T., Matsukura H., and Miyawaki T.: Autoimmune lymphoproliferative syndrome presenting with glomerulonephritis. Pediatr Nephrol 18: 454-456,2003.
    2. Hashimoto I., Ichida F., and Miyawaki T.: A case of large VSD with right sided diaphragmatic hernia. Cardiol Young 13:109-110,2003.
    3. Onoue Y., Adachi Y., Ichida F., and Miyawaki T.: Effctive use of corticosteroid in a child with life-threatening plastic bronchitis after Fontan operation. Pediatr Int 45: 107-109,2003.
    4. Aghamohammadi A., Kanegane H., Moein M., Farhoudi A., Pourpak Z., Movahedi M., Gharagozlou., Zarger AAA., and Miyawaki T.: Identification of an SH2D1A mutation in a hypogammaglobulinemic male patient with a diagnosis of common variable immunodificiency. Int J Hematol 78 : 45-47,2003.
    5. Jo EK., Futatani T., Kanegane H., Kubota T., Lee YH.,Jung JA., Song CH., Park JK., Nonoyama S., and Miyawaki T.: Mutational analysis of the WASP gene in 2 Korean families with Wiskott-Aldrich syndrome. Int J Hematol 78 : 40-44,2003.
    6. Chujo T., Yachie A., Kanegane H., Kimura H., Shiobara S., and Nakao S. : Epstein-Barr virus(EBV)-associated post-transplantation lympho-proliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation. Am J Hematol 72 : 255-258,2003.
    7. Hirokawa S., Uotani H., Okami H., Tsukada K., Futatani T., and Hashimoto I.: A case of congenital middle cervical cleft with congenital heart disease. J Pediatric Surg 38: 1099-1101, 2003.
    8. Nii M., Mori K., Yuasa Y., and Ichida F.: Isolated noncompaction of myocardium associated with calcification in the Interventricular Septum. Pediatr Cardiol. Epub,Sep.4,2003.
    9. Oshima Y., Koto K., Shimazu C., Misaki T., Ichida F., and Hashimoto I.: Transannular patching for tetralogy of Fallot with an anomalous right coronary artery. Jpn J Thorac Cardiovasc Surg. 51:73-76,2003.
    10. Oshima Y., Hashimoto I., Shimazu C., and Ichida F.: Atypical infantile form of scimitar syndrome with bronchomalacia. Interactive Cardiovascular and Thoracic Surg 2: 298-300,2003.
    11. Irga N., Wierzba J., Brozek J., Ochman K., Kanegane H., Miyawaki T., and Neuman-Laniec M.: X-linked agammaglobulinemia(XLA) associated to agranulocytosis. Wiad Lek 56: 378-380,2003.
    12. ŽíŽsq’ˆC‰Æ鈟‹IŽqC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jC‘â@´Fƒrƒ“ƒNƒŠƒXƒ`ƒ““Š—^‚É‚æ‚茰«‰»‚µ‚½Charcot-Marie-Tooth•a1AŒ^‚Ì‚P—áB“ú–{¬Ž™ŒŒ‰tŠw‰ïŽ 17F34-37,2003.
    13. ”öã—mˆêC‘«—§—YˆêC”ÂàVŽõŽqC‹´–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC’C–¤‹M”üŽqC¬–ìˆÀ¶C”ª–ØŒ´rŽFFontan pŒã‚T”N‚Å”­Ç‚µ‚½ plastic bronchitis ‚Ì‚P’jŽ™—áB“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ19F51-55,2003.
    14. ˆÉ“¡–õ“TC’†—ÑŒºˆêC–쑺ŒbŽqC‹àŒ“O˜aC‰ª•””üŒbC‹{˜e—˜’jFŒŒ‹…æÃHÇŒóŒQ‚ð‡•¹‚µ‚½ Anaplastic large cell lymphoma ‚̈ê—áB“ú–{¬Ž™‰ÈŠw‰ïŽ@107F85-92,2003.
    15. ‘“c²˜aŽqC’†–ì‹MŽiC_’J@âVC‹àŒ“O˜aC‹{˜e—˜’jFƒyƒjƒVƒŠƒ“‘Ï«”x‰Š‹…‹Û‚É‚æ‚é‹}«’†Ž¨‰Š‚Å”­Œ©‚³‚ꂽ‚w˜A½–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì‚P—áBŽ¨•@ˆôA‰ÈE“ªèò•”ŠO‰È@75F365-369,2003.
    16. Š¥–Ø’q”VC‰Í‡—˜®C‹à@Œc²Cé@G•ãC‘å‹´”Ž•¶CŒÃ¯’mŒÈC’J“à]ºGC‹àŒ“O˜aC‹{˜e—˜’jC‘åÎ@•×Fp47- phox Œ‡‘¹Œ^–«“÷‰èŽîǂ𔺂¤ Williams ÇŒóŒQ‚Ì‚P—áB—Õ°–ƉuŠw‰ïŽGŽ 26F299-303,2003.
    17. Žu…–ƒŽÀŽqC¼—Ñ@³C–Ø‘º@GC¯–ì@—mC‹àŒ“O˜aC‹{˜e—˜’jFEBƒEƒCƒ‹ƒXŠÖ˜AŒŒ‹…æÃHÇŒóŒQ‚É‚ÄŽ€–S‚µ‚½‚w˜A½ƒŠƒ“ƒp‘B«ÇŒóŒQ‚̌ǔ­—áB¬Ž™Š´õ–Ɖu 15F3-7,2003.
    18. ˆîˆäˆèŽqC‹àŒ“O˜aCX–{@ŽC^•”@~C‹{˜e—˜’jC×’J—º‘¾F“ûŽ™Šú‘Šú‚É—nŒŒ«•nŒŒ‚ÆŒŒ¬”ÂŒ¸­‚Å”­Ç‚µ‚½ Autoimmune Lympho-proliferative Syndrome ‚Ì‚P—áB“ú–{¬Ž™ŒŒ‰tŠw‰ïŽGŽ@17F492-496,2003.
  • ‘à
    1. Yachie A., Kanegane H., and Kasahara T.: Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative disease. Semin Hematol 40 : 124-132,2003.
    2. Žs“c•™ŽqF¬l‚Æ‚È‚Á‚½¬Ž™SŽ¾Š³Buæ“V«SŽ¾Š³CS‹ØÇC•s®–¬‚̈â“`‚ƈâ“`‘Š’kv¬Ž™‰Èf—ÓÁW†B1105-1110,2003.
    3. ‘«—§—YˆêF¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚é‹C“¹ƒŠƒ‚ƒfƒŠƒ“ƒO‚Ì•a‘ÔBƒAƒŒƒ‹ƒM[‚Ì—Õ°@23F759-763,2003.
    4. ‹àŒ“O˜aFEBƒEƒCƒ‹ƒXŠÖ˜AŽ¾Š³‚ÌŽ¡—ÂÌi•àB‰»Šw—Ö@‚̗̈æ@19F1591-1595,2003.
    5. ‹àŒ“O˜aC‹{˜e—˜’jFXLP‚È‚ç‚Ñ‚É‚»‚ÌŽü•ÓŽ¾Š³‚̃Qƒmƒ€ˆãŠwBƒQƒmƒ€ˆãŠw@‚RF317-322,2003.
    6. ‹àŒ“O˜aC㼈ê‰iC‹{˜e—˜’jFICOS‚̈â“`ŽqˆÙí‚É‚æ‚é–Ɖu•s‘SÇB—Õ°–Ɖu@40F499-506,2003.
    7. ‹àŒ“O˜aC‹{˜e—˜’jFƒŠƒ“ƒp‘B«Ž¾Š³‚Ææ“V“Iˆâ“`ŽqˆÙíB“ú–{—Õ°–ƉuŠw‰ï‰ïŽ@26F311-322,2003.
    8. ‹àŒ“O˜aCŽÂ茒‘¾˜YC“ñ’J@•C‹{˜e—˜’jFEBƒEƒCƒ‹ƒXŠ´õ‚ƈâ“`«ƒŠƒ“ƒp‘BŽ¾Š³B¬Ž™Š´õ–Ɖu 15F25-30,2003.
    9. ŠÇ@®_C‚“c‰prC‘å‰ê³ˆêC‹àŒ“O˜aC‹{˜e—˜’jCŒ´@Žõ˜YFƒŠƒ“ƒp‹…‚ÌŠˆ«‰»§Œä‚ƃp[ƒtƒHƒŠƒ“`‰Æ‘°«ŒŒ‹…æÃHƒŠƒ“ƒp‘gD‹…ǂ̬ˆö`B—Õ°–Ɖu@40F110-116,2003.

  • 2003”NŠw‰ï•ñ
    1. “n•Óˆê—mC㨌hˆê˜YC“n•Óˆ»‰ÀCL–ìŒbˆêCà_“¹—T“ñC‹´–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC“‡’ÃeŽuC‘哈‹`”ŽCŽOè‘ñ˜YC¬—ÑrŽ÷Fƒtƒ@ƒ[Žl’¥ÇªŽ¡pŒã‚̶”x“®–¬•ªŠò•”‹·ó‚ɑ΂µ‚ăXƒeƒ“ƒg—¯’u‚ðs‚¢CpŒã7”N‚ÉÄŠg’£‚ðs‚Á‚½1—áB‘æ14‰ñ“ú–{Pediatric Interventional Cardio-logy Œ¤‹†‰ï,2003,1,‘åã.
    2. à_“¹—T“ñCL–ìŒbˆêC“n•Óˆê—mC“n•Óˆ»‰ÀC㨌hˆê˜YC‹´–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC“‡’ÃeŽuC‘哈‹`”ŽCŽOè‘ñ˜YFMAPCA‚ɑ΂µƒRƒCƒ‹Çðp‚ª—LŒø‚Å‚ ‚Á‚½VSD, PA‚Ì1—áB‘æ14‰ñ“ú–{Pediatric Interventional Cardiology Œ¤‹†‰ï,2003,1,‘åã.
    3. “ñ’J@•C”ª–ØMˆêCÄ“¡@Ž C“‡@—FŽqC²X–Ø‘×C•l“¹—T“ñCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽF“–‰@NICU‚É‚¨‚¯‚éæ“V«SŽ¾Š³”À‘——á‚ÌŒŸ“¢`“KØ‚È”À‘—‚ª‚È‚³‚ê‚Ä‚¢‚é‚©`‘æ6‰ñ•xŽRŒ§•êŽqˆã—ÃŒ¤‹†‰ï,2003,1,•xŽR.
    4. “n粈»‰ÀC“n•Óˆê—mCà_“¹—S“ñCŽs“c•™ŽqC‹{˜e—˜’jC“¡–Ø–õŽqCƒj’J@•CŠp’JŽûŽqC¼ŽR—æ“ÞC“à@®ŽqC•Ä“c@“NC²X–Ø‘×CŽðˆä³—˜CâV“¡@Ž C“»@³‹`C“‡’ÃeŽuC‘哈‹`”ŽCŽOè‘ñ˜YF‘ÙŽ™Šú‚æ‚èŒo‰ßŠÏŽ@‚µ‚½‘“®–¬Š²ˆâŽc‚̈ê—áB‘æ9‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŒ¤‹†‰ï,2003,2,•ºŒÉ.
    5. “¡–Ø–õŽqC“n•Óˆ»‰ÀC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jFƒpƒ‹ƒ{ƒEƒCƒ‹ƒXB19Š´õ‚É‚æ‚茌¬”ÂŒ¸­‚È‚ç‚Ñ‚ÉD’†‹…Œ¸­‚𗈂µ‚½‚P’jŽ™—áB‘æ‚V‰ñŒŒ‰tŽ¾Š³‚ƃTƒCƒgƒJƒCƒ“Œ¤‹†‰ï,2003,2,‹à‘ò.
    6. Œ´ˆä•ü”üC“¡–Ø–õŽqC“n•Óˆ»‰ÀC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jCˆÀ‘º²“s‹IC‰–“cà ŽqCŒF’J¹–¾CP¼—R‹LŽqF•›•@oŒ´”­‚Ì Ewing/PNET Žîᇂ̂P—áB‘æ18‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ï,2003,2,‹à‘ò.
    7. ”‘òŽõŽqC’†—ÑŒºˆêC•£‘ò—³–çCà_“¹”ü‹IC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jFH•¨ƒAƒŒƒ‹ƒM[Ž™‚É‚¨‚¯‚é’P‹…IL-12ŽY¶”\‚ɂ‚¢‚ÄB‘æ3‰ñH•¨ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2003,2,“Œ‹ž.
    8. ‘«—§—zŽqC”‘òŽõŽqC‘«—§—YˆêC‹{˜e—˜’jC”öã—mˆêC‘ºãIŒ[F•xŽRŒ§‚Ì—c’t‰€E•Ûˆç‰€‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éHŽ–Žw“±‚ÌŽÀ‘ÔB‘æ3‰ñH•¨ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2003,2,“Œ‹ž.
    9. Itazawa T., Adachi Y., Adachi YS., Yamamoto J., Hamamichi M., Murakami G., and Miyawaki T.: Virus infection reduces theophylline metabolism in acute asthma: Increased lymphoid MxA protein as a marker for viral infection. 60th annivers-ary meeting of American academy of allergy, asthma and Immunology,2003,3,Denver,USA.
    10. ”ÂàVŽõŽqCà_“¹”ü‹ICŽíŽsq’ˆCŽRŒ³ƒŽqC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jC‘ºãIŒ[Fšb‘§”­ìŽž‚̃EƒCƒ‹ƒXŠ´õ‚ªƒeƒIƒtƒBƒŠƒ“‘ãŽÓ‚É‹y‚Ú‚·‰e‹¿|MxA’`”’‚ðŽw•W‚Æ‚µ‚Ä|B‘æ24‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2003,3,•xŽR.
    11. –쑺ŒbŽqC‘å’ØŒc•ãC‹{@ˆêŽuC‹àŒ“O˜aC‹{˜e—˜’jFHLA1À•sˆê’v‚Ì•êe‚æ‚蓯Žíœ‘ˆÚA‚ðs‚Á‚½Ž¡—Ê֘Aœ‘ˆÙŒ`¬ÇŒóŒQ‚Ì‚P—áB‘æ277‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,2003,3,‹à‘ò.
    12. “ñ’J@•C”ª–ØMˆêCÖ“¡@Ž C‹g“cärCà_“¹—T“ñCŽs“c•™ŽqC‹{˜e—˜’jCˆÉ“¡–õ“TC”¨èŠì–FF•xŽRŒ§‚É‚¨‚¯‚éæ“V«SŽ¾Š³”À‘——á‚ÌŒŸ“¢B‘æ277‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,2003,3,‹à‘ò.
    13. –{‹½˜a‹vC‹{@ˆêŽuC‰eŽR—²ŽiC“c’‡çHC¼‘òƒŽqCŽR’J”ü˜aC”ª–ØMˆêC‹{˜e—˜’jF“–‰È‚ÅŒoŒ±‚µ‚½ESESÇŒóŒQ‚Ì‚R—áB‘æ27‰ñ–k—¤‚Ä‚ñ‚©‚ñŒ¤‹†‰ï,2003,3,‹à‘ò.
    14. Hashimoto I., Barber B.J., Coffman J.E., Li X., and Sahn D.J. : Myocardial strain rate is a superior method for evaluation of left ventri-cular subendocardial function compared to TDI. The 52nd annual scientific session of American college of cardiology,2003,4,Chicago.
    15. Hashimoto I., Hejmadi A., Li X., Barber B.J., Jones M., and D. J. Sahn.: Quantitative assess-ment of regional peak myocardial acceleration during Isovolumic contraction and relaxation time by tissue doppler imaging. The 52nd annual scientific session of American college of cardiology,2003,4,Chicago.
    16. Kanegane H., and Miyawaki T.: Epstein-Barr virus infection and lymphoproliferative syndro-mes of genetic origin. The international sympo-sium on infection and immunity in childhood,2003,4,Fukuoka.
    17. –{‹½˜a‹vC‹{@ˆêŽuC“c’‡çHC¼‘òƒŽqC‰eŽR—²ŽiCŽR’J”ü˜aC”ª–ØMˆêC‹{˜e—˜’jFƒsƒŠƒhƒLƒVƒ“ˆË‘¶«áz¹‚Ì”]”gŠŒ©B‘æ106‰ñ“ú–{¬Ž™‰ÈŠw‰ï‘‰ï,2003,4,•Ÿ‰ª.
    18. ”ÂàVŽõŽqCà_“¹”ü‹ICŽíŽsq’ˆC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jCŽRŒ³ƒŽqC‘ºãIŒ[Fšb‘§”­ìŽž‚̃EƒCƒ‹ƒXŠ´õ‚ªƒeƒIƒtƒBƒŠƒ“‘ãŽÓ‚É‹y‚Ú‚·‰e‹¿|MxA’`”’‚ðŽw•W‚Æ‚µ‚Ä|B‘æ106‰ñ“ú–{¬Ž™‰ÈŠw‰ï‘‰ï,2003,4,•Ÿ‰ª.
    19. “n•Óˆ»‰ÀC“n•Óˆê—mCœA–ìŒbˆêC㨌hˆê˜YC•l“¹—T“ñC‹´–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽFSŠïŒ`‚ð‡•¹‚µ‚½S‹Øãk–§‰»áŠQ‚Ì—Õ°‘œ‚ÌŒŸ“¢B‘æ106‰ñ“ú–{¬Ž™‰ÈŠw‰ï‘‰ï,2003,4,•Ÿ‰ª.
    20. •l“¹—T“ñC‹´–{ˆè•vC–ìŒû@‹žC“n•Óˆ»‰ÀC“n•Óˆê—mCL–ìŒbˆêC㨌hˆê˜YCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽFƒtƒ@ƒ[Žl’¥ÇpŒã‰“ŠuŠú‚É‚¨‚¯‚é”x“®–¬•Ù‹t—¬’è—ʉ»‚ÌŽŽ‚ÝB‘æ106‰ñ“ú–{¬Ž™‰ÈŠw‰ï‘‰ï,2003,4,•Ÿ‰ª.
    21. ‹´–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jCD. J SahnF‘gDƒhƒbƒvƒ‰[‰Á‘¬“x‰ðÍ‚ð—p‚¢‚½¶ŽºS‹@”\‚̉ðÍB‘æ14‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ï,2003,4,_ŒË.
    22. ‹{@ˆêŽuC‘å’ØŒc•ãC•£‘ò—³–çCFè@Œ’C‰eŽR—²ŽiC“c’‡çHC–{‹½˜a‹vC”ª–ØMˆêC‹{˜e—˜’jF”]‰ŠŒã‚Ì‘J‰„«ˆÓŽ¯áŠQ‚ɑ΂µ‚ÄTRH—Ö@‚ªŒø‰Ê‚ð”F‚ß‚½ˆê—áB‘æ45‰ñ“ú–{¬Ž™_ŒoŠw‰ï‘‰ï,2003,5,•Ÿ‰ª.
    23. ‰eŽR—²ŽiC‹{@ˆêŽuC“c’‡çHC¼‘òƒŽqC–{‹½˜a‹vCŽR’J”ü˜aC”ª–ØMˆêC‹{˜e—˜’jFHHV-6”]‰Š‚Ì—Õ°Šw“I“Á’¥‚ÉŠÖ‚·‚錟“¢B‘æ45‰ñ“ú–{¬Ž™_ŒoŠw‰ï‘‰ï,2003,5,•Ÿ‰ª.
    24. –{‹½˜a‹vC‹{@ˆêŽuC“c’‡çHC¼‘òƒŽqC‰eŽR—²ŽiCŽR’J”ü˜aC”ª–ØMˆêC‹{˜e—˜’jF–ƉuƒOƒƒuƒŠƒ“—Ö@‚ª‘tŒ÷‚µ‚½”]‰ŠŒã‚Ä‚ñ‚©‚ñ‚̈ê—áB‘æ45‰ñ“ú–{¬Ž™_ŒoŠw‰ï‘‰ï,2003,5,•Ÿ‰ª.
    25. “c’‡çHC‹{@ˆêŽuC‰eŽR—²ŽiCŒIŒ´^‹IŽqC¼‘òƒŽqC–{‹½˜a‹vCŽR’J”ü˜aC”ª–ØMˆêC¼ˆäŽOŽ}C¬¼@“OC‹{˜e—˜’jF“û—cŽ™Šú‚©‚çŽvtŠú‚É‚¨‚¯‚錒픭’B”]‚Ì‚l‚q‚h‚É‚æ‚錟“¢B‘æ45‰ñ“ú–{¬Ž™_ŒoŠw‰ï‘‰ï,2003,5,•Ÿ‰ª.
    26. ’†“c@–FC–L“c‰ë•FC”‹´³ºC‘«—§—YˆêF“«‰~Œ`’E–ÑÇ‚ÌŽo–…—áD‘æ27‰ñ“ú–{¬Ž™”畆‰ÈŠw‰ï,2003,6,“Œ‹ž.
    27. ŽRŒ³ƒŽqCà_“¹”ü‹IC‘«—§—zŽqC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jF—cŽ™‚É‚¨‚¯‚éƒhƒ‰ƒCƒpƒEƒ_[‹z“ü”\—Í‚ÌŒŸ“¢|‹z“ü—¬‘¬‚Ì‘ª’è‚ð—p‚¢‚Ä|B‘æ20‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ïC2003,6,’Ã.
    28. ‘«—§—zŽqC”ÂàVŽõŽqC‘«—§—YˆêC‹{˜e—˜’jC”öã—mˆêC‘ºãIŒ[F—cŽ™‚É‚¨‚¯‚é‹z“ü—¬‘¬‚Ì‘ª’è|ƒhƒ‰ƒCƒpƒEƒ_[‚Ì‹z“ü‰Â”\”N—î‚ÌŒŸ“¢|B‘æ15‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,2003,5,‰¡•l.
    29. ŽRŒ³ƒŽqC’Ô¦áÁˆêC‘ºãIŒ[C–{ŠÔˆê³CFè@Œ’C‘«—§—YˆêFƒCƒl‰È‰Ô•²šb‘§‚ª‹^‚í‚ꂽ‚P—áB‘æ15‰ñ‰Ô•²ÇŒ¤‹†‰ï,2003,5,•xŽR.
    30. ‹àŒ“O˜aFƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‚ª‚ñ‚̈â“`“I”wŒiv‚킪‘‚É‚¨‚¯‚é‚w˜A½ƒŠƒ“ƒp‘BÇŒóŒQ‚Ì—Õ°‚ƈâ“`ŽqŒ¤‹†‰ðÍB‘æ‚X‰ñ‰Æ‘°«Žîᇌ¤‹†‰ï,2003,6,“Œ‹ž.
    31. ‹àŒ“O˜aF“Á•Êu‰‰u–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ìf’f‚ÆŽ¡—ÃBv‘æ22‰ñŽ ‰êŒŒ‰tŽ¾Š³Œ¤‹†‰ï,2003,6,Ž ‰ê.
    32. ‹´–{ˆè•vC㨌hˆê˜YC“n•Óˆ»‰ÀC“n•Óˆê—mCL–ìŒbˆêCŽs“c•™ŽqC‹{˜e—˜’jCD.J. SahnFƒXƒgƒŒƒCƒ“ƒŒ[ƒgƒCƒ[ƒWƒ“ƒO–@‚ð—p‚¢‚½¶ŽºS“à–Œ‰ºS‹Ø‘w‚Ì‹@”\•]‰¿B‘æ10‰ñ–k—¤zŠÂŠí’´‰¹”gŒ¤‹†‰ï,2003,6,‹à‘ò.
    33. ‹àŒ“O˜aF“Á•Êu‰‰u–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ìf’f‚ÆŽ¡—Ãv‘æ61‰ñ—Õ°¬Ž™Œ¤‹†‰ï,2003,7,é‹Ê.
    34. ‹àŒ“O˜aF“Á•Êu‰‰u–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ìf’f‚ÆŽ¡—Ãv‘æ64‰ñé‹Ê¬Ž™ŒŒ‰t“¯D‰ï,2003,7,é‹Ê.
    35. ‹´–{ˆè•vC“n•Óˆê—mC“n•Óˆ»‰ÀCL–ìŒbˆêC㨌hˆê˜YC•l“¹—T“ñCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽCD.J. SahnF‘ÙŽ™•s®–¬f’f‚É‚¨‚¯‚éƒXƒgƒŒƒCƒ“ƒŒ[ƒg–@‚Ì—L—p«B‘æ39‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2003,7,_ŒË.
    36. —t@”òC“n•Óˆê—mC“n•Óˆ»‰ÀCL–ìŒbˆêC㨌hˆê˜YC‹´–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jCFoell D.CRoth J.Fìè•a‹}«Šú‚É‚¨‚¯‚錌´’†S100A12‚Ì“®‘ÔB‘æ39‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2003,7,_ŒË.
    37. “n•Óˆ»‰ÀC‹´–{ˆè•vC“n•Óˆê—mCL–ìŒbˆêC㨌hˆê˜YC•l“¹—T“ñCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽFŒ’í¬Ž™‚É‚¨‚¯‚鶎ºS‹Ød—Ê‚Ì‘‰Á‚ª¶Žº“àŒŒ—¬“`”À‘¬“xflow propagation velocity‚É—^‚¦‚é‰e‹¿‚ɂ‚¢‚ÄB‘æ39‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2003,7,_ŒË.
    38. ‹´–{ˆè•vC“n•Óˆê—mC“n•Óˆ»‰ÀCL–ìŒbˆêC㨌hˆê˜YC•l“¹—T“ñCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽCD.J. SahnF‘gDƒhƒvƒ‰‰Á‘¬“x‰ðÍ‚ð—p‚¢‚½¶ŽºS‹@”\‚̉ðÍB‘æ39‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2003,7,_ŒË.
    39. ‹´–{ˆè•vC“n•Óˆê—mC“n•Óˆ»‰ÀCL–ìŒbˆêC㨌hˆê˜YC•l“¹—T“ñCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽCD.J. SahnFƒXƒgƒŒƒCƒ“ƒŒ[ƒg–@‚ð—p‚¢‚½¶ŽºS“à–Œ‰ºS‹Ø‚Ì‹@”\‰ðÍB‘æ39‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2003,7,_ŒË.
    40. “n•Óˆê—mCŒ´ˆä•ü”üC“n•Óˆ»‰ÀCL–ìŒbˆêC㨌hˆê˜YC•l“¹—T“ñC‹´–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽFæ“V«SŽ¾Š³‚ɇ•¹‚µ‚½dÇRSƒEƒBƒ‹ƒXŠ´õ‚Ì2—á`ƒpƒŠƒrƒYƒ}ƒu‚Ì“K‰žŠg‘å‚ÉŒü‚¯‚Ä`B‘æ39‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2003,7,_ŒË.
    41. ˆÉ“¡G˜aC‘«—§—YˆêC‹{˜e—˜’jC‹g“cärC“ñ’J@•FV¶Ž™‘Šú‚æ‚è”­Ç‚µ‚½ƒ~ƒ‹ƒNƒAƒŒƒ‹ƒM[‚̈ê—áB‘æ39‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2003,8,¼–{.
    42. âV“¡˜a—RC‹g“cärCóˆä³ŽkC’Ô¦áÁˆêC”öã—mˆêC‘«—§—YˆêC‹{˜e—˜’jF“–‰È‚ÅŒoŒ±‚µ‚½Plastic Bronchitis‚Ì2—áB‘æ39‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2003,8,¼–{.
    43. –{ŠÔ@mC‘«—§—zŽqC“¡–Ø–õŽqC“n•Óˆ»‰ÀC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jCœAìTˆê˜YF“–‰È‚ÅŒoŒ±‚µ‚½Malignant rhabdoid tumor of the kidney(MRTK)‚Ì2—áB‘æ39‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2003,8,¼–{.
    44. ‹àŒ“O˜aCˆÉ“¡”\´C‘哇FˆêC–쑺ŒbŽqC‹{˜e—˜’jF‚킪‘‚Ì‚w˜A½ƒŠƒ“ƒp‘BÇŒóŒQ‚É‚¨‚¯‚é—Õ°•a—Šw“I“Á’¥B‘æ65‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï,2003,8,‘åã.
    45. –쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jFŒ‹ß«g”Á‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚½Žá”N«–«œ‘«”’ŒŒ•a‚Ì‚Q—áB‘æ65‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï,2003,8,‘åã.
    46. ŽRŒ³ƒŽqC’Ô¦áÁˆêC‘ºãIŒ[C–{ŠÔˆê³CFè@Œ’C‘«—§—YˆêFƒCƒl‰È‰Ô•²šb‘§‚Ì‚P—áB‘æ‚U‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2003,9,•xŽR.
    47. ˆÉŒ\“ñ˜YC“ŒŽROKC“¡–Ø–õŽqC‰eŽR—²ŽiCrˆä”ü˜aŽqC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jCœAìTˆê˜YC¼‘q—TŠìF“§Í‚ð•K—v‚Æ‚µ‚½•ÐtŒ´”­‚ÌWilmsŽîᇂ̈ê—á,‘æ19‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ï,2003,9,‹à‘ò.
    48. ˆÉŒ\“ñ˜YC“ŒŽROKC“¡–Ø–õŽqC‰eŽR—²ŽiCrˆä”ü˜aŽqC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jCœAìTˆê˜YC¼‘q—TŠìF“§Í‚ð•K—v‚Æ‚µ‚½•ÐtŒ´”­‚ÌWilmsŽîᇂ̈ê—áB‘æ33‰ñ•xŽRŒ§tŽ¾Š³ElH“§ÍŒ¤‹†‰ï,2003,9,•xŽR.
    49. ˆÉ“¡G˜aCâV“¡˜a—RC”ÂàVŽõŽqC–쑺ŒbŽqC‹àŒ“O˜aC–{‹½˜a‹vC‹{˜e—˜’jF‰E㉺Žˆ‚Ì•sˆÓ‰^“®‚ÆŽvtŠú‘”­Ç‚ðŒ_‹@‚Éf’f‚³‚ꂽ‚g‚b‚fŽY¶”]ŽîᇂÌ1—áB‘æ27‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï,2003,9,‹à‘ò.
    50. ‘«—§—zŽqC”ÂàVŽõŽqC‘«—§—YˆêCŽRŒ³ƒŽqC”öã—mˆêC‘ºãIŒ[C‹{˜e—˜’jFH•¨ƒAƒŒƒ‹ƒM[Ž™‚ÌH•¨§ŒÀ‚ɂ‚¢‚Ă̈ãŽt‚̑Ήž‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²¸Œ‹‰ÊB‘æ53‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï,2003,10,Šò•Œ.
    51. ”ÂàVŽõŽqC‘«—§—zŽqC’†—ÑŒºˆêC•£‘ò—³–çCà_“¹”ü‹IC‘«—§—YˆêC‹{˜e—˜’jF¬Ž™šb‘§‚É‚¨‚¯‚éƒtƒ‹ƒ`ƒJƒ]ƒ“‚Ì—LŒø«|ƒxƒNƒƒƒTƒ]ƒ“‚©‚ç‚̈Ús—á‚É‚¨‚¯‚éŒo‰ß|B‘æ53‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï,2003,10,Šò•Œ.
    52. ŒÜ\—’—²•vC¼–ì³’mCˆÉ“Œ“¹•vC‘ºãIŒ[C‘«—§—YˆêC‘«—§—zŽqC”öã—mˆêFDSCG‹z“ü—Ö@‚â‹z“üƒXƒeƒƒCƒh—Ö@‚Íšb‘§Ž™‚̃Cƒ“ƒtƒ‹ƒGƒ“ƒUœëŠ³—¦‚ɉe‹¿‚ð‹y‚Ú‚·‚©B‘æ53‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï,2003,10,Šò•Œ.
    53. ŒÜ\—’—²•vC¼–ì³’mCˆÉ“Œ“¹•vC‘ºãIŒ[C‘«—§—YˆêC‘«—§—zŽqC”öã—mˆêF¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚̃qƒXƒ^ƒ~ƒ“‹z“ü臒l‚Æ”ˆöŽq‚Æ‚ÌŠÖ˜A‚ɂ‚¢‚ÄB‘æ53‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï,2003,10,Šò•Œ.
    54. –{ŠÔ@mC‘«—§—zŽqCà_“¹”ü‹IC’†—ÑŒºˆêC•£‘ò—³–çC“yŠò‘P‹IC‘«—§—YˆêC‹{˜e—˜’jFdÇšb‘§”­ì‚É”^‹¹‚𕹔­‚µ‚½‚P’jŽ™—áB‘æ40‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2003,10,Šò•Œ.
    55. ŒÜ\—’—²•vC¼–ì³’mCˆÉ“Œ“¹•vC‘ºãIŒ[C‘«—§—YˆêC‘«—§—zŽqC”öã—mˆêF‹CŠÇŽxšb‘§Š³ŽÒ‚Ì•@”S–Œ×–Ef‚Í‹C“¹‰ŠÇ‚ÌŽw•W‚ƂȂ肤‚é‚©B‘æ40‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2003,10,Šò•Œ.
    56. ”ÂàVŽõŽqC‘«—§—YˆêCˆÉ“Œ“¹•vC¼–ì³’mCŽRŒ³ƒŽqC‘ºãIŒ[CŒÜ\—’—²•vC‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚¨‚¯‚éDSCG + procaterol‚ÆDSCG’P“Æ‚Ì’èŠú‹z“ü—Ö@‚Ì’·ŠúŒø‰ÊB‘æ40‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2003,10,Šò•Œ.
    57. ‹àŒ“O˜aFŽw’艉‘èuNonanÇŒóŒQ‚ÆŽá”N«œ‘’P‹…«”’ŒŒ•aBv‘æ26‰ñ“ú–{¬Ž™ˆâ“`Šw‰ïŒ“‘æ‚R‰ñ—Õ°ˆâ“`Œ¤‹†‰ï,2003,10,’·è.
    58. –¼‘q—¢DC‘å‚TŒáC“y”ì‹`˜YC‘哈‹`”ŽCŽOè‘ñ˜YCÄ“¡˜a—RC²X–Ø‘×C‹g“cärC“ñ’J@•C‹´–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jFTwo ventricular repair‚ðŽ{s‚µ‚½¶S’áŒ`¬ÇŒóŒQ(COA, SAS, MS, ASD)‚̈ê—áB‘æ3‰ñ•xŽR¬Ž™zŠÂŠíŒ¤‹†‰ï,2003,10,•xŽR.
    59. “n•Óˆê—mC“n•Óˆ»‰ÀC‘å’ØŒc•ãCœA–ìŒbˆêC㨌hˆê˜YC“ñ’J@•C‹´–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC“y”ì‹`˜YC“‡’ÃeŽuC‘哈‹`”ŽCŽOè‘ñ˜YF“ûŽ™‘Šú‚ÉŒJ‚è•Ô‚µŒa”ç“I‘å“®–¬•ÙŒ`¬p‚ðŽ{s‚µ‚½‘å“®–¬‹|—£’f‚Ì1—áB‘æ3‰ñ•xŽR¬Ž™zŠÂŠíŒ¤‹†‰ï,2003,10,•xŽR.
    60. “n•Óˆ»‰ÀCŒ´ˆä•ü”üC“n•Óˆê—mCœA–ìŒbˆêC㨌hˆê˜YC‹´–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC“y”ì‹`˜YC“‡’ÃeŽuC‘哈‹`”ŽCŽOè‘ñ˜YC•x“c‰pF—¼‘¤”x“®–¬‹·ó‚ɑ΂µƒXƒeƒ“ƒg—¯’u‚ðŽ{s‚µ‚½‘“®–¬Š²ˆâŽc‚Ì1—áB‘æ3‰ñ•xŽR¬Ž™zŠÂŠíŒ¤‹†‰ï,2003,10,•xŽR.
    61. ‹àŒ“O˜aC–쑺ŒbŽqC˜`@˜a”üC•l–{˜aŽqC“¿ŽR”üC¬’r˜arC‹{‘º”\ŽqC‰Í@Œh¢C‰ª–{”ü•äC•Ÿ“‡@ŒhC‹{˜e—˜’jFX˜A½ƒŠƒ“ƒp‘BÇŒóŒQ‚Ìf’f‚Æ‘¢ŒŒŠ²×–EˆÚAB‘æ45‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2003,10,‹à‘ò.
    62. –쑺ŒbŽqC”\“o‹M‹vC‹àŒ“O˜aC‹{˜e—˜’jFSƒ^ƒ“ƒ|ƒi[ƒf‚Å”­Ç‚µ‚½ˆ««ƒŠƒ“ƒpŽî‚̈ê—áB‘æ45‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2003,10,‹à‘ò.
    63. ŽíŽsq’ˆC‹àŒ“O˜aC–쑺ŒbŽqC²“¡—Y–çC¬“‡¨“ñC‰Íè—T‰pC–x@_Ž÷C‰Í“‡®ŽuC’rìŽu˜YC‹{˜e—˜’jF‚킪‘‚Ì Shwachman-Diamond ÇŒóŒQ‚É‚¨‚¯‚é—Õ°“IEˆâ“`Šw“IŒŸ“¢B‘æ45‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2003,10,‹à‘ò.
    64. ‘å’ØŒc•ãC‹g“cärC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jF¶‘̊̈ÚAŒã‚É”­Ç‚µ‚½‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚̈ê—á‘æ45‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2003,10,‹à‘ò.
    65. Ichida F., Foell D., Vogl T., Ye F., Hirono K., Watanabe S., Watanabe K., Uese K., Miyawaki T., and Roth J.: S100A12 (EN-RAGE): A novel serum marker in the monitering of Kawasaki disease. The 76th scientific sessions of American heart association, 2003,11,Orlando.
    66. Hashimoto I., and Ashraf M.: Tissue Doppler derived myocardial acceleration for evaluation of left ventricular diastolic function. The 76th scientific sessions of American heart association,2003,11,Orlando.
    67. Hashimoto I., Coffman J.E., Davis. C.H.: Does color M-mode derived flow propagation velocity reflect actual flow propagation? The 76th scientific sessions of American heart association, 2003,11,Orlando.
    68. ŽíŽsq’ˆA‹àŒ“O˜aA‰¤@‰xA“ñ’J@•A‹{˜e—˜’jFX˜A½–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚Ì—Õ°f’f‚ÉŠÖ‚·‚錟“¢B‘æ35‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,2003,11,•xŽR.
    69. Š¥–Ø’q”VC‰Í‡—˜®C‹à@Œc²Cé@G•ãC‹àŒ“O˜aC‘åÎ@•×FBCGÚŽíŒã‚Ìãü‰ºƒŠƒ“ƒpߎî‘å‚ðŒ_‹@‚ÉíõF‘Ì—ò«Œ^–«“÷‰èŽîÇ‚Æf’f‚³‚ꂽ‚Q—áB‘æ35‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,2003,11,•xŽR.
    70. ”ÂàVŽõŽqC‘«—§—YˆêC”öã—mˆêCŽRŒ³ƒŽqC‘ºãIŒ[C‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚¨‚¯‚éDSCG+procaterol‚ÆDSCG’P“Æ‚Ì’èŠú‹z“ü—Ö@‚Ì’·ŠúŒø‰ÊB‘æ30‰ñ–k—¤ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2003,12,‹à‘ò.
    71. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹CŠÇŽxšb‘§‚ÌŠO—ˆŠÇ—v‘æ36 ‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,2003,11,“¿“‡.
    72. ’†—ÑŒºˆêC‰eŽR—²ŽiC–쑺ŒbŽqC‘«—§—YˆêC‹{˜e—˜’jFŠÔŽ¿«”x‰Š‚ð‡•¹‚µ‚½”畆‹Ø‰Š‚Æl‚¦‚ç‚ê‚éˆê—Ž™—áB‘æ36 ‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,2003,11,“¿“‡.
    73. å@‹v”TC”‘òŽõŽqC–{ŠÔ@mCŒ´ˆä•ü”üC“n•Óˆ»‰ÀC“yŠò‘P‹IC‘«—§—YˆêC‹{˜e—˜’jF1”NŠÔ‚ÅŒoŒ±‚µ‚½”x‰»”^Ç‚Ì3—áB‘æ36 ‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,2003,11,“¿“‡.
    74. Wang Y., Kanegane H., Futatani T., Tsukada S., and Miyawaki T.: Nation-wide survey of X-linked agammaglobulinemia by flow cytometric and mutational analysis. ‘æ33‰ñ“ú–{–ƉuŠw‰ï‘‰ï,2003,12,•Ÿ‰ª.
    75. ŽíŽsq’ˆC‹àŒ“O˜aC‹{˜e—˜’jF‰ä‚ª‘‚ÌSchwachman-Diamond ÇŒóŒQ‚Ì—Õ°“IEˆâ“`“IŒ¤‹†B‘æ11‰ñH×–E‹@”\ˆÙ팤‹†‰ï,2003,12,“Œ‹ž.
    76. ˆÉ“¡G˜aC”ÂàVŽõŽqC–쑺ŒbŽqC‹àŒ“O˜aC–{‹½˜a‹vC‹{˜e—˜’jF‰E㉺Žˆ‚Ì•sˆÓ‰^“®CŽvtŠú‘”­Ç‚Å”­Ç‚µ‚½¶Šî’êŠjgerminoma‚̈ê—áB‘æ279‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,2003,12,•xŽR.

    2002”N

  • ’˜‘
    1. Kanegane H., Futatani T., Nomura K., and Miyawaki T.FGenetic analysis of X-linked agammaglobulinaemia identified by flow cytometric analysis in unrelated 65 Japanese families. uLeucocyte typing VIIvMason D. ed.,129-131, Oxford university press,New York,2002.
    2. Nomura K., Kanegane H., Karasuyama H., and Miyawaki T.: Genetic defect in human X-linked agammaglobulinaemia impedes the maturational evolution of pro-B cells into later stage of pre-B cells in the B-cell differentiation pathway. uLeucocyte typing VIIvMason D. ed.,129-131, Oxford university press,New York,2002.
    3. ‹{˜e—˜’jA‹àŒ“O˜aFæ“V«–Ɖu•s‘Sǂ̈â“`ŽqˆÙíBu–ƉuŽ¾Š³-state of arts Ver.2v¡¼“ñ˜Y‘¼•ÒA477-482AˆãŽ•–òo”ÅA“Œ‹žA2002.
    4. Žs“c•™ŽqFŒÇ—§«S‹Øãk–§‰»áŠQB¬Ž™“à‰È‘Š§u¬Ž™Ž¾Š³f—Â̂½‚ß‚Ì•a‘Ô¶—‚Pv¬Ž™“à‰ÈE¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï•ÒA330-334A“Œ‹žˆãŠwŽÐA“Œ‹žA2002.
    5. Žs“c•™ŽqFS‹ØÇBu¬Ž™‚ÌŽ¡—ÃŽwjv¼”öé•‘¼•ÒA281-283Af’f‚ÆŽ¡—ÃŽÐA“Œ‹žA2002.
    6. Žs“c•™ŽqFŒÇ—§«S‹Øãk–§‰»áŠQBu¡“ú‚̬Ž™Ž¡—ÃŽwjv‘æ13”Å‘åŠÖ••F‘¼•ÒAˆãŠw‘‰@A“Œ‹žA2002.
    7. Žs“c•™ŽqF¬Ž™‚Ì•s®–¬Bu¡“ú‚ÌŽ¡—ÃŽwj@2003”N”ÅvŽRŒû“O‘¼•ÒA903-904AˆãŠw‘‰@A“Œ‹žA2002.
    8. ‹àŒ“O˜aA‹{˜e—˜’jFR‘ÌŽY¶•s‘S‚ðŽå‚Æ‚·‚é–Ɖu•s‘SÇBu¬Ž™‰ÈŠw‘æ‚Q”ÅvˆÉ“¡ŽŒÈ‘¼•ÒA@717-721AˆãŠw‘‰@A“Œ‹žA2002.
    9. ‹àŒ“O˜aA‹{˜e—˜’jFBTKˆÙí‚𔺂í‚È‚¢B×–EŒ‡‘¹Œ^–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇB¬Ž™“à‰È‘Š§u¬Ž™Ž¾Š³f—Â̂½‚ß‚Ì•a‘Ô¶—‚Pv¬Ž™“à‰ÈE¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï•ÒA1126-1130A“Œ‹žˆãŠwŽÐA“Œ‹žA2002.
    10. ‹àŒ“O˜aFŽ©ŒÈ–Ɖu«ƒŠƒ“ƒp‘BÇŒóŒQB¬Ž™“à‰È‘Š§u¬Ž™Ž¾Š³f—Â̂½‚ß‚Ì•a‘Ô¶—‚Pv¬Ž™“à‰ÈE¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï•ÒA1195-1199A“Œ‹žˆãŠwŽÐA“Œ‹žA2002.
  • Œ´’˜
    1. Hamamichi Y., Ichida F., Tsubata S., Uese K., Hashimoto I., Shimizu M., Seto H., and Miyawaki T., Low-dose dobutamine stress radionuclide ventriculography reveals silent myocardial dysfunction in Kawasaki disease. Jpn Circ J 66:63-69,2002.
    2. Hashimoto I., Mori Y., Rusk RA., Davies CH., Li X., Mack GK., and Sahn DJ.: Strain rate imaging: an in vitro "Validation" study using a physiologic balloon model mimicking the left ventricle. Echocardiography. 8:669-77,2002.
    3. Yoshida T., Kanegane H., Osato M., Yanagida M., Miyawaki T., Ito Y., and Shigesada K.: Functional analysis of RUNX2 mutations in Japanese patients with cleidocranial dysplasia demonstrates novel genotype-phenotype correlations. Am. J. Hum. Genet. 71: 724-738,2002.
    4. Shinozaki K., Kanegane H., Matsukura H., Sumazaki R., Tsuchida M., Makita M., Kimoto Y., Kanai R., Tsumura K., Kondoh T., Moriuchi H., and Miyawaki T.: Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection. Int Immunol 14: 1215-1223,2002.
    5. Wang Y., Kanegane H., Sanal O., Tezcan I., Ersoy F., Futatani T., and Miyawaki T.: Novel Igƒ¿(CD79a) gene mutation in a Turkish patient with B cell-deficient agammaglobulinemia. Am J Med Genet 108: 333-336,2002.
    6. Chen R., Tsuji T., Ichida F., Bowles KR., Watanabe S., Hirono K., Tsubata S., Hamamichi Y., Bowels NE., Miyawaki T., and Towbin JA.: Mutation analysis of the G4.5 gene in patients with isolated left ventricular noncompaction. Mol Genet Metab 77: 319-325,2002.
    7. Tani S. M., Wang Y., Kanegane H., Futatani T., Pinto J., Viela M. M.S., and Miyawaki T.: Identification of mutations of Bruton's tyrosine kinase gene (BTK) in Brazilian patients with X-linked agammagulobulinemia. Hum Mutat 531 : 195-205,2002.
    8. Otto F., Kanegane H., and Mundlos S.: Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Hum Mutat 19: 209-216,2002.
    9. Kawai S., Minegishi M., Ohashi Y., Sasahara Y., Kumaki S., Konno T., Miki H., Derry J., Nonoyama S., Miyawaki T., Horibe K., Tachibana N., Kudoh E., Yoshimura Y., Izumikawa Y., Sako M., and Tsuchiya S.: Flow cytometric determination of intracyto-plasmic Wiskott-Aldrich syndrome protein in peripheral blood lymphocyte subpopulations. J Immunol Method 260: 195-205,2002.
    10. Inaba K., Miyawaki T., Longnecker R., Matsukura H., Tsukada S., and Kurosaki T.: Bruton's tyrosine kinase regulates B cell antigen receptor-mediated JNK1 response through Rac1 and phospholipase C-ƒÁ2 activation. FEBS Lett 13 : 260-262,2002.
    11. Morikawa K., Morikawa S., Nakamura M., and Miyawaki T.: Characterization of granulocyte colony-stimulating factor receptor expressed on human lymphocytes. Brit J Haematol 118 : 296-304,2002.
    12. Agematsu K., Futatani T., Hokibara S., Kobayashi N., Takamoto M., Tsukada S., Suzuki H., Koyasu S., Miyawaki T., Sugane K., Komiyama A., and Ochs HD.: Absence of memory B cells in patients with common variable immunodeficiency. Clin Immunol. 103: 34-42,2002.
    13. Li J., Li X., Mori Y., Rusk RA., Lee JS., Davies CH., Hashimoto I., El-Sedfy GO., Li XN., and Sahn DJ.: Quantification of flow volume with a new digital three-dimensional color Doppler flow approach: an in vitro study. J Ultrasound Med. 12:1303-11,2001.
    14. Li X., Wanitkun S., Li XN., Hashimoto I., Mori Y., Rusk RA., Hicks SE., and Sahn DJ.: Quantification of instantaneous flow rate and dynamically changing effective orifice area using a geometry independent three-dimensional digital color Doppler method: An in vitro study mimicking mitral regurgitation. J Am Soc Echocardiogr. 10:1189-96,2002.
    15. Rein AJ., O'Donnell C., Geva T., Nir A., Perles Z., Hashimoto I., Li XK., and Sahn DJ.: Use of tissue velocity imaging in the diagnosis of fetal cardiac arrhythmias. Circulation.14:1827-33,2002.
    16. ‹àŒ“O˜aF¬Ž™–«Ž¾Š³‚Ì’·ŠúŒo‰ß‚ƃPƒAF¬ˆçˆã—Â̎‹“_‚©‚çB–ƉuŽ¾Š³B“ú–{¬Ž™‰ÈŠw‰ïŽGŽ@106F1589-1593,2002.
    17. ‹àŒ“O˜aFX-linked lymphoproliferative syndrome. “ú–{—Õ°–ƉuŠw‰ï‰ïŽ 25F129-134,2002.
    18. ‹àŒ“O˜aA–쑺ŒbŽqA“ñ’J@•A‹{˜e—˜’jF‚w˜A½–³ƒÁ-ƒOƒƒuƒŠƒ“ŒŒÇ‚É‚¨‚¯‚éƒÁ-ƒOƒƒuƒŠƒ“’uŠ·—Ö@B“ú–{—Õ°–ƉuŠw‰ï‰ïŽ 25F337-343,2002.
    19. ‹àŒ“O˜aA–쑺ŒbŽqAŠ}Œ´‘PmA‰ª‘º@ƒA–{‹½‹P–¾A–î•”‚Ý‚Í‚éA¬“‡¨“ñA‹S“ª•qKA‹{˜e—˜’jFDyskeratosis congenita‚É‚¨‚¯‚éDKC1ˆâ“`Žq‰ðÍB“ú–{¬Ž™ŒŒ‰tŠw‰ïŽGŽ@16F78-83,2002.
    20. ‹g“cärA‹àŒ“O˜aAŽª“c–F’jAˆÉ“¡‘P–çA‰iˆä•q˜YA–î–ìŒöˆêA“c’†—tŽqA¼Šª@Ž AŽR씎ŽqAŽ›–{’mŽjA‹ÊˆäLÆA•Sˆä@‹œA‘å‹´”Ž•¶A¼@”ü˜aAâV“¡–œ—¢ŽqA‹{˜e—˜’jF‚킪‘‚É‚¨‚¯‚齜“ªŠWˆÙŒ`¬Ç‚Ì—Õ°“IEˆâ“`Šw“IŒŸ“¢B“ú–{¬Ž™‰ÈŠw‰ïŽGŽ@105F442-447,2001. i2002”N“xƒtƒFƒ[ƒVƒbƒvƒAƒ[ƒhŽóÜj
  • Ç—á•ñ
    1. Matsukura H., Shinozaki K., Kageyama R., Yagi S., and Miyawaki T.: Acute poststreptococcal glomerulonephritis in a child Bardet-Biedl syndrome. Pediatr Nephrol 17: 70,2002.
    2. Kageyama R., Matsuzawa J., Hongo K., Yamatani M., Yagai S., Miyawaki T., and Konishi T.: Rashes, agranulocytosis, and hypogamma-globulinemia after carbamazepine therapy. Epilepsia 43 67,2002.
    3. Hirata D., Nara H., Inaba T., Muroi R., Kanegane H., Miyawaki T., Okazaki H., and Minota S.: von Recklinghausen disease in a patients with X-linked agammaglobulinemia. Internal Med. 41: 1039-1043,2002.
    4. Katamura K., Hattori H., Kunishima T., Kanegane H., Miyawaki T., and Nakahata T.: Non-progressive viral myelitis in X-linked agammaglobulinemia. Brain Dev-JPN 24 : 109-111,2002.
    5. –î–ìŒöˆêA‹g“cärA‹àŒ“O˜aA‰ª–{”N’jA‘哇”ü•ÛA²X–زA™–{¹–çA•Ð–ìr‰pA‘ë–{¹rFCore binding factor ƒ¿1 (CBFA1) ˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚½½œ“ªŠWˆÙŒ`¬Ç (Cleidocranial dysplasia) ‚Ì•êŽq—áBƒzƒ‹ƒ‚ƒ“‚Æ—Õ° 49F145-148,2001.
  • ‘à
    1. Kanegane H., Nomura K., Miyawaki T., and Tosato G.: Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies. Crit Rev Oncol Hematol. 44: 239-249,2002.
    2. ‹{˜e—˜’jFautoimmune-lymphoproliferativeÇŒóŒQ(ALPS)Bu¬Ž™‚ÌÇŒóŒQv¬Ž™‰Èf—Ã(‘)64F319,2001.
    3. Žs“c•™ŽqFŒÇ—§«S‹ØS‹Øãk–§‰»áŠQBS‘Ÿ@34: 139-141, 2002.
    4. Žs“c•™ŽqFæ“V«SŽ¾Š³‚Ìf’f‚ÆŽ¡—Ã`‘ÙŽ™f’f‚©‚çV¶Ž™‘ŠúŽ¡—ÂɌü‚¯‚Ä`@“ú–{ŽY•wl‰ÈŠw‰ï•xŽR’n•û•”‰ïŽGŽA70-74,2002.
    5. ‹àŒ“O˜aFŽ©ŒÈ–Ɖu‚ƃAƒ|ƒg[ƒVƒXB¬Ž™“à‰È34F1795-1798,2002.
    6. ”ÂàVŽõŽqA‘«—§—YˆêA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§‚ƃEƒCƒ‹ƒXŠ´õÇ‚ÌŠÖŒWBƒAƒŒƒ‹ƒM[‰È@13F322-328,2002.

  • 2002”NŠw‰ï•ñ
    1. à_“¹—T“ñA㨌hˆê˜YAL–ìŒbˆêA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’j, “ñ’J@•A“ŒŽROKA”ª–ØMˆêA²X–Ø‘×A“‡’ÃeŽuA‘哈‹`”ŽAŽOè‘ñ˜YFƒRƒCƒ‹Çðp‚ðŽ{s‚µ‚½ScimitarÇŒóŒQ‚ÌV¶Ž™—áB‘æ13‰ñ“ú–{Pediatric Interventional Cardiology Œ¤‹†‰ï,2002,1,“¿“‡.
    2. ‘«—§—YˆêF‘åŠwŒ¤‹†ŽºƒŒƒ|[ƒguƒAƒŒƒ‹ƒM[Ž¾Š³‚É‚¨‚¯‚éTh1/Th2ƒoƒ‰ƒ“ƒXvD‘æ12‰ñ“’“cãƒJƒ“ƒtƒ@ƒŒƒ“ƒXšb‘§ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2002,2,VŠƒ.
    3. ˆÉ“¡–õ“TA’†—ÑŒºˆêA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jA‰ª•””üŒbFŒŒ‰tæÃHÇŒóŒQ‚ð‡•¹‚µ‚½anaplastic large cell lymphoma ‚̈ê—áB‘æ‚U‰ñŒŒ‰tŽ¾Š³‚ƃTƒCƒgƒJƒCƒ“Œ¤‹†‰ï,2002,2,‹à‘ò.
    4. ‹´–{ˆè•vAL–ìŒbˆêA㨌hˆê˜YAà_“¹—T“ñA“n•Óˆ»‰ÀAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÃeŽuA‘哈‹`”ŽAŽOè‘ñ˜YFColor M-mode Doppler Echo‚ð—p‚¢‚½”xŒŒ—¬‚Ì•]‰¿B‘æ8‰ñ¬Ž™”xzŠÂŒ¤‹†‰ï,2002,2,“Œ‹ž.
    5. ‹´–{ˆè•vAL–ìŒbˆêA㨌hˆê˜YAà_“¹—T“ñA“n•Óˆ»‰ÀAŽs“c•™ŽqA‹{˜e—˜’jADavid J SahnF‘ÙŽ™•s®–¬f’f‚É‚¨‚¯‚éTissue Doppler Echo–@‚Ì—L—p«‚ɂ‚¢‚ÄB‘æ8‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŒ¤‹†‰ï,2002,2,H“c.
    6. 㨌hˆê˜YAL–ìŒbˆêAà_“¹—T“ñA“n•Óˆ»‰ÀA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÃeŽuA‘哈‹`”ŽAŽOè‘ñ˜YA¬—ÑrŽ÷Fƒtƒ@ƒ[Žl’¥ÇªŽ¡pŒã‚̶”x“®–¬•ªŠò•”‹·ó‚ɑ΂µ‚ăXƒeƒ“ƒg—¯’u‚ðs‚¢ApŒã7”N–ڂɃXƒeƒ“ƒgÄŠg’£‚ðs‚Á‚½1—áB‘æ23‰ñ–k—¤¬Ž™zŠÂŠí§˜b‰ï,2002,2,‹à‘ò.
    7. L–ìŒbˆêA㨌hˆê˜YAà_“¹—T“ñA“n•Óˆ»‰ÀA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÃeŽuA‘哈‹`”ŽAŽOè‘ñ˜YAÄ“¡„ŽA‹v•Û@ŽÀAŠÖ@‰ë”ŽFJatenepŒã10”N–ڂɶ”x“®–¬•ªŠò•”‹·ó‚ɑ΂µ‚ÄŒo”ç“I”x“®–¬Œ`¬p‚ðs‚Á‚½Š®‘S‘匌ŠÇ“]ˆÊÇ‚Ì1—áB‘æ23‰ñ–k—¤¬Ž™zŠÂŠí§˜b‰ï,2002,2,‹à‘ò.
    8. Hashimoto I., Julia C. Swanson-Birchill, Ichida F., Miyawaki T., Crispin H. Davies, David J. Sahn. : The relationship between strain rate values in orthogonal directions. 51th American college of cardiology,2002,3, Anaheim, USA.
    9. ItazawaT., Adachi Y., Onoue Y., Okabe Y., Hamamichi M., Adachi YS., and Miyawaki T.: Developmental change in IL-12 production by monocytes. 58th Annual Meeting of American Academy of Allergy, Asthma and Immunology,2002,3,New York, USA.
    10. Hongou K., Tanaka C., Matsuzawa J., Yamatani M., Yaga S., and Miyawaki T.: Various encephalopathies due to human Herpesvirus-6 infectioni‚Scase reportsj. 5Th Annual Meeting of the Infantile Seizure Society,2002,3,Tokyo.
    11. ‘«—§—zŽqA’†—ÑŒºˆêA•£àV—³–çA”ÂàVŽõŽqA‰¡“cF”VA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[F—c’t‰€E•Ûˆç‰€‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éHŽ–§ŒÀ‚ÌŽÀ‘Ô`•xŽRŒ§‚Å‚Ì’²¸Œ‹‰ÊB‘æ14‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,2002,3,ç—t.
    12. ”ÂàVŽõŽqA•l“¹”ü‹IA‰ª•””üŒbAŽRŒ³ƒŽqA”öã—mˆêA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[FƒAƒŒƒ‹ƒM[Ž¾Š³Š³ŽÒ––½ŒŒ’P‹…‚ÌIL-12ŽY¶”\`”N—î‚É‚æ‚鷈قɂ‚¢‚ÄB‘æ14‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,2002,3,ç—t.
    13. –{‹½˜a‹vA“c’‡çHA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF‘½Ê‚È”­ìÇó‚ð”F‚ß‚½‘O“ª—t‚Ä‚ñ‚©‚ñ‚Ì‚P—áB‘æ26‰ñ–k—¤‚Ä‚ñ‚©‚ñŒ¤‹†‰ï,2002,3,‹à‘ò.
    14. ‹àŒ“O˜aFƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™–«Ž¾Š³‚Ì’·ŠúŒo‰ß‚ƃPƒAF¬ˆçˆã—Â̎‹“_‚©‚çv–ƉuŽ¾Š³B‘æ105‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2002,4,–¼ŒÃ‰®.
    15. Hashimoto I., Hirono K., Watanabe S., Hamamichi Y., Uese K., Ichida F., and Miyawaki T.: Color M-mode propagation velocity of transmitral flow is useful for the assessment of left ventricular diastolic function in children with cardiomyopathy. ‘æ66‰ñ“ú–{zŠÂŠí•aŠw‰ïŠwpW‰ï,2002,4,ŽD–y.
    16. Watanabe S., Ichida F., Hamamichi Y., Rui C., Hirono K., Uese K., Hashimoto I., Miyawaki T., and Jeffrey A. Towbin. : Clinical features of isolated left ventricular noncompaction ~infantile type and juvenile type. ‘æ66‰ñ“ú–{zŠÂŠí•aŠw‰ïŠwpW‰ï,2002,4,ŽD–y.
    17. Rui C., Tsuji T., Ichida F., Karla R. Bowles, Watanabe S., Hirono K., Tsubata S., Hamamichi Y., Miyawaki T., and Jeffrey A. Towbin. : Novel gene mutation in isolated left ventricular noncompaction. ‘æ66‰ñ“ú–{zŠÂŠí•aŠw‰ïŠwpW‰ï,2002,4,ŽD–y.
    18. ‰¤@‰xA‹àŒ“O˜aA“ñ’J@•A‹{˜e—˜’jFMutation analysis of BTK gene in Brazilian patients with presumed XLA. ‘æ105‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2002,4,–¼ŒÃ‰®.
    19. ŒÜ\—’“oA”ž“‡G—YA’Â@Šî–¾A—Sì˜aŽqA‹àŒ“O˜aA’J“à]@ºFƒnƒ“ƒ^[•a(MPSII)’†ŠÔŒ^‚É‚¨‚¯‚é”ñŒŒ‰ŽÒŠÔ“¯Žíœ‘ˆÚA(UR-BMT)Œã‚Q”NŠÔ‚ÌŒo‰ßB‘æ105‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2002,4,–¼ŒÃ‰®.
    20. ”ÂàVŽõŽqA’†—ÑŒºˆêA•£àV—³–çA•l“¹”ü‹IA”öã—mˆêA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[FV¶Ž™‚É‚¨‚¯‚éIL-10AIL-12AIL-18ŽY¶”\‚ÌŒŸ“¢D‘æ105‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2002,4,–¼ŒÃ‰®.
    21. ’†—ÑŒºˆêA‹àŒ“O˜aA–{‹½˜a‹vA”ª–ØMˆêA‹{˜e—˜’jF‘‰t’†EBƒEƒCƒ‹ƒXDNA‚ð“I‚ÉŒoŽž“I‚ÉŠÏŽ@‚µ‚¦‚½EBƒEƒCƒ‹ƒX‰Š´õ‚É‚æ‚é––½_Œo‰Š‚Ì‚P—áB‘æ12‰ñEBƒEƒCƒ‹ƒXŠ´õÇŒ¤‹†‰ï,2002,5,“Œ‹ž.
    22. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€u‹CŠÇŽxšb‘§‚É‚¨‚¯‚é—Šw—Ö@@¬Ž™‰È‚Ì—§ê‚©‚çvB‘æ19‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[Ž¾Š³Šw‰ï,2002,5,‘åãD
    23. ŒIŒ´^‹IŽqA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF”玿Œ`¬ˆÙíǂɇ•¹‚µ‚½‚Ä‚ñ‚©‚ñ‚Ì—Õ°“Á’¥‚ɂ‚¢‚ÄB‘æ34‰ñ“ú–{¬Ž™_ŒoŠw‰ï,2002,6,å‘ä.
    24. •l“¹—T“ñA“n•Óˆ»‰ÀAL–ìŒbˆêA㨌hˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÃeŽuA‘哈‹`”ŽF¬Ž™S‘ŸŽèp‚É‚¨‚¯‚ép’†ŒoH“¹SƒGƒR[‚ÌŒoŒ±B‘æ9‰ñ–k—¤zŠÂŠí’´‰¹”gŒ¤‹†‰ï,2002,6,‹à‘ò.
    25. ‘«—§—YˆêFTh2ƒ}[ƒJ[‚Æ‚µ‚ẴPƒ‚ƒJƒCƒ“Žó—e‘ÌB‘æ1‰ñƒPƒ‚ƒJƒCƒ“R‘̗Ö@Œ¤‹†‰ï,2002,6,“Œ‹ž.
    26. ”‘òŽõŽqAà_“¹”ü‹IA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[F¬Ž™‹CŠÇŽxšb‘§”­ìŽž‚É‚¨‚¯‚éƒEƒCƒ‹ƒXŠ´õ|MxA’`”’‚ðŽw•W‚Æ‚µ‚Ä|D‘æ23‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2002,6,•xŽR.
    27. ŽíŽsq’ˆA–{‹½˜a‹vA”ª–ØMˆêA‹{˜e—˜’jF“Ë”­«”­]ǂɇ•¹‚µ‚½’vŽ€«”]‰Š‚̈ê—áB‘æ16‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï,2002,6,_ŒË.
    28. ”ª–ØMˆêAŽíŽsq’ˆA–{‹½˜a‹vA‹{˜e—˜’jAŽO‰Y@—mF׋۫‘–Œ‰Š‚É‚¨‚¯‚éd–Œ‰º•a•Ï‚ÌŽ¡—Õûj‚ɂ‚¢‚ÄB‘æ16‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï,2002,6,_ŒË.
    29. –쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jCœAìTˆê˜YF_Œo‰èŽîƒ}ƒXƒXƒNƒŠ[ƒjƒ“ƒO‚ÉŠÖ‚·‚éˆêlŽ@B‘æ275‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,2002,6,•Ÿˆä.
    30. Chen R, Tsuji T., Watanabe S.,Tsubata S., Hamamichi Y., Ota J., and Imai Y. : Novel G4.5 gene mutation in the isolated left ventricular noncompaction. ‘æ38‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2002,7,“Œ‹ž.
    31. ‹´–{ˆè•vA“n•Óˆ»‰ÀAL–ìŒbˆêA㨌hˆê˜YA•l“¹—T“ñA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÃeŽuA‘哈‹`”ŽFColor M-mode–@‚É‚æ‚鶎º“àŒŒ—¬“`”À‘¬“x‚ð—p‚¢‚½¶ŽºŠg’£”\‚Ì•]‰¿B‘æ38‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2002,7,“Œ‹ž.
    32. 㨌hˆê˜YA‹´–{ˆè•vA“n•Óˆ»‰ÀAL–ìŒbˆêA•l“¹—T“ñA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÃeŽuA‘哈‹`”ŽFColor M-mode–@‚É‚æ‚é”x“®–¬“àŒŒ—¬“`”À‘¬“x‚ð—p‚¢‚½”x¬ŒŒŠÇ’ïR‚Ì„’èB‘æ38‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2002,7,“Œ‹ž.
    33. •l“¹—T“ñA‹´–{ˆè•vA“n•Óˆ»‰ÀAL–ìŒbˆêA㨌hˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÃeŽuA‘哈‹`”ŽA–ìŒû@‹žFƒtƒ@ƒ[Žl’¥ÇpŒã‰“ŠuŠú‚É‚¨‚¯‚é”x“®–¬•Ù‹t—¬’è—ʉ»‚ÌŽŽ‚ÝB‘æ38‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2002,7,“Œ‹ž.
    34. œA–ìŒbˆêAChen RuiA㨌hˆê˜YA•l“¹—T“ñA“n•Óˆ»‰ÀA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jAFoell Dirk, Roth JohannesFìè•a‹}«Šú‚É‚¨‚¯‚錌´’†MRP 8/MRP 14‚Ì“®‘ÔB‘æ38‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2002,7,“Œ‹ž.
    35. “n•Óˆ»‰ÀA•l“¹—T“ñAœA–ìŒbˆêA㨌hˆê˜YA‹´–{ˆè•vA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jF”­ÇŽžŠú‚É‚æ‚éS‹Øãk–§‰»áŠQ‚Ì—Õ°‘œ‚ÌŒŸ“¢B`‘æ2•ñ`B‘æ38‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2002,7,“Œ‹ž.
    36. ŽRŒ³ƒŽqA’Ô¦áÁˆêA‘ºãIŒ[A–{ŠÔˆê³Aà_“¹”ü‹IA‘«—§—YˆêFŒŒ´KL-6‚ÌŒoŽž“I•Ï‰»‚ð‚Ý‚½–ƒ]”x‰Š‚̈ê—áB‘æ‚X‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2002,7,‚‰ª.
    37. Kanegane H., Shinozaki K., Matsukura H., and Miyawaki T.: Establishment of monoclonal anti-body against SLAM-associated protein and its clinical application to diagnosis of X-linked lymphoproliferative disease. The 29th World congress of the International society of Hematology,2002,8,Seoul.
    38. Adachi Y., Itazawa T., Adachi YS., Yamamoto J., Murakami G., and Miyawaki T.: Viral infection and asthma exacerbation -Increased lymphoid MxA expression as a marker for viral infection-. 4th APAPARI/9thTPAIS/11thPSCAI Joint Meeting,2002,9,Tokyo.
    39. –{‹½˜a‹vA‹{@ˆêŽuA‰eŽR—²ŽiA“c’‡çHAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jFd•¡áŠQ‚ÌŠÇ—-‹CŠÇØŠJ‚ÌŠÇ—-B‘æ42‰ñ–k—¤¬Ž™_Œo,2002,9,‹à‘ò.
    40. –{‹½˜a‹vA‹{@ˆêŽuA‰eŽR—²ŽiA“c’‡çHA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jFRáz¹Ü‚É‚æ‚è”ñáz¹«”­ìdÏó‘Ô‚ª—U”­‚³‚ꂽ‚Æl‚¦‚ç‚ꂽ3—áB‘æ36‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,2002,9,Œyˆä‘ò.
    41. ‰eŽR—²ŽiA‹{@ˆêŽuA“c’‡çHA¼‘òƒŽqA–{‹½˜a‹v@ŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jFAicardi ÇŒóŒQ‚̈ê—áB‘æ36‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,2002,9,Œyˆä‘ò.
    42. ‹{@ˆêŽuA‰eŽR—²ŽiA“c’‡çHA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jFCYP2CƒTƒuƒtƒ@ƒ~ƒŠ[‚̈â“`Žqf’fî•ñ‚ÉŠî‚­ƒtƒFƒjƒgƒCƒ“ŒÂ•Ê“Š—^ÝŒv–@‚Ì•]‰¿B‘æ36‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,2002,9,Œyˆä‘ò.
    43. •l“¹—T“ñA“n•Ó ˆ»‰ÀAœA–ìŒbˆêA㨌hˆê˜YA‹´–{ˆè•vA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jF”­ÇŽžŠú‚É‚æ‚éleft ventricular noncompaction‚Ì—Õ°‘œ‚ÌŒŸ“¢B‘æ50‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï,2002,9,–¼ŒÃ‰®.
    44. •l“¹—T“ñAœA“cŒåŽuA㨌hˆê˜YAš¢Šp•¶GAŒ´•õ“ñAŽs“c•™ŽqFLeft ventricular non-compaction‚̉Ƒ°—ái–UŒŸ—ájB‘æ50‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï,2002,9,–¼ŒÃ‰®.
    45. “n•Óˆ»‰ÀAœA–ìŒbˆêA㨌hˆê˜YAà_“¹—T“ñA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA“»@³‹`A“‡’ÃeŽuA‘哈‹`”ŽAŽOè‘ñ˜YFŠwZS‘ŸŒŸf‚Å”­Œ©‚³‚ꂽBWGÇŒóŒQ‚Ì1—áB‘æ24‰ñ–k—¤¬Ž™zŠÂŠíŒ¤‹†‰ï,2002,9,‹à‘ò.
    46. ‹àŒ“O˜aA˜eŒû@GA–쑺ŒbŽqA‹{˜e—˜’jF–«Šˆ“®«EBƒEƒCƒ‹ƒXŠ´õÇ—lŽ¾Š³‚É‚¨‚¯‚éFas ˆâ“`Žq•ÏˆÙB‘æ64‰ñ“ú–{ŒŒ‰tŠw‰ï,2002,9,‰¡•l.
    47. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jFŒo‰ß’†‚É Histiocytic sarcoma ‚ð‡•¹‚µ‚½ T-ALL ‚̈ê’jŽ™—áB‘æ44‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï,2002,9,‰¡•l.
    48. ‘å’ØŒc•ãA‹{@ˆêŽuA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAˆê–ØŽ”VA“yŠò‘P‹IA‚‹´”Ž”VA‚–ìN—YFHistiocytosis ‚ð‡•¹‚µ‚½cŠuŒ´”­ germ cell tumor ‚Ì‚P’jŽ™—áB‘æ17‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ï,2002,9,‹à‘ò.
    49. Amoras. A.L.B , Kanegane H., Miyawaki T., and Vilela M.M.S. : Defective Fc, CR1 and CR3-mediated monocyte phagocytosis and chemataxis in common variable immunodeficiency and X-linked agammaglobulinemia patients. 10th Meeting of Eur Soc for Immunodeficiencies,2002,10,Weimer,Germany.
    50. Tani S.M., Wang Y., Kanegane H., Futatani T., Pinto J.A., Vilela M.M.S. and Miyawaki T.: Identification of mutations in the Bruton's tyrosine kinase gene of Brazilian patients with X-linked agammaglobulinemia. 10th Meeting of Eur Soc forImmunodeficiencies,2002,10,Weimer,Germany.
    51. Kanegane H., Shinozaki K., Matsukura H., and Miyawaki T.: Establishment of a monoclonal antibody against SLAM-associated protein and its clinical application to the diagnosis of X-linked lymphoproliferative disease. 10th Meeting of Eur Soc for Immunodeficiencies,2002,10,Weimer,Germany.
    52. Kanegane H., Vilela., Matsukura H., Wang Y., Taneichi H., Futatani T., and Miyawaki T.: Glomerulonephritis in autoimmune lympho-proliferative syndrome. 10th Meeting of Eur Soc for Immunodeficiencies,2002,10,Weimer,Germany.
    53. Miyawaki T.: Clinical and molecular diagnosis of hereditary agammaglobulinemia. 2002 International Workshop of Pediatric Infection and @Immunity. 2002,10, Chongqing, China.
    54. Miyawaki T.: Epstein-Barr virus infection and lymphoproliferative syndrome of genetic origins. 2002 International Workshop of Pediatric Infection and Immunity. ,2002,10, Chongqing, China.
    55. Miyawaki T.: Epstein-Barr virus infection and lymphoproliferative syndrome of genetic origins. 2002. National Congress of Pediatric Immunology,2002,10,Haikou, China.
    56. Hashimoto I., Li X., Jones M., Sahn DJ. : Myocardial strain rate is a superior method for evaluation of leftventricular subendocardial function compared to TDI. Cardiac Ultrasound summit,2002,10,Miami,USA.
    57. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€u‹C“¹ƒAƒŒƒ‹ƒM[‚ÌŽ¡—ÃEŠ³ŽÒ‹³ˆçEƒp[ƒgƒi[ƒVƒbƒv‚Ì\’zv‘æ‚X‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2002,10,“ß”eD
    58. –쑺ŒbŽqA‹àŒ“O˜aA‰Á“¡ƒŽqAˆäŽèŒû@—TA‹{˜e—˜’jFƒfƒXƒtƒFƒ‰[ƒ‹‚Ì–éŠÔŽ‘±”牺’‚ðs‚Á‚Ä‚¢‚éƒÀ-thalassemia‚̃pƒLƒXƒ^ƒ“—Ž™—áB‘æ44‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2002,10,“Œ‹ž.
    59. ‘å’ØŒc•ãA‹{@ˆêŽuAŽíŽsq’ˆA–쑺ŒbŽqA‹àŒ“O˜aA’|’J@Œ’A—Ñ@‘×GA‹{˜e—˜’jFMLL tandem duplication ‚ð”F‚ß‚½Ž¡—Ê֘Aœ‘ˆÙŒ`¬ÇŒóŒQ‚̈ê—áB‘æ44‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2002,10,“Œ‹ž.
    60. IchidaF., Chen R., Tsuji T., Karla R. Bowles, Watanabe S., Tsubata S., Hamamichi Y., Miyawaki T., Neil E Bowles and Jeffrey A. Towbin. : Mutation analysis of the G4.5 gene in patients with isolated left ventricular noncompaction. The 75th Scientific Sessions of American Heart Association,2002,11,Chicago.
    61. “n粈»‰ÀA“n•Óˆê—mAà_“¹—S“ñAŽs“c•™ŽqA‹{˜e—˜’jA“¡–Ø–õŽqA“ñ’J@•AŠp’JŽûŽqA¼ŽR—æ“ÞA“à@®ŽqA•Ä“c@“NA²X–Ø‘×AŽðˆä³—˜AâV“¡@Ž A“»@³‹`A“‡’ÃeŽuA‘哈‹`”ŽAŽOè‘ñ˜YF‘ÙŽ™Šú‚æ‚èŒo‰ßŠÏŽ@‚µ‚½‘“®–¬Š²ˆâŽc‚̈ê—áB‘æ2‰ñ•xŽR¬Ž™zŠÂŠíŒ¤‹†‰ï,2002,11,•xŽR.
    62. 㨌hˆê˜YAV‹@—²A“n粈»‰ÀA“n•Óˆê—mAà_“¹—S“ñAŽs“c•™ŽqA“à@®ŽqA¼ŽR—æ“ÞAŽðˆä³—˜AâV“¡@Ž F‘ÙŽ™–[ŽºƒuƒƒbƒN‚Ì1—áB‘æ2‰ñ•xŽR¬Ž™zŠÂŠíŒ¤‹†‰ï,2002,11,•xŽR.
    63. ”‘òŽõŽqAà_“¹”ü‹IA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jAŽRŒ³ƒŽqA‘ºãIŒ[F“û—cŽ™‚É‚¨‚¯‚éšb‘§”­ìŽž‚̃EƒCƒ‹ƒXŠ´õ‚ªƒeƒIƒtƒBƒŠƒ“‘ãŽÓ‚É‹y‚Ú‚·‰e‹¿|MxA’`”’‚ðŽw•W‚Æ‚µ‚Ä|B‘æ52‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2002,11,‰¡•l.
    64. ‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çA‰ª•””üŒbA‚”ö@Š²A‘«—§—YˆêA‹{˜e—˜’jA”öã—mˆêF—c’t‰€E•Ûˆç‰€‚É‚¨‚¯‚éH•¨ƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éHŽ–§ŒÀ‚ÌŽÀ‘Ô|•xŽRŒ§‚É‚¨‚¯‚é’²¸Œ‹‰Ê‚»‚Ì‚Q|B‘æ52‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2002,11,‰¡•l.
    65. ¼–ì³’mAˆÉ“Œ“¹—YA‹gZ@ºA‘«—§—YˆêAŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚éDSCG‹z“ü—Ö@‚Ì—Õ°“IŒŸ“¢|‘Šú“±“ü‚Ì—LŒø«‚ɂ‚¢‚Ä|B‘æ52‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2002,11,‰¡•l.
    66. ’†—ÑŒºˆêA‘«—§—YˆêA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jAœAìTˆê˜YA¼–{^KA–{“c‹`MF”x‹CŽî‚Ìis‚ð‘jŽ~‚Å‚«‚È‚©‚Á‚½V¶Ž™ƒ}ƒ‹ƒtƒ@ƒ“ÇŒóŒQ‚Ì‚P—áD‘æ35‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,2002,11,ç—t.
    67. ‘å’ØŒc•ãA‹{@ˆêŽuA’†—ÑŒºˆêAˆÉ“¡–õ“TA•£‘ò—³–çA”‘òŽõŽqA–{‹½˜a‹vA‘«—§—YˆêA‹{˜e—˜’jFŒJ‚è•Ô‚·ŒÄ‹zŠíŠ´õ—\–h‚Ì‚½‚ß–éŠÔ‚Ì”ñNPlHŠ·‹C‚𓱓ü‚µ‚½2ΗŽ™—áD‘æ35‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,2002,11,ç—t.
    68. ¼–ì³’mA‘«—§—YˆêAŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§Š°‰ð—á‚É‚¨‚¯‚鎡—Ã’†Ž~‘OŒã‚Ì‹C“¹‰ß•q«‚Æ—\Œã‚ɂ‚¢‚Ä‚ÌŒŸ“¢B‘æ10‰ñ—Õ°šb‘§Œ¤‹†‰ï,2002,11,“Œ‹ž.
    69. ŒÜ\—’—²•vA¼–ì³’mAˆÉ“Œ“¹•vA‘ºãIŒ[A‘«—§—YˆêF’´‰¹”gƒlƒuƒ‰ƒCƒU[iƒEƒ‹ƒgƒ‰ƒXƒ|[ƒc4000WBj‚Ì—Õ°“IŒŸ“¢B‘æ39‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2002,11,·‰ª.
    70. ‘ºãIŒ[AŽRŒ³ƒŽqAŒÜ\—’—²•vA‘«—§—YˆêA‘«—§—zŽqA¼–ì³’mAˆÉ“Œ“¹•vF‹}«šb‘§”­ì‚É‚¨‚¯‚é’´‰¹”gƒlƒuƒ‰ƒCƒU[iƒEƒ‹ƒgƒ‰ƒXƒ|[ƒc400WB)‚Ì—L—p«‚ÌŒŸ“¢|3Ží—ނ̃lƒuƒ‰ƒCƒU[ŠÔ‚Ì”äŠr|B‘æ39‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2002,11,·‰ª.
    71. ¼–ì³’mAˆÉ“Œ“¹•vA‹gZ@ºA‘«—§—YˆêAŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚éDSCG‹z“ü—Ö@‚Ì—Õ°“IŒŸ“¢]­—ʂ̃À2ŽhŒƒ–ò•¹—p‚ª‹C“¹‰ß•q«‚ɉe‹¿‚ð—^‚¦‚é‚©]B‘æ39‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2002,11,·‰ª.
    72. •£‘ò—³–çA‘«—§—zŽqA”‘òŽõŽqA’†—ÑŒºˆêAà_“¹—T“ñA‹´–{ˆè•vA‘«—§—YˆêAŽs“c•™ŽqA‹{˜e—˜’jF‰^“®—U”­«ƒAƒiƒtƒBƒ‰ƒLƒV[‚Ɖ^“®—U”­«šb‘§‚Æ‚ÌŠÓ•Ê‚ª“‚¢1—áB‘æ39‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2002,11,·‰ª.
    73. à_“¹”ü‹IA‘«—§—zŽqA”‘òŽõŽqA‰ª•””üŒbA‚”ö@Š²A‘«—§—YˆêA‹{˜e—˜’jA”öã—mˆêF‹CŠÇŽxšb‘§Ž™‚É‚¨‚¯‚éƒÀŽhŒƒ–ò‹z“ü‚ɑ΂·‚锽‰ž«‚ÌŒŸ“¢|QOL’²¸•[Œ‹‰Ê‚Æ‚ÌŠÖŒW‚ɂ‚¢‚Ä|B‘æ39‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2002,11,·‰ª.
    74. ‹àŒ“O˜aFƒVƒ“ƒ|ƒWƒEƒ€uEBƒEƒCƒ‹ƒXŠ´õ‚ƈâ“`«ƒŠƒ“ƒp‘BŽ¾Š³Bv‘æ34‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,2002,11,ŽD–y.
    75. –쑺ŒbŽqA‹àŒ“O˜aA‹gì“NŽjA‹{˜e—˜’jF’°dÏ‚ðŒJ‚è•Ô‚µ‚½“Ë”­«”­]ǂ̈ê—áB‘æ34‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,2002,11,ŽD–y.
    76. “n•Óˆ»‰ÀA“¡–Ø–õŽqA–쑺ŒbŽqA‹àŒ“O˜aAÒì@‘¾A‘¾“c@–ÎA@—é–Ø@FAŒF’J¹–¾AP¼—R‹LŽqA’|’J@Œ’A—Ñ@‘×GA‹{˜e—˜’jF•›•@oŒ´”­‚ÌEwing/PNETŽîᇌQ‚Ì‚P—áB‘æ18‰ñ“ú–{¬Ž™‚ª‚ñŠw‰ï,2002,11,•Ÿ‰ª.
    77. “¡–Ø–õŽqA“n•Óˆ»‰ÀA–쑺ŒbŽqA‹àŒ“O˜aA‹›’J‰p”VAœAìTˆê˜YA”ó“nŒõ‹PA—Ñ@‘×GA`‡ˆêA‹{˜e—˜’jFMalignant rhabdoid tumor of the kidney (MRTK) ‚Ì‚P—áB‘æ18‰ñ“ú–{¬Ž™‚ª‚ñŠw‰ï,2002,11,•Ÿ‰ª.
    78. IchidaF., Chen R., Tsuji T., Haneda N., Bowles KR., Tsubata S., Use K., Hirono K., Watanabe S., Hamamichi Y., Hashimoto I., Miyawaki T., Bowles NE., and Towbin. JA. : Novel gene mutations in patients with left ventricular noncompaction and evidence for genetic heterogeneity. The 1st International symposium on Etiology and Morphogenesis of Congenital Cardiovascular Disease in the Post-Genomic Era.,2002,12,Tokyo.
    79. ”óŒû@ŽûA”‘òŽõŽqA¬¼“¹—YA¡‘º”Ž–¾AŒE“c”Ž“¹AûŠˆä³tAŒ´ˆä•ü”üA“ñ’J@•A‘«—§—YˆêA‹{˜e—˜’jA…’JW•ãAˆê–ØŽ”VA“yŠò‘P‹IA’ÓcŠî°F”x‰Š‚ðŒ_‹@‚É”­Œ©‚³‚ꂽæ“V«”X–E«‘BŽî—lŠïŒ`iCCAMj‚̈ê—áB‘æ10‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2002,12,•xŽR.
    80. à_“¹”ü‹IA‘«—§—zŽqA”‘òŽõŽqA‘«—§—YˆêA‹{˜e—˜’jA”öã—mˆêA‘ºãIŒ[F‹CŠÇŽxšb‘§Ž™‚É‚¨‚¯‚éƒÀŽhŒƒ–ò‹z“ü‚ɑ΂·‚锽‰ž«‘ª’è‚Ì—Õ°“I—L—p«B‘æ29‰ñ–k—¤ƒAƒŒƒ‹ƒM[§˜b‰ï,2002,12,‹à‘ò.
    81. •£‘ò—³–çA‘«—§—zŽqA”‘òŽõŽqA’†—ÑŒºˆêAà_“¹—S“ñA‹´–{ˆè•vA‘«—§—YˆêAŽs“c•™ŽqA‹{˜e—˜’jFEIA or EIA? i‰^“®—U”­«ƒAƒiƒtƒBƒ‰ƒLƒV[‚Ɖ^“®—U”­«šb‘§‚Æ‚ÌŠÓ•Ê‚ª“‚¢1—ájB‘æ2‰ñ•xŽRšb‘§Œ¤‹†‰ï,2002,12,•xŽR.
    82. ‹àŒ“O˜aA–쑺ŒbŽqA“ñ’J@•A‹{˜e—˜’jF‚w˜A½–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚É‚¨‚¯‚éD’†‹…Œ¸­B‘æ10‰ñH×–E‹@”\ˆÙíÇŒ¤‹†‰ï,2002,12,“Œ‹ž.

    2001”N

  • ’˜‘
    1. ‹{˜e—˜’jFŒ´”­«–ƉuÇŒóŒQBu¡“ú‚ÌŽ¡—ÃŽwj2001v‘½‰ê{K’j‘¼•ÒA837-838AˆãŠw‘‰@A“Œ‹žA2001.
    2. Žs“c•™ŽqF¶ŽºS‹Øãk–§‰»áŠQBu¬Ž™Ž¾Š³‚Ìf’fŽ¡—Êî€v¬Ž™“à‰È¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï‹¤•ÒA518-519A“Œ‹žˆãŠwŽÐA“Œ‹žA2001.
    3. Žs“c•™ŽqFS“à–ŒüˆÛ’e«ÇBu¡“ú‚ÌzŠÂŠíŽ¾Š³Ž¡—ÃŽwjA‘æ2”Åvדcºˆê‘¼•ÒA493-494AˆãŠw‘‰@A“Œ‹žA2001.
    4. Žs“c•™ŽqFæ“V«SŽ¾Š³Bu‚í‚©‚è‚â‚·‚¢“à‰ÈŠw‰ü’ù‘æ2”Åvˆä‘º—T•v‘¼•ÒA•ªŒõ“°A“Œ‹žA2001.
    5. ‹àŒ“O˜aFautoimmune lymphoproliferative syndrome(ALPS)Bu¬Ž™Ž¾Š³‚Ìf’fŽ¡—Êî€v¬Ž™“à‰È¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï‹¤•ÒA246-247A“Œ‹žˆãŠwŽÐA“Œ‹žA2001.
    6. “ñ’J@•A‹{˜e—˜’jFR‘ÌŒ‡–R‚ðŽå‚Æ‚·‚é–Ɖu•s‘SBu¬Ž™Ž¾Š³‚Ìf’fŽ¡—Êî€v¬Ž™“à‰È¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï‹¤•ÒA236-237A“Œ‹žˆãŠwŽÐA“Œ‹žA2001.
  • Œ´’˜
    1. Ichida F., Tsubata S., Bowles K.R., Haneda N., Uese K., Miyawaki T., Dreyer W.J., Messina J., Li H., Bowles N.E., and Towbin J.A. : Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 103 : 1256-1263,2001.
    2. Matsukura H., Inaba S., Shinozaki K., Yanagihara T., Hara M., Higuchi A., Takada T., Tanizawa T., and Miyawaki T.: Influence of prolonged corticosteroid therapy on the outcome of steroid-responsive nephrotic syndrome. Am J Nephrol. 21 : 362-367,2001.
    3. Kanegene H., Futatani T., Wang Y., Nomura K., Shinozaki K., Matsukura H., Kubota T., Tsukada S., and Miyawaki T.: Clinical and mutational characteristics of X-linked agammagloburinemia and its carrier identified by flow cytometric assesment combined with genetic analysis. J Allergy Clin Immunol 108 : 1012-1020,2001.
    4. Hongou K. , Konishi T., Matsuzawa J., Yagi S., and Miyawaki T.: A case of migrating partial seizures in an infant with severe eczema, conjunctivitis, and loss of hair. Epilepsia 42 : 72-73,2001.
    5. Futatani T., Watanabe C., Baba Y., Tsukada S., and Ochs HD.: Bruton's tyrosine kinase is present in normal platelets and its absence identifiespatients with X-linked agammaglobulinaemia and carrier females. Brit J Haematol. 114: 141-149,2001.
    6. Ziegner UH., Ochs HD., Schanen C., Feig SA., Seyama K., Futatani T., Gross T., Wakim M., Roberts RL., Rawlings DJ., Dovat S., Fraser JK., and Stiehm ER. : Unrelated umbilical cord stem cell transplantation for X-linked immuno-deficiencies. J Pediatr. 138 : 570-573,2001.
    7. Matsuzawa J., Matsui M., Konishi T., Noguchi K., Gur RC., Bilker W., and Miyawaki T.: Age-related volumetric changes of brain gray and white matter in healthy infants and children. Cerebral Cortex. 11 : 335-342,2001.
    8. Hamamichi Y., Ichida F., YU X., Hirono K., Uese K., Hashimoto I., Tsubata S., Yoshida T., Futatani T., Kanegane H., and Miyawaki T.: Neutrophils and mononuclear cells express vascular endothelial growth factor in acute Kawasaki disease: Its possible role in progression of coronary artery lesions. Pediatr Res 49: 74-80,2001.
    9. Hamamichi Y., Ichida F., Tsubata S., Uese K., Hashimoto I., Miyawaki T., Ono Y., and Kamiya T.: Isolated noncompaction of the ventricular myocardium -UFCT and magnetic resonance imaging - Int J Cardiac Imag 17 : 305-314,2001.
    10. Itazawa T,. Adachi Y., Imamura H., Okabe Y., Yamamoto J., Onoue Y., Adachi Y. S., Miyawaki T., and Murakami G. : Increased lymphoid MxA expression in acute asthma exacerbation in children. Allergy 56 : 895-898,2001.
    11. Wang Y., Kanegane H. , Sanal O.,Ersoy F., Tezcan I., Futatani T., Tsukada S., and Miyawaki T.: Bruton's tyrosine kinase gene mutations in Turkish patients with presumed X-linked agammaglobulinernia. Hum Mutat 18 : 356,2001.
    12. Yu X., Hashimoto I., Ichida F., Uese K., Hamamichi Y., Tsubata S., and Miyawaki T.: Dipyridamole stress ultrasonic myocardial tissue characterization in patients with history of Kawasaki disease. J Am Soc Echocardiogr 14 : 682-90,2001.
    13. Konishi T., Matsuzawa J., Hongou K., Murakami M., Yamatani M., and Yagi S.: Candidate selection for surgical treatment in children with intractable epilepsies. Epilepsia 42 : 56,2001.
    14. Xianyi Yu., Hashimoto I., Ichida F., Uese K., Hamamichi Y., Tsubata S., and Miyawaki T.: Dipyridamole stress ultrasonic myocardial tissue characterization in patients with history of Kawasaki disease. J Am Soc. Echocardio. 14:682-690, 2001.
    15. Mio T., Liu X., Toews M.L., Adachi Y. , D.J. Romberger D.J., Spurzem J.R., and Rennard S.I. : Bradykinin augments fibroblast-mediated contraction of released collagen gels. Am J Physiol Lung Cell Mol Physiol 281:L164-71,2001.
    16. Sakamoto M., Kanegane H., Fujii H., Tsukada S., Miyawaki T. , and Shinomiya N.FMaternal germinal mosaicism of X-linked agamma-globulinemia. Am J Med Genet 99 : 234-237,2001.
    17. Usui K., Sasahara Y., Tazawa R., Hagiwara K., Tsukada S., Miyawaki T., Tsuchiya S., and Nukiwa T. : Recurrent pneumonia with mild hypogammaglobulinemia diagnosed as X-linked agammaglobulinemia in adults. Respir. Res. 2:188-192,2001.
    18. Kimura H., Hoshino Y., Kanegane H., Tsuge I., Okamura T., Kawa K., and Morishima T. : Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 98 : 280-286,2001.
    19. Sumazaki R., Kanegane H., Osaki M., Fukushima T., Tsuchida M., Matsukura H., Shinozaki K., Kimura H., Matsui A., and Miyawaki T.: SH2D1A mutations in Japanese males with severe Epstein-Barr virus-associated illnesses. Blood. 98 : 1268-1270,2001.
    20. Jo E.K., Kanegane H., Nonoyama S., Tsukada S., Lee J.H., Lim K., Shong M., Song C.H., Kim H.J, Park J.K., and Miyawaki T.: Characterization of mutations, including a novel regulatory defect in the first intron, in Bruton's tyrosine kinase gene from seven Korean X-linked agammaglobulinemia families. J Immunol 167 : 4038-4045,2001.
    21. Nakamura A., Tsurusawa M., Kato A., Taga T., Hatae Y., Miyake M., Mimaya J., Onodera N., Watanabe A., Watanabe T., Kanegane H., Matsushita T., Iwai A., Hyakuna N., Gushi K., Kawakami T., Sekine I., Izichi O., Asami K., Kikuta A., Tanaka A., and Fujimoto T.(Children's Cancer and Leukemia Study Group (CCLSG)) : Prognostic impact of CD45 antigen expression in high-risk, childhood B-cell precursor acute lymphoblastic leukemia. Leukemia Lymphoma 42 : 393-398,2001.
    22. Agematsu K., Nagumo H., Hokibara S., Mori T., Wada T., Yachie H., Kanegane H., Miyawaki T., Sugita K., Karasuyama H., and Komiyama A. : Complete arrest from pro- to pre-B cells in a case of B cell-negative severe combined immunodeficiency (SCID) without recombinase activating gene (RAG) mutations. Clin Exp Immunol 124 : 461-464,2001.
    23. Ikeda N., Hayasaka S., Yano H., Kadoi C., Matsumoto M., Imamura H., and Miyawaki T.: Retinopathy of prematurity in Toyama area of Japan. Ann Ophthalmol 33 : 303-308,2001.
    24. Li J., Li X., Mori Y., Rusk RA., Lee JS., Davies CH., Hashimoto I. , El-sedfy GO., Li XN., and Sahn Dj. : Quantification of flow volume with a new digital three-dimensional color Doppler flow approach : an in vitro study. J Ultrasound Med 20 : 1303-1311,2001.
    25. Moro H., Iwai K., Mori N.,Watanabe M., Fukushi M., Oie M., Arai M., Tanaka Y., Miyawaki T., Gejyo F., Arakawa M., and Fujii M. : Interleukin-2-dependent but not independent T-cell lines infected with human T-cell leukemia virus type I selectively express CD45RO, a marker for persistent infeotion in vivo. Virus Genes 28 : 263-271,2001.
    26. ‰¡“cF”VA‘«—§—YˆêA”öã—mˆêA•l“¹”ü‹IA”ÂàVŽõŽqA‰ª•””üŒbAŽRŒ³ƒŽqA‘«—§—zŽqA‘ºãIŒ[A‹{˜e—˜’jF–òÜŽt‚É‚æ‚é‹CŠÇŽxšb‘§Š³ŽÒ‚ɑ΂·‚é‹z“üŽw“±‚ÌŽÀ‘Ô’²¸@-•xŽRŒ§“à‚Ì•a‰@–ò‹Ç‚È‚ç‚тɉ@ŠO’²Ü–ò‹Ç‚É‚¨‚¯‚鷈قɂ‚¢‚Ä -D“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@15F208-214,2001.
    27. ‹g“cärA‹àŒ“O˜aAŽª“c–F’jAˆÉ“¡‘P–çA‰iˆä•q˜YA–î–ìŒöˆêA“c’†—tŽqA¼Šª@Ž AŽR씎ŽqAŽ›–{’mŽjA‹ÊˆäLÆA•Sˆä@‹œA‘å‹´”Ž•¶A¼@”ü˜aAâV“¡–œ—¢ŽqA‹{˜e—˜’jF‚킪‘‚É‚¨‚¯‚齜“ªŠWˆÙŒ`¬Ç‚Ì—Õ°“IEˆâ“`Šw“IŒŸ“¢B“ú–{¬Ž™‰ÈŠw‰ïŽGŽ@105F442-447,2001.
  • Ç—á•ñ
    1. Itazawa T., Noguchi K., Ichida F., and Miyawaki T.: Magnetic resonance imaging for early detection of Takayasu arteritis. Pediatr. Cardiol. 22:163-164,2001.
    2. Adachi Y., Onoue Y., Matsuzawa J., Ieki A., Yagi S., and Miyawaki T.: External chest compression for the treatment of a mechanically ventilated child with status asthmaticus. Acta Pediatr 90 : 826-827,2001.
    3. ”ª–ØMˆêA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jA¬¼@“OFEyelid myoclonia with absences Eyelid myoclonia withabsences‚ÌŒZ’í—áB”]‚Æ”­’B@33F517-522,2001.
    4. Itazawa T., Noguchi K., Ichida F., and Miyawaki T.: Magnetic resonance imaging for early detection of Takayasu arteritis. Pediatr. Cardiol 22 : 163-164,2001.
    5. “n•Óˆ»‰ÀAŒIŒ´^‹IŽqA–쑺ŒbŽqA‹àŒ“O˜aA–{‹½˜a‹vA”ª–ØMˆêA‹{˜e—˜’jFGM1ƒKƒ“ƒOƒŠƒIƒVƒh[ƒVƒX‚Ì––½ŒŒ‰t‘œB¬Ž™‰È@42F137-138,2001.
    6. Uotani H., Hirosawa S., Saito F., Tauchi K., Shimoda M., Ishizawa S., Kawaguchi M., Nomura K., Kanegane H., and Tsukada K. : Non-Hodgkin's lymphoma of the ascending colon in a patient with Becker muscular dystrophy : Report of a case. Surg Today 31 : 1016-1019,2001.
  • ‘à
    1. ‹{˜e—˜’jFautoimmune-lymphoproliferativeÇŒóŒQ(ALPS)Bu¬Ž™‚ÌÇŒóŒQv¬Ž™‰Èf—Ã(‘)64F319,2001.
    2. Žs“c•™ŽqFS‹Øãk–§‰»áŠQ‚ÌŒ»‹µBuæ“V«SŽ¾Š³‚̃g[ƒ^ƒ‹ƒPƒA[v¬Ž™“à‰È@33F720-722,2001.
    3. ‘«—§—YˆêAŽRŒ³ƒŽqA‹{˜e—˜’jFƒAƒŒƒ‹ƒM[Ž¾Š³‚ƃPƒ‚ƒJƒCƒ“D•ªŽq×–EŽ¡—Ã@2F603-608,2001.
    4. ‘«—§—YˆêAŽRŒ³ƒŽqA‹{˜e—˜’jFƒAƒgƒs[«Ž¾Š³‚ƃPƒ‚ƒJƒCƒ“BMolecular Medicine 38F160-166,2001.
    5. ‹àŒ“O˜aFŒ´”­«–Ɖu•s‘SÇŒóŒQBu¬Ž™‚ÌÇŒóŒQv¬Ž™‰Èf—Ã(‘)@64F363,2001.
    6. ‹àŒ“O˜aFæ“V«ŒŒ‰t–ƉuˆÙíÇ‚Ìf’f‚Ìi•àB“ú–{¬Ž™ŒŒ‰tŠw‰ïŽ,89-94,2001.
    7. ŽÂ茒‘¾˜YA‹àŒ“O˜aA‹{˜e—˜’jFSAP(SLAM-associated protein)‚̈Ùí‚ÆEBƒEƒCƒ‹ƒXŠ´õB–Ɖu@11F109-113,2001.

  • 2001”NŠw‰ï•ñ
    1. ‘匎“N•vA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jFEBƒEƒBƒ‹ƒX‰Š´õ‚É‚æ‚錌‹…æÃHƒŠƒ“ƒp‘gD‹…‘Bǂ̈ê—áB‘æ‚T‰ñŒŒ‰tŽ¾Š³‚ƃTƒCƒgƒJƒCƒ“Œ¤‹†‰ï,2001,1,‹à‘ò.
    2. “ŒŽROKAŽíŽsq’ˆA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAœAìTˆê˜YAÎàV@LF• ’É‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚½ƒo[ƒLƒbƒgƒŠƒ“ƒpŽî‚̈ê—áB‘æ14‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ï,2001,2,‹à‘ò.
    3. ‹´–{ˆè•vA㨌hˆê˜YAà_“¹—T“ñA“ŒŽROKA“ñ’J@•AL–ìŒbˆêA“n•Óˆ»‰ÀAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÃeŽuA“y”ì‹`˜YA‘哈‹`”ŽAŽOè‘ñ˜YA²X–Ø‘×AœAìTˆê˜YA‘š“cŒõ‹`FCoil embolization‚ðŽ{s‚µ‚½A‰E‰¡Šu–Œƒwƒ‹ƒjƒAA”x•ª‰æÇAScimitarÇŒóŒQAS–[’†ŠuŒ‡‘¹A‘å“®–¬kó‚ÌV¶Ž™—áB‘æ21‰ñ–k—¤¬Ž™zŠÂŠí§˜b‰ï,2001,2,‹à‘ò.
    4. Adachi Y., Okabe Y., Onoue Y., Yamamoto J., Adachi YS., Toyoda M., Morohashi M., Matsushima K., and Miyawaki T.: Cutaneous lymphocyte antigen expression on circulating Th1- and Th2-type cells in patients with atopic dermatitis. 57th Annual Meeting of American Academy of Allergy, Asthma and Immunology,2001,3,New Orleans,USA.
    5. ‘匎“N•vAŽíŽsq’ˆA“ŒŽROKA‹´–{ˆè•vA‘«—§—YˆêAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÃeŽuA‘哈‹`”ŽAŽOè‘ñ˜YA“n•Óˆ»‰ÀA“c’‡çHA•l“¹—T“ñA’|’J“¿—YFRSƒEƒCƒ‹ƒX‚É‚æ‚é‹}«×‹CŠÇŽx‰Š”­Ç‚ðŒ_‹@‚É”­Œ©‚³‚ꂽŒŒŠÇ—Ö‚Ì1“ûŽ™—áB‘æ271‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,2001,3,‹à‘ò.
    6. –쑺ŒbŽqA‘匎“N•vA‰eŽR—²ŽiA‹àŒ“O˜aA‹{˜e—˜’jFLeukapheresis‚ðs‚Á‚½‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚Ì1’jŽ™—áB‘æ271‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,2001,3,‹à‘ò.
    7. ‰ª•””üŒbA‘«—§—YˆêA”ÂàVŽõŽqAŽRŒ³ƒŽqA”öã—mˆêA‹{˜e—˜’jF––½ŒŒ‚s×–E‚É‚¨‚¯‚éCCR7”­Œ»‚Ì”N—î“I„ˆÚ‚Æ‚»‚Ì‹@”\‚ɂ‚¢‚ÄB‘æ22‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2001,3,•xŽR.
    8. Ichida F., Haneda N., Bowles K. R., Tsubata S.,Uese K., Hamamichi Y., Hashimoto I., Miyawaki T., and Towbin J.A. : ƒ¿-Dystrobrevin mutations in nonisolated left ventricular noncompaction and evidence for genetic heterogeneity. ‘æ65‰ñ“ú–{zŠÂŠíŠw‰ï,2001,3,‹ž“s.
    9. Hamamichi Y., Ichida F., Chen R., Uese K., Hirono K.,Tsubata S., Miyawaki T., Seto H.,and Sahn D. J. : Dipyridamole stress ultrasonic myocardial tissue characterization in patients with Kawasaki disease. ‘æ65‰ñ“ú–{zŠÂŠíŠw‰ï,2001,3,‹ž“s.
    10. Hashimoto I., Ichida F., Miyawaki T., and Sahn D. J. : Angle dependency of tissue Doppler left ventricular regional wall velocities: In Vitro studies using a novel balloon phantom.‘æ65‰ñ“ú–{zŠÂŠíŠw‰ï,2001,3,‹ž“s.
    11. Hashimoto I., Ichida F., Miyawaki T., and Sahn D. J. : .Detection of modeled old myocardial infarction using tissue Doppler versus strain rate imaging: In Vitro Studies Using a "Calibrated" Myocardial Phantom. ‘æ65‰ñ“ú–{zŠÂŠíŠw‰ï,2001,3,‹ž“s.
    12. Hashimoto I., Rusk R. A., Li X., Mori Y., Mack G., Lee J. S., Wanikun S., Sahn D. J. : Improved accuracy for determination of endocardial borders and cavity volumes with second harmonic echo in real-time 3D echocardiography: In-Vitro studies. 50th American College of Cardiology,2001,3,Orland,USA.
    13. Hashimoto I., Davies C. H., Li X., Lee J. S., Ichida F., Miyawaki T., and Sahn D. J. : The angle dependency of strain rate imaging compared to B-mode strain measurements: studies in a physiologic myocardial model. 50th American College of Cardiology,2001,3,Orland,USA.
    14. ‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jADavid J. SahnFƒoƒ‹[ƒ“ƒ‚ƒfƒ‹‚ð—p‚¢‚½‚RŽŸŒ³SƒGƒR[‚̶Žº‹@”\•]‰¿‚É‚¨‚¯‚鸓x‚ÌŒŸ“¢B‘æ12‰ñ“ú–{SƒGƒR[}Šw‰ïA2001,4,“Œ‹ž.
    15. ‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jADavid J. SahnFƒoƒ‹[ƒ“ƒ‚ƒfƒ‹‚ð—p‚¢‚½Strain Rate Imaging‚̶Žº‘¤•Ç‚ł̉ðÍB‘æ12‰ñ“ú–{SƒGƒR[}Šw‰ïA2001,4,“Œ‹ž.
    16. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[‚Ì”­Ç—vˆö‚Æearly intervention@ŠÂ‹«—vˆö‚Æ‚»‚Ì‘Îô@ƒAƒŒƒ‹ƒQƒ“i‹z“üEH•¨jvB‘æ‚S‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[Œ¤‹†‰ïA2001,4,–¼ŒÃ‰®.
    17. Hashimoto I., Ichida,F., Miyawaki T., Stetten G., von Ramm O., Jones M., Panza J.A., Sachdev V., and Sahn D.J. : Accuracy of real-time three-dimensional echocardiography for determining left ventricular volumes and ejection fractions: a physiologic balloon model and experimental animal model with sonomicrometry measurements of LV volumes.The 3rd world congress of pediatric cardiology and cardiac surgery,2001,5,Toronto,Canada.
    18. Hirono K., Yu X., Ichida F., Chen R., Uese K., Hamamichi Y., Hashimoto I., Tsubata S., Terai M., and Miyawaki T.: Nitric oxide contributes to the progression of coronary artery lesions in acute Kawasaki disease. The 3rd world cogress of pediatric cardiology and cardiac surgery,2001,5,Toronto,Canada.
    19. Hirose Y., Ichida F.: A study of how pro-fessionals and mothers recognize the needs of children with congenital heart disease. The 3rd world cogress of pediatric cardiology and cardiac surgery,2001,5,Toronto,Canada.
    20. Watanabe S., Yu X., Hashimoto I., Ichida F., Chen R., Hirono K., Hamamichi Y., Uese K., Tsubata S., Miyawaki T. , Seto H., and Sahn D.J. : Dipyridamole stress ultrasonic myocardial tissue characterization in patients with Kawasaki disease. The 3rd world cogress of pediatric cardiology and cardiac surgery,2001,5,Toronto,Canada.
    21. Ichida F. , Haneda N., Bowles K.R., Tsubata S., Uese K., Hirono K., Hamamichi Y., Hashimoto I., Miyawaki T., and Towbin, J.A. : ƒ¿-Dystrobrevin mutations in nonisolated left ventricular noncompaction and evidence for genetic heterogeneity. The 3rd world cogress of pediatric cardiology and cardiac surgery,2001,5,Toronto,Canada.
    22. ‰¡“cF”VA‘«—§—zŽqA‰ª•””üŒbA”ÂàVŽõŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[F‹CŠÇŽxšb‘§Ž™‚É‚¨‚¯‚éƒÀŽhŒƒÜ‚ɑ΂·‚锽‰ž«‚ÌŒŸ“¢`Ž¡—ÂȂç‚Ñ‚É‹C“¹‰ß•q«‚Æ‚ÌŠÖŒW‚ɂ‚¢‚Ä`‘æ13‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,2001,5,‰¡•l.
    23. ”ÂàVŽõŽqA‰ª•””üŒbA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jF‰h—{•â•H•iŠJŽnŒã‚É”­Ç‚µ‚½H•¨ˆË‘¶«‰^“®—U”­«ƒAƒiƒtƒBƒ‰ƒLƒV[‚Ì‚P—áB‘æ13‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,2001,5,‰¡•l.
    24. •l“¹”ü‹IAŽRŒ³ƒŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jAFè@Œ’AŒIŒ´^‹IŽqFƒvƒƒ^ƒm[ƒ‹Ž‘±‹z“ü’†‚ÉBurugadaÇŒóŒQ—l‚ÌS“d}ˆÙí‚𗈂µ‚½‹CŠÇŽxšb‘§‚̈ê—áB‘æ13‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,2001,5,‰¡•l.
    25. Žs“c•™ŽqA‰Hª“c‹IKA’Ô¦áÁˆêAœA–ìŒbˆêA“n•Óˆ»‰ÀA㨌hˆê˜YA•l“¹—T“ñA‹´–{ˆè•vA‹{˜e—˜’jAƒWƒFƒtƒŠ[ƒ^ƒEƒrƒ“FS‹Øãk–§‰»áŠQ‚É‚¨‚¯‚éV‚µ‚¢ƒ¿-Dystrobrevin ˆâ“`ŽqˆÙíB‘æ104‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2001,5,˜a‰ÌŽR.
    26. Wang Y., Kanegane H., Miyawaki T., and Ozden S.FA novel Igƒ¿ gene mutation in a Turkish patient with B cell-deficient agammaglobuli-nemia. ‘æ104‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2001,5,˜a‰ÌŽR.
    27. Chen R., Yu X., Ichida F., Hirono K., Uese K., Hamamichi Y., Hashimoto I., Terai M., and Miyawaki T.FNitric oxide contributes to the progression of coronary artery lesions in acute Kawasaki disease. ‘æ104‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2001,5,˜a‰ÌŽR.
    28. –{‹½˜a‹vA‰eŽR—²ŽiA“c’‡çHA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jA“à“¡‰x—YFƒWƒNƒƒ|Ž_‚¨‚æ‚Ñvit.B1“Š—^Œã‚É—Õ°Ç󂨂æ‚щ摜ŠŒ©‚̉ü‘P‚ª‚Ý‚ç‚ꂽLeigh”]ǂ̈ê—áB‘æ33‰ñ“ú–{¬Ž™_ŒoŠw‰ï,2001,6,‰ªŽR.
    29. ‰eŽR—²ŽiA“c’‡çHA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF—L”MŽžáz¹dÏ‚Å”­Ç‚µ‚½2”]‰Š‚̈ê—áB‘æ33‰ñ“ú–{¬Ž™_ŒoŠw‰ï,2001,6,‰ªŽR.
    30. ”ª–ØMˆêA“c’‡çHA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jA¬¼@“OFHallervorden-Spatz syndrome‚ÌŽoA’í—áB‘æ33‰ñ“ú–{¬Ž™_ŒoŠw‰ï,2001,6,‰ªŽR.
    31. “ñ’J@•A”ª–ØMˆêAŽíŽsq’ˆA‹{˜e—˜’jA•Ä“c@“NA²X–Ø‘×AÄ“¡@Ž A‹v•Û“¹–çAŒKŽR’¼–çA•l“cG•vA‰““¡r˜YA’†—ÑŒºˆêAZ“c@—ºA“ˆ@‘å“ñ˜YFƒRƒCƒ‹Çðp‚É‚æ‚èS•s‘S‚̉ü‘P‚ª“¾‚ç‚ꂽæ“V«“ªŠW“à“®Ã–¬á‘‚ÌV¶Ž™—áB‘æ‚V‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2001,7,‚‰ª.
    32. “ñ’J@•A“ŒŽROKA²X–Ø@‘×A‰¡ŽR—TŽiA”ª–ØMˆêA¡‘º”Ž–¾AâV“¡@Ž A‹{˜e—˜’jF17”ÔõF‘̘rŠÔ‹tˆÊ‚É‚æ‚éMiller-DiekerÇŒóŒQ‚̉Ƒ°“à”­¶—áB‘æ37‰ñ“ú–{V¶Ž™Šw‰ï,2001,7,‰¡•l.
    33. Kanegane H. , Sumazaki R., Shinozaki K., Matsukura H., Kimura H., and Miyawaki T.FClinical and mutational characterization of X-linked lymphoproliferative syndrome in Japan. The 21th International Symposium of the Sapporo cancer seminar foundation Epistein-Barr virus and human cancer,2001,7,Sapporo.
    34. ¼‘q—TŠìA‘匎“N•vA•£‘ò—³–çA‹{˜e—˜’jFqí«‹›—ØáÇ‚ð‚Æ‚à‚È‚Á‚½ƒXƒeƒƒCƒh’ïR«ƒlƒtƒ[ƒ[ÇŒóŒQ‚̈ê—áB‘æ45‰ñ’†•”“ú–{Ž…‹…‘Ìt‰Š’k˜b‰ï,2001,7,–¼ŒÃ‰®.
    35. Žs“c•™ŽqA‰Hª“c‹IKA’Ô¦^ˆêAL–ìŒbˆêA㨌hˆê˜YAà_“¹—T“ñA‹´–{ˆè•vA‹{˜e—˜’jAƒWƒFƒtƒŠ[ ƒ^ƒEƒrƒ“FS‹Øãk–§‰»áŠQ‚É‚¨‚¯‚éV‚µ‚¢ƒ¿-Dystrobrevinˆâ“`Žq•ÏˆÙB‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7,ɪ.
    36. Žs“c•™ŽqA‰Hª“c‹IKA ’Ô¦^ˆêAL–ìŒbˆêA“n•Óˆ»‰ÀA㨌hˆê˜YAà_“¹—T“ñA‹´–{ˆè•vA‹{˜e—˜’jAƒWƒFƒtƒŠ[Eƒ^ƒEƒrƒ“FS‹Øãk–§‰»áŠQ‚̈â“`ŽqŒŸõB‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7,ɪ.
    37. ‹´–{ˆè•vA•l“¹—T“ñA㨌hˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÃeŽuA‘哈‹`”ŽAŽOè‘ñ˜YFS–[’†ŠuŒ‡‘¹Ç‚É‚¨‚¯‚é”x‘ÌŒŒ—¬”ä‚ÌSƒGƒR[‚É‚æ‚é„’èS–[’†ŠuŒ‡‘¹EƒTƒCƒY‚Æ‘m–X•Ù—ÖƒTƒCƒY‚É‚æ‚錟“¢B‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7, ɪ.
    38. ”öã—mˆêA‘«—§—YˆêA”ÂàVŽõŽqA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA’C–¤‹M”üŽqA‘å“àG—YA¬–ìˆÀ¶A”ª–ØŒ´rŽFFontanpŒã5”N‚Å”­Ç‚µ‚½ plastic bronchitis‚Ì1’jŽ™—áB‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7, ɪ.
    39. L–ìŒbˆêAChen RuiA㨌hˆê˜YAà_“¹—T“ñA“n•Óˆ»‰ÀA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jAŽ›ˆäŸFìè•a‹}«Šú‚É‚¨‚¯‚é—¬ŒŒ’†ŒŒŠÇ“à”ç×–E‚Å‚ÌiNOS”­Œ»‚̈Ӌ`B‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7, ɪ.
    40. •l“¹—T“ñA“n•Óˆ»‰ÀAœA–ìŒbˆêA㨌hˆê˜YA‹´–{ˆè•vA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jF”­ÇŽžŠú‚É‚æ‚éS‹Øãk–§‰»áŠQ‚Ì—Õ°‘œ‚ÌŒŸ“¢B‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7, ɪ.
    41. “n•Óˆ»‰ÀA‰Hª“c‹IKAœA–ìŒbˆêA㨌hˆê˜YA•l“¹—T“ñA‹´–{ˆè•vA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jFSŠïŒ`‚ɇ•¹‚µ‚½S‹Øãk–§‰»áŠQ‚Ì—Õ°‘œ‚ÌŒŸ“¢B‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7,ɪ.
    42. Chen R., Hirono K., Yu X., Ichida F., Uese K., Hamamichi Y., Hashimoto I., Tsubata S., Terai M., and Miyawaki T.FNitric oxide contributes to the progression of coronary artery lesions in acute Kawasaki disease. ‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7, ɪ.
    43. ”óŒû@ŽûA•£àV—³–çA‘«—§—YˆêA‹{˜e—˜’jA‹{Œ´²–íAŒ´@—SˆèAŽOè‘ñ˜YA“n•Óˆ»‰ÀAŽÂ茒‘¾˜YFŒJ‚è•Ô‚·”x‰Š‚ðŒ_‹@‚Éf’f‚³‚ꂽ”x•ª‰æǂ̈ê—áB‘æ‚V‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2001,7,‚‰ª.
    44. “ŒŽROKAŒE“c”Ž“¹A¬¼“¹—YA¡‘º”Ž–¾AûŠˆä³tA–ìàV@Š°A–kì´GAŽíŽsq’ˆA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAœAìTˆê˜NA‹g“c—çŽqF• ’É‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚½BurkittƒŠƒ“ƒpŽî‚̈ê—áB‘æ‚V‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2001,7,‚‰ª.
    45. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAˆäã—S–õA–î•”‚Ý‚Í‚éF”ñŒŒ‰ŽÒŠÔ“¯Žíœ‘ˆÚA‚ðŽ{s‚µ‚½Fanconi•nŒŒ‚̈ê—áB‘æ ‰ñ‘¢ŒŒŠ²×–EˆÚA§˜b‰ï,2001,7, .
    46. •£àV—³–çA”óŒû@ŽûA–{‹½˜a‹vA‘«—§—YˆêA‹{˜e—˜’jAXK—Iˆê˜YF•@ƒ}ƒXƒN‚É‚æ‚éNIPPV‚Ň–°Žž–³ŒÄ‹z‚ªƒRƒ“ƒgƒ[ƒ‹‰Â”\‚Æ‚È‚Á‚½”ñ•ŸŽRŒ^‹ØƒWƒXƒgƒƒtƒB[‚̈ê—áB‘æ37‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2001,8,‹à‘ò.
    47. ŽíŽsq’ˆAˆÉ“¡–õ“TA’†—ÑŒºˆêA–{‹½˜a‹vA”ª–ØMˆêA‹{˜e—˜’jFV¶Ž™Šú‚©‚ç•”•ª”­ì‚ª•p”­‚µ‚½“«‚Ä‚ñ‚©‚ñ‚̈ê—á‘æ37‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2001,8,‹à‘ò.
    48. ‹àŒ“O˜aA–쑺ŒbŽqAŠ}Œ´‘PmA‰ª‘º@ƒA–{‹½‹P–¾A–î•”‚Ý‚Í‚éA¬“‡¨“ñA‹{˜e—˜’jFDyskeratosis congenita‚É‚¨‚¯‚éDKC1ˆâ“`Žq‰ðÍB‘æ43‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2001,9,–k‹ãB.
    49. –쑺ŒbŽqA‹àŒ“O˜aA‹{@ˆêŽuA‹g“c@‹ªA–èŽjŽ¡A‹{˜e—˜’jFDŽ_‹…‘‘½‚𔺂Á‚½f(5;12)(q31;p12)‚ÌõF‘̈Ùí‚ðŽ‚ÂAMLM2Ä”­—áB‘æ43‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2001,9,–k‹ãB.
    50. ŽíŽsq’ˆA‰Æ鈟‹IŽqA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAÀ‘qŽü•FA‘â@´FALL‚ɑ΂·‚évincristine“Š—^‚É‚æ‚茰«‰»‚µ‚½Charcot-Marie-Tooth•a(1AŒ^)‚̈ê—áB‘æ43‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2001,9,–k‹ãB.
    51. Žs“c•™ŽqFæ“V«SŽ¾Š³‚Ìf’f‚ÆŽ¡—Ã`‘ÙŽ™f’f‚©‚çV¶Ž™‘ŠúŽ¡—ÂɌü‚¯‚Ä`B•½¬13”N“x“ú–{ŽY‰È•wl‰ÈŠw‰ï•xŽR’n•û‰ïƒVƒ“ƒ|ƒWƒEƒ€,2001,9,•xŽR.
    52. ‘ºãIŒ[A•l“¹”ü‹IA’Ô¦áÁˆêA–{ŠÔˆê³A•l“¹—T“ñA‘«—§—YˆêA‹ž’JªŽOFŽ¡—Ã’†’f‚É‚æ‚è‘å”­ì‚ð‚¨‚±‚µ‚½ŽvtŠúšb‘§‚Ì‘oŽq—áD‘æ‚S‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2001,9,•xŽR.
    53. ŽíŽsq’ˆA”‘òŽõŽqA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA‘«—§—YˆêA‹{˜e—˜’jA”ª–ØMˆêAò@‹IŽqA•Ä“c@“NA¬ìŽŸ˜YA“ñ’J@•FƒKƒ“ƒVƒNƒƒrƒ‹‚ª—LŒø‚Å‚ ‚Á‚½ÇŒó«æ“V«ƒTƒCƒgƒƒKƒƒEƒBƒ‹ƒXŠ´õǂ̈ê—áB‘æ40‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï,2001,9,‹à‘ò.
    54. ¼‘q—TŠìA•£‘ò—³–çA‘匎“N•vA‹{˜e—˜’jF‰ºŽˆ‚ÌŽ‡”Á‚ð‚Æ‚à‚È‚Á‚½—n˜A‹ÛŠ´õÇŒã‹}«Ž…‹…‘Ìt‰ŠB‘æ‚X‰ñ’†•”“ú–{¬Ž™t‘Ÿ•aŒ¤‹†‰ï,2001,9,•xŽR.
    55. Yu X., Ichida F., Hirono K., Chen R., Uese K., Hamamichi Y., Hashimoto I., Tsubata S. , Terai M., and Miyawaki T.: Nitric oxide contributes to the progression of coronary artery lesions in acute Kawasaki disease. The 23rd International Congress of Pediatrics,2001,9,Beijing,China.
    56. ‹àŒ“O˜aA‹{˜e—˜’jFƒŠƒ“ƒp‘BÇŒóŒQB•½¬13”N“x‘æ1‰ñŒ´”­«–Ɖu•s‘SÇŒóŒQ’²¸Œ¤‹†”ǔljï‹c,2001,9,¼–{.
    57. ¼–ì³’mAˆÉ“Œ“¹•vA‹gZ@ºA‘«—§—YˆêAŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§Š°‰ð—á‚Ì—Õ°ŒŸ“¢-Ž¡—Ã’†Ž~Œã‚ÌŒo‰ß‚Æ‹C“¹‰ß•q«‚Ì„ˆÚ‚ɂ‚¢‚Ä‘æ51‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï,2001,10,•Ÿ‰ª.
    58. ‰ª•””üŒbA•l“¹”ü‹IA”‘òŽõŽqAŽRŒ³ƒŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jF––½ŒŒ‚s×–E‚É‚¨‚¯‚éCCR7”­Œ»‚Ì”N—î“I„ˆÚ‚Æ‚»‚Ì‹@”\‚ÉŠÖ‚·‚錟“¢B‘æ51‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï,2001,10,•Ÿ‰ª.
    59. ”ÂàVŽõŽqA’†—ÑŒºˆêA•£àV—³–çA‰¡“cF”VA”öã—mˆêA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[F––½ŒŒ’P‹…‚É‚¨‚¯‚éIL-12ŽY¶”\‚ÆIL-10ŽY¶”\‚Æ‚ÌŠÖŒWB‘æ51‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï,2001,10,•Ÿ‰ª.
    60. ŽíŽsq’ˆA‘匎“N•vA“ŒŽROKA”ÂàVŽõŽqA“‡’ÃeŽuA‘哈‹`”ŽA‘«—§—YˆêA‹{˜e—˜’jF“–‰RSƒEƒCƒ‹ƒX‚É‚æ‚é׋CŠÇŽx‰Š‚Æl‚¦‚ç‚ꂽŒŒŠÇ—Ö‚Ì‚Q‚©ŒŽ—Ž™—áB‘æ34‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,2001,10,•Ÿ“‡.
    61. •£àV—³–çA‰eŽR—²ŽiA–쑺ŒbŽqA‹àŒ“O˜aA‹{Œ´²–íAŒ´@—SˆèA‘«—§—YˆêA‹{˜e—˜’jFp‘O‚É”x”^ᇂÆf’f‚³‚ê‚Ä‚¢‚½inflammatory myo-fibroblastic tumor‚Ì‚P’jŽ™—áB‘æ34‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,2001,10,•Ÿ“‡.
    62. ‘«—§—zŽqA‰¡“cF”VA•l“¹”ü‹IA‰ª•””üŒbA”ÂàVŽõŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[F‹CŠÇŽxšb‘§Ž™‚É‚¨‚¯‚éƒÀŽhŒƒ–ò‹z“ü‚ɑ΂·‚锽‰ž«‚ÌŒŸ“¢@-ŒoŽž“I‘ª’è‚É‚æ‚銳ŽÒŽw“±‚ւ̉ž—p‚ɂ‚¢‚Ä-B‘æ38‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2001,10,¬‘q.
    63. ”ÂàVŽõŽqA’†—ÑŒºˆêA•£àV—³–çAŽRŒ³ƒŽqA”öã—mˆêA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jAˆäãŽõ–ÎFƒtƒ‹ƒ`ƒJƒ]ƒ“‹z“üŠJŽnŒã‚ÉŒ°Ý‰»‚µ‚½Churg-Strauss ÇŒóŒQ‚Æl‚¦‚ç‚ê‚é1’jŽ™—áD‘æ38‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2001,10,¬‘q.
    64. “ñ’J@•A”ª–ØMˆêA‰Æ鈟‹IŽqAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÃeŽuA‘哈‹`”ŽA’Ãì@—ÍA“¿ŽR•ŽqA•Ä“c@“NAÄ“¡@Ž F‹CŠÇ“àƒXƒeƒ“ƒg—¯’u‚É‚æ‚èŒÄ‹zó‘Ԃ̉ü‘P‚ª“¾‚ç‚ꂽ¶Žå‹CŠÇ‹·óǂ̈ê—áB‘æ15‰ñ–k—¤–¢nŽ™V¶Ž™Œ¤‹†‰ï,2001,10,‹à‘ò.
    65. “ñ’J@•A”ª–ØMˆêA‹{˜e—˜’jA²X–Ø@‘×AÄ“¡@Ž F‚wõF‘Ì’·˜r•”•ª‰ßè‚𔺂Á‚½‚U”ÔõF‘Ì’Z˜r•”•ªŒ‡Ž¸‚Ì’jŽ™—áB‘æ22‰ñ–k—¤æ“VˆÙ팤‹†‰ï,2001,11,•xŽR.
    66. –쑺ŒbŽqA‹àŒ“O˜aA“ñ’J@•A‹{˜e—˜’jF‚w˜A½–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚É‚¨‚¯‚éƒÁƒOƒƒuƒŠƒ“’uŠ·—Ö@BIVIGƒgƒ„ƒ}ƒtƒH[ƒ‰ƒ€,2001,11,•xŽR.
    67. Hashimoto I., Davies C. H., Lee J.S., Ichida F., Miyawaki T., and Sahn D. J. : Improved detection of modeled old myocardial infarction using strain rate imaging in comparison to tissue doppler: In vitro studies using a "calibrated" myocardial phantom which mimics tethering. The 74rd scientific sessions of american heart association, 2001,11,Anaheim,USA.
    68. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF‚w˜A½–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚É‚¨‚¯‚éƒÁƒOƒƒuƒŠƒ“’uŠ·—Ö@B‘æ33‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,2001,11,‰F•”.
    69. ‹àŒ“O˜aA‰¤@‰xA–쑺ŒbŽqA‹{˜e—˜’jA–ìXŽRŒbÍFƒuƒ‰ƒWƒ‹‚É‚¨‚¯‚éæ“V«–Ɖu•s‘SÇ‚Ìf’fB‘æ33‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,2001,11,‰F•”.
    70. ‹àŒ“O˜aFƒVƒ“ƒ|ƒWƒEƒ€uX-linked lympho-proliferative syndromev‘æ29‰ñ“ú–{—Õ°–ƉuŠw‰ï,2001,12,‘åã.
    71. Wang Y., Nomura K., Futatani T., Kanegane H., and Miyawaki T. : A novel Igƒ¿(CD79a) gene mutation in a Turkish patient with B cell deficient agammaglobulinemia. ‘æ29‰ñ“ú–{—Õ°–ƉuŠw‰ï,2001,12,‘åã.
    72. –쑺ŒbŽqA“ñ’J@•A‹àŒ“O˜aA‹{˜e—˜’jF‚w˜A½–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚É‚¨‚¯‚éƒÁƒOƒƒuƒŠƒ“’uŠ·—Ö@B‘æ29‰ñ“ú–{—Õ°–ƉuŠw‰ï,2001,12,‘åã.
    73. “ñ’J@•A‹àŒ“O˜aA‹{˜e—˜’jA“n•Óç»AOchs HansA”nê‹`—TA’Ë“c@‘FŒŒ¬”‚ɂ¨‚¯‚éƒuƒ‹ƒgƒ“Œ^ƒ`ƒƒVƒ“ƒLƒi[ƒ[‚Ì”­Œ»‚Æ‚»‚ÌŠ³ŽÒE•ÛˆöŽÒf’f‚ւ̉ž—pB‘æ31‰ñ“ú–{–ƉuŠw‰ï,2001,12,‘åã.
    74. “ñ’J@•A”ª–ØMˆêA¬ìŽŸ˜YAŽíŽsq’ˆA‹{˜e—˜’jA•Ä“c@“NA²X–Ø‘×AÄ“¡@Ž FƒRƒCƒ‹Çðp‚É‚æ‚è‹~–½‚µ“¾‚½æ“V«“ªŠW“à“®Ã–¬á‘‚̈ê—áB‘æ46‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ï,2001,12,‰¡•l.
    75. ŽíŽsq’ˆA¬ìŽŸ˜YA•Ä“c@“NA“ñ’J@•A”ª–ØMˆêAÄ“¡@Ž A”‘òŽõŽqA‹{˜e—˜’jFæ“V«ƒTƒCƒgƒƒKƒŠ´õÇ‚É‚¨‚¯‚éMxA’`”’”­Œ»‚ÌŒoŽž“I‘ª’è‚Æ‚»‚̈Ӌ`B‘æ46‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ï,2001,12,‰¡•l.
    76. ‘«—§—zŽqA•l“¹”ü‹IA‰ª•””üŒbA”ÂàVŽõŽqA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[F‹CŠÇŽxšb‘§Ž™‚É‚¨‚¯‚éƒÀŽhŒƒ–ò‹z“ü‚ɑ΂·‚锽‰ž«‚ÌŒŸ“¢@-ŒoŽž“I‘ª’è‚É‚æ‚銳ŽÒŽw“±‚ւ̉ž—p‚ɂ‚¢‚Ä-B•xŽRšb‘§Œ¤‹†‰ï,2001,12,•xŽR.
    77. ”ÂàVŽõŽqA’†—ÑŒºˆêA•£àV—³–çA•l“¹”ü‹IA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[FV¶Ž™‚É‚¨‚¯‚éIL-12ŽY¶”\’ቺ‚ÆIL-10‚È‚ç‚Ñ‚ÉIL-18ŽY¶”\‚Æ‚ÌŠÖŒWD‘æ28‰ñ–k—¤ƒAƒŒƒ‹ƒM[§˜b‰ï,2001,12,‹à‘ò.

    2000”N

  • ’˜‘
    1. Žs“c•™ŽqFS“à–ŒüˆÛ’e«ÇBu¡“ú‚ÌzŠÂŠíŽ¾Š³Ž¡—ÃŽwjA‘æ2”Åvדcºˆê‘¼•ÒAˆãŠw‘‰@,2000.
    2. Žs“c•™ŽqFæ“V«SŽ¾Š³Bu‚í‚©‚è‚â‚·‚¢“à‰ÈŠw‰ü’ù‘æ2”Åvˆä‘º—T•v‘¼•Ò,•ªŒõ“°,“Œ‹ž,2000.
  • Œ´’˜
    1. Uese K., Hagiwara N., Miyawaki T., and Kasanuki H. : Properties of the transient outward current in sino-atrial node cells. J Mol Cell Cardiol 31 : 1975-1984,1999.
    2. Kanegane H., Nomura K., Miyawaki T., Sasahara Y., Kawai S., Tsuchiya S., Murakami G., Futatani T., and Ochs HD. : X-linked thrombocytopenia identified by flow cytometric demonstration of defective Wiskott-Aldrich syndrome protein in lymphocytes. Blood 95 : 1110-1111,2000.
    3. Kanegane H., Tsukada S., Iwata T., Futatani T., Nomura K., Yamamoto J., Yoshida T., Agematsu K., Komiyama A., and Miyawaki T.: Detection of Bruton's tyrosine kinase mutations in hypogammaglobulinaemic males registered as common variable immunodeficiency (CVID) in the Japanese Immunodeficiency Registry. Clin. Exp. Immunol.120 : 512-517 ,2000.
    4. Nomura K., Kanegane H., Karasuyama H., Tsukada S., Agematsu K., Murakami G., Sakazume S., Sako M., Tanaka R., Kuniya Y., Komeno T., Ishihara S., Hayashi K., Kishimoto T., and Miyawaki T.: The genetic defect in human X-linked agammaglobulinemia impedes a maturational evolution of pro-B cells into later stage of pre-B cells in B cell differentiation pathway. Blood 96 : 610-617,2000.
    5. Tsubata S., Bowles KR., Vatta M., Zintz C., Titus J., Muhonen L., Bowles NE., and Towbin JA. : Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardio-myopathy. J Clin Invest. 106 : 655-662,2000.
    6. Yamamoto J., Adachi Y., Onoue Y., Kanegane H., Miyawaki T., Toyoda M., Seki T., and Morohashi M. : CD30 expression on circulating memory CD4+ T cells as a Th2-dominated situation in patients with atopic dermatitis. Allergy 55 : 1011-1018,2000.
    7. Yamamoto J., Adachi Y., Onoue Y., Adachi Y.S., Okabe Y., Itazawa T., Toyoda M., Seki T., Morohashi M,. Matsushima K., and Miyawaki T.: Differential expression of the chemokine receptors by the Thl - and Th2-type effector populations within circulating CD4+ T cells . J Leuk. Biol. 68 : 568-574,2000.
    8. Striz I., Mio T., Adachi Y., Robbins R. A., Romberger D. J., Rennard S. I.: IL-4 and IL-13 stimulate human bronchial epithelial cells to release IL-8. Inflammation 23 : 545-555,1999.
    9. Striz I., Mio T., Adachi Y., Romberger D. J., Rennard S. I.: Th2-type cytokines modulate IL-6 release by human bronchial epithelial cells. Immunol. Letters 70:83-88;1999.
    10. Yamaguchi T., Murakami A., Fukahara K., Ueda T., Ichida F., Miyawaki T., and Misaki T. : Changes in T-cell receptor subsets after cardiac surgery in children.@Surg Today. 30 : 875-878,2000.
    11. Tsunoda S., Kawano M., Koni I., Kasahara Y., Yachie A., Miyawaki T., and Seki H. : Diminished expression of CD59 on activated CD8+ T Cells undergoing apoptosis in systemic lupus erythematosus and Sjgren's syndrome. Scand. J. Immunol. 51 : 293 -299,2000.
    12. Honda K., Kanegane H., Eguchi M., Kimura H., Morishima T., Masaki K., Tosato G., Miyawaki T., and Ishii E. : Large deletion of the X-linked lymphoproliferative disease gene detected by fluorescence in situ hybridization. Am. J. Hematol. 64: 128-132, 2000.
    13. Uozaki Y., Murakami A., Yanagi K., Ichida F., Hashimoto I., and Misaki T. : Total anomalous pulmonary venous connection with bronchogenic cyst in neonatal period. Jpn J Thorac Cardiovasc Surg. 48 : 583-585,2000.
    14. Bowles KR., Abraham SE., Brugada R., Zintz C., Comeaux J., Sorajja D., Tsubata S., Li H., Brandon L., Gibbs RA., Scherer SE., Bowles NE., and Towbin JA. : Construction of a highresolution physical map of the chromosome 10q22-q23 dilated cardiomyopathy locus and analysis of candidate genes. Genomics. 67 : 109-27,2000.
    15. Striz I., Mio T., Adachi Y., Carnevali S., Romberger D. J., Rennard S. I.: Effects of interferons alpha and gamma on cytokine production and phenotypic pattern of human bronchial epithelial cells. Int. J. Immuno-pharmaco. 22:573-587;2000.
    16. Miura M., Yachie A., Hashimoto I., Okabe T., Murata N., Fukuda A., and Koizumi S. : Coexistence of lymphoblastic and monoblastic populations with identical mixed lineage leukemia gene rearrangements and shared immunoglobulin heavy chain rearrangements in leukemia developed in utero. J. Pediatr. Hematol Oncol. 22 : 81-85,2000.
    17. ‹àŒ“O˜aA–쑺ŒbŽqA‹{˜e—˜’jF‚w˜A½–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚É‚¨‚¯‚éD’†‹…Œ¸­B“ú–{¬Ž™Š´õ–Ɖu@12F107-111, 2000.
    18. ŽR’J”ü˜aA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vA”ª–ØMˆêF‚Ä‚ñ‚©‚ñŽ¡—Ã’†Ž~—á‚É‚¨‚¯‚éÄ”­“Á’¥[”N—îˆöŽq‚ÌŠÖ—^‚ɂ‚¢‚Ä[B”]‚Æ”­’B@32F15-20,2000.
    19. ‰¡“cF”VA‘«—§—YˆêA‘ºãIŒ[A¼–ì³’mAŒÜ\—’—²•vA”öã—mˆêA‘«—§—zŽqAŽRŒ³ƒŽqA‰ª•””üŒbA”ÂàVŽõŽqA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‰Æ’ë‚É‚¨‚¯‚é“d“®Ž®ƒlƒuƒ‰ƒCƒU[‚ð—p‚¢‚½”­ìŽžƒÀŽhŒƒÜ‹z“ü‚ÌŽÀ‘Ô’²¸D“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@14:212-218;2000.
  • Ç—á•ñ
    1. Hamamichi Y., Okada E., and Ichida F.: Anomalous origin of the left main coronary artery from non-facing sinus of valsalva associated with sudden death in a young athlete. Cardiol Young 10 : 147-149,2000.
    2. Shinomiya N., Kanegane H., Watanabe A., Yamaguchi Y., Fuitatani T., and Miyawaki T.: Point mutation in intron 11 of Brutons's tyrosine kinase in atypical X-linked agamma-globulinemia. Pediatr Int. 42 : 689-692,2000.
    3. Ichida F.: Anomalous origin of the left main coronary artery from non-facing sinus of valsalva associated with sudden death in a young athlete. Cardiol. Young. 10 : 669,2000.
    4. ‹g“cärA‹àŒ“O˜aA‘«—§—zŽqA‹{˜e—˜’jF‘åò–åŠJ‘å‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚½½œ“ªŠWˆÙŒ`¬ÇB¬Ž™‰È@41F2061-2062,2000.
    5. ŒÃ‰®FŽqA–x“c’qåA›À@—²A•½–؉ë‹vAèŽRK—YA‹àŒ“O˜aA‹{˜e—˜’jF‚w˜A½–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚Ì‚P—áB—Õ°¬Ž™ˆãŠw@47F175-178,1999.
  • ‘à
    1. ‹{˜e—˜’jA‹àŒ“O˜aA“ñ’J@•F‚a×–E‰Šú•ª‰»áŠQ‚Æ‚µ‚Ä‚Ì–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇB“ú–{—Õ°–ƉuŠw‰ïŽ@23F435-444,2000.
    2. ‘«—§—YˆêAŽRŒ³ƒŽqA‹{˜e—˜’jF––½ŒŒ‚s×–EƒTƒuƒZƒbƒg‚É‚¨‚¯‚é×–E“àƒTƒCƒgƒJƒCƒ“‘ª’è‚Ì—Õ°“IˆÓ‹`BCYTOMETRY RESEARCH 10F9-16,2000.
    3. ‘«—§—YˆêAŽRŒ³ƒŽqA‹{˜e—˜’jFƒqƒg––½ŒŒƒwƒ‹ƒp[‚s×–Eã‚̃Pƒ‚ƒJƒCƒ“ƒŒƒZƒvƒ^[”­Œ»B—Õ°–Ɖu@34F302-308, 2000.
    4. ‘«—§—YˆêFŽvtŠúšb‘§‚ƃÀ2ŽhŒƒÜMDIBƒAƒŒƒ‹ƒM[‚Ì—Õ°@20F934-934,2000.
    5. ”ª–ØMˆêA–{‹½˜a‹vA¬¼@“OA‹{˜e—˜’jF¬Ž™‚ÌW’†Ž¡—Ã[‚¯‚¢‚ê‚ñdÏB@¬Ž™“à‰È@32F161-168,2000.
    6. ‹àŒ“O˜aA‹{˜e—˜’jF–ƉuÇŒóŒQ`‚»‚Ì‘¼‚̖ƉuŽ¾Š³‚ðŠÜ‚ß‚Ä`‚w˜A½–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇB“ú–{—Õ°—̈æ•ÊÇŒóŒQƒVƒŠ[ƒYNo.32 59-62,2000.
    7. ‹àŒ“O˜aA‹{˜e—˜’jF–ƉuÇŒóŒQ`‚»‚Ì‘¼‚̖ƉuŽ¾Š³‚ðŠÜ‚ß‚Ä`íõF‘Ì«—ò«Œ^–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇB“ú–{—Õ°@—̈æ•ÊÇŒóŒQƒVƒŠ[ƒYNo.32 63-65,2000.
    8. âV“¡–œ—¢ŽqA‹àŒ“O˜aA‹{˜e—˜’jF–ƉuÇŒóŒQ`‚»‚Ì‘¼‚̖ƉuŽ¾Š³‚ðŠÜ‚ß‚Ä`¬’·ƒzƒ‹ƒ‚ƒ“Œ‡‘¹‚𔺂¤”º«Œ^’áƒÁƒOƒƒuƒŠƒ“ŒŒÇB“ú–{—Õ°@—̈æ•ÊÇŒóŒQƒVƒŠ[ƒYNo.32 69-71,2000.
    9. ‹àŒ“O˜aAŽÂ茒‘¾˜YA‹{˜e—˜’jA{–è@—ºF‚w˜A½ƒŠƒ“ƒp‘BÇŒóŒQ‚Ì•aˆöE•a‘Ô‚ÆŽ¡—ÃB¬Ž™“à‰È@32F2024-2026 ,2000.
    10. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF_ŒoÇŒóŒQ`‚»‚Ì‘¼‚Ì_ŒoŽ¾Š³‚ðŠÜ‚ß‚Ä`Langerhans×–E‘gD‹…ÇB“ú–{—Õ°•Êû@—̈æ•ÊÇŒóŒQƒVƒŠ[ƒY 30 : 369-373,2000.
    11. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF”º«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì•aˆöE•a‘Ô‚ÆŽ¡—ÃB¬Ž™“à‰È32F1992-1995 ,2000.
    12. ‘«—§—zŽqA‘«—§—YˆêFƒAƒgƒs[«”畆‰Š“û—cŽ™‚É‚¨‚¯‚é‹CŠÇŽxšb‘§”­Ç‚Ì—\–hBšb‘§ 13F43-48 ,2000.
    13. ¼‘òƒŽqA¬¼@“OA–{‹½˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF”M«‚¯‚¢‚ê‚ñƒvƒ‰ƒX‚ð‚à‚‘S”Ê‚Ä‚ñ‚©‚ñ‰ÆŒn‚ɂ‚¢‚ÄB¬Ž™‰È—Õ°@53F23- 27,2000.
    14. âV“¡@Ž A‹{˜e—˜’jFä`‘ÑŒŒ‚Ì•ªŽq¶•¨ŠwE–Ɖu’S“–×–EBŒŒ‰tE–ƉuEŽîᇠ5 : 257-263,2000.
    15. {–è@—ºA¬—ÑçŒbAˆÉ–{‰ÄŽ÷A¼ˆä@—zA‹àŒ“O˜aA‹{˜e—˜’jFXLPFEBƒEƒCƒ‹ƒX‚É“ÁˆÙ“I‚ȖƉu•s‘SÇB‘gD”|—{HŠw 26F239-242,2000.

  • 2000”NŠw‰ï•ñ
    1. ŽíŽsq’ˆA‹g“c@‹ªA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF“¯Žíœ‘ˆÚA‚ðŽ{s‚µ‚½Ki-1 lymphomaÄ”­—áB‘æ‚S‰ñŒŒ‰tŽ¾Š³‚ƃTƒCƒgƒJƒCƒ“Œ¤‹†‰ï,2000,1,‹à‘ò.
    2. Adachi Y., Onoue Y., Yamamoto J., Adachi Y.S., Seki D., Toyoda M., Morohashi M., Matsushima K., and Miyawaki T.: Selective Expression of CD30 and CCR4, but not CCR3 on Circulating CD4+ Cells as a Marker for Th2-type. AAAI,2000,2,
    3. 㨌hˆê˜YAŒIŒ´^‹IŽqA’Ô¦áÁˆêA‘«—§—YˆêAŽs“c•™ŽqA‹{˜e—˜’jA ‰F‰—è‘×OF‹CŠÇŽx“î‰»Ç‚ð‡•¹‚µ’˜–¾‚È”x‚ŒŒˆ³‚ð‡•¹‚µ‚½SŽº’†ŠuŒ‡‘¹‚̈ê—áB‘æ19‰ñ–k—¤¬Ž™zŠÂŠí§˜b‰ï,2000,2,‹à‘ò.
    4. à_“¹—T“ñA¼“c–¤A‰ª•”@ŒhAŽO‰Y³‹`A–ìè‹IŽqAç’¹“N–çAŽs“c•™ŽqF‘ÙŽ™Šú‚æ‚è㎺«•p”‚ð’悵Ž¡—Âɓïa‚µ‚½ˆê—áB‘æ‚U‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŒ¤‹†‰ï,2000,2,_“Þì.
    5. ŒIŒ´^‹IŽqA“n•Óˆ»‰ÀA㨌hˆê˜YA’Ô¦áÁˆêA‘«—§—YˆêAŽs“c•™ŽqA‹{˜e—˜’jA‰F‰—è‘×OF‹CŠÇŽx“î‰»Ç‚ð‡•¹‚µ’˜–¾‚È”x‚ŒŒˆ³‚ð‡•¹‚µ‚½SŽº’†ŠuŒ‡‘¹‚̈ê—áB‘æ6‰ñ¬Ž™”xzŠÂŒ¤‹†‰ï,2000,2,“Œ‹ž.
    6. ŽRŒ³ƒŽqA‘«—§—YˆêA”öã—mˆêA–L“c‰ë•FAŠÖ@‘¾•ãA”‹´³ºA‹{˜e—˜’jFƒAƒgƒs[«”畆‰ŠŠ³ŽÒ––½ŒŒT×–E‚É‚¨‚¯‚éƒPƒ‚ƒJƒCƒ“EƒŒƒZƒvƒ^[”­Œ»‚ɂ‚¢‚ÄB‘æ21‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2000,2,•xŽRD
    7. ”ª–ØMˆêA¬¼@“OA“n•Óˆ»‰ÀA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jAŽRŒ³ƒŽqAFè@Œ’F‘ÙŽ™…Žî‚ð’悵‚½ƒŠƒ\ƒ\-ƒ€•a‚Ì’jŽ™—áB‘æ37‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï,2000,2,‹à‘ò.
    8. ‘«—§—zŽqA‘«—§—YˆêA”öã—mˆêA‘ºãIŒ[F¬Ž™‚É‚¨‚¯‚éƒlƒRƒAƒŒƒ‹ƒM[‚Ì—Õ°B‘æ10‰ñ“’“cãƒJƒ“ƒtƒ@ƒŒƒ“ƒXšb‘§ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2000,2,VŠƒD
    9. Hashimoto I., Mori Y., Xiaokui L., Suthep W., Rosemary A R., and D. J. Sahn. : Strain rate imaging : An in vitro validation study using a physiologic balloon model mimicking the Left ventricle. American College of Cardiology 49th Annual Scientific Session,2000,3,California.
    10. “n•Óˆ»‰ÀA‹g“cärA‹àŒ“O˜aA”ª–ØMˆêA‹{˜e—˜’jA“c’†’¼ŽqA–Ø‘º@GFƒKƒ“ƒVƒNƒƒrƒ‹“Š—^‚ðs‚Á‚½æ“V«ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠ´õǂ̈ê—áB‘æ268‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,2000,3,‹à‘ò.
    11. ¼–ì³’mAˆÉ“Œ“¹•vA‘«—§—YˆêAŒÜ\—’—²•vF’·ŠúŠÔ–³”­ì‚ÅŒo‰ß‚µ‚Ä‚¢‚é‹CŠÇŽxšb‘§Ž™‚Ì‹C“¹‰ß•q«‚¨‚æ‚ьċz‹@”\‚Ì„ˆÚ‚ɂ‚¢‚Ä‚ÌŒŸ“¢B‘æ36‰ñ‹C“¹‰ß•q«Œ¤‹†‰ï,2000,3,“Œ‹žD
    12. ”ª–ØMˆêA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jF“M…Œã‚É“_“ª‚Ä‚ñ‚©‚ñ‚ð”­Ç‚µ‚½ˆê—áB‘æ24‰ñ–k—¤‚Ä‚ñ‚©‚ñ§˜b‰ï,2000,3,‹à‘ò.
    13. –{‹½˜a‹vA¬¼@“OA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jFÇŒó«‘S”Ê‚Ä‚ñ‚©‚ñB‘æ24‰ñ–k—¤‚Ä‚ñ‚©‚ñ§˜b‰ï,2000,3,‹à‘ò.
    14. ‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‘«—§—zŽqA‹{˜e—˜’jFƒAƒgƒs[«”畆‰Š––½ŒŒƒTƒuƒZƒbƒg‚ł̃Pƒ‚ƒJƒCƒ“ƒŒƒZƒvƒ^[”­Œ»‚Ì—Õ°“IˆÓ‹`B‘æ103‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2000,4,˜a‰ÌŽR.
    15. ‹àŒ“O˜aA{–è—ºAŽÂ茒‘¾˜YA¼‘q—TŠìA¼ˆä@—zA˜`@˜a”üA]Œû^—ŽqA–{“cŒiŽqAΈäžÄˆêA‹{˜e—˜’jF‚w˜A½ƒŠƒ“ƒp‘BŽ¾Š³‚É‚¨‚¯‚é‚r‚`‚oˆâ“`ŽqˆÙíB‘æ103‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2000,4,˜a‰ÌŽR.
    16. –쑺ŒbŽqA‹àŒ“O˜aA㼈ê‰iA¬‹{ŽR~A‹{˜e—˜’jF‚w˜A½–³ƒÁ-ƒOƒƒuƒŠƒ“ŒŒÇ‚É‚¨‚¯‚霑‚a‘O‹ì×–E‚̉ðÍB‘æ103‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2000,4,˜a‰ÌŽR.
    17. ‹g“cärA‹àŒ“O˜aA‹{˜e—˜’jA¡–ìºGF½œE“ªŠWˆÙŒ`¬Ç‚É‚¨‚¯‚éCBFA1•ÏˆÙB‘æ103‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2000,4,˜a‰ÌŽR.
    18. ˜°@Œ›ˆêA‹´–{ˆè•vAŽs“c•™ŽqA㨌hˆê˜YAà_“¹—T“ñA’Ô¦áÁˆêA‹{˜e—˜’jFƒWƒsƒŠƒ_ƒ‚[ƒ‹•‰‰×Integrated Backscatter‚É‚æ‚éìè•aŒãS‹Ø‹•ŒŒ‚Ìf’fB@‘æ103‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2000,4,˜a‰ÌŽR.
    19. ‘«—§—YˆêAŽRŒ³ƒŽqA‰ª•””üŒbA”öã—mˆêA¼“‡jŽ¡A‹{˜e—˜’jF––½ŒŒ‚s×–E‚É‚¨‚¯‚éTh2ƒ}[ƒJ[‚Æ‚µ‚ẴPƒ‚ƒJƒCƒ“ƒŒƒZƒvƒ^[- CCR3‚ÆCCR4‚ɂ‚¢‚Ä -B‘æ12‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,2000,4,•Ÿ‰ª.
    20. ¼–ì³’mAˆÉ“Œ“¹•vA‘«—§—YˆêA‹gZ@ºFƒCƒ\ƒvƒƒeƒŒƒm[ƒ‹Ž‘±‹z“ü—Ö@‚Ì—Õ°“IŒŸ“¢@- dl ‘Ì‚Æ l ‘Ì‚Ì”äŠrŒŸ“¢ -B‘æ12‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,2000,4,•Ÿ‰ª.
    21. ”ÂàVŽõŽqA‘ºãIŒ[A‰¡“cF”VA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§”­ì‚É‚¨‚¯‚éƒEƒCƒ‹ƒXŠ´õ‚ÌŠÖ—^‚Ì‹Gß“I•Ï“®@-MxA’`”’‚ðŽw•W‚Æ‚µ‚Ä-B‘æ12‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,2000,4,•Ÿ‰ª.
    22. ‘«—§—zŽqA‰ª•””üŒbA”‘òŽõŽqA‘«—§—YˆêA‹{˜e—˜’jFƒAƒgƒs[«”畆‰Š“û—cŽ™‚Ìšb‘§‚ւ̈Ús‚ƃlƒR‚È‚ç‚Ñ‚ÉH•¨ƒAƒŒƒ‹ƒM[‚ÌŠÖŒWB‘æ37‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,2000,4,•xŽRD
    23. ŽÂ茒‘¾˜YA‹àŒ“O˜aA¼‘q—TŠìA‹{˜e—˜’jA{–è—ºF‚w˜A½ƒŠƒ“ƒp‘BŽ¾Š³‚̊ȈÕf’f–@‚ÌŠJ”­B‘æ10‰ñEBƒEƒBƒ‹ƒXŒ¤‹†‰ï,2000,5,“Œ‹ž.
    24. –쑺ŒbŽqA‹àŒ“O˜aA‹{@ˆêŽuA‹{˜e—˜’jA¯–ì@—mA–Ø‘º@GA–Ø‘º’¨GA‘哇FˆêF“¯Ží––½ŒŒŠ²×–EˆÚA‚ðs‚Á‚½EBƒEƒBƒ‹ƒXŠÖ˜AƒÁƒÂ-T×–EƒŠƒ“ƒpŽî‚̈ê—áB‘æ10‰ñEBƒEƒBƒ‹ƒXŒ¤‹†‰ï,2000,5,“Œ‹ž.
    25. Kanegane H., Futatani T., Nomura K., and Miyawaki T. : Genetic analysis of X-linked agammaglobulinemia identified by flow cytometricanalysis in unrelated 65 Japanese families. The 7th international workshop and conference on human leucocyte differentation antigens.,2000,6,Harrogate,U.K.
    26. Nomura K., Kanegane H., Karasuyama H., and Miyawaki T.: Genetic defect in human X-linked agammaglobulinemia impedes the maturational evolution of pro-B cells into later stage of pre-B cells in the B cell differentiation pathway. The 7th international workshop and conference on human leucocyte differentation antigens.,2000,6,Harrogate,U.K.
    27. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jA“n•Óˆ»‰ÀA’†—ÑŒºˆêA‘ºãIŒ[A–{ŠÔˆê³A–î•”‚Ý‚Í‚éFŒŒ¬”ÂŒ¸­‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚½Fanconi•nŒŒ‚̈ê—áB‘æ269‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,2000,6,‹à‘ò.
    28. ¼‘q—TŠìA”öã—mˆêA‹{˜e—˜’jFƒVƒNƒƒtƒHƒXƒAƒ~ƒhEƒpƒ‹ƒX—Ö@‚ª—LŒø‚Å‚ ‚Á‚½ƒ‹[ƒvƒXt‰Š‚̈ê—áB‘æ35‰ñ“ú–{¬Ž™‰ÈŠw‰ït‘Ÿ•aŠw‰ï,2000,6,•Ÿ‰ª.
    29. –{‹½˜a‹vA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jA¬¼@“OF”­ì«‰^“®—U”­«•‘“¥ƒAƒeƒg-ƒ[‚É_Œo’²ß«Ž¸_‚ð‡•¹‚µ‚½1—áB‘æ42‰ñ“ú–{¬Ž™_ŒoŠw‰ï,2000,6,‘åã.
    30. ¼‘òƒŽqA¬¼@“OA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêFŒ’펙”]‚Ì‚É‚¨‚¯‚éŠD”’Ž¿‚¨‚æ‚Ñ”’Ž¿‘ÌÏ‚Ì”N—î“I•Ï‰»B‘æ42‰ñ“ú–{¬Ž™_ŒoŠw‰ï,2000,6,‘åã.
    31. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jA‹{@ˆêŽuF“¯Ží––½ŒŒŠ²×–EˆÚA‚ðs‚Á‚½EBƒEƒBƒ‹ƒXŠÖ˜AƒÁƒÂ-T×–EƒŠƒ“ƒpŽî‚̈ê—áB‘æ‚T‰ñ•xŽR‘¢ŒŒŠ²×–EˆÚA§˜b‰ï,2000,6,•xŽR.
    32. ‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’j, D.J. Sahn.FTissue Doppler ƒGƒR[–@‚ÌDoppler AngleˆË‘¶«‚ÌŒŸ“¢B‘æ7‰ñ–k—¤zŠÂŠí’´‰¹”gŒ¤‹†‰ï,2000,6,‹à‘ò.
    33. ˜°@Œ›ˆêA‹´–{ˆè•vAŽs“c•™ŽqAà_“¹—T“ñA㨌hˆê˜YA’Ô¦áÁˆêA‹{˜e—˜’jAD. J. SahnA£ŒË@ŒõFTissue Doppler ƒGƒR[–@‚ÌDoppler AngleˆË‘¶«‚ÌŒŸ“¢B‘æ7‰ñ–k—¤zŠÂŠí’´‰¹”gŒ¤‹†‰ï,2000,6,‹à‘ò.
    34. Kanegane H., Yoshida T.,and Miyawaki T.: Clinical and genetic analysis of cleidocranial dysplasia in Japan. International workshop on the runt-domain transcription factors,2000,7,Kyoto.
    35. ŒIŒ´^‹IŽqAFè@Œ’Aà_“¹”ü‹IA‘«—§—YˆêF“Á”­«”xƒwƒ‚ƒWƒfƒ[ƒVƒX‚Ì‚P’jŽ™—áD‘æ‚T‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2000,7,•xŽR.
    36. ˜°@Œ›ˆêAL–ìŒbˆêAà_“¹—T“ñA㨌hˆê˜YA‹´–{ˆè•vA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jFìè•a‹}«Šú‚É‚¨‚¯‚é’P‹…‚Å‚ÌVEGF‚ÆiNOS”­Œ»‚̈Ӌ`B‘æ36‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2000,7,Ž­Ž™“‡.
    37. à_“¹—T“ñAL–ìŒbˆêA㨌hˆê˜YA‹´–{ˆè•vA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jF–{–M‚É‚¨‚¯‚éIsolated noncompaction of ventricular myo-cardium‚Ì’ÇÕ’²¸B‘æ36‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2000,7,Ž­Ž™“‡.
    38. Žs“c•™ŽqA’Ô¦áÁˆêA㨌hˆê˜YAà_“¹—T“ñA‹´–{ˆè•vA‹{˜e—˜’jAJ A. TowbinFS‹Øãk–§‰»áŠQ‚̈â“`Žq‰ðÍB‘æ36‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2000,7,Ž­Ž™“‡.
    39. 㨌hˆê˜YAŒIŒ´^‹IŽqA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA“¡–Ø@–¾F‰^“®Žž‚ÌŽ¸_”­ì‚É‚Ä”­Ç‚µ‚½Šî‘bŽ¾Š³‚Ì‚È‚¢S–[‘e“®‚̈ê—áB‘æ36‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2000,7,Ž­Ž™“‡.
    40. Kanegane H., Shinozaki K., Sumazaki R., Matsukura H., and Miyawaki T. : Genetic analysis of X-linked lymphoproliferative disease in Japan. 28th World congress of the international socity of hematology,2000,8,Toronto,Canada.
    41. ¬ìŽŸ˜YAà_“¹”ü‹IA‹g“cärA‹{˜e—˜’jA²X–Ø@‘×AœA–ìŒbˆêA”öã—mˆêFKasabach-MerrittÇŒóŒQ‚̈êV¶Ž™—áB‘æ36‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2000,8,–¼ŒÃ‰®.
    42. ‰eŽR—²ŽiA’Ô¦áÁˆêA–쑺ŒbŽqA‹àŒ“O˜aA‹´–{ˆè•vAŽs“c•™ŽqAŒE“c”Ž“¹A‹{˜e—˜’jF_Œo߉èŽîŠ°‰ðŒã‰“ŠuŠú‚É‘ˆ«‚µ‚½”ÓŠúS‹@”\áŠQ‚̈ê—áB‘æ36‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2000,8,–¼ŒÃ‰®.
    43. “ŒŽROKAŽíŽsq’ˆA–{‹½˜a‹vA”ª–ØMˆêA‹{˜e—˜’jFRGM1bR‘Ì—z«‚̃Mƒ‰ƒ“ƒoƒŒ[ÇŒóŒQ‚̈ê—áB‘æ36‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2000,8,–¼ŒÃ‰®.
    44. ‹àŒ“O˜aFƒCƒuƒjƒ“ƒOƒZƒ~ƒi[u–ƉuŠÄŽ‹‹@\‚Ì”jù‚Æ‚»‚Ì‘Îô`æ“V«ŒŒ‰t–ƉuˆÙíÇ‚Ìf’f‚Ìi•àvB‘æ42‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2000,9,‘åã.
    45. –쑺ŒbŽqAŽíŽsq’ˆA‹àŒ“O˜aA‹{˜e—˜’jFR‘ã‘ÖŒy½’PƒNƒ[ƒ“R‘Ì‚ð—p‚¢‚½‚a×–E«ƒŠƒ“ƒp«”’ŒŒ•a‚Ìוª—Þ‚ÌŽŽ‚ÝB‘æ42‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2000,9,‘åã.
    46. ŽíŽsq’ˆA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF“¯Žíœ‘ˆÚA‚ðŽ{s‚µ‚½Ki-1 lymphomaÄ”­—áB‘æ42‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2000,9,‘åã.
    47. –{‹½˜a‹vA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA¬¼@“OA‹{˜e—˜’jF”M«áz¹Œã‚ÉAŒã“ª•”ž™™”g‚ðŽ¦‚·—Ç«‚Ä‚ñ‚©‚ñ‚ð”­Ç‚µ‚½Ç—á‚Ì—Õ°“IŒŸ“¢B‘æ34‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,2000,9,‘åã.
    48. ‰eŽR—²ŽiA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jA¬¼@“OFƒJƒ‹ƒoƒ}ƒ[ƒsƒ“‚É‚æ‚è”­]A–³è÷—±‹…ÇA’áƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚𗈂µ‚½4ΗŽ™—áB‘æ34‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,2000,9,‘åã.
    49. –{‹½˜a‹vA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jAŒE“c”Ž“¹FLeigh”]ǂ̈ê—áB‘æ38‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï,2000,9,‹à‘ò.
    50. ¼‘q—TŠìA”öã—mˆêA‹{˜e—˜’jF‹}«Ž…‹…‘Ìt‰Š—l‚Ì”­Ç‚ð‚µ‚½–Œ«‘B«t‰Š‚̈ê—áB‘æ‚W‰ñ’†•”¬Ž™t‘Ÿ•aŒ¤‹†‰ï,2000,9,Šò•Œ.
    51. ’Ô¦áÁˆêA㨌hˆê˜YAà_“¹—T“ñA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA“y”ì‘P˜YA‰F‰—è‘×OF—‘‰~E‚̕½‚Ì‚½‚ߌŒŠÇ‘¢‰e‚É‚æ‚éVSD‚̈ʒu‚ÌŠm”F‚É“ïa‚µ‚½TGA(III)B‘æ20‰ñ–k—¤¬Ž™zŠÂŠí§˜b‰ï,2000,9,‹à‘ò.
    52. –{‹½˜a‹vA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jA¬¼@“OF‚Ä‚ñ‚©‚ñ‚ÌŒo‰ß’†‚ÉŒ¾ŒêáŠQ‚ð‚«‚½‚µ‚½—Ž™—áB‘æ‚W‰ñ•xŽRŒ§¬Ž™—Õ°_ŒoŠwŒ¤‹†‰ï,2000,9,•xŽR.
    53. ”ª–ØMˆêA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA‹{˜e—˜’j@¬¼@“OFƒ`ƒbƒN‚ÆŠÓ•Ê‚ð—v‚µ‚½‚Ä‚ñ‚©‚ñ‚ÌŒZ’í—áB‘æ‚W‰ñ•xŽRŒ§¬Ž™—Õ°_ŒoŠwŒ¤‹†‰ï,2000,9,•xŽR.
    54. ‰¡“cF”VA‘«—§—zŽqA”ÂàVŽõŽqA‰ª•””üŒbAŽRŒ³ƒŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jFŠO—ˆ‚Å‚Ì‹CŠÇŽxšb‘§Ž™‚ɑ΂·‚éŒÄ‹z‹@”\‘ª’è‚Ì—L—p«-ƒÀ2ŽhŒƒÜ‹z“ü‚ɑ΂·‚锽‰ž«‚ÌŒŸ“¢-B‘æ‚R‰ñ•xŽR¬Ž™šb‘§EƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2000,9,•xŽRD
    55. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€uƒAƒŒƒ‹ƒM[«Ž¾Š³‚Ì•a‘Ô‚ÆŽ¡—Ã@šb‘§‚É‚¨‚¯‚é‹C“¹ã”ç -‹C“¹ã”ç‚ƃTƒCƒgƒJƒCƒ“-vB‘æ‚R‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2000,10,“Œ‹ž.
    56. ¼–ì³’mA‘«—§—YˆêAŒÜ\—’—²•vFƒVƒ“ƒ|ƒWƒEƒ€uƒAƒŒƒ‹ƒM[«Ž¾Š³‚Ì•a‘Ô‚ÆŽ¡—Ã@šb‘§Ž™‚ÌŽ¡—ÂƊǗ -‹C“¹‰ß•q«‚Æ‚»‚̉ü‘P- vB‘æ‚R‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2000,10,“Œ‹ž.
    57. “ñ’J@•A¬ìŽŸ˜YA‰eŽR—²ŽiAâV“¡–œ—¢ŽqA‹{˜e—˜’jA²X–Ø@‘×F–òÜ‚É‚æ‚é“ñŽŸ«’áƒAƒ‹ƒhƒXƒeƒƒ“Ç‚Æl‚¦‚ç‚ꂽV¶Ž™—áB‘æ14‰ñ–k—¤–¢nŽ™§˜b‰ï,2000,10,‹à‘ò.
    58. Ichida F., Haneda N., Karla R.B., Tsubata S., Miyawaki T., Hua Li, Neil E. B., and J.A. Towbin. : ƒ¿-Dystrobrevin mutations in nonisolated left ventricular noncompaction and evidence for genetic heterogeneity. The 73rd scientific sessions of American heart association,2000,11,New Orleans.
    59. Hashimoto I., Gordon Mack, and D.J Sahn. : Strain rate imaging: an in vitro "Validation" study using a balloon model mimicking the left ventricle. The 73rd scientific sessions of American heart association,2000,11,New Orleans.
    60. Xianyi Yu, Hashimoto I., Ichida F., Uese K., Hamamichi Y., Tsubata S., and Miyawaki T.: Dipyridamole Stress Ultrasonic Myocardial Tissue Characterization in Patients with History of Kawasaki Disease. The 73rd scientific sessions of American heart association,2000,11,New Orleans.
    61. ‰Æ鈟‹IŽqA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAŽðˆä³—˜AâV“¡@Ž AˆäoŒû@—TFƒÀ-thalassemia‚ɑ΂·‚éo¶‘Of’fB‘æ21‰ñ–k—¤æ“VˆÙ팤‹†‰ï,2000,11,•Ÿˆä.
    62. ‹àŒ“O˜aA“ñ’J@•A–쑺ŒbŽqA’Ë“c@‘A‹{˜e—˜’jF’áƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚É‚¨‚¯‚éBtkˆâ“`Žq•ÏˆÙFŠÈˆÕf’f‚ƈâ“`Žq‰ðÍB‘æ30‰ñ“ú–{–ƉuŠw‰ï,2000,11,å‘ä.
    63. ŽÂ茒‘¾˜YA‹àŒ“O˜aA¼‘q—TŠìA{–è@—ºA‹{˜e—˜’jFRSAP’PƒNƒ[ƒ“R‘Ì‚Ì쬂Ƃw˜A½ƒŠƒ“ƒp‘BÇŒóŒQ‚̊ȈÕf’fB‘æ30‰ñ“ú–{–ƉuŠw‰ï,2000,11,å‘ä.
    64. ‘«—§—YˆêA”ÂàVŽõŽqA‰ª•””üŒbA”öã—mˆêA‘«—§—zŽqA‘ºãIŒ[A‹{˜e—˜’jF‰@“àE‰@ŠO–ò‹Ç‚É‚¨‚¯‚éšb‘§Š³ŽÒ‚ɑ΂·‚é‹z“üŽw“±‚ÌŽÀ‘Ô’²¸B‘æ33‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,2000,11,Ž­Ž™“‡.
    65. ‘«—§—YˆêFƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u‹z“ü—Ö@‚ÌŽÀÛ -ƒÀŽhŒƒÜ‚ɂ‚¢‚Ä-vB‘æ37‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2000,11,‘O‹´.
    66. ”ÂàVŽõŽqA‰ª•””üŒbAŽRŒ³ƒŽqA”öã—mˆêA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jF––½ŒŒ’P‹…‚©‚ç‚ÌIL-12ŽY¶”\@-”N—î‚É‚æ‚鷈قɂ‚¢‚Ä-B‘æ37‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2000,11,‘O‹´.
    67. •l“¹—T“ñA¼“c–¤A‰ª•”@ŒhAŽO‰Y³‹`A‘«—§—YˆêA‹{˜e—˜’jF‘Šú‚̃Cƒ\ƒvƒƒeƒŒƒm[ƒ‹Ž‘±‹z“ü—Ö@‚É‚æ‚è‹~–½‚µ“¾‚½ˆÓŽ¯áŠQ‚𔺂¤šb‘§‘å”­ìiƒjƒAƒ~ƒXj‚Ì‚P—áB‘æ37‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2000,11,‘O‹´.
    68. ‰¡“cF”VA‘«—§—zŽqA‰ª•””üŒbA”ÂàVŽõŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jF‹CŠÇŽxšb‘§¬Ž™‚É‚¨‚¯‚éƒÀŽhŒƒÜ‹z“ü‚ɑ΂·‚锽‰ž«‚ÌŒŸ“¢@-Ž¡—ÂƂ̊֌W‚ɂ‚¢‚Ä-B‘æ37‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2000,11,‘O‹´.
    69. ‘«—§—zŽqA•l“¹”ü‹IA”öã—mˆêAŠâ’J‰ëŽqAŠžŒ´¹ŽqA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jFƒAƒŒƒ‹ƒM[«Ž¾Š³Š³Ž™‚É‚¨‚¯‚éƒlƒRRŒ´œ‹ŽŽw“±‚ÌŒø‰Ê‚ɂ‚¢‚ÄB‘æ37‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2000,11,‘O‹´.
    70. ‹àŒ“O˜aA‰¤@‰xAŽÂ茒‘¾˜YA‹{˜e—˜’jA¯–ì@—mA–Ø‘º@GF–«Šˆ“®«EBƒEƒBƒ‹ƒXŠ´õÇ‚É‚¨‚¯‚éSAP/SH2D1Aˆâ“`Žq‰ðÍB‘æ32‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,2000,11,“Œ‹ž.
    71. ‘匎“N•vA–쑺ŒbŽqA‰¤@‰xA‹àŒ“O˜aA‹{˜e—˜’jAŒIŒ´^‹IŽqAFè@Œ’A¯–ì@—mA–Ø‘ºGFEBƒEƒBƒ‹ƒX‰Š´õ‚É‚æ‚錌‹…æÃHƒŠƒ“ƒp‘gD‹…‘BÇ‚Ì‚P—áB‘æ32‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,2000,11,“Œ‹ž.
    72. –쑺ŒbŽqA“n•Óˆ»‰ÀA‹g“cärA‹àŒ“O˜aA‹{˜e—˜’jA“c’†’¼ŽqA–Ø‘º@GFƒTƒCƒgƒƒKƒƒEƒBƒ‹ƒX-DNAƒRƒs[”‚ðŒoŽž“I‚ÉŠÏŽ@‚µ‚¦‚½æ“V«ƒTƒCƒgƒƒKƒƒEƒBƒ‹ƒXŠ´õÇ‚Ì‚P—áB‘æ32‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,2000,11,“Œ‹ž.
    73. “n•Óˆ»‰ÀA–{‹½˜a‹vA”ª–ØMˆêA‹{˜e—˜’jFƒCƒ“ƒtƒ‹ƒGƒ“ƒUŠ´õ‚É”º‚¢BickerstaffŒ^”]Š²”]‰Š‘œ‚ð’悵‚½‹}«ŽUÝ«”]Ò‘‰Š‚Ì—Ž™—áB‘æ32‰ñ“ú–{¬Ž™Š´õ–ƉuŠw‰ï,2000,11,“Œ‹ž.
    74. ‰ª•””üŒbA‘«—§—YˆêAŽRŒ³ƒŽqA”ÂàVŽõŽqA‹{˜e—˜’jA–L“c‰ë•FAŠÖ@‘¾•ãA”‹´³ºA¼“‡jŽ¡FƒAƒgƒs[«”畆‰Š––½ŒŒ‚s×–E‚É‚¨‚¯‚éCLA‚ƃPƒ‚ƒJƒCƒ“ƒŒƒZƒvƒ^[”­Œ»‚ÌŠÖŒWB‘æ50‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2000,11,‰¡•l.
    75. ‘«—§—YˆêA‰¡“cF”VA”ÂàVŽõŽqA‰ª•””üŒbAŽRŒ³ƒŽqA”öã—mˆêA‘«—§—zŽqA‘ºãIŒ[A‹{˜e—˜’jF–òÜŽt‚É‚æ‚éšb‘§Š³ŽÒ‹z“üŽw“±‚ÌŽÀ‘Ô’²¸B‘æ50‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2000,11,‰¡•l.
    76. ‘«—§—zŽqA”öã—mˆêA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jFƒAƒŒƒ‹ƒM[«Ž¾Š³Š³Ž™‚É‚¨‚¯‚éƒlƒRRŒ´‚ÌŠÖ—^‚Æ‚»‚Ì‘ÎôB‘æ27‰ñ–k—¤ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2000,11,‹à‘ò.
    77. ”ÂàVŽõŽqA‘ºãIŒ[A‘«—§—YˆêA‹{˜e—˜’jF¬Ž™‚Ìšb‘§”­ì‚É‚¨‚¯‚éƒEƒCƒ‹ƒXŠ´õ‚ÌŠÖ—^-––½ŒŒƒŠƒ“ƒp‹…“à‚ÌMxA’`”’”­Œ»‚ðŽw•W‚Æ‚µ‚Ä-B‘æ9‰ñ—Õ°–ò—EƒAƒŒƒ‹ƒM[E–ƉuŒ¤‹†‰ï‚È‚ç‚Ñ‚É‘æ‚P‰ñH•¨ƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,2000,11,“Œ‹žD
    78. ‹g“cärA‹àŒ“O˜aAâV“¡–œ—¢ŽqAd’èŸÆAˆÉ“¡‰Ã–¾AˆÀˆä‰Ä¶A‹{˜e—˜’jF‚킪‘‚É‚¨‚¯‚齜“ªŠWˆÙŒ`¬Ç‚Ì—Õ°“IEˆâ“`Šw“IŒŸ“¢B‘æ12‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïœŒn“Ž¾Š³Œ¤‹†‰ï,2000,11,ç—t.
    79. ¼‘q—TŠìAŽíŽsq’ˆA‹{˜e—˜’jAV’J®‹vFƒPƒCƒLƒTƒŒ[ƒgˆ—ƒ~ƒ‹ƒN‚É‚æ‚è‚‚jŒŒÇ‚ðƒRƒ“ƒgƒ[ƒ‹o—ˆ‚½“ûŽ™–«t•s‘S‚̈ê—áB‘æ14‰ñ–k—¤CAPD—Õ°§˜b‰ï,2000,12,‹à‘ò.
    80. ŽíŽsq’ˆA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jFä`‘ÑŒŒŠ²×–EˆÚA‚ðs‚È‚Á‚½gp91-phoxŒ‡‘¹–«“÷‰èŽîÇB‘æ‚W‰ñH×–E‹@”\Œ¤‹†‰ï,2000,12,“Œ‹ž.

    1999”N

  • ’˜‘
    1. Žs“c•™ŽqFŒ´”­«”x‚ŒŒˆ³ÇBu¬Ž™‚ÌŽ¡—ÃŽwjv‘OìŠì•½‘¼•Ò,261-263,f’f‚ÆŽ¡—ÃŽÐ,“Œ‹ž,1999.
    2. Žs“c•™ŽqF”ì‘åŒ^S‹ØÇBu¡“ú‚̬Ž™Ž¡—ÃŽwj‘æ12”Åv–î“cƒˆê‘¼•Ò,111,ˆãŠw‘‰@,1999.
    3. Žs“c•™ŽqFS“à–ŒüˆÛ’e«ÇBu¡“ú‚ÌzŠÂŠíŽ¾Š³Ž¡—ÃŽwj‘æ‚Q”Åvדcºˆê‘¼•Ò,ˆãŠw‘‰@,1999.
    4. ¡‘º”Ž–¾A‹{˜e—˜’jF–ƉuŠw“IŒŸ¸Bu¬Ž™‰ÈŒ¤Cˆãƒm[ƒgvŽR’†—´G‘¼•Ò,387-390,f’f‚ÆŽ¡—ÃŽÐ,“Œ‹ž,1999.
    5. ‹àŒ“O˜aA‹{˜e—˜’jA{–è@—ºF‚w˜A½ƒŠƒ“ƒp‘BŽ¾Š³iDuncan•aj‚ÆSAPˆâ“`ŽqˆÙíBuAnnual Review –Ɖu2000v–î“cƒˆê‘¼•Ò,335-341,’†ŠOˆãŠwŽÐ,“Œ‹ž,1999.
    6. ‹àŒ“O˜aA‹{˜e—˜’jF—Õ°‚ɖ𗧂Âf’f“I–ƉuŠw‚Ö‚Ì—U‚¢BuJAMA–ƉuEƒAƒŒƒ‹ƒM[“ÁWvŠÝ–{’‰ŽOŠÄC,33-46,–ˆ“úV•·ŽÐ,“Œ‹ž,1999.
    7. ”öã—mˆêFƒSƒLƒuƒŠ‚Æšb‘§Bu‹CŠÇŽx‚º‚ñ‘§‚ÉŠÖ‚í‚é‰Æ’ë“à‹z“üƒAƒŒƒ‹ƒQƒ“@Œ»Ý‚Ì’mŒ©‚Æ‚»‚Ì‘Îôv,¬‰®“ñ˜Z,‰i‘qr˜a•Ò,ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐ,“Œ‹ž,203-212,1999.
    8. ”öã—mˆêFƒ`ƒƒƒ^ƒeƒ€ƒV‚Æšb‘§Bu‹CŠÇŽx‚º‚ñ‘§‚ÉŠÖ‚í‚é‰Æ’ë“à‹z“üƒAƒŒƒ‹ƒQƒ“@Œ»Ý‚Ì’mŒ©‚Æ‚»‚Ì‘Îôv¬‰®“ñ˜Z,‰i‘qr˜a•Ò,ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐ,“Œ‹ž,219-226,1999.
  • Œ´’˜
    1. Ichida F., Hashimoto I., Tsubata S., Hamamichi Y., Uese K., Miyazaki A., Fukahara K., Murakami A., Nakajima A., Futatsuya R., and Miyawaki T. : Evaluation of pulmonary blood supply by multiplanar cine magnetic resonance imaging in patients with pulmonary atresia and severe pulmonary stenosis. Int. J. of Cardiac Imaging 15:306-312,1999.
    2. Ichida F., Hashimoto I., Tsubata S., Hamamichi Y., Uese K., Murakami A., and Miyawaki T.: Novel technique using biplane cine magnetic resonance imaging for evaluation of left ventricular volume in children. Int. J. of Cardiac Imaging. 15:412-416,1999.
    3. Ichida F., Hamamichi Y., Miyawaki T., Ono Y., Kamiya T., Akagi T.,Hamada H., MD, Hirose O., Isobe T., Yamada K., Kurotobi S., Mito H.,Miyake T., Murakami Y., Nishi T., Shinohara M., Seguchi M., Tashiro S., and Tomimatsu H. : Clinical features of isolated noncompaction of the ventricular myocardium. Long-term clinical course, hemodynamic properties, and genetic background. J. Am. Coll. Cardiol. 34 : 233-240,1999.
    4. Kanegane H., Wakiguchi H., Kanegane C., Kurashige T., Miyawaki T., and Tosato G.FIncreased cell-free viral DNA in fatal cases of chronic active Epstein-Barr virus infection. Clin. Infect. Dis. 28:906-909,1999.
    5. Hashimoto I., Ichida F., Tsubata S., Hamamichi Y., Uese K., Miyazaki A., and Miyawaki T.: A novel method for indexing echocardiographic left ventricular mass in infants, children and adolescents: Evaluation of obesity-induced left ventricular hypertrophy. Pediatr. Int. : 41,126-131,1999.
    6. Hashimoto I., Ichida F., Miura M., Okabe T., Kanegane H., Uese K., Hamamichi Y., Misaki T., Koizumi S., and Miyawaki T.: Automatic border detection identifies asymptomatic anthracycline cardiotoxicity in children with malignancy. Circulation 99:2367-2370,1999.
    7. Tsurusawa M., Katano N., Yamamoto Y., Hirota T., Koizumi S., Watanabe A., Takeda T., Hatae Y., Yatabe M., Mimaya J., Gushiken T., Nishi K., Anami K., Kikuta A., Kanegane H., Asami K., Nishikawa K., Sekine I., Kawano Y., Iwai A., Furuyama T., Ijichi O., Miyake M., Mugishima H., Ota S., and Fujimoto T.FImprovement in CNS protective treatment in Non-High-Risk childhood acute lymphoblastic leukemia: Report from the Japanese children's cancer and leukemia study group. Med. Pediatr. Oncol. 32: 259-266,1999.
    8. Hashimoto S., Miyawaki T., Futatani T., Kanegane H., Usui K., Nukiwa T., Namiuchi S., Matsushita M., Yamadori T., Suemura M., Kishimoto T., and Tsukada S. : Atypical X-Iinked agammaglobulinemia diagnosed in three adults.Intern. Medi. 38 : 722-725,1999.
    9. Striz I., Mio T., Adachi Y., Heires P., Robbins R. I., Spurzem J. R., Illig M. J., Romberger D. J., and Rennard S.I. : IL-4 induces ICAM-1 expression in human bronchial epithelial cells and potentiates TNF-ƒ¿. Am. J. Physiol. 277 : L58-L64, 1999.
    10. ¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA”ª–ØMˆêF•”•ª”­ìÇó‚ð”F‚ß‚½Œ‡_‚Ä‚ñ‚©‚ñÇ—á‚Ì—Õ°”]”g“Á’¥B”]‚Æ”­’B 31 : 395-401,1999.
    11. ¼‘òƒŽqA¬¼@“OA–{‹½˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF”M«‚¯‚¢‚ê‚ñ‚Ì—\–h“Š—^‚ÆÄ”­|AED˜A‘±“Š—^‚ÆDZPŠÔŒ‡“Š—^–@‚Ì”äŠrˆêB¬Ž™‰È—Õ° 52F21-26,1999.
  • Ç—á•ñ
    1. Kanegane H., Nomura K., Miyawaki T., Sasahara Y., Kawai S., Tsuchiya S., Murakami G., Futatani T., and Ochs MD.FX-linked thrombocytopenia identified by flow cytometric demonstration of detective Wiskott-Aldrich protein in lymphocytes. Blood. 95: 1110-1111, 1999.
  • ‘à
    1. Kanegane H., Miyawaki T., Yachie A., Oh-ishi T., Bahtia K., and Tosato G. : Development of EBV-positive T-cell lymphoma following infection of peripheral blood Tcells with EBV. Leuk. Lym. 34 : 603-607,1999.
    2. ‘«—§—YˆêF‹CŠÇŽxšb‘§‚Ì‹C“¹‰ß•q«B¬Ž™‰È—Õ°@52F1665-1669,1999.
    3. ”ª–ØMˆêA‹{˜e—˜’jF¬Ž™‚Ì”MŽË•aE”M’†ÇB@“ú–{çÎŽ–V•ñ@3926 : 28-32,1999.
    4. –{‹½˜a‹vA¬¼@“OA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF‚¯‚¢‚ê‚ñB¬Ž™“à‰È@31(‘)F278-284,1999.
    5. –{‹½˜a‹vA¬¼@“OA‘ŽqDA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF‚¯‚¢‚ê‚ñ«Ž¾Š³‚Ìf’fAŽ¡—ÂƗ\–h—Ç«“ûŽ™‚¯‚¢‚ê‚ñB¬Ž™“à‰È@31F551-555,1999.
    6. ‹àŒ“O˜aA‹{˜e—˜’jF‚w˜A½–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇB—Õ°ŒŸ¸ 43F425-428,1999.
    7. ‹àŒ“O˜aA{–è@—ºA‹{˜e—˜’jF‚w˜A½ƒŠƒ“ƒp‘B«ÇŒóŒQ‚̬ˆö‚Æ‚µ‚Ä‚Ì‚r‚`‚oˆâ“`ŽqˆÙíB—Õ°–Ɖu@32F631-636,1999.
    8. ‹àŒ“O˜aA‹{˜e—˜’jF–¾‚ç‚©‚É‚³‚ꂽ‚w˜A½ƒŠƒ“ƒp‘B«ÇŒóŒQ‚ÌŒ´ˆöˆâ“`ŽqBˆãŠw‚Ì‚ ‚ä‚Ý 189F898-899,1999.
    9. ‹àŒ“O˜aA‹{˜e—˜’jFŒ´”­«–ƉuÇŒóŒQiŽå‚Æ‚µ‚ÄR‘ÌŽY¶•s‘S‚ðŽ¦‚·‚à‚ÌjB¬Ž™‰Èf—à 62(‘)F118-119,1999.
    10. ‹àŒ“O˜aA˜eŒû@GFEBƒEƒBƒ‹ƒXŠ´õÇ‚É‚¨‚¯‚éƒCƒ“ƒ^[ƒƒCƒLƒ“10B¬Ž™Š´õ–Ɖu11F151-156 ,1999.

  • 1999”NŠw‰ï•ñ
    1. ”ÂàVŽõŽqA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jFATGAƒVƒNƒƒXƒ|ƒŠƒ“‚`AG-CSF“Š—^‚É‚æ‚芰‰ð‚𓾂½“Á”­«Ä¶•s—Ç«•nŒŒ‚Ì—Ž™—áB‘æ‚R‰ñŒŒ‰tŽ¾Š³‚ƃTƒCƒgƒJƒCƒ“Œ¤‹†‰ï,1999,1,‹à‘ò.
    2. ‘«—§—YˆêAŽRŒ³ƒŽqA”öã—mˆêA‹{˜e—˜’jA–L“c‰ë•FAŠÖ@‘¾•ãA”‹´³ºFƒAƒgƒs[«”畆‰ŠŠ³ŽÒ––½ŒŒ‚s×–Eã‚É”­Œ»‚·‚éCD30‚̈Ӌ`- Th2ƒ^ƒCƒv—DˆÊ‚ÌŽw•W‚Æ‚µ‚Ä-A‘æ20‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,1999,1,•xŽR.
    3. ŽR’J”ü˜aA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vA‘ºã”ü–çŽqA”ª–ØMˆêA‹{˜e—˜’jFParoxysmal kinesigenic choreoathetosis ‚Ì‚P‰ÆŒnB‘æ35‰ñ¬Ž™_Œo–k—¤’n•û‰ï,1999,2,•xŽR.
    4. ¼‘òƒŽqA¬¼@“OA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF¬Ž™_ŒoŽ¾Š³‚É‚¨‚¯‚éƒvƒƒgƒ“MRS‚Ì—Õ°‰ž—p.‘æ35‰ñ¬Ž™_ŒoŠw‰ï–k—¤’n‰ï,1999,2,‹à‘ò.
    5. Hamamichi Y., Ichida F., Tsubata S., Hashimoto I., Uese K., and Miyawaki T.FLow-dose dobutamine stress radionuclide ventriculography reveal silent myocardial dysfunction in Kawasaki Disease. The 6th Int. Kawasaki disease sympo.1999,2,Hawaii.
    6. Ichida F., Hashimoto I., Tsubata S., Hamamichi Y., Uese K., Miyazaki A., and Miyawaki T.FDipyridamole stress cine MRI of coronary arteries in Kawasaki disease. The 6th Int. Kawasaki disease sympo.1999,2,Hawaii.
    7. Ichida F., Hamamichi Y., Uese K., Hashimoto I., Futatani T., Kanegane H., and Miyawaki T.FVascular endothlial growth factor in acute Kawasaki disease. The 6th Int. Kawasaki disease sympo.1999,2,Hawaii.
    8. Hashimoto I., Ichida F., Uese K., Hamamichi Y., and Miyawaki T.FEvaluation of silent myocardial ischemia using dipyridamole stress acoustic densitometry in children with convalescent Kawasaki disease. The 6th Int. Kawasaki disease sympo.1999,2,Hawaii.
    9. Adachi Y., Onoue Y., Yamamoto J., Adachi YS., Seki D., Toyoda M., Morohashi M., and Miyawaki T.FCD30 expression on T cell is a better marker for role of Th2-type cell compared with soluble CD30 level in atopic dermatitis. AAAAI,1999,2,Florida.
    10. ¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jFƒ[ƒ‰ƒ“ƒh”­ì‚Æ’èŒ^Œ‡_”­ì‚𓯎ž‚É”F‚ß‚½‚PÇ—áB‘æ23‰ñ–k—¤‚Ä‚ñ‚©‚ñ§˜b‰ï,1999,3,‹à‘ò.
    11. ŒIŒ´–ƒ‹IŽqA–{‹½˜a‹vA’|’J“¿—YA¬¼@“OA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêF—Ç«“ûŽ™‚¯‚¢‚ê‚ñ‚Ì‚Q—áB‘æ23‰ñ–k—¤‚Ä‚ñ‚©‚ñ§˜b‰ï,1999,3,‹à‘ò.
    12. ”‘òŽõŽqA¼‘q—TŠìAŽs“c•™ŽqA‹{˜e—˜’jA‰Æ鈟‹IŽqA“ˆ‘å“ñ˜YFEarly pre-pulseless phase ‚©‚çŠÏŽ@‚µ‚½‘å“®–¬‰ŠÇŒóŒQ‚̈ê—áB‘æ265‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,1999,3,•Ÿˆä.
    13. Kanegane H., Miyawaki T., Nomura K., Hashimoto S., Tsukada S.FGenetic analysis of X-linked agammagloburinemia identified by flow cytometric analysis in unrelated 36 Japanease families. 99' Experimental Biology,1999,4, Washington D.C.
    14. Yagi S., Konishi T., Matsuzawa J., Hongou K., Yamatani M., and Miyawaki T.: A infantile case with myoclonic epilepsy induced by eye closure. 2nd Conference on Seizures in Infancy and Early Childhood,4,1999, Tokyo.
    15. Matsuzawa J., Konishi T., Hongou K., Yamatani M., Yagi S., and Miyawaki T.: Recognition of 15 families with generalized epilepsy with febrile seizures plus(GEFS+). 2nd Conference on Seizures in Infancy and Early Childhood,4,1999,Tokyo.
    16. ‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‘«—§—zŽqA‰¡“cF”VA‰ª•””üŒbA”‘òŽõŽqA‹{˜e—˜’jFƒAƒgƒs[«”畆‰ŠŠ³ŽÒ‚É‚¨‚¯‚é‚s×–ECD30”­Œ»—¦‚ÆŒŒ’†soluble CD30’l‚ÌŠÖŒWB‘æ102‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1999,4,“Œ‹ž.
    17. ”ª–ØMˆêA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jF׋۫‘–Œ‰Š‚Ìd–Œ‰º•a•ÏB‘æ102‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1999,4,“Œ‹ž.
    18. ‹àŒ“O˜aA–쑺ŒbŽqA‹{˜e—˜’jAŠâ“c@—ÍA¬‹{ŽR~F•ª—Þ•s”\Œ^–Ɖu•s‘SÇ‚É‚¨‚¯‚éBtkˆâ“`Žq‰ðÍB‘æ102‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1999,4,“Œ‹ž.
    19. ‘«—§—zŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jFƒAƒŒƒ‹ƒM[«Ž¾Š³“û—cŽ™‚É‚¨‚¯‚é“úí“I‚ȃlƒR‚Æ‚ÌÚG‚ƌċzŠíÇó‚ÌŠÖŒWB‘æ35‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1999,4,•xŽR.
    20. ‹g“cärA¬¼@“OA‹{˜e—˜’jA¡‘º”Ž–¾F“–‰@‚É‚¨‚¯‚é‚o‚u‚kƒnƒCƒŠƒXƒNŽ™‚ɂ‚¢‚Ä‚ÌŒŸ“¢B‘æ35‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1999,4,•xŽR.
    21. ¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jFŒo‰ß’†‚ÉŒõŠ´Žó«“Ë”­”g‚ðŽ¦‚·‹ÇÝŠÖ˜A«‚Ä‚ñ‚©‚ñ‚̈êŒQ‚ɂ‚¢‚ÄB‘æ41‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1999,5,“Œ‹ž.
    22. ŽR’J”ü˜aA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vA”ª–ØMˆêA‹{˜e—˜’jF“û—cŽ™“«‚Ä‚ñ‚©‚ñ‚É‚¨‚¯‚釖°ŠoÁƒŠƒYƒ€‚ÌáŠQ`—Õ°”­ì‚Æ‚ÌŠÖŒWB‘æ41‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1999,5,“Œ‹ž.
    23. ”ª–ØMˆêA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA‹{˜e—˜’jFEyelid myoclonia with absences‚ÌŒZ’í—áB‘æ41‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1999,5,“Œ‹ž.
    24. ¼‘òƒŽqA¬¼@“OA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF”M«‚¯‚¢‚ê‚ñƒvƒ‰ƒX‚ð‚à‚‘S”Ê‚Ä‚ñ‚©‚ñ‰ÆŒn‚ɂ‚¢‚ÄB‘æ41‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1999,5,“Œ‹ž.
    25. ‘«—§—YˆêF‹z“ü—Ö@‚̬Ž™‚Ƭl‚É‚¨‚¯‚é—˜“_‚ÆŒ‡“_|ƒÀŽhŒƒÜ‚̃^ƒCƒ€ƒŠ[ƒ†[ƒX`¬Ž™‰È‚©‚ç`‘æ11‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G‘å‰ïƒVƒ“ƒ|ƒWƒEƒ€,1999,5,‘åã.
    26. ”öã—mˆêAŽRŒ³ƒŽqA‘«—§—YˆêA‹{˜e—˜’jA–L“c‰ë•FAŠÖ@‘¾•ãA”‹´³ºA¼“‡jŽ¡FƒAƒgƒs[«”畆‰ŠŠ³ŽÒ‚É‚¨‚¯‚é––½ŒŒ‚s×–Eã‚ÌŠeŽíƒPƒ‚ƒJƒCƒ“EƒŒƒZƒvƒ^[‚Ì”­Œ»B‘æ11‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G‘å‰ï,1999,5,‘åã.
    27. ”ÂàVŽõŽqA‘ºãIŒ[AŽRŒ³ƒŽqA”öã—mˆêA‰ª•””üŒbA‰¡“cF”VA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§”­ì‚É‚¨‚¯‚éƒEƒCƒ‹ƒXŠ´õ‚ÌŠÖ—^[MxA’`”’‚ðŽw•W‚Æ‚µ‚Ä[‘æ11‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G‘å‰ï,1999,5,‘åã.
    28. ¼–ì³’mAˆÉ“Œ“¹•vA‹gZ@ºAŠâ’J‰ëŽqA‘«—§—YˆêAŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§Š°‰ð—á‚Ì‹C“¹‰ß•q«‚Ì„ˆÚ-ÅI”­ìŽž”N—î‚©‚ç‚Ý‚½ŒŸ“¢-B‘æ11‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,1999,5,‘åã.
    29. ‹àŒ“O˜aA‹{˜e—˜’jA{–è—ºA˜`@˜a”üA‹{“c—Y—SA–Ø‘º@GAX“‡P—YA–{“cŒiŽqAΈäžÄˆêA]Œû^—ŽqA‘¾“c˜aGA’J“à]ºGF–{–M‚É‚¨‚¯‚éX˜A½ƒŠƒ“ƒp‘B«ÇŒóŒQ‚̈â“`Žq‰ðÍB‘æ‚X‰ñEBƒEƒBƒ‹ƒXŠ´õÇŒ¤‹†‰ï,1999,5,“Œ‹ž.
    30. ‚ˆä—¢A¼‘q—TŠìAŽÂ茒‘¾˜YArˆä”ü˜aŽqAŽðˆä—R‹IA’†–¾‹žŽqA‹{˜e—˜’jFŒoŽž“I‚Ét¶ŒŸ‚ðŽ{s‚µ‚½IgAtÇ‚ÉŠÖ‚·‚錟“¢B‘æ34‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ï,1999,5,VŠƒ.
    31. ¼‘q—TŠìAŽÂ茒‘¾˜YArˆä”ü˜aŽqAŽðˆä—R‹IA‚ˆä—¢A‹{˜e—˜’jFæ“V«…tÇ‚É‚¨‚¯‚éMRI urography‚ÌŽg—pŒoŒ±B‘æ34‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ï,1999,5,VŠƒ.
    32. ¼‘q—TŠìA–L“ˆSˆê˜YA‹{˜e—˜’jFæ“V«…tÇ‚É‚¨‚¯‚éMR urography‚ÌŽg—pŒoŒ±B‘æ44‰ñ“ú–{t‘Ÿ•aŠw‰ï,1999,6,‰¡•l.
    33. ‹{˜e—˜’jAŽRŒ³ƒŽqA‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€u×–E“àƒTƒCƒgƒJƒCƒ“‚Ì—Õ°‰ž—p‚Ö‚Ìí—ªBv‘æ‚X‰ñ“ú–{ƒTƒCƒgƒƒgƒŠ[Šw‰ï,1999,6,ŽD–y.
    34. ’†—ÑŒºˆêAA‘º”ü‹IA‘ºãIŒ[A–{ŠÔˆê³A‹àŒ“O˜aF–{‘Ô«ŒŒ¬”ÂŒŒÇ‚Ì10Ë’jŽ™—áB‘æ‚R‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1999,7,•xŽR.
    35. “n粈»‰ÀAŒIŒ´^‹IŽqA”ÂàVŽõŽqA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAœAìTˆê˜YFŽ©‰Æ––½ŒŒŠ²×–EˆÚA‚ðs‚Á‚½—‘‰©”XŠà(stageE)‚̈ꗎ™—áB‘æ‚R‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1999,7,•xŽR.
    36. ŽRŒ³ƒŽqAFè@Œ’A”ÂàVŽõŽqA¬¼@“OA¬ŒIˆºŽqFŒŒ´ƒAƒ~ƒmƒgƒ‰ƒ“ƒXƒtƒFƒ‰[ƒ[‚’l‚É‚æ‚è‹ô‘RŒ©‚‚©‚Á‚½‹ØƒWƒXƒgƒƒtƒB[‚Ì‚PÎ’jŽ™—áB‘æ‚R‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1999,7,•xŽR.
    37. ¼‘q—TŠìA“n粈»‰ÀAŒIŒ´^‹IŽqA‹{˜e—˜’jF“«‚ÌCAPD• –Œ‰Š‚𔽕œ‚µ‚Ä‚¢‚éˆê¬Ž™—áB‘æ‚R‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1999,7,•xŽR.
    38. ‹àŒ“O˜aA–쑺ŒbŽqA“ñ’J@•A‹{˜e—˜’jA‘ºãIŒ[Fƒtƒ[ƒTƒCƒgƒƒgƒŠ[‚É‚Äf’f‚µ‚½‚w˜A½ŒŒ¬”ÂŒ¸­Ç‚̈ê’jŽ™—áB‘æ15‰ñ•xŽRŒ§ŒŒ‰tŽ¾Š³Œ¤‹†‰ï,1999,7,•xŽR.
    39. –{‹½˜a‹vA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA¬¼@“OA‹{˜e—˜’jFCongenital hypomyelinating neuropathy ‚ÌŽo–…—áB‘æ35‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,8,1999,•Ÿˆä.
    40. –쑺ŒbŽqA‹àŒ“O˜aAŽíŽsq’ˆA]Œû^—ŽqA¡hWìA‹{˜e—˜’jFT-lymphoblastic lymphoma with myeloid hyperplasia‚̈ê’jŽ™—áB‘æ41‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,1999,9,“Œ‹ž.
    41. ‹àŒ“O˜aA–쑺ŒbŽqA{–è@—ºA¼ˆä@—zA˜`@˜a”üA‹{“c—Y—SA]Œû^—ŽqA–{“cŒiŽqAΈäžÄˆêA‹{˜e—˜’jF‚w˜A½ƒŠƒ“ƒp‘BÇŒóŒQ‚̈â“`Žq‰ðÍB‘æ41‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,1999,9,“Œ‹ž.
    42. ¼‘q—TŠìA‹{˜e—˜’jF“«CAPD• –Œ‰Š‚̈êÇ—áB‘æ‚V‰ñ’†•”¬Ž™t‘Ÿ•aŒ¤‹†‰ï,1999,9,¼–{.
    43. ”ÂàVŽõŽqA‘ºãIŒ[A”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§”­ì‚É‚¨‚¯‚éƒEƒCƒ‹ƒXŠ´õ‚ÌŠÖ—^‚Ì‹Gß•Ï“®-MxA’`”’‚ðŽw•W‚Æ‚µ‚Ä-B‘æ‚Q‰ñ•xŽR¬Ž™šb‘§EƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,1999,9,•xŽR.
    44. ”ª–ØMˆêA¬¼@“OAL–ìŒbˆêA¼‘òƒŽqA”öã—mˆêA–{‹½˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jF“ÁˆÙ‚È”]‰ŠE”]Ç—ÞŽ—‚ÌŒo‰ß‚ð’悵‚½’jŽ™—áB‘æ36‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï,9,1999,‹à‘ò.
    45. –{‹½˜a‹vA“n•Óˆê—mA¼‘òƒŽqA¡‘º”Ž–¾A”ª–ØMˆêA¬¼@“OA‹{˜e—˜’jFV¶Ž™Šú‚©‚çd“x‚̋؋ْ£’ቺ‚ðŽ¦‚µ‚½‚QÇ—á`ŠÓ•Êf’f‚ð’†S‚ÉB‘æ‚V‰ñ•xŽRŒ§—Õ°¬Ž™_ŒoŠwŒ¤‹†‰ï,9,1999,•xŽR.
    46. ‹àŒ“O˜aA{–è@—ºA¼ˆä@—zA’J“à]ºGA‹{˜e—˜’jF–{–M‚É‚¨‚¯‚é‚w˜A½ƒŠƒ“ƒp‘B«ÇŒóŒQ‚̈â“`Žq‰ðÍB‘æ27‰ñ“ú–{—Õ°–ƉuŠw‰ï,1999,10,‰F“s‹{.
    47. ”öã—mˆêAŽRŒ³ƒŽqA‘«—§—YˆêA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF“`õ«’PŠjÇ––½ŒŒ‚s×–E‚É‚¨‚¯‚éƒPƒ‚ƒJƒCƒ“ƒŒƒZƒvƒ^[iCXCR3j‚Ì”­Œ»‘‰ÁB‘æ27‰ñ“ú–{—Õ°–ƉuŠw‰ï‘‰ï,1999,10,‰F“s‹{.
    48. ‹àŒ“O˜aA–쑺ŒbŽqA‹{˜e—˜’jF‚w˜A½–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚É‚¨‚¯‚éD’†‹…Œ¸­B‘æ31‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,1999,10,•Ÿ“‡.
    49. –쑺ŒbŽqA‹àŒ“O˜aA”ª–ØMˆêA‹{˜e—˜’jF‚RÜ•¹—p—Ö@‚É‚æ‚Á‚Ä’˜–¾‚ȉü‘P‚ª‚Ý‚ç‚ꂽ•êŽqŠ´õŒãAIDS‘Šú”­ÇŒ^‚Ì‚P—áB‘æ31‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,1999,10,•Ÿ“‡.
    50. ‹{@ˆêŽuA–쑺ŒbŽqA‹àŒ“O˜aA”ª–ØMˆêA‹{˜e—˜’jA–Ø‘º@GAX“‡P—YF’†•_Œo•a•Ï‚ð‡•¹‚µ‚½EBƒEƒBƒ‹ƒXŠÖ˜AƒÁƒÂ-‚s×–EƒŠƒ“ƒpŽî@‚Ì‚P—áB‘æ31‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,1999,10,•Ÿ“‡.
    51. ‘«—§—YˆêA‘ºãIŒ[A‘«—§—zŽqA”‘òŽõŽqA‰ª•””üŒbA‰¡“cF”VAŠâ’J‰ëŽqAŠžŒ´¹ŽqA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚鎩‘î‚Å‚Ì“d“®Ž®ƒlƒuƒ‰ƒCƒU[‚ð—p‚¢‚½”­ìŽžƒÀŽhŒƒÜ‹z“ü‚ÌŽw“±ó‹µB‘æ49‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ïA1999,10,L“‡.
    52. ŽRŒ³ƒŽqA‘«—§—YˆêA”öã—mˆêA‹{˜e—˜’jA–L“c‰ë•FAŠÖ@‘¾•ãA”‹´³ºA¼“‡jŽ¡FƒPƒ‚ƒJƒCƒ“ƒŒƒZƒvƒ^[”­Œ»‚É‚æ‚蕪•Ê‚³‚ê‚é––½ŒŒƒwƒ‹ƒp[T×–EˆŸŒQ‚̃TƒCƒgƒJƒCƒ“ŽY¶ƒpƒ^[ƒ“B‘æ49‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ïA1999,10,L“‡.
    53. ‘«—§—zŽqA‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‰¡“cF”VA‰ª•””üŒbA”‘òŽõŽqAŠžŒ´¹ŽqAŠâ’J‰ëŽqA‹{˜e—˜’jA‘ºãIŒ[FƒAƒgƒs[«”畆‰Š“û—cŽ™‚Ìšb‘§‚ւ̈Ús‚ƃlƒR‚È‚ç‚Ñ‚ÉH•¨ƒAƒŒƒ‹ƒM[‚ÌŠÖŒWB‘æ36‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïA1999,10,ç—t.
    54. ¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA”ª–ØMˆêF¬Ž™“«‚Ä‚ñ‚©‚ñ‚É‚¨‚¯‚éŠO‰È“IŽ¡—Ẩ”\«‚ɂ‚¢‚ÄB‘æ33‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,10,1999,å‘ä.
    55. ”ª–ØMˆêA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aFŠááÙƒ~ƒIƒNƒƒj[‚¨‚æ‚ÑŠá‹…ã“]‚ð”­ì’†ŠjÇó‚Æ‚·‚é‚Ä‚ñ‚©‚ñÇ—á‚ɂ‚¢‚ÄB‘æ33‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,10,1999,å‘ä.
    56. –{‹½˜a‹vA¬¼@“OA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jA’|’J“¿—YFŒo‰ß’†‚É’E–ÑAŒƒ‚µ‚¢Ž¼]‚ð”F‚ß‚½Migrating Partial Seizures in Infancy‚Ì‚P—áB‘æ33‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,10,1999,å‘ä.
    57. ¼‘òƒŽqA¬¼@“OA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF—Ç«“ûŽ™‚¯‚¢‚ê‚ñ‚X—á‚Ì”­ìŽž”]”g‚ɂ‚¢‚ÄB‘æ33‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,10,1999,å‘ä.
    58. Itazawa T., Noguchi K., Ichida F., Hashimoto I., Seto H., and Miyawaki T.FMagnetic resonance imaging for early detection of Takayasu arteritis. The 27th Annual meeting of the North American society for cardiac imaging,1999,11,Atlanta.
    59. ‹g“cärA‹àŒ“O˜aA‹{˜e—˜’jA¡–ìºGFCBFA1•ÏˆÙ‚ð”F‚ß‚½½œE“ªŠWˆÙŒ`¬Ç‚Ì‚U—áB‘æ20‰ñ–k—¤æ“VˆÙ팤‹†‰ï,1999,11,‹à‘ò.
    60. ‘«—§—YˆêA‘ºãIŒ[A”öã—mˆêA‘«—§—zŽqA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚鎩‘î‚Å‚Ì“d“®Ž®ƒlƒuƒ‰ƒCƒU[‚ð—p‚¢‚½”­ìŽžƒÀŽhŒƒÜ‹z“ü‚ÌŽÀÛ -ƒAƒ“ƒP[ƒg’²¸-B‘æ32‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,1999,11,•Ÿˆä.
    61. ‹àŒ“O˜aA{–è—ºA¼‘q—TŠìA–쑺ŒbŽqA’J“à]ºGA’Ë“c@‘A‹{˜e—˜’jF‚w˜A½ƒŠƒ“ƒp‘BŽ¾Š³‚É‚¨‚¯‚é‚r‚`‚oˆâ“`ŽqˆÙíB‘æ29‰ñ“ú–{–ƉuŠw‰ï,1999,12,‹ž“s.
    62. ŽRŒ³ƒŽqA‘«—§—YˆêA¼“‡jŽ¡A‹{˜e—˜’jFƒqƒg––½ŒŒƒwƒ‹ƒp[T×–E‚É‚¨‚¯‚éƒPƒ‚ƒJƒCƒ“ƒŒƒZƒvƒ^[”­Œ»‚Ì—Õ°“IˆÓ‹`B‘æ29‰ñ“ú–{–ƉuŠw‰ï,1999,12,‹ž“s.
    63. –쑺ŒbŽqA‹àŒ“O˜aA’Ë“c@‘A‰GŽR@ˆêA㼈ê‰iA¬‹{ŽR~A‹{˜e—˜’jF‚w˜A½–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚É‚¨‚¯‚霑‚a‘O‹ì×–E‚̉ðÍB‘æ29‰ñ“ú–{–ƉuŠw‰ï,1999,12,‹ž“s.
    64. ‘«—§—zŽqA‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‹{˜e—˜’jA‘ºãIŒ[FƒAƒgƒs[«”畆‰Š“û—cŽ™‚Ìšb‘§‚Ö‚Ìi“W‚ƃlƒRƒAƒŒƒ‹ƒM[‚ÌŠÖŒWB‘æ26‰ñ–k—¤ƒAƒŒƒ‹ƒM[§˜b‰ï,1999,12,‹à‘ò.
    65. ‹g“cärA‹àŒ“O˜aA‹{˜e—˜’jA¡–ìºGF½œE“ªŠWˆÙŒ`¬Ç‚É‚¨‚¯‚éCBFA1•ÏˆÙB‘æ‚S‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1999,12,•xŽR.
    66. ŒIŒ´^‹IŽqA㨌hˆê˜YA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA“¡–Ø@–¾AŠÛŽR–¾•vF‰^“®ŽžŽ¸_”­ì‚Å”­Ç‚µ‚½“Á”­«S–[‘e“®‚̈ê—áB‘æ‚S‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1999,12,•xŽR.

    1998”N

  • ’˜‘
    1. Žs“c•™ŽqFS‹Øãk–§‘wŒ`¬•s‘SBuAnnual@Review zŠÂŠí1998v,™–{P–¾‘¼•Ò,’†ŠOˆãŠwŽÐ,“Œ‹ž,179-184,1998.
    2. ˆîê@iA‰ª“c•q•vFEŠe˜_Et‰ŠBu¬Ž™”å”AŠí‰ÈŠw‘v,쑺@–ÒE¬–ö’m•F•Ò,‹àŒ´o”Å,“Œ‹ž,184-193,1998.
    3. ‹àŒ“O˜aA‹{˜e—˜’jFHermans syndromeBuÇŒóŒQŽ–“Tv‰Y•”»•v‘¼•ÒAf’f‚ÆŽ¡—ÃŽÐA“Œ‹ž,620,1998.
    4. ‹àŒ“O˜aA‹{˜e—˜’jFNezelof syndromeBuÇŒóŒQŽ–“Tv‰Y•”»•v‘¼•ÒAf’f‚ÆŽ¡—ÃŽÐA“Œ‹ž,630,1998.
    5. ‹àŒ“O˜aA‹{˜e—˜’jFOmenn syndromeBuÇŒóŒQŽ–“Tv‰Y•”»•v‘¼•ÒAf’f‚ÆŽ¡—ÃŽÐA“Œ‹ž,631,1998.
    6. Žs“c•™ŽqFæ“V«SŽ¾Š³Bu‚í‚©‚è‚â‚·‚¢“à‰ÈŠwvˆä‘º—T•v‘¼•Ò,•ªŒõ“°,“Œ‹ž,119-134,1998.
  • Œ´’˜
    1. Ichida F., Uese K., Hamamichi Y., Hashimoto I., Tsubata S., Fukahara K., Murakami A., Miyawaki T.: Chronic effect of oral prostacyclin analogue on thromboxane A2 and prostacyclin biosysthesis in pulmonary hypertension. Acta Paediatr Jpn 40 : 14-19,1998.
    2. Futatani T., Miyawaki T.,Tsukada S., Hashimoto S., Kunikata T., Arai S., Kurimoto M., Niida Y., Matsuoka H., Sakiyama Y., Iwata T., Tsuchiya S., Tatsuzawa O., Yoshizaki K., and Kishimoto T.FDeficient expression of Bruton's tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection. Blood 91F595-602,1998.
    3. Mio T., Liu X-D., Adachi Y., Striz I., Magnus Skold C., Romberger D.J., Spurzem J.R., Illig M.G., Ertl R., and Rennard S.I. : Human bronchial epithelial cells modulate collagen gel contraction by fibroblasts. Am. J.Physiol. 274 : L119-L126,1998.
    4. Ichida F, Uese K, Tsubata S, Hashimoto I, Hamamichi Y., Fukahara K, Murakami A, Miyawaki T. : Beneficial effect of Beraprost Sodium, a stable analogue of prostacyclin, on pulmonary hypertension in children. Cardiol Young : 205-210,1998.
    5. Tsubata S, Ichida F, Miyawaki T.: Noninvasive diagnosis of coronary arterial fistulas using multiplanar cine magnetic resonance imaging. Cardiol Young 8:250-252,1998.
    6. Kasahara Y., Wada T., Niida Y., Yachie A., Seki H., Ishida Y., Sakai T., Koizumi F., Koizumi S., Miyawaki T. and Taniguchi N.: Novel Fas (CD 95/AP0-1) mutations in infants with a lymphoproliferative disorder. Int. Immunol. 10 : 195-202,1998.
    7. Adachi Y., Mio T., Takigawa K., Striz I., Romberger D.J., Spurzem J.R., and Rennard S.I. : Fibronectin production by cultured human lung fibroblasts in three-dimensional collagen gel culture. In Vitro Cell. Dev. Biol. 34 : 203-210,1998.
    8. Ichida F., Uese K., Tsubata S., Hashimoto I., Hamamichi Y., Fukahara K., Murakami A., and Miyawaki T.: Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension. Am. J. Cardiol. 80:662-664, 1997.
    9. Ichida F., Uese K., Hashimoto I., Hamamichi Y., Tsubata S., Fukahara K., Murakami A., and Miyawaki T.: Acute effect of oral prostacyclin and inhaled nitric oxide on pulmonary hypertension in children .J. Cardiol. 29 : 217-224,1997.
    10. Hashimoto I., Ichida F., Okabe T., Miura M., Okabe T., Shimura S., Uese K., Hamamichi Y., Tsubata S., Miyawaki T., Fukahara K., and Murakami A.: Evaluation of left ventricular volume using automatic border detection system in children.: A comparison with conventional off-line echocardiographic quantification. Acta Paediatr Jpn 40:226-231, 1998.
    11. Kanegane H., Kishor B., Guiterres M., Kaneda H., Wada T., Yachie A., Seki H., Arai T., Kagimoto S., Okazaki M., Oh-ishi T., Moghaddam A., Wang F., and Tosato G. : A syndrome of peripheral blood T-cell infection with Epstein-barr virus(EBV) followed by EBV-positive T-cell lymphoma. Blood 91 : 2085-2091,1998.
    12. Mehrotra P.T., Donnelly R. P., Wong S., Kanegane H., Geremew A., Mostowski H.S., Furuke K., Siegel J.P., and Bloom E.T.: Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. J. Immunol. 160: 2637-2644, 1998.
    13. Hongou K., Konishi T., Yagi S., Araki K.,and Miyawaki T.: Rotavirus encephalitis mimicking afebrile benign convulsions in infants. Pediatr Neurol 18:354-357,1998.
    14. Kanegane H., Yachie A., Miyawaki T., and Tosato G. : EBV-NK cells interactions and lymphoproliferative disorders. Leuk. and Lymph. 29 : 491-498,1998.
    15. Morikawa K., Nemoto K., Miyawaki T., and Morikawa S. : Deoxyspergualin preferentially inhibits the growth and maturation of anti-CD40-activated surface IgD+ B lymphocytes. Clin. Exp. Immunol. 112 : 495-500,1998.
    16. Wada T., Seki H., Konno A., Ohta K., Nunogami K., Kaneda H., Kasahara Y., Yachie A., Koizumi S., Taniguchi N., and Miyawaki T.: Developmental changes and functional properties of human memory T cell subpopulations defined by CD60 expression. Cell. Immunol. 187 : 117 -123,1998.
    17. Kanegane C., Sgadari C., Kanegane H., Teruya-Feldstein J., Yao L., Gupta G., Farber JM., Liao F., Lin L., and Tosato G. : Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J. Leuk. Biol. 64: 384-392,1998.
    18. Matsuzawa J., Konishi T., Masuko K., Hongou K., Yamatani M., Yagi S, and Miyawaki T. : SPECT and localized proton MRS of epilepsy in children with cortical dysplasia. Epilepsia 39 (suppl. 5):70-71,1998.
    19. Striz I., Mio T., Adachi Y., Bazil S., and Rennard S.I. : The CD14 molecle participates in regulation of IL-8 and IL-6 release by bronchial epithelial cells. Immunol. Letters 62:177-181,1998.
    20. Žs“c•™ŽqAŽÂ茒‘¾˜YAà_“¹—T“ñA㨌hˆê˜YA‹´–{ˆè•vA’Ô¦áÁˆêA‹{è‚ ‚ä‚ÝA‹{˜e—˜’jA¬–ìˆÀ¶A_’J“N˜YAÔ–Ø’õŽ¡A•l“c—m’ÊAL£CAˆé•”„ŽuAŒÃ鹓WA•”òr“ñAŽOŒË”ŽŽuAŽO‘îrŽ¡A‘ºã•Û•vA¼@–ÒAŽÂŒ´@^A£Œû³ŽjA“c‘ãT“ñ˜YA•x¼G•¶F–{–M‚É‚¨‚¯‚鬎™ŠúIsolated noncompaction of the ventricular myocardium‚Ì—Õ°‘œ`‘S‘’²¸Œ‹‰Ê`B“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 14F402-412,1998.
    21. Γc•¶GA¬—Ñ@ŒõAÄ“¡@”ŽA“ñ’J@•A‹{˜e—˜’jA´àVŒ¤“¹Fƒtƒ[ƒTƒCƒgƒƒgƒŠ[‚É‚æ‚éBtk’`”’Œ‡‘¹‚É‚Äf’f‚µ“¾‚½”º«—ò«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇŒÇ”­—áB—Õ°ŒŒ‰t@39F44-47,1998.
    22. ’ß‘ò³mCŽR–{‰ÃŽjC•Ð–ì’¼”VCœA“c‹M‹vA‹{˜e—˜’jA–ö£‘ì–çA¬ò»ˆêA“àŠCŽ¡˜YA󌩌bŽqC“c’†@“ÄC”ž“‡G—YC’†ŽR‰ë•FA”¨]–F˜YCŠÖª—E•vC“y’J‹ª‹`CŽR‘º‘׈êAŠâˆä’©KA‰Í–ì‰Ã•¶C‰º‰Í’B—YC¼ìŒ’ˆêA¼‰º’|ŽŸC—é‹{~ŽiC‘哇FˆêA‹e’r¹OAŽO‘î@“TC“n•Ó@VC‹àŽqˆÀ”äŒÃA’J“c•”“¹•vA“Œ@Š°C‰¡“c¸•½C‹ïŽuŒ˜rŽ÷A‹e“c“ÖAŽOŠÔ‰®~C‰ª“c@ç°C_‰€~ŽiC“¡–{–Ð’jA]Œût•FF¬Ž™”ñHodgkinƒŠƒ“ƒpŽî‚ÌŽ¡—ÃŒ¤‹†ˆê¬Ž™Šà”’ŒŒ•aŒ¤‹†ƒOƒ‹[ƒviCCLSGjNHL855^890Œ¤‹†‚Ì’·ŠúŽ¡—ìтƓñŽŸŠà‚Ì”­Ç—¦ˆêB—Õ°ŒŒ‰t@39F281-289,1998.
    23. ’Ë“c@‘A‹{˜e—˜’jF–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ìf’f‚ƌċzŠíŽ¾Š³B•ªŽqŒÄ‹zŠí•a 2 : 422-429,1998.
    24. ’ß‘ò³mA•Ð–ì’¼”VAœA“c‹M‹vAˆÉ“¡m–çA–ö£‘ì–çA󌩌bŽqA¬ò»ˆêA’†ŽR‰ë•FA‹{˜e—˜’jA—é‹{~ŽiA¼ìŒ’ˆêA”ž“‡G—YA–x‰z‘×—YA”¨]–F˜YAŠâˆä’©KAˆ¢“쌒ˆêA‹e’r¹OA‘哇FˆêA‹àŽqˆÀ”äŒÃA•Ð‰ª@“NA“c’†@“ÄA’Â@Šî–¾A‘½‰ê@’A“n•Ó@VAì–ž@“OA‹ïŽuŒ˜rŽ÷Aìã@´A‹e“c@“ÖAŽOŠÔ‰®ƒˆêA“¡–{–Ð’jF¬Ž™”ñHodgkinƒŠƒ“ƒpŽî‚ÌŽ¡—ÃŒ¤‹†ˆê¬Ž™Šà”’ŒŒ•aŒ¤‹†ƒOƒ‹[ƒviCCLSGj‚ÌVƒvƒƒgƒR[ƒ‹NHL960‚Ì’·ŠúŽ¡—ìшêB—Õ°ŒŒ‰t 39F1092-1098 ,1998.
  • Ç—á•ñ
    1. Wada H., Akiyama H., Seki H., Ichihara T., Ueno K., Miyawaki T., and Koizumi S. : Spinal canal involvement in infantile myofibromatosis: case report and review of the literature. J. Pediatric Hematology/ Oncology. 20: 353-356, 1998.
    2. rˆä”ü˜aŽqAˆîê@iAŽÂ茒‘¾˜YAŽðˆä—R‹IA•£‹žŽqAˆ¢•”KŽqA¼‘q—TŠìA‹{˜e—˜’jF”A’†Podocyte‚Ì„ˆÚ‚ð‚Ý‚½¬Ž™Ž‡”Á•a«t‰Š‚Ì1—á|Ž…‹…‘Ì“à‹ÃŒÅ‚Æ‚ÌŠÖ˜A«|Bt‚Æ“§Í 44F120-124,1998.
    3. ‹àŒ“O˜aA¼‘òƒŽqAŽs“c•™ŽqAFè@Œ’A¬’rŒ’ˆêA‹{˜e—˜’jFŽá”NŒ^–«œ‘«”’ŒŒ•a‚ÌŽ©‘RŠ°‰ð‚ð‚Ý‚½NoonanÇŒóŒQ‚Ì‚P’jŽ™—áB“ú–{¬Ž™‰ÈŠw‰ïŽGŽ 102F1102-1105,1998.
  • ‘à
    1. ”ª–ØMˆêA‹{˜e—˜’jFŠ´õ–ƉuŒŸ¸`ƒƒ^ƒEƒBƒ‹ƒXR‘ÌA•Ö’†ƒƒ^ƒEƒBƒ‹ƒXRŒ´B‘‡—Õà¬47(‘)F1735-1737,1998.

  • 1998”NŠw‰ï•ñ
    1. 㨌hˆê˜YA’Ô¦áÁˆêA‹´–{ˆè•vA•l“¹—T“ñAŽs“c•™ŽqA‹{˜e—˜’jA‹{è‚ ‚ä‚ÝA¼”ö‰ÄlF‚‘ψ³¬ŒŒŠÇŠg’£ƒJƒe[ƒeƒ‹‚ðŽg—p‚µ‚½Blalock-Taussing’Z—ŒŒŠÇ‚Ì‹·óA•Âǂɑ΂·‚éƒoƒ‹[ƒ“Šg‘åpB‘æ‚X‰ñ“ú–{Pediatric Inter-ventional CardiologyŒ¤‹†‰ï,1998,1,‹ž“s.
    2. ‹àŒ“O˜aA‹{˜e—˜’jAŠÛ”¢Œ\ŽqAŒÜ\—’“oAŠ}Œ´‘PmFEBƒEƒCƒ‹ƒXŠÖ˜AŽ¾Š³‚É‚¨‚¯‚éƒCƒ“ƒ^[ƒƒCƒLƒ“10. ‘æ‚Q‰ñŒŒ‰tŽ¾Š³‚ƃTƒCƒgƒJƒCƒ“Œ¤‹†‰ï,1998, 2,‹à‘ò.
    3. ”ª–ØMˆêA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jF׋۫‘–Œ‰Š‚Ìd–Œ‰º•a•Ï‚ɂ‚¢‚ÄB‘æ33‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï,1998,2,‹à‘ò.
    4. ŽRŒ³ƒŽqA¼‘òƒŽqAŠ™’JˆŸ‹IŽqA”ª–ØMˆêA‘«—§—YˆêA‹{˜e—˜’jFlHŠ·‹C‚É”½‰ž‚¹‚¸ External Chest Compressioni—pŽè‹¹Šsˆ³”—Š·‹C•â•j‚É‚æ‚芷‹C•s‘S‚©‚ç’Eo‚µ“¾‚½‹CŠÇŽxšb‘§dÏ”­ì‚̈ê’jŽ™—áD‘æ19‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ¤‹†‰ï1998,2,•xŽR.
    5. ‹´–{ˆè•vA㨌hˆê˜YA•l“¹—T“ñA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jFŒoŒûPGI2‚Ì‹}«Œø‰Ê‚¨‚æ‚Ñ–«Œø‰Ê‚ª”F‚ß‚ç‚ꂽŒ´”­«”x‚ŒŒˆ³Ç‚Ì1“ûŽ™—áB‘æ‚S‰ñ¬Ž™”xzŠÂŒ¤‹†‰ï,1998,2,“Œ‹ž.
    6. ¡‘º”Ž–¾A…ŒûŽu‰êŽqA–؉ëŽqA΋àŒbŽqAœAãáÁ—ŽqA‘º“¡—ŠŽqA–kì—mŽqA‹«@”ü‘ãŽqA‹g“cˆèŽqAŽO‘º‘וFA“c“àŽ“TA—Ž‡@GA…“‡–LFNICU‚É‚¨‚¯‚éMRSA‘Îô‚ɂ‚¢‚ÄB‘æ13‰ñ“ú–{ŠÂ‹«Š´õŠw‰ï,1998,2,“Œ‹ž.
    7. ‘«—§—YˆêF‹C“¹‰ŠÇ‚ƃŠƒ‚ƒfƒŠƒ“ƒOD‘æ‚T‰ñ¬Ž™‹CŠÇŽxšb‘§•a‘ÔŒ¤‹†‰ï,1998,3,‹ž“s.
    8. ¬¼@“OA¼àVƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF—Ç«“ûŽ™áz¹‚Ì’·Šú—\Œã|BECT‚ÅÄ”­H‚µ‚½‚P—á‚ð’†S‚É|B‘æ14‰ñRDŒ¤‹†‰ï,1998,3,‘åã.
    9. ŽÂ茒‘¾˜YA‹àŒ“O˜aA”ª–ØMˆêA‹{˜e—˜’jAÀ“cŽOŽ}ŽqF¶‘lŒa•”Œ´”­ƒzƒWƒLƒ“•a‚̈ê—áB‘æ262‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,1998,3,‹à‘ò.
    10. ‹àŒ“O˜aA‹k@çHA—Ñ@ŒbŽOA‹{˜e—˜’jF•p‰ñ‚ÉÄ”­‚ðŒJ‚è•Ô‚µ‚Ä‚¢‚éLangerhans cell histiocytosis‚̈ê—áB‘æ‚W‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ï,1998,3,‹à‘ò.
    11. Adachi Y., Onoue Y., Yamamoto J., Adachi Y.S., Seki D., Toyota M., Morohashi M., Miyawaki T.: CD30 Expression on T Cells as a Marker for Role of Th2-type Cell in Atopic Dermatitis. 54th Annual Meeting of American Academy of Asthma, Allergy and Immunology,1998,3,Washington DC, USA.
    12. ŽRŒ³ƒŽqA‘«—§—YˆêA‰ª•””üŒbA”öã—mˆêA‘«—§—zŽqA‹{˜e—˜’jA‘ºãIŒ[F‹CŠÇŽxšb‘§dÏ”­ìŒã‚Ɉê‰ß«‰º‚‘Ì‹@”\’ቺ‚ð’悵‚½‚P’jŽ™—áD‘æ10‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,1998,4,–¼ŒÃ‰®D
    13. ‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‰ª•””üŒbA‘«—§—zŽqA‹{˜e—˜’jA‘ºãIŒ[A¼–ì³’mFƒCƒ\ƒvƒƒeƒŒƒm[ƒ‹Ž‘±‹z“ü—Ö@‚É‚¨‚¯‚éŒø‰Ê”»’è@-S””‚ÍŽw•W‚ɬ‚蓾‚é‚©-D‘æ10‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,1998,4,–¼ŒÃ‰®.
    14. ¼–ì³’mAˆÉ“Œ“¹•vAŒ´@³‘¥A–öŒ´r—YA‘«—§—YˆêFƒ_ƒj‚̬“ü‚µ‚½‚¨D‚ÝÄ‚«‚ðH‚ׂ½ŒãA‘SgÇó‚ð’悵‚½‚P’jŽ™—áB‘æ10‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,1998,4,–¼ŒÃ‰®.
    15. ¬¼@“OA‘ŽqDA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jFƒtƒFƒjƒgƒCƒ“ŽUÜ‚Ì bioavailability FƒAƒŒƒrƒAƒ`ƒ“10”{ŽU‚Ö‚Ì•ÏX‚ÉÛ‚µ‚ÄB‘æ22‰ñ–k—¤‚Ä‚ñ‚©‚ñ§˜b‰ï,1998,4,‹à‘ò.
    16. ”ª–ØMˆêA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA‹{˜e—˜’jFŒõ—U”­«‚Ä‚ñ‚©‚ñ‚Ì—Õ°”]”g“Á’¥B‘æ22‰ñ–k—¤‚Ä‚ñ‚©‚ñ§˜b‰ï,1998,4,‹à‘ò.
    17. ¼‘òƒŽqA¬¼@“OA–{‹½˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF”M«‚¯‚¢‚ê‚ñ—\–h“Š—^’†‚Ì”­ìÄ”­-AEDŽ‘±“Š—^‚ÆDZPŠÔŒ‡“Š—^–@‚Ì”äŠr-B‘æ‚P‰ñ“û—cŽ™‚¯‚¢‚ê‚ñŒ¤‹†‰ï,1998,4,“Œ‹ž.
    18. ”ª–ØMˆêA¬¼@“OAA‘º”ü‹IA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jFV¶Ž™Šú‚æ‚èŒQ”­‚·‚é•¡ŽG•”•ª”­ì‚ð”F‚ß‚½“«‚Ä‚ñ‚©‚ñ‚̈ê—áB‘æ‚P‰ñ“û—cŽ™‚¯‚¢‚ê‚ñŒ¤‹†‰ï,1998,4,“Œ‹ž.
    19. ˆÉ“Œ^—ŽqA¬¼@“OA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jFŽ©•ÂŒXŒü‚ɑ΂·‚é‘Šú—Èç-—ÈçŠÂ‹«‚Ì’²®‚¨‚æ‚Ñ•êe‰‡•‚ÌŠî–{-B‘æ33‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1998,4,•xŽR.
    20. ‘«—§—zŽqA‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‰ª•””üŒbA‹{˜e—˜’jFƒAƒŒƒ‹ƒM[«Ž¾Š³“û—cŽ™‚É‚¨‚¯‚éƒlƒRRAST—z«—¦‚Æ‚»‚Ì—Õ°“IˆÓ‹`B‘æ33‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1998,4,•xŽR.
    21. ”ª–ØMˆêA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jFƒCƒ“ƒtƒ‹ƒGƒ“ƒU—¬sŽž‚É‚Ý‚ç‚ꂽ”]‰ŠE”]ǂɂ‚¢‚Ä.‘æ33‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1998,4,•xŽR.
    22. ‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‘«—§—zŽqA‰¡“cF”VA‰ª•””üŒbA‹{˜e—˜’jA‘ºãIŒ[FƒAƒgƒs[«”畆‰ŠŠ³ŽÒ––½ŒŒ‚s×–E‚É‚¨‚¯‚éCD30”­Œ»‚Æ×–E“àƒTƒCƒgƒJƒCƒ“”­Œ»ƒpƒ^[ƒ“D‘æ101‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1998,5.•ÄŽq.
    23. ‹àŒ“O˜aA“ñ’J@•A˜eŒû@GA‹vì_ÍA‘q‹Ù—²MAVˆä“c@—vAŠ}Œ´‘PmA‹{˜e—˜’jF–«Šˆ“®«EBƒEƒBƒ‹ƒXŠ´õÇ‚Æ‚µ‚Ä’·ŠúŠÔƒtƒHƒ[‚³‚ê‚Ä‚¢‚½Fasˆâ“`ŽqˆÙí‚̈ê—áD‘æ101‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1998,5,•ÄŽq.
    24. ¡‘º”Ž–¾A“ñ’J@•A¬ìŽŸ˜YA‹g“c˜aŽiA‹g“cärA‹{˜e—˜’jFNICU‚É‚¨‚¯‚éMRSA‘Îô‚Ì—Õ°“IŒŸ“¢`ƒsƒIƒNƒ^ƒjƒ“ˆŸ‰”‰Ø“îp‚ƃ€ƒsƒƒVƒ“•@o—p“îp‚ÌŒø‰Ê‚ɂ‚¢‚ÄB‘æ101‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1998,5,•ÄŽq.
    25. ‹àŒ“O˜aA‰ª•””üŒbA–쑺ŒbŽqA”ª–ØMˆêA‹{˜e—˜’jAÎàV@LA”ö–î„ŽuA¬ò•x”ü’©AŒE“c”Ž“¹FEBƒEƒBƒ‹ƒXƒQƒmƒ€—z«angiocentric lymphoma‚̈ꗎ™—áD‘æ‚W‰ñ‚d‚aƒEƒBƒ‹ƒXŠ´õÇŒ¤‹†‰ï,1998,5,“Œ‹ž.
    26. ¬¼@“OA‘ŽqDA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF•”•ª”­ìÇó‚ð”F‚ß‚½Œ‡_‚Ä‚ñ‚©‚ñÇ—á‚Ì—Õ°”]”g“Á’¥B‘æ40‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1998,6,‰¡•l.
    27. ŽR’J”ü˜aA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vA‘ºã”ü–çŽqA”ª–ØMˆêA‹{˜e—˜’jF‚Ä‚ñ‚©‚ñŽ¡—Ã’†Ž~—á‚É‚¨‚¯‚éÄ”­“Á’¥-”N—îˆöŽq‚ÌŠÖ—^‚ɂ‚¢‚Ä-B‘æ40‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1998,6,‰¡•l.
    28. ”ª–ØMˆêA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jF׋۫‘–Œ‰Š‚Ìd–Œ‰º•a•Ï‚ɂ‚¢‚ÄB‘æ40‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1998,6,‰¡•l.
    29. –{‹½˜a‹vA¬¼@“OA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jA’|’J“¿—YFMigrating partial seizure in infancy‚ÆŽv‚í‚ê‚é‚Q—áB‘æ40‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1998,6,‰¡•l.
    30. ¼‘òƒŽqA¬¼@“OA‘ŽqDA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF”]‰ŠE”]ÇŒãˆâÇŠ³Ž™‚É‚¨‚¯‚éMRSŠŒ©‚ɂ‚¢‚ÄB‘æ40‰ñ“ú–{¬Ž™_Œo‰ï,1998,6,‰¡•l.
    31. ¼‘q—TŠìAŽÂ茒‘¾˜YBŽðˆä—R‹IArˆä”ü˜aŽqA•£‹žŽqAˆ¢•”KŽqAˆîê@iA‹{˜e—˜’jF‚W”NŒo‰ßŒã‚ÌĶŒŸ‚É‚Ähemispherical deposits‚ð”F‚ß‚½¬Ž™IgAtǂ̈ê—áB‘æ33‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ï,1998,6,‰¡•l.
    32. ”öã—mˆêA‘ê“cˆê˜NA¼‘q—TŠìAŽRŒ³ƒŽqA‘«—§—YˆêAŽs“c•™ŽqA‹{˜e—˜’jFFontanpŒã‚É”­Ç‚µ‚½plastic bronchitis‚̈ê’jŽ™—áB‘æ263‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,1998,6,•Ÿˆä.
    33. œA–ìŒbˆêAÝ“c—FŽqA‹g“cärA‘«—§—YˆêA‹{˜e—˜’jA‹àˆä‰pŽqF‰¼«ƒNƒ‹[ƒv‚Æ‚ÌŠÓ•Ê‚É‹ê—¶‚µ‚½æ“V«‹CŠÇ‹·ïǂ̈ê—áB‘æ‚P‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1998,7,•xŽR.
    34. ¬¼@“OF“Á•Êu‰‰uŒõ—U”­«EŒõ‰ß•q«‚Ä‚ñ‚©‚ñ‚Ì—Õ°“Á’¥v‘æ‚P‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1998,7,‚‰ª.
    35. 㨌hˆê˜YAŠ™’JˆŸŠóŽqA•l“¹—T“ñA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA‘ºã@VA“¡–Ø@–¾Fƒtƒ@ƒ[Žl’¥ÇpŒã‚ÉSŽº•p”‚𔺂Á‚½QT‰„’·ÇŒóŒQ‚Ì1—áB‘æ34‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1998,7,“Œ‹ž.
    36. ”‘òŽõŽqA•l“¹—T“ñA‹´–{ˆè•vA’Ô¦^ˆêAŽs“c•™ŽqA‹{è‚ ‚ä‚ÝA‹{˜e—˜’jA‘ºã@VA…–qŒ÷ˆêA‰ª“c‰p‹gAFè@Œ’F‰^“®‚É‚æ‚è“Ë‘RŽ€‚𗈂µ‚½‹H‚Èæ“V«Š¥“®–¬‹NŽnˆÙí‚̈êÇ—áB‘æ34‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1998,7,“Œ‹ž.
    37. ‹{è‚ ‚ä‚ÝA㨌hˆê˜YA•l“¹—T“ñA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA“¡–Ø@–¾FQT‰„’·ÇŒóŒQ‚É‚¨‚¯‚éŒðŠ´_ŒoŒnŽhŒƒ–òÜ•‰‰×S“d}ŒŸ¸‚̈Ӌ`B‘æ34‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1998,7,“Œ‹ž.
    38. ‹´–{ˆè•vA•l“¹—T“ñA㨌hˆê˜YA’Ô¦áÁˆêAŽs“c•™ŽqA‹àŒ“O˜aA‹{˜e—˜’jAŽOè‘ñ˜YAŽO‰Y³‹`A‰ª•”@ŒhA‘º“c“Þ”üA¬ò¹ˆêFAutomatic Border Detection‚ð—p‚¢‚½¬Ž™‰»Šw—Ö@Š³Ž™‚É‚¨‚¯‚éƒAƒ“ƒgƒ‰ƒTƒCƒNƒŠƒ“S‹ØáŠQ‚Ì‘Šúf’f‚̉”\«B‘æ34‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 1998,7,“Œ‹ž.
    39. •l“¹—T“ñA‹´–{ˆè•vA㨌hˆê˜YAŽs“c•™ŽqA¬¼@“OA‹{˜e—˜’jA…–qŒ÷ˆêA“¡–Ø@–¾F¬Ž™‚Ì_Œo’²ß«Ž¸_‚ɑ΂·‚éHead-up tiltŽŽŒ±‚Ì—L—p«‚ÌŒŸ“¢B‘æ34‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1998, 7,“Œ‹ž.
    40. ¼‘q—TŠìA‘ê“cˆê˜NA”öã—mˆêA‹{˜e—˜’jA¡–ìºGA´…@áÁF•aŒ´«‘å’°‹Û‚n26‚ÌŠ´õ‚É”º‚¢táŠQ‚ð”F‚ß‚½ˆê—áB‘æ‚P‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1998,7,•xŽR.
    41. ”ÂàVŽõŽqAFè@Œ’AŽíŽsq’ˆA”öã—mˆêA‹àŒ“O˜aA”ª–ØMˆêF‰ºŽˆ‚Ìáu’É‚ðŽå‘i‚Æ‚µ‚½Neuroblastoma(NB)‚̈ê—áB‘æ‚P‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1998,7,•xŽR.
    42. ¼‘q—TŠìAŽÂ茒‘¾˜YA‹{˜e—˜’jA‹{è‚ ‚ä‚ÝF‚RÎŽž‚É“Ë‘R‚Ì“÷Šá“IŒŒ”A‚É‚Ä”­Ç‚µ‚½Alport's syndrome‚̈ê—áB‘æ34‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1998,8,–¼ŒÃ‰®.
    43. ‹g“cärA¡‘º”Ž–¾A‹{˜e—˜’jA‰ê—ˆ–œ—R”üA”ª”¦‹`lF“ú—î‚P‚ÉŒðŠ·—AŒŒ‚ð•K—v‚Æ‚µ‚½ˆâ“`«‹…óÔŒŒ‹…ǂ̈ê—áB‘æ34‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1998,8,–¼ŒÃ‰®.
    44. ’†—ÑŒºˆêA‹´–{ˆè•vA‹àŒ“O˜aA¬¼@“OA‹{˜e—˜’jA—Sì˜aŽqFI-cell•a(ƒ€ƒRƒŠƒsƒh[ƒVƒXEŒ^)‚Ì‚UƒJŒŽ’jŽ™—áB‘æ34‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1998,8,–¼ŒÃ‰®.
    45. •£àV—³–çA‹k@çHA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jA¬—Ñ’B–çFŽc‘¶Žîᇂɑ΂µƒKƒ“ƒ}ƒiƒCƒt‚ªŒø‰Ê“I‚Å‚ ‚Á‚½¬”]‘‰èŽî‚̈ê—áB‘æ34‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1998,8,–¼ŒÃ‰®.
    46. ¼‘q—TŠìAŽÂ茒‘¾˜YA‹{˜e—˜’jA‹{è‚ ‚ä‚ÝF‚RÎŽž‚É“Ë‘R‚Ì“÷Šá“IŒŒ”A‚É‚Ä”­Ç‚µ‚½Alport's syndrome‚̈ê—áB‘æ20‰ñ“ú–{¬Ž™t•s‘SŠw‰ï,1998,9,VŠƒ.
    47. ‹àŒ“O˜aA–쑺ŒbŽqA‹{˜e—˜’jFƒtƒ[ƒTƒCƒgƒƒgƒŠ[–@‚É‚æ‚蓯’肳‚ꂽV‚½‚ÈXLAÇ—á‚ÆBtkˆâ“`Žq•ÏˆÙ‰ðÍBŒú¶È“Á’莾Š³Œ´”­«–Ɖu•s‘SÇŒóŒQ’²¸Œ¤‹†”Ç•½¬10”N“x‘æ‚P‰ñ”ljï‹c‘‰ï,1998,9,Œyˆä‘ò.
    48. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jA“c’†’¼ŽqA–Ø‘º@GFƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒX‰Š´õ‚É‚æ‚é‚ÆŽv‚í‚ꂽ‹}«ŒŒ¬”ÂŒ¸­«Ž‡”Á•a‚̈ê“ûŽ™—áB‘æ@‚U‰ñ–k—¤ƒwƒ‹ƒyƒXŒ¤‹†‰ï,1998,9,‹à‘ò.
    49. Matsukura H., Shinozaki K., Inaba S., Miyawaki T.: Long-term Follow-up of Steroid Responsive Nephrotic Syndrome in 86 Children.IPNA,1998,9,London.
    50. Takai R, Matsukura H. and Miyawaki T.: Glomerular podocyte vacuolation in childhood IgA nephropathy. IPNA,1998,9,London.
    51. ¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF¬Ž™“«‚Ä‚ñ‚©‚ñ‚É‚¨‚¯‚éŠO‰È“IŽ¡—Ẩ”\«‚ɂ‚¢‚ÄB‘æ34‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï,1998,9,‹à‘ò.
    52. ”ª–ØMˆêA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA‹{˜e—˜’jF‹»–¡‚ ‚é”]”gŠŒ©‚ð’悵‚½eyelids myoclonia‚ÌŒZ’í—áB‘æ34‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—¤’n•û‰ï,1998,9,‹à‘ò.
    53. ¼‘òƒŽqA¬¼@“OA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF¬Ž™‚Ä‚ñ‚©‚ñ‚ÌŠO‰È“IŽ¡—Ẩ”\«‚ɂ‚¢‚ÄB‘æ‚U‰ñ•xŽRŒ§—Õ°¬Ž™_ŒoŠwŒ¤‹†‰ï,1998,9,•xŽR.
    54. ‘«—§—zŽqA‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‰ª•””üŒbA‰¡“cF”VAŠžŒ´¹ŽqAŠâ’J‰ëŽqA‹{˜e—˜’jA‘ºãIŒ[FƒAƒŒƒ‹ƒM[«Ž¾Š³“û—cŽ™‚É‚¨‚¯‚é“úí“I‚ȃlƒR‚Æ‚ÌÚG‚ƌċzŠíÇó‚ÌŠÖŒWB‘æ35‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,1998,9,‘åã.
    55. ¼‘q—TŠìAŽÂ茒‘¾˜YArˆä”ü˜aŽqAŽðˆä—R‹IAˆ¢•”KŽqA‚ˆä—¢A‹{˜e—˜’jA–L“‡Sˆê˜YFæ“V«…tǂ𔺂¤Š®‘Sd•¡tá±”AŠÇ‚Ìf’f‚ÉMR urography‚ª—L—p‚Å‚ ‚Á‚½ˆê—áB‘æ28‰ñ“ú–{t‘ŸŠw‰ï¼•”Šwp‘å‰ï,1998,10,“Þ—Ç.
    56. ¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF¬Ž™‚Ä‚ñ‚©‚ñ‚É‚¨‚¯‚éŒõ‰ß•q«‚ÌŒŸ“¢-Œõ‰ß•q«”]”gˆÙí‚ðŽ¦‚µ‚½Ç—á‚ɂ‚¢‚Ä-B‘æ32‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,1998,10,‰¡•l.
    57. ”ª–ØMˆêA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jF¬Ž™‚Ä‚ñ‚©‚ñ‚É‚¨‚¯‚éŒõ‰ß•q«‚ÌŒŸ“¢-Œõ‰ß•q«”­ì‚ðŽ¦‚µ‚½Ç—á‚ɂ‚¢‚Ä-B‘æ32‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,1998,10,‰¡•l.
    58. ŽR’J”ü˜aA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vA‘ºã”ü–çŽqA”ª–ØMˆêF“û—cŽ™Šú‚̓«‚Ä‚ñ‚©‚ñ‚É‚¨‚¯‚釖°ŠoÁƒŠƒYƒ€‚ÌáŠQB‘æ32‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,1998,10,‰¡•l.
    59. ¼‘òƒŽqA¬¼@“OA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF¬Ž™“«EÇŒó«‚Ä‚ñ‚©‚ñ‚É‚¨‚¯‚éƒvƒƒgƒ“‚l‚q‚rŠŒ©B‘æ32‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,1998,10,‰¡•l.
    60. ‘«—§—zŽqA‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‹{˜e—˜’jFƒAƒŒƒ‹ƒM[«Ž¾Š³“û—cŽ™‚É‚¨‚¯‚éƒlƒRƒAƒŒƒ‹ƒM[‚Ì—Õ°“IˆÓ‹`B‘æ‚P‰ñ•xŽR¬Ž™šb‘§Œ¤‹†‰ï,1998,10,•xŽR.
    61. Konishi T, Matsuzawa J, Hongou K, Yamatani M, Yagi S, and Miyawaki T.: Disturbance of sleep-wake rhythm in infants with intractable epilepsy. 2nd Asian Oceanian Epilepsy Organization,1998,11,Taipei,Taiwan.
    62. Matsuzawa J, Konishi T, Hongou K, Yamatani M, Yagi S, and Miyawaki T.: Proton MRS findings of children with intractable epilepsy. 2nd Asian Oceanian Epilepsy Organization,1998,11,Taipei,Taiwan.
    63. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jFEBVƒQƒmƒ€—z«ƒÁƒÂT×–EƒŠƒ“ƒpŽî‚̈ꗎ™—áB‘æ40‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï,1998,11,‹à‘ò.
    64. ‹àŒ“O˜aA–쑺ŒbŽqA‹{˜e—˜’jA‹´–{Í“ñA’Ë“c@‘AŠâ“c@—ÍA¬‹{ŽR@~Fƒtƒ[ƒTƒCƒgƒƒgƒŠ[–@‚É‚Äf’f‚³‚ꂽ‚w˜A½«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚ÌBtkˆâ“`Žq‰ðÍB‘æ40‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï,1998,11,‹à‘ò.
    65. ”öã—mˆêA‘ê“cˆê˜NA¼‘q—TŠìAŽRŒ³ƒŽqA‘«—§—YˆêA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jFFontanpŒã‚É”­Ç‚µ‚½plastic bronchitis‚Ì’jŽ™—áB‘æ31‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,1998,11,‰¡•l.
    66. •£‘ò—³–çA–쑺ŒbŽqA¼‘òƒŽqA‹àŒ“O˜aA”ª–ØMˆêA‹{˜e—˜’jFGuillain-BarreÇŒóŒQ‚É‚¨‚¯‚éŒoŽž“IƒŠƒ“ƒp‹…ƒTƒuƒZƒbƒg‚Ì„ˆÚB‘æ30‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,1998,11,¼–{.
    67. –쑺ŒbŽqA•£‘ò—³–çA¼‘q—TŠìA‹{˜e—˜’jAFè@Œ’F•aŒ´«‘å’°‹ÛO-26‚É‚æ‚é—nŒŒ«”A“ÅÇÇŒóŒQ‚̈ê—áB‘æ30‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,1998,11,¼–{.
    68. ¼‘òƒŽqA¬¼@“OAÝ“c—FŽqA‹àŒ“O˜aA–{‹½˜a‹vA”ª–ØMˆêA‹{˜e—˜’jF‹»–¡‚ ‚é—Õ°Œo‰ß‚ðŽ¦‚µ‚½ƒqƒgƒwƒ‹ƒyƒXƒEƒBƒ‹ƒX‚UŒ^”]‰ŠE”]Ç‚Ì‚P—áB‘æ30‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,1998,11,¼–{.
    69. ‹àŒ“O˜aA˜eŒû@GFEBƒEƒCƒ‹ƒXŠ´õÇ‚É‚¨‚¯‚éƒCƒ“ƒ^[ƒƒCƒLƒ“10. ‘æ30‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,1998,11,¼–{.
    70. ‹àŒ“O˜aA‹{˜e—˜’jA‘¾“c˜aGAŒÜ\—’@“oA—Sì˜aŽqFHunterÇŒóŒQ(ƒ€ƒR‘½“œ—ÞEŒ^)‚Q—á‚̈â“`Žq‰ðÍB‘æ19‰ñ–k—¤æ“VˆÙ팤‹†‰ï,1998,12,•xŽR.
    71. ”‘òŽõŽqA‘ºãIŒ[AŽRŒ³ƒŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§‚É‚¨‚¯‚éƒEƒBƒ‹ƒXŠ´õ‚ÌŠÖ—^[MxA’`”’‚ðŽw•W‚Æ‚µ‚Ä[B‘æ25‰ñ–k—¤ƒAƒŒƒ‹ƒM[§˜b‰ï,1998,12,‹à‘ò.
    72. Ý“c—FŽqA”ª–ØMˆêA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF–«“÷‰èŽîÇ“ûŽ™—á‚É‚Ý‚ç‚ꂽ‰ŠÇ«’°•a•Ï[’·ŠúƒXƒeƒƒCƒh­—Ê“Š—^‚Æ‘å’°ƒtƒ@ƒCƒo[‚É‚æ‚éŒoŽž“IŠÏŽ@[B‘æ‚U‰ñH×–E‹@”\ˆÙíÇŒ¤‹†‰ï,1998,12,“Œ‹ž.
    73. ‹àŒ“O˜aA”ŒãËŒ´ËA㼈ê‰iA‹´–{ÍŽiA’Ë“c@‘AŠâ“c@—ÍA¬‹{ŽR~A‹{˜e—˜’jFƒtƒ[ƒTƒCƒgƒƒgƒŠ[–@‚É‚Äf’f‚³‚ꂽ‚w˜A½«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚ÌBtkˆâ“`Žq‰ðÍB‘æ28‰ñ“ú–{–ƉuŠw‰ï‘‰ï,1998,12,_ŒË.
    74. ‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‘«—§—zŽqA‰¡“cF”VA‰ª•””üŒbA‹{˜e—˜’jA–L“c‰ë•FAŠÖ@‘¾•ãA”‹´³ºFƒAƒgƒs[«”畆‰Š(AD)Š³ŽÒ‚É‚¨‚¯‚é‚s×–ECD30”­Œ»—¦‚ÆŒŒ’†solubleCD30’l‚ÌŠÖŒWB‘æ48‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,1998,12,_ŒË.
    75. ”öã—mˆêA‘«—§—YˆêAŽRŒ³ƒŽqA‘«—§—zŽqA‰¡“cF”VA‰ª•””üŒbA‹{˜e—˜’jA–L“c‰ë•FAŠÖ@‘¾•ãA”‹´³ºFƒAƒgƒs[«”畆‰Š(AD)Š³ŽÒ‚É‚¨‚¯‚é––½ŒŒƒŠƒ“ƒp‹…ƒTƒCƒgƒJƒCƒ“ŽY¶[×–E“àƒTƒCƒgƒJƒCƒ“‚ðŽw•W‚Æ‚µ‚Ä[‘æ48‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,1998,12,_ŒË.
    76. ŽíŽsq’ˆA”ÂàVŽõŽqA‹àŒ“O˜aA‹{˜e—˜’jAA‘º”ü‹IA‘ºãIŒ[FD’†‹…Œ¸­Ç‚𔺂Á‚½–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚̈ê—áB‘æ‚Q‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1998,12,•xŽR.
    77. ¼‘q—TŠìA‹{˜e—˜’jA–L“‡Sˆê˜YFæ“V«…tÇ‚É‚¨‚¯‚éMagnetic Resonance UrographyiMRUj‚ÌŽg—pŒoŒ±‚ɂ‚¢‚ÄB‘æ‚Q‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1998,12,•xŽR.
    78. Hashimoto I., Ichida F., Uese K., Hamamichi Y., Miyawaki T.: THP-ADR induces lower degree of cardiotoxicity than ADR: Determination of cardiotoxicity by automatic border detection. The 26th Annual Meeting of the North American Society for Cardiac Imaging,1998,11,Dallas,USA.
    79. Hamamichi Y., Ichida F., Uese K., Hashimoto I., Tsubata S., Miyawaki T., Ono Y., Kamiya T. : Isolated noncompaction of the ventricular myocardium -UFCT and magnetic resonance imaging- The 26th Annual Meeting of the North American Society for Cardiac Imaging,1998,11,Dallas,USA.
    80. Ichida F., Hashimoto I., Tsubata S., Hamamichi Y., Uese K., Miyazaki A., Fukahara K., Murakami A., Nakajima A., Futatsuya R., Miyawaki T.: Evaluation of pulmonary blood supply by multiplanar cine magnetic resonance imaging in patients with pulmonary atresia and severe pulmonary stenosis. The 26th Annual Meeting of the North American Society for Cardiac Imaging,1998,11,Dallas,USA.
    81. Ichida F., Hashimoto I., Tsubata S., Hamamichi Y., Uese K., Murakami A., Miyawaki T.: Novel technique using biplane cine magnetic resonance imaging for evaluation of left ventri-cular volume in children. The 26th Annual Meeting of the North American Society for Cardiac Imaging,1998,11,Dallas,USA.
    82. Ichida F., Hamamichi Y., Uese K., Hashimoto I., Futatani T., Kanegane H., and Miyawaki T.: Neutrophils and mononuclear cells secrete vascular endothelial growth factor in acute Kawasaki disease. The 71st Scientific Sessions of American Heart Association,1998,11,Dallas,USA.

    1997”N

  • ’˜‘
    1. Vˆä“c@—vC“ñ’J@•C‹{˜e—˜’jF‚w˜A½«–³ƒÁ-ƒOƒƒuƒŠƒ“ŒŒÇ‚̈â“`Žqf’fuAnnual ReviewŒŒ‰tv‚‹vŽj–›‘¼•Ò,185-193,’†ŠOˆãŠwŽÐ,“Œ‹ž,1997.
    2. ‹{˜e—˜’jFŒ´”­«–Ɖu•s‘SÇŒóŒQDu1997E¡“ú‚ÌŽ¡—ÃŽwj‘æ11”Åv–î“cƒˆê‘¼•Ò,222,ˆãŠw‘‰@,“Œ‹ž,1997.
    3. ˆîê@iF—nŒŒ«”A“ÅÇÇŒóŒQ(HUS)Du1997E¡“ú‚̬Ž™Ž¡—ÃŽwj‘æ11”Åv–î“cƒˆê‘¼•Ò,401-402,ˆãŠw‘‰@,“Œ‹ž,1997.
    4. ‹{˜e—˜’jFŒ´”­«–Ɖu•s‘SÇDu¬Ž™‰ÈŠwv”’–ؘa•v‘¼•Ò,695-700,ˆãŠw‘‰@,“Œ‹ž,1997.
    5. ¬¼@“OFÒ‘Ž¾Š³Du¬Ž™‰ÈŠwv”’–ؘa•v‘¼•Ò,1431-1434,ˆãŠw‘‰@,“Œ‹ž,1997.
    6. ‹{˜e—˜’jF–Ɖu‹@”\‚Ì”­’BDu•W€–ƉuŠwv’JŒû@ŽA‹{â¹”V•Ò,480-486,ˆãŠw‘‰@,“Œ‹ž,1997.
    7. ’Ë“c@‘A“ñ’J@•A‹{˜e—˜’jF“ú–{‚ÌBrutonŒ^–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‰ÆŒn‚É‚¨‚¯‚éBtk•ÏˆÙu–Ɖu1997-98vŠÝ–{’‰ŽO•Ò,222-232,’†ŽR‘“X,“Œ‹ž,1997.
    8. “ñ’J@•A‹{˜e—˜’jFˆâ“`ŽqˆÙí‚É‚æ‚é–Ɖu•s‘SDuÅV“à‰ÈŠw‘åŒnƒvƒƒOƒŒƒX‚Sv‹ààVˆê˜Y‘¼•Ò,182-193,’†ŽR‘“X,“Œ‹ž,1997.
    9. ’Ë“c@‘A“ñ’J@•A‹{˜e—˜’jFu–Ɖu1997-98vŠÝ–{’‰ŽO•Ò,222-232,’†ŽR‘“X,“Œ‹ž,1997.
    10. “ñ’J@•A‹{˜e—˜’jF“û—cŽ™ˆê‰ß«’áƒÁƒOƒƒuƒŠƒ“ŒŒÇF¬Ž™“à‰È•Êûu¬Ž™Ž¾Š³f—Â̂½‚ß‚Ì•a‘Ô¶—v¬Ž™“à‰È•ÒWˆÏˆõ‰ï•Ò,963-965,“Œ‹žˆãŠwŽÐ,“Œ‹ž,1997.
    11. “ñ’J@•A‹{˜e—˜’jFˆâ“`ŽqˆÙí‚É‚æ‚é–Ɖu•s‘SDuÅV“à‰ÈŠw‘åŒnƒvƒƒOƒŒƒX‚Sv‹ààVˆê˜Y‘¼•Ò,182-193,’†ŽR‘“X,“Œ‹ž,1997.
  • Œ´’˜
    1. Kasahara Y., Iwai K., Yachie A., Ohta K., Konno A., Seki H., Miyawaki T. and Taniguchi N.: Involvement of reactive oxygen intermediates in spontaneous CD95(Fas/AP0-1)-mediated apoptosis of neutrophils. Blood@89 : 1748-1753,1997.
    2. C. Sgadari., J. M. Farber., A. L. Angiolillo., F. Liao., J. Teruya-Feldstein., P. R. G. Gupta., Kanegane C., and Tosato G. : Mig, the monokine induced by Interferon-ƒÁpromotes tumor necrosis In vivo. Blood 89 : 2635-2643,1997.
    3. Kanegane H., Wada T., Nunogami K., Seki H., Taniguchi N., and Tosato G. : Chronic persistent Epstein-Barr virus infection of natural killer cells and B cells associated with granular lymphocytes expansion. British Journal of Haematology : 95, 116-122, 1996.
    4. Kanegane H., and Tosato G. : Activation of naive and memory T cells by Interleukin-15. Blood 88 : 230-235,1996.
    5. Kanegane H., Wang F., and Tosato G. : Virus-cell interactions in a Natural Killer-like cell line from a patient with lymphoblastic lymphoma. Blood 88 : 4667-4675,1996.
    6. Angiolillo A.L., Kanegane H., Sgadari C.,Reeman G.R., and Tosato G. : Interleukin-15 promotes angiogenesis in Vivo. Biochemical and Biophysical Research Communications 233 : 231-237,1997.
    7. Kanegane H., Kanegane C., Yachie A., Miyawaki T., and Tosato G. : Infectious mononucleosis as a disease of early childhood in Japan caused by primary Epstein-Barr virus infection. Acta Paediatrica Japonica 39:166-171,1997.
    8. Kanegane H., Wakiguchi H., Kanegane C., Kurashige T., and Giovanna T. : Viral Interleukin-10 in chronic active Epstein-Barr virus infection. The Jounal of Infection DIseases 176 : 254-257,1997.
    9. Yamamoto S., Inaba S., Yoshida R., Takahashi T., Ishihara S., Sakai Y., Arai M., Kurose K., Matsukura H., and Miyawaki T.: Clinicopathological characteristics of the focal and segmental form of idiopathic membranous nephropathy: Comparison with the typical form of this disease. Acta Paediatrica Japonica 39 : 349-353 ,1997.
    10. Yagi S., Konishi T., Masuko K., Matsuzawa J., Hongou K., Yamatani M., and Miyawaki T.: Clinical features of patients with tonic spasms; Persistence beyond infacy. Epilepsia 38:77-78,1997.
    11. Miura M., Okabe T., Tsubata S., Takizawa N., and Sawaguchi T. : Chronic infantile neurological cutaneous articular syndrome in a patient from Japan. Eur J Pediatr 156 : 624-626,1997.
    12. Naganuma Y., Konishi T., Hongou K., Okada T., Tohyama J., and Uchiyama M. : Event-related Potentials (P300) and EEG activity in childhood partial epilepsy. Brain & Development 19 : 117-121,1997.
    13. Naganuma Y., Konishi T., Hongou K., Tohyama J., and Uchiyama M. : Epileptic seizures and event-related potentials (P300) in childhood partial epilepsies. Clinical Electroencephalography 28 : 106-111,1997.
    14. Ichida F.,Tsubata S., Hashimoto I., Hamamichi Y., Uese K., Fukahara K., Murakami A., and Miyawaki T.: Effect of oral prostacyclin and inhaled NO on pulmonary hypertension in children. J of Cardiology 29 : 217-224,1997.
    15. Ichida F., Uese K., Tsubata S., Hashimoto I., Hamamichi Y., Fukahara K., Murakami A., and Miyawaki T.: Additive effect of Beraprost on pulmonary vasodilation by nitric oxide in children with pulmonary hypertension. Am J Cardiol 80 : 662-664,1997.
    16. Tsubata S., Ichida F., and Miyawaki T.: Balloon angioplasty for isolated coarctation of the aorta with mirror image right aortic arch in an infant.Cardiol Young. 7 : 458-461,1997.
    17. Uese K., Ichida F., Tsubata S., Hashimoto I., Hamamichi Y., Fukahara K., Murakami A., and Miyawaki T.: Oral prostacyclin analogue enhances the pulmonary vasodilatory effect of nitric oxide in children with pulmonary hypertension. Cardiol Young. 7 : 362-369,1997.
    18. Murakami A., Fukahara K., Ichida F., Yahagi N., and Kumon K. : Significance of nitric oxide inhalation for reperfused lung. Artificial Organ. 21: 83-87,1997.
    19. Fukahara K., Murakami A., Ueda T., Doki Y., Tsubata S., Ichida F., and Misaki T. : Scheduled autologous blood donation at the time of cardiac catheterization in infants and children. J Thorac Cardiovasc Surg. 114 : 504-505,1997.
    20. Yokoyama Y., Narahara K., Teraoka M., Koyama K., Seino Y.,Yagi S., Konishi T., and Miyawaki T.: Cryptic pericentric inversion of chromosome 17 detected by fluorescence in situ hybridization study in familial Miller-Dieker syndrome. Am J @of Medical Genetics 71:236-237,1997.
    21. Y. Adachi, T. Mio, K. Takigawa, I. Striz, D. J. Romberger, R. A. Robbins, J. R. Spurzem, P. Heires, S. I. Rennard. Mutual inhibition by TGF-beta and IL-4 in cultured human bronchial epithelial cells. Am. J. Physiol. 273: L701-708; 1997.
    22. Feldstein J.T., Jaffe E.S., Burd P.R., Kanegane H., Kigma D. W., Wilson W. H., Longo D. L., and Tosato G. : The role of Mig, the monokine induced by interferon-ƒÁ, and IP-10 , the interferon-ƒÁ-Inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 90 : 4099-4105,1997.
    23. ‘ŽqDA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jFNIHŠÜˆÓ•¶(1980)A”M«‚¯‚¢‚ê‚ñ§˜b‰ïŽ¡—ÃŽwj(1988)AŽw“±ƒKƒCƒhƒ‰ƒCƒ“(1996)‚É‚æ‚é”M«‚¯‚¢‚ê‚ñ—\–h“Š—^‚ÌŽÀÛD¬Ž™‰È—Õ° 50F65-71,1997.
    24. ‰z“c—ŒbA‹´–{_”VA‰œ“c‘¥•FA¬¼šõŽqA‘å–ìˆê˜YA’J“à]ºGA‹{˜e—˜’jFæ“V«ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠ´õÇ|‘½Ê‚È—Õ°‘œ‚Ì”äŠrŒŸ“¢‚¨‚æ‚Ñ”D•w‚ÌR‘Ì•Û—L—¦‚ƃEƒCƒ‹ƒXƒQƒmƒ€‚ÌŒŸo‚ÌŽŽ‚Ý|D“ú–{V¶Ž™Šw‰ïŽGŽ@33:228-233,1997.
  • Ç—á•ñ
    1. Kanegane H., Wada T., Nunogami K., Seki H., Taniguchi N., and Tosato G. : Chronic persistent Epstein-Barr virus infection of natural killer cells and B cells associated with granular lymphocytes expansion. British Journal of Haematology : 95, 116-122, 1996.
    2. ˆîê@iArˆä”ü˜aŽqA•£‹žŽqAŽðˆä—R‹IAˆ¢•”KŽqA¼‘q—TŠìA‹{˜e—˜’jF“÷Šá“IŒŒ”A”­ìŽž‚Ɉê‰ß«‚Ìt‹@”\’ቺ‚ð”F‚ß‚½IgAtÇ‚Ì‚P—áB“ú–{¬Ž™t•s‘SŠw‰ïŽGŽ@17F39-40,1997.
    3. ‹g“c@–LA‰i“c‹`‹BAL“cKŽŸ˜YAŽÄ“cŒbŽOAΣ@~A–k@‹`lA‹àŒ“O˜aF‘½‘ŸŠí•s‘S‚ð‡•¹‚µ‚½ƒCƒ“ƒtƒ‹ƒGƒ“ƒU‚`ƒEƒCƒ‹ƒXŠ´õ‚Ì‚PÇ—áD“ú–{W’†Ž¡—ÈãŠw‰ïŽGŽ@4F375-380,1997.
    4. ‰ª•”@ŒhAŽs‘º¸‰xA‹´–{ˆè•vA ŽO‰Y³‹`A’·’Jì@Œ’F"Growth without GH"‚ð’悵‚½Rathke”X–E‚Ì‚P—áDƒzƒ‹ƒ‚ƒ“‚Æ—Õ° 45F38-42,1997.
    5. ‹´–{ˆè•vAŽO‰Y³‹`AŽs‘º¸‰xA‰ª•”@ŒhA㨌hˆê˜YA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA“¡–{@–¾FƒJƒeƒRƒ‰ƒ~ƒ“—U”­«‘½Œ`¬SŽº«•p”‚Ì‚P—Ž™—áD“ú–{¬Ž™‰ÈŠw‰ïŽGŽA101F1616-1619,1997.
  • ‘à
    1. ˆîê@iF”÷¬•Ï‰»Œ^ƒlƒtƒ[ƒ[ÇŒóŒQ‚ÌŽ¡—ÃD¬Ž™‰È 38:221-227,1997.
    2. ˆîê@iFt‘ŸÇŒóŒQ|‚»‚Ì‘¼‚Ìt‘ŸŽ¾Š³‚ðŠÜ‚ß‚Ä(ã)|•ªßót’áŒ`¬D“ú–{—Õ°—̈æ•ÊÇŒóŒQƒVƒŠ[ƒYNo.16 397-399,“ú–{—Õ°ŽÐ,‘åã,1997.
    3. ˆîê@iFt‘ŸÇŒóŒQ|‚»‚Ì‘¼‚Ìt‘ŸŽ¾Š³‚ðŠÜ‚ß‚Ä(‰º)|‘̈ʫ’`”’”AB“ú–{—Õ°—̈æ•ÊÇŒóŒQƒVƒŠ[ƒYNo.17 672-674,“ú–{—Õ°ŽÐ,‘åã,1997.
    4. ˆîê@iF–Œ«tÇB¬Ž™“à‰È 29:638-640,1997.
    5. ‹{˜e—˜’jF‚w˜A½ƒŠƒ“ƒp‘BÇŒóŒQBˆãŠw‚Ì‚ ‚ä‚Ý 182:758-761,1997.
    6. ‘«—§—YˆêA‹{˜e—˜’jFTh2×–E‚ÆCD30B—Õ°–Ɖu 29F1533-1538,1997.
    7. Š}Œ´‘PmA‹{˜e—˜’jFEBVŠ´õ‚É‚¨‚¯‚éT×–EŠˆ«‰»‚Æ×–EŽ€DBIC Forum 2:79-84,1997.
    8. ¬¼@“OFŒ¾—t‚Ì’x‚êD¬Ž™‰Èf—à 60(‘)F491-494,1997.
    9. ¬¼@“OF‚Ä‚ñ‚©‚ñ‚ÌÅVf’fEŒŸ¸–@DŽ¡—à 79F1993-1999,1997.

  • 1997”NŠw‰ï”­•\
    1. 㨌hˆê˜YA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA‚”©ÍŽiFŠ®‘S–[ŽºƒuƒƒbƒN‚ð‡•¹‚µ‚½S‹Ø‰Š‚̈ê—áD‘æ13‰ñ–k—¤¬Ž™zŠÂŠí§˜b‰ï,1997,1,‹à‘ò.
    2. –{‹½˜a‹vA¬¼@“OA‘ŽqDA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF—Ç«“ûŽ™áz¹‚Ì—Õ°‘œD‘æ31‰ñ–k—¤¬Ž™_Œo§˜b‰ï,1997,2,‹à‘ò.
    3. Adachi Y., Onoue Y., Tamamoto J., Adachi Y.S., Seki D., Morohashi M., Murakami G.,and Miyawaki T.: CD30 expression on lymphocytes of patients with allergic diseases. American Academy of Allergy, Asthema and Immunology Meeting,1997, 2,San Francisco, USA.
    4. ¬¼@“OA‘ŽqDA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jFRolandic discharge ‚ª“Ë‘RÁŽ¸‚Ü‚½‚Í‘¼‚Ì“Ë”­”g‚É•Ï—e‚µ‚½Ç—á‚Ì—Õ°“Á’¥D‘æ13‰ñRDŒ¤‹†‰ï,1997,2,“Œ‹ž.
    5. –{‹½˜a‹vA¬¼@“OA‹g“c˜aŽiA‘ŽqDA¼‘òƒŽqA”ª–ØMˆêA‹{˜e—˜’jA‹àˆä‰pŽqF‹»–¡‚ ‚é‰æ‘œŠŒ©‚ðŽ¦‚µ‚½ƒ‰ƒCÇŒóŒQ‚̈ê—áD‘æ258‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,1997,3,•xŽR.
    6. –쑺ŒbŽqAÝ“c—FŽqA”ª–ØMˆêA‹{˜e—˜’jA²“¡”üŒbA ‘ºãIŒ[A–{ŠÔˆê³Fœ‘üˆÛǂ𔺂Á‚½‹}«‹Šj‰è‹…«”’ŒŒ•a(M7)‚̈ê—áD‘æ258‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,1997,3,•xŽR.
    7. ‹´–{ˆè•vAŽO‰Y³‹`A‰ª•”@ŒhAŽs‘º¸‰xA㨌hˆê˜YA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA“¡–Ø@–¾FƒJƒeƒRƒ‰ƒ~ƒ“—U”­«‘½Œ`«SŽº«•p”‚Ì‚P—áD‘æ258‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,1997,3,•xŽR.
    8. ”ª–ØMˆêA ¬¼@“OA‘ŽqDA–{‹½˜a‹vAŽR’J”ü˜aA ‹{˜e—˜’jF•”•ª”­ìÇó‚ðŽ¦‚µ‚½West ÇŒóŒQD‘æ21‰ñ–k—¤‚Ä‚ñ‚©‚ñ§˜b‰ï,1997,3,‹à‘ò.
    9. ¼‘òƒŽqA¬¼@“OA‘ŽqDA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF•¡ŽG•”•ª”­ìŒQ”­‚Å”­Ç‚µ‚½‘¤“ª—t‚Ä‚ñ‚©‚ñ‚Ì‚P—á|‰æ‘œŠŒ©‚ð’†S‚É|D‘æ21‰ñ–k—¤‚Ä‚ñ‚©‚ñ§˜b‰ï,1997,3,‹à‘ò.
    10. Ý“c—FŽqA”ª–ØMˆêA–쑺ŒbŽqA‹{˜e—˜’jAŽR‰º–F˜NAVˆä‰pŽ÷A‘Žq@—mF‰ŠÇ«’°Ž¾Š³—ÞŽ—‚Ì’°ŠÇ•a•Ï‚ð’悵‚½–«“÷‰èŽîÇ‚Ì‚P—áD‘æ18‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ¤‹†‰ï,1997,3,•xŽR.
    11. à_“¹—T“ñA’Ô¦áÁˆêA‹´–{ˆè•vA㨌hˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jFIsolated Noncompaction of the Ventricular Myocardium‚̉Ƒ°“àWÏ—á`‚»‚Ìclinical entity‚Æ‚µ‚Ä‚Ì“Æ—§«‚ÌŒŸ“¢‚ð’†S‚É`‘æ61‰ñ“ú–{zŠÂŠíŠw‰ï,1997,3,“Œ‹ž.
    12. à_“¹—T“ñA㨌hˆê˜YA‹´–{ˆè•vA’Ô¦áÁˆêA“ñ’J@•A‘«—§—YˆêA‹{è‚ ‚ä‚ÝAˆîê@iAŽs“c•™ŽqA‹{˜e—˜’jA ‘ºãIŒ[AFè@Œ’Fìè•a‹y‚ÑŠeŽíŽ¾Š³‚É‚¨‚¯‚錌’†ŒŒŠÇ“à”ç‘BˆöŽq‚Ì“®‘Ô‚Æ—Õ°“IˆÓ‹`D‘æ100‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1997,4,“Œ‹ž.
    13. “ñ’J@•A¡‘º”Ž–¾A‹{˜e—˜’jFƒtƒ[ƒTƒCƒgƒƒgƒŠ[‚ð—p‚¢‚½X˜A½«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚ÌŠ³ŽÒE•ÛˆöŽÒf’fD‘æ100‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1997,4,“Œ‹ž.
    14. ‹{˜e—˜’jFƒVƒ“ƒ|ƒWƒEƒ€u–ƉuŒn‚ÌŠî‘b‚Æ—Õ°v`‚w˜A½«–Ɖu•s‘SÇFˆâ“`Šw“I—‰ð‚ÆV‚µ‚¢•ÛˆöŽÒf’fD‘æ100‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1997,4,“Œ‹ž.
    15. ’Ô¦áÁˆêA㨌hˆê˜YAà_“¹—T“ñA‹´–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jF“–‰È‚É‚¨‚¯‚éìè•adÇS‡•¹‚𔺂Á‚½Šw“¶‚ÌŠÇ—D‘æ31‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1997,4,•xŽR.
    16. ¡‘º”Ž–¾A“ñ’J@•F“–‰È‚É‚¨‚¯‚é’´E‹É’áo¶‘ÌdŽ™‚Ìg‘Ì”­ˆç‚ɂ‚¢‚ÄD‘æ31‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1997,4,•xŽR.
    17. ˆÉ“Œ^—ŽqAÝ“c—FŽqA‘ŽqDA¼‘òƒŽqA¬¼@“OFŽá”N”­Ç‚ÌÛHáŠQŽ™‚É‚¨‚¯‚é—Õ°S—Šw“I“Á’¥D‘æ31‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1997,4,•xŽR.
    18. ‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‘«—§—zŽqA‰¡“cF”VA‹{˜e—˜’jA‘ºãIŒ[FCyclosporin A•¹—p‚É‚æ‚èƒXƒeƒƒCƒhŒ¸—Ê‚ðŽŽ‚Ý‚½‹CŠÇŽxšb‘§‚Ì‚P’jŽ™—áD‘æ9‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï,1997,5,ç—t.
    19. Uese K., Ichida F., Tsubata S., Hashimoto I., Hamamichi Y., Fukahara K., Murakami A., and Miyawaki T.: Oral Prostacyclin Analogue Enhances the Pulmonary Vasodilator Effect of Nitric Oxide in Children with Pulmonary Hypertension. The 2nd World Congress of Pediatric Cardiology and Cardiac Surgery. 1997,5,Hawaii.(Young investigators award, The first Prize)
    20. Ichida F., Hamamichi Y., Uese K., Hashimoto I., Tsubata S., Miyawaki T., Ono Y., Kamiya T., Akagi T., Hamada H., Hirose O., Isobe T., Kojou M., Kurotobi S., Mito H., Miyake T., Nishi T., and Tomimatsu H.: Clinical Features of Isolated Noncompaction of Ventricular Myocardium in Japanese Children. The 2nd World Congress of Pediatric Cardiology and Cardiac Surgery, 1997,5,Hawaii.
    21. Hamamichi Y., Ichida F., Uese K., Hashimoto I., Tsubata S., Futatani T., Miyazaki A., Murakami G., Suzaki K., Inaba S., Murakami A., and Miyawaki T.: Increased Serum Levels of Vascular Endothelial Growth Factor in Kawasaki Disease. The 2nd World Congress of Pediatric Cardiology and Cardiac Surgery,1997,5,Hawaii.
    22. Hashimoto I., Uese K., Hamamichi Y., Tsubata S.,Miyazaki A., Ichida F., Murakami A., Miyawaki T., Arakaki Y., and Kamiya T. : A novel method for indexing angiographic left ventricular mass in normals and children with left ventricular hypertrophy. The 2nd World Congress of Pediatric Cardiology and Cardiac Surgery,1997,5,Hawaii.
    23. ‹àŒ“O˜aA‹àŒ“çtA˜eŒû@GA‘q”É—²MA‹à“c@®A˜a“c‘׎OA’J“à]ºGAŠÖ@GrArˆä@FAŒ®–{¹ˆêA‰ªè@ŽÀA‘åÎ@•×AGiovanna TosatoF–«Šˆ“®«Epstein-BarrƒEƒCƒ‹ƒXŠ´õÇ‚É‚¨‚¯‚éƒCƒ“ƒ^[ƒƒCƒLƒ“10D‘æ‚V‰ñ‚d‚aƒEƒCƒ‹ƒXŠ´õÇŒ¤‹†‰ï,1997,5,“Œ‹ž.
    24. ˆîê@iArˆä”ü˜aŽqAˆ¢•”KŽqAŽðˆä—R‹IAŽÂ茒‘¾˜YA•£‹žŽqA¼‘q—TŠìA‹{˜e—˜’jF¬Ž™t•s‘S•Û‘¶Šú‚É‚¨‚¯‚éTJ-23‚ÌŒø‰ÊD‘æ40‰ñ“ú–{t‘ŸŠw‰ï,1997,5,VŠƒ.
    25. rˆä”ü˜aŽqAˆîê@iAˆ¢•”KŽqAŽðˆä—R‹IAŽÂ茒‘¾˜YA•£‹žŽqA¼‘q—TŠìA‹{˜e—˜’jF¬Ž™“«ƒlƒtƒ[ƒ[ÇŒóŒQ‚ÌCiclosporin—Ö@D‘æ40‰ñ“ú–{t‘ŸŠw‰ï,1997,5,VŠƒ.
    26. Ý“c—FŽqA”ª–ØMˆêA–쑺ŒbŽqA‹{˜e—˜’jF–«“÷‰èŽîÇ‚É‚¨‚¯‚é’°ŠÇ•a•Ï‚ÌŒŸ“¢D‘æ ‰ñ–k—¤—Õ°–ƉuŒ¤‹†‰ï,1997,5,‹à‘ò.
    27. ¬¼@“OA‘ŽqDA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêFRolandic discharge ‚ÌŒo‰ß’†•Ï‰»‚Ì‘½—l«‚Æ—Õ°‘œD‘æ39‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1997,6,–¼ŒÃ‰®.
    28. ‘ŽqDA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêF”M«áz¹‚É‚¨‚¯‚é”­ìÄ”­‚ÉŠÖ‚·‚錟“¢ \—\–h“Š—^‚ðŽÀŽ{‚µ‚½Ç—á‚ɂ‚¢‚Ä\D‘æ39‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1997,6,–¼ŒÃ‰®.
    29. ¼‘òƒŽqA‘ŽqDA¬¼@“OA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêF‘å”]”玿Œ`¬ˆÙí‚ÌŠeŽí‰æ‘œŠŒ©‚Æ—Õ°Çó‚ÌŠÖ˜A«‚ɂ‚¢‚ÄD‘æ39‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1997,6,–¼ŒÃ‰®.
    30. ”ª–ØMˆêA¼‘òƒŽqA‘ŽqDA¬¼@“OA –{‹½˜a‹vAŽR’J”ü˜aF—¼‘¤Ž‹°•a•Ï‚ð’悵‚½”]‰ŠE”]ǂ̉摜ŠŒ©‚ɂ‚¢‚ÄD‘æ39‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1997,6,–¼ŒÃ‰®.
    31. –{‹½˜a‹vA¬¼@“OA‘ŽqDA¼‘òƒŽqAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF‚QΖ¢–ž”­Ç‚Ì—Ç«“ûŽ™áz¹‚Ì”­ì—\ŒãD|‚T”NˆÈã‚Ì’ÇÕ—á‚É‚¨‚¯‚錟“¢|D‘æ39‰ñ“ú–{¬Ž™_Œo‰ï,1997,6,–¼ŒÃ‰®.
    32. ‹´–{ˆè•vAŽO‰Y³‹`A‰ª•”@ŒhA‘º“c“Þ”üAŽs“c•™ŽqA•l“¹—T“ñA‹{˜e—˜’jFAutomatic Border Detection System‚ð—p‚¢‚½¬Ž™—á‚É‚¨‚¯‚鶎º‹@”\‚ÌŒŸ“¢D‘æ4‰ñ–k—¤zŠÂŠí’´‰¹”gŒ¤‹†‰ï,1997,6,‹à‘ò.
    33. ¬ìŽŸ˜YA“ñ’J@•A¡‘º”Ž–¾A‹{˜e—˜’jFæ“V«‹Ø‹Ù’£«ƒWƒXƒgƒƒtƒB[‚̈ê—áD‘æ259‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,1997,6,•Ÿˆä.
    34. ¼‘òƒŽqA–{‹½˜a‹vA¬¼@“OA‘ŽqDAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF•”•ª”­ì‚ð’悵‚½WestÇŒóŒQ‚̈ê—áD‘æ259‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,1997,6,•Ÿˆä.
    35. ˆîê@iA‹{˜e—˜’jA–öŒ´r—YAŒ´@³‘¥A”óŒû@WA‚“cP˜YA’JàV—²–MF¬Ž™“Á”­«ƒlƒtƒ[ƒ[ÇŒóŒQ‚Ì’·Šú—\Œã‚ÆŽ¡—ÂÌÄŒŸ“¢D‘æ32‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ï,1997,6,‘åã.
    36. ŽÂ茒‘¾˜YAˆîê@iA¼‘q—TŠìArˆä”ü˜aŽqAŽðˆä—R‹IAˆ¢•”KŽqA•£‹žŽqA¬¼@“OA‹{˜e—˜’jAŒE“c”Ž“¹A—é–ØD•¶FCockayneÇŒóŒQ‚Ìt•a•ÏD‘æ32‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ï,1997,6,‘åã.
    37. ŽÂ茒‘¾˜YArˆä”ü˜aŽqAˆ¢•”KŽqA•£‹žŽqAŽðˆä—R‹IA¼‘q—TŠìAˆîê@iA‹{˜e—˜’jFŒoŽž“I‚É”A’†Ž…‹…‘Ìã”ç×–E”‚ðŒŸ“¢‚µ‚½Ž‡”Á•a«t‰Š‚̈ê—áD‘æ27‰ñ•xŽRŒ§tŽ¾Š³lH“§ÍŒ¤‹†‰ï,1997,6,•xŽR.
    38. Konishi T., Masuko K., Matsuzawa J., Hongou K., Yamatani M., Yagi S., and Miyawaki T.: Neuroradiological evaluation of cortical dysplasia in children with epilepsy. 22th International Epilepsy Congress,1997, 7,Dublin,Ireland
    39. ‹àŒ“O˜aA‰ª•””üŒbA–쑺ŒbŽqA‹{˜e—˜’jA¬ò•x”ü’©F’˜–¾‚Èœ‘üˆÛǂ𔺂Á‚½‹}«‹Šj‰è‹…«”’ŒŒ•aiM7j‚̈ꗎ™—áD‘æ13‰ñ•xŽRŒ§ŒŒ‰tŽ¾Š³Œ¤‹†‰ï,1997,7,•xŽR.
    40. A‘º”ü‹IA‰ª•””üŒbA‘«—§—zŽqA‘«—§—YˆêA”ª–ØMˆêA‹{˜e—˜’jFƒ^ƒ“ƒiƒ‹ƒrƒ“•ž—p‚É‚æ‚èƒAƒiƒtƒBƒ‰ƒLƒV[ƒVƒ‡ƒbƒN‚ð‚¨‚±‚µ‚½ƒAƒgƒs[«”畆‰Š‚̈ê—áD‘æ33‰ñ•xŽRŒ§¬Ž™‰ÈW’k‰ï,1997, 7,•xŽR.
    41. ‹àŒ“O˜aA–쑺ŒbŽqA‹{˜e—˜’jAŒE“c”Ž“¹F‚d‚aƒEƒBƒ‹ƒXŠÖ˜A‚s×–EƒŠƒ“ƒpŽî‚̈ê—áD‘æ33‰ñ•xŽRŒ§¬Ž™‰ÈW’k‰ï,1997,7,•xŽR.
    42. à_“¹—T“ñA㨌hˆê˜YA‹´–{ˆè•vA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA´…³ŽiA£ŒË@ŒõFìè•a‚É‚¨‚¯‚éƒhƒuƒ^ƒ~ƒ“•‰‰×Sƒv[ƒ‹‚É‚æ‚é¶SƒpƒtƒH[ƒ}ƒ“ƒX‚ÌŒŸ“¢D‘æ28‰ñ–k—¤zŠÂŠíŠjˆãŠwŒ¤‹†‰ï,1997,7,‹à‘ò.
    43. 㨌hˆê˜YA‹´–{ˆè•vAŽO‰Y³‹`A’Ô¦áÁˆêAŽs“c•™ŽqAà_“¹—T“ñA‹{˜e—˜’jFCathecho-laminergic polymorphic ventricular tachycardia‚̬Ž™—áD‘æ33‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1997,7,‹ž“s.
    44. ‹´–{ˆè•vAŽO‰Y³‹`A‰ª•”@ŒhAŽs‘º¸‰xAŽs“c•™ŽqA‹{˜e—˜’jFAutomatic Border Detection System‚ð—p‚¢‚½¬Ž™¶ŽºŽûk”\AŠg’£”\‚Ì•]‰¿D‘æ33‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1997, 7,‹ž“s.
    45. à_“¹—T“ñA㨌hˆê˜YA‹´–{ˆè•vA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jF“ûŽ™Šú‚Ìnative coarctation‚Ì‚R—á‚ɑ΂·‚éŒo”ç“IŒŒŠÇŒ`¬p‚ÌŒoŒ±D‘æ33‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1997,7,‹ž“s.
    46. Žs“c•™ŽqAŽÂ茒‘¾˜YA㨌hˆê˜YAà_“¹—T“ñA‹´–{ˆè•vA’Ô¦áÁˆêA‹{˜e—˜’jA‹{è‚ ‚ä‚ÝA¬–ìˆÀ¶A_’J“N˜YAÔ–Ø’õŽ¡A•l“c—m’ÊAL£@CAˆé•”„ŽuAŒÃ鹓WA•”òr“ñAŽOŒË”ŽŽuAŽO‘îrŽ¡A‘ºã•Û•vA¼@–ÒA“c‘ãT“ñ˜YA•x¼G•¶F–{–M‚É‚¨‚¯‚éIsolated noncompaction of ventricular myocardium‚Ì—Õ°‘œ`‘S‘’²¸Œ‹‰Ê`D‘æ33‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1997, 7,‹ž“s.
    47. ¼‘q—TŠìArˆä”ü˜aŽqAˆ¢•”KŽqAŽÂ茒‘¾˜YAŽðˆä—R‹IA•£‹žŽqAˆîê@iA‹{˜e—˜’jFCiclosporin associated arteriolopathy ‚ð”F‚ß‚½“Á”­«ƒlƒtƒ[ƒ[ÇŒóŒQ‚̈ê—áD‘æ‚T‰ñ’†•”¬Ž™t‘Ÿ•aŒ¤‹†‰ï,1997,7,‹à‘ò.
    48. ¼‘q—TŠìArˆä”ü˜aŽqAˆ¢•”KŽqAŽÂ茒‘¾˜YAŽðˆä—R‹IA•£‹žŽqAˆîê@iA‹{˜e—˜’jFƒtƒƒZƒ~ƒh‚Ƀƒgƒ‰ƒ]ƒ“‚𕹗p‚µŒ€“I‚È—˜”AŒø‰Ê‚ð”F‚ß‚½¬Ž™ƒlƒtƒ[ƒ[ÇŒóŒQ‚̈ê—áD‘æ19‰ñ¬Ž™‘̉tŒ¤‹†‰ï,1997,7,“Œ‹ž.
    49. 㨌hˆê˜YA‹k@çHAà_“¹—T“ñA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA‚”©ÍŽiA‹àŒ“çtFŠ®‘S–[ŽºƒuƒƒbƒN‚ð‡•¹‚µ‚½S‹Ø‰Š‚Ì‚QÇ—áD‘æ33‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1997,8,•xŽR.
    50. ‹àŒ“O˜aA‹{˜e—˜’jA‹à“c@®A’J“à]ºGAŠÖ@GrArˆä@FA‘åÎ@•×AMarina Gutierrez, Kishor Bhatia, Giovanna TosatoFŒo‰ß’†‚É‚d‚aƒEƒCƒ‹ƒXŠÖ˜A‚s×–EƒŠƒ“ƒpŽî‚ð‡•¹‚µ‚½–«Šˆ“®«‚d‚aƒEƒCƒ‹ƒXŠ´õÇ‚Ì‚Q—áD‘æ33‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1997,8,•xŽR.
    51. Ý“c—FŽqA‘ºãIŒ[A–{ŠÔˆê³F“–‰È‚É‚¨‚¯‚éƒCƒ\ƒvƒƒeƒŒƒm[ƒ‹Ž‘±‹z“ü—Ö@‚ðs‚Á‚½‹CŠÇŽxšb‘§Ç—á‚Ì—Õ°“IŒŸ“¢D‘æ33‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1997,8,•xŽR.
    52. ŽÂ茒‘¾˜YAˆîê@iAŽðˆä—R‹IAˆ¢•”KŽqArˆä”ü˜aŽqA•£‹žŽqA¼‘q—TŠìA¬¼@“OA‹{˜e—˜’jAŒE“c”Ž“¹A—é–ØD•¶FCockayneÇŒóŒQ‚Ìt•a•ÏD‘æ33‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1997,8,•xŽR.
    53. ŽÂ茒‘¾˜YA¼‘q—TŠìAŠ™’JˆŸ‹IŽqAˆîê@iA‹{˜e—˜’jFBardet-BiedleÇŒóŒQ‚ÌŒo‰ß’†‚É‹}«Ž…‹…‘Ìt‰Š‚𕹔­‚µ‹}«t•s‘S‚ɊׂÁ‚½ˆê—áD‘æ45‰ñ’†•”t‘Ÿ•a’k˜b‰ï,1997,9,–¼ŒÃ‰®.
    54. ¼‘òƒŽqA¬¼@“OA‘ŽqDA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF”]‰ŠE”]ÇŒãˆâÇŠ³Ž™‚Ì‚l‚q‚rŠŒ©‚ɂ‚¢‚ÄD‘æ32‰ñ–k—¤¬Ž™_Œo§˜b‰ï,1997,9,‹à‘ò.
    55. ¼‘q—TŠìAŽÂ茒‘¾˜YAŠ™’JˆŸ‹IŽqAˆîê@iA‹{˜e—˜’jAŒIŒ´^‹IŽqA”¨èŠì–FF’á•â‘ÌŒŒÇ‚ð’悵‹}«t•s‘S‚ð‡•¹‚µ‚½Ž…‹…‘Ìt‰Š‚Ì‚QÇ—áD‘æ19‰ñ“ú–{¬Ž™t•s‘SŠw‰ï,1997,9,Œyˆä‘ò.
    56. –쑺ŒbŽqA“ñ’J@•A‹{˜e—˜’jA’J“à]ºGAŠ}Œ´‘PmA˜a“c‘׎OA•zãFŽuF¶Œã‘Šú‚æ‚èŒÄ‹zŠíŠ´õǂ𔽕œ‚·‚é’jŽ™—á`CD3Œ‡‘¹Ç‚©HD‘æ25‰ñ“ú–{—Õ°–ƉuŠw‰ï,1997,9,“Œ‹ž.
    57. “ñ’J@•A‹àŒ“O˜aA‹{˜e—˜’jA’Ë“c@‘A‹´–{ÍŽiAVˆä“c@—vF‚w˜A½«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì•ÛˆöŽÒf’f‚ƈâ“`“I”wŒiD‘æ25‰ñ“ú–{—Õ°–ƉuŠw‰ï,1997,9,“Œ‹ž.
    58. ¼‘òƒŽqA¬¼@“OA‘ŽqDA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF‘å”]”玿Œ`¬ˆÙí‚ð—L‚·‚é‚Ä‚ñ‚©‚ñ‚ÌSPECTAMRSŠŒ©‚ɂ‚¢‚ÄD‘æ31‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,1997,9,‹ž“s.
    59. ‘ŽqDA¬¼@“OA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêA‹{˜e—˜’jF”ñáz¹«‚Ä‚ñ‚©‚ñdÏÇ‚Ì”­ìŽž‚r‚o‚d‚b‚sŠŒ©D‘æ31‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,1997,9,‹ž“s.
    60. ¬¼@“OA ‘ŽqDA¼‘òƒŽqA–{‹½˜a‹vAŽR’J”ü˜aA”ª–ØMˆêFPhenitoin ŽUÜ‚Ì bioavailability –òÜ•ÏXŽž‚Ì—Õ°“I—¯ˆÓ“_D‘æ‚T‰ñ•xŽRŒ§¬Ž™—Õ°_ŒoŒ¤‹†‰ï,1997,9,•xŽR.
    61. ‹k@çHAŽRŒ³ƒŽqA‹àŒ“O˜aA‹{˜e—˜’jA¬—Ñ’B–çFŽc‘¶Žîᇂɑ΂µ‚ăKƒ“ƒ}ƒiƒCƒt‚É‚æ‚é’èˆÊ•úŽËüŠO‰È—Ö@‚ðŽŽ‚Ý‚½¬Ž™‘‰èŽî‚̈ê—áD‘æ‚V‰ñ–k—¤¬Ž™ŠàǗጟ“¢‰ï,1997,9,‹à‘ò.
    62. ‘«—§—YˆêAŽRŒ³ƒŽqA”öã—mˆêA‰ª•””üŒbA‘«—§—zŽqA‹{˜e—˜’jA–L“c‰ë•FAŠÖ@‘¾•ãA”‹´³ºA…“‡@–LFƒAƒgƒs[«”畆‰ŠŠ³ŽÒ‚Ì––½ŒŒƒwƒ‹ƒp[‚s×–E‚É‚¨‚¯‚éCD30”­Œ»|‘æ‚Q•ñ@—Õ°‘œ‚Æ‚ÌŠÖŒW-D‘æ47‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹G‘å‰ï,1997,9,‰¡•l.
    63. ”öã—mˆêA‘«—§—YˆêAŠžŒ´¹ŽqAŠâ’J‰ëŽqA‰¡“cF”VA‹{˜e—˜’jA‘ºãIŒ[A¼–ì³’mA•“¡“Ö•FF‰Æ‰®o’†ƒ`ƒƒƒ^ƒeƒ€ƒVRŒ´—Ê`’nˆæ“I·ˆÙ‚¨‚æ‚Ñ‹Gß“I•Ï“®‚ɂ‚¢‚ÄD‘æ47‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹G‘å‰ï,1997,9,‰¡•l.
    64. Š™’JˆŸ‹IŽqAŽÂ茒‘¾˜YA㨌hˆê˜YAà_“¹—T“ñA‹´–{ˆè•vA‹{˜e—˜’jA‘ºã@VA‚”©ÍŽiFFallotŽl’¥Ç‚ÌpŒã‚ÉSŽº•p”‚𔺂Á‚½‚p‚s‰„’·ÇŒóŒQ‚̈ê—áD‘æ260‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,1997,9,‹à‘ò.
    65. à_“¹—T“ñA㨌hˆê˜YA‹´–{ˆè•vA’Ô¦áÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA´…³ŽiA£ŒË@ŒõFTc-99mƒhƒuƒ^ƒ~ƒ“•‰‰×Sƒv[ƒ‹ƒCƒ[ƒWƒ“ƒO‚É‚æ‚éìè•aŠ¥“®–¬áŠQ—á‚̶Žº‹@”\‚ÌŒŸ“¢D‘æ17‰ñìè•aŒ¤‹†‰ï,1997,10,ŽD–y.
    66. ‹àŒ“O˜aA“ñ’J@•A‹{˜e—˜’jF–«Šˆ“®«‚d‚aƒEƒCƒ‹ƒXŠ´õÇ‚É‚¨‚¯‚éƒEƒCƒ‹ƒXEƒCƒ“ƒ^[ƒƒCƒLƒ“10‚Ì”­Œ»D‘æ27‰ñ“ú–{–ƉuŠw‰ï‘‰ï,1997,10,ŽD–y.
    67. ¼‘q—TŠìAŠÝ@—TKA‹{˜e—˜’jA‘ºŒû@“ÄFwhnˆâ“`ŽqŽY•¨‚Ì‹¹‘BƒXƒgƒ[ƒ}×–E‚É‚¨‚¯‚é‹@”\D‘æ27‰ñ“ú–{–ƉuŠw‰ï‘‰ï,1997,10,ŽD–y.
    68. “ñ’J@•A’Ë“c@‘A‹´–{ÍŽiA‹àŒ“O˜aA‹{˜e—˜’jFƒtƒ[ƒTƒCƒgƒƒgƒŠ[–@‚É‚æ‚é‚w˜A½«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì•ÛˆöŽÒf’f‚ƈâ“`“I”wŒi‚ɂ‚¢‚ÄD‘æ27‰ñ“ú–{–ƉuŠw‰ï‘‰ï,1997,10,ŽD–y.
    69. Ý“c—FŽqA‘«—§—YˆêA–쑺ŒbŽqA¼‘òƒŽqA“ñ’J@•A‹àŒ“O˜aA”ª–ØMˆêA‹{˜e—˜’jF”­Ç‘Šú‚ÉÁ‰»ŠÇ“÷‰è•a•Ï‚ðŠÏŽ@‚µ“¾‚½–«“÷‰èŽîÇ“ûŽ™‚Q—áD‘æ29‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,1997,11,²‰ê.
    70. ‹àŒ“O˜aAŠ™’JˆŸ‹IŽqA–쑺ŒbŽqA“ñ’J@•A‹{˜e—˜’jA‘哇FˆêF––½ŒŒ‚s×–EƒŒƒZƒvƒ^[ƒÁƒÂ½—z«T×–E‚Ì‘‰Á‚𔺂Á‚½–«Šˆ“®«‚d‚aƒEƒBƒ‹ƒXŠ´õǂ̈ê—áD‘æ29‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,1997,11,²‰ê.
    71. ¼‘òƒŽqA¬¼@“OA‘ŽqDA–{‹½˜a‹vA”ª–ØMˆêA‹{˜e—˜’jAX“‡P—YFÄ”­Žž‚ÉŒ°’˜‚È•sˆÓ‰^“®‚ð’悵‚½ƒwƒ‹ƒyƒX”]‰Š‚Ì‚P—áD‘æ29‰ñ“ú–{¬Ž™Š´õÇŠw‰ï,1997,11,²‰ê.
    72. Hamamichi Y., Ichida F., Tsubata S., Uese K., Hashimoto I., Miyawaki T., Miyazaki A., and Seto H. : Low-dose dobutamine stress radionuclide ventriculography for evaluation of left ventricular performance in Kawasaki disease. The 70th Scientific sessions of American Heart Association,1997,11, Orland,USA.
    73. Hashimoto I., Ichida F., Okabe T., Miura M., Nomura K., Uese K., Hamamichi Y., Tsubata S., Miyawaki T., and Misaki T.: Evaluation of left ventricular diastolic function using automatic border detection system in children after chemotherapy for malignant neoplasms. The 70th Scientific sessions of American Heart Association, 1997,11,Orland,USA.
    74. ‘«—§—zŽqA‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‰ª•””üŒbA‰¡“cF”VAŠžŒ´¹ŽqAŠâ’J‰ëŽqA‹{˜e—˜’jA‘ºãIŒ[FƒAƒŒƒ‹ƒM[«Ž¾Š³“û—cŽ™‚É‚¨‚¯‚éƒlƒRRAST—z«—¦‚Æ‚»‚Ì—Õ°“IˆÓ‹`D‘æ34‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,1997,11,“Œ‹žD
    75. ²“¡¹ŽqA¼–ì³’mAˆÉ“Œ“¹•vAŒ´@³‘¥A–öŒ´r—YA‘«—§—YˆêA“àŽR@¹F‹CŠÇŽxšb‘§dÏ”­ì‚ɑ΂·‚éƒCƒ\ƒvƒƒeƒŒƒm[ƒ‹­—ÊŽ‘±‹z“ü—Ö@‚Ì—Õ°“IŒŸ“¢D‘æ34‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,1997,11,“Œ‹žD
    76. ŽRŒ³ƒŽqA¼‘òƒŽqAŠ™’JˆŸ‹IŽqAŽÂ茒‘¾˜YA“ñ’J@•A‘«—§—YˆêA‹{˜e—˜’jF‘}ŠÇŒã‚ÌSqueezingi—pŽè‹¹Šsˆ³”—Š·‹C•â•j‚É‚æ‚芷‹C•s‘S‚©‚ç’Eo‚µ“¾‚½‹CŠÇŽxšb‘§dÏ”­ì‚̈ê’jŽ™—áD‘æ30‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,1997,11,‘åãD
    77. ¼–ì³’mAˆÉ“Œ“¹•vA‘«—§—YˆêAŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§‚ÌŠ°‰ð‚ÉŽŠ‚é‰ß’ö‚Å‚Ì‹C“¹‰ß•q«‚Ì„ˆÚ‚ɂ‚¢‚ÄD‘æ30‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽ¾Š³Šw‰ï,1997,11,‘åãD
    78. ŽRŒ³ƒŽqA‰ª•””üŒbA”öã—mˆêA‘«—§—YˆêA”ª–ØMˆêA‹{˜e—˜’jA‘ºãIŒ[F’·ŠúŠÔ‚ÌlHŠ·‹C‚ð—]‹V‚È‚­‚³‚ꂽ‹CŠÇŽxšb‘§”­ì‚̈ê’jŽ™—áD‘æ23‰ñ–k—¤ƒAƒŒƒ‹ƒM[§˜b‰ï,1997,11,‹à‘òD
    79. Kanegane H., Kamaya A., Nomura K., Futatani T., Oshima K., and Miyawaki T.: Epstein-Barr virus-bearing T cell receptor ƒÁƒÂ-positive T-cell lymphoproliferative disorder with recurrent oral ulcerations. American Society of Hematology 39th annual meeting,1997,12,San Diego,U.S.A.
    80. Futatani T., Tsubata S., Hashimoto S., Kanegane H., Kishimoto T., and Miyawaki T. : Flowcytometric detection of Bruton's tyrosine kinase deficiency and its carrier in X-linked agammaglobulinemia. American Society of Hematology 39th annual meeting. 1997,12,San Diego,U.S.A.
    81. A‘º”ü‹IA‹àŒ“O˜aA”ª–ØMˆêA‹{˜e—˜’jA•£‹žŽqFŒ‹ß«g”Á—l”ç]‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚½Žá”NŒ^–«œ‘«”’ŒŒ•a‚Ì‚SÎ’jŽ™—áD‘æ261‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,1997,12,•xŽR.
    82. ¼‘q—TŠìAŽÂ茒‘¾˜YArˆä”ü˜aŽqAŽðˆä—R‹IA•£‹žŽqAˆ¢•”KŽqAˆîê@iA‹{˜e—˜’jFCAPD’†‚Ì–«t•s‘SŠ³Ž™‚ɬ’·ƒzƒ‹ƒ‚ƒ“‚ð“Š—^‚µ‚½‚QÇ—áD‘æ261‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—¤’n•û‰ï,1997,12,•xŽR.

    ƒAƒbƒvƒf[ƒg:2020.11.20 by X“àmŽu